[
  {
    "id": 1,
    "paragraph": "The EMBO Journal Vol.18 No.13 pp.3564–3574, 1999 The Mll–AF9 gene fusion in mice controls myeloproliferation and speciﬁes acute myeloid leukaemogenesis C.L.Dobson, A.J.Warren, R.Pannell, A.Forster, I.Lavenir, J.Corral1, A.J.H.Smith2 and T.H.Rabbitts3 MRC Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry, Hills Road, Cambridge, CB2 2QH, UK",
    "jurnal": "003564.pdf",
    "processed": "embo journal vol18 no13 pp3564–3574 1999 mll–af9 gene fusion mice controls myeloproliferation speciﬁes acute myeloid leukaemogenesis cldobson ajwarren rpannell aforster ilavenir jcorral1 ajhsmith2 thrabbitts3 mrc laboratory molecular biology division protein nucleic acid chemistry hills road cambridge cb2 2qh uk"
  },
  {
    "id": 2,
    "paragraph": "1Present address: Centro Regional de Hemodonacion, Servicio de Hematologia, Hospital Clinico Universitario, Ronda de Garay s/n, Murcia 30003, Spain 2Present address: Centre for Genome Research, University of Edinburgh, King’s Buildings, West Mains Road, Edinburgh EH9 3JQ, UK 3Corresponding author The MLL gene from human chromosome 11q23 is",
    "jurnal": "003564.pdf",
    "processed": "1present address centro regional de hemodonacion servicio de hematologia hospital clinico universitario ronda de garay sn murcia 30003 spain 2present address centre genome research university edinburgh king ’ buildings west mains road edinburgh eh9 3jq uk 3corresponding author mll gene human chromosome 11q23"
  },
  {
    "id": 3,
    "paragraph": "involved in >30 different chromosomal translocations resulting in a plethora of different MLL fusion proteins. Each of these tends to associate with a speciﬁc leuk- aemia type, for example, MLL–AF9 is found mainly in acute myeloid leukaemia. We have studied the role",
    "jurnal": "003564.pdf",
    "processed": "involved 30 different chromosomal translocations resulting plethora different mll fusion proteins tends associate speciﬁc leuk aemia type example mll–af9 found mainly acute myeloid leukaemia studied role"
  },
  {
    "id": 4,
    "paragraph": "of the Mll–AF9 gene fusion made in mouse embryonic stem cells by an homologous recombination knock- in. Acute leukaemias developed in heterozygous mice carrying this fusion as well as in chimeric mice. As with human chromosomal translocation t(9;11), the majority of cases were acute myeloid leukaemias",
    "jurnal": "003564.pdf",
    "processed": "mll–af9 gene fusion made mouse embryonic stem cells homologous recombination knock acute leukaemias developed heterozygous mice carrying fusion well chimeric mice human chromosomal translocation t911 majority cases acute myeloid leukaemias"
  },
  {
    "id": 5,
    "paragraph": "involving immature myeloblasts, but a (AMLs) minority were acute lymphoblastic leukaemia. The AMLs were preceded by effects on haematopoietic differentiation involving a myeloproliferation resulting in accumulation of Mac-1/Gr-1 double-positive mature myeloid cells in bone marrow as early as 6 days after",
    "jurnal": "003564.pdf",
    "processed": "involving immature myeloblasts amls minority acute lymphoblastic leukaemia amls preceded effects haematopoietic differentiation involving myeloproliferation resulting accumulation mac1gr1 doublepositive mature myeloid cells bone marrow early 6 days"
  },
  {
    "id": 6,
    "paragraph": "birth. Therefore, non-malignant expansion of myeloid precursors is the ﬁrst stage of Mll–AF9-mediated leuk- aemia followed by accumulation of malignant cells in bone marrow and other tissues. Thus, the late onset of overt tumours suggests that secondary tumorigenic mutations are necessary for malignancy associated with",
    "jurnal": "003564.pdf",
    "processed": "birth therefore nonmalignant expansion myeloid precursors ﬁrst stage mll–af9mediated leuk aemia followed accumulation malignant cells bone marrow tissues thus late onset overt tumours suggests secondary tumorigenic mutations necessary malignancy associated"
  },
  {
    "id": 7,
    "paragraph": "MLL–AF9 gene fusion and that myeloproliferation provides the pool of cells in which such events can occur. Keywords: ALL-1/chromosomal translocations/ haematopoiesis/HRX/leukaemia Introduction Chromosomal translocations are present in many tumours and are involved in the development of the tumours which carry them (Rabbitts, 1994; Look, 1997). The cloning of",
    "jurnal": "003564.pdf",
    "processed": "mll–af9 gene fusion myeloproliferation provides pool cells events occur keywords all1chromosomal translocations haematopoiesishrxleukaemia introduction chromosomal translocations present many tumours involved development tumours carry rabbitts 1994 look 1997 cloning"
  },
  {
    "id": 8,
    "paragraph": "translocation the genes involved in the chromosomal breakpoints in leukaemias and solid tumours of mesen- chymal origin, have shown that a major molecular con- sequence of these aberrant chromosomes is creation of fusion genes, and therefore of fusion proteins, when the",
    "jurnal": "003564.pdf",
    "processed": "translocation genes involved chromosomal breakpoints leukaemias solid tumours mesen chymal origin shown major molecular con sequence aberrant chromosomes creation fusion genes therefore fusion proteins"
  },
  {
    "id": 9,
    "paragraph": "breaks occur between exons of genes on each chromosome. This was ﬁrst recognized for the fusion of BCR and ABL genes resulting from the Philadelphia chromosome (Nowell and Hungerford, 1960; Rowley, 1973; de Klein et al., 1982; Bartram et al., 1983; Groffen et al., 1984).",
    "jurnal": "003564.pdf",
    "processed": "breaks occur exons genes chromosome ﬁrst recognized fusion bcr abl genes resulting philadelphia chromosome nowell hungerford 1960 rowley 1973 de klein et al 1982 bartram et al 1983 groffen et al 1984"
  },
  {
    "id": 10,
    "paragraph": "Molecular studies of these chromosomal breakpoints demonstrated that two forms of the BCR–ABL fusion gene result from distinct chromosomal breakage within the BCR gene, linking it to the same coding part of the ABL gene (Bartram et al., 1983; de Klein et al., 1986). More recently,",
    "jurnal": "003564.pdf",
    "processed": "molecular studies chromosomal breakpoints demonstrated two forms bcr–abl fusion gene result distinct chromosomal breakage within bcr gene linking coding part abl gene bartram et al 1983 de klein et al 1986 recently"
  },
  {
    "id": 11,
    "paragraph": "complex situations have been described in subsets of leukaemias with breaks in chromosome 11, band q23 within the MLL/HRX/ALL-1 gene (Ziemin-van der Poel et al., 1991; Djabali et al., 1992; Gu et al., 1992; McCabe et al., 1992; Tkachuk et al., 1992; Domer et al., 1993)",
    "jurnal": "003564.pdf",
    "processed": "complex situations described subsets leukaemias breaks chromosome 11 band q23 within mllhrxall1 gene zieminvan der poel et al 1991 djabali et al 1992 gu et al 1992 mccabe et al 1992 tkachuk et al 1992 domer et al 1993"
  },
  {
    "id": 12,
    "paragraph": "and in sarcomas such as those with breaks within the EWS and FUS/TLS genes (Delattre et al., 1992; Crozat et al., 1993; Rabbitts et al., 1993; Aman et al., 1996; Panagopoulos et al., 1996). Under these circumstances, the respective genes become involved with a multitude of",
    "jurnal": "003564.pdf",
    "processed": "sarcomas breaks within ews fustls genes delattre et al 1992 crozat et al 1993 rabbitts et al 1993 aman et al 1996 panagopoulos et al 1996 circumstances respective genes become involved multitude"
  },
  {
    "id": 13,
    "paragraph": "different chromosomal translocations which are predomin- antly associated with a particular sub-type of leukaemia or sarcoma. Furthermore, the FUS gene has a role in translocations in both sarcomas and in acute myeloid leukaemia (Ichikawa et al., 1994; Panagopoulos et al., 1994) depending on the cell type or on the fusion partner.",
    "jurnal": "003564.pdf",
    "processed": "different chromosomal translocations predomin antly associated particular subtype leukaemia sarcoma furthermore fus gene role translocations sarcomas acute myeloid leukaemia ichikawa et al 1994 panagopoulos et al 1994 depending cell type fusion partner"
  },
  {
    "id": 14,
    "paragraph": "These observations raise issues about possible roles of the fusion genes in tumour type, particularly the role the fusion partner might play in the speciﬁcity of the tumour phenotype. The chromosome 11 region q23 is involved in ~10% of acute myeloid leukaemias (AMLs) and acute lympho-",
    "jurnal": "003564.pdf",
    "processed": "observations raise issues possible roles fusion genes tumour type particularly role fusion partner might play speciﬁcity tumour phenotype chromosome 11 region q23 involved 10 acute myeloid leukaemias amls acute lympho"
  },
  {
    "id": 15,
    "paragraph": "blastic leukaemias (ALLs), as well as in mixed lineage leukaemias and in some lymphomas. In addition, balanced chromosome 11q23 translocations are also observed in therapy-related leukaemias, especially in patients pre- viously treated with inhibitors of topoisomerase II (Ratain et al., 1987; Pui et al., 1989; Cimino et al., 1997; Nasr",
    "jurnal": "003564.pdf",
    "processed": "blastic leukaemias alls well mixed lineage leukaemias lymphomas addition balanced chromosome 11q23 translocations also observed therapyrelated leukaemias especially patients pre viously treated inhibitors topoisomerase ii ratain et al 1987 pui et al 1989 cimino et al 1997 nasr"
  },
  {
    "id": 16,
    "paragraph": "et al., 1997; Rowley et al., 1997; Sobulo et al., 1997; Atlas et al., 1998; Felix, 1998). The cloning of the chromosome 11q23 breakpoint region (Ziemin-van der Poel et al., 1991) revealed the MLL/HRX/ALL-1 gene (Djabali et al., 1992; Gu et al., 1992; McCabe et al.,",
    "jurnal": "003564.pdf",
    "processed": "et al 1997 rowley et al 1997 sobulo et al 1997 atlas et al 1998 felix 1998 cloning chromosome 11q23 breakpoint region zieminvan der poel et al 1991 revealed mllhrxall1 gene djabali et al 1992 gu et al 1992 mccabe et al"
  },
  {
    "id": 17,
    "paragraph": "1992; Tkachuk et al., 1992; Domer et al., 1993) (herein designated the MLL gene), which encodes a 432 kDa protein with several regions of structural homology to other proteins, for instance to Drosophila trithorax (Mazo et al., 1990; Djabali et al., 1992; Gu et al., 1992; Tkachuk",
    "jurnal": "003564.pdf",
    "processed": "1992 tkachuk et al 1992 domer et al 1993 herein designated mll gene encodes 432 kda protein several regions structural homology proteins instance drosophila trithorax mazo et al 1990 djabali et al 1992 gu et al 1992 tkachuk"
  },
  {
    "id": 18,
    "paragraph": "et al., 1992). More than 30 different chromosomal bands translocations with have been found in chromosomal chromosome 11q23, and molecular showed rearrangements with the MLL gene in all cases (reviewed in Rowley, 1993; Thirman et al., 1993; Bernard and Berger, 1995; Rubnitz et al., 1996b; Gilliland, 1998).",
    "jurnal": "003564.pdf",
    "processed": "et al 1992 30 different chromosomal bands translocations found chromosomal chromosome 11q23 molecular showed rearrangements mll gene cases reviewed rowley 1993 thirman et al 1993 bernard berger 1995 rubnitz et al 1996b gilliland 1998"
  },
  {
    "id": 19,
    "paragraph": "Among the most common reciprocal translocations are studies 3564 © European Molecular Biology Organization t(4;11)(q21;q23), t(9;11)(p22;q23) and t(11;19)(p13;q23). These fuse MLL with AF4/FEL, AF9/LTG9 and ENL/ LTG19 genes, respectively (Gu et al., 1992; Tkachuk et al., 1992; Chen et al., 1993; Iida et al., 1993; Morrissey",
    "jurnal": "003564.pdf",
    "processed": "among common reciprocal translocations studies 3564 © european molecular biology organization t411q21q23 t911p22q23 t1119p13q23 fuse mll af4fel af9ltg9 enl ltg19 genes respectively gu et al 1992 tkachuk et al 1992 chen et al 1993 iida et al 1993 morrissey"
  },
  {
    "id": 20,
    "paragraph": "et al., 1993; Nakamura et al., 1993; Yamamoto et al., 1993). There is a strong correlation between the leukaemia phenotype and each of these speciﬁc MLL translocation fusions (Corral et al., 1993; Thirman et al., 1993). The translocation t(9;11)(p22;q23) is mainly associated with",
    "jurnal": "003564.pdf",
    "processed": "et al 1993 nakamura et al 1993 yamamoto et al 1993 strong correlation leukaemia phenotype speciﬁc mll translocation fusions corral et al 1993 thirman et al 1993 translocation t911p22q23 mainly associated"
  },
  {
    "id": 21,
    "paragraph": "AMLs (Iida et al., 1993; Nakamura et al., 1993) while the translocation t(4;11)(q21;q23) is found predominantly in ALLs (Gu et al., 1992; Domer et al., 1993; Iida et al., 1993; Morrissey et al., 1993; Nakamura et al., 1993; Downing et al., 1994). The t(11;19)(p13;q23) translocation",
    "jurnal": "003564.pdf",
    "processed": "amls iida et al 1993 nakamura et al 1993 translocation t411q21q23 found predominantly alls gu et al 1992 domer et al 1993 iida et al 1993 morrissey et al 1993 nakamura et al 1993 downing et al 1994 t1119p13q23 translocation"
  },
  {
    "id": 22,
    "paragraph": "on the other hand occurs in both ALL and AML but with higher frequency in ALL (Nakamura et al., 1993; Yamamoto et al., 1993; Rubnitz et al., 1996a). These ﬁndings suggest that the incoming fusion partner of MLL helps to specify the cell type of the tumour. Thus, the",
    "jurnal": "003564.pdf",
    "processed": "hand occurs aml higher frequency nakamura et al 1993 yamamoto et al 1993 rubnitz et al 1996a ﬁndings suggest incoming fusion partner mll helps specify cell type tumour thus"
  },
  {
    "id": 23,
    "paragraph": "fusion protein itself may inﬂuence tumour type if the chromosomal translocation occurs in a pluripotent pre- cursor cell. It is nonetheless possible that the chromosomal translocation may occur in a committed precursor because the chromosomal region is accessible for the chromosomal",
    "jurnal": "003564.pdf",
    "processed": "fusion protein may inﬂuence tumour type chromosomal translocation occurs pluripotent pre cursor cell nonetheless possible chromosomal translocation may occur committed precursor chromosomal region accessible chromosomal"
  },
  {
    "id": 24,
    "paragraph": "translocation event, in which case the protein fusion would not strictly specify tumour type. Several biological models have been established to gain insights into the role of the MLL fusions in tumorigenesis. The use of retroviruses encoding the MLL/HRX–ENL fusion to infect primitive",
    "jurnal": "003564.pdf",
    "processed": "translocation event case protein fusion would strictly specify tumour type several biological models established gain insights role mll fusions tumorigenesis use retroviruses encoding mllhrx–enl fusion infect primitive"
  },
  {
    "id": 25,
    "paragraph": "cells showed that myeloid cell proliferation could be observed and that tumours of this lineage emerged (Lavau et al., 1997; Slany et al., 1997). These experiments suggest that a gain-of-function mechanism at least partly explains the role of this fusion protein which is made after the",
    "jurnal": "003564.pdf",
    "processed": "cells showed myeloid cell proliferation could observed tumours lineage emerged lavau et al 1997 slany et al 1997 experiments suggest gainoffunction mechanism least partly explains role fusion protein made"
  },
  {
    "id": 26,
    "paragraph": "chromosomal translocation t(11;19) in humans. The fusion of the AF9 gene with the Mll gene also resulted in the emergence of AML in mice (Corral et al., 1996). In the present study we show that an Mll–AF9 gene fusion [made in embryonic stem (ES) cells by homologous",
    "jurnal": "003564.pdf",
    "processed": "chromosomal translocation t1119 humans fusion af9 gene mll gene also resulted emergence aml mice corral et al 1996 present study show mll–af9 gene fusion made embryonic stem es cells homologous"
  },
  {
    "id": 27,
    "paragraph": "recombination] carried in the mouse germline contributes to AML. In both chimeras and heterozygous mice, the majority of mice developed AML and a small percentage developed ALL. The features of this disease reﬂect those of the disease which develops in humans carrying the",
    "jurnal": "003564.pdf",
    "processed": "recombination carried mouse germline contributes aml chimeras heterozygous mice majority mice developed aml small percentage developed features disease reﬂect disease develops humans carrying"
  },
  {
    "id": 28,
    "paragraph": "MLL–AF9 translocation. Furthermore, a selective prolifer- ation of Gr-1-positive myeloid bone marrow cells was observed in heterozygous animals before the symptoms of leukaemia occurred. The propensity for myeloid tumour formation therefore seems to be a consequence of the advantageous growth of myeloid precursors caused by the",
    "jurnal": "003564.pdf",
    "processed": "mll–af9 translocation furthermore selective prolifer ation gr1positive myeloid bone marrow cells observed heterozygous animals symptoms leukaemia occurred propensity myeloid tumour formation therefore seems consequence advantageous growth myeloid precursors caused"
  },
  {
    "id": 29,
    "paragraph": "Mll–AF9 fusion, thereby providing a pool of cells in which secondary mutations, necessary for overt tumour development, can occur. Results Mll–AF9 mice develop acute leukaemia An Mll–AF9 fusion gene was created in mouse ES cells, by knock-in homologous recombination (Corral et al.,",
    "jurnal": "003564.pdf",
    "processed": "mll–af9 fusion thereby providing pool cells secondary mutations necessary overt tumour development occur results mll–af9 mice develop acute leukaemia mll–af9 fusion gene created mouse es cells knockin homologous recombination corral et al"
  },
  {
    "id": 30,
    "paragraph": "1996), in which an AF9 cDNA was fused into exon 8 of one allele of the endogenous Mll gene (a diagram of the targeted allele is shown in Figure 1A). These ES cells were injected into C57Bl/6 blastocysts and chimeric mice",
    "jurnal": "003564.pdf",
    "processed": "1996 af9 cdna fused exon 8 one allele endogenous mll gene diagram targeted allele shown figure 1a es cells injected c57bl6 blastocysts chimeric mice"
  },
  {
    "id": 31,
    "paragraph": "Mll–AF9 fusion causes myeloproliferation Fig. 1. Germ-line transmission of the Mll–AF9 targeted allele in mice. (A) A diagrammatic map of the Mll–AF9 targeted allele is shown (Corral et al., 1996). The human AF9 cDNA sequences were fused at exon 8 of Mll and MC1-neo-poly(A) cassette (Thomas and Capecchi,",
    "jurnal": "003564.pdf",
    "processed": "mll–af9 fusion causes myeloproliferation fig 1 germline transmission mll–af9 targeted allele mice diagrammatic map mll–af9 targeted allele shown corral et al 1996 human af9 cdna sequences fused exon 8 mll mc1neopolya cassette thomas capecchi"
  },
  {
    "id": 32,
    "paragraph": "1987) was cloned into the targeting vector as a positive selection marker. The restriction fragments corresponding to the wild-type Mll and the targeted Mll–AF9 genes are 10 and 13 kb BglII fragments, respectively. The probe used to detect homologous recombination events [1.5RXT2 (Corral et al., 1996)] is indicated. (B) Filter",
    "jurnal": "003564.pdf",
    "processed": "1987 cloned targeting vector positive selection marker restriction fragments corresponding wildtype mll targeted mll–af9 genes 10 13 kb bglii fragments respectively probe used detect homologous recombination events 15rxt2 corral et al 1996 indicated b filter"
  },
  {
    "id": 33,
    "paragraph": "hybridization of tail biopsy DNA. Lanes a–j show hybridization of DNA extracted from a litter of Mll–AF9 mice produced by crossing a male chimera with a wild-type mouse. The DNA was digested with BglII and hybridized with the EcoRI–XhoI fragment from clone",
    "jurnal": "003564.pdf",
    "processed": "hybridization tail biopsy dna lanes a–j show hybridization dna extracted litter mll–af9 mice produced crossing male chimera wildtype mouse dna digested bglii hybridized ecori–xhoi fragment clone"
  },
  {
    "id": 34,
    "paragraph": "p1.5RXT2. Two heterozygous carrier mice were present. 129 DNA corresponds to a 129 mouse liver and B1-89 represents DNA from the original Mll–AF9 targeted ES clone. Germline and targeted alleles are indicated. were produced which developed haematopoietic tumours, mainly AML, after 6 months (Corral et al., 1996). Germ-",
    "jurnal": "003564.pdf",
    "processed": "p15rxt2 two heterozygous carrier mice present 129 dna corresponds 129 mouse liver b189 represents dna original mll–af9 targeted es clone germline targeted alleles indicated produced developed haematopoietic tumours mainly aml 6 months corral et al 1996 germ"
  },
  {
    "id": 35,
    "paragraph": "line transmission of this Mll–AF9 fusion gene was obtained by crossing chimeras with wild-type females. Hetero- zygotes obtained from these crosses were identiﬁed by ﬁlter hybridization of somatic DNA using an internal probe from the targeting region (1.5RXT2 probe, Figure 1A). The probe detects a 10 kb germ-line Mll band and a",
    "jurnal": "003564.pdf",
    "processed": "line transmission mll–af9 fusion gene obtained crossing chimeras wildtype females hetero zygotes obtained crosses identiﬁed ﬁlter hybridization somatic dna using internal probe targeting region 15rxt2 probe figure 1a probe detects 10 kb germline mll band"
  },
  {
    "id": 36,
    "paragraph": "13 kb band corresponding to the homologous recombin- ation fusion gene (Figure 1B shows the hybridization of DNA from one litter, designated a–j, compared with 129 liver DNA and DNA from an initial targeted ES clone B1-89). No homozygous Mll–AF9 mice were found in",
    "jurnal": "003564.pdf",
    "processed": "13 kb band corresponding homologous recombin ation fusion gene figure 1b shows hybridization dna one litter designated a–j compared 129 liver dna dna initial targeted es clone b189 homozygous mll–af9 mice found"
  },
  {
    "id": 37,
    "paragraph": "any litter from a heterozygous cross (41 pups from four litters were analysed), indicating embryonic lethality of the knock-in gene as reported for the Mll null mutant mice (Yu et al., 1995). Our previous report on the Mll–AF9 fusion gene expressed in chimeric mice showed that most animals",
    "jurnal": "003564.pdf",
    "processed": "litter heterozygous cross 41 pups four litters analysed indicating embryonic lethality knockin gene reported mll null mutant mice yu et al 1995 previous report mll–af9 fusion gene expressed chimeric mice showed animals"
  },
  {
    "id": 38,
    "paragraph": "succumbed to acute leukaemia within one year (Corral et al., 1996). Whilst many of these were diagnosed as myeloid, a complete analysis was not performed in all cases. A detailed investigation of the leukaemias in Mll– AF9 heterozygous and chimeric mice has now been",
    "jurnal": "003564.pdf",
    "processed": "succumbed acute leukaemia within one year corral et al 1996 whilst many diagnosed myeloid complete analysis performed cases detailed investigation leukaemias mll– af9 heterozygous chimeric mice"
  },
  {
    "id": 39,
    "paragraph": "undertaken to deﬁne more precisely the type of malignancy and to address issues relating to the mode of onset of overt malignancy. Cohorts of Mll–AF9 mice were com- pared with mice which had been made with an epitope tag fused (this line of mice has been designated Mll–myc;",
    "jurnal": "003564.pdf",
    "processed": "undertaken deﬁne precisely type malignancy address issues relating mode onset overt malignancy cohorts mll–af9 mice com pared mice made epitope tag fused line mice designated mll–myc"
  },
  {
    "id": 40,
    "paragraph": "Corral et al., 1996) at the same Mll exon 8 position at 3565 C.L.Dobson et al. Fig. 2. Acute leukaemia occurrence in Mll–AF9 mice. The rate of leukaemia occurrence (age in months of detection of disease versus number of mice with disease) in Mll–AF9 chimeric and heterozygous",
    "jurnal": "003564.pdf",
    "processed": "corral et al 1996 mll exon 8 position 3565 cldobson et al fig 2 acute leukaemia occurrence mll–af9 mice rate leukaemia occurrence age months detection disease versus number mice disease mll–af9 chimeric heterozygous"
  },
  {
    "id": 41,
    "paragraph": "mice. Diagnosis of leukaemia was obtained by histological analysis of bone marrow, spleen, thymus and liver, and in most cases by FACS analysis of cell surface marker expression. AML developed in 21 out of 28 heterozygous Mll–AF9 mice (circles), in 22 out of 24 Mll–AF9",
    "jurnal": "003564.pdf",
    "processed": "mice diagnosis leukaemia obtained histological analysis bone marrow spleen thymus liver cases facs analysis cell surface marker expression aml developed 21 28 heterozygous mll–af9 mice circles 22 24 mll–af9"
  },
  {
    "id": 42,
    "paragraph": "chimeras (squares) and ALL developed in two out of 24 Mll–AF9 chimeras (diamonds). No Mll–myc heterozygous mice developed a malignancy in the 18 month period of this experiment (four tumours were detected in the cohort of 27 Mll–myc mice but these occurred at",
    "jurnal": "003564.pdf",
    "processed": "chimeras squares developed two 24 mll–af9 chimeras diamonds mll–myc heterozygous mice developed malignancy 18 month period experiment four tumours detected cohort 27 mll–myc mice occurred"
  },
  {
    "id": 43,
    "paragraph": "28, 29, 32 and 32 months). which the AF9 sequences were fused. These groups were analysed over a period of 18 months, and during this time both the Mll–AF9 chimeras and heterozygotes began to show signs of distress. No disease was observed in Mll–",
    "jurnal": "003564.pdf",
    "processed": "28 29 32 32 months af9 sequences fused groups analysed period 18 months time mll–af9 chimeras heterozygotes began show signs distress disease observed mll–"
  },
  {
    "id": 44,
    "paragraph": "myc mice within the 18 month experimental period (there were 27 Mll–myc mice in the control group; four developed AML tumours but these occurred after two years sug- gesting that they were of sporadic origin rather than due to the manipulation of the Mll gene).",
    "jurnal": "003564.pdf",
    "processed": "myc mice within 18 month experimental period 27 mll–myc mice control group four developed aml tumours occurred two years sug gesting sporadic origin rather due manipulation mll gene"
  },
  {
    "id": 45,
    "paragraph": "Post-mortem examination of Mll–AF9 mice showed consistent evidence of haematological disease. Signs included pale femurs, splenomegaly, heptomegaly and pale kidneys. All the mice analysed were diagnosed as having acute leukaemias and no tumours of other tissues were observed, despite widespread activity of the Mll",
    "jurnal": "003564.pdf",
    "processed": "postmortem examination mll–af9 mice showed consistent evidence haematological disease signs included pale femurs splenomegaly heptomegaly pale kidneys mice analysed diagnosed acute leukaemias tumours tissues observed despite widespread activity mll"
  },
  {
    "id": 46,
    "paragraph": "promoter (Yu et al., 1995; Corral et al., 1996). The development of these acute leukaemias is shown in Figure 2. The disease was classiﬁed as predominantly AML with rare examples of ALL, mirroring the spectrum and ratio of acute leukaemias found in humans with the",
    "jurnal": "003564.pdf",
    "processed": "promoter yu et al 1995 corral et al 1996 development acute leukaemias shown figure 2 disease classiﬁed predominantly aml rare examples mirroring spectrum ratio acute leukaemias found humans"
  },
  {
    "id": 47,
    "paragraph": "chromosomal translocation t(9;11). The rate of develop- ment of AML was overall slightly faster in heterozygous animals compared with the chimeras (Figure 2), the point at which 50% of each cohort had succumbed to AML being 5 and 7 months for heterozygotes and chimeras,",
    "jurnal": "003564.pdf",
    "processed": "chromosomal translocation t911 rate develop ment aml overall slightly faster heterozygous animals compared chimeras figure 2 point 50 cohort succumbed aml 5 7 months heterozygotes chimeras"
  },
  {
    "id": 48,
    "paragraph": "respectively. Twenty-two of the 24 chimeras and 21 of the 28 heterozygous Mll–AF9 mice developed AML in the 18 month period. Two Mll–AF9 chimeras developed ALL rather than AML. Acute myeloid and lymphoblastic leukaemia in Mll–AF9 mice Almost all Mll–AF9 heterozygous and chimeric mice",
    "jurnal": "003564.pdf",
    "processed": "respectively twentytwo 24 chimeras 21 28 heterozygous mll–af9 mice developed aml 18 month period two mll–af9 chimeras developed rather aml acute myeloid lymphoblastic leukaemia mll–af9 mice almost mll–af9 heterozygous chimeric mice"
  },
  {
    "id": 49,
    "paragraph": "developed malignancy within one and a half years. 3566 Detailed tissue histology was carried out on mice as pathological signs of disease developed, to classify the types of leukaemia present and to establish a diagnosis of disease. This analysis conﬁrmed the presence of acute",
    "jurnal": "003564.pdf",
    "processed": "developed malignancy within one half years 3566 detailed tissue histology carried mice pathological signs disease developed classify types leukaemia present establish diagnosis disease analysis conﬁrmed presence acute"
  },
  {
    "id": 50,
    "paragraph": "leukaemias in all the mice with symptoms and showed the occurrence of either myeloid or lymphoid malignancies. Marked inﬁltration of leukaemic cells was seen in the bone marrow, peripheral blood and liver of Mll–AF9 mice. Figure 3 shows a comparison of the histology of tissues",
    "jurnal": "003564.pdf",
    "processed": "leukaemias mice symptoms showed occurrence either myeloid lymphoid malignancies marked inﬁltration leukaemic cells seen bone marrow peripheral blood liver mll–af9 mice figure 3 shows comparison histology tissues"
  },
  {
    "id": 51,
    "paragraph": "from an Mll–myc mouse (Figure 3A) with those from Mll–AF9 mice. The AML was observed in two different forms, overt myeloid leukaemia and extramedullary leuk- aemia. Mice exhibiting overt myeloid leukaemia were distinguished by (cid:249)30% of nucleated cells in the bone",
    "jurnal": "003564.pdf",
    "processed": "mll–myc mouse figure 3a mll–af9 mice aml observed two different forms overt myeloid leukaemia extramedullary leuk aemia mice exhibiting overt myeloid leukaemia distinguished cid24930 nucleated cells bone"
  },
  {
    "id": 52,
    "paragraph": "marrow being blasts. Heavy inﬁltration of the peripheral blood with myeloblasts was observed in these mice (either chimeras or heterozygotes). The myeloblasts were charac- terized by their large, granular appearance and were frequently observed in the liver (Figure 3B shows histology",
    "jurnal": "003564.pdf",
    "processed": "marrow blasts heavy inﬁltration peripheral blood myeloblasts observed mice either chimeras heterozygotes myeloblasts charac terized large granular appearance frequently observed liver figure 3b shows histology"
  },
  {
    "id": 53,
    "paragraph": "from a heterozygous mouse and Figure 3C shows histology from a chimeric mouse, both with AML). Other tissues were also involved at this stage, for instance kidney. The alternative form of myeloid disease was extramedullary leukaemia (Figure 3D), in which extensive extramedullary",
    "jurnal": "003564.pdf",
    "processed": "heterozygous mouse figure 3c shows histology chimeric mouse aml tissues also involved stage instance kidney alternative form myeloid disease extramedullary leukaemia figure 3d extensive extramedullary"
  },
  {
    "id": 54,
    "paragraph": "inﬁltration of myeloblasts was found in the liver, with peri-vascular deposits of malignant cells. In the example shown (histology from a chimeric mouse), the bone marrow shows signiﬁcantly (cid:44)30% inﬁltration with myelo- blasts. Similarly, few abnormal cells were observed in the peripheral blood in the extramedullary stage of the",
    "jurnal": "003564.pdf",
    "processed": "inﬁltration myeloblasts found liver perivascular deposits malignant cells example shown histology chimeric mouse bone marrow shows signiﬁcantly cid4430 inﬁltration myelo blasts similarly abnormal cells observed peripheral blood extramedullary stage"
  },
  {
    "id": 55,
    "paragraph": "malignancy. Detailed analysis of tissue histology in the Mll–AF9 mice (one example is shown in Figure 3E) indicated that two ALLs arose. In these mice the bone marrow samples were hypercellular, with normal haematopoiesis sup- pressed, and (cid:46)90% of the mononuclear cells were lympho-",
    "jurnal": "003564.pdf",
    "processed": "malignancy detailed analysis tissue histology mll–af9 mice one example shown figure 3e indicated two alls arose mice bone marrow samples hypercellular normal haematopoiesis sup pressed cid4690 mononuclear cells lympho"
  },
  {
    "id": 56,
    "paragraph": "blasts with many active mitoses seen. An enlarged thymus was evident in these mice in addition to a pale femur, enlarged, pale spleen and pale kidneys. Extra-medullary haematopoiesis was evident in the liver which showed the characteristic peri-vascular accumulation of leukaemic",
    "jurnal": "003564.pdf",
    "processed": "blasts many active mitoses seen enlarged thymus evident mice addition pale femur enlarged pale spleen pale kidneys extramedullary haematopoiesis evident liver showed characteristic perivascular accumulation leukaemic"
  },
  {
    "id": 57,
    "paragraph": "cells. The circulating blood of the mouse shown is packed with lymphoblasts. In addition, the peripheral blood ﬁlm indicates that this mouse was also suffering from anaemia. Immunoglobulin gene rearrangement analysis showed that both of the ALLs were of B cell origin. Filter",
    "jurnal": "003564.pdf",
    "processed": "cells circulating blood mouse shown packed lymphoblasts addition peripheral blood ﬁlm indicates mouse also suffering anaemia immunoglobulin gene rearrangement analysis showed alls b cell origin filter"
  },
  {
    "id": 58,
    "paragraph": "hybridization was carried out with an immunoglobulin heavy chain probe and spleen cell DNA of the two ALL- bearing mice compared with a myeloma cell line (J558) and a T cell line (BW) and kidney DNA from C57Bl/6 and 129 mice (Figure 4A). The probe detects a 6.5 kb",
    "jurnal": "003564.pdf",
    "processed": "hybridization carried immunoglobulin heavy chain probe spleen cell dna two bearing mice compared myeloma cell line j558 cell line bw kidney dna c57bl6 129 mice figure 4a probe detects 65 kb"
  },
  {
    "id": 59,
    "paragraph": "EcoRI germ-line band in the kidney DNA samples and the BW (T cell) DNA, but detects two rearranged bands in the myeloma (B cell) DNA representing heavy-chain gene rearrangements. DNA from both of the Mll–AF9 tumours similarly had two distinct rearranged bands",
    "jurnal": "003564.pdf",
    "processed": "ecori germline band kidney dna samples bw cell dna detects two rearranged bands myeloma b cell dna representing heavychain gene rearrangements dna mll–af9 tumours similarly two distinct rearranged bands"
  },
  {
    "id": 60,
    "paragraph": "together with faint germ-line bands, indicative of clonal B cell tumours in these mice. Rearrangement of T cell receptor b -chain genes was also investigated with Jb 2 and Cb 1 probes, but no rearrangements were found in the tumour DNA from either ALL mouse (data not shown).",
    "jurnal": "003564.pdf",
    "processed": "together faint germline bands indicative clonal b cell tumours mice rearrangement cell receptor b chain genes also investigated jb 2 cb 1 probes rearrangements found tumour dna either mouse data shown"
  },
  {
    "id": 61,
    "paragraph": "FACS analysis of bone marrow cells from mouse 1 Mll–AF9 fusion causes myeloproliferation Fig. 3. Histology of leukaemias arising in Mll–AF9 mice. Histology was carried out on tissues from all mice with symptoms of disease. Tissues were dissected and ﬁxed in 10% formalin. Sections were prepared from wax-embedded specimens and stained with haematoxylin and eosin (H&E).",
    "jurnal": "003564.pdf",
    "processed": "facs analysis bone marrow cells mouse 1 mll–af9 fusion causes myeloproliferation fig 3 histology leukaemias arising mll–af9 mice histology carried tissues mice symptoms disease tissues dissected ﬁxed 10 formalin sections prepared waxembedded specimens stained haematoxylin eosin"
  },
  {
    "id": 62,
    "paragraph": "Blood ﬁlms were stained with May–Gru¨nwald–Giemsa (MGG). Representative examples of histology are shown. (A) Mll–myc mouse 2021 (age 24 months): this mouse had no symptoms of disease and serves as a control. (B) Mll–AF9 heterozygous mouse 4134 (age 6 months) with overt",
    "jurnal": "003564.pdf",
    "processed": "blood ﬁlms stained may–gru¨nwald–giemsa mgg representative examples histology shown mll–myc mouse 2021 age 24 months mouse symptoms disease serves control b mll–af9 heterozygous mouse 4134 age 6 months overt"
  },
  {
    "id": 63,
    "paragraph": "AML. In this example, the bone marrow is extensively inﬁltrated with myeloblasts and the liver has signiﬁcant deposits. The peripheral blood has many circulating myeloblasts. (C) Mll–AF9 chimera 4039 (age 7 months) with overt AML similar to heterozygous mouse 4134. (D) Mll–AF9",
    "jurnal": "003564.pdf",
    "processed": "aml example bone marrow extensively inﬁltrated myeloblasts liver signiﬁcant deposits peripheral blood many circulating myeloblasts c mll–af9 chimera 4039 age 7 months overt aml similar heterozygous mouse 4134 mll–af9"
  },
  {
    "id": 64,
    "paragraph": "chimera 4019 (age 12 months) showing signs of extramedullary leukaemia with myeloblast deposits in the liver but normal bone marrow pattern. (E) Mll–AF9 chimera 4005 (age 12 months). This mouse has ALL, with lymphoblasts in the bone marrow and peripheral blood. The liver has",
    "jurnal": "003564.pdf",
    "processed": "chimera 4019 age 12 months showing signs extramedullary leukaemia myeloblast deposits liver normal bone marrow pattern e mll–af9 chimera 4005 age 12 months mouse lymphoblasts bone marrow peripheral blood liver"
  },
  {
    "id": 65,
    "paragraph": "signiﬁcant lymphoblast inﬁltration. 3567 C.L.Dobson et al. Fig. 4. Mll–AF9 mice develop ALL at low frequency. Two Mll–AF9 chimeric mice showed acute leukaemia (ages 11 and 12 months) with cells morphologically identiﬁed as lymphoblasts (see Figure 3E); mouse 1: number 4005, mouse 2: 4020. Bone marrow cells were",
    "jurnal": "003564.pdf",
    "processed": "signiﬁcant lymphoblast inﬁltration 3567 cldobson et al fig 4 mll–af9 mice develop low frequency two mll–af9 chimeric mice showed acute leukaemia ages 11 12 months cells morphologically identiﬁed lymphoblasts see figure 3e mouse 1 number 4005 mouse 2 4020 bone marrow cells"
  },
  {
    "id": 66,
    "paragraph": "examined by gene rearrangement using ﬁlter hybridization (A) and lymphoid surface marker expression (B) to specify the lineage. (A) Filter hybridization. DNA was extracted from the spleen of Mll–AF9 mice, of J558 (myeloma) or BW (T) cells and of C57Bl/6 or",
    "jurnal": "003564.pdf",
    "processed": "examined gene rearrangement using ﬁlter hybridization lymphoid surface marker expression b specify lineage filter hybridization dna extracted spleen mll–af9 mice j558 myeloma bw cells c57bl6"
  },
  {
    "id": 67,
    "paragraph": "129 kidney. DNA was digested with HindIII, separated by gel electrophoresis and transferred to nylon membranes. The membranes were hybridized with a radiolabelled immunoglobulin enhancer probe (Neuberger and Williams, 1986) and the washed ﬁlters autoradio- graphed at –70°C with pre-fogged ﬁlm. (B) FACS analysis of Mll–",
    "jurnal": "003564.pdf",
    "processed": "129 kidney dna digested hindiii separated gel electrophoresis transferred nylon membranes membranes hybridized radiolabelled immunoglobulin enhancer probe neuberger williams 1986 washed ﬁlters autoradio graphed –70°c prefogged ﬁlm b facs analysis mll–"
  },
  {
    "id": 68,
    "paragraph": "AF9 mouse 4005 (mouse 1): bone marrow cells were prepared as single cell suspensions from mouse 4005 or an age-matched wild-type mouse and were stained with ﬂuorescent antibodies recognizing the T cell marker CD4, the B cell marker B220 and the myeloid marker",
    "jurnal": "003564.pdf",
    "processed": "af9 mouse 4005 mouse 1 bone marrow cells prepared single cell suspensions mouse 4005 agematched wildtype mouse stained ﬂuorescent antibodies recognizing cell marker cd4 b cell marker b220 myeloid marker"
  },
  {
    "id": 69,
    "paragraph": "Gr-1. Graphs represent cell number (y-axis) versus ﬂuorescence intensity (x-axis). Similar data were obtained with Mll–AF9 mouse 4020 (mouse 2). No evidence of mixed lineage phenotype was found for either of the ALL tumour-bearing Mll–AF9 mice. conﬁrmed that the tumour was comprised of predominantly",
    "jurnal": "003564.pdf",
    "processed": "gr1 graphs represent cell number yaxis versus ﬂuorescence intensity xaxis similar data obtained mll–af9 mouse 4020 mouse 2 evidence mixed lineage phenotype found either tumourbearing mll–af9 mice conﬁrmed tumour comprised predominantly"
  },
  {
    "id": 70,
    "paragraph": "B220 antigen-expressing B lymphocytes, which are usually found in low numbers in the bone marrow. In contrast, the normal constituents of the bone marrow (Figure 4B) such as Gr-1- or CD4-positive cells are depleted compared with wild-type mouse controls. A similar pattern of surface",
    "jurnal": "003564.pdf",
    "processed": "b220 antigenexpressing b lymphocytes usually found low numbers bone marrow contrast normal constituents bone marrow figure 4b gr1 cd4positive cells depleted compared wildtype mouse controls similar pattern surface"
  },
  {
    "id": 71,
    "paragraph": "marker expression was observed with bone marrow for ALL mouse 2 (data not shown). No evidence of mixed lineage tumours was obtained. Glucose phosphate iso- merase (GPI) analysis (Papaioannou and Johnson, 1993) was performed on spleen samples from the two mice with",
    "jurnal": "003564.pdf",
    "processed": "marker expression observed bone marrow mouse 2 data shown evidence mixed lineage tumours obtained glucose phosphate iso merase gpi analysis papaioannou johnson 1993 performed spleen samples two mice"
  },
  {
    "id": 72,
    "paragraph": "ALL to estimate the contribution originating from the 3568 CCB-derived ES cells, injected into the C57Bl/6 blasto- cysts. Both mice had signiﬁcant CCB ES cell contribution in the spleen (data not shown) suggesting that the lympho- blastic tumours are of ES cell origin.",
    "jurnal": "003564.pdf",
    "processed": "estimate contribution originating 3568 ccbderived es cells injected c57bl6 blasto cysts mice signiﬁcant ccb es cell contribution spleen data shown suggesting lympho blastic tumours es cell origin"
  },
  {
    "id": 73,
    "paragraph": "Myeloproliferation is observed in Mll–AF9 mice prior to leukaemia occurrence The normal function of Mll appears to be related to the embryonic developmental plan by affecting Hox gene expression proﬁles (Yu et al., 1995) and it may also have a speciﬁc role in some aspects of haematopoiesis (Fidanza",
    "jurnal": "003564.pdf",
    "processed": "myeloproliferation observed mll–af9 mice prior leukaemia occurrence normal function mll appears related embryonic developmental plan affecting hox gene expression proﬁles yu et al 1995 may also speciﬁc role aspects haematopoiesis fidanza"
  },
  {
    "id": 74,
    "paragraph": "et al., 1996; Hess et al., 1997). One of several possible roles for the tumour-speciﬁc MLL–AF9 fusion protein is an inﬂuence on the molecular interactions which are important for haematopoietic differentiation, which could thus partly explain the predominant association of the",
    "jurnal": "003564.pdf",
    "processed": "et al 1996 hess et al 1997 one several possible roles tumourspeciﬁc mll–af9 fusion protein inﬂuence molecular interactions important haematopoietic differentiation could thus partly explain predominant association"
  },
  {
    "id": 75,
    "paragraph": "chromosomal translocation t(9;11) with myeloid malig- nancies. A corollary of this is that the lineage from which the majority of tumours arise (i.e. the myeloid lineage) is selectively increased in the heterozygous Mll–AF9 mice. In order to assess this situation, we ﬁrst examined the",
    "jurnal": "003564.pdf",
    "processed": "chromosomal translocation t911 myeloid malig nancies corollary lineage majority tumours arise ie myeloid lineage selectively increased heterozygous mll–af9 mice order assess situation ﬁrst examined"
  },
  {
    "id": 76,
    "paragraph": "surface antigen phenotype of the myeloid tumours. Anti- bodies binding to surface proteins of myeloid cells (Mac-1 and Gr-1), B-lymphocytes (B220) and T lymphocytes (CD3 and CD4) were used to detect antigen expression on spleen and bone marrow cells. On the whole, tumour",
    "jurnal": "003564.pdf",
    "processed": "surface antigen phenotype myeloid tumours anti bodies binding surface proteins myeloid cells mac1 gr1 blymphocytes b220 lymphocytes cd3 cd4 used detect antigen expression spleen bone marrow cells whole tumour"
  },
  {
    "id": 77,
    "paragraph": "cells were found in bone marrow and in spleen, and in mice with AML malignant cells typically expressed Mac-1 and Gr-1 surface markers. Figure 5 shows FACS analysis of the bone marrow and spleen cells from a typical Mll– AF9 heterozygous mouse (mouse number 4299) with",
    "jurnal": "003564.pdf",
    "processed": "cells found bone marrow spleen mice aml malignant cells typically expressed mac1 gr1 surface markers figure 5 shows facs analysis bone marrow spleen cells typical mll– af9 heterozygous mouse mouse number 4299"
  },
  {
    "id": 78,
    "paragraph": "AML. The inﬁltration of Gr-1-positive tumour cells into the spleen population is very marked with the concomitant loss of B220(cid:49) B cells and CD4(cid:49) T cells, compared with splenocytes from a wild-type mouse. In the bone marrow there was also a striking difference between AML-bearing",
    "jurnal": "003564.pdf",
    "processed": "aml inﬁltration gr1positive tumour cells spleen population marked concomitant loss b220cid49 b cells cd4cid49 cells compared splenocytes wildtype mouse bone marrow also striking difference amlbearing"
  },
  {
    "id": 79,
    "paragraph": "mice and wild-type mice. In the latter, there are usually ~50% Gr-1(cid:49) cells exhibiting a narrow ﬂuoresence proﬁle corresponding to mature myeloid cells, the ﬂuorescence proﬁle of the Mll–AF9 mouse had a broad appearance consistent with there being mainly immature myeloid cells",
    "jurnal": "003564.pdf",
    "processed": "mice wildtype mice latter usually 50 gr1cid49 cells exhibiting narrow ﬂuoresence proﬁle corresponding mature myeloid cells ﬂuorescence proﬁle mll–af9 mouse broad appearance consistent mainly immature myeloid cells"
  },
  {
    "id": 80,
    "paragraph": "(Figure 5). A small population of B220(cid:49) bone marrow cells found in the wild-type mouse was absent from the Mll–AF9 mouse. The examination of the Gr-1(cid:49)/Mac-1(cid:49) population in young heterozygous Mll–AF9 mice was used as a basis for determining whether a pre-leukaemic effect on myeloid",
    "jurnal": "003564.pdf",
    "processed": "figure 5 small population b220cid49 bone marrow cells found wildtype mouse absent mll–af9 mouse examination gr1cid49mac1cid49 population young heterozygous mll–af9 mice used basis determining whether preleukaemic effect myeloid"
  },
  {
    "id": 81,
    "paragraph": "cell differentiation resulted from the presence of the fusion gene. FACS analysis was carried out on young Mll–AF9 mice using Gr-1 and Mac-1 (myeloid markers), Ter119 (erythrocyte marker), B220 (B cell marker), CD4 (T cell marker), Thy 1.2 (T-lymphocytes, monocytes, B-lymphocytes), Sca-1 (multipotent haematopoietic stem",
    "jurnal": "003564.pdf",
    "processed": "cell differentiation resulted presence fusion gene facs analysis carried young mll–af9 mice using gr1 mac1 myeloid markers ter119 erythrocyte marker b220 b cell marker cd4 cell marker thy 12 tlymphocytes monocytes blymphocytes sca1 multipotent haematopoietic stem"
  },
  {
    "id": 82,
    "paragraph": "cells, mature myeloid cells), CD44 (leukocytes, erythro- cytes, epithelia) and c-Kit (haematopoietic progenitor cells and mast cells). Only effects on the myeloid markers were detectable. Bone marrow from Mll–AF9 heterozygous mice of either 6 days or 5 weeks of age were analysed",
    "jurnal": "003564.pdf",
    "processed": "cells mature myeloid cells cd44 leukocytes erythro cytes epithelia ckit haematopoietic progenitor cells mast cells effects myeloid markers detectable bone marrow mll–af9 heterozygous mice either 6 days 5 weeks age analysed"
  },
  {
    "id": 83,
    "paragraph": "and compared with either wild-type or Mll–myc mice of similar age (Figure 6). While there was a modest increase in Mac-1/Gr-1 double-positive cells in the Mll–AF9 bone marrow compared with the two controls at 6 days of age Mll–AF9 fusion causes myeloproliferation",
    "jurnal": "003564.pdf",
    "processed": "compared either wildtype mll–myc mice similar age figure 6 modest increase mac1gr1 doublepositive cells mll–af9 bone marrow compared two controls 6 days age mll–af9 fusion causes myeloproliferation"
  },
  {
    "id": 84,
    "paragraph": "Fig. 5. Surface phenotype of AMLs in Mll–AF9 mice. Mll–AF9 mice with signs of disease were sacriﬁced and single cell suspensions were made from the spleen and bone marrow. Cells were stained with ﬂuorescent antibodies recognizing the myeloid marker, Gr-1, the T cell markers, CD3 and",
    "jurnal": "003564.pdf",
    "processed": "fig 5 surface phenotype amls mll–af9 mice mll–af9 mice signs disease sacriﬁced single cell suspensions made spleen bone marrow cells stained ﬂuorescent antibodies recognizing myeloid marker gr1 cell markers cd3"
  },
  {
    "id": 85,
    "paragraph": "CD4, and the B cell marker, B220. Twelve out of 24 Mll–AF9 chimeras and 15 out of 28 Mll–AF9 heterozygotes were analysed. In the representative example shown, the Mll–AF9 heterozygous mouse 4299 developed AML (age 4 months) and FACS analysis was performed and",
    "jurnal": "003564.pdf",
    "processed": "cd4 b cell marker b220 twelve 24 mll–af9 chimeras 15 28 mll–af9 heterozygotes analysed representative example shown mll–af9 heterozygous mouse 4299 developed aml age 4 months facs analysis performed"
  },
  {
    "id": 86,
    "paragraph": "compared with a wild-type mouse of comparable age. Graphs represent cell number (y-axis) versus ﬂuorescence intensity (x-axis). (35% compared with 21 and 15% for wild-type and Mll– myc mice, respectively), a much larger population (~85%) was observed in the Mll–AF9 mice at 5 weeks compared",
    "jurnal": "003564.pdf",
    "processed": "compared wildtype mouse comparable age graphs represent cell number yaxis versus ﬂuorescence intensity xaxis 35 compared 21 15 wildtype mll– myc mice respectively much larger population 85 observed mll–af9 mice 5 weeks compared"
  },
  {
    "id": 87,
    "paragraph": "with either the wild-type (48%) or the Mll–myc (54%) mice. The Gr-1(cid:49) cells in the Mll–AF9 heterozygotes seem to represent a true increase in myeloid lineage cells, rather than overtly leukaemic cells. This is indicated by the narrow ﬂuorescence proﬁle which is similar to those of",
    "jurnal": "003564.pdf",
    "processed": "either wildtype 48 mll–myc 54 mice gr1cid49 cells mll–af9 heterozygotes seem represent true increase myeloid lineage cells rather overtly leukaemic cells indicated narrow ﬂuorescence proﬁle similar"
  },
  {
    "id": 88,
    "paragraph": "the control mice (wild type or Mll–myc; Figure 6), as compared with the broad proﬁle found with AML bone marrow. These data indicate that an early proliferation of cells in the myeloid lineage, driven by the Mll–AF9 fusion protein, occurs prior to the development of malignancy.",
    "jurnal": "003564.pdf",
    "processed": "control mice wild type mll–myc figure 6 compared broad proﬁle found aml bone marrow data indicate early proliferation cells myeloid lineage driven mll–af9 fusion protein occurs prior development malignancy"
  },
  {
    "id": 89,
    "paragraph": "The increase in proportion of Mac-1/Gr-1 double-positive cells in Mll–AF9 heterozygous mice at 6 days of age compared with wild-type or heterozygous Mll–myc mice was veriﬁed using cells obtained from 6 day pups from litters obtained by mating heterozygous Mll–myc or",
    "jurnal": "003564.pdf",
    "processed": "increase proportion mac1gr1 doublepositive cells mll–af9 heterozygous mice 6 days age compared wildtype heterozygous mll–myc mice veriﬁed using cells obtained 6 day pups litters obtained mating heterozygous mll–myc"
  },
  {
    "id": 90,
    "paragraph": "heterozygous Mll–AF9 mice. The bone marrow cells were analysed by FACS and the percentage of Mac-1/Gr-1 double-positive cells determined (Figure 7A). In these litters, there were four Mll–AF9 heterozygous mice, three of which had high Mac-1/Gr-1 double-positive cell counts compared with the (cid:49)/– Mll–myc or (cid:49)/(cid:49) litter mates. Thus,",
    "jurnal": "003564.pdf",
    "processed": "heterozygous mll–af9 mice bone marrow cells analysed facs percentage mac1gr1 doublepositive cells determined figure 7a litters four mll–af9 heterozygous mice three high mac1gr1 doublepositive cell counts compared cid49– mll–myc cid49cid49 litter mates thus"
  },
  {
    "id": 91,
    "paragraph": "a high Mac-1/Gr-1 double-positive count is predictive of Mll–AF9 heterozygosity soon after birth. As the number of Mac-1/Gr-1 bone marrow cells naturally increases as mice mature, we examined groups of littermates at between 5 and 12 weeks of age in which environmental disturbances",
    "jurnal": "003564.pdf",
    "processed": "high mac1gr1 doublepositive count predictive mll–af9 heterozygosity soon birth number mac1gr1 bone marrow cells naturally increases mice mature examined groups littermates 5 12 weeks age environmental disturbances"
  },
  {
    "id": 92,
    "paragraph": "should be less signiﬁcant. In this analysis, we examined bone marrow cells from seven Mll–AF9 (cid:49)/– mice, eight wild-type (cid:49)/(cid:49) mice (Figure 7B) and 14 Mll–myc (cid:49)/– mice (Figure 7C). Of the seven Mll–AF9 heterozygous mice analysed, the proportion of Mac-1/Gr-1 double-",
    "jurnal": "003564.pdf",
    "processed": "less signiﬁcant analysis examined bone marrow cells seven mll–af9 cid49– mice eight wildtype cid49cid49 mice figure 7b 14 mll–myc cid49– mice figure 7c seven mll–af9 heterozygous mice analysed proportion mac1gr1 double"
  },
  {
    "id": 93,
    "paragraph": "positive cells in the bone marrow ranged from 71–93%, with an average of 82%. These ﬁgures are consistently higher than those we observed for wild-type mice (Figure 7B), in which the average number of Mac-1/Gr-1 double- positive cells is 52%; one mouse had 77% double-positive",
    "jurnal": "003564.pdf",
    "processed": "positive cells bone marrow ranged 71–93 average 82 ﬁgures consistently higher observed wildtype mice figure 7b average number mac1gr1 double positive cells 52 one mouse 77 doublepositive"
  },
  {
    "id": 94,
    "paragraph": "bone marrow cells but this was exceptional. Furthermore, the 14 Mll–myc heterozygous mice had an average of 50% Mac-1/Gr-1 bone marrow cells, ranging from 43– 60%. The standard errors from these cohorts of mice were calculated at 3, 4 and 1.2% for Mll–AF9, (cid:49)/(cid:49) wild-type",
    "jurnal": "003564.pdf",
    "processed": "bone marrow cells exceptional furthermore 14 mll–myc heterozygous mice average 50 mac1gr1 bone marrow cells ranging 43– 60 standard errors cohorts mice calculated 3 4 12 mll–af9 cid49cid49 wildtype"
  },
  {
    "id": 95,
    "paragraph": "and Mll–myc mice, respectively, indicating a signiﬁcant proliferative advantage for the myeloid cell compartment in the bone marrow of the Mll–AF9 mice. Only the 3569 C.L.Dobson et al. Fig. 6. Young Mll–AF9 mice exhibit increased myeloproliferation. Mll–AF9 heterozygous mice were analysed at 6 days or 5 weeks of age to",
    "jurnal": "003564.pdf",
    "processed": "mll–myc mice respectively indicating signiﬁcant proliferative advantage myeloid cell compartment bone marrow mll–af9 mice 3569 cldobson et al fig 6 young mll–af9 mice exhibit increased myeloproliferation mll–af9 heterozygous mice analysed 6 days 5 weeks age"
  },
  {
    "id": 96,
    "paragraph": "determine the status of haematopoietic differentiation, prior to the development of overt leukaemia. Mice were selected from litters of Mll–AF9, Mll–myc and wild-type mice at 6 days or 5 weeks of age and single cell suspensions were made from the bone marrow. Cells were stained with an",
    "jurnal": "003564.pdf",
    "processed": "determine status haematopoietic differentiation prior development overt leukaemia mice selected litters mll–af9 mll–myc wildtype mice 6 days 5 weeks age single cell suspensions made bone marrow cells stained"
  },
  {
    "id": 97,
    "paragraph": "anti-Mac-1 antibody coupled with phycoerythrin (PE) together with an anti-Gr-1 antibody coupled with ﬂuorescein isothiocyanate (FITC) to detect the myeloid population of cells. (A) Populations of bone marrow cells expressing both Mac-1 and Gr-1 markers are depicted. Percentage values are shown for the upper right-hand quadrant of Gr-1/Mac-1 double-positive cells. (B) Fluorescence proﬁles of the same bone marrow cell populations",
    "jurnal": "003564.pdf",
    "processed": "antimac1 antibody coupled phycoerythrin pe together antigr1 antibody coupled ﬂuorescein isothiocyanate fitc detect myeloid population cells populations bone marrow cells expressing mac1 gr1 markers depicted percentage values shown upper righthand quadrant gr1mac1 doublepositive cells b fluorescence proﬁles bone marrow cell populations"
  },
  {
    "id": 98,
    "paragraph": "for anti-Gr-1 antibody binding. The peaks of ﬂuorescence intensity for wild-type and Mll–AF9 mouse bone marrow cells are similar indicating these are not transformed myeloid cells (compared with the AML bone marrow shown in Figure 5) at the stage of analysis, but rather there is an increase",
    "jurnal": "003564.pdf",
    "processed": "antigr1 antibody binding peaks ﬂuorescence intensity wildtype mll–af9 mouse bone marrow cells similar indicating transformed myeloid cells compared aml bone marrow shown figure 5 stage analysis rather increase"
  },
  {
    "id": 99,
    "paragraph": "in myeloid cell compartment size. presence of the Mll–AF9 gene fusion was capable of eliciting this change, and not the truncation of the Mll gene by addition of the myc epitope. Thus, one function of the Mll–AF9 fusion gene appears to be to confer a",
    "jurnal": "003564.pdf",
    "processed": "myeloid cell compartment size presence mll–af9 gene fusion capable eliciting change truncation mll gene addition myc epitope thus one function mll–af9 fusion gene appears confer"
  },
  {
    "id": 100,
    "paragraph": "proliferative advantage for cells of the myeloid lineage, prior to the onset of AML. 3570 Mll–AF9 fusion causes myeloproliferation Discussion In vivo fusion of Mll and AF9 in mice provides a model for human cancer caused by chromosome 11q23 translocations In vivo models of cancer development occurring after",
    "jurnal": "003564.pdf",
    "processed": "proliferative advantage cells myeloid lineage prior onset aml 3570 mll–af9 fusion causes myeloproliferation discussion vivo fusion mll af9 mice provides model human cancer caused chromosome 11q23 translocations vivo models cancer development occurring"
  },
  {
    "id": 101,
    "paragraph": "chromosomal translocations are needed for a compre- hensive understanding of the biological consequences of these aberrant chromosomes and as a means to test possible therapies. The propensity of the MLL gene to form fusion genes after chromosomal translocations is important because (cid:46)15% of all acute leukaemias in man have MLL",
    "jurnal": "003564.pdf",
    "processed": "chromosomal translocations needed compre hensive understanding biological consequences aberrant chromosomes means test possible therapies propensity mll gene form fusion genes chromosomal translocations important cid4615 acute leukaemias man mll"
  },
  {
    "id": 102,
    "paragraph": "gene fusions and because there is an association of particular MLL fusions with particular subtypes of acute leukaemia. For instance, MLL–AF4/FEL fusions are typic- ally found in lymphoblastic tumours, whereas MLL–AF9 fusions are typically found in myeloid tumours (Djabali et al., 1992; Gu et al., 1992; Domer et al., 1993; Iida",
    "jurnal": "003564.pdf",
    "processed": "gene fusions association particular mll fusions particular subtypes acute leukaemia instance mll–af4fel fusions typic ally found lymphoblastic tumours whereas mll–af9 fusions typically found myeloid tumours djabali et al 1992 gu et al 1992 domer et al 1993 iida"
  },
  {
    "id": 103,
    "paragraph": "et al., 1993; Morrissey et al., 1993; Nakamura et al., 1993). This implies a speciﬁc role for the chimeric protein in determination of the type of leukaemia which develops. Nonetheless, an alternative possibility is based purely on mechanism and accessibility of genes in chromosomes.",
    "jurnal": "003564.pdf",
    "processed": "et al 1993 morrissey et al 1993 nakamura et al 1993 implies speciﬁc role chimeric protein determination type leukaemia develops nonetheless alternative possibility based purely mechanism accessibility genes chromosomes"
  },
  {
    "id": 104,
    "paragraph": "Thus the ability of MLL and AF9 or MLL and AF4 genomic regions to take part in an inter-chromosomal translocation may be greater in committed myeloid or lymphoid cells, respectively. The alternative models can be assessed using animal models of disease in which gene",
    "jurnal": "003564.pdf",
    "processed": "thus ability mll af9 mll af4 genomic regions take part interchromosomal translocation may greater committed myeloid lymphoid cells respectively alternative models assessed using animal models disease gene"
  },
  {
    "id": 105,
    "paragraph": "fusion is either controlled by speciﬁc interchromosomal events (Smith et al., 1995; van Deursen et al., 1995) or by knock-in of the fusion gene partner (Thomas and Capecchi, 1987; Corral et al., 1996). We have developed and analysed a model for MLL–AF9-induced leukaemia",
    "jurnal": "003564.pdf",
    "processed": "fusion either controlled speciﬁc interchromosomal events smith et al 1995 van deursen et al 1995 knockin fusion gene partner thomas capecchi 1987 corral et al 1996 developed analysed model mll–af9induced leukaemia"
  },
  {
    "id": 106,
    "paragraph": "using homologous recombination to knock-in the AF9 into the endogenous mouse Mll gene (Corral et al., 1996). In this model system, we ﬁnd that the fusion causes tumours in both chimeric mice and mice heterozygous for the Mll– AF9 fusion gene. The majority of tumours observed in",
    "jurnal": "003564.pdf",
    "processed": "using homologous recombination knockin af9 endogenous mouse mll gene corral et al 1996 model system ﬁnd fusion causes tumours chimeric mice mice heterozygous mll– af9 fusion gene majority tumours observed"
  },
  {
    "id": 107,
    "paragraph": "these mice were myeloid as has been reported in humans translocation t(9;11). Two acute with chromosomal lymphoblastic tumours also arise reﬂecting the relative occurrence of AML:ALL in humans. In the knock-in mice, the ALL cases occurred with a longer latency than the",
    "jurnal": "003564.pdf",
    "processed": "mice myeloid reported humans translocation t911 two acute chromosomal lymphoblastic tumours also arise reﬂecting relative occurrence amlall humans knockin mice cases occurred longer latency"
  },
  {
    "id": 108,
    "paragraph": "acute myeloid tumours. The pathological features of the haematopoietic malig- nancies in the Mll–AF9 mice were very similar to those of human MLL–AF9 associated tumours, providing a striking counterpart between the pathology of the murine and human leukaemias associated with the t(9;11). In",
    "jurnal": "003564.pdf",
    "processed": "acute myeloid tumours pathological features haematopoietic malig nancies mll–af9 mice similar human mll–af9 associated tumours providing striking counterpart pathology murine human leukaemias associated t911"
  },
  {
    "id": 109,
    "paragraph": "man, the most common French-American-British (FAB) subtypes found in this context are AML, M5 (monoblastic/ monocytic), M4 (myelomonocytic), and occasionally M1 or M2 (Bain, 1993). Comparable morphologies were evident in the mice used in the investigation. The pattern of organ inﬁltration described in the mice has close",
    "jurnal": "003564.pdf",
    "processed": "man common frenchamericanbritish fab subtypes found context aml m5 monoblastic monocytic m4 myelomonocytic occasionally m1 m2 bain 1993 comparable morphologies evident mice used investigation pattern organ inﬁltration described mice close"
  },
  {
    "id": 110,
    "paragraph": "similarities to the clinical ﬁndings in man. Thus, enlarge- ment of the superﬁcial lymph nodes, liver and spleen is common in human AML, with 90% of cases showing inﬁltration of the liver and spleen at autopsy. Extramedul- lary inﬁltration of leukaemic myeloblasts is most common",
    "jurnal": "003564.pdf",
    "processed": "similarities clinical ﬁndings man thus enlarge ment superﬁcial lymph nodes liver spleen common human aml 90 cases showing inﬁltration liver spleen autopsy extramedul lary inﬁltration leukaemic myeloblasts common"
  },
  {
    "id": 111,
    "paragraph": "in monocytic or myelomonocytic leukaemia. Although usually diffuse, disease may occur as tumorous deposits (granulocytic sarcoma). This may be the initial manifesta- 3571 Fig. 7. Mll–AF9 mice exhibit myeloproliferation prior to development of overt leukaemia. The cell populations of bone marrow, from mice",
    "jurnal": "003564.pdf",
    "processed": "monocytic myelomonocytic leukaemia although usually diffuse disease may occur tumorous deposits granulocytic sarcoma may initial manifesta 3571 fig 7 mll–af9 mice exhibit myeloproliferation prior development overt leukaemia cell populations bone marrow mice"
  },
  {
    "id": 112,
    "paragraph": "aged 6 days or between 5 and 12 weeks, were analysed by ﬂow cytometry. Single cell suspensions were made from the bone marrow and cells stained with an anti-Mac-1 antibody coupled with PE together with an anti-Gr-1 antibody coupled with FITC. Data are",
    "jurnal": "003564.pdf",
    "processed": "aged 6 days 5 12 weeks analysed ﬂow cytometry single cell suspensions made bone marrow cells stained antimac1 antibody coupled pe together antigr1 antibody coupled fitc data"
  },
  {
    "id": 113,
    "paragraph": "expressed as the percentage of double staining cells. Genotypes were determined by ﬁlter hybridization of DNA from tail biopsies. (A) Histogram showing the percentage of Gr-1(cid:49)Mac-1(cid:49) cells in the bone marrow of individual 6 day old mice from one litter of a",
    "jurnal": "003564.pdf",
    "processed": "expressed percentage double staining cells genotypes determined ﬁlter hybridization dna tail biopsies histogram showing percentage gr1cid49mac1cid49 cells bone marrow individual 6 day old mice one litter"
  },
  {
    "id": 114,
    "paragraph": "heterozygous Mll–myc cross (nine pups) and one litter of Mll–AF9 mated with a wild-type mouse (12 pups). (B) Histogram showing the percentage of Gr-1(cid:49)Mac-1(cid:49) cells in the bone marrow of 5- to 12- week-old wild-type (eight mice) or Mll–AF9 mice (seven mice).",
    "jurnal": "003564.pdf",
    "processed": "heterozygous mll–myc cross nine pups one litter mll–af9 mated wildtype mouse 12 pups b histogram showing percentage gr1cid49mac1cid49 cells bone marrow 5 12 weekold wildtype eight mice mll–af9 mice seven mice"
  },
  {
    "id": 115,
    "paragraph": "(C) Histogram showing the percentage of Gr-1(cid:49)Mac-1(cid:49) cells in the bone marrow of 5- to 12-week-old Mll–myc mice (14 mice). C.L.Dobson et al. tion of AML, with the appearance of the disease in the bone marrow following later if the patient remains",
    "jurnal": "003564.pdf",
    "processed": "c histogram showing percentage gr1cid49mac1cid49 cells bone marrow 5 12weekold mll–myc mice 14 mice cldobson et al tion aml appearance disease bone marrow following later patient remains"
  },
  {
    "id": 116,
    "paragraph": "untreated. Hepatic inﬁltration by leukaemic myeloblasts in the absence of heavy marrow disease was a recurrent feature of the t(9;11) leukaemia in our mice. Since the mice in our experimental group develop a malignancy which mimics the disease occurring in humans with the",
    "jurnal": "003564.pdf",
    "processed": "untreated hepatic inﬁltration leukaemic myeloblasts absence heavy marrow disease recurrent feature t911 leukaemia mice since mice experimental group develop malignancy mimics disease occurring humans"
  },
  {
    "id": 117,
    "paragraph": "translocation t(9;11), they could be used to test therapies which might later be applicable to human cancer management. An early effect of Mll–AF9 on myeloproliferation Various fusion partners can be linked to the MLL gene after the formation of the abnormal chromosomes (reviewed in",
    "jurnal": "003564.pdf",
    "processed": "translocation t911 could used test therapies might later applicable human cancer management early effect mll–af9 myeloproliferation various fusion partners linked mll gene formation abnormal chromosomes reviewed"
  },
  {
    "id": 118,
    "paragraph": "Rowley, 1993; Bernard and Berger, 1995; Rubnitz et al., 1996b; Gilliland, 1998). However, it is not clear whether the timing of the translocation is important for determining the type of leukaemia which develops or whether the incoming fusion partner has an important role in determin-",
    "jurnal": "003564.pdf",
    "processed": "rowley 1993 bernard berger 1995 rubnitz et al 1996b gilliland 1998 however clear whether timing translocation important determining type leukaemia develops whether incoming fusion partner important role determin"
  },
  {
    "id": 119,
    "paragraph": "ing the nature of the tumour. We have found that myelo- proliferation occurs prior to the acute myeloid disease that arises in most Mll–AF9 mice. These data therefore suggest that the disease in the majority of animals initiates in a proliferating pool of myeloblasts from which leukaemic",
    "jurnal": "003564.pdf",
    "processed": "ing nature tumour found myelo proliferation occurs prior acute myeloid disease arises mll–af9 mice data therefore suggest disease majority animals initiates proliferating pool myeloblasts leukaemic"
  },
  {
    "id": 120,
    "paragraph": "precursors arise as a result of secondary mutations. The surviving Mll–AF9 mice without tumours are presumbaly ones in which secondary mutations have not occurred. Thus, our observations with the Mll–AF9 knock-in mice suggest that the role of the MLL–AF9 fusion is to specify",
    "jurnal": "003564.pdf",
    "processed": "precursors arise result secondary mutations surviving mll–af9 mice without tumours presumbaly ones secondary mutations occurred thus observations mll–af9 knockin mice suggest role mll–af9 fusion specify"
  },
  {
    "id": 121,
    "paragraph": "lineage. However, a number of other factors need to be taken into account. No signﬁcant numbers of tumours arose in Mll–myc mice (Corral et al., 1996) and further study showed that four out of 27 mice developed AML after two years. Similarly, no signiﬁcant numbers of mice",
    "jurnal": "003564.pdf",
    "processed": "lineage however number factors need taken account signﬁcant numbers tumours arose mll–myc mice corral et al 1996 study showed four 27 mice developed aml two years similarly signiﬁcant numbers mice"
  },
  {
    "id": 122,
    "paragraph": "developed tumours when the lacZ gene was fused to exon 3 of Mll (Corral et al., 1996). However, we have recently found that fusion of Mll exon 8 with lacZ results in the occurrence of AML (C.L.Dobson, A.J.Warren, A.Forster, R.Pannell and T.H.Rabbitts, unpublished) but",
    "jurnal": "003564.pdf",
    "processed": "developed tumours lacz gene fused exon 3 mll corral et al 1996 however recently found fusion mll exon 8 lacz results occurrence aml cldobson ajwarren aforster rpannell thrabbitts unpublished"
  },
  {
    "id": 123,
    "paragraph": "with a much longer latency than seen with Mll–AF9 fusion mice. This implies that formation of a stable MLL fusion protein per se is sufﬁcient for tumorigenesis and that fusion of Mll with AF9 in mice has an accelerating function due to speciﬁcation of the myeloid lineage cell",
    "jurnal": "003564.pdf",
    "processed": "much longer latency seen mll–af9 fusion mice implies formation stable mll fusion protein per se sufﬁcient tumorigenesis fusion mll af9 mice accelerating function due speciﬁcation myeloid lineage cell"
  },
  {
    "id": 124,
    "paragraph": "population. that the chromosomal A further complicating issue is that a small proportion of the Mll–AF9 mice develop lymphoblastic malignancies, as do humans with the t(9;11) translocation. This would translocation does not suggest usually occur in a committed myeloid progenitor cell but",
    "jurnal": "003564.pdf",
    "processed": "population chromosomal complicating issue small proportion mll–af9 mice develop lymphoblastic malignancies humans t911 translocation would translocation suggest usually occur committed myeloid progenitor cell"
  },
  {
    "id": 125,
    "paragraph": "rather in an early progenitor, which retains the ability to differentiate along lymphoid or myeloid lineages and thus form tumours of either type. The latency of the tumours in Mll–AF9 mice suggests that secondary mutations must be occurring prior to overt leukaemia. The corollary is",
    "jurnal": "003564.pdf",
    "processed": "rather early progenitor retains ability differentiate along lymphoid myeloid lineages thus form tumours either type latency tumours mll–af9 mice suggests secondary mutations must occurring prior overt leukaemia corollary"
  },
  {
    "id": 126,
    "paragraph": "that different mutations are likely to accompany lymphoid as opposed to myeloid leukaemia. Furthermore, at least one of these must occur early for a lymphoid tumour to arise, as the myeloproliferation conferred by the MLL– AF9 fusion would presumably commit the majority of cells",
    "jurnal": "003564.pdf",
    "processed": "different mutations likely accompany lymphoid opposed myeloid leukaemia furthermore least one must occur early lymphoid tumour arise myeloproliferation conferred mll– af9 fusion would presumably commit majority cells"
  },
  {
    "id": 127,
    "paragraph": "beyond the boundary for lymphoid tumour development. These arguments suggest that other major recurring MLL fusions, such as with AF4/FEL or ENL/LTG19 also 3572 function to specify the lineage of the tumours, which explains why there is such a strong association between",
    "jurnal": "003564.pdf",
    "processed": "beyond boundary lymphoid tumour development arguments suggest major recurring mll fusions af4fel enlltg19 also 3572 function specify lineage tumours explains strong association"
  },
  {
    "id": 128,
    "paragraph": "these fusions and lymphoblastic tumours (Gu et al., 1992; Domer et al., 1993; Morrissey et al., 1993; Nakamura et al., 1993; Yamamoto et al., 1993; Downing et al., 1994; Rubnitz et al., 1996a). In the case of MLL–ENL fusions, retroviral transduction experiments with mouse bone",
    "jurnal": "003564.pdf",
    "processed": "fusions lymphoblastic tumours gu et al 1992 domer et al 1993 morrissey et al 1993 nakamura et al 1993 yamamoto et al 1993 downing et al 1994 rubnitz et al 1996a case mll–enl fusions retroviral transduction experiments mouse bone"
  },
  {
    "id": 129,
    "paragraph": "marrow cells have clearly shown that a gain-of-function mechanism is operational (Lavau et al., 1997; Slany et al., 1997) and that myeloid differentiation and myeloid transformation are paramount. Therefore, the spectrum of mutations in other genes, which must occur in cells with",
    "jurnal": "003564.pdf",
    "processed": "marrow cells clearly shown gainoffunction mechanism operational lavau et al 1997 slany et al 1997 myeloid differentiation myeloid transformation paramount therefore spectrum mutations genes must occur cells"
  },
  {
    "id": 130,
    "paragraph": "chromosomal translocations involving the MLL gene, may well differ in the context of tumour types with the different MLL fusions. The nature of these mutations, the pattern of perturbation of gene expression and the biological consequences of AF4 fusion with MLL are now our major",
    "jurnal": "003564.pdf",
    "processed": "chromosomal translocations involving mll gene may well differ context tumour types different mll fusions nature mutations pattern perturbation gene expression biological consequences af4 fusion mll major"
  },
  {
    "id": 131,
    "paragraph": "objectives. Materials and methods Construction of the targeting vectors and analysis of targeted ES cells The plasmid constructs for gene targeting have been described (Corral et al., 1996). Mll–AF9 comprises a knock-in of the AF9 short form (Iida et al., 1993; Nakamura et al., 1993) into exon 8 of the mouse Mll gene",
    "jurnal": "003564.pdf",
    "processed": "objectives materials methods construction targeting vectors analysis targeted es cells plasmid constructs gene targeting described corral et al 1996 mll–af9 comprises knockin af9 short form iida et al 1993 nakamura et al 1993 exon 8 mouse mll gene"
  },
  {
    "id": 132,
    "paragraph": "whilst Mll–myc comprises a knock-in of a short epitope tag into the same location in exon 8. CCB ES cells were transfected with the Mll– AF9 targeting vector DNA as described previously (Warren et al., 1994). Homologous recombination was assessed by ﬁlter hybridization of BglII",
    "jurnal": "003564.pdf",
    "processed": "whilst mll–myc comprises knockin short epitope tag location exon 8 ccb es cells transfected mll– af9 targeting vector dna described previously warren et al 1994 homologous recombination assessed ﬁlter hybridization bglii"
  },
  {
    "id": 133,
    "paragraph": "digested DNA using the EcoRI–XhoI fragment from clone p1.5RXT2 as a probe. The presence of a single insertion site was conﬁrmed with a neomycin probe. Targeted ES cell clones were injected into C57Bl/6 blastocysts, which were transferred into recipient females. Chimeric",
    "jurnal": "003564.pdf",
    "processed": "digested dna using ecori–xhoi fragment clone p15rxt2 probe presence single insertion site conﬁrmed neomycin probe targeted es cell clones injected c57bl6 blastocysts transferred recipient females chimeric"
  },
  {
    "id": 134,
    "paragraph": "mice thereby generated were estimated by coat colour. Heterozygous mice were obtained for both Mll–AF9 and Mll–myc fusion genes by crossing chimeric males with wild-type MF1 females. Mouse pathology Leukaemia development in mice was characterized by indolent habit, hunched gait and rufﬂed hair. On developing sickness, mice were culled",
    "jurnal": "003564.pdf",
    "processed": "mice thereby generated estimated coat colour heterozygous mice obtained mll–af9 mll–myc fusion genes crossing chimeric males wildtype mf1 females mouse pathology leukaemia development mice characterized indolent habit hunched gait rufﬂed hair developing sickness mice culled"
  },
  {
    "id": 135,
    "paragraph": "and a post-mortem carried out. Tissues were taken for analysis and were ﬁxed in 10% formalin and embedded in parafﬁn wax. Blocks were sectioned and slides were processed and stained with haematoxylin and eosin (H&E) by routine techniques. Blood ﬁlms were stained with May–",
    "jurnal": "003564.pdf",
    "processed": "postmortem carried tissues taken analysis ﬁxed 10 formalin embedded parafﬁn wax blocks sectioned slides processed stained haematoxylin eosin routine techniques blood ﬁlms stained may–"
  },
  {
    "id": 136,
    "paragraph": "Giemsa–Gru¨nwald (MGG) stain. Slides were photographed using Kodak Tungsten 160 ﬁlm. Glucose phosphate isomerase (GPI) isozyme analysis was performed on spleen samples as described previously (Papaioannou and Johnson, 1993). Immunoglobulin gene rearrangement assays DNA was prepared from various tissues using standard procedures. The",
    "jurnal": "003564.pdf",
    "processed": "giemsa–gru¨nwald mgg stain slides photographed using kodak tungsten 160 ﬁlm glucose phosphate isomerase gpi isozyme analysis performed spleen samples described previously papaioannou johnson 1993 immunoglobulin gene rearrangement assays dna prepared various tissues using standard procedures"
  },
  {
    "id": 137,
    "paragraph": "DNA was digested with HindIII, and fractionated on 0.8% agarose gels, transferred to nylon membranes (Southern, 1975) and hybridized with randomly labelled probe (Feinberg and Vogelstein, 1983). An immuno- globulin heavy chain enhancer probe originating from the intron between JH and Cm gene segments (Neuberger and Williams, 1986) was used.",
    "jurnal": "003564.pdf",
    "processed": "dna digested hindiii fractionated 08 agarose gels transferred nylon membranes southern 1975 hybridized randomly labelled probe feinberg vogelstein 1983 immuno globulin heavy chain enhancer probe originating intron jh cm gene segments neuberger williams 1986 used"
  },
  {
    "id": 138,
    "paragraph": "For T cell rearrangement, DNA was digested with EcoRI or HindIII and ﬁlter hybridizations carried out with probes for either Jb 2 or Cb 1 (Malissen et al., 1984). Flow-cytometric analysis of cell surface marker expression Single-cell suspensions were prepared from mouse thymus, spleen and",
    "jurnal": "003564.pdf",
    "processed": "cell rearrangement dna digested ecori hindiii ﬁlter hybridizations carried probes either jb 2 cb 1 malissen et al 1984 flowcytometric analysis cell surface marker expression singlecell suspensions prepared mouse thymus spleen"
  },
  {
    "id": 139,
    "paragraph": "bone marrow. Cells (100 m l; 5(cid:51)107/ml) were incubated at 4°C for 20 min in phosphate-buffered saline (PBS) with 5% fetal calf serum (FCS) with the following antibodies (PharMingen, San Diego, CA): anti-Gr-1 and anti-Mac-1 (granulocytes), anti-B220 (B cells), anti-CD3 and anti-",
    "jurnal": "003564.pdf",
    "processed": "bone marrow cells 100 l 5cid51107ml incubated 4°c 20 min phosphatebuffered saline pbs 5 fetal calf serum fcs following antibodies pharmingen san diego ca antigr1 antimac1 granulocytes antib220 b cells anticd3 anti"
  },
  {
    "id": 140,
    "paragraph": "CD4 (T cells), anti-Ter119 (erythrocytes), anti-c-Kit (haematopoietic progenitor cells), anti-Thy 1.2 (T lymphocytes, monocytes, B lympho- cytes), anti-CD44 (leukocytes, erythrocytes, epithelia) and anti-Sca-1 (multipotent haematopoietic stem cells). Antibodies were conjugated with either ﬂuorescein isothiocyanate (FITC), or phycoerythrin (PE). Isotype-matched ﬂuoresceinated antibodies were used as controls for",
    "jurnal": "003564.pdf",
    "processed": "cd4 cells antiter119 erythrocytes antickit haematopoietic progenitor cells antithy 12 lymphocytes monocytes b lympho cytes anticd44 leukocytes erythrocytes epithelia antisca1 multipotent haematopoietic stem cells antibodies conjugated either ﬂuorescein isothiocyanate fitc phycoerythrin pe isotypematched ﬂuoresceinated antibodies used controls"
  },
  {
    "id": 141,
    "paragraph": "non-speciﬁc immunoﬂuorescence. After antibody labelling, cells were washed once with PBS containing 5% FCS and resuspended in 1 ml of PBS/5% FCS. Flow cytometric analysis was performed using a FACSCALIBUR (Becton Dickinson, San Jose, CA). Data analysis was performed with Cell Quest (Becton Dickinson). Each phenotype analysis",
    "jurnal": "003564.pdf",
    "processed": "nonspeciﬁc immunoﬂuorescence antibody labelling cells washed pbs containing 5 fcs resuspended 1 ml pbs5 fcs flow cytometric analysis performed using facscalibur becton dickinson san jose ca data analysis performed cell quest becton dickinson phenotype analysis"
  },
  {
    "id": 142,
    "paragraph": "was generated by analysis of 10 000 cells. Acknowledgements This work was supported by the MRC and partly by a grant from the Kay Kendall Leukaemia Research Fund. A.J.W. is the recipient of an MRC Clinician Scientist Fellowship held within the University of",
    "jurnal": "003564.pdf",
    "processed": "generated analysis 10 000 cells acknowledgements work supported mrc partly grant kay kendall leukaemia research fund ajw recipient mrc clinician scientist fellowship held within university"
  },
  {
    "id": 143,
    "paragraph": "Genomics, 37, 1–8. Atlas,M., Head,D., Behm,F., Schmidt,E., Zeleznik-Le,N.J., Roe,B.A., Burian,D. and Domer,P.H. (1998) Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints. Leukemia, 12, 1895–1902. Bain,B.J. (1993). Leukaemia Diagnosis: A Guide To The FAB Classiﬁcation. Wolfe Publishing, London, UK. Bartram,C.R. et al. (1983) Translocation of c-abl oncogene correlates",
    "jurnal": "003564.pdf",
    "processed": "genomics 37 1–8 atlasm headd behmf schmidte zelezniklenj roeba buriand domerph 1998 cloning sequence analysis four t911 therapyrelated leukemia breakpoints leukemia 12 1895–1902 bainbj 1993 leukaemia diagnosis guide fab classiﬁcation wolfe publishing london uk bartramcr et al 1983 translocation cabl oncogene correlates"
  },
  {
    "id": 144,
    "paragraph": "with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature, 306, 277–280. Bernard,O. and Berger,R. 11q23 rearrangements in hematopoietic malignant proliferations. Genes Chromo. Cancer, 13, 75–85. (1995) Molecular basis of Chen,C.-S., Hilden,J.M., Frestedt,J., Domer,P.H., Moore,R., Korsmeyer, S.J. and Kersey,J.H. (1993) The chromosome 4q21 gene (AF-4/FEL)",
    "jurnal": "003564.pdf",
    "processed": "presence philadelphia chromosome chronic myelocytic leukaemia nature 306 277–280 bernardo bergerr 11q23 rearrangements hematopoietic malignant proliferations genes chromo cancer 13 75–85 1995 molecular basis chencs hildenjm frestedtj domerph moorer korsmeyer sj kerseyjh 1993 chromosome 4q21 gene af4fel"
  },
  {
    "id": 145,
    "paragraph": "is widely expressed in normal tissues and shows breakpoint diversity in t(4;11)(q21;q23) acute leukemia. Blood, 4, 1080–1085. Cimino,C. et al. (1997) Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. Cancer Res., 57, 2879–2883.",
    "jurnal": "003564.pdf",
    "processed": "widely expressed normal tissues shows breakpoint diversity t411q21q23 acute leukemia blood 4 1080–1085 ciminoc et al 1997 infant acute leukemias show biased distribution all1 gene breaks topoisomerase ii related secondary acute leukemias cancer res 57 2879–2883"
  },
  {
    "id": 146,
    "paragraph": "Corral,J. et al. (1993) Acute leukaemias of different lineages have similar MLL1 gene fusions encoding related chimeric proteins resulting from chromosomal translocations. Proc. Natl Acad. Sci. USA, 90, 8538–8542. Corral,J. et al. (1996) An Mll-Af9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to",
    "jurnal": "003564.pdf",
    "processed": "corralj et al 1993 acute leukaemias different lineages similar mll1 gene fusions encoding related chimeric proteins resulting chromosomal translocations proc natl acad sci usa 90 8538–8542 corralj et al 1996 mllaf9 fusion gene made homologous recombination causes acute leukemia chimeric mice method"
  },
  {
    "id": 147,
    "paragraph": "create fusion oncogenes. Cell, 85, 853–861. Crozat,A., Aman,P., Mandahl,N. and Ron,D. (1993) Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature, 363, 640–644. de Klein,A. et al. (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature,",
    "jurnal": "003564.pdf",
    "processed": "create fusion oncogenes cell 85 853–861 crozata amanp mandahln rond 1993 fusion chop novel rnabinding protein human myxoid liposarcoma nature 363 640–644 de kleina et al 1982 cellular oncogene translocated philadelphia chromosome chronic myelocytic leukaemia nature"
  },
  {
    "id": 148,
    "paragraph": "300, 765–767. de Klein,A. et al. (1986) bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukaemia. Blood, 68, 1369–1375. Delattre,O. et al. (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature, 359,",
    "jurnal": "003564.pdf",
    "processed": "300 765–767 de kleina et al 1986 bcr rearrangement translocation cabl oncogene philadelphia positive acute lymphoblastic leukaemia blood 68 1369–1375 delattreo et al 1992 gene fusion ets dnabinding domain caused chromosome translocation human tumours nature 359"
  },
  {
    "id": 149,
    "paragraph": "162–165. Djabali,M., Selleri,L., Parry,P., Bower,M., Young,B.D. and Evans,G.A. (1992) A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nature Genet., 2, 113–118. Domer,P.H., Fakharzadeh,S.S., Chen,C.S., Johansen,L., Silverman,G.A., Kersey,J.H. and Korsmeyer,S.J. (1993) Acute mixed- lineage t(4;11)(q21;q23) generates an MLL–AF4 fusion product. Proc.",
    "jurnal": "003564.pdf",
    "processed": "162–165 djabalim selleril parryp bowerm youngbd evansga 1992 trithoraxlike gene interrupted chromosome 11q23 translocations acute leukaemias nature genet 2 113–118 domerph fakharzadehss chencs johansenl silvermanga kerseyjh korsmeyersj 1993 acute mixed lineage t411q21q23 generates mll–af4 fusion product proc"
  },
  {
    "id": 150,
    "paragraph": "Natl Acad. Sci. USA, 90, 7884–7888. Jockel,J., Downing,J.R. et al. (1994) The der (11)-encoded MLL/AF-4 fusion transcript is consistently detected in t(4;11)(q21;q23)-containing acute lymphoblastic leukemia. Blood, 83, 330–335. Feinberg,A.P. and Vogelstein,B.A. (1983) A technique for radiolabelling DNA restriction endonuclease fragments to high speciﬁc activity.",
    "jurnal": "003564.pdf",
    "processed": "natl acad sci usa 90 7884–7888 jockelj downingjr et al 1994 der 11encoded mllaf4 fusion transcript consistently detected t411q21q23containing acute lymphoblastic leukemia blood 83 330–335 feinbergap vogelsteinba 1983 technique radiolabelling dna restriction endonuclease fragments high speciﬁc activity"
  },
  {
    "id": 151,
    "paragraph": "Anal. Biochem., 132, 6–13. Felix,C.A. (1998) Secondary leukemias induced by topoisomerase- targeted drugs. Biochim. Biophys. Acta, 1400, 233–255. Fidanza,V., Melotti,P., Yano,T., Nakamura,T., Bradley,A., Canaani,E., Mll–AF9 fusion causes myeloproliferation Calabretta,B. and Croce,C.M. (1996) Double knockout of the ALL-1 gene blocks hematopoietic differentiation in vitro. Cancer Res., 56,",
    "jurnal": "003564.pdf",
    "processed": "anal biochem 132 6–13 felixca 1998 secondary leukemias induced topoisomerase targeted drugs biochim biophys acta 1400 233–255 fidanzav melottip yanot nakamurat bradleya canaanie mll–af9 fusion causes myeloproliferation calabrettab crocecm 1996 double knockout all1 gene blocks hematopoietic differentiation vitro cancer res 56"
  },
  {
    "id": 152,
    "paragraph": "1179–1183. Gilliland,D.G. (1998) Molecular genetics of human leukemia. Leukemia, 12, S7–S12. Groffen,J., Stephenson,J.R., Heisterkamp,N., de Klein,A., Bartram,C.R. and Grosveld,G. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromsome 22. Cell, 36, 93–99. Gu,Y., Nakamura,T., Alder,H., Prasad,R., Canaani,O., Cimino,G.,",
    "jurnal": "003564.pdf",
    "processed": "1179–1183 gillilanddg 1998 molecular genetics human leukemia leukemia 12 s7–s12 groffenj stephensonjr heisterkampn de kleina bartramcr grosveldg 1984 philadelphia chromosomal breakpoints clustered within limited region bcr chromsome 22 cell 36 93–99 guy nakamurat alderh prasadr canaanio ciminog"
  },
  {
    "id": 153,
    "paragraph": "Croce,C.M. chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell, 71, 701–708. and Canaani,E. (1992) The t(4;11) Hess,J.L., Yu,B.D., Li,B., Hanson,R. and Korsmeyer,S.J. (1997) Defects in yolk sac hematopoiesis in Mll-Null embryos. Blood, 90, 1799–1806.",
    "jurnal": "003564.pdf",
    "processed": "crocecm chromosome translocation human acute leukemias fuses all1 gene related drosophila trithorax af4 gene cell 71 701–708 canaanie 1992 t411 hessjl yubd lib hansonr korsmeyersj 1997 defects yolk sac hematopoiesis mllnull embryos blood 90 1799–1806"
  },
  {
    "id": 154,
    "paragraph": "Ichikawa,H., Shimizu,K., Hayashi,Y. and Ohki,M. (1994) An RNA- binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res., 54, 2865–2868. Iida,S. et al. (1993) MLLT3 gene on 9p22 in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13.",
    "jurnal": "003564.pdf",
    "processed": "ichikawah shimizuk hayashiy ohkim 1994 rna binding protein gene tlsfus fused erg human myeloid leukemia t1621 chromosomal translocation cancer res 54 2865–2868 iidas et al 1993 mllt3 gene 9p22 t911 leukemia encodes serineproline rich protein homologous mllt1 19p13"
  },
  {
    "id": 155,
    "paragraph": "Oncogene, 8, 3085–3092. Lavau,C., Szilvassy,S.J., Slany,R. and Cleary,M.L. (1997) Immortaliz- ation and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J., 16, 4226–4237. Look,A.T. (1997) Oncogenic transcription factors in the human acute leukemias. Science, 278, 1059–1065. Malissen,M. et al. (1984) Mouse T cell antigen receptor: structure and",
    "jurnal": "003564.pdf",
    "processed": "oncogene 8 3085–3092 lavauc szilvassysj slanyr clearyml 1997 immortaliz ation leukemic transformation myelomonocytic precursor retrovirally transduced hrxenl embo j 16 4226–4237 lookat 1997 oncogenic transcription factors human acute leukemias science 278 1059–1065 malissenm et al 1984 mouse cell antigen receptor structure"
  },
  {
    "id": 156,
    "paragraph": "organization of constant and joining gene segments encoding the b polypeptide. Cell, 37, 1101–1110. Mazo,A.M., Huang,D.-H., Mozer,B.A. and Dawid,I.B. (1990) The trithorax gene, a trans-acting regulator of the bithorax complex in Drosophila, encodes a protein with zinc-ﬁnger domains. Proc. Natl Acad. Sci. USA, 87, 2112–2116.",
    "jurnal": "003564.pdf",
    "processed": "organization constant joining gene segments encoding b polypeptide cell 37 1101–1110 mazoam huangdh mozerba dawidib 1990 trithorax gene transacting regulator bithorax complex drosophila encodes protein zincﬁnger domains proc natl acad sci usa 87 2112–2116"
  },
  {
    "id": 157,
    "paragraph": "McCabe,N.R. et al. (1992) Cloning of cDNAs of the MLL gene that detect DNA rearrangements and altered RNA transcripts in human leukemic cells with 11q23 translocations. Proc. Natl Acad. Sci. USA, 89, 11794–11798. Morrissey,J., Tkachuk,D.C., Milatovitch,A., Francke,U., Link,M. and Cleary,M.L. (1993) A serine/proline-rich protein is fused to HRX in",
    "jurnal": "003564.pdf",
    "processed": "mccabenr et al 1992 cloning cdnas mll gene detect dna rearrangements altered rna transcripts human leukemic cells 11q23 translocations proc natl acad sci usa 89 11794–11798 morrisseyj tkachukdc milatovitcha franckeu linkm clearyml 1993 serineprolinerich protein fused hrx"
  },
  {
    "id": 158,
    "paragraph": "t(4;11) acute leukemias. Blood, 81, 1124–1131. Nakamura,T. et al. (1993) Genes on chromosome 4, 9 and 19 involved in 11q23 abnormalities in acute leukemia share homology and/or common motifs. Proc. Natl Acad. Sci. USA, 90, 4631–4635. Nasr,F., Macintyre,E., Venuat,A.M., Bayle,C., Carde,P. and Ribrag,V.",
    "jurnal": "003564.pdf",
    "processed": "t411 acute leukemias blood 81 1124–1131 nakamurat et al 1993 genes chromosome 4 9 19 involved 11q23 abnormalities acute leukemia share homology andor common motifs proc natl acad sci usa 90 4631–4635 nasrf macintyree venuatam baylec cardep ribragv"
  },
  {
    "id": 159,
    "paragraph": "(1997) Translocation t(4;11)(q21;q23) and MLL gene rearrangement in acute lymphoblastic leukemia secondary to anti topoisomerase II anticancer agents. Leuk. Lymph., 25, 399–401. Neuberger,M.S. and Williams,G.T. (1986) Construction of novel antibodies by use of DNA transfection: design of plasmid vectors. Phil. Trans. R. Soc. Lond., 317, 425–432.",
    "jurnal": "003564.pdf",
    "processed": "1997 translocation t411q21q23 mll gene rearrangement acute lymphoblastic leukemia secondary anti topoisomerase ii anticancer agents leuk lymph 25 399–401 neubergerms williamsgt 1986 construction novel antibodies use dna transfection design plasmid vectors phil trans r soc lond 317 425–432"
  },
  {
    "id": 160,
    "paragraph": "Nowell,P.C. and Hungerford,D.A. (1960) A minute chromosome in human granulocytic leukemia. Science, 132, 1497–1500. Panagopoulos,I., Aman,P., Fioretos,T., Hoglund,M., Johannson,B., Mandahl,N., Heim,S., Behrendtz,M. and Mitelman,F. (1994) Fusion of the FUS gene in acute myeloid leukemia with t(16;21)(p11;q22). Genes Chromo. Cancer, 11, 256–262.",
    "jurnal": "003564.pdf",
    "processed": "nowellpc hungerfordda 1960 minute chromosome human granulocytic leukemia science 132 1497–1500 panagopoulosi amanp fioretost hoglundm johannsonb mandahln heims behrendtzm mitelmanf 1994 fusion fus gene acute myeloid leukemia t1621p11q22 genes chromo cancer 11 256–262"
  },
  {
    "id": 161,
    "paragraph": "Panagopoulos,I., Hoglund,M., Mertens,F., Mandhal,N., Mitelman,F. and Aman,P. (1996) Fusion of the EWS and CHOP gene in myxoid liposarcoma. Oncogene, 12, 489–494. Papaioannou,V. and Johnson,R. (1993). Production of chimeras and genetically deﬁned offspring from targeted ES cells. In Joyner,A.C. (ed.), Gene Targeting: A Practical Approach. Oxford University Press,",
    "jurnal": "003564.pdf",
    "processed": "panagopoulosi hoglundm mertensf mandhaln mitelmanf amanp 1996 fusion ews chop gene myxoid liposarcoma oncogene 12 489–494 papaioannouv johnsonr 1993 production chimeras genetically deﬁned offspring targeted es cells joynerac ed gene targeting practical approach oxford university press"
  },
  {
    "id": 162,
    "paragraph": "Oxford, UK, pp. 107–146. Pui,C.-H. et al. (1989) Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N. Engl. J. Med., 321, 136–142. translocations in human cancer. Rabbitts,T.H. (1994) Chromosomal Nature, 372, 143–149. Rabbitts,T.H., Forster,A., Larson,R. and Nathan,P. (1993) Fusion of the",
    "jurnal": "003564.pdf",
    "processed": "oxford uk pp 107–146 puich et al 1989 secondary acute myeloid leukemia children treated acute lymphoid leukemia n engl j med 321 136–142 translocations human cancer rabbittsth 1994 chromosomal nature 372 143–149 rabbittsth forstera larsonr nathanp 1993 fusion"
  },
  {
    "id": 163,
    "paragraph": "dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nature Genet., 4, 175–180. Ratain,M.J. et al. (1987) Acute non-lymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non- small cell carcinoma of the lung. Blood, 70, 1412–1417.",
    "jurnal": "003564.pdf",
    "processed": "dominant negative transcription regulator chop novel gene fus translocation t1216 malignant liposarcoma nature genet 4 175–180 ratainmj et al 1987 acute nonlymphocytic leukemia following etoposide cisplatin combination chemotherapy advanced non small cell carcinoma lung blood 70 1412–1417"
  },
  {
    "id": 164,
    "paragraph": "3573 C.L.Dobson et al. Rowley,J.D. (1973) A new consistent chromosomal abnormality in chronic myelogeneous leukemia identiﬁed by quinaurine ﬂuorescence and giemsa staining. Nature, 243, 290–293. Rowley,J.D. (1993) Rearrangements involving chromosome 11Q23 in acute leukaemia. Semin. Cancer Biol., 4, 387–385. Rowley,J.D. et al. (1997) All patients with the t(11;16)(q23;p13.3) that",
    "jurnal": "003564.pdf",
    "processed": "3573 cldobson et al rowleyjd 1973 new consistent chromosomal abnormality chronic myelogeneous leukemia identiﬁed quinaurine ﬂuorescence giemsa staining nature 243 290–293 rowleyjd 1993 rearrangements involving chromosome 11q23 acute leukaemia semin cancer biol 4 387–385 rowleyjd et al 1997 patients t1116q23p133"
  },
  {
    "id": 165,
    "paragraph": "involves MLL and CBP have treatment-related hematologic disorders. Blood, 90, 535–541. Rubnitz,J.E., Behm,F.G., Curcio-Brint,A.M., Pinheiro,V.R.P., Carroll, (1996a) t(11;19) breakpoints in childhood acute A.J., Raimondi,S.C., Shurtleff,S.A. Molecular analysis of leukemias. Blood, 87, 4804–4808. and Downing,J.R. Rubnitz,J.E., Behm,F.G. and Downing,J.R. (1996b) 11q23 rearrange-",
    "jurnal": "003564.pdf",
    "processed": "involves mll cbp treatmentrelated hematologic disorders blood 90 535–541 rubnitzje behmfg curciobrintam pinheirovrp carroll 1996a t1119 breakpoints childhood acute aj raimondisc shurtleffsa molecular analysis leukemias blood 87 4804–4808 downingjr rubnitzje behmfg downingjr 1996b 11q23 rearrange"
  },
  {
    "id": 166,
    "paragraph": "ments in acute leukemia. Leukemia, 10, 74–82. Slany,R.K., Lavau,C. and Cleary,M.L. (1997) The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol. Cell. Biol., 18, 122–129. Smith,A.J.H., De Sousa,M.A., Kwabi-Addo,B., Heppell-Parton,A.,",
    "jurnal": "003564.pdf",
    "processed": "ments acute leukemia leukemia 10 74–82 slanyrk lavauc clearyml 1997 oncogenic capacity hrxenl requires transcriptional transactivation activity enl dna binding motifs hrx mol cell biol 18 122–129 smithajh de sousama kwabiaddob heppellpartona"
  },
  {
    "id": 167,
    "paragraph": "(1995) A site-directed chromosomal stem cells by Cre-loxP Impey,H. and Rabbitts,P.H. translocation induced in embryonic recombination. Nature Genet., 9, 376–384. Sobulo,O.M. et al. fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc. Natl Acad. Sci. USA, 94, 8732–8737.",
    "jurnal": "003564.pdf",
    "processed": "1995 sitedirected chromosomal stem cells creloxp impeyh rabbittsph translocation induced embryonic recombination nature genet 9 376–384 sobuloom et al fused cbp histone acetyltransferase therapyrelated acute myeloid leukemia t1116q23p133 proc natl acad sci usa 94 8732–8737"
  },
  {
    "id": 168,
    "paragraph": "(1997) MLL is Southern,E.M. (1975) Detection of Speciﬁc Sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol., 98, 503–517. Thirman,M.J. et al. (1993) Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N. Engl. J. Med., 329, 909–914.",
    "jurnal": "003564.pdf",
    "processed": "1997 mll southernem 1975 detection speciﬁc sequences among dna fragments separated gel electrophoresis j mol biol 98 503–517 thirmanmj et al 1993 rearrangement mll gene acute lymphoblastic acute myeloid leukemias 11q23 chromosomal translocations n engl j med 329 909–914"
  },
  {
    "id": 169,
    "paragraph": "Thomas,K.R. and Capecchi,M.R. (1987) Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell, 51, 503–512. Tkachuk,D.C., Kohler,S. and Cleary,M.L. (1992) Involvement of a chromosomal homolog 11q23 translocations in acute leukemias. Cell, 71, 691–700. of Drosophila Trithorax by van Deursen,J., Fornerod,M., van Rees,B. and Grosveld,G. (1995) Cre-",
    "jurnal": "003564.pdf",
    "processed": "thomaskr capecchimr 1987 sitedirected mutagenesis gene targeting mouse embryoderived stem cells cell 51 503–512 tkachukdc kohlers clearyml 1992 involvement chromosomal homolog 11q23 translocations acute leukemias cell 71 691–700 drosophila trithorax van deursenj fornerodm van reesb grosveldg 1995 cre"
  },
  {
    "id": 170,
    "paragraph": "mediated site-speciﬁc translocation between nonhomologous mouse chromosomes. Proc. Natl Acad. Sci. USA, 92, 7376–7380. Warren,A.J., Colledge,W.H., Carlton,M.B.L., Evans,M.J., Smith,A.J.H. and Rabbitts,T.H. (1994) The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell, 78, 45–58. Yamamoto,K. et al. (1993) Two distinct portions of LTG19/ENL at",
    "jurnal": "003564.pdf",
    "processed": "mediated sitespeciﬁc translocation nonhomologous mouse chromosomes proc natl acad sci usa 92 7376–7380 warrenaj colledgewh carltonmbl evansmj smithajh rabbittsth 1994 oncogenic cysteinerich lim domain protein rbtn2 essential erythroid development cell 78 45–58 yamamotok et al 1993 two distinct portions ltg19enl"
  },
  {
    "id": 171,
    "paragraph": "19p13 are involved in t(11;19) leukaemia. Oncogene, 8, 2617–2625. Yu,B.D., Hess,J.L., Horning,S.E., Brown,G.A.J. and Korsmeyer,S.J. (1995) Altered Hox expression and segmental identity in Mll-mutant mice. Nature, 378, 505–508. Ziemin-van der Poel,S. et al. (1991) Identiﬁcation of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human",
    "jurnal": "003564.pdf",
    "processed": "19p13 involved t1119 leukaemia oncogene 8 2617–2625 yubd hessjl horningse browngaj korsmeyersj 1995 altered hox expression segmental identity mllmutant mice nature 378 505–508 zieminvan der poels et al 1991 identiﬁcation gene mll spans breakpoint 11q23 translocations associated human"
  },
  {
    "id": 172,
    "paragraph": "leukemias. Proc. Natl Acad. Sci. USA, 88, 10735–10739. Received March 24, 1999; revised and accepted April 27, 1999 3574",
    "jurnal": "003564.pdf",
    "processed": "leukemias proc natl acad sci usa 88 10735–10739 received march 24 1999 revised accepted april 27 1999 3574"
  },
  {
    "id": 173,
    "paragraph": "LITERATURE REVIEW: DETEKSI DINI PENYAKIT TUMOR SEL DARAH ACUTE MYELOID LEUKIMIA (AML) MENGGUNAKAN PEWARNAAN GIEMSA, WRIGHT, DAN KOMBINASI WRIGHT-GIEMSA NASKAH PUBLIKASI Disusun oleh: Natasa Irawati 1711304040 PROGRAM STUDI SARJANA TERAPAN TEKNOLOGI LABORATORIUM MEDIS FAKULTAS ILMU KESETAHAN UNIVERSITAS ‘AISYIYAH YOGYAKARTA 2022 LITERATURE REVIEW: DETEKSI DINI PENYAKIT",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "literature review deteksi dini penyakit tumor sel darah acute myeloid leukimia aml menggunakan pewarnaan giemsa wright dan kombinasi wrightgiemsa naskah publikasi disusun oleh natasa irawati 1711304040 program studi sarjana terapan teknologi laboratorium medis fakultas ilmu kesetahan universitas ‘ aisyiyah yogyakarta 2022 literature review deteksi dini penyakit"
  },
  {
    "id": 174,
    "paragraph": "TUMOR SEL DARAH ACUTE MYELOID LEUKIMIA (AML) MENGGUNAKAN PEWARNAAN GIEMSA, WRIGHT, DAN KOMBINASI WRIGHT-GIEMSA NASKAH PUBLIKASI Diajukan Guna Melengkapi Sebagian Syarat Mencapai Gelar Sarjana Terapan Kesehatan Program Studi Sarjana Terapan Teknologi Laboratorium Medis Fakultas Ilmu Kesehatan di Universitas ‘Aisyiyah Yogyakarta Disusun oleh:",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "tumor sel darah acute myeloid leukimia aml menggunakan pewarnaan giemsa wright dan kombinasi wrightgiemsa naskah publikasi diajukan guna melengkapi sebagian syarat mencapai gelar sarjana terapan kesehatan program studi sarjana terapan teknologi laboratorium medis fakultas ilmu kesehatan di universitas ‘ aisyiyah yogyakarta disusun oleh"
  },
  {
    "id": 175,
    "paragraph": "Natasa Irawati 1711304040 PROGRAM STUDI SARJANA TERAPAN TEKNOLOGI LABORATORIUM MEDIS FAKULTAS ILMU KESETAHAN UNIVERSITAS ‘AISYIYAH YOGYAKARTA 2022 LITERATURE REVIEW: DETEKSI DINI PENYAKIT TUMOR SEL DARAH ACUTE MYELOID LEUKIMIA (AML) MENGGUNAKAN PEWARNAAN GIEMSA, WRIGHT, DAN KOMBINASI WRIGHT-GIEMSA1) Natasa Irawati2), Yuyun Nailufar3) ABSTRAK",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "natasa irawati 1711304040 program studi sarjana terapan teknologi laboratorium medis fakultas ilmu kesetahan universitas ‘ aisyiyah yogyakarta 2022 literature review deteksi dini penyakit tumor sel darah acute myeloid leukimia aml menggunakan pewarnaan giemsa wright dan kombinasi wrightgiemsa1 natasa irawati2 yuyun nailufar3 abstrak"
  },
  {
    "id": 176,
    "paragraph": "Leukimia merupakan kanker yang berasal dari sel-sel. Leukimia dapat dibedakan menjadi akut dan kronis. Penyakit Acute Myeloid Leukimia atau AML merupakan kanker darah yang dapat ditandai dengan transformasi ganas dan gangguan diferensiasi sel progenitor dari seri meiloid. Penelitian ini bertujuan menjelaskan hasil penelusuran literature terkait gejala dari penyakit AML lebih",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "leukimia merupakan kanker yang berasal dari selsel leukimia dapat dibedakan menjadi akut dan kronis penyakit acute myeloid leukimia atau aml merupakan kanker darah yang dapat ditandai dengan transformasi ganas dan gangguan diferensiasi sel progenitor dari seri meiloid penelitian ini bertujuan menjelaskan hasil penelusuran literature terkait gejala dari penyakit aml lebih"
  },
  {
    "id": 177,
    "paragraph": "awal menggunakan metode pewarnaan Giemsa, Wright, dan kombinasi Wright- Giemsa. Metode yang digunakan adalah metode literature review pada beberapa data base antara lain Google Scholar, Pubmet.gov, dan ScienceDirect. Screening literatur dilakukan dengan metode PRISMA (Preferred Reporting Items For Systematic Reviews and Meta Analyses) pemilihan literatur berdasarkan kriteria",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "awal menggunakan metode pewarnaan giemsa wright dan kombinasi wright giemsa metode yang digunakan adalah metode literature review pada beberapa data base antara lain google scholar pubmetgov dan sciencedirect screening literatur dilakukan dengan metode prisma preferred reporting items systematic reviews meta analyses pemilihan literatur berdasarkan kriteria"
  },
  {
    "id": 178,
    "paragraph": "inklusi. Terdapat 10 jurnal yang digunakan sebagai sumber literature yang dianalisis secara deskriptif kualitatif. Berdasarkan hasil penelitian menunjukkan bahwa apusan darah tepi pasien penderita AML memiliki persentase sel blast leukosit >20% yaitu berkisar antara 21-93,5% dengan sebagian kasus yang menunjukkan adanya gambaran sel darah merah (eritrosit) normokromik",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "inklusi terdapat 10 jurnal yang digunakan sebagai sumber literature yang dianalisis secara deskriptif kualitatif berdasarkan hasil penelitian menunjukkan bahwa apusan darah tepi pasien penderita aml memiliki persentase sel blast leukosit 20 yaitu berkisar antara 21935 dengan sebagian kasus yang menunjukkan adanya gambaran sel darah merah eritrosit normokromik"
  },
  {
    "id": 179,
    "paragraph": "normositer dan berinti serta adanya giant trombosit. Hasil penelitian menunjukkan apusan darah tepi dengan pewarnaan Giemsa menunjukkan inti sel berwarna biru keunguan, granula berwarna merah muda. Pewarnaan Wright inti sel dan granula tampak lebih jelas terlihat kemerahan dengan warna yang lebih jelas dibandingkan",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "normositer dan berinti serta adanya giant trombosit hasil penelitian menunjukkan apusan darah tepi dengan pewarnaan giemsa menunjukkan inti sel berwarna biru keunguan granula berwarna merah muda pewarnaan wright inti sel dan granula tampak lebih jelas terlihat kemerahan dengan warna yang lebih jelas dibandingkan"
  },
  {
    "id": 180,
    "paragraph": "dengan Giemsa. Pewarnaan kombinasi Wright-Giemsa terdapat kelebihan dari setiap zat warna granula, plasma, dan inti lebih jelas terlihat. Perlu adanya penelitian lanjutan mengenai perbandingan ketiga pewarnaan untuk menemukan pewarnaan yang baik dalam sediaan apusan darah. Kata kunci Kepustakaan :Acute Myeloid Leukimia, Pewarnaan Giemsa, Pewarnaan",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "dengan giemsa pewarnaan kombinasi wrightgiemsa terdapat kelebihan dari setiap zat warna granula plasma dan inti lebih jelas terlihat perlu adanya penelitian lanjutan mengenai perbandingan ketiga pewarnaan untuk menemukan pewarnaan yang baik dalam sediaan apusan darah kata kunci kepustakaan acute myeloid leukimia pewarnaan giemsa pewarnaan"
  },
  {
    "id": 181,
    "paragraph": "Wright, dan Pewarnaan Wright-Giemsa. : 10 jurnal (2012-2022) Keterangan: 1) Judul skripsi 2) Mahasiswa TLM Fakultas Ilmu Kesehatan Universitas ‘Aisyiyah Yogyakarta 3) Dosen TLM Fakultas Ilmu Kesehatan Universitas ‘Aisyiyah Yogyakarta A LITERATURE REVIEW: EARLY DETECTION OF ACUTE MYELOID LEUKIMIA BLOOD CELL",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "wright dan pewarnaan wrightgiemsa 10 jurnal 20122022 keterangan 1 judul skripsi 2 mahasiswa tlm fakultas ilmu kesehatan universitas ‘ aisyiyah yogyakarta 3 dosen tlm fakultas ilmu kesehatan universitas ‘ aisyiyah yogyakarta literature review early detection acute myeloid leukimia blood cell"
  },
  {
    "id": 182,
    "paragraph": "TUMOR DISEASE (AML) USING GIEMSA, WRIGHT, AND WRIGHT-GIEMSA COMBINATION 1) Natasa Irawati2), Yuyun Nailufar3) ABSTRACT Leukemia is cancer that originates from blood cells. Leukemia can be divided into acute and chronic. Acute Myeloid Leukemia or AML is a blood cancer that can be characterized by malignant transformation and impaired",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "tumor disease aml using giemsa wright wrightgiemsa combination 1 natasa irawati2 yuyun nailufar3 abstract leukemia cancer originates blood cells leukemia divided acute chronic acute myeloid leukemia aml blood cancer characterized malignant transformation impaired"
  },
  {
    "id": 183,
    "paragraph": "differentiation of progenitor cells from the meiloid series. This study aims to explain the results of literature searches related to symptoms of early AML disease using the Giemsa, Wright, and Wright- Giemsa staining methods. The method used is the literature review method on several databases, including Google",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "differentiation progenitor cells meiloid series study aims explain results literature searches related symptoms early aml disease using giemsa wright wright giemsa staining methods method used literature review method several databases including google"
  },
  {
    "id": 184,
    "paragraph": "Scholar, Pubmet.gov, and ScienceDirect. Literature screening was carried out using the PRISMA (Preferred Reporting Items For Systematic Reviews and Meta Analyses) method of selecting literature based on inclusion criteria. There were 10 journals used as sources of literature which were analyzed descriptively",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "scholar pubmetgov sciencedirect literature screening carried using prisma preferred reporting items systematic reviews meta analyses method selecting literature based inclusion criteria 10 journals used sources literature analyzed descriptively"
  },
  {
    "id": 185,
    "paragraph": "qualitatively. Based on the results of the study, it showed that the peripheral blood smear of patients with AML had a leukocyte blast cell percentage > 20%, ranging from 21-93.5% with some cases showing a normochromic normocyter and nucleated red blood cell (erythrocyte) picture and the presence of giant platelets.",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "qualitatively based results study showed peripheral blood smear patients aml leukocyte blast cell percentage 20 ranging 21935 cases showing normochromic normocyter nucleated red blood cell erythrocyte picture presence giant platelets"
  },
  {
    "id": 186,
    "paragraph": "The results showed that the peripheral blood smear with Giemsa staining showed blue- purple cell nuclei, pink granules. Wright's staining of cell nuclei and granules appeared more distinctly reddish with a clearer color than Giemsa's. The Wright- Giemsa combination staining has the advantages of each of the granule, plasma,",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "results showed peripheral blood smear giemsa staining showed blue purple cell nuclei pink granules wrights staining cell nuclei granules appeared distinctly reddish clearer color giemsas wright giemsa combination staining advantages granule plasma"
  },
  {
    "id": 187,
    "paragraph": "and core dyes being more clearly visible. There is a need for further research on the comparison of the three stains to find a good stain in blood smear preparations. Keywords Literature :Acute Myeloid Leukemia, Giemsa stain, Wright stain, and Wright- Giemsa stain.",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "core dyes clearly visible need research comparison three stains find good stain blood smear preparations keywords literature acute myeloid leukemia giemsa stain wright stain wright giemsa stain"
  },
  {
    "id": 188,
    "paragraph": ": 10 Journals (2012-2022) Information: 1) Title 2) Student of Medical Laboratory Technology Faculty of Health Sciences, University of ‘Aisyiyah Yogyakarta 3) Lecturer of Faculty of Health Sciences, University of ‘Aisyiyah Yogyakarta PENDAHULUAN adalah Leukimia kanker yang berasal dari sel - sel darah.",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "10 journals 20122022 information 1 title 2 student medical laboratory technology faculty health sciences university ‘ aisyiyah yogyakarta 3 lecturer faculty health sciences university ‘ aisyiyah yogyakarta pendahuluan adalah leukimia kanker yang berasal dari sel sel darah"
  },
  {
    "id": 189,
    "paragraph": "Leukimia sendiri dapat terjadi secara akut ataupun kronik yang bergantung pada cepatnya penyakit muncul dan berkembang. Leukosit paling sedikit dalam sekitar 4.000-11.000/mm3 berfungsi untuk melindungi infeksi. (Anwar, 2017). tubuh dari jumlahnya tubuh sel Leukimia Myeloid akut atau (AML) Acute Myeloid Leukimia",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "leukimia sendiri dapat terjadi secara akut ataupun kronik yang bergantung pada cepatnya penyakit muncul dan berkembang leukosit paling sedikit dalam sekitar 400011000mm3 berfungsi untuk melindungi infeksi anwar 2017 tubuh dari jumlahnya tubuh sel leukimia myeloid akut atau aml acute myeloid leukimia"
  },
  {
    "id": 190,
    "paragraph": "merupakan penyakit keganasan yang ditandai dengan diferensiasi dan induk abnormal proliferasi hematopoetik yang bersifat sistemik dan secara malignan melakukan transformasi sehingga menyebabkan penggantian dan penekanan komponen sumsum tulang belakang yang normal (Khasanah & Suminar, 2021). Kebanyakan kasus AML, tubuh memproduksi terlalu banyak",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "merupakan penyakit keganasan yang ditandai dengan diferensiasi dan induk abnormal proliferasi hematopoetik yang bersifat sistemik dan secara malignan melakukan transformasi sehingga menyebabkan penggantian dan penekanan komponen sumsum tulang belakang yang normal khasanah suminar 2021 kebanyakan kasus aml tubuh memproduksi terlalu banyak"
  },
  {
    "id": 191,
    "paragraph": "sel darah putih yang disebut myeloblas yang masih bersifat immatur. Sel-sel darah yang immatur ini tidak sebaik sel darah putih yang telah mature dalam melawan adanya infeksi. French- Berdasarkan AML America-British diklasifikasikan menjadi 8 sub tipe yaitu M0, M1, M2, M3, M4, M5,",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "sel darah putih yang disebut myeloblas yang masih bersifat immatur selsel darah yang immatur ini tidak sebaik sel darah putih yang telah mature dalam melawan adanya infeksi french berdasarkan aml americabritish diklasifikasikan menjadi 8 sub tipe yaitu m0 m1 m2 m3 m4 m5"
  },
  {
    "id": 192,
    "paragraph": "M6, M7 (Bell, A. & Sallah, S., 2005). (FAB), Data di Amerika Serikat, angka kejadian baru dari AML sekitar 4/100.000 orang per tahun. Di dunia, jumlah total angka kejadian AML pada tahun 2012 berada dikisaran 265.000 orang. Data penyebaran kasus AML di Indonesia",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "m6 m7 bell sallah 2005 fab data di amerika serikat angka kejadian baru dari aml sekitar 4100000 orang per tahun di dunia jumlah total angka kejadian aml pada tahun 2012 berada dikisaran 265000 orang data penyebaran kasus aml di indonesia"
  },
  {
    "id": 193,
    "paragraph": "pernah dilaporkan insidens penyakit AML di Jogjakarta yaitu 8 per satu juta populasi. Kasus AML hingga saat ini masih menjadi jenis leukimia pada orang dewasa dengan penderita terbanyak didunia (WHO, 2014). hematologis Diagnosis penyakit khusus yang berfungsi AML dapat dilakukan dengan beberapa",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "pernah dilaporkan insidens penyakit aml di jogjakarta yaitu 8 per satu juta populasi kasus aml hingga saat ini masih menjadi jenis leukimia pada orang dewasa dengan penderita terbanyak didunia 2014 hematologis diagnosis penyakit khusus yang berfungsi aml dapat dilakukan dengan beberapa"
  },
  {
    "id": 194,
    "paragraph": "metode salah satunya dengan metode apusan darah tepi. Pemeriksaan apusan darah tepi merupakan pemeriksaan hematologi rutin dan untuk mengidentifikasi dan mengevaluasi morfologi sel dari komponen darah tepi dalam menunjang diagnosis penyakit secara hematologis maupun (Dalimoenthe, non 2002). Terdapat dua jenis sediaan",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "metode salah satunya dengan metode apusan darah tepi pemeriksaan apusan darah tepi merupakan pemeriksaan hematologi rutin dan untuk mengidentifikasi dan mengevaluasi morfologi sel dari komponen darah tepi dalam menunjang diagnosis penyakit secara hematologis maupun dalimoenthe non 2002 terdapat dua jenis sediaan"
  },
  {
    "id": 195,
    "paragraph": "yaitu sediaan apusan darah tebal dan sediaan apusan darah tipis (SADT). Prinsip pemeriksaan ini adalah dengan meneteskan darah pada ujung obyek glass kemudian dipaparkan membentuk apusan darah dengan kaca objek dan melakukan pengecatan dengan menggunakan pewarnaan Giemsa, Wright, ataupun lainnya kemudian",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "yaitu sediaan apusan darah tebal dan sediaan apusan darah tipis sadt prinsip pemeriksaan ini adalah dengan meneteskan darah pada ujung obyek glass kemudian dipaparkan membentuk apusan darah dengan kaca objek dan melakukan pengecatan dengan menggunakan pewarnaan giemsa wright ataupun lainnya kemudian"
  },
  {
    "id": 196,
    "paragraph": "pewarnaan identifikasi dilakukan pada (Kiswari, 2014). mikroskop Keuntungan dari metode pemeriksaan apusan darah tepi ini adalah mampu untuk menilai berbagai unsur sel darah tepi seperti morfologi eritrosit, sel leukosit, dan trombosit dan mengidentifikasi adanya parasit. Selain itu prosedur pemeriksaan apusan darah tepi yang",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "pewarnaan identifikasi dilakukan pada kiswari 2014 mikroskop keuntungan dari metode pemeriksaan apusan darah tepi ini adalah mampu untuk menilai berbagai unsur sel darah tepi seperti morfologi eritrosit sel leukosit dan trombosit dan mengidentifikasi adanya parasit selain itu prosedur pemeriksaan apusan darah tepi yang"
  },
  {
    "id": 197,
    "paragraph": "sangat aman, murah, sederhana, dan mudah/praktis untuk dilakukan secara manual tanpa menggunakan alat (Savitri & Kustiningsih, 2022). Pewarnaan apusan darah tepi yang paling banyak digunakan adalah pewarnaan Romanowsky yaitu pewarnaan Giemsa, Wright, dan kombinasi Wright-Giemsa (Bain, 2010). Gambaran morfologi dengan pewarnaan Giemsa menunjukkan inti",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "sangat aman murah sederhana dan mudahpraktis untuk dilakukan secara manual tanpa menggunakan alat savitri kustiningsih 2022 pewarnaan apusan darah tepi yang paling banyak digunakan adalah pewarnaan romanowsky yaitu pewarnaan giemsa wright dan kombinasi wrightgiemsa bain 2010 gambaran morfologi dengan pewarnaan giemsa menunjukkan inti"
  },
  {
    "id": 198,
    "paragraph": "sel berwarna biru keunguan dan granula tampak cukup jelas terlihat berwarna merah muda, dan apusan lebih tahan lama. Pewarnaan Wright inti sel dan granula menunjukan tampak lebih jelas terlihat kemerahan dengan warna yang lebih menonjol dibandingkan dengan pewarnaan Giemsa namun kekurangan pewarna",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "sel berwarna biru keunguan dan granula tampak cukup jelas terlihat berwarna merah muda dan apusan lebih tahan lama pewarnaan wright inti sel dan granula menunjukan tampak lebih jelas terlihat kemerahan dengan warna yang lebih menonjol dibandingkan dengan pewarnaan giemsa namun kekurangan pewarna"
  },
  {
    "id": 199,
    "paragraph": "Wright yaitu tidak tahan lama dalam iklim dengan tropis. Apusan pewarnaan kombinasi Wright- Giemsa terdapat kelebihan dari setiap zat warna yaitu granula, plasma dan inti lebih jelas terlihat dan pewarnaan lebih tahan lama disimpan. ini penelitian Berdasarkan uraian diatas, maka penting",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "wright yaitu tidak tahan lama dalam iklim dengan tropis apusan pewarnaan kombinasi wright giemsa terdapat kelebihan dari setiap zat warna yaitu granula plasma dan inti lebih jelas terlihat dan pewarnaan lebih tahan lama disimpan ini penelitian berdasarkan uraian diatas maka penting"
  },
  {
    "id": 200,
    "paragraph": "dilakukan. Hal ini bertujuan agar tenaga medis mampu mengetahui gejala dari penyakit AML lebih awal menggunakan metode pewarnaan Giemsa, pewarnaan Wright, dan pewarnaan kombinasi Wright- Giemsa. METODE PENELITIAN studi Penelitian ini menggunakan desain penelitian literature review dengan metode penelitian deskriptif kasus. Sumber",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "dilakukan hal ini bertujuan agar tenaga medis mampu mengetahui gejala dari penyakit aml lebih awal menggunakan metode pewarnaan giemsa pewarnaan wright dan pewarnaan kombinasi wright giemsa metode penelitian studi penelitian ini menggunakan desain penelitian literature review dengan metode penelitian deskriptif kasus sumber"
  },
  {
    "id": 201,
    "paragraph": "kualitatif pencarian literature didapatkan dari Google Scholar, PubMed dan Scient Direct. Literature yang digunakan adalah memiliki periode antara tahun 2012 hingga 2022, atau 10 tahun terakhir serta dapat diakses full text dan kunci Wright”, dalam format pdf tanpa batasan bahasa. Pencarian",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "kualitatif pencarian literature didapatkan dari google scholar pubmed dan scient direct literature yang digunakan adalah memiliki periode antara tahun 2012 hingga 2022 atau 10 tahun terakhir serta dapat diakses full text dan kunci wright ” dalam format pdf tanpa batasan bahasa pencarian"
  },
  {
    "id": 202,
    "paragraph": "Negara literature dilakukan sesuai dengan kata “Acute Myeloid Leukimia”, “Pewarnaan Giemsa”, “Pewarnaan dan “Pewarnaan Wright-Giemsa” yang sebelumnya ditentukan berdasarkan metode PICO. Literature yang diperoleh artikel berbahasa Indonesia maupun artikel berbahasa Inggris. Total literature yang didapatkan adalah sebanyak jurnal kemudian diseleksi 5712",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "negara literature dilakukan sesuai dengan kata “ acute myeloid leukimia ” “ pewarnaan giemsa ” “ pewarnaan dan “ pewarnaan wrightgiemsa ” yang sebelumnya ditentukan berdasarkan metode pico literature yang diperoleh artikel berbahasa indonesia maupun artikel berbahasa inggris total literature yang didapatkan adalah sebanyak jurnal kemudian diseleksi 5712"
  },
  {
    "id": 203,
    "paragraph": "berdasarkan kriteria inklusi dan sehingga didapatkan 10 ekslusi jurnal. berupa dapat HASIL DAN PEMBAHASAN Hasil penelitian dari literature review didapatkan dengan cara penelusuran pustaka melalui jurnal elektronik internet berupa yang diperoleh Google Scholar, Science Direct, atau PubMegov yang kemudian berdasarkan diseleksi",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "berdasarkan kriteria inklusi dan sehingga didapatkan 10 ekslusi jurnal berupa dapat hasil dan pembahasan hasil penelitian dari literature review didapatkan dengan cara penelusuran pustaka melalui jurnal elektronik internet berupa yang diperoleh google scholar science direct atau pubmegov yang kemudian berdasarkan diseleksi"
  },
  {
    "id": 204,
    "paragraph": "topik yang akan dibahas berdasarkan kriteria inklusi dan ekslusi. Pencarian literature dilakukan sesuai dengan kata kunci menggunakan literature metode PICO. Setelah diperoleh, dilakukan proses skrining judul dan abstrak yang sesuai dengan topik penelitian. Setelah screening diltemukan 10 jurnal yang sesuai sebagai berikut :",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "topik yang akan dibahas berdasarkan kriteria inklusi dan ekslusi pencarian literature dilakukan sesuai dengan kata kunci menggunakan literature metode pico setelah diperoleh dilakukan proses skrining judul dan abstrak yang sesuai dengan topik penelitian setelah screening diltemukan 10 jurnal yang sesuai sebagai berikut"
  },
  {
    "id": 205,
    "paragraph": "kata Tabel 4. 1 Ringkasan Jurnal NO Judul/ Penulis/Tahun 1. Clinical Characteristic and Laboratory Analyses of Acute Myeloid Leukimia (16;21) with (p11;q22) (Zhang et al., 2015) t Populasi/ Sampel 3 pasien dengan leukemia myeloid akut (AML) yang memiliki kelainan genetik spesifik",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "kata tabel 4 1 ringkasan jurnal judul penulistahun 1 clinical characteristic laboratory analyses acute myeloid leukimia 1621 p11q22 zhang et al 2015 populasi sampel 3 pasien dengan leukemia myeloid akut aml yang memiliki kelainan genetik spesifik"
  },
  {
    "id": 206,
    "paragraph": "Hasil Penelitian Berdasarkan hasil pemeriksaan identifikasi leukemia blast cell dengan pewarnaa Wright- Giemsa pada pasien 1 (M4) sebesar 77,5%, pasien 2 (M1) sebesar 93,5% , dan pasien 3 (M2) sebesar 62% 2. Abnormal Expression of CD79a, CD59, and CD7 Acute in",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "hasil penelitian berdasarkan hasil pemeriksaan identifikasi leukemia blast cell dengan pewarnaa wright giemsa pada pasien 1 m4 sebesar 775 pasien 2 m1 sebesar 935 dan pasien 3 m2 sebesar 62 2 abnormal expression cd79a cd59 cd7 acute"
  },
  {
    "id": 207,
    "paragraph": "Myeloid Leukimia (Elyamany et., al 2017) 1 pasien laki-laki penderita AML, diabetes, hipertensi, iskemik penyakit jantung, dan HBV 1 pasien anak laki- penderita laki AML berusia 26 tanpa bulan adanya riwayat penyakit hematologi 1 pasien laki-laki berumur 70 tahun dengan diagnosis",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "myeloid leukimia elyamany et al 2017 1 pasien lakilaki penderita aml diabetes hipertensi iskemik penyakit jantung dan hbv 1 pasien anak laki penderita laki aml berusia 26 tanpa bulan adanya riwayat penyakit hematologi 1 pasien lakilaki berumur 70 tahun dengan diagnosis"
  },
  {
    "id": 208,
    "paragraph": "myelofibrosis primer 3. A Case Report : Myeloid (FAB Acute Leukimia M7) (Masoumi-Deshiri, 2014) 4. Acute Myeoloid Leukimia Evolving From JAK-2 Positive Primary Myelofibrosis and Concominant CD5- Negative Mantle Cell Lymphoma : A Case Report and The Review Literature (Treaba 2012)",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "myelofibrosis primer 3 case report myeloid fab acute leukimia m7 masoumideshiri 2014 4 acute myeoloid leukimia evolving jak2 positive primary myelofibrosis concominant cd5 negative mantle cell lymphoma case report review literature treaba 2012"
  },
  {
    "id": 209,
    "paragraph": "al., of et sel sedang peningkatan pemeriksaan Wright- Hasil Giemsa pada penderita AML menunjukkan sel blast sebesar 21% dari total sel darah putih, hingga berukuran besar,terdapat nukleus lebih dari satu, terdapat sitoplasma yang relatif melimpah, mengalami basofil Berdasarkan hasil pemeriksaan pewarnaan Wright-Giemsa pada",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "al et sel sedang peningkatan pemeriksaan wright hasil giemsa pada penderita aml menunjukkan sel blast sebesar 21 dari total sel darah putih hingga berukuran besarterdapat nukleus lebih dari satu terdapat sitoplasma yang relatif melimpah mengalami basofil berdasarkan hasil pemeriksaan pewarnaan wrightgiemsa pada"
  },
  {
    "id": 210,
    "paragraph": "penderita AML terdapat jumlah leukosit diferensial sebesar 5% eusinofil, 62% limfosit, dan 31% neutrofil dan berbentuk pita 1% Berdasarkan hasil pemeriksaan Wright-Giemsa pewarnaan terdapat jumlah neutrofil yang meningkat, terdapat hipersegmentasi neutrofil. Sel darah putih diferensial meliputi neutrofil bersegmen 78%, monosit 5%, limfosit 11%, dan",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "penderita aml terdapat jumlah leukosit diferensial sebesar 5 eusinofil 62 limfosit dan 31 neutrofil dan berbentuk pita 1 berdasarkan hasil pemeriksaan wrightgiemsa pewarnaan terdapat jumlah neutrofil yang meningkat terdapat hipersegmentasi neutrofil sel darah putih diferensial meliputi neutrofil bersegmen 78 monosit 5 limfosit 11 dan"
  },
  {
    "id": 211,
    "paragraph": "basofil 6% 5. A Rare Type of Acute Leukemia in Peripheral Blood (Suarez 2022) et al., 6. Karakteristik Penderita Leukimia Akut yang Dirawat di RSUP Sanglah Denpasar 2014-2015 (Prashanti, 2020) Tahun 7. A Case of Chronic Myeloid Leukimia with Features of",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "basofil 6 5 rare type acute leukemia peripheral blood suarez 2022 et al 6 karakteristik penderita leukimia akut yang dirawat di rsup sanglah denpasar 20142015 prashanti 2020 tahun 7 case chronic myeloid leukimia features"
  },
  {
    "id": 212,
    "paragraph": "Essential Thrombocythemia in Peripheral Blood and Bone Marrow (Byun, 2014) 8. Pendekatan Diagnostik Terhadap Leukimia Akut (Hartoyo Kurniawan, 2016) & 9. Seorang Penderita Myeloid (AML) yang tumor Acute Leukimia (M4) Mengalami lysis syndrom (Nugraha 2017) dkk., Lanjutan Tabel 4.1 1 pasien wanita",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "essential thrombocythemia peripheral blood bone marrow byun 2014 8 pendekatan diagnostik terhadap leukimia akut hartoyo kurniawan 2016 9 seorang penderita myeloid aml yang tumor acute leukimia m4 mengalami lysis syndrom nugraha 2017 dkk lanjutan tabel 41 1 pasien wanita"
  },
  {
    "id": 213,
    "paragraph": "penderita AML berusia 80 tahun Pasien penderita LLA 11 orang dan penderita 30 orang LMA penderita pewarnaan Wright Hasil menunjukkan proliferasi neoplastik >80% dengan 30% proeritoblas tanpa tanda komponen myeloblastik yang signifikan Penderita AML pada apusan leukosit tepi darah penderita menunjukkan",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "penderita aml berusia 80 tahun pasien penderita lla 11 orang dan penderita 30 orang lma penderita pewarnaan wright hasil menunjukkan proliferasi neoplastik 80 dengan 30 proeritoblas tanpa tanda komponen myeloblastik yang signifikan penderita aml pada apusan leukosit tepi darah penderita menunjukkan"
  },
  {
    "id": 214,
    "paragraph": "leukosit dengan penderita normal, leukositosis, dan 2 lainnya leukopenia gambaran 15 1 1 pasien wanita yang berusia 21 tahun tanpa ada riwayat penyakit atau hematologi kelainan genetik pewarnaan Wright- Hasil Giemsa menunjukkan diferensiasi sel darah putih meliputi neutrofil 63%, limfosit 33%, eosinofil 1%, basofil 3%,",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "leukosit dengan penderita normal leukositosis dan 2 lainnya leukopenia gambaran 15 1 1 pasien wanita yang berusia 21 tahun tanpa ada riwayat penyakit atau hematologi kelainan genetik pewarnaan wright hasil giemsa menunjukkan diferensiasi sel darah putih meliputi neutrofil 63 limfosit 33 eosinofil 1 basofil 3"
  },
  {
    "id": 215,
    "paragraph": "dan monosit 0% 1 pasien wanita penderita AML berusia 17 tahun tanpa ada riwayat penyakit kronik 1 pasien laki-laki penderita AML dengan usia 16 tahu Hasil apus darah tepi pada pewarnaan Giemsa menunjukkan bisitopenia sel blast dengan dominan limfosit 26% suspek leukemia",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "dan monosit 0 1 pasien wanita penderita aml berusia 17 tahun tanpa ada riwayat penyakit kronik 1 pasien lakilaki penderita aml dengan usia 16 tahu hasil apus darah tepi pada pewarnaan giemsa menunjukkan bisitopenia sel blast dengan dominan limfosit 26 suspek leukemia"
  },
  {
    "id": 216,
    "paragraph": "akut. Sel-sel blast berukuran besar dengan nucleoli jelas dan ratio inti-sitoplasma rendah. Meioblas bewarna biru-keabuan Gambaran leukosit didominasi oleh sel monosit dan promosit >20%; Sel myeloid mengalami proliferasi, megakariosit, dan jaringan lemak matur. Kadar sel darah putih >25x103 ul hanya 1%",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "akut selsel blast berukuran besar dengan nucleoli jelas dan ratio intisitoplasma rendah meioblas bewarna birukeabuan gambaran leukosit didominasi oleh sel monosit dan promosit 20 sel myeloid mengalami proliferasi megakariosit dan jaringan lemak matur kadar sel darah putih 25x103 ul hanya 1"
  },
  {
    "id": 217,
    "paragraph": "10. Practical Staining Method of Well- 1 pasien wanita penderita AML Berdasarkan hasil penelitian tenik apusan darah tentang unstained Haematological Specimens (Yokus 2017) et al., yang yang berumur 28 tahun dan 38 tahun dan dengan pewarnaan May- dengan Giemsa Grunwald dilakukan",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "10 practical staining method well 1 pasien wanita penderita aml berdasarkan hasil penelitian tenik apusan darah tentang unstained haematological specimens yokus 2017 et al yang yang berumur 28 tahun dan 38 tahun dan dengan pewarnaan may dengan giemsa grunwald dilakukan"
  },
  {
    "id": 218,
    "paragraph": "cara dikeringkan pada suhu kamar reagen dan sebanyak 5-7 tetes kemudian didiamkan selama 1,5 menit. Diberi pewarnaan Giemsa sebanyak 5-7 tetes dan menuangkan didiamkan 4 menit. Berdasarkan hasil penelusuran yang disajikan dalam Tabel 4.1 diperoleh 10 jurnal dengan 7 jurnal internasional dengan menggunakan",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "cara dikeringkan pada suhu kamar reagen dan sebanyak 57 tetes kemudian didiamkan selama 15 menit diberi pewarnaan giemsa sebanyak 57 tetes dan menuangkan didiamkan 4 menit berdasarkan hasil penelusuran yang disajikan dalam tabel 41 diperoleh 10 jurnal dengan 7 jurnal internasional dengan menggunakan"
  },
  {
    "id": 219,
    "paragraph": "Bahasa Inggris dan 3 jurnal nasional dengan Bahasa menggunakan Indonesia. Subjek yang digunakan pada penelitian berjumlah 52 pasien dari jumlah pasien keseluruhan pada jurnal penderita AML. Subjek 10 tersebut berjenis kelamin laki-laki maupun perempuan dengan rentang usia 26 bulan – 80 tahun dengan atau",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "bahasa inggris dan 3 jurnal nasional dengan bahasa menggunakan indonesia subjek yang digunakan pada penelitian berjumlah 52 pasien dari jumlah pasien keseluruhan pada jurnal penderita aml subjek 10 tersebut berjenis kelamin lakilaki maupun perempuan dengan rentang usia 26 bulan – 80 tahun dengan atau"
  },
  {
    "id": 220,
    "paragraph": "tanpa adanya riwayat penyakit bawaan hematologi. Jenis kanker darah ini paling sering terjadi pada orang yang berusia di atas 65 tahun. Dalam penelitian ini sampel yang digunakan berasal dari darah manusia serta sel yang diamati adalah sel leukosit. Tujuan dari pewarnaan",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "tanpa adanya riwayat penyakit bawaan hematologi jenis kanker darah ini paling sering terjadi pada orang yang berusia di atas 65 tahun dalam penelitian ini sampel yang digunakan berasal dari darah manusia serta sel yang diamati adalah sel leukosit tujuan dari pewarnaan"
  },
  {
    "id": 221,
    "paragraph": "pada sediaan apusan darah yaitu untuk atau memperjelas mempertajam morfologi sel darah sehingga sel darah dapat dibedakan di bawah mikroskop. Berdasarkan hasil pengamatan secara mikroskopis pada apusan darah tepi yang sudah diwarnai menggunakan pewarnaan Giemsa, Wrigth, dan Kombinasi Wright-Giemsa didapat hasil yang menunjukkan perbedaan",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "pada sediaan apusan darah yaitu untuk atau memperjelas mempertajam morfologi sel darah sehingga sel darah dapat dibedakan di bawah mikroskop berdasarkan hasil pengamatan secara mikroskopis pada apusan darah tepi yang sudah diwarnai menggunakan pewarnaan giemsa wrigth dan kombinasi wrightgiemsa didapat hasil yang menunjukkan perbedaan"
  },
  {
    "id": 222,
    "paragraph": "inti sel pada warna granula dan leukosit serta perbedaan ketahanan lama penyimpanan preparat apusan darah tepi yaitu : 1. Pewarnaan Giemsa Gambar 4. 1Hasil Pewarnaan Giemsa (Kurniawan, 2016) Hasil pewarnaan Giemsa pada Gambar 4.1 oleh peneliti Hartoyo & Kurniawan, (2016) didapatkan hasil",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "inti sel pada warna granula dan leukosit serta perbedaan ketahanan lama penyimpanan preparat apusan darah tepi yaitu 1 pewarnaan giemsa gambar 4 1hasil pewarnaan giemsa kurniawan 2016 hasil pewarnaan giemsa pada gambar 41 oleh peneliti hartoyo kurniawan 2016 didapatkan hasil"
  },
  {
    "id": 223,
    "paragraph": "gambaran morfologi leukosit pada sediaan menunjukkan warna granula berwarna merah muda dengan inti sel berwarna biru keunguan. Hal ini dikarenakan Giemsa mengandung larutan methylene blue dengan larutan eosin. Sehingga apabila sediaan darah diwarnai dengan larutan tersebut maka leukosit akan terlihat menjadi bewarna lembayung tua atau",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "gambaran morfologi leukosit pada sediaan menunjukkan warna granula berwarna merah muda dengan inti sel berwarna biru keunguan hal ini dikarenakan giemsa mengandung larutan methylene blue dengan larutan eosin sehingga apabila sediaan darah diwarnai dengan larutan tersebut maka leukosit akan terlihat menjadi bewarna lembayung tua atau"
  },
  {
    "id": 224,
    "paragraph": "biru keunguan. Pewarnaan Giemsa pewarnaan iklim tahan pada tropis sehingga pewarnaan ini banyak digunakan di Indonesia. 2. Pewarnaan Wright Gambar 4. 2 Hasil Pewarnaan Wright (Suarez et al, 2022) sedangkan warna Hasil pewarnaan Wright pada gambar 4.2 oleh peneliti Suarez et al.,",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "biru keunguan pewarnaan giemsa pewarnaan iklim tahan pada tropis sehingga pewarnaan ini banyak digunakan di indonesia 2 pewarnaan wright gambar 4 2 hasil pewarnaan wright suarez et al 2022 sedangkan warna hasil pewarnaan wright pada gambar 42 oleh peneliti suarez et al"
  },
  {
    "id": 225,
    "paragraph": "2022 morfologi leukosit pada sediaan tersebut granula nampak berwarna inti kemerahan, Jika selnya dibandingkan pewarnaan sebelumnya yaitu pewarnaan Giemsa, pewarnaan Wright lebih jelas yaitu granula nampak berwarna kemerahan, berwarna sedangkan kebiruan. kebiruan. berwarna dengan selnya inti 3. Pewarnaan Kombinasi Wright- Giemsa",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "2022 morfologi leukosit pada sediaan tersebut granula nampak berwarna inti kemerahan jika selnya dibandingkan pewarnaan sebelumnya yaitu pewarnaan giemsa pewarnaan wright lebih jelas yaitu granula nampak berwarna kemerahan berwarna sedangkan kebiruan kebiruan berwarna dengan selnya inti 3 pewarnaan kombinasi wright giemsa"
  },
  {
    "id": 226,
    "paragraph": "berwarna Hasil pewarnaan kombinasi Wright-Giemsa pada Gambar 4.3 oleh et., al 2017 peneliti Elyamany morfologi sediaan leukosit pada tersebut warna granula cukup jelas terlihat kemerahan sedangkan warna inti selnya berwarna biru tua. Jika dibandingkan dengan pewarnaan sebelumnya yaitu Giemsa dan Wright pewarnaan kombinasi",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "berwarna hasil pewarnaan kombinasi wrightgiemsa pada gambar 43 oleh et al 2017 peneliti elyamany morfologi sediaan leukosit pada tersebut warna granula cukup jelas terlihat kemerahan sedangkan warna inti selnya berwarna biru tua jika dibandingkan dengan pewarnaan sebelumnya yaitu giemsa dan wright pewarnaan kombinasi"
  },
  {
    "id": 227,
    "paragraph": "Wright dan Giemsa terlihat sangat jelas terlihat dan terwarnai dengan sangat baik. Hasil warna yang didapatkan dengan pewarnaan Wright- Giemsa lebih tegas jika dibandingkan dengan pewarnaan sebelumnya. Hal ini dikarenakan zat warna yang terkandung dalam pewarna Giemsa dan Wright bereaksi dengan sifat",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "wright dan giemsa terlihat sangat jelas terlihat dan terwarnai dengan sangat baik hasil warna yang didapatkan dengan pewarnaan wright giemsa lebih tegas jika dibandingkan dengan pewarnaan sebelumnya hal ini dikarenakan zat warna yang terkandung dalam pewarna giemsa dan wright bereaksi dengan sifat"
  },
  {
    "id": 228,
    "paragraph": "kimiawi dalam sel. sediaan Jenis-jenis sementara, ketahanannya sediaan dapat berdasarkan jenis yaitu dibedakan menjadi 3 sediaan semi permanen, dan sediaan permanen atau awetan (Latifa, 2015) Berdasarkan hasil literature yang didapat sediaan bersifat yang bersifat permanen kualitas sementara setelah sediaan dilakukan dengan",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "kimiawi dalam sel sediaan jenisjenis sementara ketahanannya sediaan dapat berdasarkan jenis yaitu dibedakan menjadi 3 sediaan semi permanen dan sediaan permanen atau awetan latifa 2015 berdasarkan hasil literature yang didapat sediaan bersifat yang bersifat permanen kualitas sementara setelah sediaan dilakukan dengan"
  },
  {
    "id": 229,
    "paragraph": "menggunakan Giemsa, Wright, dan kombinasi Wright-Giemsa hanya dapat bertahan beberapa hari saja dan sediaan tidak diawetkan tersebut dengan menggunakan entelan. tidak digunakan atau hanya saja. Karena diperoleh pewarnaan yang Gambar 4. 3 Hasil Pewarnaan Kombinasi Wright-Giemsa (Elyamany dkk, 2013) Pasien penderita AML tahap",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "menggunakan giemsa wright dan kombinasi wrightgiemsa hanya dapat bertahan beberapa hari saja dan sediaan tidak diawetkan tersebut dengan menggunakan entelan tidak digunakan atau hanya saja karena diperoleh pewarnaan yang gambar 4 3 hasil pewarnaan kombinasi wrightgiemsa elyamany dkk 2013 pasien penderita aml tahap"
  },
  {
    "id": 230,
    "paragraph": "awal menimbulkan beberapa gejala yang menyerupai flu seperti; demam, keringat nafsu makan, hilang berlebihan terutama malam hari, mudah lelah, dan sakit kepala. yang factor Sementara dapat meningkatkan resiko seseorang AML adalah manusia berusia 65 tahun atau lebih, daya lemah, tahan kelainan darah/genetik, riwayat AML",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "awal menimbulkan beberapa gejala yang menyerupai flu seperti demam keringat nafsu makan hilang berlebihan terutama malam hari mudah lelah dan sakit kepala yang factor sementara dapat meningkatkan resiko seseorang aml adalah manusia berusia 65 tahun atau lebih daya lemah tahan kelainan darahgenetik riwayat aml"
  },
  {
    "id": 231,
    "paragraph": "dalam pernah serta keluarga kemoterapi dan radioterapi. tubuh (AML) Pemeriksaan penunjang penderita Acute Myeloid pasien Leukemia akan memiliki gambaran apusan darah tepi sebagai berikut : 1. Leukositas berat 20.000- permulaan lebih dari 50.000/mm3 pada kemudian biasanya 100.000/mm3. 2. Menunjukkan spectrum lengkap",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "dalam pernah serta keluarga kemoterapi dan radioterapi tubuh aml pemeriksaan penunjang penderita acute myeloid pasien leukemia akan memiliki gambaran apusan darah tepi sebagai berikut 1 leukositas berat 20000 permulaan lebih dari 50000mm3 pada kemudian biasanya 100000mm3 2 menunjukkan spectrum lengkap"
  },
  {
    "id": 232,
    "paragraph": "seri granulosit mulai dari segmen sampai neutrofil, myeloblast paling menonjol komponen neutrofil adalah (hipersegmen) dan mielosit. Metamielost, promielosit >30%, dan myeloblast juga dijumpai. Sel blast >20% dan sel darah merah bernukleus. 3. Jumlah basofil dalam darah meningkat (>20%). 4. Trombosit bisa meningkat,",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "seri granulosit mulai dari segmen sampai neutrofil myeloblast paling menonjol komponen neutrofil adalah hipersegmen dan mielosit metamielost promielosit 30 dan myeloblast juga dijumpai sel blast 20 dan sel darah merah bernukleus 3 jumlah basofil dalam darah meningkat 20 4 trombosit bisa meningkat"
  },
  {
    "id": 233,
    "paragraph": "normal, atau menurun. Fase awal lebih sering meningkat. 5. Fosfatase neutrofil alkali (neutrophil alkaline phospatase) selalu rendah. Tabel 4. 2 Hasil Literature Review apusan darah tepi pasien penderita AML Eritrosit Trombosit Leukosit Pewarnaan Apusan Darah Tepi Wright-Giemsa Presentase Sel Blast (%)",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "normal atau menurun fase awal lebih sering meningkat 5 fosfatase neutrofil alkali neutrophil alkaline phospatase selalu rendah tabel 4 2 hasil literature review apusan darah tepi pasien penderita aml eritrosit trombosit leukosit pewarnaan apusan darah tepi wrightgiemsa presentase sel blast"
  },
  {
    "id": 234,
    "paragraph": "62-93,5 % Wright-Giemsa 21% - - - - Wright-Giemsa - Berinti Giant Trombosit Wright-Giemsa - - - Memiliki pseudopodia Ukuran sedang- besar 5% eusinofil, 62% limfosit, dan 31 % neutrophil dan berbentuk pita 1% Neutrofil bersegmen 78%, monosit 5%, Jurnal Jurnal",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "62935 wrightgiemsa 21 wrightgiemsa berinti giant trombosit wrightgiemsa memiliki pseudopodia ukuran sedang besar 5 eusinofil 62 limfosit dan 31 neutrophil dan berbentuk pita 1 neutrofil bersegmen 78 monosit 5 jurnal jurnal"
  },
  {
    "id": 235,
    "paragraph": "1 Jurnal 2 Jurnal 3 Jurnal 4 Lanjutan Tabel 4.2 Wright 30% - - - Eritrosit normokromik normosifer 73,3% Wright-Giemsa - Giemsa 26% - ≥ 20% Maygrundwald- Giemsa - - - - - Jurnal 5 Jurnal 6 Jurnal 7 Jurnal 8",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "1 jurnal 2 jurnal 3 jurnal 4 lanjutan tabel 42 wright 30 eritrosit normokromik normosifer 733 wrightgiemsa giemsa 26 ≥ 20 maygrundwald giemsa jurnal 5 jurnal 6 jurnal 7 jurnal 8"
  },
  {
    "id": 236,
    "paragraph": "Jurnal 9 Jurnal 10 limfosit 11%, dan basofil 6% - - neutrofil 63%, limfosit 33%, eosinofil 1%, basofil 3%, dan monosit 0%. - - - - - - - - - oleh Berdasarkan Tabel 4.2 penderita AML memiliki persentase sel blast",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "jurnal 9 jurnal 10 limfosit 11 dan basofil 6 neutrofil 63 limfosit 33 eosinofil 1 basofil 3 dan monosit 0 oleh berdasarkan tabel 42 penderita aml memiliki persentase sel blast"
  },
  {
    "id": 237,
    "paragraph": "leukosit >20% yaitu berkisar antara 21-93,5%. Terdapat kelainan pada sel darah merah dan sel trombosit. Hal ini dapat terjadi karena sel darah manusia diproduksi tulang belakang. Produksi sel darah putih secara berlebihan dapat mengganggu produksi sel darah lainnya yang sehat, sel darah merah dan",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "leukosit 20 yaitu berkisar antara 21935 terdapat kelainan pada sel darah merah dan sel trombosit hal ini dapat terjadi karena sel darah manusia diproduksi tulang belakang produksi sel darah putih secara berlebihan dapat mengganggu produksi sel darah lainnya yang sehat sel darah merah dan"
  },
  {
    "id": 238,
    "paragraph": "termasuk sehingga menyebabkan trombosit, penderita AML dapat mengalami anemia dan terdapat kelainan pada sel trombositnya. sumsum SIMPULAN Berdasarkan penelitian literature review ini dapat disimpulkan bahwa hasil pewarnaan apusan sel darah tepi manusia dengan pewarnaan Giemsa menunjukkan inti sel bewarna biru keunguan dan granula berwarna",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "termasuk sehingga menyebabkan trombosit penderita aml dapat mengalami anemia dan terdapat kelainan pada sel trombositnya sumsum simpulan berdasarkan penelitian literature review ini dapat disimpulkan bahwa hasil pewarnaan apusan sel darah tepi manusia dengan pewarnaan giemsa menunjukkan inti sel bewarna biru keunguan dan granula berwarna"
  },
  {
    "id": 239,
    "paragraph": "merah muda. Pewarnaan Wright inti sel dan granula menunjukkan tampak lebih jelas terlihat kemerahan dengan warna yang lebih terang dan jelas dibanding Giemsa. Apusan dengan pewarnaan kombinasi Wright- Giemsa terdapat kelebihan dari setiap zat warna dimana granula, plasma dan inti lebih jelas terlihat dan warna yang",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "merah muda pewarnaan wright inti sel dan granula menunjukkan tampak lebih jelas terlihat kemerahan dengan warna yang lebih terang dan jelas dibanding giemsa apusan dengan pewarnaan kombinasi wright giemsa terdapat kelebihan dari setiap zat warna dimana granula plasma dan inti lebih jelas terlihat dan warna yang"
  },
  {
    "id": 240,
    "paragraph": "M.A.(2017). Acute Myeilod Leukimia.Jurnal KedokteranI, 1- 51. Bain, J. B., Bates, I., Laffan, A. M., & Lewis, S. M. (2012), Dacie and Lewis Practical Haematology (11th ed.). London: Elsevier Churchill Livingstone. Bell. A. & Sallah, S., (2015). The Morphology of Human Blood",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "ma2017 acute myeilod leukimiajurnal kedokterani 1 51 bain j b bates laffan lewis 2012 dacie lewis practical haematology 11th ed london elsevier churchill livingstone bell sallah 2015 morphology human blood"
  },
  {
    "id": 241,
    "paragraph": "Seventh Edition. Cells – of Memphis : Devision of Hematology. University Tennessee Health Science Center. Dalimoenthe, NZ. (2002). Penilaian Sediaan Hapus Darah Tepi dan Sumsum Tulang. Jurnal Badan Patologi Klinik, 129-148. Elyamany, G., Alabdulaay, A., & Fadalla, K. (2013). Abnormal Expression of CD79a, CD56,",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "seventh edition cells – memphis devision hematology university tennessee health science center dalimoenthe nz 2002 penilaian sediaan hapus darah tepi dan sumsum tulang jurnal badan patologi klinik 129148 elyamany g alabdulaay fadalla k 2013 abnormal expression cd79a cd56"
  },
  {
    "id": 242,
    "paragraph": "and CD7 in Acute Myeloid Leukemia. Pathology Discovery Hebert Open Access Journals. 2052(7896) : 1-6. Hartoyo, V., & Kurniawan, A. (2017). Pendekatan Diagnostik Terhadap Leukemia Akut. Medicinus. 6(1) : 14-17. Kiswari Rukman. (2014) Hematologi & Transfusi.Jakarta : Erlangga. Kurniawan, A. (2010). Perbedaan",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "cd7 acute myeloid leukemia pathology discovery hebert open access journals 20527896 16 hartoyo v kurniawan 2017 pendekatan diagnostik terhadap leukemia akut medicinus 61 1417 kiswari rukman 2014 hematologi transfusijakarta erlangga kurniawan 2010 perbedaan"
  },
  {
    "id": 243,
    "paragraph": "Hasil Pewarnaan Giemsa dan Wright Terhadap Morfologi Eritrosit Dan Kualitas Cat Pada Preparat Darah Apus. KTI. Universitas Muhammadiyah Semarang. Latifa, Roimil. (2015). Peningkatan Kualitas Preparat Histologi Berbasis Kegiatan Praktikum di Laboratorium Biologi. Prosiding Seminar Nasional Pendidikan Biologi. Malang: Jurusan Biologi Fakultas Keguruan dan Ilmu",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "hasil pewarnaan giemsa dan wright terhadap morfologi eritrosit dan kualitas cat pada preparat darah apus kti universitas muhammadiyah semarang latifa roimil 2015 peningkatan kualitas preparat histologi berbasis kegiatan praktikum di laboratorium biologi prosiding seminar nasional pendidikan biologi malang jurusan biologi fakultas keguruan dan ilmu"
  },
  {
    "id": 244,
    "paragraph": "Pendidikan Universitas Muhammadiyah Malang Masoumi-Deshiri et al.,(2014). A Case Report : Acute Myeloid Leukimia (FAB M7). Iran J Ped Hematol Oncol, 4(4): 188–190. Tumor Nugraha, I. B. A., & Adnyana, I. W. L. (2017). Seorang Penderita Acute Myeloid Leukemia (AML) yang",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "pendidikan universitas muhammadiyah malang masoumideshiri et al2014 case report acute myeloid leukimia fab m7 iran j ped hematol oncol 44 188–190 tumor nugraha b adnyana w l 2017 seorang penderita acute myeloid leukemia aml yang"
  },
  {
    "id": 245,
    "paragraph": "Mengalami Lysis Syndrome. Jurnal Penyakit Dalam Udayana. 1(1) : 8-16. Prashanti, N. A., & Rena, N. M. R. A. (2020). Karakteristik Penderita Leukemia Akut yang Dirawat di RSUP Sanglah Denpasar Tahun 2014-2015. Jurnal Medika Udayana. 9(4) : 1-6. Suarez, E. U., Cortti, M.J., & Soto de",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "mengalami lysis syndrome jurnal penyakit dalam udayana 11 816 prashanti n rena n r 2020 karakteristik penderita leukemia akut yang dirawat di rsup sanglah denpasar tahun 20142015 jurnal medika udayana 94 16 suarez e u cortti mj soto de"
  },
  {
    "id": 246,
    "paragraph": "Ozaeta, C. (2022). A Rare Type of Acute Leukemia in Peripheral Blood Smear Hematology, Transfusion, and Cell Therapy. 1-2. Treaba, D.O., Khedr, S., Mangray, S., Jackson, C., Castillo, J.J., & Winer, E. S., (2012). Acute Myeloid Lekemia Elvolving from JAK 2-Positive Primary",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "ozaeta c 2022 rare type acute leukemia peripheral blood smear hematology transfusion cell therapy 12 treaba khedr mangray jackson c castillo jj winer e 2012 acute myeloid lekemia elvolving jak 2positive primary"
  },
  {
    "id": 247,
    "paragraph": "Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma : A Case Report and Review of the Literature. Case Report in Hematology. 1-6. World Health Organization. Acute Myelogenous Leukemia and Acute Promyelocytic Leukemia. (2014), dari diunduh http://www.who.int/selection_m edicines/committees/expert/20/a pplications/AML_APL.pdf Diakses Tanggal 19 April 2022.",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "myelofibrosis concomitant cd5negative mantle cell lymphoma case report review literature case report hematology 16 world health organization acute myelogenous leukemia acute promyelocytic leukemia 2014 dari diunduh httpwwwwhointselectionm edicinescommitteesexpert20a pplicationsamlaplpdf diakses tanggal 19 april 2022"
  },
  {
    "id": 248,
    "paragraph": "Yokus, O., Gedik, H., & Sahin, E.C. Staining Practical of Well-Unstained Specimens. Transfusion : (2017). Method Haematological Hematology & International Journal. 4(5) 136-137. Y. Zhang, Z., Zou, J., Li, Y., Liu, Z., Xu, R., Tian, W., Zhao, Z., Sun, H., Han, J., Wang, J., Zhang, B., &",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "yokus gedik h sahin ec staining practical wellunstained specimens transfusion 2017 method haematological hematology international journal 45 136137 zhang z zou j li liu z xu r tian w zhao z sun h han j wang j zhang b"
  },
  {
    "id": 249,
    "paragraph": "Ju, Clinical (2015). Characteristic and Laboratory Analyses of Acute Myeloid with Leukekia t(16;21)(p11;q22). Oncology Letters. 1-5. Khasanah, N. A. ., & Suminar, I. T. (2021). Pengaruh Kemoterapi terhadap Status Gizi pada Anak dengan Leukemia Limfoblastik Akut (LLA) : Literature Review. UNISA Yogyakarta,",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "ju clinical 2015 characteristic laboratory analyses acute myeloid leukekia t1621p11q22 oncology letters 15 khasanah n suminar 2021 pengaruh kemoterapi terhadap status gizi pada anak dengan leukemia limfoblastik akut lla literature review unisa yogyakarta"
  },
  {
    "id": 250,
    "paragraph": "1–12. http://digilib.unisayogya.ac.id/56 22/1/NOVI AGUSTINA NK_1710201179_KEPERAWA TAN - NK%281%29.pdf Agustina Novi Savitri, M. V., & Kustiningsih. (2022). Hubungan Tahap Kemoterapi Status Gizi Anak dengan Penderita Leukimia Limfoblastik Review. Akut : Literature 1–12. UNISA Yogyakarta, http://digilib.unisayogya.ac.id/66 03/1/1810201100 NASKAH PUBLIKASI MASRIYATI VITRIA SAVITRI - Linda Ayu",
    "jurnal": "1711304040-TLM-NATASA_IRAWATI_-_Natasa_Irawati.pdf",
    "processed": "1–12 httpdigilibunisayogyaacid56 221novi agustina nk1710201179keperawa tan nk28129pdf agustina novi savitri v kustiningsih 2022 hubungan tahap kemoterapi status gizi anak dengan penderita leukimia limfoblastik review akut literature 1–12 unisa yogyakarta httpdigilibunisayogyaacid66 0311810201100 naskah publikasi masriyati vitria savitri linda ayu"
  },
  {
    "id": 251,
    "paragraph": "Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 R E S E A R C H A R T I C L E Open Access Gene profiling of the erythro- and megakaryoblastic leukaemias induced by the Graffi murine retrovirus Veronique Voisin1,2, Philippe Legault1, Diana Paulina Salazar Ospina1, Yaacov Ben-David2, Eric Rassart1*",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 r e e r c h r c l e open access gene profiling erythro megakaryoblastic leukaemias induced graffi murine retrovirus veronique voisin12 philippe legault1 diana paulina salazar ospina1 yaacov bendavid2 eric rassart1"
  },
  {
    "id": 252,
    "paragraph": "Abstract Background: Acute erythro- and megakaryoblastic leukaemias are associated with very poor prognoses and the mechanism of blastic transformation is insufficiently elucidated. The murine Graffi leukaemia retrovirus induces erythro- and megakaryoblastic leukaemias when inoculated into NFS mice and represents a good model to study",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "abstract background acute erythro megakaryoblastic leukaemias associated poor prognoses mechanism blastic transformation insufficiently elucidated murine graffi leukaemia retrovirus induces erythro megakaryoblastic leukaemias inoculated nfs mice represents good model study"
  },
  {
    "id": 253,
    "paragraph": "these leukaemias. Methods: To expand our understanding of genes specific to these leukaemias, we compared gene expression profiles, measured by microarray and RT-PCR, of all leukaemia types induced by this virus. Results: The transcriptome level changes, present between the different leukaemias, led to the identification of",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "leukaemias methods expand understanding genes specific leukaemias compared gene expression profiles measured microarray rtpcr leukaemia types induced virus results transcriptome level changes present different leukaemias led identification"
  },
  {
    "id": 254,
    "paragraph": "specific cancerous signatures. We reported numerous genes that may be potential oncogenes, may have a function related to erythropoiesis or megakaryopoiesis or have a poorly elucidated physiological role. The expression pattern of these genes has been further tested by RT-PCR in different samples, in a Friend",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "specific cancerous signatures reported numerous genes may potential oncogenes may function related erythropoiesis megakaryopoiesis poorly elucidated physiological role expression pattern genes tested rtpcr different samples friend"
  },
  {
    "id": 255,
    "paragraph": "erythroleukaemic model and in human leukaemic cell lines. We also screened the megakaryoblastic leukaemias for viral integrations and identified genes targeted by these integrations and potentially implicated in the onset of the disease. Conclusions: Taken as a whole, the data obtained from this global gene profiling experiment have provided a",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "erythroleukaemic model human leukaemic cell lines also screened megakaryoblastic leukaemias viral integrations identified genes targeted integrations potentially implicated onset disease conclusions taken whole data obtained global gene profiling experiment provided"
  },
  {
    "id": 256,
    "paragraph": "detailed characterization of Graffi virus induced erythro- and megakaryoblastic leukaemias with many genes reported specific to the transcriptome of these leukaemias for the first time. Background Human acute megakaryoblastic (FAB-AML7, [1]) and erythroleukaemias (FAB-AML6, [2]) are regarded as relatively rare entities of acute myeloid leukaemia but",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "detailed characterization graffi virus induced erythro megakaryoblastic leukaemias many genes reported specific transcriptome leukaemias first time background human acute megakaryoblastic fabaml7 1 erythroleukaemias fabaml6 2 regarded relatively rare entities acute myeloid leukaemia"
  },
  {
    "id": 257,
    "paragraph": "are associated with a very poor prognosis [3-7]. The poor outcome linked to these 2 types of leukaemias stems from a combination of failure to achieve complete remission, a high relapse rate and therapy-related toxi- city, highlighting the need for more powerful therapies.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "associated poor prognosis 37 poor outcome linked 2 types leukaemias stems combination failure achieve complete remission high relapse rate therapyrelated toxi city highlighting need powerful therapies"
  },
  {
    "id": 258,
    "paragraph": "Furthermore, AML6 or AML7 diagnosis represents a greater challenge than other types of acute myeloid leu- kaemia (AML) and additional markers are needed [8]. Furthermore, the blasts of patients with AML6 and AML7 share common markers [9] indicating that they * Correspondence: rassart.eric@uqam.ca",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "furthermore aml6 aml7 diagnosis represents greater challenge types acute myeloid leu kaemia aml additional markers needed 8 furthermore blasts patients aml6 aml7 share common markers 9 indicating correspondence rassartericuqamca"
  },
  {
    "id": 259,
    "paragraph": "1Laboratoire de Biologie Moléculaire, Département des Sciences Biologiques, Centre BioMed, Université du Québec à Montréal, Case Postale 8888 Succursale Centre-ville, Montréal, QC, H3C-3P8, Canada originate from closely related haematopoietic lineages derived from a common bipotent progenitor [10,11]. We have recently shown that the murine retrovirus",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "1laboratoire de biologie moléculaire département des sciences biologiques centre biomed université du québec à montréal case postale 8888 succursale centreville montréal qc h3c3p8 canada originate closely related haematopoietic lineages derived common bipotent progenitor 1011 recently shown murine retrovirus"
  },
  {
    "id": 260,
    "paragraph": "Graffi is able to induce a broad spectrum of leukaemias when inoculated into newborn mice. The leukaemias developed by these mice are of lymphoid (T-cell and B-cell) and non lymphoid (myeloid, erythroid and mega- karyoblastic) origins. The incidence of erythro- and",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "graffi able induce broad spectrum leukaemias inoculated newborn mice leukaemias developed mice lymphoid tcell bcell non lymphoid myeloid erythroid mega karyoblastic origins incidence erythro"
  },
  {
    "id": 261,
    "paragraph": "megakaryoblastic leukaemias is particularly high in NFS or FVB/n mice inoculated with the GV-1.4 variant of the Graffi virus [12]. The activation of the targeted proto-oncogene or the repression of tumor suppressor genes represents early events in the development of the",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "megakaryoblastic leukaemias particularly high nfs fvbn mice inoculated gv14 variant graffi virus 12 activation targeted protooncogene repression tumor suppressor genes represents early events development"
  },
  {
    "id": 262,
    "paragraph": "murine leukaemia retrovirus (MuLV) induced leukae- mia. It is then followed by a deregulation of numerous additional genes resulting in a cell, blocked at a very immature stage, which aggressively divides and escapes apoptosis. To analyze these cancerous signatures, we © 2010 Voisin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "murine leukaemia retrovirus mulv induced leukae mia followed deregulation numerous additional genes resulting cell blocked immature stage aggressively divides escapes apoptosis analyze cancerous signatures © 2010 voisin et al licensee biomed central ltd open access article distributed terms creative commons"
  },
  {
    "id": 263,
    "paragraph": "Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 2 of 17 compared the gene profiles of each type of leukaemia",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "attribution license httpcreativecommonsorglicensesby20 permits unrestricted use distribution reproduction medium provided original work properly cited voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 page 2 17 compared gene profiles type leukaemia"
  },
  {
    "id": 264,
    "paragraph": "(T-cell, B-cell, myeloid, erythroid, megakaryoblastic) induced by the Graffi virus. These analyses highlight many genes that may be potential oncogenes and may have a function related to erythropoiesis or megakaryo- poiesis. The results support the importance of the known transcription factors Gata1, Fog1, Fli1, Scl and",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "tcell bcell myeloid erythroid megakaryoblastic induced graffi virus analyses highlight many genes may potential oncogenes may function related erythropoiesis megakaryo poiesis results support importance known transcription factors gata1 fog1 fli1 scl"
  },
  {
    "id": 265,
    "paragraph": "Lmo2 in both erythro- and megakaryoblastic leukaemias and the role of Runx1, Pbx1, Meis, Evi1 and Evi3 in the megakaryoblastic leukaemias. Moreover, numerous genes are being reported for the first time and some of these genes are candidate oncogenes: Fgf3, Nmyc, Fap,",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "lmo2 erythro megakaryoblastic leukaemias role runx1 pbx1 meis evi1 evi3 megakaryoblastic leukaemias moreover numerous genes reported first time genes candidate oncogenes fgf3 nmyc fap"
  },
  {
    "id": 266,
    "paragraph": "Myct1, Gucy1a3, Gulp1 and Fkbp9 specific to megakar- yoblastic leukaemias and Ssx2ip, Rab11a, Ncoa3, Snca, Ltbp2, Rabgef1 and Btbd14a specific to erythroleukae- mias. A screening for viral integrations was performed in mouse tumors. Several genes, amongst which Kit, Gata2, Irf8 and Itga1, were identified as potentially",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "myct1 gucy1a3 gulp1 fkbp9 specific megakar yoblastic leukaemias ssx2ip rab11a ncoa3 snca ltbp2 rabgef1 btbd14a specific erythroleukae mias screening viral integrations performed mouse tumors several genes amongst kit gata2 irf8 itga1 identified potentially"
  },
  {
    "id": 267,
    "paragraph": "implicated in the onset development of the megakaryo- blastic leukaemias. Methods Virus production and mice GV-1.4 viral stock was made as previously described [12]. GV-1.4 viral particles (0.1 ml at a titer of 1.106 PFU/ml) were injected into 1 day newborn NFS mice. The mice",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "implicated onset development megakaryo blastic leukaemias methods virus production mice gv14 viral stock made previously described 12 gv14 viral particles 01 ml titer 1106 pfuml injected 1 day newborn nfs mice mice"
  },
  {
    "id": 268,
    "paragraph": "were checked routinely for clinical signs of disease and moribund mice were sacrificed. Twenty-four diseased mice and 36 control mice were used for the microarray and RT-PCR experiments. Bone marrow cell suspension was prepared by flushing the femurs with IMDM 2% foe-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "checked routinely clinical signs disease moribund mice sacrificed twentyfour diseased mice 36 control mice used microarray rtpcr experiments bone marrow cell suspension prepared flushing femurs imdm 2 foe"
  },
  {
    "id": 269,
    "paragraph": "tal bovine serum (FBS) and spleen cell suspension was prepared by mincing the spleen with scissors and aspirat- ing the pieces up and down through a 1cc syringe in IMDM 2% FBS. The spleen and bone marrow cell sus- pensions were filtered through 70 μm cell strainers (Bec-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "tal bovine serum fbs spleen cell suspension prepared mincing spleen scissors aspirat ing pieces 1cc syringe imdm 2 fbs spleen bone marrow cell sus pensions filtered 70 μm cell strainers bec"
  },
  {
    "id": 270,
    "paragraph": "ton Dickson, Mississauga, Canada). All the experimental procedures are conformed to the Helsinki Declaration and were approved by the Animal Care and Use Com- mittees of Université du Québec à Montréal. Flow cytometry analyses and cell sorting The flow cytometry staining procedure was performed as",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "ton dickson mississauga canada experimental procedures conformed helsinki declaration approved animal care use com mittees université du québec à montréal flow cytometry analyses cell sorting flow cytometry staining procedure performed"
  },
  {
    "id": 271,
    "paragraph": "previously described [12]. The antibodies used were as follows: CD4, CD8a, CD3, CD90, CD19, B220, CD11b, Gr1, CD71, Ter119, CD41, Kit and Sca1 (BD Pharmin- gen, Mississauga, Canada). The leukaemic populations were isolated from the haematopoietic organs by positive selection using magnetic beads with the EasySep Kit",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "previously described 12 antibodies used follows cd4 cd8a cd3 cd90 cd19 b220 cd11b gr1 cd71 ter119 cd41 kit sca1 bd pharmin gen mississauga canada leukaemic populations isolated haematopoietic organs positive selection using magnetic beads easysep kit"
  },
  {
    "id": 272,
    "paragraph": "(StemCell Technologies, Vancouver, Canada) according to the manufacturer’s protocol. The rates of purity and viability of the sorted cells were fixed to be equal to or greater than 95%. Leukaemic T-cells were sorted from the thymus of leukaemic NFS mice, B-cell from the",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "stemcell technologies vancouver canada according manufacturer ’ protocol rates purity viability sorted cells fixed equal greater 95 leukaemic tcells sorted thymus leukaemic nfs mice bcell"
  },
  {
    "id": 273,
    "paragraph": "enlarged lymph nodes and erythro- and megakaryoblastic leukaemic cells were sorted from the infiltrated spleen. Control cells were sorted from the haematopoietic organs of 12 pooled non-infected NFS mice: T-cells were obtained from the thymus, B-cells from the spleen, and erythroblasts from the bone marrow.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "enlarged lymph nodes erythro megakaryoblastic leukaemic cells sorted infiltrated spleen control cells sorted haematopoietic organs 12 pooled noninfected nfs mice tcells obtained thymus bcells spleen erythroblasts bone marrow"
  },
  {
    "id": 274,
    "paragraph": "RNA extraction and microarray processing Total RNA was extracted from the sorted cell popula- tions with Trizol reagent (Invitrogen, Burlington, Canada) followed by column purification using the Qia- gen RNeasy Kit (QIAGEN, Mississauga, Canada) and processed for hybridization to Affymetrix GeneChip®",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "rna extraction microarray processing total rna extracted sorted cell popula tions trizol reagent invitrogen burlington canada followed column purification using qia gen rneasy kit qiagen mississauga canada processed hybridization affymetrix genechip®"
  },
  {
    "id": 275,
    "paragraph": "Mouse Genome 430 2.0 arrays (Genome Quebec Inno- vation Centre, Montreal, Canada). Data analysis Data Set Normalization: Affymetrix MicroArray Suite version 5.0 was used to scan and quantify the arrays. Normalization of gene expression data were performed using the Bioconductor implementation of RMA",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "mouse genome 430 20 arrays genome quebec inno vation centre montreal canada data analysis data set normalization affymetrix microarray suite version 50 used scan quantify arrays normalization gene expression data performed using bioconductor implementation rma"
  },
  {
    "id": 276,
    "paragraph": "(Robust Multi Array, B. Bolstad, University of California, Berkeley) available from the Flexarray software (1.2, R 2.7.2, [13]). Unsupervised learning: Hierarchical clustering (com- plete linkage clustering, correlation uncentered, [14]) and Self-Organization Maps (SOM, parameters G 1-5, A 1-10, [15]) were constructed using GeneCluster software",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "robust multi array b bolstad university california berkeley available flexarray software 12 r 272 13 unsupervised learning hierarchical clustering com plete linkage clustering correlation uncentered 14 selforganization maps som parameters g 15 110 15 constructed using genecluster software"
  },
  {
    "id": 277,
    "paragraph": "(M. Eisen). 3,000 transcripts were selected to be included in the analyses based on the differential expres- sion from the mean. The deviation from the mean was calculated from the RMA values of the 45,000 probesets and the data were ranked in decreasing order to extract",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "eisen 3000 transcripts selected included analyses based differential expres sion mean deviation mean calculated rma values 45000 probesets data ranked decreasing order extract"
  },
  {
    "id": 278,
    "paragraph": "the first 3,000 genes. Only deviations equal or above 0.585 (1.5 fold change) and equal or below -0.585 (-1.5 fold change) were considered as significant. Supervised learning: Significance Analysis of microar- rays (SAM, [16]). SAM analyses were performed using Flexarray software using the normalized data of the",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "first 3000 genes deviations equal 0585 15 fold change equal 0585 15 fold change considered significant supervised learning significance analysis microar rays sam 16 sam analyses performed using flexarray software using normalized data"
  },
  {
    "id": 279,
    "paragraph": "45,000 probesets. Data with p-values equal or below 0.01 and False Discover Rates (Benjamini Hochberg) equal or below 0.20 were included in further analyses. The data were ranked in decreasing order of the SAM d-score to obtain the list of the differentially expressed genes.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "45000 probesets data pvalues equal 001 false discover rates benjamini hochberg equal 020 included analyses data ranked decreasing order sam dscore obtain list differentially expressed genes"
  },
  {
    "id": 280,
    "paragraph": "The NetAffx website (Affymetrix, Santa Clara, CA, USA) was used to retrieve gene ontology (GO) annota- tions, probe sequences, and was utilized as a link to Unigene (NCBI) for further functional studies. The microarray dataset was deposited at Gene Expres- sion Omnibus under accession number [GSE12581].",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "netaffx website affymetrix santa clara ca usa used retrieve gene ontology go annota tions probe sequences utilized link unigene ncbi functional studies microarray dataset deposited gene expres sion omnibus accession number gse12581"
  },
  {
    "id": 281,
    "paragraph": "Cell line and differentiation assay The murine erythroleukaemic cell line HB22.2 was obtained from murine erythroblasts infected with Friend Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 3 of 17 Murine Leukaemia Virus (F-MuLV) [17]. This cell line was maintained in alpha minimum essential medium",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "cell line differentiation assay murine erythroleukaemic cell line hb222 obtained murine erythroblasts infected friend voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 page 3 17 murine leukaemia virus fmulv 17 cell line maintained alpha minimum essential medium"
  },
  {
    "id": 282,
    "paragraph": "(a-MEM) supplemented with 10% (FBS) (Invitrogen, Frederick, MD) plus a penicillin/streptomycin cocktail. To induce differentiation, HB22.2 cells were incubated in the presence of hemin (Sigma-aldrich H5533) at a concentration of 100 μM. The cells were harvested 24 hours and 72 hours after addition of hemin. K562",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "amem supplemented 10 fbs invitrogen frederick md plus penicillinstreptomycin cocktail induce differentiation hb222 cells incubated presence hemin sigmaaldrich h5533 concentration 100 μm cells harvested 24 hours 72 hours addition hemin k562"
  },
  {
    "id": 283,
    "paragraph": "(ATCC, USA), HEL (ATCC, USA), Jurkat (ATCC, USA) and Tk6 (ATCC, USA) cells were grown in RMPI sup- plemented with 10% FBS plus a penicillin/streptomycin cocktail. MEG-01 (ATCC, USA), CMK (DSMZ, Ger- many) and LAMA84 (DSMZ, Germany) cells were grown in RPMI supplemented with 20% FBS plus a",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "atcc usa hel atcc usa jurkat atcc usa tk6 atcc usa cells grown rmpi sup plemented 10 fbs plus penicillinstreptomycin cocktail meg01 atcc usa cmk dsmz ger many lama84 dsmz germany cells grown rpmi supplemented 20 fbs plus"
  },
  {
    "id": 284,
    "paragraph": "penicillin/streptomycin cocktail with a concentration of 105 cells/ml. England Biolabs, Pickering, Canada). The ligated product was then digested with ClaI (New England Biolabs, Picker- ing, Canada). A PCR followed by a nested PCR (150 ng of the ligated product) were performed using a primer",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "penicillinstreptomycin cocktail concentration 105 cellsml england biolabs pickering canada ligated product digested clai new england biolabs picker ing canada pcr followed nested pcr 150 ng ligated product performed using primer"
  },
  {
    "id": 285,
    "paragraph": "located in the Graffi virus U3 sequence (5’GGTCTC- TTGAAA-CTGCTGAGGG 3’ and 5’GACCTTGATCT- GAACTT-CCCTATTC3’) and one corresponding to the splinkerette oligonucleotide. The PCR program was the following: 94°C for 1 min, 68°C for 30 s (2 cycles), 94°C for 15 s, 58°C for 30 s, 72°C 3 min (27 cycles), 72°C 10 min.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "located graffi virus u3 sequence 5 ’ ggtctc ttgaaactgctgaggg 3 ’ 5 ’ gaccttgatct gaacttccctattc3 ’ one corresponding splinkerette oligonucleotide pcr program following 94°c 1 min 68°c 30 2 cycles 94°c 15 58°c 30 72°c 3 min 27 cycles 72°c 10 min"
  },
  {
    "id": 286,
    "paragraph": "The PCR products were cloned (PCR Cloning Kit, Qiagen, Mississauga, Canada,) and sent for sequencing (Genome Quebec Innovation Centre, Montreal, Canada). The sequences were subjected to BLAST analysis against the annotated mouse genome database using Ensembl Gen- ome Browser (release 45).",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "pcr products cloned pcr cloning kit qiagen mississauga canada sent sequencing genome quebec innovation centre montreal canada sequences subjected blast analysis annotated mouse genome database using ensembl gen ome browser release 45"
  },
  {
    "id": 287,
    "paragraph": "RT-PCR Oligo d(T) primed reverse transcription was performed using Omniscript Reverse Transcriptase (QIAGEN, Mis- sissauga, Canada) in a 20 μl reaction volume (42°C, 1 h) by taking equal amounts of RNA (100 ng) from the Graffi-leukaemic cells and the murine HB22.2 cell line.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "rtpcr oligo dt primed reverse transcription performed using omniscript reverse transcriptase qiagen mis sissauga canada 20 μl reaction volume 42°c 1 h taking equal amounts rna 100 ng graffileukaemic cells murine hb222 cell line"
  },
  {
    "id": 288,
    "paragraph": "cDNA (4 μl) was amplified using Taq polymerase (QIA- GEN, Mississauga, Canada) at 94°C for 5 min, 72°C for 45 s, 57°C for 45 s, 72°C for 45 s, 72°C for 10 min. 25 and 28 cycles were used for the Graffi-leukaemic cells",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "cdna 4 μl amplified using taq polymerase qia gen mississauga canada 94°c 5 min 72°c 45 57°c 45 72°c 45 72°c 10 min 25 28 cycles used graffileukaemic cells"
  },
  {
    "id": 289,
    "paragraph": "and 27 cycles were used for the HB22.2 cell line. 0.01 μl of cDNA and 25 cycles were used to amplify ubiqui- tously expressed b-actin and Gapdh genes. cDNA from the human haematopoietic cell lines was amplified using 500 ng of total RNA and the PCR reactions were per-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "27 cycles used hb222 cell line 001 μl cdna 25 cycles used amplify ubiqui tously expressed bactin gapdh genes cdna human haematopoietic cell lines amplified using 500 ng total rna pcr reactions per"
  },
  {
    "id": 290,
    "paragraph": "formed using 4 μl of cDNA and 30 PCR cycles. Ubiqui- tously expressed human GAPDH gene was amplified using 0.01 μl of cDNA and 25 cycles. The primer sets are listed in supplementary data (Additional file 1). PCR products were analyzed on 2% agarose gels containing",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "formed using 4 μl cdna 30 pcr cycles ubiqui tously expressed human gapdh gene amplified using 001 μl cdna 25 cycles primer sets listed supplementary data additional file 1 pcr products analyzed 2 agarose gels containing"
  },
  {
    "id": 291,
    "paragraph": "0.5 μg/ml ethidium bromide. The gels were scanned (Molecular Dynamics Phosphorimager) and the density of the RT-PCR bands were assessed using the Quantity One software. Amplification of retroviral integration sites This protocol was adapted from A. Berns and colleagues [18]. Tumor DNA from the spleen (10 μg) was digested",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "05 μgml ethidium bromide gels scanned molecular dynamics phosphorimager density rtpcr bands assessed using quantity one software amplification retroviral integration sites protocol adapted berns colleagues 18 tumor dna spleen 10 μg digested"
  },
  {
    "id": 292,
    "paragraph": "with BamHI (New England Biolabs, Pickering, Canada). A splinkerette adaptor was generated by annealing 2 oligo- nucleotides (5’CATGGGCTAAAGAGGACTAATAA- CAAGCGTGGCTGAATGAGACTGGTGTCGA CAC- TAGTGG3’, 5’GATCCCACTAGTGTCGACACCAGT- CTCTAATTTTTTTTTTC AAAAAAA3’, 95°C 5 min, cool-down to room temperature). 1 μg of digested DNA was ligated to the splinkerette oligonucleotide (molar ratio",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "bamhi new england biolabs pickering canada splinkerette adaptor generated annealing 2 oligo nucleotides 5 ’ catgggctaaagaggactaataa caagcgtggctgaatgagactggtgtcga cac tagtgg3 ’ 5 ’ gatcccactagtgtcgacaccagt ctctaattttttttttc aaaaaaa3 ’ 95°c 5 min cooldown room temperature 1 μg digested dna ligated splinkerette oligonucleotide molar ratio"
  },
  {
    "id": 293,
    "paragraph": "DNA/splinkerette 1:10) using a T4 DNA ligase (New Results Erythro- and megakaryoblastic leukaemias induced by the murine Graffi retrovirus and hybridization on microarrays NFS newborn mice inoculated with the Graffi murine retrovirus develop an average of 20% of erythroleukemia and 20% of megakaryoblastic leukemias with a latency",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "dnasplinkerette 110 using t4 dna ligase new results erythro megakaryoblastic leukaemias induced murine graffi retrovirus hybridization microarrays nfs newborn mice inoculated graffi murine retrovirus develop average 20 erythroleukemia 20 megakaryoblastic leukemias latency"
  },
  {
    "id": 294,
    "paragraph": "of about 148 days [12]. These mice suffer from severe anaemia and hepatosplenomegaly. The erythroleukaemic cells, Ter119+CD71+, and the megakaryoblastic leukae- mic cells, CD41+Kit+ or CD41-Kit+, are mainly found in the bone marrow and spleen of the diseased mice [12]. As opposed to Graffi-lymphoid leukaemias, the presence",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "148 days 12 mice suffer severe anaemia hepatosplenomegaly erythroleukaemic cells ter119cd71 megakaryoblastic leukae mic cells cd41kit cd41kit mainly found bone marrow spleen diseased mice 12 opposed graffilymphoid leukaemias presence"
  },
  {
    "id": 295,
    "paragraph": "of blast cells is rare in blood smears of both erythro- and megakaryoblastic leukaemias, consistent with clini- cal data on human acute erythroleukaemia [8]. To gain insight into the cancerous signatures of the different leukaemias induced by Graffi MuLV, microar- ray experiments were designed to compare the expres-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "blast cells rare blood smears erythro megakaryoblastic leukaemias consistent clini cal data human acute erythroleukaemia 8 gain insight cancerous signatures different leukaemias induced graffi mulv microar ray experiments designed compare expres"
  },
  {
    "id": 296,
    "paragraph": "sion signature of genes from each type of leukaemia. Cells from the infiltrated haematopoietic organs of the leukaemic mice were isolated (Additional file 2) and subjected to microarray analysis. Unsupervised learning methods, hierarchical clustering, and SOM analyses were used to uncover the primary pattern in the data",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "sion signature genes type leukaemia cells infiltrated haematopoietic organs leukaemic mice isolated additional file 2 subjected microarray analysis unsupervised learning methods hierarchical clustering som analyses used uncover primary pattern data"
  },
  {
    "id": 297,
    "paragraph": "(Figure 1). Altogether, four distinct gene clusters repre- senting T-cells (T), B-cells (B), megakaryoblastic/mye- loid cells (Mk/M) and erythroid cells (E) emerged from the clustering (Figure 1A). A more detailed SOM analysis performed on the ery- throid and megakaryoblastic genes further classified",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "figure 1 altogether four distinct gene clusters repre senting tcells bcells b megakaryoblasticmye loid cells mkm erythroid cells e emerged clustering figure 1a detailed som analysis performed ery throid megakaryoblastic genes classified"
  },
  {
    "id": 298,
    "paragraph": "them into 3 major signatures: erythroid-megakaryoblas- tic EMk (19%), erythroid E (42%) and megakaryoblastic Mk (39%) (Figure 1B). E and Mk represent the genes over-expressed in the erythro- and megakaryoblastic leukaemias, respectively, and EMk represents the genes specifically over-expressed in both types. MkE1 indicates",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "3 major signatures erythroidmegakaryoblas tic emk 19 erythroid e 42 megakaryoblastic mk 39 figure 1b e mk represent genes overexpressed erythro megakaryoblastic leukaemias respectively emk represents genes specifically overexpressed types mke1 indicates"
  },
  {
    "id": 299,
    "paragraph": "genes over-expressed in the 3 megakaryoblastic Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 4 of 17 A B 1 1 T T 2 2 T T 3 3 T T 2 2 B B 1 1 B B",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "genes overexpressed 3 megakaryoblastic voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 page 4 17 b 1 1 2 2 3 3 2 2 b b 1 1 b b"
  },
  {
    "id": 300,
    "paragraph": "3 3 B B 1 1 k k M M 3 3 k k M M 1 1 2ME 2ME k k M M 2 2 E E 3 3 E E 3 T 2 2 T T 1 1 T",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "3 3 b b 1 1 k k 3 3 k k 1 1 2me 2me k k 2 2 e e 3 3 e e 3 2 2 1 1"
  },
  {
    "id": 301,
    "paragraph": "T 3 3 B B 2 2 B B 1 M 1 M B B 2 2 k k M M 1 1 k k M M 3 3 k k M M 1 1 E E 2 2 E E",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "3 3 b b 2 2 b b 1 1 b b 2 2 k k 1 1 k k 3 3 k k 1 1 e e 2 2 e e"
  },
  {
    "id": 302,
    "paragraph": "3 3 E E Mk only MkE1 MkM MkMB Mk 39% E only EMk3 E 42% EMk 19% T B M k M E Figure 1 Hierarchical clustering and data scatter. (A) Heat map of the hierarchical clustering and SOM analyses of all data. (B) Heat",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "3 3 e e mk mke1 mkm mkmb mk 39 e emk3 e 42 emk 19 b k e figure 1 hierarchical clustering data scatter heat map hierarchical clustering som analyses data b heat"
  },
  {
    "id": 303,
    "paragraph": "map of the clustering and SOM analyses of the erythroid and megakaryoblastic over-expressed genes. Each column represents a leukaemia (T-cell: T1, T2, T3; B-cell: B1, B2, B3; Myeloid: M; Erythroid: E1, E2, E3; Megakaryoblastic: Mk1, Mk2, Mk3) and each row is",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "map clustering som analyses erythroid megakaryoblastic overexpressed genes column represents leukaemia tcell t1 t2 t3 bcell b1 b2 b3 myeloid erythroid e1 e2 e3 megakaryoblastic mk1 mk2 mk3 row"
  },
  {
    "id": 304,
    "paragraph": "assigned to a transcript. A red colour means a positive deviation of 0.595 and above from the mean (over-expression) and a green colour means a negative deviation of -0.595 and below from the mean (under-expression). The black colour corresponds to values",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "assigned transcript red colour means positive deviation 0595 mean overexpression green colour means negative deviation 0595 mean underexpression black colour corresponds values"
  },
  {
    "id": 305,
    "paragraph": "comprised between 0.595 and -0.595. The result of the clustering on the arrays is shown as a dendrogram on the top of the figure. The nodes of the tree indicate the degrees of similarity between the leukaemias. leukaemias (Mk1-Mk3) and the erythroleukaemia E1.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "comprised 0595 0595 result clustering arrays shown dendrogram top figure nodes tree indicate degrees similarity leukaemias leukaemias mk1mk3 erythroleukaemia e1"
  },
  {
    "id": 306,
    "paragraph": "Similarly, EMk3 corresponds to genes over-expressed in 3 erythroleukaemias (E1-E3) and the megakaryoblastic leukaemia Mk3. These results indicate that the leukae- mias E1 and Mk3 are biphenotypic and express both erythroid and megakaryoblastic markers, which was pre- viously observed in some Graffi-induced erythro- and",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "similarly emk3 corresponds genes overexpressed 3 erythroleukaemias e1e3 megakaryoblastic leukaemia mk3 results indicate leukae mias e1 mk3 biphenotypic express erythroid megakaryoblastic markers pre viously observed graffiinduced erythro"
  },
  {
    "id": 307,
    "paragraph": "megakaryoblastic leukaemias [12]. The MkMB signature includes genes over-expressed in megakaryoblastic leu- kaemias (Mk1-Mk3), myeloid leukaemia (M) and B-cell leukaemias (B1-B3). A detailed analysis of Mk, E and EMk signatures has revealed that many of the genes have not yet been reported in relation to the erythroid",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "megakaryoblastic leukaemias 12 mkmb signature includes genes overexpressed megakaryoblastic leu kaemias mk1mk3 myeloid leukaemia bcell leukaemias b1b3 detailed analysis mk e emk signatures revealed many genes yet reported relation erythroid"
  },
  {
    "id": 308,
    "paragraph": "or the megakaryocytic lineages or to the corresponding leukaemias. The complete lists of genes detailing these non-lymphoid signatures are publicly available at http:// www.biomed.uqam.ca/rassart/microarray.html[19]. The lineage specific expression of genes involved in heme biosynthesis, the megakaryocytic fibrinogen recep- tors and the expression of well known transcription fac-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "megakaryocytic lineages corresponding leukaemias complete lists genes detailing nonlymphoid signatures publicly available http wwwbiomeduqamcarassartmicroarrayhtml19 lineage specific expression genes involved heme biosynthesis megakaryocytic fibrinogen recep tors expression well known transcription fac"
  },
  {
    "id": 309,
    "paragraph": "tors validate the true lineage of these erythro- and megakaryoblastic leukaemias (Table 1). The megakaryoblastic signature The megakaryoblastic specific genes assigned with a functional annotation (GO terms) were divided into dif- ferent functional classes. Table 2 lists some genes poten- tially implicated in the disease but the complete data are",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "tors validate true lineage erythro megakaryoblastic leukaemias table 1 megakaryoblastic signature megakaryoblastic specific genes assigned functional annotation go terms divided dif ferent functional classes table 2 lists genes poten tially implicated disease complete data"
  },
  {
    "id": 310,
    "paragraph": "readily available [19]. Within this list of genes, the onco- genes Meis1 (Myeloid ecotropic viral integration site 1), Pbx1 (Pre B-cell leukaemia transcription factor 1), Evi1 (ecotropic viral integration site 1), Evi3 (Zfp521, zinc fin- ger protein 521) and the co-repressor Cbfa2t3h (Core-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "readily available 19 within list genes onco genes meis1 myeloid ecotropic viral integration site 1 pbx1 pre bcell leukaemia transcription factor 1 evi1 ecotropic viral integration site 1 evi3 zfp521 zinc fin ger protein 521 corepressor cbfa2t3h core"
  },
  {
    "id": 311,
    "paragraph": "binding factor, runt domain, alpha subunit 2, translo- cated to, 3 (human), Eto2) have already been related to megakaryoblastic leukaemias or megakaryocytic lineage [20-25]. However, several other genes, for example Nmyc (Neuroblastoma myc-related oncogene 1), Fgf3 (Fibro- blast growth factor 3) and Fap (Fibroblast activation",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "binding factor runt domain alpha subunit 2 translo cated 3 human eto2 already related megakaryoblastic leukaemias megakaryocytic lineage 2025 however several genes example nmyc neuroblastoma mycrelated oncogene 1 fgf3 fibro blast growth factor 3 fap fibroblast activation"
  },
  {
    "id": 312,
    "paragraph": "protein), that are also known oncogenes [26-29], have never been reported with megakaryoblastic leukaemias. Myct1 (Myc target 1) is also potentially implicated in the disease as it is positively regulated by Myc and con- tains tumorigenic properties by itself [30]. Among the list of genes identified as the MkMB sig-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "protein also known oncogenes 2629 never reported megakaryoblastic leukaemias myct1 myc target 1 also potentially implicated disease positively regulated myc con tains tumorigenic properties 30 among list genes identified mkmb sig"
  },
  {
    "id": 313,
    "paragraph": "nature, we found Jun (Jun oncogene), Fosl2 (Fos-like antigen 2) and Fes (Feline sarcoma oncogene) (Table 2, [31,32]). The co-repressor Ctbp2 (C-terminal binding protein 2), Sfpi1 (SFFV proviral integration 1, PU.1) and Kit (Kit oncogene) are also MkMB signature elements. Ctbp2 is known to interact with Evi1 and Fog [33]. Sfpi1",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "nature found jun jun oncogene fosl2 foslike antigen 2 fes feline sarcoma oncogene table 2 3132 corepressor ctbp2 cterminal binding protein 2 sfpi1 sffv proviral integration 1 pu1 kit kit oncogene also mkmb signature elements ctbp2 known interact evi1 fog 33 sfpi1"
  },
  {
    "id": 314,
    "paragraph": "was shown to regulate the expression of the integrin aIIb (Itga2B, CD41) in a TPO-induced Mpl-UT7 model [34,35] and it was reported as an insertional target of the Graffi MuLV [36]. Due to technical limitations, no megakaryoblastic con- trol was present in our study. Normal megakaryocytes and",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "shown regulate expression integrin aiib itga2b cd41 tpoinduced mplut7 model 3435 reported insertional target graffi mulv 36 due technical limitations megakaryoblastic con trol present study normal megakaryocytes"
  },
  {
    "id": 315,
    "paragraph": "therefore megakaryoblasts represent a minor population in normal mice and it was not possible to obtain enough pur- ified cells with the technique utilized for other samples. We therefore compared our dataset to a study of murine megakaryocytic maturation indicating up- or down-regula-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "therefore megakaryoblasts represent minor population normal mice possible obtain enough pur ified cells technique utilized samples therefore compared dataset study murine megakaryocytic maturation indicating downregula"
  },
  {
    "id": 316,
    "paragraph": "tion during differentiation (dataset GSE6593, [37]). Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 5 of 17 Table 1 Genes specific to the erythroid and megakaryoblastic leukaemias probeset gene SAM results * FDR d-score Fibrinogen receptor and related genes",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "tion differentiation dataset gse6593 37 voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 page 5 17 table 1 genes specific erythroid megakaryoblastic leukaemias probeset gene sam results fdr dscore fibrinogen receptor related genes"
  },
  {
    "id": 317,
    "paragraph": "T1 T2 T3 B1 B2 B3 M E1 E2 E3 Mk1 MK2 Mk3 Leukaemic samples** 1417758_at 1421511_at 1416066_at 1456085_x_at 1420558_at 1457782_at 1424595_at 1451097_at 1418261_at 1455349_at Heme biosynthesis 1451675_a_at 1424877_a_at 1426475_at 1423482_at 1417206_at 1422493_at 1416618_at 1418699_s_at Itga2b Itgb3 Cd9 Cd151 Selp Tln1",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "t1 t2 t3 b1 b2 b3 e1 e2 e3 mk1 mk2 mk3 leukaemic samples 1417758at 1421511at 1416066at 1456085xat 1420558at 1457782at 1424595at 1451097at 1418261at 1455349at heme biosynthesis 1451675aat 1424877aat 1426475at 1423482at 1417206at 1422493at 1416618at 1418699sat itga2b itgb3 cd9 cd151 selp tln1"
  },
  {
    "id": 318,
    "paragraph": "F11r Vasp Syk Rap1b Alas2 Alad Hmbs Uros Urod Cpox Ppox Fech 10.58 <0.001 - 5.5 7.56 12.03 7.19 5.58 5.24 16.04 4.63 8.85 8.91 13.44 - 10.87 22.18 4.58 8.61 >0.01 0.002 <0.001 <0.001 <0.001 0.002 <0.001 <0.001 <0.001 <0.001",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "f11r vasp syk rap1b alas2 alad hmbs uros urod cpox ppox fech 1058 0001 55 756 1203 719 558 524 1604 463 885 891 1344 1087 2218 458 861 001 0002 0001 0001 0001 0002 0001 0001 0001 0001"
  },
  {
    "id": 319,
    "paragraph": "<0.001 <0.001 - <0.001 <0.001 0.004 <0.001 Erythroid and megakaryoblastic transcription factors 0.01 0.02 <0.01 0.03 0.01 EMk 1450333_a_at Gata2 1423603_at 1449389_at 1454086_a_at 1452001_at EMk3 1449232_at MkE1 Zfpm1(Fog1) Scl/Tal1 Lmo2 Nfe2 Gata1 1441584_at Fli1 Erythroid transcription factors EMk3 1418600_at Klf1 7.4",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "0001 0001 0001 0001 0004 0001 erythroid megakaryoblastic transcription factors 001 002 001 003 001 emk 1450333aat gata2 1423603at 1449389at 1454086aat 1452001at emk3 1449232at mke1 zfpm1fog1 scltal1 lmo2 nfe2 gata1 1441584at fli1 erythroid transcription factors emk3 1418600at klf1 74"
  },
  {
    "id": 320,
    "paragraph": "5.4 20.8 4.5 8.3 4.6 5.3 6.8 1419311_at Megakaryoblastic transcription factors Trim10 8.9 -2.7 -1.0 1.1 -1.2 -1.0 -0.7 -0.9 -0.8 -2.4 -0.7 -3.4 -1.2 -1.2 -0.6 0.0 -1.6 -0.5 -0.7 -1.9 -1.2 -3.3 -5.1 -4.2 -1.6 -0.7 -2.5 -1.1 -1.2",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "54 208 45 83 46 53 68 1419311at megakaryoblastic transcription factors trim10 89 27 10 11 12 10 07 09 08 24 07 34 12 12 06 00 16 05 07 19 12 33 51 42 16 07 25 11 12"
  },
  {
    "id": 321,
    "paragraph": "-0.4 -0.8 -1.3 -2.8 -0.8 0.3 -0.4 -1.0 -0.3 -0.4 -1.2 -0.1 -1.0 -1.6 -1.7 -2.5 -3.8 -3.0 -2.6 -0.7 2.5 -0.7 -1.9 -1.4 -0.9 0.1 -2.8 -1.1 -0.9 0.0 -0.4 -0.2 -0.3 -0.2 -0.3 -0.3 -1.9 -1.4 -3.1 -4.6 -3.4",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "04 08 13 28 08 03 04 10 03 04 12 01 10 16 17 25 38 30 26 07 25 07 19 14 09 01 28 11 09 00 04 02 03 02 03 03 19 14 31 46 34"
  },
  {
    "id": 322,
    "paragraph": "-2.9 -0.8 -3.5 -0.7 -1.6 -0.3 -0.8 0.3 2.9 -0.6 -2.5 -1.3 -1.5 -0.3 -1.2 -0.5 0.1 -1.9 -1.7 0.1 -3.2 0.7 -3.8 -2.6 -0.7 -3.6 -0.9 -1.5 -0.8 -0.6 -0.3 2.5 -1.2 -3.8 -1.6 -1.1 0.1 -0.9 -0.8 -0.2 -1.9",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "29 08 35 07 16 03 08 03 29 06 25 13 15 03 12 05 01 19 17 01 32 07 38 26 07 36 09 15 08 06 03 25 12 38 16 11 01 09 08 02 19"
  },
  {
    "id": 323,
    "paragraph": "-1.8 -0.6 -2.5 -1.3 -3.0 -2.7 -0.9 -3.6 -0.6 -1.7 -1.0 -1.0 0.3 2.8 -1.0 -3.2 -0.7 -1.1 0.2 -1.0 -1.0 -0.4 -2.0 -1.9 -0.2 -2.5 -0.9 -3.2 -1.6 -0.6 0.6 -0.3 -1.1 0.9 -0.6 0.7 1.4 -0.2 -1.3 -1.6 -1.1",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "18 06 25 13 30 27 09 36 06 17 10 10 03 28 10 32 07 11 02 10 10 04 20 19 02 25 09 32 16 06 06 03 11 09 06 07 14 02 13 16 11"
  },
  {
    "id": 324,
    "paragraph": "-0.9 -0.3 -1.5 0.0 -0.4 -1.1 -3.9 -2.5 0.7 1.3 3.8 1.6 1.9 1.4 -0.9 2.3 0.2 0.0 -1.5 2.1 4.9 2.2 2.6 0.7 1.8 2.7 0.7 2.5 -0.6 2.0 4.1 2.8 3.7 0.8 -0.7 -1.8 -0.2 -1.7 -1.5 -0.6 -0.6",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "09 03 15 00 04 11 39 25 07 13 38 16 19 14 09 23 02 00 15 21 49 22 26 07 18 27 07 25 06 20 41 28 37 08 07 18 02 17 15 06 06"
  },
  {
    "id": 325,
    "paragraph": "-2.0 -0.3 4.9 2.2 3.4 1.5 1.6 3.1 1.4 3.1 2.2 2.0 3.8 3.0 3.5 1.1 -0.7 -2.1 -0.3 -1.6 -0.5 -0.6 -1.0 -3.1 0.9 4.8 2.0 2.7 0.2 1.4 3.2 0.6 2.2 0.6 2.0 3.5 2.9 3.3 3.6 -0.6 3.0",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "20 03 49 22 34 15 16 31 14 31 22 20 38 30 35 11 07 21 03 16 05 06 10 31 09 48 20 27 02 14 32 06 22 06 20 35 29 33 36 06 30"
  },
  {
    "id": 326,
    "paragraph": "1.8 4.3 0.8 2.0 0.8 1.5 0.7 -2.8 0.4 -0.8 0.0 -0.6 -1.0 -0.6 -0.7 3.4 1.3 2.6 1.3 2.5 3.6 2.9 4.4 0.8 5.7 1.4 3.1 1.2 1.6 0.9 -0.5 -0.9 -0.9 -0.5 -0.5 -0.7 -0.4 0.0 3.4 0.8 2.9",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "18 43 08 20 08 15 07 28 04 08 00 06 10 06 07 34 13 26 13 25 36 29 44 08 57 14 31 12 16 09 05 09 09 05 05 07 04 00 34 08 29"
  },
  {
    "id": 327,
    "paragraph": "2.5 3.7 3.8 3.1 3.5 2.1 4.1 1.3 1.5 0.7 1.8 1.4 3.5 1.2 0.5 0.0 0.3 -0.4 -0.4 1.1 2.8 0.9 2.9 1.8 2.8 0.03 -1.9 -1.9 -2.1 -2.1 -2.3 -2.7 -1.9 4.5 4.1 4.5 0.6 -1.4 2.5 0.1 -0.2",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "25 37 38 31 35 21 41 13 15 07 18 14 35 12 05 00 03 04 04 11 28 09 29 18 28 003 19 19 21 21 23 27 19 45 41 45 06 14 25 01 02"
  },
  {
    "id": 328,
    "paragraph": "-0.4 -0.5 0.7 0.6 0.5 0.7 2.6 -4.8 -4.9 1.8 2.4 1.6 0.04 0.02 -2.9 -2.0 -2.3 -1.4 -2.4 -2.1 -2.7 -2.1 -2.7 -2.1 -2.8 -2.0 -1.8 -1.5 4.8 5.0 5.4 4.1 5.3 3.8 1.7 -1.0 -1.7 -0.8 2.1 2.1 MkE1",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "04 05 07 06 05 07 26 48 49 18 24 16 004 002 29 20 23 14 24 21 27 21 27 21 28 20 18 15 48 50 54 41 53 38 17 10 17 08 21 21 mke1"
  },
  {
    "id": 329,
    "paragraph": "1421461_at Mpl 16.1 <0.001 0.07 -1.9 -1.6 -2.1 -2.0 -2.1 -2.0 -1.3 1.3 -1.0 -1.7 4.9 4.4 MkE1 1440878_at Runx1 4.5 0.11 0.6 -1.8 -1.0 0.2 0.2 0.5 -0.5 0.9 -0.8 -0.1 0.7 0.8 0.3 * SAM p-value less than 0,001 for every sample",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "1421461at mpl 161 0001 007 19 16 21 20 21 20 13 13 10 17 49 44 mke1 1440878at runx1 45 011 06 18 10 02 02 05 05 09 08 01 07 08 03 sam pvalue less 0001 every sample"
  },
  {
    "id": 330,
    "paragraph": "** amplitude of deviation from the mean calculated from the RMA values According to the megakaryocytic GSE6593 dataset, Fgf3 Jun, Kit, Sfpi, Fes and Bmyc are down-regulated upon megakaryocytic differentiation (Table 2). When genes within the MkMB signature were com- pared to GO annotations, one gene class was over-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "amplitude deviation mean calculated rma values according megakaryocytic gse6593 dataset fgf3 jun kit sfpi fes bmyc downregulated upon megakaryocytic differentiation table 2 genes within mkmb signature com pared go annotations one gene class"
  },
  {
    "id": 331,
    "paragraph": "represented. Many of these genes were membrane receptors and extra-cellular factors known to be expressed by antigen presenting cells (APC) as well as implicated in inflammatory response [19]. For example, Tlr2 (Toll-like receptor 2), Tlr4 (toll-like receptor 4), Syk (Spleen tyrosine kinase) and Ebi3 (Epstein-Barr virus",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "represented many genes membrane receptors extracellular factors known expressed antigen presenting cells apc well implicated inflammatory response 19 example tlr2 tolllike receptor 2 tlr4 tolllike receptor 4 syk spleen tyrosine kinase ebi3 epsteinbarr virus"
  },
  {
    "id": 332,
    "paragraph": "induced gene 3) are part of the Toll-like receptor signal- ing pathway to respond to microbial stimuli (LPS) and induce inflammation (Table 2). Confirming our data, Tlr2, Tlr4 and Syk are already known to be expressed by the megakaryocytic lineage [38,39].",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "induced gene 3 part tolllike receptor signal ing pathway respond microbial stimuli lps induce inflammation table 2 confirming data tlr2 tlr4 syk already known expressed megakaryocytic lineage 3839"
  },
  {
    "id": 333,
    "paragraph": "Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 6 of 17 Table 2 Genes over-expressed in the megakaryoblastic leukaemias Probeset Gene SAM results d-score p-value FDR T1 T2 T3 B1 B2 Leukaemic samples * E2 B3 M E1 E3 Mk1 Mk2 Mk3",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 page 6 17 table 2 genes overexpressed megakaryoblastic leukaemias probeset gene sam results dscore pvalue fdr t1 t2 t3 b1 b2 leukaemic samples e2 b3 e1 e3 mk1 mk2 mk3"
  },
  {
    "id": 334,
    "paragraph": "GSE 6593 Genes potentially implicated in the disease ** Mk 1443260_at 1428647_at 1417155_at 1451332_at 1441350_at 1417552_at 1438325_at Meis1 Pbx1 Nmyc Evi3 Fgf3 Fap Evi1 12.0 10.2 16.0 13.0 5.4 7.2 4.5 <0.001 <0.001 <0.001 <0.001 0.002 <0.001 0.005 1440964_s_at Cbfa2t3h 11.0",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "gse 6593 genes potentially implicated disease mk 1443260at 1428647at 1417155at 1451332at 1441350at 1417552at 1438325at meis1 pbx1 nmyc evi3 fgf3 fap evi1 120 102 160 130 54 72 45 0001 0001 0001 0001 0002 0001 0005 1440964sat cbfa2t3h 110"
  },
  {
    "id": 335,
    "paragraph": "<0.001 0.1 0.07 0.08 0.08 0.12 0.09 0.16 0.08 -1.5 -1.6 -2.0 -1.1 -0.7 -1.7 -1.8 -0.4 -1.3 -1.1 -1.6 -1.3 -0.7 -1.6 -0.9 -0.7 -1.7 -1.1 -1.9 -1.1 -0.6 -1.7 -1.4 -1.1 -1.5 -1.3 -0.7 -1.1 -0.6 -1.8 -1.7 -0.3",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "0001 01 007 008 008 012 009 016 008 15 16 20 11 07 17 18 04 13 11 16 13 07 16 09 07 17 11 19 11 06 17 14 11 15 13 07 11 06 18 17 03"
  },
  {
    "id": 336,
    "paragraph": "-1.3 -1.3 -0.6 -1.0 -0.7 -1.7 -1.7 -0.6 -1.7 -1.6 -1.2 -0.9 -0.8 -1.7 -1.4 -0.3 -1.4 -1.2 -1.6 -0.7 -0.6 -1.7 -1.8 -0.1 -1.4 -1.2 -1.8 -0.7 -0.4 -1.5 -1.1 0.2 -1.3 -1.1 -1.5 -0.6 -0.6 -1.6 -1.4 -0.6 -1.3",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "13 13 06 10 07 17 17 06 17 16 12 09 08 17 14 03 14 12 16 07 06 17 18 01 14 12 18 07 04 15 11 02 13 11 15 06 06 16 14 06 13"
  },
  {
    "id": 337,
    "paragraph": "-1.4 -1.9 -0.9 -0.5 -1.4 -1.5 -0.2 4.5 4.3 4.8 3.5 1.3 5.9 7.3 1.4 5.9 5.3 5.6 3.3 2.9 7.0 2.4 1.4 4.0 3.3 4.4 2.6 1.9 3.6 4.8 1.2 Myct1 7.2 <0.001 0.07 -2.0 -1.7 -1.7 -1.6 -1.5 -1.6",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "14 19 09 05 14 15 02 45 43 48 35 13 59 73 14 59 53 56 33 29 70 24 14 40 33 44 26 19 36 48 12 myct1 72 0001 007 20 17 17 16 15 16"
  },
  {
    "id": 338,
    "paragraph": "-1.4 2.0 -1.1 0.6 3.0 4.5 2.5 MkE1 1452072_at MkMB 1437247_at 1417409_at 1434705_at 1452514_a_at 1418747_at 1452410_a_at 1428669_at 1420710_at FosL2 Jun Ctbp2 Kit Sfpi1 Fes Bmyc Rel 10.3 5.1 15.3 10.5 9.9 10.2 5.8 5.8 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "14 20 11 06 30 45 25 mke1 1452072at mkmb 1437247at 1417409at 1434705at 1452514aat 1418747at 1452410aat 1428669at 1420710at fosl2 jun ctbp2 kit sfpi1 fes bmyc rel 103 51 153 105 99 102 58 58 0001 0001 0001 0001 0001 0001 0001"
  },
  {
    "id": 339,
    "paragraph": "<0.001 0.01 0.03 0.01 0.01 <0.01 <0.01 0.04 0.02 Genes potentially implicated in inflammation response MkMB 1449222_at 1418262_at 1419132_at 1418163_at 1456046_at Ebi3 Syk Tlr2 Tlr4 C1qr1 11.2 <0.001 0.01 1.6 6.7 6.3 8.1 <0.001 <0.01 <0.001 <0.001 <0.001 0.01 0.01 <0.01",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "0001 001 003 001 001 001 001 004 002 genes potentially implicated inflammation response mkmb 1449222at 1418262at 1419132at 1418163at 1456046at ebi3 syk tlr2 tlr4 c1qr1 112 0001 001 16 67 63 81 0001 001 0001 0001 0001 001 001 001"
  },
  {
    "id": 340,
    "paragraph": "Genes selected for RT-PCR validation 1434141_at Gucy1a3 1437687_x_at 1453771_at 1448561_at Fkbp9 Gulp1 Ncf2 1450333_a_at Gata2 18.2 23.7 14.2 18.5 7.4 <0.001 <0.001 <0.001 0.07 0.07 0.07 <0.001 <0.01 <0.001 0.01 -0.8 -0.3 -1.1 -2.2 -2.6 -2.3 0.8 -0.4 -1.4 -2.4 -0.8",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "genes selected rtpcr validation 1434141at gucy1a3 1437687xat 1453771at 1448561at fkbp9 gulp1 ncf2 1450333aat gata2 182 237 142 185 74 0001 0001 0001 007 007 007 0001 001 0001 001 08 03 11 22 26 23 08 04 14 24 08"
  },
  {
    "id": 341,
    "paragraph": "-1.8 -2.2 -1.2 -1.4 -0.7 -2.6 -2.3 -0.5 -1.4 -1.0 -2.1 -1.7 -1.7 -0.9 0.0 -1.3 -2.5 -1.4 -1.6 -3.7 -0.6 -1.3 -0.7 -2.4 -2.0 -0.8 -3.3 -1.6 -2.2 -1.7 -1.7 0.9 -0.8 -1.2 -2.8 -1.6 -1.4 -4.2 -1.0 -1.6 -0.5",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "18 22 12 14 07 26 23 05 14 10 21 17 17 09 00 13 25 14 16 37 06 13 07 24 20 08 33 16 22 17 17 09 08 12 28 16 14 42 10 16 05"
  },
  {
    "id": 342,
    "paragraph": "-2.1 -2.3 -0.7 1 -0.9 -2.2 1.4 1.8 -1.5 0.4 -0.7 1.1 -1.1 -2.3 0.9 0.5 -1.2 1.0 -0.8 1.4 -1.3 1.2 1.1 1.0 -0.5 0.9 -1.4 -1.2 -1.3 2.8 0.6 0.5 4.1 -1.0 -1.3 -0.6 2.0 -2.1 2.4 0.1 1.8",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "21 23 07 1 09 22 14 18 15 04 07 11 11 23 09 05 12 10 08 14 13 12 11 10 05 09 14 12 13 28 06 05 41 10 13 06 20 21 24 01 18"
  },
  {
    "id": 343,
    "paragraph": "3.9 -1.1 -1.3 -0.9 1.6 -2.4 2.6 0.6 2.2 4.1 -1.2 -1.3 -0.9 1.6 -1.9 1.8 4.1 3.2 2.8 3.0 3.0 1.3 1.0 3.6 1.5 2.4 2.5 3.7 -1.0 -1.1 -0.9 3.0 -1.6 -0.5 -1.3 -1.2 -1.7 -1.7 -1.4 -1.6 -0.9",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "39 11 13 09 16 24 26 06 22 41 12 13 09 16 19 18 41 32 28 30 30 13 10 36 15 24 25 37 10 11 09 30 16 05 13 12 17 17 14 16 09"
  },
  {
    "id": 344,
    "paragraph": "-0.7 -1.6 -0.9 -1.2 -2.3 0.2 -1.0 -1.0 -2.1 0.2 -0.5 -1.5 -1.4 -1.6 -1.4 -2.0 -1.2 -1.3 -1.1 -2.2 -1.4 -0.8 -2.2 -1.1 -1.0 -0.9 -2.2 2.4 -0.6 -2.3 -1.9 -2.2 -1.8 -1.9 -1.4 -1.1 -1.6 -2.8 -1.5 -1.3 -4.1",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "07 16 09 12 23 02 10 10 21 02 05 15 14 16 14 20 12 13 11 22 14 08 22 11 10 09 22 24 06 23 19 22 18 19 14 11 16 28 15 13 41"
  },
  {
    "id": 345,
    "paragraph": "-1.0 -1.1 -0.9 -2.4 1.1 1.6 0.8 3.3 3.8 1.2 1.4 1.7 0.6 2.2 1.4 1 0.4 0.9 3.0 4.1 3.1 1.6 3.6 1.6 0.8 2.7 4.6 2.1 2.2 2.2 -0.1 3.1 1.6 2 0.7 0.6 3.2 4.6 2.6 2.5 4.0",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "10 11 09 24 11 16 08 33 38 12 14 17 06 22 14 1 04 09 30 41 31 16 36 16 08 27 46 21 22 22 01 31 16 2 07 06 32 46 26 25 40"
  },
  {
    "id": 346,
    "paragraph": "0.8 0.91 2.4 4.0 1.1 1.1 1.4 0.6 2.23 1.96 0.9 0.0 1.4 2.7 3.9 2.3 1.6 3.4 ND ND NS NS ↓ ND ND NS NS ND ↓ NS ↓ ↓ ↓ ↓ NS ↓ NS ↓ ND ND -",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "08 091 24 40 11 11 14 06 223 196 09 00 14 27 39 23 16 34 nd nd ns ns ↓ nd nd ns ns nd ↓ ns ↓ ↓ ↓ ↓ ns ↓ ns ↓ nd nd"
  },
  {
    "id": 347,
    "paragraph": "NS - NS ↓ * amplitude of deviation from the mean calculated from the RMA values ** cell cycle/cell growth/development/angiogenesis/DNA repair/transcription regulation ND (not determined), NS (not significant) To validate the microarray data, the expression of sev- eral megakaryoblastic specific genes was tested by semi-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "ns ns ↓ amplitude deviation mean calculated rma values cell cyclecell growthdevelopmentangiogenesisdna repairtranscription regulation nd determined ns significant validate microarray data expression sev eral megakaryoblastic specific genes tested semi"
  },
  {
    "id": 348,
    "paragraph": "quantitative RT-PCR in samples different from those analyzed in the microarray experiments (Table 2 and Fig- ure 2). Within these genes, Kit and Gata2 were tested due to their important roles in haematopoiesis. The other genes were selected for experimentation since they",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "quantitative rtpcr samples different analyzed microarray experiments table 2 fig ure 2 within genes kit gata2 tested due important roles haematopoiesis genes selected experimentation since"
  },
  {
    "id": 349,
    "paragraph": "had no prior association with megakaryocytic lineages or with the corresponding leukaemia and also since their ‘Genes function remained poorly studied (Table 2, selected for RT-PCR validation’). Within these genes, Gulp1 (Engulfment adaptor PTB domain containing 1) and Gucy1a3 (Guanylate cyclase 1, soluble, alpha 3) gave",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "prior association megakaryocytic lineages corresponding leukaemia also since ‘ genes function remained poorly studied table 2 selected rtpcr validation ’ within genes gulp1 engulfment adaptor ptb domain containing 1 gucy1a3 guanylate cyclase 1 soluble alpha 3 gave"
  },
  {
    "id": 350,
    "paragraph": "the highest specificity in the RT-PCR experiments with a strong expression in the 3 megakaryoblastic leukaemias (Figure 2). Most of the non-megakaryoblastic leukaemias showed very low or no expression of these genes. Ncf2 (Neutrophil cytosilic factor 2) is highly expressed in the",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "highest specificity rtpcr experiments strong expression 3 megakaryoblastic leukaemias figure 2 nonmegakaryoblastic leukaemias showed low expression genes ncf2 neutrophil cytosilic factor 2 highly expressed"
  },
  {
    "id": 351,
    "paragraph": "B-cell and megakaryoblastic leukaemias in accordance with the microarray data (Table 2). Fkbp9 (FK506 binding protein 9) is strongly expressed in the megakaryoblastic leukaemias with a weaker but sustained expression in other types of leukaemias. Gata2 is strongly expressed in the megakaryoblastic leukaemias and to a lower level in",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "bcell megakaryoblastic leukaemias accordance microarray data table 2 fkbp9 fk506 binding protein 9 strongly expressed megakaryoblastic leukaemias weaker sustained expression types leukaemias gata2 strongly expressed megakaryoblastic leukaemias lower level"
  },
  {
    "id": 352,
    "paragraph": "Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 7 of 17 Figure 2 Megakaryoblastic specific genes. Semi-quantitative RT-PCR analysis in 3 T-cell (T, 1-3), 3 B-cell (B, 4-7), 1 myeloid (M, 8), 3 erythroid (E, 8-10) and 3 megakaryoblastic leukaemias (Mk, 11-13). RT-PCRs have been performed in quadruplicate for each sample. Two out of 4 RT-PCR",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 page 7 17 figure 2 megakaryoblastic specific genes semiquantitative rtpcr analysis 3 tcell 13 3 bcell b 47 1 myeloid 8 3 erythroid e 810 3 megakaryoblastic leukaemias mk 1113 rtpcrs performed quadruplicate sample two 4 rtpcr"
  },
  {
    "id": 353,
    "paragraph": "runs are shown for the leukaemic samples (lane a: 25 PCR cycles; lane b: 28 PCR cycles) and 1 out of 4 are shown for the b-actin internal control (lane c). The histograms represent the quantification of the density of the bands relative to the b-actin sample including all RT-PCR runs for each",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "runs shown leukaemic samples lane 25 pcr cycles lane b 28 pcr cycles 1 4 shown bactin internal control lane c histograms represent quantification density bands relative bactin sample including rtpcr runs"
  },
  {
    "id": 354,
    "paragraph": "type of leukaemia (T, B, M, E, Mk). the 3 erythroleukaemias. Finally, Kit was amplified in all leukaemias but with the strongest expression in the megakaryoblastic ones (Figure 2). The erythroid signature The results of the erythroid signature were compared to",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "type leukaemia b e mk 3 erythroleukaemias finally kit amplified leukaemias strongest expression megakaryoblastic ones figure 2 erythroid signature results erythroid signature compared"
  },
  {
    "id": 355,
    "paragraph": "the transcriptome analysis of G1E cells during GATA1 induced differentiation (dataset GSE628, [40]). Our results correlate neatly with this dataset although the Affymetrix Genechip MG-U74A used by Welch and col- leagues contains only one third the probes of the MOE 430.2 used in our study. In the Welch et al study, the",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "transcriptome analysis g1e cells gata1 induced differentiation dataset gse628 40 results correlate neatly dataset although affymetrix genechip mgu74a used welch col leagues contains one third probes moe 4302 used study welch et al study"
  },
  {
    "id": 356,
    "paragraph": "genes that displayed increased expression during differ- entiation tended to be under-expressed in the Graffi- induced erythroleukaemias compared to the control sample and vice-versa. This suggests that the Graffi- induced erythroleukaemias are blocked in an earlier stage than the control sample taken from a population",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "genes displayed increased expression differ entiation tended underexpressed graffi induced erythroleukaemias compared control sample viceversa suggests graffi induced erythroleukaemias blocked earlier stage control sample taken population"
  },
  {
    "id": 357,
    "paragraph": "of Ter119+CD71+ erythroblasts in the bone marrow. Table 3 provides examples of this correlation between the two studies. For example, Car1 (Carbonic anhydrase 1) is over-expressed in the leukaemias in comparison to the control (positive value, column ‘E-CE’) and its expression decreases during erythroid differentiation",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "ter119cd71 erythroblasts bone marrow table 3 provides examples correlation two studies example car1 carbonic anhydrase 1 overexpressed leukaemias comparison control positive value column ‘ ece ’ expression decreases erythroid differentiation"
  },
  {
    "id": 358,
    "paragraph": "Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 8 of 17 Table 3 Genes specific to the erythroid leukaemias FDR T1 T2 T3 B1 B2 B3 M E1 E2 E3 Mk1 MK2 Mk3 E-CE G1E Leukaemic samples* Probeset Gene",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 page 8 17 table 3 genes specific erythroid leukaemias fdr t1 t2 t3 b1 b2 b3 e1 e2 e3 mk1 mk2 mk3 ece g1e leukaemic samples probeset gene"
  },
  {
    "id": 359,
    "paragraph": "SAM results p- value d- score Correlation with the G1E database 1416193_at 1422316_at 1422817_at Car1 Gp1ba Gp5 1424968_at 1425677_a_at 2210023G05Rik Ank1 1416464_at 1451675_a_at 1418699_s_at Slc4a1 Alas2 Fech 8.2 12.7 7.5 12.3 18.2 11.6 11.0 8.9 <0.001 <0.001 <0.001 <0.001 0.001 <0.001",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "sam results p value score correlation g1e database 1416193at 1422316at 1422817at car1 gp1ba gp5 1424968at 1425677aat 2210023g05rik ank1 1416464at 1451675aat 1418699sat slc4a1 alas2 fech 82 127 75 123 182 116 110 89 0001 0001 0001 0001 0001 0001"
  },
  {
    "id": 360,
    "paragraph": "<0.001 <0.001 Genes potentially implicated in the disease *** E 1417514_at 1460057_at 1419665_a_at 1443969_at 1417165_at 1449256_a_at 1417396_at EMk3 1422737_at 1435458_at Ssx2ip Gdf3 Nupr1 Irs2 Mbd2 Rab11a Podxl Ncoa3 Pim1 13.97 <0.001 9.4 8.7 6.5 <0.001 <0.001 <0.001 17.38 <0.001 10.59 <0.001",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "0001 0001 genes potentially implicated disease e 1417514at 1460057at 1419665aat 1443969at 1417165at 1449256aat 1417396at emk3 1422737at 1435458at ssx2ip gdf3 nupr1 irs2 mbd2 rab11a podxl ncoa3 pim1 1397 0001 94 87 65 0001 0001 0001 1738 0001 1059 0001"
  },
  {
    "id": 361,
    "paragraph": "6.5 <0.001 0.02 0.01 0.03 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.02 -3.4 -2.5 -3.6 -2.4 -1.5 -2.3 -3.4 -0.8 -1.1 -1.3 -1.5 0.1 -0.7 -1.0 -0.8 -2.1 -2.1 -2.3 -2.3 -1.3 -1.4 0.3 -1.0 -0.8",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "65 0001 002 001 003 001 001 002 002 002 001 001 001 002 001 001 002 34 25 36 24 15 23 34 08 11 13 15 01 07 10 08 21 21 23 23 13 14 03 10 08"
  },
  {
    "id": 362,
    "paragraph": "-1.2 -1.5 -0.1 -0.1 -0.3 -0.9 -3.2 -1.9 -3.0 -2.1 -1.3 -2.0 -0.9 -0.7 -1.4 -1.0 -1.3 -1.5 -0.4 -1.2 -1.0 -3.0 -1.9 -3.0 -2.2 -1.5 -2.4 -2.5 -1.4 -0.3 -1.3 -1.3 -0.2 0.0 -0.6 -1.0 -3.0 -2.0 -2.9 -2.2 -1.1",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "12 15 01 01 03 09 32 19 30 21 13 20 09 07 14 10 13 15 04 12 10 30 19 30 22 15 24 25 14 03 13 13 02 00 06 10 30 20 29 22 11"
  },
  {
    "id": 363,
    "paragraph": "-2.7 -3.8 -1.7 -0.3 -0.9 -1.3 -0.4 -0.1 -0.6 -0.9 -3.2 -2.4 -2.8 -1.9 -0.9 -2.0 -3.2 -1.5 -0.5 -1.0 -1.7 0.4 -0.3 -0.3 -0.7 -2.4 -1.9 -1.9 -1.9 -1.0 -1.2 -1.3 -0.5 -0.5 2.0 0.3 -1.0 -0.6 -0.4 -1.0 4.1",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "27 38 17 03 09 13 04 01 06 09 32 24 28 19 09 20 32 15 05 10 17 04 03 03 07 24 19 19 19 10 12 13 05 05 20 03 10 06 04 10 41"
  },
  {
    "id": 364,
    "paragraph": "5.4 0.003 <0.001 0.10 0.06 -0.3 -1.0 -1.2 -1.3 -0.1 -2.0 -0.5 -0.6 -0.4 -0.4 0.3 -0.4 -0.3 -0.2 Genes selected for RT-PCR validation 1449232_at 1425571_at 1418493_a_at 1418061_at 1419069_at 1427357_at 1417152_at Gata1 Slamf1 Snca Ltbp2 Rabgef1 Cda Btbd14a 4.58 9.9 10.2",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "54 0003 0001 010 006 03 10 12 13 01 20 05 06 04 04 03 04 03 02 genes selected rtpcr validation 1449232at 1425571at 1418493aat 1418061at 1419069at 1427357at 1417152at gata1 slamf1 snca ltbp2 rabgef1 cda btbd14a 458 99 102"
  },
  {
    "id": 365,
    "paragraph": "15 25.0 25.0 9.5 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.03 0.02 0.02 0.01 0.01 0.01 0.02 -1.9 -1.3 -3.3 -0.7 -0.5 -1.5 -0.6 -1.9 -1.6 -0.2 -0.7 -0.8 -1.6 -0.9 -2.1 -1.7 -1.0 -0.7 -0.4 -1.6 -0.9 -2.1 -1.2",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "15 250 250 95 0001 0001 0001 0001 0001 0001 0001 003 002 002 001 001 001 002 19 13 33 07 05 15 06 19 16 02 07 08 16 09 21 17 10 07 04 16 09 21 12"
  },
  {
    "id": 366,
    "paragraph": "-2.5 -0.7 -0.9 -1.7 -0.9 -2.3 -1.6 -3.2 -0.8 -1.3 -1.8 -0.8 -2.7 -1.5 -1.8 -0.7 -1.2 -0.6 -0.9 -1.9 -2.0 -1.5 -0.9 -0.8 -1.3 -0.5 * amplitude of deviation from the mean calculated from the RMA values ** ratio E-CE: mean of the deviation of E1, E2 and E3/erythroid control value",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "25 07 09 17 09 23 16 32 08 13 18 08 27 15 18 07 12 06 09 19 20 15 09 08 13 05 amplitude deviation mean calculated rma values ratio ece mean deviation e1 e2 e3erythroid control value"
  },
  {
    "id": 367,
    "paragraph": "*** cell cycle/cell growth/development/angiogenesis/DNA repair/transcriptionregulation 6.0 4.3 4.5 4.4 3.1 4.7 4.9 2.2 2.8 2.2 3.9 1.1 1.3 1.7 1.3 1.5 1.5 4.5 4.1 4.6 2.2 2.2 4.3 2.3 5.9 3.3 3.6 5.5 3.6 4.6 4.9 2.5 2.7 2.4 2.5 2.1",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "cell cyclecell growthdevelopmentangiogenesisdna repairtranscriptionregulation 60 43 45 44 31 47 49 22 28 22 39 11 13 17 13 15 15 45 41 46 22 22 43 23 59 33 36 55 36 46 49 25 27 24 25 21"
  },
  {
    "id": 368,
    "paragraph": "1.3 1.7 1.6 0.4 1.5 4.1 3.0 4.2 1.5 2.3 4.8 1.5 1.7 1.7 1.7 5.1 3.3 1.7 1.7 1.7 3.0 2.8 3.3 1.4 1.3 1.3 1.7 0.8 1.0 4.5 1.7 1.7 1.7 2.3 4.9 1.7 1.4 0.1 2.4 -0.2 -0.5",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "13 17 16 04 15 41 30 42 15 23 48 15 17 17 17 51 33 17 17 17 30 28 33 14 13 13 17 08 10 45 17 17 17 23 49 17 14 01 24 02 05"
  },
  {
    "id": 369,
    "paragraph": "-1.8 -2.8 -0.2 -2.4 -1.3 -0.9 -1.2 -0.6 -0.3 1.6 0.0 0.1 0.6 -0.3 -1.0 -0.5 -0.4 -1.6 -0.4 -2.1 -0.1 1.6 -1.1 -1.1 0.2 -0.5 0.0 -1.4 -1.3 -0.6 -0.5 -0.7 -0.1 0.2 -0.7 0.9 -1.4 -1.2 -0.7 -0.8 -0.4",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "18 28 02 24 13 09 12 06 03 16 00 01 06 03 10 05 04 16 04 21 01 16 11 11 02 05 00 14 13 06 05 07 01 02 07 09 14 12 07 08 04"
  },
  {
    "id": 370,
    "paragraph": "-1.7 -0.4 3.0 3.7 3.4 1.4 0.1 3.2 3.5 1.3 0.3 -0.1 0.2 -0.2 -0.2 0.2 -0.1 0.6 0.9 2.5 1.9 2.7 1.4 -0.1 -0.7 1.0 1.2 2.9 3.8 1.3 -0.8 -2.4 -1.1 -2.4 1.1 2.9 4.0 1.2 0.9 1.7 2.4",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "17 04 30 37 34 14 01 32 35 13 03 01 02 02 02 02 01 06 09 25 19 27 14 01 07 10 12 29 38 13 08 24 11 24 11 29 40 12 09 17 24"
  },
  {
    "id": 371,
    "paragraph": "2.2 0.6 0.4 4.8 -2.6 2.0 4.8 6.0 2.3 ↓ ↓ ↓ ↓ ↑ ↑ ↑ ↑ ↓ NS - ↑ - - NS NS ↑ ↑ - ↑ NS - - NS (descending arrow, column ‘G1E’). Alas2 (Aminolevuli- nic acid synthase 1), involved in the heme biosynthesis,",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "22 06 04 48 26 20 48 60 23 ↓ ↓ ↓ ↓ ↑ ↑ ↑ ↑ ↓ ns ↑ ns ns ↑ ↑ ↑ ns ns descending arrow column ‘ g1e ’ alas2 aminolevuli nic acid synthase 1 involved heme biosynthesis"
  },
  {
    "id": 372,
    "paragraph": "is under-expressed in the leukaemias in comparison to the control and its expression increases during erythroid differentiation. Table 3 presents a summary of the erythroid specific genes over-expressed in comparison to the control sample and potentially implicated in the disease but the complete",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "underexpressed leukaemias comparison control expression increases erythroid differentiation table 3 presents summary erythroid specific genes overexpressed comparison control sample potentially implicated disease complete"
  },
  {
    "id": 373,
    "paragraph": "data are readily available [19]. Within these genes, Gdf3 (Growth differentiation factor 3), Podxl (Podocalyxin-like), Nupr1 (Nuclear protein 1), Pim1 (Proviral integration site 1) and Isr2 (Insulin receptor substrate 2) are known to be regulated by erythropoietin [41-43]. The oncogene Pim1",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "data readily available 19 within genes gdf3 growth differentiation factor 3 podxl podocalyxinlike nupr1 nuclear protein 1 pim1 proviral integration site 1 isr2 insulin receptor substrate 2 known regulated erythropoietin 4143 oncogene pim1"
  },
  {
    "id": 374,
    "paragraph": "was found rearranged in Friend helper MuLV-induced erythroleukaemias and Graffi-induced leukaemias [36,44]. Ssx2ip (Synovial sarcoma, X breakpoint 2 interacting pro- tein) was found over-expressed in some AML patients and is expressed by K562 erythroid cells [45]. Rab11a (RAB11a, member RAS oncogene family) was reported to",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "found rearranged friend helper mulvinduced erythroleukaemias graffiinduced leukaemias 3644 ssx2ip synovial sarcoma x breakpoint 2 interacting pro tein found overexpressed aml patients expressed k562 erythroid cells 45 rab11a rab11a member ras oncogene family reported"
  },
  {
    "id": 375,
    "paragraph": "regulate the recycling of the transferrin receptor [46]. This protein interacts with Evi5 [47] and has a potential role in cancer [48]. The oncogene Ncoa3 (Nuclear receptor coacti- vator 3) is over-expressed in numerous cancer types such as breast, prostate, ovarian, gastric, pancreatic and colorec-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "regulate recycling transferrin receptor 46 protein interacts evi5 47 potential role cancer 48 oncogene ncoa3 nuclear receptor coacti vator 3 overexpressed numerous cancer types breast prostate ovarian gastric pancreatic colorec"
  },
  {
    "id": 376,
    "paragraph": "tal cancers [49]. Many genes have not yet been reported in relation to erythroid leukaemias and several others have a still unknown function and some of them have been selected for RT-PCR validation (Table 3 and Figure 3). Gata1 was tested due to its important role in haematopoiesis",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "tal cancers 49 many genes yet reported relation erythroid leukaemias several others still unknown function selected rtpcr validation table 3 figure 3 gata1 tested due important role haematopoiesis"
  },
  {
    "id": 377,
    "paragraph": "(Figure 3). Among the 7 tested erythroid genes (Table 3, ‘Genes selected for RT-PCR validation’), both Cda (Cyti- dine deaminase) and Ltbp2 (Latent transforming growth factor beta binding protein 2) showed a very high and Voisin et al. BMC Medical Genomics 2010, 3:2",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "figure 3 among 7 tested erythroid genes table 3 ‘ genes selected rtpcr validation ’ cda cyti dine deaminase ltbp2 latent transforming growth factor beta binding protein 2 showed high voisin et al bmc medical genomics 2010 32"
  },
  {
    "id": 378,
    "paragraph": "http://www.biomedcentral.com/1755-8794/3/2 Page 9 of 17 Figure 3 Erythroid specific genes. Semi-quantitative RT-PCR analysis in 3 T-cell (T, 1-3), 3 B-cell (B, 4-7), 1 myeloid (M, 8), 3 erythroid (E, 8-10) and 3 megakaryoblastic leukaemias (Mk, 11-13) was utilized for each of the 6 tested genes. RT-PCRs have been performed in quadruplicate for",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "httpwwwbiomedcentralcom1755879432 page 9 17 figure 3 erythroid specific genes semiquantitative rtpcr analysis 3 tcell 13 3 bcell b 47 1 myeloid 8 3 erythroid e 810 3 megakaryoblastic leukaemias mk 1113 utilized 6 tested genes rtpcrs performed quadruplicate"
  },
  {
    "id": 379,
    "paragraph": "each sample. Two out of 4 RT-PCR runs are shown for the leukaemic samples (lane a: 25 PCR cycles; lane b: 28 PCR cycles) and 1 out of 4 are shown for the b-actin control sample (lane c). The histograms represent the quantification of the density of the bands relative to the b-actin",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "sample two 4 rtpcr runs shown leukaemic samples lane 25 pcr cycles lane b 28 pcr cycles 1 4 shown bactin control sample lane c histograms represent quantification density bands relative bactin"
  },
  {
    "id": 380,
    "paragraph": "sample including all RT-PCR runs for each type of leukaemia (T, B, M, E, Mk). Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 10 of 17 specific expression in the 3 erythroleukaemias (Figure 3). Slamf1 (Signaling lymphocytic activation molecule family",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "sample including rtpcr runs type leukaemia b e mk voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 page 10 17 specific expression 3 erythroleukaemias figure 3 slamf1 signaling lymphocytic activation molecule family"
  },
  {
    "id": 381,
    "paragraph": "member 1), Snca (Synuclein alpha) and Btbd14a (BTB/ POZ domain containing 14A) are higher expressed in the erythroleukaemias and lower in the megakaryoblas- tic leukaemias but were also amplified in other types of leukaemias. Rabgef1 is specifically expressed in the ery-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "member 1 snca synuclein alpha btbd14a btb poz domain containing 14a higher expressed erythroleukaemias lower megakaryoblas tic leukaemias also amplified types leukaemias rabgef1 specifically expressed ery"
  },
  {
    "id": 382,
    "paragraph": "throleukaemias at 25 PCR cycles (lane a) but was ampli- fied in all samples at 28 PCR cycles (lane b). Gata1 is equally highly expressed in the erythroid and in the megakaryoblastic leukaemias (Figure 3). RT-PCR validation in a Friend virus murine",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "throleukaemias 25 pcr cycles lane ampli fied samples 28 pcr cycles lane b gata1 equally highly expressed erythroid megakaryoblastic leukaemias figure 3 rtpcr validation friend virus murine"
  },
  {
    "id": 383,
    "paragraph": "erythroleukaemia cell line The expression of the erythroid and megakaryoblastic specific transcripts validated by RT-PCR (Figures 2 and 3) was further assessed on a different erythroid model (Figure 4). The erythroleukaemia cell line HB22.2 has been derived from a leukaemia induced by the Friend",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "erythroleukaemia cell line expression erythroid megakaryoblastic specific transcripts validated rtpcr figures 2 3 assessed different erythroid model figure 4 erythroleukaemia cell line hb222 derived leukaemia induced friend"
  },
  {
    "id": 384,
    "paragraph": "Murine Leukaemia virus (F-MuLV) and it presents a very immature erythroid phenotype (Kit+CD71+Ter119- CD41-) ([17]). The 6 erythroid genes (Slamf1, Snca, Ltbp2, Rabgef1, Cda and Btbd14a) are expressed in HB22.2 but the intensity of the Ltbp2 and Btdb14a bands were weaker (Figure 4A). In accordance with our",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "murine leukaemia virus fmulv presents immature erythroid phenotype kitcd71ter119 cd41 17 6 erythroid genes slamf1 snca ltbp2 rabgef1 cda btbd14a expressed hb222 intensity ltbp2 btdb14a bands weaker figure 4a accordance"
  },
  {
    "id": 385,
    "paragraph": "expectations, the megakaryoblastic genes, Ncf2, Gucy1a3 and Gulp1, could not be amplified. Fkbp9 is the only megakaryoblastic gene that gave a weak signal in this erythroid cell line. Indeed, Fkbp9 showed the strongest erythroid amplification in the RT-PCR validation experi- ment (Figure 2). Thus, these results show that, despite",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "expectations megakaryoblastic genes ncf2 gucy1a3 gulp1 could amplified fkbp9 megakaryoblastic gene gave weak signal erythroid cell line indeed fkbp9 showed strongest erythroid amplification rtpcr validation experi ment figure 2 thus results show despite"
  },
  {
    "id": 386,
    "paragraph": "relationship between erythroid and the close Figure 4 Expression of the erythroid and megakaryoblastic specific genes in the murine erythroleukaemia cell line HB22.2 during hemin-induced differentiation. (A) Semi-quantitative RT-PCR analysis of 6 erythroid specific genes (E) and 4 megakaryoblastic specific genes",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "relationship erythroid close figure 4 expression erythroid megakaryoblastic specific genes murine erythroleukaemia cell line hb222 hemininduced differentiation semiquantitative rtpcr analysis 6 erythroid specific genes e 4 megakaryoblastic specific genes"
  },
  {
    "id": 387,
    "paragraph": "(Mk). The first lane (M) indicates the low-range DNA marker. (B) Hemin-induced differentiation assay of HB22.2 cells. Semi-quantitative RT-PCR analysis of Hba as differentiation control, Btbd14a and Ltbp2 was performed in non-induced (NI) and induced (Hemin) cells at day 1 (D1) and",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "mk first lane indicates lowrange dna marker b hemininduced differentiation assay hb222 cells semiquantitative rtpcr analysis hba differentiation control btbd14a ltbp2 performed noninduced ni induced hemin cells day 1 d1"
  },
  {
    "id": 388,
    "paragraph": "day 3 (D3) following hemin addition. GAPDH expression was used as internal control. Three independent RT-PCR reactions were performed on each sample using increasing amount of the RT reaction (0.75 volume, 1 volume, 1.25 volume). The band intensity was measured and indicated",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "day 3 d3 following hemin addition gapdh expression used internal control three independent rtpcr reactions performed sample using increasing amount rt reaction 075 volume 1 volume 125 volume band intensity measured indicated"
  },
  {
    "id": 389,
    "paragraph": "below each band. On the right half of the figure, the histograms show the average results of the band intensities relative to the Gapdh control sample. Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 11 of 17 megakaryoblastic leukaemias, this experiment’s design",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "band right half figure histograms show average results band intensities relative gapdh control sample voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 page 11 17 megakaryoblastic leukaemias experiment ’ design"
  },
  {
    "id": 390,
    "paragraph": "enabled us to find genes that can distinguish these 2 types of murine leukaemias from each other. We then induced HB22.2 differentiation with hemin and tested the expression of the erythroid specific genes at different time-points (Figure 4). Integration of F-MuLV upstream of Fli-1 is shown to block differen-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "enabled us find genes distinguish 2 types murine leukaemias induced hb222 differentiation hemin tested expression erythroid specific genes different timepoints figure 4 integration fmulv upstream fli1 shown block differen"
  },
  {
    "id": 391,
    "paragraph": "tiation of this cell line [17]. However, these cells are able to undergo differentiation with hemin associated induction of alpha globin (Figure 4B). Among the 6 ery- throid genes tested, both Btbd14a and Ltbp2 showed reproducible changes with a decrease and an increase",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "tiation cell line 17 however cells able undergo differentiation hemin associated induction alpha globin figure 4b among 6 ery throid genes tested btbd14a ltbp2 showed reproducible changes decrease increase"
  },
  {
    "id": 392,
    "paragraph": "with differentiation, respectively (Figure 4B). The increased expression of Ltbp2 indicates that it likely plays a role in mature erythroid cells whereas Btbd14a is likely to play a role in immature erythroid cells and this correlates well with a putative oncogenic role for",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "differentiation respectively figure 4b increased expression ltbp2 indicates likely plays role mature erythroid cells whereas btbd14a likely play role immature erythroid cells correlates well putative oncogenic role"
  },
  {
    "id": 393,
    "paragraph": "this gene. Validation in human leukaemic cell lines The proteins encoded by these erythroid and megakaryo- blastic specific genes have high homologies with their human counterparts. This makes it likely that these human and murine proteins have the same functional role. Gene expression was first tested in 2 human ery-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "gene validation human leukaemic cell lines proteins encoded erythroid megakaryo blastic specific genes high homologies human counterparts makes likely human murine proteins functional role gene expression first tested 2 human ery"
  },
  {
    "id": 394,
    "paragraph": "throid-like cell lines, HEL and K562, a human B-cell leu- kaemia cell line, TK6, and a human T-cell leukaemia cell line, Jurkat (Figure 5A). Because HEL and K562 are known to harbour mixed myeloid lineage phenotype, the genes were further tested in 2 human megakaryoblastic",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "throidlike cell lines hel k562 human bcell leu kaemia cell line tk6 human tcell leukaemia cell line jurkat figure 5a hel k562 known harbour mixed myeloid lineage phenotype genes tested 2 human megakaryoblastic"
  },
  {
    "id": 395,
    "paragraph": "cell lines, MEG-01 and CMK, and 1 erythroid cell line LAMA-84 (Figure 5B). The results show that all tested erythroid and mega- karyoblastic specific genes were amplified in some or all of the cell lines confirming their expression in human erythroid or megakaryoblastic cell lines. Moreover, sev-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "cell lines meg01 cmk 1 erythroid cell line lama84 figure 5b results show tested erythroid mega karyoblastic specific genes amplified cell lines confirming expression human erythroid megakaryoblastic cell lines moreover sev"
  },
  {
    "id": 396,
    "paragraph": "eral were also amplified in the lymphoid lines TK6 and/ or in Jurkat. RABGEF1 and BTBD14A were the most ubiquitous genes with a strong amplification in lym- phoid and non-lymphoid cell lines. GULP1 and SNCA were the most specific to the non-lymphoid lineage with",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "eral also amplified lymphoid lines tk6 jurkat rabgef1 btbd14a ubiquitous genes strong amplification lym phoid nonlymphoid cell lines gulp1 snca specific nonlymphoid lineage"
  },
  {
    "id": 397,
    "paragraph": "no expression in TK6 or Jurkat cell lines. Viral integrations in the megakaryoblastic leukaemias We also identified retroviral integration sites (RIS) in the 3 megakaryoblastic leukaemias (Mk1-3) in order to search for genes that may have contributed to the oncogenic transformation. Several RIS were amplified,",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "expression tk6 jurkat cell lines viral integrations megakaryoblastic leukaemias also identified retroviral integration sites ris 3 megakaryoblastic leukaemias mk13 order search genes may contributed oncogenic transformation several ris amplified"
  },
  {
    "id": 398,
    "paragraph": "cloned and sequenced in these 3 tumors (11 in Mk1, 5 in Mk2 and 10 in Mk3) (Table 4). No common inte- gration sites (CIS) that could clearly indicate the con- tribution to the oncogenic events were found. Therefore, the results were compared to the retroviral",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "cloned sequenced 3 tumors 11 mk1 5 mk2 10 mk3 table 4 common inte gration sites cis could clearly indicate con tribution oncogenic events found therefore results compared retroviral"
  },
  {
    "id": 399,
    "paragraph": "tagged cancer gene database (RTCGD, [50]) that compiles the RIS identified in different murine cancer models (underlined in Table 4). Genes identified in multiple screens have a high probability of involvement in oncogenic transformation. Eleven genes near the RIS were found in the RTCGD (underlined in Table 4).",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "tagged cancer gene database rtcgd 50 compiles ris identified different murine cancer models underlined table 4 genes identified multiple screens high probability involvement oncogenic transformation eleven genes near ris found rtcgd underlined table 4"
  },
  {
    "id": 400,
    "paragraph": "Some of these genes, such as Ccnd1 and Myc, are lar- gely known to be involved in leukaemia. Foxf1 is a transcription factor known to regulate the megakaryo- cytic integrin b3 (CD61) [51]. Interestingly, Kit and Gata2 are also part of RIS. The presence of the RIS",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "genes ccnd1 myc lar gely known involved leukaemia foxf1 transcription factor known regulate megakaryo cytic integrin b3 cd61 51 interestingly kit gata2 also part ris presence ris"
  },
  {
    "id": 401,
    "paragraph": "near Kit in Mk1 and near Gata2 in Mk3 has been vali- dated by PCR in the sorted leukaemic megakaryoblas- tic population (not shown). Two other genes, Irf8 and Itga1 targeted by a RIS (Table 4) are also of interest: Irf8 is not included in the RTCGD database but is a",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "near kit mk1 near gata2 mk3 vali dated pcr sorted leukaemic megakaryoblas tic population shown two genes irf8 itga1 targeted ris table 4 also interest irf8 included rtcgd database"
  },
  {
    "id": 402,
    "paragraph": "known CIS [52] and the ITGA1 locus is repressed by methylation during megakaryopoiesis in humans [53]. Discussion Characterization of genes specific to erythro- and megakaryoblastic leukaemias Patient survey studies revealed that erythroleukaemias represent an average of 5% of all cases of acute myeloid",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "known cis 52 itga1 locus repressed methylation megakaryopoiesis humans 53 discussion characterization genes specific erythro megakaryoblastic leukaemias patient survey studies revealed erythroleukaemias represent average 5 cases acute myeloid"
  },
  {
    "id": 403,
    "paragraph": "leukaemias [3-5] and megakaryoblastic leukaemias have an incidence of approximately 1% in adults and 5-10% in children [6,7]. However, the overall survival rate is extremely poor and ranges from 6% to 17% [3,7]. Chil- dren suffering from Down Syndrome are an exception",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "leukaemias 35 megakaryoblastic leukaemias incidence approximately 1 adults 510 children 67 however overall survival rate extremely poor ranges 6 17 37 chil dren suffering syndrome exception"
  },
  {
    "id": 404,
    "paragraph": "as they have a higher risk of developing megakaryoblas- tic leukaemias but respond better to therapy [54]. Acute erythro- and megakaryoblastic leukaemias are less stu- died than the more frequent types of leukaemias. Thus, genes involved in the development of these leukaemias",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "higher risk developing megakaryoblas tic leukaemias respond better therapy 54 acute erythro megakaryoblastic leukaemias less stu died frequent types leukaemias thus genes involved development leukaemias"
  },
  {
    "id": 405,
    "paragraph": "remain insufficiently elucidated. Our experimental design is based on the comparison of non-lymphoid versus lymphoid murine leukaemias and provides the whole picture of genes specific to these 2 groups and subgroups. The sole comparison of the non-lymphoid leukaemias and their respective con-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "remain insufficiently elucidated experimental design based comparison nonlymphoid versus lymphoid murine leukaemias provides whole picture genes specific 2 groups subgroups sole comparison nonlymphoid leukaemias respective con"
  },
  {
    "id": 406,
    "paragraph": "trols without including the lymphoid group would not have provided such a dataset. Therefore, numerous genes not described previously or uncharacterized emerged from this study. We estimated that, within the identified gene signatures, there are oncogenes directly implicated in the disease and also genes",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "trols without including lymphoid group would provided dataset therefore numerous genes described previously uncharacterized emerged study estimated within identified gene signatures oncogenes directly implicated disease also genes"
  },
  {
    "id": 407,
    "paragraph": "related to the normal commitment of the cells toward the erythro- or megakaryoblastic lineages. To deter- mine which genes are potential oncogenes, we first compared the erythroleukaemias to the erythroid con- trol samples and to the study of Welch and colleagues",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "related normal commitment cells toward erythro megakaryoblastic lineages deter mine genes potential oncogenes first compared erythroleukaemias erythroid con trol samples study welch colleagues"
  },
  {
    "id": 408,
    "paragraph": "[40]. The comparison with the Welch’s study enabled to assess the differentiation state of the leukaemias and the control. Consequently, we could assume that the genes under-expressed in comparison to the control Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "40 comparison welch ’ study enabled assess differentiation state leukaemias control consequently could assume genes underexpressed comparison control voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432"
  },
  {
    "id": 409,
    "paragraph": "Page 12 of 17 Figure 5 Validation in human cell lines. (A) RT-PCR analysis in the erythroid-like human cell lines K562 and HEL, the B- cell lymphoblastic cell line TK6 and the T-cell leukaemia cell line Jurkat. (B) RT-PCR analysis in the human megakaryoblastic cell lines MEG-01 and CMK and the human",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "page 12 17 figure 5 validation human cell lines rtpcr analysis erythroidlike human cell lines k562 hel b cell lymphoblastic cell line tk6 tcell leukaemia cell line jurkat b rtpcr analysis human megakaryoblastic cell lines meg01 cmk human"
  },
  {
    "id": 410,
    "paragraph": "erythroid cell line LAMA-84. The left and right parts of each panel correspond to genes identified in the erythro- and megakaryoblastic leukaemias, respectively. GAPDH was used as internal control. are late stage genes and that oncogenes are more likely to be within the over-expressed genes. We validated",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "erythroid cell line lama84 left right parts panel correspond genes identified erythro megakaryoblastic leukaemias respectively gapdh used internal control late stage genes oncogenes likely within overexpressed genes validated"
  },
  {
    "id": 411,
    "paragraph": "this hypothesis with Ltbp2 and Btbd14a in a differen- tiation assay in the HB22.2 erythroid cell line. Second, to gain more insights into the function of the megakar- yoblastic genes and in the absence of a control sample, we compared our list of genes to the study of Shivda-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "hypothesis ltbp2 btbd14a differen tiation assay hb222 erythroid cell line second gain insights function megakar yoblastic genes absence control sample compared list genes study shivda"
  },
  {
    "id": 412,
    "paragraph": "sani and colleagues [37]. The comparison with the stu- dies of Welch for the erythroid leukaemias [40] and of Shivadasani [37] for the megakaryoblastic leukaemias provides valuable information about the behaviour of the genes during normal differentiation. However, their respective microarray chips contained less probesets",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "sani colleagues 37 comparison stu dies welch erythroid leukaemias 40 shivadasani 37 megakaryoblastic leukaemias provides valuable information behaviour genes normal differentiation however respective microarray chips contained less probesets"
  },
  {
    "id": 413,
    "paragraph": "than ours and we could not perform the comparison on the whole dataset. Therefore, further experiments are required to identify the unknown role played by these genes and megakaryoblastic leukaemias. in erythro- Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "could perform comparison whole dataset therefore experiments required identify unknown role played genes megakaryoblastic leukaemias erythro voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432"
  },
  {
    "id": 414,
    "paragraph": "Page 13 of 17 Table 4 Graffi-virus integration sites in the megakaryoblastic leukaemias Sample Chromosome Genome Upstream genes* Integra-tion within a gene Downstream genes* Mk1 Mk2 Mk3 1D 1G2 4B1 5E 1 6F3 6G1 11B4 11B5 15D3 15F2 16B3 1 E4",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "page 13 17 table 4 graffivirus integration sites megakaryoblastic leukaemias sample chromosome genome upstream genes integration within gene downstream genes mk1 mk2 mk3 1d 1g2 4b1 5e 1 6f3 6g1 11b4 11b5 15d3 15f2 16b3 1 e4"
  },
  {
    "id": 415,
    "paragraph": "6A3 8 E1 12C1 93018002 153451217 gene 1 Gm817 Rnf2 41816941 2310028H24Rik 75741720 128801887 135264443 70471623 80139013 62283939 95582212 33700976 132543823 25759728 123703449 52786246 Pdgfra Klrb1b Gsg1 Pfn1** Rhot1 Pvt1 Dbx2 Heg1 Pfkb2 Pot 1a Irf8 Hectd1 Pelo kb 17 188",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "6a3 8 e1 12c1 93018002 153451217 gene 1 gm817 rnf2 41816941 2310028h24rik 75741720 128801887 135264443 70471623 80139013 62283939 95582212 33700976 132543823 25759728 123703449 52786246 pdgfra klrb1b gsg1 pfn1 rhot1 pvt1 dbx2 heg1 pfkb2 pot 1a irf8 hectd1 pelo kb 17 188"
  },
  {
    "id": 416,
    "paragraph": "133 216 10 61 0.8 55 211 100 13 0.4 14 81 120 46 gene 2 Lrrfip1 1190005F20Rik 1700066J25Rik Gsh2 Clec2h Hebp1) Rnf167 Rnf135 Myc** Nell2 Slc12a8 C4bp Grp37 Cox4i1 EG544864 Itga1 13D2.3 116255725 1C5 1F 2H3 5B1 6D2 7B4 7F5",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "133 216 10 61 08 55 211 100 13 04 14 81 120 46 gene 2 lrrfip1 1190005f20rik 1700066j25rik gsh2 clec2h hebp1 rnf167 rnf135 myc nell2 slc12a8 c4bp grp37 cox4i1 eg544864 itga1 13d23 116255725 1c5 1f 2h3 5b1 6d2 7b4 7f5"
  },
  {
    "id": 417,
    "paragraph": "13A1 14C3 19A Glrp1 146 Spp2 139621937 165618991 43941 88086902 45356428 144856850 3830652 53491694 4301566 - Prkcbp1** Rheb Rpn1 Bax Ccnd1** Calm13 Prmt5 Ankrd13d 43 23 16 21 Eya2 Cryng EG434064 Flt1 107 Oraov1 27 20 18 Rem2 Ssh3 kb 60",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "13a1 14c3 19a glrp1 146 spp2 139621937 165618991 43941 88086902 45356428 144856850 3830652 53491694 4301566 prkcbp1 rheb rpn1 bax ccnd1 calm13 prmt5 ankrd13d 43 23 16 21 eya2 cryng eg434064 flt1 107 oraov1 27 20 18 rem2 ssh3 kb 60"
  },
  {
    "id": 418,
    "paragraph": "230 138 382 159 130 4 123 463 225 118 54 120 149 35 33 230 156 83 115 28 167 57 32 Ramp1** Niban Dnaic1 - - - - Rhbd13 - - - - - - - - - -",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "230 138 382 159 130 4 123 463 225 118 54 120 149 35 33 230 156 83 115 28 167 57 32 ramp1 niban dnaic1 rhbd13"
  },
  {
    "id": 419,
    "paragraph": "- - Dhdh - - - kb 95 92 29 114 50 10 1.7 60 gene 1 Ube2f Edem3 Cntfr Kit** Clec21 Pbp2 Eno3 Zfp207 - - Muc13 12 gene 2 Scly Q8K3Do Dcnt3 Kdr Klrb1f Dynlt1 Spag7 Psmd11 - Tmem16f",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "dhdh kb 95 92 29 114 50 10 17 60 gene 1 ube2f edem3 cntfr kit clec21 pbp2 eno3 zfp207 muc13 12 gene 2 scly q8k3do dcnt3 kdr klrb1f dynlt1 spag7 psmd11 tmem16f"
  },
  {
    "id": 420,
    "paragraph": "Itgb5 ** Yod1 - Foxf1a** Heatr5a - Arl14c Ptprc Ncoa3 Prkag2** Gata2** Nucb1 Tpcn2) Calm4 D14Ertd500e 0.8 AA986890 - Mthfsd 6530401NO4Rik - Sh3bp4 Atp6v1g3 Sulf2 1500035N22Rik Dnajb8 Tulp2 Mrgprf Calm5 Jub FBXL13 269 11 161 257 65 20 72 4 167",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "itgb5 yod1 foxf1a heatr5a arl14c ptprc ncoa3 prkag2 gata2 nucb1 tpcn2 calm4 d14ertd500e 08 aa986890 mthfsd 6530401no4rik sh3bp4 atp6v1g3 sulf2 1500035n22rik dnajb8 tulp2 mrgprf calm5 jub fbxl13 269 11 161 257 65 20 72 4 167"
  },
  {
    "id": 421,
    "paragraph": "6 4 15 kb 130 199 86 472 208 50 8.2 105 36 48 1 280 124 413 466 146 144 100 25 253 22 31 15 Adrbk1** Fbxl13 * the 2 most proximal genes located at a maximum distance of 500kb upstream (5’) or downstream (3’) of the integration site",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "6 4 15 kb 130 199 86 472 208 50 82 105 36 48 1 280 124 413 466 146 144 100 25 253 22 31 15 adrbk1 fbxl13 2 proximal genes located maximum distance 500kb upstream 5 ’ downstream 3 ’ integration site"
  },
  {
    "id": 422,
    "paragraph": "** genes present in the RTCGD database Erythroid and megakaryoblastic genes Erythroid and megakaryoblastic lineages, emerging from the same bipotent progenitor, are very closely related [11] and, as confirmed by our study, several transcrip- tion factors are commonly expressed. This strengthens",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "genes present rtcgd database erythroid megakaryoblastic genes erythroid megakaryoblastic lineages emerging bipotent progenitor closely related 11 confirmed study several transcrip tion factors commonly expressed strengthens"
  },
  {
    "id": 423,
    "paragraph": "the hypothesis that a very fine tuning of these factors influences the commitment toward the erythroid or megakaryocytic lineages. Our microarray data indicate that Gata1, Gata2, Fog1, Scl and Lmo2 are expressed both in the Graffi-induced erythro- and megakaryoblastic leukaemias (Table 1).",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "hypothesis fine tuning factors influences commitment toward erythroid megakaryocytic lineages microarray data indicate gata1 gata2 fog1 scl lmo2 expressed graffiinduced erythro megakaryoblastic leukaemias table 1"
  },
  {
    "id": 424,
    "paragraph": "They are known to act on the promoter of their target as multimeric complexes. Our study highlights that PU.1 (Sfpi1), Ctbp2, Cbfa2t3h (Eto2), Evi1 and Runx1 have a strong megakaryoblastic pattern. PU.1 is a known determinant of erythroid versus megakaryoblastic differ-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "known act promoter target multimeric complexes study highlights pu1 sfpi1 ctbp2 cbfa2t3h eto2 evi1 runx1 strong megakaryoblastic pattern pu1 known determinant erythroid versus megakaryoblastic differ"
  },
  {
    "id": 425,
    "paragraph": "entiation and the Gata2 protein acts on PU.1 [55]. The Cbfa2t3h protein binds to the multimeric complex formed by Gata1, Fog1, Scl and Lmo2 and is known to repress the transcription of the target genes. The co- repressor Ctbp2 is known to bind to Evi1 and Fog1 [56].",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "entiation gata2 protein acts pu1 55 cbfa2t3h protein binds multimeric complex formed gata1 fog1 scl lmo2 known repress transcription target genes co repressor ctbp2 known bind evi1 fog1 56"
  },
  {
    "id": 426,
    "paragraph": "Runx1 cooperates with Gata1 during megakaryocytic commitment [22,23] and the Runx1-Evi1 fusion protein leads preferentially to the development of megakaryo- blastic leukaemias in transgenic mice [57]. In a model of in vitro differentiation, Evi1 is strongly induced and sus- tained upon thrombopoietin treatment of CD34+ cells in",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "runx1 cooperates gata1 megakaryocytic commitment 2223 runx1evi1 fusion protein leads preferentially development megakaryo blastic leukaemias transgenic mice 57 model vitro differentiation evi1 strongly induced sus tained upon thrombopoietin treatment cd34 cells"
  },
  {
    "id": 427,
    "paragraph": "a pattern very similar to Gata2 and PU.1 but only weakly upon erythropoietin treatment [58]. Great evi- dence indicates that Evi1 is a direct activating target of Gata2 [59]. Thus, our study reinforces the importance of these genes in the megakaryoblastic leukaemias.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "pattern similar gata2 pu1 weakly upon erythropoietin treatment 58 great evi dence indicates evi1 direct activating target gata2 59 thus study reinforces importance genes megakaryoblastic leukaemias"
  },
  {
    "id": 428,
    "paragraph": "RT-PCR validated megakaryoblastic genes The specific megakaryoblastic expression of several genes with poorly elucidated physiological roles was validated by Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 14 of 17 RT-PCR. Our study reports for the first time Gucy1a3,",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "rtpcr validated megakaryoblastic genes specific megakaryoblastic expression several genes poorly elucidated physiological roles validated voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 page 14 17 rtpcr study reports first time gucy1a3"
  },
  {
    "id": 429,
    "paragraph": "Gulp1 and Fkbp9 as being specific to megakaryoblastic leukaemias. The function of these genes, related to the normal development or transformation of megakaryocytic cells, has yet to be elucidated. Insight into their physiologi- cal roles can be provided by their already known functions",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "gulp1 fkbp9 specific megakaryoblastic leukaemias function genes related normal development transformation megakaryocytic cells yet elucidated insight physiologi cal roles provided already known functions"
  },
  {
    "id": 430,
    "paragraph": "in other cell types. Gucy1a3 is known to heterodimerize with Gucy1b3, which gene is also specific to the Graffi- induced megakaryoblastic leukaemias. The Gucy1a3/b3 complex produces cGMP after activation by nitric oxide (NO) itself produced by the NADPH oxidase from reactive",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "cell types gucy1a3 known heterodimerize gucy1b3 gene also specific graffi induced megakaryoblastic leukaemias gucy1a3b3 complex produces cgmp activation nitric oxide produced nadph oxidase reactive"
  },
  {
    "id": 431,
    "paragraph": "oxygen species. As expected, Ncf2 and other components of the NADPH oxidase (Ncf1, Ncf4, Cybb) are specifically over-expressed in the Graffi-induced megakaryoblastic leukaemias (Figure 2 and not shown). In human cancerous glioma cell lines, it is hypothesized that GUCY1a3/b3 may be responsible for VEGF over-expression resulting in an",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "oxygen species expected ncf2 components nadph oxidase ncf1 ncf4 cybb specifically overexpressed graffiinduced megakaryoblastic leukaemias figure 2 shown human cancerous glioma cell lines hypothesized gucy1a3b3 may responsible vegf overexpression resulting"
  },
  {
    "id": 432,
    "paragraph": "increased amount of NO [60]. NO is also known to play a role in platelet activation [61]. Gulp1 could be involved in the intracellular vesicular trafficking [62] which is of high importance in megakaryocytes for transporting the mole- cules in the storage organelles and during proplatelet for-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "increased amount 60 also known play role platelet activation 61 gulp1 could involved intracellular vesicular trafficking 62 high importance megakaryocytes transporting mole cules storage organelles proplatelet"
  },
  {
    "id": 433,
    "paragraph": "mation. Fkbp9 is poorly studied and this present study reports its expression for the first time in cells of haemato- poietic origin. It is strongly expressed in our megakaryo- blastic leukaemias, in human non-lymphoid leukaemias HEL, K562, CMK, Meg-01 and LAMA84, and to a lesser",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "mation fkbp9 poorly studied present study reports expression first time cells haemato poietic origin strongly expressed megakaryo blastic leukaemias human nonlymphoid leukaemias hel k562 cmk meg01 lama84 lesser"
  },
  {
    "id": 434,
    "paragraph": "extent, in the murine erythroid leukaemias and cell line. RT-PCR validated erythroid genes The selected erythroid genes with poorly elucidated phy- siological roles were Slamf1, Snca, Ltbp2, Rabgef1, Cda and Btbd1a. Slamf1 is known to be expressed by activated lymphocytes but not yet identified in relation to erythroid",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "extent murine erythroid leukaemias cell line rtpcr validated erythroid genes selected erythroid genes poorly elucidated phy siological roles slamf1 snca ltbp2 rabgef1 cda btbd1a slamf1 known expressed activated lymphocytes yet identified relation erythroid"
  },
  {
    "id": 435,
    "paragraph": "leukaemias. The expression of Slamf1 in Friend virus- induced erythroleukaemic cell line HB22.2 confirms the Graffi model. The gene was recently revealed as a marker of haematopoietic stem cells distinguishing these cells from more differentiated progenitors [63]. Snca has already been reported in erythrocytes [64,65]. Its over-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "leukaemias expression slamf1 friend virus induced erythroleukaemic cell line hb222 confirms graffi model gene recently revealed marker haematopoietic stem cells distinguishing cells differentiated progenitors 63 snca already reported erythrocytes 6465"
  },
  {
    "id": 436,
    "paragraph": "expression in the control sample and its increased expres- sion during erythroid differentiation (G1E dataset, Table 3) indicate that it may be implicated in normal erythroid cells function. We did not observe a significant increase during HB22.2 induced differentiation. Ltbp2 is strongly",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "expression control sample increased expres sion erythroid differentiation g1e dataset table 3 indicate may implicated normal erythroid cells function observe significant increase hb222 induced differentiation ltbp2 strongly"
  },
  {
    "id": 437,
    "paragraph": "expressed in our erythroleukaemias and increases signifi- cantly during differentiation. It shows a non-lymphoid expression pattern in the tested human cell lines and is identified in relation to haematopoietic cells for the first time. Some studies suggest a role for Ltbp2 in cell adhe-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "expressed erythroleukaemias increases signifi cantly differentiation shows nonlymphoid expression pattern tested human cell lines identified relation haematopoietic cells first time studies suggest role ltbp2 cell adhe"
  },
  {
    "id": 438,
    "paragraph": "sion and in cell migration [66]. Rabgef1 has never been reported in relation to erythroid lineage or leukaemia and the encoded protein is known to interact with Rab5, Rab21 or Rab22 [67]. Rab22a is indeed specifically over-expressed in the 3 tested erythroleukaemias (not",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "sion cell migration 66 rabgef1 never reported relation erythroid lineage leukaemia encoded protein known interact rab5 rab21 rab22 67 rab22a indeed specifically overexpressed 3 tested erythroleukaemias"
  },
  {
    "id": 439,
    "paragraph": "shown). RAB proteins are implicated in the intra-cellular vesicular traffic regulation and Rabgef1 is expressed in mast cells where it acts on Kit internalization [68]. Even though Rabgef1 expression pattern is more erythroid, it was amplified in all other Graffi-induced leukaemias and",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "shown rab proteins implicated intracellular vesicular traffic regulation rabgef1 expressed mast cells acts kit internalization 68 even though rabgef1 expression pattern erythroid amplified graffiinduced leukaemias"
  },
  {
    "id": 440,
    "paragraph": "in all the tested human cell lines, indicating its ubiquitous expression in haematopoietic cells. Cda, responsible for resistance to chemotherapy treatment, is highly expressed in our erythroleukaemias, in HB22.2, K562 and HEL. The GEO database shows that CDA is up-regulated during the",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "tested human cell lines indicating ubiquitous expression haematopoietic cells cda responsible resistance chemotherapy treatment highly expressed erythroleukaemias hb222 k562 hel geo database shows cda upregulated"
  },
  {
    "id": 441,
    "paragraph": "differentiation of human CD34+ cells toward the erythroid lineage (NCBI GEO, GSE4655). As of this day, Btbd14a has never been studied. It is highly expressed in the Graffi- induced erythroleukaemias and in HB22.2. Finally, Btbd14a appears ubiquitously expressed in the haemato-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "differentiation human cd34 cells toward erythroid lineage ncbi geo gse4655 day btbd14a never studied highly expressed graffi induced erythroleukaemias hb222 finally btbd14a appears ubiquitously expressed haemato"
  },
  {
    "id": 442,
    "paragraph": "poietic system. The BTB/POZ domain of Btb14a is pre- sent in many oncogenes involved in the development of leukaemia and is often found at the N-terminus of tran- scription factors. Thus, this gene is particularly interesting to further study as it shows a decreased expression during",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "poietic system btbpoz domain btb14a pre sent many oncogenes involved development leukaemia often found nterminus tran scription factors thus gene particularly interesting study shows decreased expression"
  },
  {
    "id": 443,
    "paragraph": "HB22.2 induced differentiation and could represent a potential oncogene. The MkMB Signature Numerous genes were commonly over-expressed in the megakaryoblastic, the myeloid leukaemias and/or the B- cell leukaemias. These genes are, in most cases, already known to be expressed by cells implicated in innate",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "hb222 induced differentiation could represent potential oncogene mkmb signature numerous genes commonly overexpressed megakaryoblastic myeloid leukaemias andor b cell leukaemias genes cases already known expressed cells implicated innate"
  },
  {
    "id": 444,
    "paragraph": "immunity. Platelets function is too often considered lim- ited to blood coagulation and formation of thrombosis but some studies now emphasize that the platelets’ role is underestimated in innate immunity and inflammation response [39,69-72]. Upon activation, platelets can release microbicidal proteins, interleukins that trigger a",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "immunity platelets function often considered lim ited blood coagulation formation thrombosis studies emphasize platelets ’ role underestimated innate immunity inflammation response 396972 upon activation platelets release microbicidal proteins interleukins trigger"
  },
  {
    "id": 445,
    "paragraph": "general inflammation response and chemokines that recruit immune cells such as leukocytes. Pathogens such as bacteria and lentiviruses can be ingested by platelets [73]. The MkMB signature seems to reflect partly the complexity of the platelet function. Only very few exam-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "general inflammation response chemokines recruit immune cells leukocytes pathogens bacteria lentiviruses ingested platelets 73 mkmb signature seems reflect partly complexity platelet function exam"
  },
  {
    "id": 446,
    "paragraph": "ples are shown in Table 2 but the complete list is avail- able in the supplementary data [19]. The unique design of this gene expression study that compared different types of leukaemias highlights this signature. Retroviral integration and genes potentially implicated in",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "ples shown table 2 complete list avail able supplementary data 19 unique design gene expression study compared different types leukaemias highlights signature retroviral integration genes potentially implicated"
  },
  {
    "id": 447,
    "paragraph": "the onset of the disease The analysis of retroviral integration enables the identi- fication of genes that may be responsible for malignant transformation. In this study, we screened the 3 mega- karyoblastic leukaemias for viral integration sites as oncogenic transformation events leading to megakaryo-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "onset disease analysis retroviral integration enables identi fication genes may responsible malignant transformation study screened 3 mega karyoblastic leukaemias viral integration sites oncogenic transformation events leading megakaryo"
  },
  {
    "id": 448,
    "paragraph": "blastic leukaemias remain unknown. No CIS were iden- tified but some genes in the RTCGD have drawn our Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 15 of 17 attention due to their known functions. Within these genes, Kit and Gata2 are of particular interest as accu-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "blastic leukaemias remain unknown cis iden tified genes rtcgd drawn voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 page 15 17 attention due known functions within genes kit gata2 particular interest accu"
  },
  {
    "id": 449,
    "paragraph": "mulating evidences point at their role in megakaryopoi- esis and megakaryoblastic leukaemias. Gata2 was recently reported for the first time as a com- mon integration site in leukaemias induced by the MOL4070LTR retrovirus in the NHD13 mouse [74]. In vitro studies showed that Gata2 over-expression redirects",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "mulating evidences point role megakaryopoi esis megakaryoblastic leukaemias gata2 recently reported first time com mon integration site leukaemias induced mol4070ltr retrovirus nhd13 mouse 74 vitro studies showed gata2 overexpression redirects"
  },
  {
    "id": 450,
    "paragraph": "the haematopoietic differentiation from the macrophage lineage toward the erythroid or the megakaryocytic lineages or from the erythroid toward the megakaryocytic lineage [55,75]. The importance of Gata2 on megakaryo- poiesis was also demonstrated in a differentiation study in which this gene is strongly induced and sustained",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "haematopoietic differentiation macrophage lineage toward erythroid megakaryocytic lineages erythroid toward megakaryocytic lineage 5575 importance gata2 megakaryo poiesis also demonstrated differentiation study gene strongly induced sustained"
  },
  {
    "id": 451,
    "paragraph": "upon thrombopoietin treatment of CD34+ cells but only weakly induced upon erythropoietin treatment [58]. The authors made the interesting hypothesis that GATA2 might repress the expression of the erythroid markers in maturing megakaryocytic cells since its activation inhibits erythroid differentiation in some systems.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "upon thrombopoietin treatment cd34 cells weakly induced upon erythropoietin treatment 58 authors made interesting hypothesis gata2 might repress expression erythroid markers maturing megakaryocytic cells since activation inhibits erythroid differentiation systems"
  },
  {
    "id": 452,
    "paragraph": "Kit is involved in many cancers and is regulated by the SCL complex (Gata1/2, SCL, Lmo2) in haematopoietic cells [76]. More evidence begins to emerge for its role in very early stages of megakaryopoiesis [77,78] and in megakaryoblastic leukaemias [79,80]. Bourquin et al.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "kit involved many cancers regulated scl complex gata12 scl lmo2 haematopoietic cells 76 evidence begins emerge role early stages megakaryopoiesis 7778 megakaryoblastic leukaemias 7980 bourquin et al"
  },
  {
    "id": 453,
    "paragraph": "reported increased levels of KIT, GATA2 and MYC in DS AMKL cells harbouring a GATA1 mutation com- pared to non-DS AMKL cells. They hypothesized that the mutated GATA1 in DS AMKL cells failed to repress the expression of these 3 genes [79].",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "reported increased levels kit gata2 myc ds amkl cells harbouring gata1 mutation com pared nonds amkl cells hypothesized mutated gata1 ds amkl cells failed repress expression 3 genes 79"
  },
  {
    "id": 454,
    "paragraph": "The 3 megakaryoblastic leukaemias express very high levels of Kit and Gata2. We hypothesize that the viral inte- grations may block the repression of these genes by con- tinuously activating the transcription or inhibiting the binding of repressor molecules. Kit and Gata2 levels nor-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "3 megakaryoblastic leukaemias express high levels kit gata2 hypothesize viral inte grations may block repression genes con tinuously activating transcription inhibiting binding repressor molecules kit gata2 levels"
  },
  {
    "id": 455,
    "paragraph": "mally decrease during megakaryocytic differentiation (Table 2 ‘GSE6593’). These 2 genes, affected by the retro- viral integration, would send continuous signals of prolif- eration and survival to the cell. The analysis of a larger sample of Graffi-induced megakaryoblastic leukaemias would be required to prove more efficiently the involve-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "mally decrease megakaryocytic differentiation table 2 ‘ gse6593 ’ 2 genes affected retro viral integration would send continuous signals prolif eration survival cell analysis larger sample graffiinduced megakaryoblastic leukaemias would required prove efficiently involve"
  },
  {
    "id": 456,
    "paragraph": "ment of Gata2 and Kit in this particular type of leukaemia. Conclusions In this report, we compared the gene profiles of the ery- thro- and megakaryoblastic leukaemias induced by the Graffi virus. Our study identifies genes that are highly expressed in the Graffi-induced erythro- and megakar-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "ment gata2 kit particular type leukaemia conclusions report compared gene profiles ery thro megakaryoblastic leukaemias induced graffi virus study identifies genes highly expressed graffiinduced erythro megakar"
  },
  {
    "id": 457,
    "paragraph": "yoblastic leukaemias. The complete dataset of this study is readily available (GSE12581 and [19]). Within the data, numerous genes have not yet been assigned with a known function and some of them could be used as markers for specific types of leukaemias and even the",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "yoblastic leukaemias complete dataset study readily available gse12581 19 within data numerous genes yet assigned known function could used markers specific types leukaemias even"
  },
  {
    "id": 458,
    "paragraph": "target of new therapies. We selected and RT-PCR validated genes those functions in normal cells are poorly characterized. For the majority, their expression in these lineages is shown for the first time and further functional characterization will surely complement the knowledge of erythroid and megakaryocytic lineages.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "target new therapies selected rtpcr validated genes functions normal cells poorly characterized majority expression lineages shown first time functional characterization surely complement knowledge erythroid megakaryocytic lineages"
  },
  {
    "id": 459,
    "paragraph": "Additional file 1: Oligonucleotides utilized in the RT-PCR experiments. sequences of forward and reverse primers utilized in the RT-PCR experiments Click here for file [ http://www.biomedcentral.com/content/supplementary/1755-8794-3-2- S1.DOC ] Additional file 2: Immunophenotype of the leukaemic samples selected for the microarray experiments. the table lists the leukaemias",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "additional file 1 oligonucleotides utilized rtpcr experiments sequences forward reverse primers utilized rtpcr experiments click file httpwwwbiomedcentralcomcontentsupplementary1755879432 s1doc additional file 2 immunophenotype leukaemic samples selected microarray experiments table lists leukaemias"
  },
  {
    "id": 460,
    "paragraph": "included in the microarray experiments including sample name, leukaemia type, immunophenotype, antibody used for sorting and tumor origins. Click here for file [ http://www.biomedcentral.com/content/supplementary/1755-8794-3-2- S2.DOC ] Acknowledgements We thank André Ponton, Michal Blazejczyk and Mathieu Miron from McGill University and Genome Quebec Innovation Centre (Montreal, Canada) for",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "included microarray experiments including sample name leukaemia type immunophenotype antibody used sorting tumor origins click file httpwwwbiomedcentralcomcontentsupplementary1755879432 s2doc acknowledgements thank andré ponton michal blazejczyk mathieu miron mcgill university genome quebec innovation centre montreal canada"
  },
  {
    "id": 461,
    "paragraph": "their help with the design and analyses of the microarray experiments. This work was supported by Canadian Institutes of Health Research grants MOP- 37994 (ER) and MOP-84460 (YBD). Author details 1Laboratoire de Biologie Moléculaire, Département des Sciences Biologiques, Centre BioMed, Université du Québec à Montréal, Case Postale 8888",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "help design analyses microarray experiments work supported canadian institutes health research grants mop 37994 er mop84460 ybd author details 1laboratoire de biologie moléculaire département des sciences biologiques centre biomed université du québec à montréal case postale 8888"
  },
  {
    "id": 462,
    "paragraph": "Succursale Centre-ville, Montréal, QC, H3C-3P8, Canada. 2Sunnybrook Health Sciences Center, 2075 Bayview Ave. S223B, Toronto. ON, M4N 3M5, Canada. Authors’ contributions VV designed and performed the microarray, RT-PCR, differentiation assay and cloning of the viral insertion sites experiments, analyzed and interpreted the",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "succursale centreville montréal qc h3c3p8 canada 2sunnybrook health sciences center 2075 bayview ave s223b toronto m4n 3m5 canada authors ’ contributions vv designed performed microarray rtpcr differentiation assay cloning viral insertion sites experiments analyzed interpreted"
  },
  {
    "id": 463,
    "paragraph": "data, and wrote the manuscript. PL performed the RT-PCR experiments on the human haematopoietic cell lines. DPSO optimized the protocol for the cloning of viral integration sites. YBD provided the HB22.2, K562 and HEL cell lines and critically revised the manuscript. ER guided the project and",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "data wrote manuscript pl performed rtpcr experiments human haematopoietic cell lines dpso optimized protocol cloning viral integration sites ybd provided hb222 k562 hel cell lines critically revised manuscript er guided project"
  },
  {
    "id": 464,
    "paragraph": "Sultan C: Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103(3):460-462. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. French-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "sultan c criteria diagnosis acute leukemia megakaryocyte lineage m7 report frenchamericanbritish cooperative group ann intern med 1985 1033460462 bennett jm catovsky daniel mt flandrin g galton da gralnick hr sultan c proposals classification acute leukaemias french"
  },
  {
    "id": 465,
    "paragraph": "American-British (FAB) co-operative group. British journal of haematology 1976, 33(4):451-458. Colita A, Belhabri A, Chelghoum Y, Charrin C, Fiere D, Thomas X: Prognostic factors and treatment effects on survival in acute myeloid leukemia of M6 subtype: A retrospective study of 54 cases. Annals of Oncology 2001,",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "americanbritish fab cooperative group british journal haematology 1976 334451458 colita belhabri chelghoum charrin c fiere thomas x prognostic factors treatment effects survival acute myeloid leukemia m6 subtype retrospective study 54 cases annals oncology 2001"
  },
  {
    "id": 466,
    "paragraph": "12:451-455. 2. 3. 4. Wells AW, Bown N, Reid MM, Hamilton PJ, Jackson GH, Taylor PR: Erythroleukaemia in the north of England: a population based study. Journal of Clinical Pathology 2001, 54:608-612. Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "12451455 2 3 4 wells aw bown n reid mm hamilton pj jackson gh taylor pr erythroleukaemia north england population based study journal clinical pathology 2001 54608612 voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432"
  },
  {
    "id": 467,
    "paragraph": "Page 16 of 17 5. 6. 7. 8. 9. Domingo-Claros A, Larriba I, Rozman M, Irriguible D, Vallespi T, Aventin A, Ayats R, Milla F, Sole F, Florensa L, et al: Acute erythroid neoplastic proliferations. A biological study based on 62 patients. Haematologica",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "page 16 17 5 6 7 8 9 domingoclaros larriba rozman irriguible vallespi aventin ayats r milla f sole f florensa l et al acute erythroid neoplastic proliferations biological study based 62 patients haematologica"
  },
  {
    "id": 468,
    "paragraph": "2002, 87(2):148-153. Rogelio Paredes-Aguilera LR-GNL-SRAT: Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children. American Journal of Hematology 2003, 73:71-80. Garderet L, Labopin M, Gorin NC, Polge E, Baruchel A, Meloni G, Ortega J, Vossen J, Bunjes D, Leverger G, et al: Hematopoietic stem cell",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "2002 872148153 rogelio paredesaguilera lrgnlsrat biology clinical hematologic features acute megakaryoblastic leukemia children american journal hematology 2003 737180 garderet l labopin gorin nc polge e baruchel meloni g ortega j vossen j bunjes leverger g et al hematopoietic stem cell"
  },
  {
    "id": 469,
    "paragraph": "transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2005, 105(1):405-409. Park S, Picard F, Dreyfus F: Erythroleukemia: a need for a new definition. Leukemia 2002, 16(8):1399-1401.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "transplantation de novo acute megakaryocytic leukemia first complete remission retrospective study european group blood marrow transplantation ebmt blood 2005 1051405409 park picard f dreyfus f erythroleukemia need new definition leukemia 2002 16813991401"
  },
  {
    "id": 470,
    "paragraph": "Linari S, Vannucchi AM, Ciolli S, Leoni F, Caporale R, Grossi A, Pagliai G, Santini V, Paoletti F, Ferrini PR: Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias. British journal of haematology 1998, 102(5):1335-1337.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "linari vannucchi ciolli leoni f caporale r grossi pagliai g santini v paoletti f ferrini pr coexpression erythroid megakaryocytic genes acute erythroblastic fab m6 megakaryoblastic fab m7 leukaemias british journal haematology 1998 102513351337"
  },
  {
    "id": 471,
    "paragraph": "10. Debili N, Coulombel L, Croisille L, Katz A, Guichard J, Breton-Gorius J, Vainchenker W: Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood 1996, 88(4):1284-1296. 11. Nakorn TN, Miyamoto T, Weissman IL: Characterization of mouse clonogenic megakaryocyte progenitors. Proceedings of the National",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "10 debili n coulombel l croisille l katz guichard j bretongorius j vainchenker w characterization bipotent erythromegakaryocytic progenitor human bone marrow blood 1996 88412841296 11 nakorn tn miyamoto weissman il characterization mouse clonogenic megakaryocyte progenitors proceedings national"
  },
  {
    "id": 472,
    "paragraph": "Academy of Sciences of the United States of America 2003, 100(1):205-210. 12. Voisin V, Barat C, Hoang T, Rassart E: Novel insights into the pathogenesis of the Graffi murine leukemia retrovirus. J Virol 2006, 80(8):4026-4037. 13. Blazejczyk M, Miron M, Nadon R: FlexArray: A statistical data analysis",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "academy sciences united states america 2003 1001205210 12 voisin v barat c hoang rassart e novel insights pathogenesis graffi murine leukemia retrovirus j virol 2006 80840264037 13 blazejczyk miron nadon r flexarray statistical data analysis"
  },
  {
    "id": 473,
    "paragraph": "15. 14. software for gene expression microarrays. Genome Quebec, Montreal, Canada, URL http://genomequebec.mcgill.ca/FlexArray. 2007. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(25):14863-14868.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "15 14 software gene expression microarrays genome quebec montreal canada url httpgenomequebecmcgillcaflexarray 2007 eisen mb spellman pt brown po botstein cluster analysis display genomewide expression patterns proceedings national academy sciences united states america 1998 95251486314868"
  },
  {
    "id": 474,
    "paragraph": "Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES, Golub TR: Interpreting patterns of gene expression with self- organizing maps: methods and application to hematopoietic differentiation. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(6):2907-2912.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "tamayo p slonim mesirov j zhu q kitareewan dmitrovsky e lander es golub tr interpreting patterns gene expression self organizing maps methods application hematopoietic differentiation proceedings national academy sciences united states america 1999 96629072912"
  },
  {
    "id": 475,
    "paragraph": "Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(9):5116-5121. 17. Wong KS, Li YJ, Howard J, Ben-David Y: Loss of p53 in F-MuLV induced-",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "tusher vg tibshirani r chu g significance analysis microarrays applied ionizing radiation response proceedings national academy sciences united states america 2001 98951165121 17 wong ks li yj howard j bendavid loss p53 fmulv induced"
  },
  {
    "id": 476,
    "paragraph": "erythroleukemias accelerates the acquisition of mutational events that confers immortality and growth factor independence. Oncogene 1999, 18(40):5525-5534. 16. 18. Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E, Berns A: High- throughput retroviral tagging to identify components of specific",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "erythroleukemias accelerates acquisition mutational events confers immortality growth factor independence oncogene 1999 184055255534 16 18 mikkers h allen j knipscheer p romeijn l hart vink e berns high throughput retroviral tagging identify components specific"
  },
  {
    "id": 477,
    "paragraph": "signaling pathways in cancer. Nature genetics 2002, 32(1):153-159. 19. Voisin V, Rassart E: Erythroid and megakaryoblastic leukemias induced by the murine retrovirus Graffi Gene expression profiling MOE 430.2 GEO: GSE12581 Additional analyses and Downloadable excel filesURL: http:// www.biomed.uqam.ca/rassart/microarray.html. 2009. 20. Hao X, Shin MS, Zhou JX, Lee CH, Qi CF, Naghashfar Z, Hartley JW,",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "signaling pathways cancer nature genetics 2002 321153159 19 voisin v rassart e erythroid megakaryoblastic leukemias induced murine retrovirus graffi gene expression profiling moe 4302 geo gse12581 additional analyses downloadable excel filesurl http wwwbiomeduqamcarassartmicroarrayhtml 2009 20 hao x shin ms zhou jx lee ch qi cf naghashfar z hartley jw"
  },
  {
    "id": 478,
    "paragraph": "Fredrickson TN, Ward JM, Morse HC: Histologic and molecular characterizations of megakaryocytic leukemia in mice. Leuk Res 2006, 30(4):397-406, Epub 2005 Oct 2010.. 21. Hamlett I, Draper J, Strouboulis J, Iborra F, Porcher C, Vyas P: Characterization of megakaryocyte GATA1-interacting proteins: the",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "fredrickson tn ward jm morse hc histologic molecular characterizations megakaryocytic leukemia mice leuk res 2006 304397406 epub 2005 oct 2010 21 hamlett draper j strouboulis j iborra f porcher c vyas p characterization megakaryocyte gata1interacting proteins"
  },
  {
    "id": 479,
    "paragraph": "corepressor ETO2 and GATA1 interact to regulate terminal megakaryocyte maturation. Blood 2008, 112(7):2738-2749. 22. Nucifora G, Laricchia-Robbio L, Senyuk V: EVI1 and hematopoietic 23. disorders: history and perspectives. Gene 2006, 368:1-11. Kilbey A, Alzuherri H, McColl J, Cales C, Frampton J, Bartholomew C: The",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "corepressor eto2 gata1 interact regulate terminal megakaryocyte maturation blood 2008 112727382749 22 nucifora g laricchiarobbio l senyuk v evi1 hematopoietic 23 disorders history perspectives gene 2006 368111 kilbey alzuherri h mccoll j cales c frampton j bartholomew c"
  },
  {
    "id": 480,
    "paragraph": "Evi1 proto-oncoprotein blocks endomitosis in megakaryocytes by inhibiting sustained cyclin-dependent kinase 2 catalytic activity. British journal of haematology 2005, 130(6):902-911. 24. Bond HM, Mesuraca M, Carbone E, Bonelli P, Agosti V, Amodio N, De 25. Hentges KE, Weiser KC, Schountz T, Woodward LS, Morse HC, Justice MJ:",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "evi1 protooncoprotein blocks endomitosis megakaryocytes inhibiting sustained cyclindependent kinase 2 catalytic activity british journal haematology 2005 1306902911 24 bond hm mesuraca carbone e bonelli p agosti v amodio n de 25 hentges ke weiser kc schountz woodward ls morse hc justice mj"
  },
  {
    "id": 481,
    "paragraph": "Evi3, a zinc-finger protein related to EBFAZ, regulates EBF activity in B- cell leukemia. Oncogene 2005, 24(7):1220-1230. 26. Hu L, Sham JS, Xie D, Wen JM, Wang WS, Wang Y, Guan XY: Up-regulation of fibroblast growth factor 3 is associated with tumor metastasis and",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "evi3 zincfinger protein related ebfaz regulates ebf activity b cell leukemia oncogene 2005 24712201230 26 hu l sham js xie wen jm wang ws wang guan xy upregulation fibroblast growth factor 3 associated tumor metastasis"
  },
  {
    "id": 482,
    "paragraph": "recurrence in human hepatocellular carcinoma. Cancer Lett 2007, 252(1):36-42. van Lohuizen M, Breuer M, Berns A: N-myc is frequently activated by proviral insertion in MuLV-induced T cell lymphomas. Embo J 1989, 8(1):133-136. 27. 28. Yancopoulos GD, Nisen PD, Tesfaye A, Kohl NE, Goldfarb MP, Alt FW: N-myc",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "recurrence human hepatocellular carcinoma cancer lett 2007 25213642 van lohuizen breuer berns nmyc frequently activated proviral insertion mulvinduced cell lymphomas embo j 1989 81133136 27 28 yancopoulos gd nisen pd tesfaye kohl ne goldfarb mp alt fw nmyc"
  },
  {
    "id": 483,
    "paragraph": "can cooperate with ras to transform normal cells in culture. Proc Natl Acad Sci USA 1985, 82(16):5455-5459. 29. Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM: Abrogation of fibroblast activation protein",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "cooperate ras transform normal cells culture proc natl acad sci usa 1985 821654555459 29 cheng jd valianou canutescu aa jaffe ek lee ho wang h lai jh bachovchin ww weiner lm abrogation fibroblast activation protein"
  },
  {
    "id": 484,
    "paragraph": "enzymatic activity attenuates tumor growth. Mol Cancer Ther 2005, 4(3):351-360. 30. Rogulski KR, Cohen DE, Corcoran DL, Benos PV, Prochownik EV: Deregulation of common genes by c-Myc and its direct target, MT-MC1. Proceedings of the National Academy of Sciences of the United States of",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "enzymatic activity attenuates tumor growth mol cancer ther 2005 43351360 30 rogulski kr cohen de corcoran dl benos pv prochownik ev deregulation common genes cmyc direct target mtmc1 proceedings national academy sciences united states"
  },
  {
    "id": 485,
    "paragraph": "America 2005, 102(52):18968-18973. 32. 31. Yates KE, Gasson JC: Role of c-Fes in normal and neoplastic hematopoiesis. Stem cells (Dayton, Ohio) 1996, 14(1):117-123. Emilia G, Donelli A, Ferrari S, Torelli U, Selleri L, Zucchini P, Moretti L, Venturelli D, Ceccherelli G, Torelli G: Cellular levels of mRNA from c-myc,",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "america 2005 102521896818973 32 31 yates ke gasson jc role cfes normal neoplastic hematopoiesis stem cells dayton ohio 1996 141117123 emilia g donelli ferrari torelli u selleri l zucchini p moretti l venturelli ceccherelli g torelli g cellular levels mrna cmyc"
  },
  {
    "id": 486,
    "paragraph": "c-myb and c-fes onc-genes in normal myeloid and erythroid precursors of human bone marrow: an in situ hybridization study. British journal of haematology 1986, 62(2):287-292. Fox AH, Liew C, Holmes M, Kowalski K, Mackay J, Crossley M: Transcriptional cofactors of the FOG family interact with GATA proteins",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "cmyb cfes oncgenes normal myeloid erythroid precursors human bone marrow situ hybridization study british journal haematology 1986 622287292 fox ah liew c holmes kowalski k mackay j crossley transcriptional cofactors fog family interact gata proteins"
  },
  {
    "id": 487,
    "paragraph": "by means of multiple zinc fingers. The EMBO journal 1999, 18(10):2812-2822. 33. 34. Hromas R, Orazi A, Neiman RS, Maki R, Van Beveran C, Moore J, Klemsz M: Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1. Blood 1993, 82(10):2998-3004.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "means multiple zinc fingers embo journal 1999 181028122822 33 34 hromas r orazi neiman rs maki r van beveran c moore j klemsz hematopoietic lineage stagerestricted expression ets oncogene family member pu1 blood 1993 821029983004"
  },
  {
    "id": 488,
    "paragraph": "35. Doubeikovski A, Uzan G, Doubeikovski Z, Prandini MH, Porteu F, Gisselbrecht S, Dusanter-Fourt I: Thrombopoietin-induced expression of the glycoprotein IIb gene involves the transcription factor PU.1/Spi-1 in UT7-Mpl cells. The Journal of biological chemistry 1997, 272(39):24300-24307. 36. Denicourt C, Edouard E, Rassart E: Oncogene activation in myeloid",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "35 doubeikovski uzan g doubeikovski z prandini mh porteu f gisselbrecht dusanterfourt thrombopoietininduced expression glycoprotein iib gene involves transcription factor pu1spi1 ut7mpl cells journal biological chemistry 1997 272392430024307 36 denicourt c edouard e rassart e oncogene activation myeloid"
  },
  {
    "id": 489,
    "paragraph": "leukemias by Graffi murine leukemia virus proviral integration. J Virol 1999, 73(5):4439-4442. 37. Chen Z, Hu M, Shivdasani RA: Expression analysis of primary mouse megakaryocyte differentiation and its application in identifying stage- specific molecular markers and a novel transcriptional target of NF-E2.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "leukemias graffi murine leukemia virus proviral integration j virol 1999 73544394442 37 chen z hu shivdasani ra expression analysis primary mouse megakaryocyte differentiation application identifying stage specific molecular markers novel transcriptional target nfe2"
  },
  {
    "id": 490,
    "paragraph": "Blood 2007, 109(4):1451-1459. 38. Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P: Platelets express functional Toll-like receptor-4. Blood 2005, 106(7):2417-2423. 39. Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O: Evidence of Toll-like receptor molecules on human platelets. Immunology",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "blood 2007 109414511459 38 andonegui g kerfoot sm mcnagny k ebbert kv patel kd kubes p platelets express functional tolllike receptor4 blood 2005 106724172423 39 cognasse f hamzeh h chavarin p acquart genin c garraud evidence tolllike receptor molecules human platelets immunology"
  },
  {
    "id": 491,
    "paragraph": "and cell biology 2005, 83(2):196-198. 40. Welch JJ, Watts JA, Vakoc CR, Yao Y, Wang H, Hardison RC, Blobel GA, 41. 42. 43. Chodosh LA, Weiss MJ: Global regulation of erythroid gene expression by transcription factor GATA-1. Blood 2004, 104(10):3136-3147. Fang J, Menon M, Kapelle W, Bogacheva O, Bogachev O, Houde E,",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "cell biology 2005 832196198 40 welch jj watts ja vakoc cr yao wang h hardison rc blobel ga 41 42 43 chodosh la weiss mj global regulation erythroid gene expression transcription factor gata1 blood 2004 1041031363147 fang j menon kapelle w bogacheva bogachev houde e"
  },
  {
    "id": 492,
    "paragraph": "Browne S, Sathyanarayana P, Wojchowski DM: EPO modulation of cell- cycle regulatory genes, and cell division, in primary bone marrow erythroblasts. Blood 2007, 110(7):2361-2370. Sathyanarayana P, Menon MP, Bogacheva O, Bogachev O, Niss K, Kapelle WS, Houde E, Fang J, Wojchowski DM: Erythropoietin modulation",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "browne sathyanarayana p wojchowski dm epo modulation cell cycle regulatory genes cell division primary bone marrow erythroblasts blood 2007 110723612370 sathyanarayana p menon mp bogacheva bogachev niss k kapelle ws houde e fang j wojchowski dm erythropoietin modulation"
  },
  {
    "id": 493,
    "paragraph": "of podocalyxin and a proposed erythroblast niche. Blood 2007, 110(2):509-518. Sathyanarayana P, Dev A, Fang J, Houde E, Bogacheva O, Bogachev O, Menon M, Browne S, Pradeep A, Emerson C, et al: EPO receptor circuits for primary erythroblast survival. Blood 2008, 111(11):5390-5399.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "podocalyxin proposed erythroblast niche blood 2007 1102509518 sathyanarayana p dev fang j houde e bogacheva bogachev menon browne pradeep emerson c et al epo receptor circuits primary erythroblast survival blood 2008 1111153905399"
  },
  {
    "id": 494,
    "paragraph": "Rosa G, Di Nicola M, Gianni AM, Moore MA, et al: Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells. Blood 2004, 103(6):2062-2070. 44. Dreyfus F, Sola B, Fichelson S, Varlet P, Charon M, Tambourin P, Wendling F,",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "rosa g di nicola gianni moore et al early hematopoietic zinc finger protein ehzf human homolog mouse evi3 highly expressed primitive human hematopoietic cells blood 2004 103620622070 44 dreyfus f sola b fichelson varlet p charon tambourin p wendling f"
  },
  {
    "id": 495,
    "paragraph": "Gisselbrecht S: Rearrangements of the Pim-1, c-myc, and p53 genes in Friend helper virus-induced mouse erythroleukemias. Leukemia 1990, 4(8):590-594. Voisin et al. BMC Medical Genomics 2010, 3:2 http://www.biomedcentral.com/1755-8794/3/2 Page 17 of 17 45. Breslin A, Denniss FA, Guinn BA: SSX2IP: an emerging role in cancer.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "gisselbrecht rearrangements pim1 cmyc p53 genes friend helper virusinduced mouse erythroleukemias leukemia 1990 48590594 voisin et al bmc medical genomics 2010 32 httpwwwbiomedcentralcom1755879432 page 17 17 45 breslin denniss fa guinn ba ssx2ip emerging role cancer"
  },
  {
    "id": 496,
    "paragraph": "Biochemical and biophysical research communications 2007, 363(3):462-465. 46. Ren M, Xu G, Zeng J, De Lemos-Chiarandini C, Adesnik M, Sabatini DD: Hydrolysis of GTP on rab11 is required for the direct delivery of transferrin from the pericentriolar recycling compartment to the cell",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "biochemical biophysical research communications 2007 3633462465 46 ren xu g zeng j de lemoschiarandini c adesnik sabatini dd hydrolysis gtp rab11 required direct delivery transferrin pericentriolar recycling compartment cell"
  },
  {
    "id": 497,
    "paragraph": "surface but not from sorting endosomes. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(11):6187-6192. 47. Westlake CJ, Junutula JR, Simon GC, Pilli M, Prekeris R, Scheller RH, 65. presynaptic protein implicated in Parkinson’s disease, in erythropoietic",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "surface sorting endosomes proceedings national academy sciences united states america 1998 951161876192 47 westlake cj junutula jr simon gc pilli prekeris r scheller rh 65 presynaptic protein implicated parkinson ’ disease erythropoietic"
  },
  {
    "id": 498,
    "paragraph": "lineage. Biochemical and biophysical research communications 2007, 358(1):104-110. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, Ney PA, Ng J, McGoldrick M, Mollenhauer B, et al: GATA transcription factors directly regulate the Parkinson’s disease-linked gene alpha-synuclein. Proceedings",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "lineage biochemical biophysical research communications 2007 3581104110 scherzer cr grass ja liao z pepivani zheng b eklund ac ney pa ng j mcgoldrick mollenhauer b et al gata transcription factors directly regulate parkinson ’ diseaselinked gene alphasynuclein proceedings"
  },
  {
    "id": 499,
    "paragraph": "of the National Academy of Sciences of the United States of America 2008, 105(31):10907-10912. Jackson PK, Eldridge AG: Identification of Rab11 as a small GTPase binding protein for the Evi5 oncogene. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(4):1236-1241.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "national academy sciences united states america 2008 105311090710912 jackson pk eldridge ag identification rab11 small gtpase binding protein evi5 oncogene proceedings national academy sciences united states america 2007 104412361241"
  },
  {
    "id": 500,
    "paragraph": "66. Vehvilainen P, Hyytiainen M, Keski-Oja J: Latent Transforming Growth Factor-b-binding Protein 2 Is an Adhesion Protein for Melanoma Cells. The Journal of Biochemical Chemistry 2003, 278:24705-24713. 48. Palmieri D, Bouadis A, Ronchetti R, Merino MJ, Steeg PS: Rab11a 67. Mattera R, Tsai YC, Weissman AM, Bonifacino JS: The Rab5 guanine",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "66 vehvilainen p hyytiainen keskioja j latent transforming growth factorbbinding protein 2 adhesion protein melanoma cells journal biochemical chemistry 2003 2782470524713 48 palmieri bouadis ronchetti r merino mj steeg ps rab11a 67 mattera r tsai yc weissman bonifacino js rab5 guanine"
  },
  {
    "id": 501,
    "paragraph": "differentially modulates epidermal growth factor-induced proliferation and motility in immortal breast cells. Breast cancer research and treatment 2006, 100(2):127-137. 49. Yan J, Tsai SY, Tsai MJ: SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta pharmacologica Sinica 2006, 27(4):387-394. 50. Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG: RTCGD:",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "differentially modulates epidermal growth factorinduced proliferation motility immortal breast cells breast cancer research treatment 2006 1002127137 49 yan j tsai sy tsai mj src3aib1 transcriptional coactivator oncogenesis acta pharmacologica sinica 2006 274387394 50 akagi k suzuki stephens rm jenkins na copeland ng rtcgd"
  },
  {
    "id": 502,
    "paragraph": "retroviral tagged cancer gene database. Nucleic acids research 2004, , 32 Database: D523-527. 51. Malin D, Kim IM, Boetticher E, Kalin TV, Ramakrishna S, Meliton L, Ustiyan V, Zhu X, Kalinichenko VV: Forkhead box F1 is essential for migration of mesenchymal cells and directly induces integrin-beta3 expression.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "retroviral tagged cancer gene database nucleic acids research 2004 32 database d523527 51 malin kim im boetticher e kalin tv ramakrishna meliton l ustiyan v zhu x kalinichenko vv forkhead box f1 essential migration mesenchymal cells directly induces integrinbeta3 expression"
  },
  {
    "id": 503,
    "paragraph": "Molecular and cellular biology 2007, 27(7):2486-2498. 52. Ma SL, Sorensen AB, Kunder S, Sorensen KD, Quintanilla-Martinez L, Morris DW, Schmidt J, Pedersen FS: The Icsbp locus is a common proviral insertion site in mature B-cell lymphomas/plasmacytomas induced by exogenous murine leukemia virus. Virology 2006, 352(2):306-318.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "molecular cellular biology 2007 27724862498 52 sl sorensen ab kunder sorensen kd quintanillamartinez l morris dw schmidt j pedersen fs icsbp locus common proviral insertion site mature bcell lymphomasplasmacytomas induced exogenous murine leukemia virus virology 2006 3522306318"
  },
  {
    "id": 504,
    "paragraph": "53. Cheli Y, Kanaji S, Jacquelin B, Chang M, Nugent DJ, Kunicki TJ: Transcriptional and epigenetic regulation of the integrin collagen receptor locus ITGA1-PELO-ITGA2. Biochimica et biophysica acta 2007, 1769(9-10):546-558. 54. Hitzler JK, Zipursky A: Origins of leukaemia in children with Down",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "53 cheli kanaji jacquelin b chang nugent dj kunicki tj transcriptional epigenetic regulation integrin collagen receptor locus itga1peloitga2 biochimica et biophysica acta 2007 1769910546558 54 hitzler jk zipursky origins leukaemia children"
  },
  {
    "id": 505,
    "paragraph": "55. syndrome. Nat Rev Cancer 2005, 5(1):11-20. Kitajima K, Tanaka M, Zheng J, Yen H, Sato A, Sugiyama D, Umehara H, Sakai E, Nakano T: Redirecting differentiation of hematopoietic progenitors by a transcription factor, GATA-2. Blood 2006, 107(5):1857-1863. 56. Chinnadurai G: CtBP, an unconventional transcriptional corepressor in",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "55 syndrome nat rev cancer 2005 511120 kitajima k tanaka zheng j yen h sato sugiyama umehara h sakai e nakano redirecting differentiation hematopoietic progenitors transcription factor gata2 blood 2006 107518571863 56 chinnadurai g ctbp unconventional transcriptional corepressor"
  },
  {
    "id": 506,
    "paragraph": "development and oncogenesis. Molecular cell 2002, 9(2):213-224. 57. Maki K, Yamagata T, Asai T, Yamazaki I, Oda H, Hirai H, Mitani K: Dysplastic definitive hematopoiesis in AML1/EVI1 knock-in embryos. Blood 2005, 106(6):2147-2155. Terui K, Takahashi Y, Kitazawa J, Toki T, Yokoyama M, Ito E: Expression of",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "development oncogenesis molecular cell 2002 92213224 57 maki k yamagata asai yamazaki oda h hirai h mitani k dysplastic definitive hematopoiesis aml1evi1 knockin embryos blood 2005 106621472155 terui k takahashi kitazawa j toki yokoyama ito e expression"
  },
  {
    "id": 507,
    "paragraph": "transcription factors during megakaryocytic differentiation of CD34+ cells from human cord blood induced by thrombopoietin. The Tohoku journal of experimental medicine 2000, 192(4):259-273. 58. 68. nucleotide exchange factor Rabex-5 binds ubiquitin (Ub) and functions as a Ub ligase through an atypical Ub-interacting motif and a zinc",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "transcription factors megakaryocytic differentiation cd34 cells human cord blood induced thrombopoietin tohoku journal experimental medicine 2000 1924259273 58 68 nucleotide exchange factor rabex5 binds ubiquitin ub functions ub ligase atypical ubinteracting motif zinc"
  },
  {
    "id": 508,
    "paragraph": "finger domain. The Journal of biological chemistry 2006, 281(10):6874-6883. Kalesnikoff J, Rios EJ, Chen C-C, Nakae S, Zabel BA, Butcher EC, Tsai M, Tam S-Y, Galli SJ: RabGEF1 regulates stem cell factor/c-Kit-mediated signaling events and biological responses in mast cells. Proceedings of",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "finger domain journal biological chemistry 2006 2811068746883 kalesnikoff j rios ej chen cc nakae zabel ba butcher ec tsai tam sy galli sj rabgef1 regulates stem cell factorckitmediated signaling events biological responses mast cells proceedings"
  },
  {
    "id": 509,
    "paragraph": "the National Academy of Sciences of the United States of America 2006, 103:2659-2664. 69. Weyrich AS, Zimmerman GA: Platelets: signaling cells in the immune 70. 71. 72. 73. 74. 75. 76. continuum. Trends in immunology 2004, 25(9):489-495. Elzey BD, Sprague DL, Ratliff TL: The emerging role of platelets in",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "national academy sciences united states america 2006 10326592664 69 weyrich zimmerman ga platelets signaling cells immune 70 71 72 73 74 75 76 continuum trends immunology 2004 259489495 elzey bd sprague dl ratliff tl emerging role platelets"
  },
  {
    "id": 510,
    "paragraph": "adaptive immunity. Cellular immunology 2005, 238(1):1-9. Sprague DL, Sowa JM, Elzey BD, Ratliff TL: The role of platelet CD154 in the modulation in adaptive immunity. Immunologic research 2007, 39(1- 3):185-193. von Hundelshausen P, Weber C: Platelets as immune cells: bridging inflammation and cardiovascular disease. Circulation research 2007,",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "adaptive immunity cellular immunology 2005 238119 sprague dl sowa jm elzey bd ratliff tl role platelet cd154 modulation adaptive immunity immunologic research 2007 391 3185193 von hundelshausen p weber c platelets immune cells bridging inflammation cardiovascular disease circulation research 2007"
  },
  {
    "id": 511,
    "paragraph": "100(1):27-40. Tanaka M, Aze Y, Fujita T: Adhesion molecule LFA-1/ICAM-1 influences on LPS-induced megakaryocytic emperipolesis in the rat bone marrow. Veterinary pathology 1997, 34(5):463-466. Slape C, Hartung H, Lin YW, Bies J, Wolff L, Aplan PD: Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "10012740 tanaka aze fujita adhesion molecule lfa1icam1 influences lpsinduced megakaryocytic emperipolesis rat bone marrow veterinary pathology 1997 345463466 slape c hartung h lin yw bies j wolff l aplan pd retroviral insertional mutagenesis identifies genes collaborate nup98hoxd13"
  },
  {
    "id": 512,
    "paragraph": "during leukemic transformation. Cancer research 2007, 67(11):5148-5155. Ikonomi P, Rivera CE, Riordan M, Washington G, Schechter AN, Noguchi CT: Overexpression of GATA-2 inhibits erythroid and promotes megakaryocyte differentiation. Experimental hematology 2000, 28(12):1423-1431. Lecuyer E, Hoang T: SCL: from the origin of hematopoiesis to stem cells",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "leukemic transformation cancer research 2007 671151485155 ikonomi p rivera ce riordan washington g schechter noguchi ct overexpression gata2 inhibits erythroid promotes megakaryocyte differentiation experimental hematology 2000 281214231431 lecuyer e hoang scl origin hematopoiesis stem cells"
  },
  {
    "id": 513,
    "paragraph": "and leukemia. Experimental hematology 2004, 32(1):11-24. 77. Antonchuk J, Hyland CD, Hilton DJ, Alexander WS: Synergistic effects on erythropoiesis, thrombopoiesis, and stem cell competitiveness in mice deficient in thrombopoietin and steel factor receptors. Blood 2004, 104(5):1306-1313. 59. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski ML,",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "leukemia experimental hematology 2004 3211124 77 antonchuk j hyland cd hilton dj alexander ws synergistic effects erythropoiesis thrombopoiesis stem cell competitiveness mice deficient thrombopoietin steel factor receptors blood 2004 104513061313 59 yuasa h oike iwama nishikata sugiyama perkins mucenski ml"
  },
  {
    "id": 514,
    "paragraph": "78. Zeuner A, Signore M, Martinetti D, Bartucci M, Peschle C, De Maria R: 60. Suda T, Morishita K: Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. The EMBO journal 2005, 24(11):1976-1987. Saino M, Maruyama T, Sekiya T, Kayama T, Murakami Y: Inhibition of",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "78 zeuner signore martinetti bartucci peschle c de maria r 60 suda morishita k oncogenic transcription factor evi1 regulates hematopoietic stem cell proliferation gata2 expression embo journal 2005 241119761987 saino maruyama sekiya kayama murakami inhibition"
  },
  {
    "id": 515,
    "paragraph": "angiogenesis in human glioma cell lines by antisense RNA from the soluble guanylate cyclase genes, GUCY1A3 and GUCY1B3. Oncology reports 2004, 12(1):47-52. 62. 61. Battinelli E, Willoughby SR, Foxall T, Valeri CR, Loscalzo J: Induction of platelet formation from megakaryocytoid cells by nitric oxide.",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "angiogenesis human glioma cell lines antisense rna soluble guanylate cyclase genes gucy1a3 gucy1b3 oncology reports 2004 1214752 62 61 battinelli e willoughby sr foxall valeri cr loscalzo j induction platelet formation megakaryocytoid cells nitric oxide"
  },
  {
    "id": 516,
    "paragraph": "Proceedings of the National Academy of Sciences of the United States of America 2001, 98(25):14458-14463. Kiss RS, Ma Z, Nakada-Tsukui K, Brugnera E, Vassiliou G, McBride HM, Ravichandran KS, Marcel YL: The lipoprotein receptor-related protein-1 (LRP) adapter protein GULP mediates trafficking of the LRP ligand",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "proceedings national academy sciences united states america 2001 98251445814463 kiss rs z nakadatsukui k brugnera e vassiliou g mcbride hm ravichandran ks marcel yl lipoprotein receptorrelated protein1 lrp adapter protein gulp mediates trafficking lrp ligand"
  },
  {
    "id": 517,
    "paragraph": "prosaposin, leading to sphingolipid and free cholesterol accumulation in late endosomes and impaired efflux. The Journal of biological chemistry 2006, 281(17):12081-12092. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ: SLAM family receptors distinguish hematopoietic stem and progenitor cells",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "prosaposin leading sphingolipid free cholesterol accumulation late endosomes impaired efflux journal biological chemistry 2006 281171208112092 kiel mj yilmaz oh iwashita yilmaz oh terhorst c morrison sj slam family receptors distinguish hematopoietic stem progenitor cells"
  },
  {
    "id": 518,
    "paragraph": "and reveal endothelial niches for stem cells. Cell 2005, 121(7):1109-1121. 63. 64. Nakai M, Fujita M, Waragai M, Sugama S, Wei J, Akatsu H, Ohtaka- Maruyama C, Okado H, Hashimoto M: Expression of alpha-synuclein, a Chemotherapy-induced thrombocytopenia derives from the selective",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "reveal endothelial niches stem cells cell 2005 121711091121 63 64 nakai fujita waragai sugama wei j akatsu h ohtaka maruyama c okado h hashimoto expression alphasynuclein chemotherapyinduced thrombocytopenia derives selective"
  },
  {
    "id": 519,
    "paragraph": "death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer research 2007, 67(10):4767-4773. 79. Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, Baruchel A, Cave H, Dastugue N, Hasle H, et al: Identification of",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "death megakaryocyte progenitors rescued stem cell factor cancer research 2007 671047674773 79 bourquin jp subramanian langebrake c reinhardt bernard ballerini p baruchel cave h dastugue n hasle h et al identification"
  },
  {
    "id": 520,
    "paragraph": "distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(9):3339-3344. Toki T, Kanezaki R, Adachi S, Fujino H, Xu G, Sato T, Suzuki K, Tauchi H,",
    "jurnal": "1755-8794-3-2.pdf",
    "processed": "distinct molecular phenotypes acute megakaryoblastic leukemia gene expression profiling proceedings national academy sciences united states america 2006 103933393344 toki kanezaki r adachi fujino h xu g sato suzuki k tauchi h"
  },
  {
    "id": 521,
    "paragraph": "British Journal of Cancer (2004) 90, 756 – 760 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com Minireview ALL-1/MLL1, a homologue of Drosophila TRITHORAX, modifies chromatin and is directly involved in infant acute leukaemia (cid:1)(cid:1) (cid:1)",
    "jurnal": "90-6601639a.pdf",
    "processed": "british journal cancer 2004 90 756 – 760 2004 cancer research uk rights reserved 0007 – 092004 2500 wwwbjcancercom minireview all1mll1 homologue drosophila trithorax modifies chromatin directly involved infant acute leukaemia cid1cid1 cid1"
  },
  {
    "id": 522,
    "paragraph": "(cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) (cid:1) E Canaani*,1, T Nakamura2, T Rozovskaia1, ST Smith2, T Mori2, CM Croce2 and A Mazo*,2",
    "jurnal": "90-6601639a.pdf",
    "processed": "cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 cid1 e canaani1 nakamura2 rozovskaia1 st smith2 mori2 cm croce2 mazo2"
  },
  {
    "id": 523,
    "paragraph": "1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel 76100; 2Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA Rearrangements of the ALL-1/MLL1 gene underlie the majority of infant acute leukaemias, as well as of therapy-related leukaemias developing in cancer patients treated with inhibitors of topoisomerase II, such as VP16 and doxorubicin. The rearrangements fuse",
    "jurnal": "90-6601639a.pdf",
    "processed": "1department molecular cell biology weizmann institute science rehovot israel 76100 2kimmel cancer center thomas jefferson university philadelphia pa 19107 usa rearrangements all1mll1 gene underlie majority infant acute leukaemias well therapyrelated leukaemias developing cancer patients treated inhibitors topoisomerase ii vp16 doxorubicin rearrangements fuse"
  },
  {
    "id": 524,
    "paragraph": "& 2004 Cancer Research UK Keywords: acute lymphoblastic and myelogeneous leukaemia; mouse models; chromatin; epigenetic marking ACUTE LEUKAEMIAS ASSOCIATED WITH ALL-1 REARRANGEMENTS Chromosome band 11q23 is involved in reciprocal chromosome translocations in 5 – 10% of children and adults with acute",
    "jurnal": "90-6601639a.pdf",
    "processed": "2004 cancer research uk keywords acute lymphoblastic myelogeneous leukaemia mouse models chromatin epigenetic marking acute leukaemias associated all1 rearrangements chromosome band 11q23 involved reciprocal chromosome translocations 5 – 10 children adults acute"
  },
  {
    "id": 525,
    "paragraph": "lymphoblastic leukaemia (ALL) or acute myelogeneous leukaemia (AML). Nearly all these rearrangements affect the ALL-1 gene, also termed MLL1, HRX and HTRX, located at 11q23. The transloca- tions occur within an 8.3 kb breakpoint cluster region of the gene and result in the replacement of ALL-1-coding sequence 3’ to the",
    "jurnal": "90-6601639a.pdf",
    "processed": "lymphoblastic leukaemia acute myelogeneous leukaemia aml nearly rearrangements affect all1 gene also termed mll1 hrx htrx located 11q23 transloca tions occur within 83 kb breakpoint cluster region gene result replacement all1coding sequence 3 ’"
  },
  {
    "id": 526,
    "paragraph": "breakpoint by the coding sequence of the translocation partner (Gu et al, 1992; Tkachuk et al, 1992). In a second and less frequent type of rearrangement, ALL-1 undergoes partial tandem duplica- tion (self-fusion), resulting in the production of a larger protein",
    "jurnal": "90-6601639a.pdf",
    "processed": "breakpoint coding sequence translocation partner gu et al 1992 tkachuk et al 1992 second less frequent type rearrangement all1 undergoes partial tandem duplica tion selffusion resulting production larger protein"
  },
  {
    "id": 527,
    "paragraph": "(Schichman et al, 1995). The most common ALL-1 translocations are t(4; 11), t(9; 11), t(11; 19), t(6; 11) and t(10; 11), accounting for 40, 27, 12, 5 and 5% of cases, respectively. However, the total number of different loci participating in ALL-1 translocations is",
    "jurnal": "90-6601639a.pdf",
    "processed": "schichman et al 1995 common all1 translocations t4 11 t9 11 t11 19 t6 11 t10 11 accounting 40 27 12 5 5 cases respectively however total number different loci participating all1 translocations"
  },
  {
    "id": 528,
    "paragraph": "amazingly high and has already exceeded 50 (Huret et al, 2001). There is an association between particular chromosomal translocations involving ALL-1 and subtypes of leukaemias. Thus, t(4; 11) nearly always occurs in ALL, t(9; 11) is mostly associated with AML, as are t(11; 19)(q23;p13.1), t(6;11), t(10;11) and the",
    "jurnal": "90-6601639a.pdf",
    "processed": "amazingly high already exceeded 50 huret et al 2001 association particular chromosomal translocations involving all1 subtypes leukaemias thus t4 11 nearly always occurs t9 11 mostly associated aml t11 19q23p131 t611 t1011"
  },
  {
    "id": 529,
    "paragraph": "partial duplications. t(11; 19)(q23;p13.3) occurs in both AML and ALL. ALL1-associated ALLs are characterised as CD10(cid:1), CD19 þ and by B-cell precursor phenotype (pro B), with a high frequency of myeloid-associated (CD15 and/or CD65) antigen expression. Hence, they are also designated biphenotypic or mixed-lineage",
    "jurnal": "90-6601639a.pdf",
    "processed": "partial duplications t11 19q23p133 occurs aml all1associated alls characterised cd10cid1 cd19 þ bcell precursor phenotype pro b high frequency myeloidassociated cd15 andor cd65 antigen expression hence also designated biphenotypic mixedlineage"
  },
  {
    "id": 530,
    "paragraph": "leukaemia. The AMLs are usually of the myelomonocytic (FAB- M4) or monoblastic (FAB-M5) morphological subtypes and sometimes express cell-surface lymphoid markers. The prognosis *Correspondence: E Canaani; E-mail: eli_canaani@weizmann.ac.il or A Mazo; E-mail: A_Mazo@lac.jci.tju.edu Received 12 August 2003; revised 14 December 2003; accepted 15",
    "jurnal": "90-6601639a.pdf",
    "processed": "leukaemia amls usually myelomonocytic fab m4 monoblastic fabm5 morphological subtypes sometimes express cellsurface lymphoid markers prognosis correspondence e canaani email elicanaaniweizmannacil mazo email amazolacjcitjuedu received 12 august 2003 revised 14 december 2003 accepted 15"
  },
  {
    "id": 531,
    "paragraph": "December 2003 of patients with 11q23 abnormalities is dismal. Age is an important prognostic factor. Thus, less than 25% of infants (o1 year) and adults older than 40 or 50 years, with t(4; 11) or t(9; 11), are cured. Patients of intermediate age, in particular 2 – 9 or 1 – 14 years old,",
    "jurnal": "90-6601639a.pdf",
    "processed": "december 2003 patients 11q23 abnormalities dismal age important prognostic factor thus less 25 infants o1 year adults older 40 50 years t4 11 t9 11 cured patients intermediate age particular 2 – 9 1 – 14 years old"
  },
  {
    "id": 532,
    "paragraph": "have significantly better prognosis (Johansson et al, 1998; Swans- bury et al, 1998; Pui et al, 2002). The hallmark of ALL1-associated leukaemias is their epidemiol- ogy (reviewed in Greaves, 1999; Biondi et al, 2000). They predominate infant acute leukaemia (80% of ALL and 65% of",
    "jurnal": "90-6601639a.pdf",
    "processed": "significantly better prognosis johansson et al 1998 swans bury et al 1998 pui et al 2002 hallmark all1associated leukaemias epidemiol ogy reviewed greaves 1999 biondi et al 2000 predominate infant acute leukaemia 80 65"
  },
  {
    "id": 533,
    "paragraph": "AML), and account for the majority of therapy-related (secondary) leukaemias developing in 5 – 15% of primary cancer patients who had received intensive chemotherapy, including epipodophyllo- toxins (VP16) and anthracyclines (doxorubicin) (Pui and Relling, 2000). These drugs are inhibitors of topoisomerase II, and act by",
    "jurnal": "90-6601639a.pdf",
    "processed": "aml account majority therapyrelated secondary leukaemias developing 5 – 15 primary cancer patients received intensive chemotherapy including epipodophyllo toxins vp16 anthracyclines doxorubicin pui relling 2000 drugs inhibitors topoisomerase ii act"
  },
  {
    "id": 534,
    "paragraph": "stabilising double-strand DNA breaks generated by this enzyme. In the latency period is both infant and secondary leukaemias, remarkably brief. In infants, ALL-1 rearrangements can be already detected in utero and the average age at diagnosis is 6 months, and in secondary leukaemias, latency averages around 18 – 30 months",
    "jurnal": "90-6601639a.pdf",
    "processed": "stabilising doublestrand dna breaks generated enzyme latency period infant secondary leukaemias remarkably brief infants all1 rearrangements already detected utero average age diagnosis 6 months secondary leukaemias latency averages around 18 – 30 months"
  },
  {
    "id": 535,
    "paragraph": "(reviewed in Greaves, 1999; Pui and Relling, 2000). The very brief in time between the initiating event and clinical disease, conjunction with the high rate of concordance in identical twins with infant leukaemia, points to the effectiveness of ALL-1 fusion proteins in driving the initial clone into frank leukaemia. Based on",
    "jurnal": "90-6601639a.pdf",
    "processed": "reviewed greaves 1999 pui relling 2000 brief time initiating event clinical disease conjunction high rate concordance identical twins infant leukaemia points effectiveness all1 fusion proteins driving initial clone frank leukaemia based"
  },
  {
    "id": 536,
    "paragraph": "the findings from therapy-related leukaemia, it was hypothesised (Ross et al, 1994) that transplacental exposure of the foetus to natural (such as flavonoids in foods and drinks) might play a role in infant leukaemia. Such exposure will induce accumulation of DNA’s",
    "jurnal": "90-6601639a.pdf",
    "processed": "findings therapyrelated leukaemia hypothesised ross et al 1994 transplacental exposure foetus natural flavonoids foods drinks might play role infant leukaemia exposure induce accumulation dna ’"
  },
  {
    "id": 537,
    "paragraph": "free ends from within the breakpoint cluster region of ALL-1, and this would eventually result in 11q23 translocations. The results of recent biochemical experiments (Strick et al, 2000) are consistent with this hypothesis. A structural feature shared by many topoisomerase II inhibitors, including anticancer drugs,",
    "jurnal": "90-6601639a.pdf",
    "processed": "free ends within breakpoint cluster region all1 would eventually result 11q23 translocations results recent biochemical experiments strick et al 2000 consistent hypothesis structural feature shared many topoisomerase ii inhibitors including anticancer drugs"
  },
  {
    "id": 538,
    "paragraph": "is the quinone moiety. The metabolism of quinones is controlled by the enzyme NQO1 that converts toxic benzoquinones to topoisomerase II substances inhibit that hydroxyquinones. A polymorphism in nucleotide 609 of the enzyme substitutes a proline into serine and consequently inactivates the enzyme. Comparison of paediatric leukaemias with",
    "jurnal": "90-6601639a.pdf",
    "processed": "quinone moiety metabolism quinones controlled enzyme nqo1 converts toxic benzoquinones topoisomerase ii substances inhibit hydroxyquinones polymorphism nucleotide 609 enzyme substitutes proline serine consequently inactivates enzyme comparison paediatric leukaemias"
  },
  {
    "id": 539,
    "paragraph": "and without ALL-1 rearrangement indicated significant bias in the former for NQO1 genotypes conferring low or no enzymatic activity (Wiemels et al, 1999; Smith et al, 2002), suggesting that inactivating NQO1 polymorphism increases the risk for ALL-1- associated leukaemias. MOUSE MODELS OF ALL-1 LEUKAEMOGENESIS",
    "jurnal": "90-6601639a.pdf",
    "processed": "without all1 rearrangement indicated significant bias former nqo1 genotypes conferring low enzymatic activity wiemels et al 1999 smith et al 2002 suggesting inactivating nqo1 polymorphism increases risk all1 associated leukaemias mouse models all1 leukaemogenesis"
  },
  {
    "id": 540,
    "paragraph": "Two methodologies have been used to generate mouse models of ALL-1 leukaemogenesis. Knockin of the partner gene AF9 into the ALL-1 locus by homologous recombination resulted in animals that developed AML at approximately 6 months (Dobson et al, 1999). Transmission of the transgene in the germ line and its",
    "jurnal": "90-6601639a.pdf",
    "processed": "two methodologies used generate mouse models all1 leukaemogenesis knockin partner gene af9 all1 locus homologous recombination resulted animals developed aml approximately 6 months dobson et al 1999 transmission transgene germ line"
  },
  {
    "id": 541,
    "paragraph": "expression during embryogenesis resulted in viable progeny. This, together with the observation that mice carrying a single null allele of ALL-1 were not predisposed to AML (Corral et al, 1996), rules out a model of leukaemogenesis due to haploinsufficiency (passive loss of function). Rather, an extensive series of investigations",
    "jurnal": "90-6601639a.pdf",
    "processed": "expression embryogenesis resulted viable progeny together observation mice carrying single null allele all1 predisposed aml corral et al 1996 rules model leukaemogenesis due haploinsufficiency passive loss function rather extensive series investigations"
  },
  {
    "id": 542,
    "paragraph": "applying retro viral transduction into cultured haematopoietic followed by transplantation into mice, have progenitor cells, established that ALL-1 fusion genes act as dominant alleles and the disease is due to ALL-1 gain of function. Structure – function analysis of several ALL-1 fusion proteins showed that particular",
    "jurnal": "90-6601639a.pdf",
    "processed": "applying retro viral transduction cultured haematopoietic followed transplantation mice progenitor cells established all1 fusion genes act dominant alleles disease due all1 gain function structure – function analysis several all1 fusion proteins showed particular"
  },
  {
    "id": 543,
    "paragraph": "elements within the partner proteins, such as transcription effector domains and protein – protein interaction motifs, are critical for the leukaemogenic activity (reviewed in Ayton and Cleary, 2001). The presence of dimerisation domains in some of the partner proteins, such as AF6, AF10, AF17, AF1p, GAS7 and AF3p21",
    "jurnal": "90-6601639a.pdf",
    "processed": "elements within partner proteins transcription effector domains protein – protein interaction motifs critical leukaemogenic activity reviewed ayton cleary 2001 presence dimerisation domains partner proteins af6 af10 af17 af1p gas7 af3p21"
  },
  {
    "id": 544,
    "paragraph": "suggested that self-association might underlie the role of the partner proteins with such motifs in the leukaemogenicity of ALL- 1 fusion proteins. The most compelling experimental evidence for this is that homodimerisation of ALL-1 by synthetic dimerisation modules mimics many of the features of ALL-1 fusion proteins",
    "jurnal": "90-6601639a.pdf",
    "processed": "suggested selfassociation might underlie role partner proteins motifs leukaemogenicity 1 fusion proteins compelling experimental evidence homodimerisation all1 synthetic dimerisation modules mimics many features all1 fusion proteins"
  },
  {
    "id": 545,
    "paragraph": "(Dobson et al, 2000; So et al, 2003b, Martin et al, 2003). Also, disruption of the dimerisation motifs in some partner proteins eliminated pathogenicity. Although self-dimerisation appears to play a key role in leukaemogenesis associated with partner proteins containing a dimerisation motif,",
    "jurnal": "90-6601639a.pdf",
    "processed": "dobson et al 2000 et al 2003b martin et al 2003 also disruption dimerisation motifs partner proteins eliminated pathogenicity although selfdimerisation appears play key role leukaemogenesis associated partner proteins containing dimerisation motif"
  },
  {
    "id": 546,
    "paragraph": "the most common fusions – ALL-1/AF4, ALL-1/AF9 and ALL-1/ENL – do not dimerise. Both the knockin and retroviral transduction approaches turned out to be biased towards myeloid leukaemia. However, very recent studies with virally transduced ALL1-ENL (Zeisig et al, 2003) and",
    "jurnal": "90-6601639a.pdf",
    "processed": "common fusions – all1af4 all1af9 all1enl – dimerise knockin retroviral transduction approaches turned biased towards myeloid leukaemia however recent studies virally transduced all1enl zeisig et al 2003"
  },
  {
    "id": 547,
    "paragraph": "ALL1-GAS7 (So et al, 2003a) showed transformation of bipheno- typic lymphoid/myeloid cells and induction of biphenotypic leukaemia. So et al serially plated the transduced bone marrows in methylcellulose and found that the fusion protein conferred long-term growth capacity to multipotential progenitors. The",
    "jurnal": "90-6601639a.pdf",
    "processed": "all1gas7 et al 2003a showed transformation bipheno typic lymphoidmyeloid cells induction biphenotypic leukaemia et al serially plated transduced bone marrows methylcellulose found fusion protein conferred longterm growth capacity multipotential progenitors"
  },
  {
    "id": 548,
    "paragraph": "progenitors spontaneously differentiated into biphenotypic and myeloid progenitors during culturing in vitro. Moreover, mice injected with the transduced serially-plated progenitors developed either biphenotypic leukaemia, or AML or ALL. On the basis of these experiments, it was proposed that ALL-1 fusion proteins",
    "jurnal": "90-6601639a.pdf",
    "processed": "progenitors spontaneously differentiated biphenotypic myeloid progenitors culturing vitro moreover mice injected transduced seriallyplated progenitors developed either biphenotypic leukaemia aml basis experiments proposed all1 fusion proteins"
  },
  {
    "id": 549,
    "paragraph": "enhance the self-renewal potential of multipotent progenitors that retain an ability to differentiate into downstream progeny. The latter are more susceptible to differentiation blocking by ALL-1 fusion proteins, or are prone to secondary mutations required for full malignant transformation. GENE EXPRESSION PROFILES OF ALL-1 LEUKAEMIAS",
    "jurnal": "90-6601639a.pdf",
    "processed": "enhance selfrenewal potential multipotent progenitors retain ability differentiate downstream progeny latter susceptible differentiation blocking all1 fusion proteins prone secondary mutations required full malignant transformation gene expression profiles all1 leukaemias"
  },
  {
    "id": 550,
    "paragraph": "DNA microarrays technology has been recently applied to construct expression profiles of ALLs and/or AMLs with ALL-1 rearrangements (Rozovskaia et al, 2001, 2003; Armstrong et al, 2002; Yeoh et al, 2002). Both ALL-1-associated ALLs and AMLs 757 ALL-1/MLL1 and acute leukaemia",
    "jurnal": "90-6601639a.pdf",
    "processed": "dna microarrays technology recently applied construct expression profiles alls andor amls all1 rearrangements rozovskaia et al 2001 2003 armstrong et al 2002 yeoh et al 2002 all1associated alls amls 757 all1mll1 acute leukaemia"
  },
  {
    "id": 551,
    "paragraph": "E Canaani et al have distinct expression patterns that distinguish them from other types of ALL and AML, respectively. The distinction is more robust for ALL, probably reflecting the unusual clinical and biological features and the biphenotypic trait of the disease, not shared",
    "jurnal": "90-6601639a.pdf",
    "processed": "e canaani et al distinct expression patterns distinguish types aml respectively distinction robust probably reflecting unusual clinical biological features biphenotypic trait disease shared"
  },
  {
    "id": 552,
    "paragraph": "by other classes of ALL. In one study (Rozovskaia et al, 2003), genes whose expression pattern separated ALLs with t(4;11) from other ALLs were further subdivided, enabling the identification of two subfamilies of t(4;11) tumours. In that study, a substantial number of the genes, which were found to correlate in their",
    "jurnal": "90-6601639a.pdf",
    "processed": "classes one study rozovskaia et al 2003 genes whose expression pattern separated alls t411 alls subdivided enabling identification two subfamilies t411 tumours study substantial number genes found correlate"
  },
  {
    "id": 553,
    "paragraph": "expression with the t(4;11) genotype, had been previously associated with cancer, apoptosis or growth control. These included overexpressed oncogenes (such as HOX A9, HOX A10, MEIS1, LMO2 and MYC), overexpressed genes involved in protection from apoptosis and in survival, underexpressed proapoptotic genes, overexpressed genes",
    "jurnal": "90-6601639a.pdf",
    "processed": "expression t411 genotype previously associated cancer apoptosis growth control included overexpressed oncogenes hox a9 hox a10 meis1 lmo2 myc overexpressed genes involved protection apoptosis survival underexpressed proapoptotic genes overexpressed genes"
  },
  {
    "id": 554,
    "paragraph": "involved in drug resistance and underexpressed tumour suppressors and growth inhibitors such as FHIT and DAPK1. Determination of which of the genes pointed out in the DNA microarrays analyses plays a direct role in pathogenesis might come from experiments with mice. One approach will be to alter",
    "jurnal": "90-6601639a.pdf",
    "processed": "involved drug resistance underexpressed tumour suppressors growth inhibitors fhit dapk1 determination genes pointed dna microarrays analyses plays direct role pathogenesis might come experiments mice one approach alter"
  },
  {
    "id": 555,
    "paragraph": "the expression (e.g. by interference RNA) of a suspected gene in cell lines with 11q23 translocations, and examine whether the capacity of the cell lines to induce leukaemia in mice is lost. The second approach will be to transduce the fusion genes into mice",
    "jurnal": "90-6601639a.pdf",
    "processed": "expression eg interference rna suspected gene cell lines 11q23 translocations examine whether capacity cell lines induce leukaemia mice lost second approach transduce fusion genes mice"
  },
  {
    "id": 556,
    "paragraph": "null for genes suspected of playing an essential role in ALL-1 pathogenesis, and examine the effect on leukaemia development. Such an experiment has been recently reported for HOX A9 and HOX A7 (Ayton and Cleary, 2003). These two genes were found",
    "jurnal": "90-6601639a.pdf",
    "processed": "null genes suspected playing essential role all1 pathogenesis examine effect leukaemia development experiment recently reported hox a9 hox a7 ayton cleary 2003 two genes found"
  },
  {
    "id": 557,
    "paragraph": "required for in vitro myeloid immortalisation by the MLL/ENL fusion protein transduced by a retroviral vector into bone marrow cells. Further, HOX A9 was found to be indispensable for ALL-1- dependent leukaemogenesis in vivo. Applying a complementary approach, Kumar et al (2004) bred mice to obtain animals",
    "jurnal": "90-6601639a.pdf",
    "processed": "required vitro myeloid immortalisation mllenl fusion protein transduced retroviral vector bone marrow cells hox a9 found indispensable all1 dependent leukaemogenesis vivo applying complementary approach kumar et al 2004 bred mice obtain animals"
  },
  {
    "id": 558,
    "paragraph": "transgenic for MLL-AF9 and null for HOX A9 and examined leukaemia development. Surprisingly, the absence of HOX A9 did not affect the incidence and latency of leukaemia, although the malignant cells displayed a more immature myeloid phenotype. The authors suggest that several HOX genes might have to be",
    "jurnal": "90-6601639a.pdf",
    "processed": "transgenic mllaf9 null hox a9 examined leukaemia development surprisingly absence hox a9 affect incidence latency leukaemia although malignant cells displayed immature myeloid phenotype authors suggest several hox genes might"
  },
  {
    "id": 559,
    "paragraph": "inactivated to impair leukaemogenicity. The reasons for the contrasting conclusion obtained by the two approaches are currently not known. BIOLOGICAL AND BIOCHEMICAL ACTIVITY OF ALL-1 AND ITS DROSOPHILA HOMOLOGUE TRITHORAX (TRX) ALL-1 and TRX are members of the evolutionary conserved gene",
    "jurnal": "90-6601639a.pdf",
    "processed": "inactivated impair leukaemogenicity reasons contrasting conclusion obtained two approaches currently known biological biochemical activity all1 drosophila homologue trithorax trx all1 trx members evolutionary conserved gene"
  },
  {
    "id": 560,
    "paragraph": "family termed as the Trx group (TrxG) that are positive regulators of the homeotic gene complex (HOX) during development, and whose activity is opposed by the repressive activity of the Polycomb group (PcG). The TrxG and PcG proteins are not required for initiation of HOX genes activity, but act to maintain",
    "jurnal": "90-6601639a.pdf",
    "processed": "family termed trx group trxg positive regulators homeotic gene complex hox development whose activity opposed repressive activity polycomb group pcg trxg pcg proteins required initiation hox genes activity act maintain"
  },
  {
    "id": 561,
    "paragraph": "transcriptional states through later stages of development (re- viewed in Brock and van Lohuizen, 2001; Simon and Tamkun, 2002). ALL-1 also acts at the stage of maintenance (Yu et al, 1998). Since considerably more genetic and biological information is in comparison to ALL-1, here we will",
    "jurnal": "90-6601639a.pdf",
    "processed": "transcriptional states later stages development viewed brock van lohuizen 2001 simon tamkun 2002 all1 also acts stage maintenance yu et al 1998 since considerably genetic biological information comparison all1"
  },
  {
    "id": 562,
    "paragraph": "available about TRX, emphasise studies of the former. Approximately 20 genes have been characterised as members of the fly TrxG; however, this number is rapidly growing based on genetic and molecular criteria (Gildea et al, 2000; Faucheux et al, 2003). Further, it has became",
    "jurnal": "90-6601639a.pdf",
    "processed": "available trx emphasise studies former approximately 20 genes characterised members fly trxg however number rapidly growing based genetic molecular criteria gildea et al 2000 faucheux et al 2003 became"
  },
  {
    "id": 563,
    "paragraph": "apparent that the target genes of the TrxG are not limited to HOX genes (Kuzin et al, 1994; Maurange and Paro, 2002; Beltran et al, 2003). In this context, we have recently demonstrated (Smith et al, 2004) that following heat induction, the TRX complex is quickly",
    "jurnal": "90-6601639a.pdf",
    "processed": "apparent target genes trxg limited hox genes kuzin et al 1994 maurange paro 2002 beltran et al 2003 context recently demonstrated smith et al 2004 following heat induction trx complex quickly"
  },
  {
    "id": 564,
    "paragraph": "recruited to several heat-shock genes on salivary polytene chromosomes, where it is required to maintain a high level of & 2004 Cancer Research UK British Journal of Cancer (2004) 90(4), 756 – 760 758 ALL-1/MLL1 and acute leukaemia E Canaani et al",
    "jurnal": "90-6601639a.pdf",
    "processed": "recruited several heatshock genes salivary polytene chromosomes required maintain high level 2004 cancer research uk british journal cancer 2004 904 756 – 760 758 all1mll1 acute leukaemia e canaani et al"
  },
  {
    "id": 565,
    "paragraph": "already initiated transcription. Such a role is similar to the role of TRX in HOX gene expression. Much effort was devoted to in vivo analysis of the properties of TrxG and PcG response elements (TRE and PRE, respectively) at target loci in Drosophila. The emerging picture of the best studied",
    "jurnal": "90-6601639a.pdf",
    "processed": "already initiated transcription role similar role trx hox gene expression much effort devoted vivo analysis properties trxg pcg response elements tre pre respectively target loci drosophila emerging picture best studied"
  },
  {
    "id": 566,
    "paragraph": "target, the regulatory region of the Drosophila Bithorax complex BX-C gene Ubx, suggests that although TREs and PREs are intermingled within a 1.5 kb region bxd, they may represent separable regulatory elements (Tillib et al, 1999). It is still not clear",
    "jurnal": "90-6601639a.pdf",
    "processed": "target regulatory region drosophila bithorax complex bxc gene ubx suggests although tres pres intermingled within 15 kb region bxd may represent separable regulatory elements tillib et al 1999 still clear"
  },
  {
    "id": 567,
    "paragraph": "whether the TrxG and PcG proteins occupy their respective responsive elements at all time, or only when the target gene is active or repressed, respectively. Evidence that these proteins may occupy their binding sites depending on the status of gene expression came recently from analysis of Drosophila larval fat",
    "jurnal": "90-6601639a.pdf",
    "processed": "whether trxg pcg proteins occupy respective responsive elements time target gene active repressed respectively evidence proteins may occupy binding sites depending status gene expression came recently analysis drosophila larval fat"
  },
  {
    "id": 568,
    "paragraph": "body (Marchetti et al, 2003). BX-C genes are repressed in the anterior region of the fat body, but are active in the mid-posterior part. In parallel, the PC protein (but not TRX) was detected at the cytological site of bithorax on polytene chromosomes from",
    "jurnal": "90-6601639a.pdf",
    "processed": "body marchetti et al 2003 bxc genes repressed anterior region fat body active midposterior part parallel pc protein trx detected cytological site bithorax polytene chromosomes"
  },
  {
    "id": 569,
    "paragraph": "the anterior part of the fat body, while a strong signal of TRX (but not of PC) was detected on chromosomes from the mid-posterior fat body. The mechanism by which TRX and ALL-1 reach their target loci is not known. The absence of sequence-specific DNA-binding",
    "jurnal": "90-6601639a.pdf",
    "processed": "anterior part fat body strong signal trx pc detected chromosomes midposterior fat body mechanism trx all1 reach target loci known absence sequencespecific dnabinding"
  },
  {
    "id": 570,
    "paragraph": "protein among components of the TRX and ALL-1 complexes (see later) emphasises this quandary. Several recent studies (Bender and Fitzgerald, 2002; Hogga and Karch, 2002; Rank et al, 2002) showed that ectopic or induced transcription through regulatory elements of the Bithorax complex switches the elements from",
    "jurnal": "90-6601639a.pdf",
    "processed": "protein among components trx all1 complexes see later emphasises quandary several recent studies bender fitzgerald 2002 hogga karch 2002 rank et al 2002 showed ectopic induced transcription regulatory elements bithorax complex switches elements"
  },
  {
    "id": 571,
    "paragraph": "silenced to activated states. On the basis of this, it was proposed that passage of the RNA polymerase II complex through a regulatory element displaces the repressive PcG complex, set there by default, and enables recruitment of the TRX complex that",
    "jurnal": "90-6601639a.pdf",
    "processed": "silenced activated states basis proposed passage rna polymerase ii complex regulatory element displaces repressive pcg complex set default enables recruitment trx complex"
  },
  {
    "id": 572,
    "paragraph": "imprints epigenetic marks instructing transcription of the adjacent HOX gene. Chromatin immunoprecipitation (ChIP) experiments previously identified TRX both on TREs and on promoters within the Bithorax gene complex (Orlando et al, 1998). The ChIP methodology was recently applied to ALL-1 (Nakamura et al,",
    "jurnal": "90-6601639a.pdf",
    "processed": "imprints epigenetic marks instructing transcription adjacent hox gene chromatin immunoprecipitation chip experiments previously identified trx tres promoters within bithorax gene complex orlando et al 1998 chip methodology recently applied all1 nakamura et al"
  },
  {
    "id": 573,
    "paragraph": "2002; Milne et al, 2002) and the protein was found bound at the promoters of HOX A9 and HOX C8 in cultured cells expressing these genes (homologues of Drosophila TREs and PREs have not been identified yet in mammals). Elimination of ALL-1, by",
    "jurnal": "90-6601639a.pdf",
    "processed": "2002 milne et al 2002 protein found bound promoters hox a9 hox c8 cultured cells expressing genes homologues drosophila tres pres identified yet mammals elimination all1"
  },
  {
    "id": 574,
    "paragraph": "applying interference RNA methodology, blocked transcription of HOX A9. Both studies showed that ALL-1 is a histone methyltransferase that methylates lysine 4 of histone H3. The enzymatic activity is conferred by the C-terminal SET domain. The presence of ALL-1 on the promoters of the two HOX genes is",
    "jurnal": "90-6601639a.pdf",
    "processed": "applying interference rna methodology blocked transcription hox a9 studies showed all1 histone methyltransferase methylates lysine 4 histone h3 enzymatic activity conferred cterminal set domain presence all1 promoters two hox genes"
  },
  {
    "id": 575,
    "paragraph": "linked to H3-Lys4 methylation as well as to acetylation of histones H3 and H4 at the promoter. Several other TrxG, PcG, and other chromatin – associated proteins containing SET domains – were recently shown to methylate histones at specific residues (reviewed",
    "jurnal": "90-6601639a.pdf",
    "processed": "linked h3lys4 methylation well acetylation histones h3 h4 promoter several trxg pcg chromatin – associated proteins containing set domains – recently shown methylate histones specific residues reviewed"
  },
  {
    "id": 576,
    "paragraph": "in Orlando, 2003). Such marking of histones (as are acetylation, phosphorylation and ubiquitination of specific histone residues) conveys heritable transcription patterns (expression or silencing) in an epigenetic manner. the TAC1 complex that The molecular mechanisms by which TRX and ALL-1 act was",
    "jurnal": "90-6601639a.pdf",
    "processed": "orlando 2003 marking histones acetylation phosphorylation ubiquitination specific histone residues conveys heritable transcription patterns expression silencing epigenetic manner tac1 complex molecular mechanisms trx all1 act"
  },
  {
    "id": 577,
    "paragraph": "further elucidated by the identification and characterisation of stable protein complexes associated with the two proteins. TRX is a component of includes the histone acetyltransferase (HAT) dCBP, and a SET - binding factor, SBF1 (Petruk et al, 2001). The recruitment of TAC1 components to the",
    "jurnal": "90-6601639a.pdf",
    "processed": "elucidated identification characterisation stable protein complexes associated two proteins trx component includes histone acetyltransferase hat dcbp set binding factor sbf1 petruk et al 2001 recruitment tac1 components"
  },
  {
    "id": 578,
    "paragraph": "following heat HSP70 locus in enhanced induction results the gene and correlates with acetylation and expression of methylation of histones (Smith et al, 2004). The ALL-1 complex (Nakamura et al, 2002) completely varies from that of TRX. It contains at least 29 proteins. The majority of",
    "jurnal": "90-6601639a.pdf",
    "processed": "following heat hsp70 locus enhanced induction results gene correlates acetylation expression methylation histones smith et al 2004 all1 complex nakamura et al 2002 completely varies trx contains least 29 proteins majority"
  },
  {
    "id": 579,
    "paragraph": "the latter are components of seven subcomplexes involved in transcription preinitiation, nucleosome remodelling, histone deacetylation, histone methylation or RNA processing. The purified ALL-1 complex methylates, acetylates, deacetylates and remodels nucleo- somes and is bound at the promoter of the target gene HOX A9. It",
    "jurnal": "90-6601639a.pdf",
    "processed": "latter components seven subcomplexes involved transcription preinitiation nucleosome remodelling histone deacetylation histone methylation rna processing purified all1 complex methylates acetylates deacetylates remodels nucleo somes bound promoter target gene hox a9"
  },
  {
    "id": 580,
    "paragraph": "appears that a major role of ALL-1 is to assemble this large supercomplex of enzymatic activities. In summary, the recent biochemical experiments indicate that TRX and ALL-1 recruit to target genes a host of enzymatic activities, mostly involved in epigenetic marking. The way in which these marks are inherited to",
    "jurnal": "90-6601639a.pdf",
    "processed": "appears major role all1 assemble large supercomplex enzymatic activities summary recent biochemical experiments indicate trx all1 recruit target genes host enzymatic activities mostly involved epigenetic marking way marks inherited"
  },
  {
    "id": 581,
    "paragraph": "progeny cells (memorized) is not known (they have to survive DNA replication, during which the histones are thought to be stripped off the DNA), but it has been speculated (Turner, 2000; Richards and Elgin, 2002) that the modified histones stay at or",
    "jurnal": "90-6601639a.pdf",
    "processed": "progeny cells memorized known survive dna replication histones thought stripped dna speculated turner 2000 richards elgin 2002 modified histones stay"
  },
  {
    "id": 582,
    "paragraph": "near the replication fork and are incorporated into the daughter DNA strands. UNRESOLVED ISSUES AND FUTURE DIRECTIONS raises the Drosophila BX-C genes While considerable progress was made in identification of the biochemical activities of the ALL-1 and TRX protein complexes, the mechanism by which these complexes are recruited to specific",
    "jurnal": "90-6601639a.pdf",
    "processed": "near replication fork incorporated daughter dna strands unresolved issues future directions raises drosophila bxc genes considerable progress made identification biochemical activities all1 trx protein complexes mechanism complexes recruited specific"
  },
  {
    "id": 583,
    "paragraph": "sequences (genes) is completely unknown. The recent reports that transcription of regulatory regions induces heritable transcrip- tional activation of the possibility that such a mechanism is involved in the recruitment of TRX and ALL-1 complexes. Another outstanding issue is the identification of genes, other than HOX, that are regulated by ALL-",
    "jurnal": "90-6601639a.pdf",
    "processed": "sequences genes completely unknown recent reports transcription regulatory regions induces heritable transcrip tional activation possibility mechanism involved recruitment trx all1 complexes another outstanding issue identification genes hox regulated"
  },
  {
    "id": 584,
    "paragraph": "1 and TRX. The demonstration that the mammalian PcG protein BMI-1 regulates the important cell cycle locus INK4a/ARF (Jacobs et al, 1999) suggests that looking for additional ALL-1/TRX targets (e.g. by conditional elimination or activation of the two proteins, followed by DNA microarray analysis) might be rewarding.",
    "jurnal": "90-6601639a.pdf",
    "processed": "1 trx demonstration mammalian pcg protein bmi1 regulates important cell cycle locus ink4aarf jacobs et al 1999 suggests looking additional all1trx targets eg conditional elimination activation two proteins followed dna microarray analysis might rewarding"
  },
  {
    "id": 585,
    "paragraph": "Further, the process by which the ALL-1-mediated histone H3- Lys4 methylation induces chromatin alteration (presumably decondensation) and gene expression, and the precise roles of the transcriptional subcomplexes within ALL-1 supercomplex, have yet to be determined. A new line of investigation is likely to",
    "jurnal": "90-6601639a.pdf",
    "processed": "process all1mediated histone h3 lys4 methylation induces chromatin alteration presumably decondensation gene expression precise roles transcriptional subcomplexes within all1 supercomplex yet determined new line investigation likely"
  },
  {
    "id": 586,
    "paragraph": "originate from the recent remarkable finding that the PHD finger motif of the ING2 protein binds phosphoinositides, and that this interaction regulates the biological activity of the latter (Gozani et al, 2003). The presence of four PHD finger motifs in both ALL-1",
    "jurnal": "90-6601639a.pdf",
    "processed": "originate recent remarkable finding phd finger motif ing2 protein binds phosphoinositides interaction regulates biological activity latter gozani et al 2003 presence four phd finger motifs all1"
  },
  {
    "id": 587,
    "paragraph": "and TRX points to a potential central mechanism by which these the reason why ALL-1 (and proteins are regulated. Finally, presumably TRX) is proteolytically cleaved by an evolutionary conserved enzyme into two polypeptides, which are held together, is not known (Nakamura et al, 2002; Yokoyama et al, 2002; Hsieh",
    "jurnal": "90-6601639a.pdf",
    "processed": "trx points potential central mechanism reason all1 proteins regulated finally presumably trx proteolytically cleaved evolutionary conserved enzyme two polypeptides held together known nakamura et al 2002 yokoyama et al 2002 hsieh"
  },
  {
    "id": 588,
    "paragraph": "et al, 2003). Mouse models have recently identified the type of precursor cell transformed by ALL-1 fusion proteins, and DNA microarrays analyses focused attention on genes that might play a direct role in leukaemogenesis. Identification of such genes is clearly a focal",
    "jurnal": "90-6601639a.pdf",
    "processed": "et al 2003 mouse models recently identified type precursor cell transformed all1 fusion proteins dna microarrays analyses focused attention genes might play direct role leukaemogenesis identification genes clearly focal"
  },
  {
    "id": 589,
    "paragraph": "point for understanding the disease in molecular terms and for future therapeutic intervention. However, other central questions remain. First, do all ALL-1 fusions, including self-fusions, trigger a single pathway leading to disease? Why are most fusions associated with specific leukaemia subtype (e.g. ALL1-AF4 with ALL, ALL1-",
    "jurnal": "90-6601639a.pdf",
    "processed": "point understanding disease molecular terms future therapeutic intervention however central questions remain first all1 fusions including selffusions trigger single pathway leading disease fusions associated specific leukaemia subtype eg all1af4 all1"
  },
  {
    "id": 590,
    "paragraph": "AF6 with AML)? Second, since the fusion proteins lack the SET domain with its histone H3-Lys4 methylation activity, how do they retain transcriptional activation capacity? Do they target all genes regulated by normal ALL-1? Do they compete with normal ALL-1 on the same targets? Do they block transcription of some loci?",
    "jurnal": "90-6601639a.pdf",
    "processed": "af6 aml second since fusion proteins lack set domain histone h3lys4 methylation activity retain transcriptional activation capacity target genes regulated normal all1 compete normal all1 targets block transcription loci"
  },
  {
    "id": 591,
    "paragraph": "Also, the absence of the PHD fingers in ALL-1 fusion proteins should relieve them from potential regulation by phosphoinosi- tides; whether this is an important aspect of the leukaemogenic activity of these proteins has yet to be determined. A third issue is",
    "jurnal": "90-6601639a.pdf",
    "processed": "also absence phd fingers all1 fusion proteins relieve potential regulation phosphoinosi tides whether important aspect leukaemogenic activity proteins yet determined third issue"
  },
  {
    "id": 592,
    "paragraph": "whether ALL-1 fusions confer resistance to apoptosis. ALL-1- associated leukaemias are notorious for their poor prognosis with chemotherapy, and exhibit drug resistance. Since it is now believed British Journal of Cancer (2004) 90(4), 756 – 760 & 2004 Cancer Research UK",
    "jurnal": "90-6601639a.pdf",
    "processed": "whether all1 fusions confer resistance apoptosis all1 associated leukaemias notorious poor prognosis chemotherapy exhibit drug resistance since believed british journal cancer 2004 904 756 – 760 2004 cancer research uk"
  },
  {
    "id": 593,
    "paragraph": "ALL-1/MLL1 and acute leukaemia E Canaani et al 759 that the cytotoxic action of most chemotherapeutic drugs is through activation of apoptotic pathways, drug resistance of ALL-1 leukaemias might be due to disruption of apoptotic processes. Such disruptions appear to be crucial for the development of many tumours (reviewed",
    "jurnal": "90-6601639a.pdf",
    "processed": "all1mll1 acute leukaemia e canaani et al 759 cytotoxic action chemotherapeutic drugs activation apoptotic pathways drug resistance all1 leukaemias might due disruption apoptotic processes disruptions appear crucial development many tumours reviewed"
  },
  {
    "id": 594,
    "paragraph": "in Johnstone et al, 2002). Still, very little has been reported about this issue with regard to ALL-1 leukaemias. In one study (Kersey et al, 1998), ALLs with t(4; 11) were compared to similar tumours without t(4; 11) and found to be dramatically more resistant to serum",
    "jurnal": "90-6601639a.pdf",
    "processed": "johnstone et al 2002 still little reported issue regard all1 leukaemias one study kersey et al 1998 alls t4 11 compared similar tumours without t4 11 found dramatically resistant serum"
  },
  {
    "id": 595,
    "paragraph": "deprivation stress. A recent investigation (Wiederschain et al, 2003) showed nuclear colocalisation of the fusion protein ALL1-ELL with p53, and loss of p53-mediated apoptosis. Whether this phenomenon is unique to that particular fusion protein or is it of a more general",
    "jurnal": "90-6601639a.pdf",
    "processed": "deprivation stress recent investigation wiederschain et al 2003 showed nuclear colocalisation fusion protein all1ell p53 loss p53mediated apoptosis whether phenomenon unique particular fusion protein general"
  },
  {
    "id": 596,
    "paragraph": "nature is presently not known. ACKNOWLEDGEMENTS We apologise to our colleagues whose work was not cited, due to space limitations. Work in the authors’ laboratories was supported by NCI Grant CA50507 and by grants from the Israeli Academy of Science, the Israeli Cancer Research Fund and US – Israel BSF.",
    "jurnal": "90-6601639a.pdf",
    "processed": "nature presently known acknowledgements apologise colleagues whose work cited due space limitations work authors ’ laboratories supported nci grant ca50507 grants israeli academy science israeli cancer research fund us – israel bsf"
  },
  {
    "id": 597,
    "paragraph": "Ayton PM, Cleary ML (2001) Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20: 5695 – 5707 Ayton PM, Cleary ML (2003) Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17: 2298 – 2307",
    "jurnal": "90-6601639a.pdf",
    "processed": "ayton pm cleary ml 2001 molecular mechanisms leukemogenesis mediated mll fusion proteins oncogene 20 5695 – 5707 ayton pm cleary ml 2003 transformation myeloid progenitors mll oncoproteins dependent hoxa7 hoxa9 genes dev 17 2298 – 2307"
  },
  {
    "id": 598,
    "paragraph": "Beltran S, Blanco E, Serras F, Perez-Villamil B, Guigo R, Artavanis- Tsakonas S, Corominas M (2003) Transcriptional network controlled by the trithorax-group gene ash2 in Drosophila melanogaster. Proc Natl Acad Sci USA 100: 3293 – 3298 Bender W, Fitzgerald DP (2002) Transcription activates repressed domains",
    "jurnal": "90-6601639a.pdf",
    "processed": "beltran blanco e serras f perezvillamil b guigo r artavanis tsakonas corominas 2003 transcriptional network controlled trithoraxgroup gene ash2 drosophila melanogaster proc natl acad sci usa 100 3293 – 3298 bender w fitzgerald dp 2002 transcription activates repressed domains"
  },
  {
    "id": 599,
    "paragraph": "in the Drosophila bithorax complex. Development 129: 4923 – 4930 Biondi A, Cimino G, Pieters R, Pui C-H (2000) Biological and therapeutic aspects of infant leukemia. Blood 96: 24 – 33 Brock HW, van Lohuizen M (2001) The polycomb group – no longer an",
    "jurnal": "90-6601639a.pdf",
    "processed": "drosophila bithorax complex development 129 4923 – 4930 biondi cimino g pieters r pui ch 2000 biological therapeutic aspects infant leukemia blood 96 24 – 33 brock hw van lohuizen 2001 polycomb group – longer"
  },
  {
    "id": 600,
    "paragraph": "exclusive club? Curr Opin Genet Dev 11: 175 – 181 Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, Bell S, McKenzie AN, King G, Rabbitts TH (1996) An MLL-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric",
    "jurnal": "90-6601639a.pdf",
    "processed": "exclusive club curr opin genet dev 11 175 – 181 corral j lavenir impey h warren aj forster larson ta bell mckenzie king g rabbitts th 1996 mllaf9 fusion gene made homologous recombination causes acute leukemia chimeric"
  },
  {
    "id": 601,
    "paragraph": "mice: a method to create fusion oncogenes. Cell 85: 853 – 861 Dobson CL, Warren AJ, Pannel R, Forster A, Lavenir I, Corral J, Smith AJ, Rabbitts TH (1999) The MLL – AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukemogenesis. EMBO",
    "jurnal": "90-6601639a.pdf",
    "processed": "mice method create fusion oncogenes cell 85 853 – 861 dobson cl warren aj pannel r forster lavenir corral j smith aj rabbitts th 1999 mll – af9 gene fusion mice controls myeloproliferation specifies acute myeloid leukemogenesis embo"
  },
  {
    "id": 602,
    "paragraph": "J 18: 3564 – 3574 Dobson CL, Warren AJ, Pannell R, Forster A, Rabbitts TH (2000) Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene. EMBO J 19: 843 – 851 Faucheux M, Roignant JY, Netter S, Charollais J, Antoniewski C, Theodore",
    "jurnal": "90-6601639a.pdf",
    "processed": "j 18 3564 – 3574 dobson cl warren aj pannell r forster rabbitts th 2000 tumorigenesis mice fusion leukaemia oncogene mll bacterial lacz gene embo j 19 843 – 851 faucheux roignant jy netter charollais j antoniewski c theodore"
  },
  {
    "id": 603,
    "paragraph": "L (2003) Batman interacts with polycomb and trithorax group genes and encodes a BTB/POZ protein that is included in a complex containing GAGA factor. Mol Cell Biol 23: 1181 – 1195 Gildea JJ, Lopez R, Shearn A (2000) A screen for new trithorax group genes",
    "jurnal": "90-6601639a.pdf",
    "processed": "l 2003 batman interacts polycomb trithorax group genes encodes btbpoz protein included complex containing gaga factor mol cell biol 23 1181 – 1195 gildea jj lopez r shearn 2000 screen new trithorax group genes"
  },
  {
    "id": 604,
    "paragraph": "identified little imaginal discs, the Drosophila melanogaster homologue of human retinoblastoma binding protein 2. Genetics 156: 645 – 663 Gozani O, Karuman P, Jones DR, Ivanov D, Cha J, Lugovskoy AA, Baird CL, Zhu H, Field SJ, Lessnick SL, Villasenor J, Mehrotra B, Chen J, Rao VR,",
    "jurnal": "90-6601639a.pdf",
    "processed": "identified little imaginal discs drosophila melanogaster homologue human retinoblastoma binding protein 2 genetics 156 645 – 663 gozani karuman p jones dr ivanov cha j lugovskoy aa baird cl zhu h field sj lessnick sl villasenor j mehrotra b chen j rao vr"
  },
  {
    "id": 605,
    "paragraph": "Brugge JS, Ferguson CG, Payrastre B, Myszka DG, Cantley LC, Wagner G, Divecha N, Prestwich GD, Yuan J (2003) The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinosi- tide receptor. Cell 114: 99 – 111 Greaves M (1999) Molecular genetics, natural history and the demise of",
    "jurnal": "90-6601639a.pdf",
    "processed": "brugge js ferguson cg payrastre b myszka dg cantley lc wagner g divecha n prestwich gd yuan j 2003 phd finger chromatinassociated protein ing2 functions nuclear phosphoinosi tide receptor cell 114 99 – 111 greaves 1999 molecular genetics natural history demise"
  },
  {
    "id": 606,
    "paragraph": "childhood leukaemia. Eur J Cancer 35: 1941 – 1953 Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G, Croce CM, Canaani E (1992) The t(4;11) chromosome translocation of human acute leukemia fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-",
    "jurnal": "90-6601639a.pdf",
    "processed": "childhood leukaemia eur j cancer 35 1941 – 1953 gu nakamura alder h prasad r canaani cimino g croce cm canaani e 1992 t411 chromosome translocation human acute leukemia fuses all1 gene related drosophila trithorax af"
  },
  {
    "id": 607,
    "paragraph": "4 gene. Cell 71: 701 – 708 Hogga I, Karch F (2002) Transcription through the iab-7 cis-regulatory domain of the bithorax complex interferes with Polycomb mediated silencing. Development 129: 4915 – 4922 Hsieh JJ, Cheng EH, Korsmeyer SJ (2003) Taspasel: a threonine aspartase",
    "jurnal": "90-6601639a.pdf",
    "processed": "4 gene cell 71 701 – 708 hogga karch f 2002 transcription iab7 cisregulatory domain bithorax complex interferes polycomb mediated silencing development 129 4915 – 4922 hsieh jj cheng eh korsmeyer sj 2003 taspasel threonine aspartase"
  },
  {
    "id": 608,
    "paragraph": "required for cleavage of MLL and proper HOX gene expression. Cell 115: 293 – 303 Huret JL, Dessen P, Bernheim A (2001) An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners. Leukemia 15: 987 – 989 Jacobs JJL, Kieboom K, Marino S, DePinho RA, van Lohuizen M (1999) The",
    "jurnal": "90-6601639a.pdf",
    "processed": "required cleavage mll proper hox gene expression cell 115 293 – 303 huret jl dessen p bernheim 2001 atlas chromosomes hematological malignancies example 11q23 mll partners leukemia 15 987 – 989 jacobs jjl kieboom k marino depinho ra van lohuizen 1999"
  },
  {
    "id": 609,
    "paragraph": "oncogene and Polycomb group gene bmi-1 regulates cell proliferation and senescence through the INK4a locus. Nature 397: 164 – 168 Johansson B, Moorman AV, Haas OA, Watmore AE, Cheung KL, Swanton S, Secker-Walker LM (1998) Hemotologic malignancies with t(4;11) (q21;q23): a cytogenetic, morphologic, immunophenotypic and clinical",
    "jurnal": "90-6601639a.pdf",
    "processed": "oncogene polycomb group gene bmi1 regulates cell proliferation senescence ink4a locus nature 397 164 – 168 johansson b moorman av haas oa watmore ae cheung kl swanton seckerwalker lm 1998 hemotologic malignancies t411 q21q23 cytogenetic morphologic immunophenotypic clinical"
  },
  {
    "id": 610,
    "paragraph": "study of 183 cases. Leukemia 12: 779 – 787 Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153 – 164 Kersey JH, Wang D, Oberto M (1998) Resistance of t(4;11)(MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for",
    "jurnal": "90-6601639a.pdf",
    "processed": "study 183 cases leukemia 12 779 – 787 johnstone rw ruefli aa lowe sw 2002 apoptosis link cancer genetics chemotherapy cell 108 153 – 164 kersey jh wang oberto 1998 resistance t411mllaf4 fusion gene leukemias stressinduced cell death possible mechanism"
  },
  {
    "id": 611,
    "paragraph": "extensive extramedullary accumulation of cells and poor prognosis. Leukemia 12: 1561 – 1564 Kumar AR, Hudson WA, Chen W, Nishiuchi R, Yao Q, Kersey JH (2004) Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood, inpress, Epub 2003, Nov 13",
    "jurnal": "90-6601639a.pdf",
    "processed": "extensive extramedullary accumulation cells poor prognosis leukemia 12 1561 – 1564 kumar ar hudson wa chen w nishiuchi r yao q kersey jh 2004 hoxa9 influences phenotype incidence mllaf9 fusion gene leukemia blood inpress epub 2003 nov 13"
  },
  {
    "id": 612,
    "paragraph": "Kuzin B, Tillib S, Sedkov Y, Mizrokhi L, Mazo A (1994) The Drosophila trithorax gene encodes a chromosomal protein and directly regulates the region-specific homeotic gene forkhead. Genes Dev 8: 2478 – 2490 Marchetti M, Fanti L, Berloco M, Pimpinelli S (2003) Differential expression",
    "jurnal": "90-6601639a.pdf",
    "processed": "kuzin b tillib sedkov mizrokhi l mazo 1994 drosophila trithorax gene encodes chromosomal protein directly regulates regionspecific homeotic gene forkhead genes dev 8 2478 – 2490 marchetti fanti l berloco pimpinelli 2003 differential expression"
  },
  {
    "id": 613,
    "paragraph": "of the Drosophila BX-C in polytene chromosomes in cells of larval fat bodies: a cytological approach to identifying in vivo targets of the homeotic Ubx, Abd-A and Abd-B proteins. Development 130: 3683 – 3689 Martin ME, Milne TA, Bloyer S, Galoian K, Shen W, Gibbs D, Brock HW,",
    "jurnal": "90-6601639a.pdf",
    "processed": "drosophila bxc polytene chromosomes cells larval fat bodies cytological approach identifying vivo targets homeotic ubx abda abdb proteins development 130 3683 – 3689 martin milne ta bloyer galoian k shen w gibbs brock hw"
  },
  {
    "id": 614,
    "paragraph": "JL (2003) Dimerization of MLL fusion proteins Slany R, Hess immortalizes hematopoietic cells. Cancer Cell 4: 197 – 207 Maurange C, Paro R (2002) A cellular memory module conveys epigenetic inheritance of hedgehog expression during Drosophila wing imaginal disc development. Genes Dev 16: 2672 – 2683",
    "jurnal": "90-6601639a.pdf",
    "processed": "jl 2003 dimerization mll fusion proteins slany r hess immortalizes hematopoietic cells cancer cell 4 197 – 207 maurange c paro r 2002 cellular memory module conveys epigenetic inheritance hedgehog expression drosophila wing imaginal disc development genes dev 16 2672 – 2683"
  },
  {
    "id": 615,
    "paragraph": "Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, Hess JL (2002) MLL targets SET domain methyltransferase activity to HOX gene promoters. Mol Cell 10: 1107 – 1117 Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, Wassel R,",
    "jurnal": "90-6601639a.pdf",
    "processed": "milne ta briggs sd brock hw martin gibbs allis cd hess jl 2002 mll targets set domain methyltransferase activity hox gene promoters mol cell 10 1107 – 1117 nakamura mori tada krajewski w rozovskaia wassel r"
  },
  {
    "id": 616,
    "paragraph": "Dubois G, Mazo A, Croce CM, Canaani E (2002) ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 10: 1119 – 1128 Orlando V (2003) Polycomb, epigenomes and control of cell identity. Cell",
    "jurnal": "90-6601639a.pdf",
    "processed": "dubois g mazo croce cm canaani e 2002 all1 histone methyltransferase assembles supercomplex proteins involved transcriptional regulation mol cell 10 1119 – 1128 orlando v 2003 polycomb epigenomes control cell identity cell"
  },
  {
    "id": 617,
    "paragraph": "112: 599 – 606 Orlando V, Jane EP, Chinwalla V, Harte PJ, Paro R (1998) Binding of Trithorax and Polycomb proteins to the bithorax complex: dynamic changes during early Drosophila embryogenesis. EMBO J 17: 5141 – 5150 Petruk S, Sedkov Y, Smith S, Tillib S, Kraevski V, Nakamura T, Canaani E,",
    "jurnal": "90-6601639a.pdf",
    "processed": "112 599 – 606 orlando v jane ep chinwalla v harte pj paro r 1998 binding trithorax polycomb proteins bithorax complex dynamic changes early drosophila embryogenesis embo j 17 5141 – 5150 petruk sedkov smith tillib kraevski v nakamura canaani e"
  },
  {
    "id": 618,
    "paragraph": "Croce CM, Mazo A (2001) Trithorax and dCBP acting in a complex to maintain expression of homeotic gene. Science 294: 1331 – 1334 Pui C-H, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DD, Vilmer E, Schrappe M, Camitta B",
    "jurnal": "90-6601639a.pdf",
    "processed": "croce cm mazo 2001 trithorax dcbp acting complex maintain expression homeotic gene science 294 1331 – 1334 pui ch gaynon ps boyett jm chessells jm baruchel kamps w silverman lb biondi harms dd vilmer e schrappe camitta b"
  },
  {
    "id": 619,
    "paragraph": "(2002) Outcome of treatment in childhood acute lymphoblastic leukemia with rearrangements of the 11q23 chromosomal region. Lancet 359: 1909 – 1915 Pui C-H, Relling MV (2000) Topoisomerase II inhibitor-related acute myeloid leukemia. Br J Haematol 109: 13 – 23 Rank G, Prestel M, Paro R (2002) Transcription through intergenic",
    "jurnal": "90-6601639a.pdf",
    "processed": "2002 outcome treatment childhood acute lymphoblastic leukemia rearrangements 11q23 chromosomal region lancet 359 1909 – 1915 pui ch relling mv 2000 topoisomerase ii inhibitorrelated acute myeloid leukemia br j haematol 109 13 – 23 rank g prestel paro r 2002 transcription intergenic"
  },
  {
    "id": 620,
    "paragraph": "chromosomal memory elements of the Drosophila bithorax complex correlates with an epigenetic switch. Mol Cell Biol 22: 8026 – 8034 Richards EJ, Elgin SCR (2002) Epigenetic codes for heterochromatin formation and silencing. Rounding up the usual suspects. Cell 108: 489 – 500",
    "jurnal": "90-6601639a.pdf",
    "processed": "chromosomal memory elements drosophila bithorax complex correlates epigenetic switch mol cell biol 22 8026 – 8034 richards ej elgin scr 2002 epigenetic codes heterochromatin formation silencing rounding usual suspects cell 108 489 – 500"
  },
  {
    "id": 621,
    "paragraph": "Ross JA, Potter JD, Robison LL (1994) Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J Natl Cancer Inst 86: 1678 – 1680 & 2004 Cancer Research UK British Journal of Cancer (2004) 90(4), 756 – 760 760 ALL-1/MLL1 and acute leukaemia",
    "jurnal": "90-6601639a.pdf",
    "processed": "ross ja potter jd robison 1994 infant leukemia topoisomerase ii inhibitors mll gene j natl cancer inst 86 1678 – 1680 2004 cancer research uk british journal cancer 2004 904 756 – 760 760 all1mll1 acute leukaemia"
  },
  {
    "id": 622,
    "paragraph": "E Canaani et al Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, Nakamura T, Croce CM, Cimino G, Canaani E (2001) Upregulation of Meis1 and HOXA9 in acute lymphocytic leukemias with the (4;11) abnormality. Oncogene 20: 874 – 878",
    "jurnal": "90-6601639a.pdf",
    "processed": "e canaani et al rozovskaia feinstein e mor foa r blechman j nakamura croce cm cimino g canaani e 2001 upregulation meis1 hoxa9 acute lymphocytic leukemias 411 abnormality oncogene 20 874 – 878"
  },
  {
    "id": 623,
    "paragraph": "Rozovskaia T, Ravid-Amir O, Tillib S, Getz G, Feinstein E, Agrawal H, Nagler A, Rappaport EF, Issaeva I, Matsuo Y, Kees UR, Lapidot T, Lo Coco F, Foa R, Mazo A, Nakamura T, Croce CM, Cimino G, Domany E, Canaani E (2003) Expression profiles of acute lymphoblastic and",
    "jurnal": "90-6601639a.pdf",
    "processed": "rozovskaia ravidamir tillib getz g feinstein e agrawal h nagler rappaport ef issaeva matsuo kees ur lapidot lo coco f foa r mazo nakamura croce cm cimino g domany e canaani e 2003 expression profiles acute lymphoblastic"
  },
  {
    "id": 624,
    "paragraph": "myeloblastic leukemias with ALL-1 rearrangements. Proc Natl Acad Sci USA 100: 7853 – 7858 Schichman SA, Canaani E, Croce CM (1995) Self fusion of the ALL-1 gene. A new genetic mechanism for acute leukemia. JAMA 273: 571 – 576 Simon JA, Tamkun JW (2002) Programming off and on states in chromatin:",
    "jurnal": "90-6601639a.pdf",
    "processed": "myeloblastic leukemias all1 rearrangements proc natl acad sci usa 100 7853 – 7858 schichman sa canaani e croce cm 1995 self fusion all1 gene new genetic mechanism acute leukemia jama 273 571 – 576 simon ja tamkun jw 2002 programming states chromatin"
  },
  {
    "id": 625,
    "paragraph": "mechanisms of polycomb and trithorax group complexes. Curr Opin Genet Dev 12: 210 – 218 Smith MT, Wang Y, Skibola CF, Slater DJ, Lo Nigro L, Nowell PC, Lange BJ, Felix CA (2002) Low NAD(P)H : quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in",
    "jurnal": "90-6601639a.pdf",
    "processed": "mechanisms polycomb trithorax group complexes curr opin genet dev 12 210 – 218 smith mt wang skibola cf slater dj lo nigro l nowell pc lange bj felix ca 2002 low nadph quinone oxidoreductase activity associated increased risk leukemia mll translocations"
  },
  {
    "id": 626,
    "paragraph": "infants and children. Blood 100: 4590 – 4593 Smith ST, Petruk S, Sedkov Y, Cho E, Tillib S, Canaani E, Mazo A (2004) Modulation of heat shock gene expression by TAC1 chromatin modifying complex. Nat Cell Biol, in press So CW, Karsunky H, Passegue´ E, Cozzio A, Weissman IL, Cleary ML",
    "jurnal": "90-6601639a.pdf",
    "processed": "infants children blood 100 4590 – 4593 smith st petruk sedkov cho e tillib canaani e mazo 2004 modulation heat shock gene expression tac1 chromatin modifying complex nat cell biol press cw karsunky h passegue´ e cozzio weissman il cleary ml"
  },
  {
    "id": 627,
    "paragraph": "(2003a) MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 3: 161 – 171 So CW, Lin M, Ayton PM, Chen EH, Cleary ML (2003b) Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.",
    "jurnal": "90-6601639a.pdf",
    "processed": "2003a mllgas7 transforms multipotent hematopoietic progenitors induces mixed lineage leukemias mice cancer cell 3 161 – 171 cw lin ayton pm chen eh cleary ml 2003b dimerization contributes oncogenic activation mll chimeras acute leukemias"
  },
  {
    "id": 628,
    "paragraph": "Cancer Cell 4: 99 – 110 Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD (2000) Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci USA 97: 4790 – 4795 Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM (1998)",
    "jurnal": "90-6601639a.pdf",
    "processed": "cancer cell 4 99 – 110 strick r strissel pl borgers smith sl rowley jd 2000 dietary bioflavonoids induce cleavage mll gene may contribute infant leukemia proc natl acad sci usa 97 4790 – 4795 swansbury gj slater r bain bj moorman av seckerwalker lm 1998"
  },
  {
    "id": 629,
    "paragraph": "Hematological malignancies with t(9;11)(p21-22;q23): a laboratory and clinical study of 125 cases. Leukemia 12: 792 – 800 Tillib S, Petruk S, Sedkov Y, Kuzin A, Fujioka M, Goto T, Mazo A (1999) Trithorax- and Polycomb-group response elements within an ultra- bithorax transcription maintenance unit consist of closely situated but",
    "jurnal": "90-6601639a.pdf",
    "processed": "hematological malignancies t911p2122q23 laboratory clinical study 125 cases leukemia 12 792 – 800 tillib petruk sedkov kuzin fujioka goto mazo 1999 trithorax polycombgroup response elements within ultra bithorax transcription maintenance unit consist closely situated"
  },
  {
    "id": 630,
    "paragraph": "separable sequences. Mol Cell Biol 19: 5189 – 5202 Tkachuk DC, Kohler S, Cleary ML (1992) Involvement of a homologue of Drosophila trithorax by 11q23 chromosome translocations in acute leukemias. Cell 71: 691 – 700 Turner BM (2000) Histone acetylation and an epigenetic code. BioEssays 22:",
    "jurnal": "90-6601639a.pdf",
    "processed": "separable sequences mol cell biol 19 5189 – 5202 tkachuk dc kohler cleary ml 1992 involvement homologue drosophila trithorax 11q23 chromosome translocations acute leukemias cell 71 691 – 700 turner bm 2000 histone acetylation epigenetic code bioessays 22"
  },
  {
    "id": 631,
    "paragraph": "836 – 845 Wiederschain D, Kawai H, Gu J, Shilatifard A, Yuan Z-M (2003) Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL. Mol Cell Biol 23: 4230 – 4246 Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves",
    "jurnal": "90-6601639a.pdf",
    "processed": "836 – 845 wiederschain kawai h gu j shilatifard yuan zm 2003 molecular basis p53 functional inactivation leukemic protein mllell mol cell biol 23 4230 – 4246 wiemels jl pagnamenta taylor gm eden ob alexander fe greaves"
  },
  {
    "id": 632,
    "paragraph": "MF (1999) A lack of a functional NAD(P)H : quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res 59: 4095 – 4099 Yeoh E-J, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm",
    "jurnal": "90-6601639a.pdf",
    "processed": "mf 1999 lack functional nadph quinone oxidoreductase allele selectively associated pediatric leukemias mll fusions cancer res 59 4095 – 4099 yeoh ej ross shurtleff sa williams wk patel mahfouz r behm"
  },
  {
    "id": 633,
    "paragraph": "FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui C-H, Evans WE, Naeve C, Wong L, Downing JR (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.",
    "jurnal": "90-6601639a.pdf",
    "processed": "fg raimondi sc relling mv patel cheng c campana wilkins zhou x li j liu h pui ch evans naeve c wong l downing jr 2002 classification subtype discovery prediction outcome pediatric acute lymphoblastic leukemia gene expression profiling"
  },
  {
    "id": 634,
    "paragraph": "Cancer Cell 1: 133 – 143 Yokoyama A, Kitabayashi I, Ayton PM, Cleary ML, Ohki M (2002) Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. Blood 100: 3710 – 3718 Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ (1998) MLL, a",
    "jurnal": "90-6601639a.pdf",
    "processed": "cancer cell 1 133 – 143 yokoyama kitabayashi ayton pm cleary ml ohki 2002 leukemia protooncoprotein mll proteolytically processed 2 fragments opposite transcriptional properties blood 100 3710 – 3718 yu bd hanson rd hess jl horning se korsmeyer sj 1998 mll"
  },
  {
    "id": 635,
    "paragraph": "mammalian trithorax-group gene, functions as a transcriptional main- tenance factor in morphogenesis. Proc Natl Acad Sci USA 95: 10632 – 10636 Zeisig BB, Garcia-Cuellar MP, Winkler TH, Slany RK (2003) The oncoprotein MLL – ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell. Oncogene 22:",
    "jurnal": "90-6601639a.pdf",
    "processed": "mammalian trithoraxgroup gene functions transcriptional main tenance factor morphogenesis proc natl acad sci usa 95 10632 – 10636 zeisig bb garciacuellar mp winkler th slany rk 2003 oncoprotein mll – enl disturbs hematopoietic lineage determination transforms biphenotypic lymphoidmyeloid cell oncogene 22"
  },
  {
    "id": 636,
    "paragraph": "1629 – 1637 British Journal of Cancer (2004) 90(4), 756 – 760 & 2004 Cancer Research UK",
    "jurnal": "90-6601639a.pdf",
    "processed": "1629 – 1637 british journal cancer 2004 904 756 – 760 2004 cancer research uk"
  },
  {
    "id": 637,
    "paragraph": "Jurnal Kesehatan Perintis 9 (2) 2022 : 76-81 Contents list available at JKP website Jurnal Kesehatan Perintis Journal homepage: https://jurnal.upertis.ac.id/index.php/JKP Nilai Leukosit, Eritrosit dan Trombosit pada Penderita Leukemia Limfoblastik Akut Pasien Anak Rifka Rahmat1, Djong Hon Tjong2 , Almurdi Almurdi3, Meri Wulandari4",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "jurnal kesehatan perintis 9 2 2022 7681 contents list available jkp website jurnal kesehatan perintis journal homepage httpsjurnalupertisacidindexphpjkp nilai leukosit eritrosit dan trombosit pada penderita leukemia limfoblastik akut pasien anak rifka rahmat1 djong hon tjong2 almurdi almurdi3 meri wulandari4"
  },
  {
    "id": 638,
    "paragraph": "1)Program Studi Bioteknologi Pascasarjana Universitas Andalas, Sumatera Barat, Indonesia 2)Jurusan Biologi Fakultas MIPA Universitas Andalas, Sumatera Barat, Indonesia 3)Fakultas Kedokteran Universitas Andalas, Sumatera Barat, Indonesia 4)Fakultas Kesehatan Universitas Perintis Indonesia, Sumatera Barat, Indonesia Article Information : Received;08 Sept 2022; Accepted 26 Dec 2022; Published online 31 Dec 2022",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "1program studi bioteknologi pascasarjana universitas andalas sumatera barat indonesia 2jurusan biologi fakultas mipa universitas andalas sumatera barat indonesia 3fakultas kedokteran universitas andalas sumatera barat indonesia 4fakultas kesehatan universitas perintis indonesia sumatera barat indonesia article information received08 sept 2022 accepted 26 dec 2022 published online 31 dec 2022"
  },
  {
    "id": 639,
    "paragraph": "*Corresponding author : rifkarahmat@gmail.com ABSTRAK Leukemia merupakan suatu penyakit keganasan sel darah yang ditandai proliferasi leukosit secara tidak terkendali dengan manifestasi adanya sel-sel abnormal. Di Sumatera Barat penyakit ini menunjukkan prevalensi leukemia sebesar 2,4%. Penelitian ini bertujuan untuk melihat gambaran nilai Leukosit, Eritrosit dan Trombosit pada Penderita Leukemia",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "corresponding author rifkarahmatgmailcom abstrak leukemia merupakan suatu penyakit keganasan sel darah yang ditandai proliferasi leukosit secara tidak terkendali dengan manifestasi adanya selsel abnormal di sumatera barat penyakit ini menunjukkan prevalensi leukemia sebesar 24 penelitian ini bertujuan untuk melihat gambaran nilai leukosit eritrosit dan trombosit pada penderita leukemia"
  },
  {
    "id": 640,
    "paragraph": "Limfoblastik Akut (LLA) Pasien Anak di RSUP DR. M. Djamil Padang. Populasi dalam penelitan ini adalah pasien LLA anak yang menjalani kontrol di poliklinik khusus anak dan melakukan pemeriksaan darah di laboratorium sentral RSUP Dr. M Djamil yang terdiri dari 12",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "limfoblastik akut lla pasien anak di rsup dr djamil padang populasi dalam penelitan ini adalah pasien lla anak yang menjalani kontrol di poliklinik khusus anak dan melakukan pemeriksaan darah di laboratorium sentral rsup dr djamil yang terdiri dari 12"
  },
  {
    "id": 641,
    "paragraph": "anak laki-laki dan 6 orang anak perempuan. Sampel adalah pasien yang memenuhi kriteria inklusi. Parameter yang diperiksa adalah trombosit. Prinsip pemeriksaan darah adalah flow cytometri dengan teknik impedance. Dari penelitian yang telah dilakukan bahwa hasil darah pasien LLA anak memperlihatkan rerata jumlah leukosit",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "anak lakilaki dan 6 orang anak perempuan sampel adalah pasien yang memenuhi kriteria inklusi parameter yang diperiksa adalah trombosit prinsip pemeriksaan darah adalah flow cytometri dengan teknik impedance dari penelitian yang telah dilakukan bahwa hasil darah pasien lla anak memperlihatkan rerata jumlah leukosit"
  },
  {
    "id": 642,
    "paragraph": "72,10±155,91 pada laki-laki dan 4,50±3,01 pada perempuan, jumlah eritrosit 4,19±0,84 pada laki-laki dan 3,66±0,81 pada perempuan. Selanjutnya rerata trombosit 280±138,69 pada laki- laki dan 243±1,58 pada perempuan. Dari hasil tersebut bahwa terjadi peningkatan leukosit pada laki-laki (72,10±155,91) sedangkan pada anak perempuan masih dalam rentang normal",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "7210±15591 pada lakilaki dan 450±301 pada perempuan jumlah eritrosit 419±084 pada lakilaki dan 366±081 pada perempuan selanjutnya rerata trombosit 280±13869 pada laki laki dan 243±158 pada perempuan dari hasil tersebut bahwa terjadi peningkatan leukosit pada lakilaki 7210±15591 sedangkan pada anak perempuan masih dalam rentang normal"
  },
  {
    "id": 643,
    "paragraph": "(4,50±3,01) (standar normal leukosit: 4,5-13,5). leukosit, eritrosit, dan Kata kunci : Leukosit, eritrosit, trombosit, leukemia limfoblastik akut, anak ABSTRACT Leukemia is a malignant disease of blood cells which is characterized by irregular and uncontrolled proliferation of leukocytes with the manifestation of abnormal cells in the",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "450±301 standar normal leukosit 45135 leukosit eritrosit dan kata kunci leukosit eritrosit trombosit leukemia limfoblastik akut anak abstract leukemia malignant disease blood cells characterized irregular uncontrolled proliferation leukocytes manifestation abnormal cells"
  },
  {
    "id": 644,
    "paragraph": "peripheral blood. In West Sumatra showed the prevalence of leukemia disease was 2.4%, based on medical record data at the DR. M. Djamil showed an increase in cases of acute lymphoblastic leukemia in children every year. This study aims to describe the value of",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "peripheral blood west sumatra showed prevalence leukemia disease 24 based medical record data dr djamil showed increase cases acute lymphoblastic leukemia children every year study aims describe value"
  },
  {
    "id": 645,
    "paragraph": "leukocytes, erythrocytes and platelets in patients with acute lymphoblastic leukemia in pediatric patients at RSUP DR. M. Djamil Padang. The population in this study were pediatric ALL patients who underwent control at a special pediatric clinic and performed blood tests at",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "leukocytes erythrocytes platelets patients acute lymphoblastic leukemia pediatric patients rsup dr djamil padang population study pediatric patients underwent control special pediatric clinic performed blood tests"
  },
  {
    "id": 646,
    "paragraph": "leukocytes, erythrocytes, and platelets. The principle of blood hematology examination with XN1500i is flow cytometry with impedance technique. From the research that has been done that the blood results of pediatric ALL patients showed an average leukocyte count of 72.10±155.91 in males and 4.50±3.01 in females, the erythrocyte count was 4.19±0.84 in",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "leukocytes erythrocytes platelets principle blood hematology examination xn1500i flow cytometry impedance technique research done blood results pediatric patients showed average leukocyte count 7210±15591 males 450±301 females erythrocyte count 419±084"
  },
  {
    "id": 647,
    "paragraph": "males. and 3.66 ± 0.81 in women. Furthermore, the mean of platelets was 280±138.69 in men and 243±1.58 in women. From these results, there was an increase in leukocytes in men (72.10±155.91) while in girls it was still in the normal range (4.50±3.01) (normal standard of",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "males 366 ± 081 women furthermore mean platelets 280±13869 men 243±158 women results increase leukocytes men 7210±15591 girls still normal range 450±301 normal standard"
  },
  {
    "id": 648,
    "paragraph": "leukocytes: 4.5-13.5) . Keywords : Leukocytes, erythrocytes, platelets, acute lymphoblastic leukemia, children PENDAHULUAN Leukemia faktor termasuk penyebab merupakan penyakit keganasan sel darah yang ditandai dengan proliferasi leukosit secara tidak teratur dan tidak terkendali dengan manifestasi adanya sel-sel abnormal dalam darah tepi.",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "leukocytes 45135 keywords leukocytes erythrocytes platelets acute lymphoblastic leukemia children pendahuluan leukemia faktor termasuk penyebab merupakan penyakit keganasan sel darah yang ditandai dengan proliferasi leukosit secara tidak teratur dan tidak terkendali dengan manifestasi adanya selsel abnormal dalam darah tepi"
  },
  {
    "id": 649,
    "paragraph": "jenis kanker yang Leukemia menyerang banyak usia dan masih merupakan utama kematian diseluruh dunia. Prevalensi leukemia pada tahun 2018 di seluruh negara dijumpai 2,4% kasus baru dan 3,2% kasus kematian. Berdasarkan data American Cancer Society (ACS) menunjukkan peningkatan kasus leukemia pada tahun",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "jenis kanker yang leukemia menyerang banyak usia dan masih merupakan utama kematian diseluruh dunia prevalensi leukemia pada tahun 2018 di seluruh negara dijumpai 24 kasus baru dan 32 kasus kematian berdasarkan data american cancer society acs menunjukkan peningkatan kasus leukemia pada tahun"
  },
  {
    "id": 650,
    "paragraph": "2016 sampai 2017 di Amerika Serikat. Kasus baru sekitar 60.140 kasus, dengan kematian 24.500 kasus pada tahun 2016, dan pada tahun 2018 didapat sekitar 60.300 kasus baru dengan kematian 24.370. Pada tahun 2019 terdapat 61.780 kasus baru dan 22.840 kasus kematian (ACS, 2019).",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "2016 sampai 2017 di amerika serikat kasus baru sekitar 60140 kasus dengan kematian 24500 kasus pada tahun 2016 dan pada tahun 2018 didapat sekitar 60300 kasus baru dengan kematian 24370 pada tahun 2019 terdapat 61780 kasus baru dan 22840 kasus kematian acs 2019"
  },
  {
    "id": 651,
    "paragraph": "Leukemia Limfoblastik Akut (LLA) merupakan keganasan akibat mutasi somatik sel progenitor limfoid pada salah satu dari beberapa tahap perkembangan limfoblast di proliferasi dan akumulasi sumsum tersebut dapat menyebabkan penekanan hematopoesis yang mengakibatkan terjadinya anemia, neutropenia dan trombositopenia. Proliferasi limfoblast dapat terjadi pada beberapa",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "leukemia limfoblastik akut lla merupakan keganasan akibat mutasi somatik sel progenitor limfoid pada salah satu dari beberapa tahap perkembangan limfoblast di proliferasi dan akumulasi sumsum tersebut dapat menyebabkan penekanan hematopoesis yang mengakibatkan terjadinya anemia neutropenia dan trombositopenia proliferasi limfoblast dapat terjadi pada beberapa"
  },
  {
    "id": 652,
    "paragraph": "jaringan ekstrameduler seperti bold liver, limpa, kelenjar getah bening Gejala klinis LLA diantaranya adalah rasa lelah, kulit terlihat terjadi lebam, demam, mudah pendarahan atau mimisan, pembesaran kelenjar limfa serta nyeri tulang.Leukemia limfoblastik akut (LLA) berkembang dengan cepat dan berakibat fatal dalam beberapa",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "jaringan ekstrameduler seperti bold liver limpa kelenjar getah bening gejala klinis lla diantaranya adalah rasa lelah kulit terlihat terjadi lebam demam mudah pendarahan atau mimisan pembesaran kelenjar limfa serta nyeri tulangleukemia limfoblastik akut lla berkembang dengan cepat dan berakibat fatal dalam beberapa"
  },
  {
    "id": 653,
    "paragraph": "tulang. Proses minggu atau bulan jika (Hunger & Mullighan, 2015) tidak diobati. Di Indonesia, menurut WHO pada tahun 2019 menunjukkan angka kejadian leukemia sebanyak 35.870 kasus dalam lima tahun terakhir dengan kematian mencapai 11.314 (WHO, 2019). Sumatera Barat jiwa menunjukkan prevalensi leukemia sebesar",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "tulang proses minggu atau bulan jika hunger mullighan 2015 tidak diobati di indonesia menurut pada tahun 2019 menunjukkan angka kejadian leukemia sebanyak 35870 kasus dalam lima tahun terakhir dengan kematian mencapai 11314 2019 sumatera barat jiwa menunjukkan prevalensi leukemia sebesar"
  },
  {
    "id": 654,
    "paragraph": "2,4%, yang merupakan kejadian terbanyak kedua setelah provinsi Yogyakarta 4,9% (Riskesdas, 2018). Berdasarkan data rekam medis di rumah sakit M djamil menunjukkan peningkatan kasus limfoblastik akut pada anak setiap tahunnya. Tahun 2016 terdapat 51 anak yang terkena LLA. Selanjutnya pada tahun 2017 didapatkan 89",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "24 yang merupakan kejadian terbanyak kedua setelah provinsi yogyakarta 49 riskesdas 2018 berdasarkan data rekam medis di rumah sakit djamil menunjukkan peningkatan kasus limfoblastik akut pada anak setiap tahunnya tahun 2016 terdapat 51 anak yang terkena lla selanjutnya pada tahun 2017 didapatkan 89"
  },
  {
    "id": 655,
    "paragraph": "kasus baru dan terjadi peningkatan dengan didapatkan 142 kasus baru. (Rekam Medis RSUP Dr. M. Djamil Padang, 2019). tahun 2018 leukemia Leukemia limfoblastik akut merupakan jenis kanker anak terbanyak dan dapat jenis kelamin dan menyerang berbagai tingkatan usia di dunia. Jenis leukemia",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "kasus baru dan terjadi peningkatan dengan didapatkan 142 kasus baru rekam medis rsup dr djamil padang 2019 tahun 2018 leukemia leukemia limfoblastik akut merupakan jenis kanker anak terbanyak dan dapat jenis kelamin dan menyerang berbagai tingkatan usia di dunia jenis leukemia"
  },
  {
    "id": 656,
    "paragraph": "limfoblastik akut (LLA) ditemukan sekitar 74% pada anak-anak, dimana banyak terjadi di usia 0-14 tahun. Insidensi puncak kedua terjadi pada dewasa tua, diatas usia 40 tahun. Manifestasi klinis LLA pada umumnya adalah demam, pendarahan, tulang dan lesu, nyeri wajah pucat, persendian, pembesaran hati, limpa dan",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "limfoblastik akut lla ditemukan sekitar 74 pada anakanak dimana banyak terjadi di usia 014 tahun insidensi puncak kedua terjadi pada dewasa tua diatas usia 40 tahun manifestasi klinis lla pada umumnya adalah demam pendarahan tulang dan lesu nyeri wajah pucat persendian pembesaran hati limpa dan"
  },
  {
    "id": 657,
    "paragraph": "77 Jurnal Kesehatan Perintis 9 (2) 2022 : 76-81 paparan lingkungan. Anak dengan cacat genetik (Sindrom Down, Sindrom Bloom, neutropenia kongenital, Anemia Fancoti, anemia Diamond-Blackfan dan Diskeratosis kongenital) mempunyai kemungkinan lebih tinggi untuk menderita leukemia anak (Isnaini dan Tuntun, 2016). tulang. Gejala",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "77 jurnal kesehatan perintis 9 2 2022 7681 paparan lingkungan anak dengan cacat genetik sindrom sindrom bloom neutropenia kongenital anemia fancoti anemia diamondblackfan dan diskeratosis kongenital mempunyai kemungkinan lebih tinggi untuk menderita leukemia anak isnaini dan tuntun 2016 tulang gejala"
  },
  {
    "id": 658,
    "paragraph": "Gejala klinis LLA pada umumnya adalah anemia, trombositopenia dan leukopenia yang merupakan kegagalan dari proses hematopoesis. Namun pada anak-anak, sekitar 40-50% gejala klinis yang muncul adalah nyeri pada tulang sendi atau artalgia yang disebabkan karna terjadinya infiltrasi ke periosteum, tulang sendi dan perluasan",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "gejala klinis lla pada umumnya adalah anemia trombositopenia dan leukopenia yang merupakan kegagalan dari proses hematopoesis namun pada anakanak sekitar 4050 gejala klinis yang muncul adalah nyeri pada tulang sendi atau artalgia yang disebabkan karna terjadinya infiltrasi ke periosteum tulang sendi dan perluasan"
  },
  {
    "id": 659,
    "paragraph": "rongga sumsum lainnya adalah nyeri punggung, hal ini disebabkan karena adanya massa intradural dan mesti diwaspadai kemungkinan patah tulang belakang. Sekitar 16% penderita LLA pada fraktur vertebral saat anak didapatkan diagnosis, 55% nyeri punggung dan 35% keduanya. penderita mengalami Limfadenopati, dan",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "rongga sumsum lainnya adalah nyeri punggung hal ini disebabkan karena adanya massa intradural dan mesti diwaspadai kemungkinan patah tulang belakang sekitar 16 penderita lla pada fraktur vertebral saat anak didapatkan diagnosis 55 nyeri punggung dan 35 keduanya penderita mengalami limfadenopati dan"
  },
  {
    "id": 660,
    "paragraph": "splenomegali merupakan manifestasi leukemia ekstrameduler. Hepatosplenomegali muncul pada dua pertiga pasien dan biasanya tidak disadari (asymptomatic). Limfadenopati biasanya tidak terasa sakit namun bisa teraba secara lokal atau general (Boer, and Boer, 2017). hepatomegali pada juga disebabkan oleh Prekursor sel-B Leukemia Limfoblastik",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "splenomegali merupakan manifestasi leukemia ekstrameduler hepatosplenomegali muncul pada dua pertiga pasien dan biasanya tidak disadari asymptomatic limfadenopati biasanya tidak terasa sakit namun bisa teraba secara lokal atau general boer boer 2017 hepatomegali pada juga disebabkan oleh prekursor selb leukemia limfoblastik"
  },
  {
    "id": 661,
    "paragraph": "Akut (BCP-LLA) merupakan keganasan paling umum pada anak yang disebabkan oleh ekspansi progenitor B-limfoid yang tidak terkontrol di sumsum tulang. Penyakit translokasi ini kromosom dan akan terlihat jika progenitor leukemia mengakumulasi sejumlah delesi gen dan mutasi yang akan mendorong perkembangan penyakit. Meskipun protokol",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "akut bcplla merupakan keganasan paling umum pada anak yang disebabkan oleh ekspansi progenitor blimfoid yang tidak terkontrol di sumsum tulang penyakit translokasi ini kromosom dan akan terlihat jika progenitor leukemia mengakumulasi sejumlah delesi gen dan mutasi yang akan mendorong perkembangan penyakit meskipun protokol"
  },
  {
    "id": 662,
    "paragraph": "pengobatan dengan pendekatan survival jangka panjang telah mendekati 90%, namun pasien relaps masih menimbulkan tantangan klinis yang signifikan (Hunger dan Mullighan, 2015). upaya Kejadian LLA pada anak yang terus meningkat memerlukan yang mutakhir untuk menekan penyakit ini. Upaya tersebut sudah banyak dilakukan oleh",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "pengobatan dengan pendekatan survival jangka panjang telah mendekati 90 namun pasien relaps masih menimbulkan tantangan klinis yang signifikan hunger dan mullighan 2015 upaya kejadian lla pada anak yang terus meningkat memerlukan yang mutakhir untuk menekan penyakit ini upaya tersebut sudah banyak dilakukan oleh"
  },
  {
    "id": 663,
    "paragraph": "praktisi dan peneliti seperti pendekatan molekuler dengan mencari berbagai gen yang berhubungan dengan penyakit agar terapi dapat dilakukan dengan lebih efektif, supaya angka kesembuhan lebih baik. jumlah trombosit Hasil penelitian Munthe menunjukkan distribusi pasien anak penderita LLA berdasarkan karakteristik jumlah trombosit",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "praktisi dan peneliti seperti pendekatan molekuler dengan mencari berbagai gen yang berhubungan dengan penyakit agar terapi dapat dilakukan dengan lebih efektif supaya angka kesembuhan lebih baik jumlah trombosit hasil penelitian munthe menunjukkan distribusi pasien anak penderita lla berdasarkan karakteristik jumlah trombosit"
  },
  {
    "id": 664,
    "paragraph": "lebih banyak yang mengalami adalah yaitu kelainan trombositopenia sebanyak 36 orang (43,9%) dan trombositosis sebanyak 7 orang (8,5%) yang mana ditemukan sebanyak 15 orang tanda-tanda perdarahan yang terdapat mengalami kelainan jumlah hb, dan leukosit (Munthe and Jeremia, 2021). Sementara penelitian Alfani menunjukkan bahwa kadar",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "lebih banyak yang mengalami adalah yaitu kelainan trombositopenia sebanyak 36 orang 439 dan trombositosis sebanyak 7 orang 85 yang mana ditemukan sebanyak 15 orang tandatanda perdarahan yang terdapat mengalami kelainan jumlah hb dan leukosit munthe jeremia 2021 sementara penelitian alfani menunjukkan bahwa kadar"
  },
  {
    "id": 665,
    "paragraph": "eritrosit pada terapi yang dilakukan selama enam minggu mengalami hasil yang normal. Tetapi setelah terapi jangka panjang kadar eritrosit mengalami penurunan. Penurunan terapi sehingga tersebut mengakibatkan hematologi. Kadar leukosit setelah terapi mengalami kenaikan sebesar >50.000/µL, karena tubuh pasien sedang melawan infeksi yang terjadi",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "eritrosit pada terapi yang dilakukan selama enam minggu mengalami hasil yang normal tetapi setelah terapi jangka panjang kadar eritrosit mengalami penurunan penurunan terapi sehingga tersebut mengakibatkan hematologi kadar leukosit setelah terapi mengalami kenaikan sebesar 50000µl karena tubuh pasien sedang melawan infeksi yang terjadi"
  },
  {
    "id": 666,
    "paragraph": "baik dari penyakitnya (LLA) ataupun akibat dari terapi.Kadar trombosit setelah terapi mengalami penurunan sebesar <30.000/ mm3 Penurunan terjadi akibat kemoterapi yang sedang dijalani oleh pasien (Alfani, 2021). terjadi akibat gangguan tersebut Penelitian ini bertujuan untuk melihat gambaran nilai Leukosit, Eritrosit dan",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "baik dari penyakitnya lla ataupun akibat dari terapikadar trombosit setelah terapi mengalami penurunan sebesar 30000 mm3 penurunan terjadi akibat kemoterapi yang sedang dijalani oleh pasien alfani 2021 terjadi akibat gangguan tersebut penelitian ini bertujuan untuk melihat gambaran nilai leukosit eritrosit dan"
  },
  {
    "id": 667,
    "paragraph": "Trombosit Leukemia pada Penderita Limfoblastik Akut (LLA) Pasien Anak di RSUP DR. M. Djamil Padang karena pada pasien anak penderita LLA lebih banyak yang mengalami kelainan jumlah trombosit dan eritrosit, namun tidak lebih banyak (lebih sedikit). METODE PENELITIAN inklusi yaitu dengan",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "trombosit leukemia pada penderita limfoblastik akut lla pasien anak di rsup dr djamil padang karena pada pasien anak penderita lla lebih banyak yang mengalami kelainan jumlah trombosit dan eritrosit namun tidak lebih banyak lebih sedikit metode penelitian inklusi yaitu dengan"
  },
  {
    "id": 668,
    "paragraph": "Populasi dalam penelitan ini adalah pasien LLA anak yang menjalani kontrol di poliklinik khusus anak dan melakukan pemeriksaan darah di laboratorium sentral RSUP Dr. M Djamil sebanyak 50 orang Sampel adalah pasien yang memenuhi identifikasi kriteria mengenai identitas dan riwayat LLA pasien,",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "populasi dalam penelitan ini adalah pasien lla anak yang menjalani kontrol di poliklinik khusus anak dan melakukan pemeriksaan darah di laboratorium sentral rsup dr djamil sebanyak 50 orang sampel adalah pasien yang memenuhi identifikasi kriteria mengenai identitas dan riwayat lla pasien"
  },
  {
    "id": 669,
    "paragraph": "78 Jurnal Kesehatan Perintis 9 (2) 2022 : 76-81 berdasarkan Sampel yang sudah dikumpulkan diperiksa parameter hematologi dengan menggunakan alat hematology analyzer yaitu, sysmex XN1500i di laboratorium Sentral RSUP Dr. Mdjamil. Prosedur Standard pemeriksaan Operasional Procedur yang dijalankan oleh tersebut. Parameter yang",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "78 jurnal kesehatan perintis 9 2 2022 7681 berdasarkan sampel yang sudah dikumpulkan diperiksa parameter hematologi dengan menggunakan alat hematology analyzer yaitu sysmex xn1500i di laboratorium sentral rsup dr mdjamil prosedur standard pemeriksaan operasional procedur yang dijalankan oleh tersebut parameter yang"
  },
  {
    "id": 670,
    "paragraph": "laboratorium leukosit, eritrosit, dan diperiksa adalah trombosit. Prinsip pemeriksaan darah hematologi dengan alat XN1500i adalah flow cytometri dengan teknik impedance, dimana cairan darah yang masuk dalam saluran pengukuran diukur berdasarkan kapasitas energi listrik yang dihasilkan dari setiap sel yang masuk.Pemeriksaan hematologi",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "laboratorium leukosit eritrosit dan diperiksa adalah trombosit prinsip pemeriksaan darah hematologi dengan alat xn1500i adalah flow cytometri dengan teknik impedance dimana cairan darah yang masuk dalam saluran pengukuran diukur berdasarkan kapasitas energi listrik yang dihasilkan dari setiap sel yang masukpemeriksaan hematologi"
  },
  {
    "id": 671,
    "paragraph": "dilakukan dengan beberapa tahapan diantaranya: pertama seluruh sampel yang telah disiapkan diinkubasi ke dalam suhu kamar (25-30oC), kedua adalah dengan melakukan homogenisasi sampel agar kadar EDTA yang tercampur dengan cairan darah dapat merata sehingga tidak terjadi bekuan. Selanjutnya diisi identitas sampel",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "dilakukan dengan beberapa tahapan diantaranya pertama seluruh sampel yang telah disiapkan diinkubasi ke dalam suhu kamar 2530oc kedua adalah dengan melakukan homogenisasi sampel agar kadar edta yang tercampur dengan cairan darah dapat merata sehingga tidak terjadi bekuan selanjutnya diisi identitas sampel"
  },
  {
    "id": 672,
    "paragraph": "berdasarkan data sampel. Lalu dimasukkan ke dalam rak sampel untuk dibaca oleh alat. Terakhir, hasil darah yang telah diukur dengan alat hematology Analyzer XN1500i dianalisis parameter berdasarkan hematologi yang telah ditentukan. HASIL DAN PEMBAHASAN sampel Karakteristik penelitian berdasarkan Umur, Jenis Kelamin, Jumlah",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "berdasarkan data sampel lalu dimasukkan ke dalam rak sampel untuk dibaca oleh alat terakhir hasil darah yang telah diukur dengan alat hematology analyzer xn1500i dianalisis parameter berdasarkan hematologi yang telah ditentukan hasil dan pembahasan sampel karakteristik penelitian berdasarkan umur jenis kelamin jumlah"
  },
  {
    "id": 673,
    "paragraph": "leukosit, eritrosit, trombosit dan Tabel 1. Tabel karakteristik penelitian Leukemia Limfoblastik Akut pasien anak berdasarkan jenis kelamin, umur, dan immunofenotipe LLA (n=18) Jenis Kelamin Jumlah Persentase (%) Rerata Umur (th/sd) Immunofenotipe (%) LLA-B LLA-T Laki-laki Perempuan 12,00 6,00 66,67 33,33 7,2±4,3",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "leukosit eritrosit trombosit dan tabel 1 tabel karakteristik penelitian leukemia limfoblastik akut pasien anak berdasarkan jenis kelamin umur dan immunofenotipe lla n18 jenis kelamin jumlah persentase rerata umur thsd immunofenotipe llab llat lakilaki perempuan 1200 600 6667 3333 72±43"
  },
  {
    "id": 674,
    "paragraph": "7,7±4,5 16 (88,89) 2 (11,11) Immunofenotipe LLA (tabel 1). Tabel 1 menunjukkan bahwa LLA-B lebih banyak dibanding LLA-T. Penelitian Hurtz et al., (2019) mengatakan sekitar 85% LLA sel B ditemukan pada anak-anak dengan jumlah kasus yang sama baik laki- laki maupun perempuan. Dan sekitar 15%",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "77±45 16 8889 2 1111 immunofenotipe lla tabel 1 tabel 1 menunjukkan bahwa llab lebih banyak dibanding llat penelitian hurtz et al 2019 mengatakan sekitar 85 lla sel b ditemukan pada anakanak dengan jumlah kasus yang sama baik laki laki maupun perempuan dan sekitar 15"
  },
  {
    "id": 675,
    "paragraph": "LLA adalah jenis sel T. Rata-rata penderita LLA yang mengalami banyak keluhan yakni diumur 17 Tahun kebawah (Prashanti dan Rena, 2020). Pada pasien anak penderita LLA lebih banyak yang mengalami kelainan jumlah trombosit dan eritrosit, namun lebih juga yang mengalami kelainan",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "lla adalah jenis sel ratarata penderita lla yang mengalami banyak keluhan yakni diumur 17 tahun kebawah prashanti dan rena 2020 pada pasien anak penderita lla lebih banyak yang mengalami kelainan jumlah trombosit dan eritrosit namun lebih juga yang mengalami kelainan"
  },
  {
    "id": 676,
    "paragraph": "banyak jumlah hb dan (Munthe dan Jeremia, 2021). leukosit limfoblastik Hasil pemeriksaan hematologi pasien terhadap leukemia parameter leukosit, eritrosit dan trombosit berdasarkan jenis kelamin dapat dilihat pada tabel 2. akut dan laki-laki Hasil darah pasien LLA anak pada tabel 2 memperlihatkan rerata jumlah leukosit",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "banyak jumlah hb dan munthe dan jeremia 2021 leukosit limfoblastik hasil pemeriksaan hematologi pasien terhadap leukemia parameter leukosit eritrosit dan trombosit berdasarkan jenis kelamin dapat dilihat pada tabel 2 akut dan lakilaki hasil darah pasien lla anak pada tabel 2 memperlihatkan rerata jumlah leukosit"
  },
  {
    "id": 677,
    "paragraph": "72,10±155,91 pada laki-laki dan 4,50±3,01 pada perempuan, jumlah eritrosit 4,19±0,84 pada pada perempuan. Selanjutnya rerata trombosit 280±138,69 pada laki-laki dan 243±1,58 pada perempuan. Terjadi peningkatan leukosit pada laki-laki yaitu 72,10±155,91 sedangkan pada perempuan berada dalam rentang normal 4,50±3,01 (normal: 4,5-13,5) (tabel 2).",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "7210±15591 pada lakilaki dan 450±301 pada perempuan jumlah eritrosit 419±084 pada pada perempuan selanjutnya rerata trombosit 280±13869 pada lakilaki dan 243±158 pada perempuan terjadi peningkatan leukosit pada lakilaki yaitu 7210±15591 sedangkan pada perempuan berada dalam rentang normal 450±301 normal 45135 tabel 2"
  },
  {
    "id": 678,
    "paragraph": "3,66±0,81 Tabel 3 memperlihatkan nilai leukosit pasien LLA saat didiagnosis. Terdapat 13(72,22%) pasien LLA dengan leukosit normal, 2(11,11%) dan 3(16,67%) dengan leukopenia atau penurunan jumlah leukosit. Proliferasi teratur merupakan ciri khas LLA, dimana terdapat kondisi normal, leukositosis dan leukopenia leukosit secara",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "366±081 tabel 3 memperlihatkan nilai leukosit pasien lla saat didiagnosis terdapat 137222 pasien lla dengan leukosit normal 21111 dan 31667 dengan leukopenia atau penurunan jumlah leukosit proliferasi teratur merupakan ciri khas lla dimana terdapat kondisi normal leukositosis dan leukopenia leukosit secara"
  },
  {
    "id": 679,
    "paragraph": "tidak Tabel 2. Rarata Nilai Leukosit pasien Leukemia Limfoblastik Akut Anak berdasarkan jenis kelamin. Jenis Kelamin L (n=12) P (n=6) Rerata Nilai Trombosit*** (x103/mm3) 280±138,69 243±1,58 Rerata Nilai Eritrosit** (x106/ul) 4,19±0,84 3,66±0,81 Rerata Nilai Leukosit* (x103/mm3) 72,10±155,91 4,50±3,01 Ket : Nilai Normal *: 4,5-13,5; **: 4,0-5,40; ***: 150-450",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "tidak tabel 2 rarata nilai leukosit pasien leukemia limfoblastik akut anak berdasarkan jenis kelamin jenis kelamin l n12 p n6 rerata nilai trombosit x103mm3 280±13869 243±158 rerata nilai eritrosit x106ul 419±084 366±081 rerata nilai leukosit x103mm3 7210±15591 450±301 ket nilai normal 45135 40540 150450"
  },
  {
    "id": 680,
    "paragraph": "rentang nilai leukosit yang ditampilkan pada Tabel 3. Jumlah leukosit normal berada pada rentang 4,5-13,5; sedangkan jumlah leukosit >13,5 dikatakan peningkatan jumlah leukosit atau leukositosis dan jika jumlah leukosit berada dibawah 4,5 maka dikatakan penurunan leukosit atau leukopenia. Jumlah leukosit yang berada >50000 dikatakan",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "rentang nilai leukosit yang ditampilkan pada tabel 3 jumlah leukosit normal berada pada rentang 45135 sedangkan jumlah leukosit 135 dikatakan peningkatan jumlah leukosit atau leukositosis dan jika jumlah leukosit berada dibawah 45 maka dikatakan penurunan leukosit atau leukopenia jumlah leukosit yang berada 50000 dikatakan"
  },
  {
    "id": 681,
    "paragraph": "hiperleukositosis. Dalam penelitian ini didapatkan 2 pasien dengan leukositosis bahkan jumlah leukosit yang sangat tinggi atau hiperleukositosis. Hiperleukositosis terjadi akibat gangguan dari sumsum tulang leukosit yang beredar dalam sehingga sirkulasi berlebihan. Hiperleukositosis terjadi pada 9- 13% kasus LLA anak. Hal ini",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "hiperleukositosis dalam penelitian ini didapatkan 2 pasien dengan leukositosis bahkan jumlah leukosit yang sangat tinggi atau hiperleukositosis hiperleukositosis terjadi akibat gangguan dari sumsum tulang leukosit yang beredar dalam sehingga sirkulasi berlebihan hiperleukositosis terjadi pada 9 13 kasus lla anak hal ini"
  },
  {
    "id": 682,
    "paragraph": "dapat mengakibatkan viskositas darah meningkat, agregasi dan trombus sel blast pada mikrosirkulasi. Hiperleukositosis juga onkologi merupakan kegawatdaruratan pada pasien tersebut. Meskipun tidak semua kasus LLA didapatkan hiperleukositosis, namun kejadian ini perlu ditangani segera karena dapat menyebabkan efek yang buruk, pada penderita hingga menjadi",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "dapat mengakibatkan viskositas darah meningkat agregasi dan trombus sel blast pada mikrosirkulasi hiperleukositosis juga onkologi merupakan kegawatdaruratan pada pasien tersebut meskipun tidak semua kasus lla didapatkan hiperleukositosis namun kejadian ini perlu ditangani segera karena dapat menyebabkan efek yang buruk pada penderita hingga menjadi"
  },
  {
    "id": 683,
    "paragraph": "pemicu kematian pada pasien LLA anak. (Chiaretti, S. et al. 2016). KESIMPULAN dan laki-laki 4,50±3,01 Rerata jumlah leukosit 72,10±155,91 pada pada perempuan, jumlah eritrosit 4,19±0,84 pada laki-laki dan 3,66±0,81 pada perempuan. Rerata trombosit 280±138,69 pada laki-laki dan 243±1,58 pada perempuan. Terjadi",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "pemicu kematian pada pasien lla anak chiaretti et al 2016 kesimpulan dan lakilaki 450±301 rerata jumlah leukosit 7210±15591 pada pada perempuan jumlah eritrosit 419±084 pada lakilaki dan 366±081 pada perempuan rerata trombosit 280±13869 pada lakilaki dan 243±158 pada perempuan terjadi"
  },
  {
    "id": 684,
    "paragraph": "peningkatan laki-laki (72,10±155,91) sedangkan pada anak perempuan masih dalam rentang normal (4,50±3,01) (standar normal leukosit: 4,5- 13,5). leukosit pada UCAPAN TERIMA KASIH Ucapan terima kasih pada Laboratorium RSUP Dr. M Djamil Padang dan Parameter Leukosit Leukositosis >13,5 2(11,11%) Leukopenia <4,5 3(16,67%)",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "peningkatan lakilaki 7210±15591 sedangkan pada anak perempuan masih dalam rentang normal 450±301 standar normal leukosit 45 135 leukosit pada ucapan terima kasih ucapan terima kasih pada laboratorium rsup dr djamil padang dan parameter leukosit leukositosis 135 21111 leukopenia 45 31667"
  },
  {
    "id": 685,
    "paragraph": "Laboratorium Genetik Universitas Andalas yang telah membantu penelitian ini selesai. REFERENSI Alfani, H. 2021. Literature Review: Gambaran Hasil Pemeriksaan Eritrosit, Leukosit Dan Trombosit Pada Pasien Anak Dengan Leukemia Limfoblastik Akut (LLA) Setelah Terapi. Universitas ‘Aisyiyah Yogyakarta. American Cancer Society (ACS). 2019.",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "laboratorium genetik universitas andalas yang telah membantu penelitian ini selesai referensi alfani h 2021 literature review gambaran hasil pemeriksaan eritrosit leukosit dan trombosit pada pasien anak dengan leukemia limfoblastik akut lla setelah terapi universitas ‘ aisyiyah yogyakarta american cancer society acs 2019"
  },
  {
    "id": 686,
    "paragraph": "Acute Lymphoblastic Leukemia (ALL). Cancer.org. 1.800.27.2345 12 February 2019. Boer, J. M. and den Boer, M. L. 2017. BCR- ABL1-like lymphoblastic acute leukaemia: From bench to bedside’, European Journal of Cancer. Elsevier Ltd, 82, pp. 203–218. Chiaretti, S. et al. 2016. Advances in the",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "acute lymphoblastic leukemia cancerorg 1800272345 12 february 2019 boer j den boer l 2017 bcr abl1like lymphoblastic acute leukaemia bench bedside ’ european journal cancer elsevier ltd 82 pp 203–218 chiaretti et al 2016 advances"
  },
  {
    "id": 687,
    "paragraph": "Genetics and Therapy of Acute Lymphoblastic Leukemia’, American Oncology Society Educational Book, 36, pp. e314–e322. Clinical of leukemia lymphoblastic Hunger, S. P. dan Mullighan, C. G. 2015. Acute in children’, New England Journal of Medicine. Massachussetts Medical Hurtz, C. et al. 2019. Rationale for targeting",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "genetics therapy acute lymphoblastic leukemia ’ american oncology society educational book 36 pp e314–e322 clinical leukemia lymphoblastic hunger p dan mullighan c g 2015 acute children ’ new england journal medicine massachussetts medical hurtz c et al 2019 rationale targeting"
  },
  {
    "id": 688,
    "paragraph": "BCL6 acute in MLL-rearranged lymphoblastic leukemia’, Genes and Development. Cold Spring Harbor Laboratory Press, 33(17–18), pp. 1265– 1279. Iacobucci, I. and Mullighan, C. G. 2017. Genetic basis of acute lymphoblastic leukemia’, Journal of Clinical Oncology, 35(9), pp. 975–983. Isnaini, S. A. dan Tuntun, M. 2016. Kejadian",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "bcl6 acute mllrearranged lymphoblastic leukemia ’ genes development cold spring harbor laboratory press 3317–18 pp 1265– 1279 iacobucci mullighan c g 2017 genetic basis acute lymphoblastic leukemia ’ journal clinical oncology 359 pp 975–983 isnaini dan tuntun 2016 kejadian"
  },
  {
    "id": 689,
    "paragraph": "Anemia Pada Penderita Leukemia Limfoblastik Akut di RSUD Dr. H. Abdul Moeloek Provinsi Lampung. Jurnal Analis Kesehatan : Volume 5 No. 1 Maret 2016. Munthe dan Jeremia, J. P. 2021. Gambaran Jumlah Trombosit Pada Penyakit Leukemia Limfoblastik Akut (LLA) Anak di RSUP Haji Adam Malik Medan Tahun",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "anemia pada penderita leukemia limfoblastik akut di rsud dr h abdul moeloek provinsi lampung jurnal analis kesehatan volume 5 1 maret 2016 munthe dan jeremia j p 2021 gambaran jumlah trombosit pada penyakit leukemia limfoblastik akut lla anak di rsup haji adam malik medan tahun"
  },
  {
    "id": 690,
    "paragraph": "Sanglah Denpasar Tahun 2014-2015. Jurnal Medika Udayana, Vol. 9 No. 4 April 2020. Rekam Medis RSUP Dr. M. Djamil Padang, Leukimia. Pemeriksaan 2019. Laboratorium Analis. Padang. Riskesdas. Laporan Provinsi Sumatera Barat. Badan Penelitian dan 2018. Pengembangan Kesehatan. Smith OP, Hann IM. 2006. Clinical",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "sanglah denpasar tahun 20142015 jurnal medika udayana vol 9 4 april 2020 rekam medis rsup dr djamil padang leukimia pemeriksaan 2019 laboratorium analis padang riskesdas laporan provinsi sumatera barat badan penelitian dan 2018 pengembangan kesehatan smith op hann im 2006 clinical"
  },
  {
    "id": 691,
    "paragraph": "features and therapy of lymphoblastic leukemia. In: Arceci RJ, editor. Pediatric Hematology (Third edition). Oxford: Blackwell Publishing Ltd Terwilliger, T. and Abdul-Hay, M. 2017. leukemia: a Acute review and 2017 comprehensive update’, Blood cancer journal, 7(6), p. e577. lymphoblastic WHO. 2019. Kematian Akibat Leukemia di",
    "jurnal": "admin2.RifkaRahmat.pdf",
    "processed": "features therapy lymphoblastic leukemia arceci rj editor pediatric hematology third edition oxford blackwell publishing ltd terwilliger abdulhay 2017 leukemia acute review 2017 comprehensive update ’ blood cancer journal 76 p e577 lymphoblastic 2019 kematian akibat leukemia di"
  },
  {
    "id": 692,
    "paragraph": "British Journal of Cancer (1996) 73, 1141-1147 © 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 % Childhood leukaemias in New Zealand: time trends and ethnic differences JD Dockerty, B Cox and MG Cockburn Department of Preventive and Social Medicine, University of Otago Medical School, PO Box 913, Dunedin, New Zealand.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "british journal cancer 1996 73 11411147 © 1996 stockton press rights reserved 0007092096 1200 childhood leukaemias new zealand time trends ethnic differences jd dockerty b cox mg cockburn department preventive social medicine university otago medical school po box 913 dunedin new zealand"
  },
  {
    "id": 693,
    "paragraph": "Summary Registrations from the New Zealand Cancer Registry were used to examine time trends in the incidence of leukaemias among children aged 0- 14. There was a statistically significant increase in the incidence of leukaemia among children aged 0-4 during 1953-57 to 1988 -90. In this age group, the recorded",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "summary registrations new zealand cancer registry used examine time trends incidence leukaemias among children aged 0 14 statistically significant increase incidence leukaemia among children aged 04 195357 1988 90 age group recorded"
  },
  {
    "id": 694,
    "paragraph": "incidence rate increased from 4.89 per 100 000 person -years in 1953 -57 to 7.92 in 1988 -90. During 1973 -77 to 1988-90 (and probably in earlier years), the increase was due to an increase in acute lymphoblastic leukaemia (ALL). The trends were unlikely to be due to changes in diagnosis or case ascertainment. The",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "incidence rate increased 489 per 100 000 person years 1953 57 792 1988 90 1973 77 198890 probably earlier years increase due increase acute lymphoblastic leukaemia trends unlikely due changes diagnosis case ascertainment"
  },
  {
    "id": 695,
    "paragraph": "childhood leukaemia trends might be related to trends in family size, maternal age, socioeconomic level or exposure to infections. However, there are uncertainties about the importance of these factors or about their trends. The incidence of acute non-lymphoblastic leukaemia (ANLL) decreased between 1968-72 and 1988-",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "childhood leukaemia trends might related trends family size maternal age socioeconomic level exposure infections however uncertainties importance factors trends incidence acute nonlymphoblastic leukaemia anll decreased 196872 1988"
  },
  {
    "id": 696,
    "paragraph": "90. The time trends highlight the likely importance of environmental factors in the aetiology of childhood leukaemias in New Zealand. The risk of ALL was lower in the Maori than in the non-Maori population (relative risk Maori/non-Maori 0.74). The risk of ANLL was higher among Maori (relative risk 1.84).",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "90 time trends highlight likely importance environmental factors aetiology childhood leukaemias new zealand risk lower maori nonmaori population relative risk maorinonmaori 074 risk anll higher among maori relative risk 184"
  },
  {
    "id": 697,
    "paragraph": "Keywords: leukaemia; child; epidemiology; trend; aetiology; incidence al., Information on the incidence of childhood leukaemias has been collected by the New Zealand Cancer Registry since 1948. Until 1972, the Registry was mainly public hospital based, but since then it has included registrations from",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "keywords leukaemia child epidemiology trend aetiology incidence al information incidence childhood leukaemias collected new zealand cancer registry since 1948 1972 registry mainly public hospital based since included registrations"
  },
  {
    "id": 698,
    "paragraph": "private hospitals, death certificates and autopsy reports (Cooke et al., 1988). The Registry was regarded as being truly population based from 1974 (Cooke et 1988). Childhood leukaemias are serious diseases, and affected children would usually have been admitted to hospital. Data",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "private hospitals death certificates autopsy reports cooke et al 1988 registry regarded truly population based 1974 cooke et 1988 childhood leukaemias serious diseases affected children would usually admitted hospital data"
  },
  {
    "id": 699,
    "paragraph": "on completeness suggest that registration of lymphatic and haematopoietic cancers was nearly complete from about 1953-55 (Medical Statistics Branch of the Department of Health, 1955). (Department Maori ethnicity 1992). Children of sole At the 1991 census, 14% of the childhood (ages 0-14)",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "completeness suggest registration lymphatic haematopoietic cancers nearly complete 195355 medical statistics branch department health 1955 department maori ethnicity 1992 children sole 1991 census 14 childhood ages 014"
  },
  {
    "id": 700,
    "paragraph": "residents of New Zealand were reported as being of solely Maori ethnicity, and a further 7% were reported as being of mixed New Zealand of Statistics, Island ethnic groups made up 5% of the resident childhood population of Cancer registration data for Maori are thought to have been more",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "residents new zealand reported solely maori ethnicity 7 reported mixed new zealand statistics island ethnic groups made 5 resident childhood population cancer registration data maori thought"
  },
  {
    "id": 701,
    "paragraph": "closely related to sole Maori ethnicity than to mixed (plus sole) Maori ethnicity (New Zealand Health Information Service, 1995). 'Non-Maori' has been used in cancer registry publications to refer to the rest of the population, which is predominantly of British origin. Pacific Islanders form a",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "closely related sole maori ethnicity mixed plus sole maori ethnicity new zealand health information service 1995 nonmaori used cancer registry publications refer rest population predominantly british origin pacific islanders form"
  },
  {
    "id": 702,
    "paragraph": "small part of the non-Maori population. total Statistics, (Department 1993a). Pacific In a review of 49 countries, the highest age-standardised incidence rate for childhood acute lymphoblastic leukaemia (ALL) (ages 0- 14) was found in Costa Rica (4.5 per 100 000 person-years) (Parkin et al., 1988a). The rates of childhood",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "small part nonmaori population total statistics department 1993a pacific review 49 countries highest agestandardised incidence rate childhood acute lymphoblastic leukaemia ages 0 14 found costa rica 45 per 100 000 personyears parkin et al 1988a rates childhood"
  },
  {
    "id": 703,
    "paragraph": "ALL in New Zealand were 3.2 per 100000 person-years among non -Maori and 1.3 per 100 000 person -years among Maori (Parkin et al., 1988a). New Zealand Maori had the highest rate of childhood ANLL of any population studied (Parkin et al., 1988b), while non-Maori New Zealanders had",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "new zealand 32 per 100000 personyears among non maori 13 per 100 000 person years among maori parkin et al 1988a new zealand maori highest rate childhood anll population studied parkin et al 1988b nonmaori new zealanders"
  },
  {
    "id": 704,
    "paragraph": "the highest rate of any predominantly white population (Parkin et al., 1988a). Three studies of time trends in multiple countries have included data from the New Zealand Cancer Registry, and have given different results. Breslow and Langholz (1983) found no significant trends in the incidence of childhood",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "highest rate predominantly white population parkin et al 1988a three studies time trends multiple countries included data new zealand cancer registry given different results breslow langholz 1983 found significant trends incidence childhood"
  },
  {
    "id": 705,
    "paragraph": "leukaemia for Maori or non-Maori over 1962-66 to 1972- Correspondence: J Dockerty Received 20 June 1995; revised 14 November 1995; accepted 23 November 1995 76. Draper et al. (1994) calculated the cumulative incidence of combined childhood leukaemias among non-Maori as 66.0",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "leukaemia maori nonmaori 196266 1972 correspondence j dockerty received 20 june 1995 revised 14 november 1995 accepted 23 november 1995 76 draper et al 1994 calculated cumulative incidence combined childhood leukaemias among nonmaori 660"
  },
  {
    "id": 706,
    "paragraph": "(per 100 000) in 1972-76, with this decreasing to 62.1 in 1978-82, then increasing to 79.0 in 1983-87. Statistical tests for trends were not presented. Coleman et al. (1993) found that boys in New Zealand (but not girls) had a statistically",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "per 100 000 197276 decreasing 621 197882 increasing 790 198387 statistical tests trends presented coleman et al 1993 found boys new zealand girls statistically"
  },
  {
    "id": 707,
    "paragraph": "significant increase in the cumulative risk of childhood leukaemia during the period 1965-85. The present study examines the recorded incidence of childhood leukaemia in New Zealand between 1948 and 1990. Materials and methods Childhood (ages 0- 14 years) leukaemia registrations were",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "significant increase cumulative risk childhood leukaemia period 196585 present study examines recorded incidence childhood leukaemia new zealand 1948 1990 materials methods childhood ages 0 14 years leukaemia registrations"
  },
  {
    "id": 708,
    "paragraph": "obtained from the New Zealand Cancer Registry for each year during 1948 - 90. For the division into the different types [ALL, acute non-lymphoblastic leukaemia (ANLL), other and unspecified leukaemias] only the period 1968 -90 was used. The International Classification of Diseases (ICD) codes used",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "obtained new zealand cancer registry year 1948 90 division different types acute nonlymphoblastic leukaemia anll unspecified leukaemias period 1968 90 used international classification diseases icd codes used"
  },
  {
    "id": 709,
    "paragraph": "for the leukaemia registrations in this study were decided after discussions with haematologists and Cancer Registry staff, and after referring to the literature. In classifying the leukaemias, the aim was to ensure comparability across the time periods studied. During 1948 - 67, the combined leukaemias were",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "leukaemia registrations study decided discussions haematologists cancer registry staff referring literature classifying leukaemias aim ensure comparability across time periods studied 1948 67 combined leukaemias"
  },
  {
    "id": 710,
    "paragraph": "represented by the following ICD-7 codes: 204.0, 204.1, 204.2, 204.3 and 204.4. During 1968 -77, the different types of childhood leukaemia were assigned to the following ICD-8 codes: ALL 204.0, 207.0 and 204.9; ANLL 205.0, 206.0 and 207.2; 'other and unspecified' 204.1, 205.1, 206.1, 206.9, 207.1",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "represented following icd7 codes 2040 2041 2042 2043 2044 1968 77 different types childhood leukaemia assigned following icd8 codes 2040 2070 2049 anll 2050 2060 2072 unspecified 2041 2051 2061 2069 2071"
  },
  {
    "id": 711,
    "paragraph": "and 207.9. During 1978-87 (ICD-9) and 1988-90 (ICD-9 CM), the codes were: ALL 204.0, 204.8, 204.9 and 208.0; ANLL 205.0, 206.0, 207.0, 207.2, 205.3 and 206.8; 'other and unspecified' 204.1, 204.2, 205.1, 205.2, 205.8, 205.9, 206.1, 206.2, 206.9, 208.1, 208.2, 208.8 and 208.9. Childhood tumours",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "2079 197887 icd9 198890 icd9 cm codes 2040 2048 2049 2080 anll 2050 2060 2070 2072 2053 2068 unspecified 2041 2042 2051 2052 2058 2059 2061 2062 2069 2081 2082 2088 2089 childhood tumours"
  },
  {
    "id": 712,
    "paragraph": "such as acute unspecified leukaemias were classified under acute lymphoblastic leukaemia because of the high likelihood that most were in this category in earlier years. The study was restricted to children who had New Zealand residential addresses at registration. The correct birth date was available for 380 of the 444",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "acute unspecified leukaemias classified acute lymphoblastic leukaemia high likelihood category earlier years study restricted children new zealand residential addresses registration correct birth date available 380 444"
  },
  {
    "id": 713,
    "paragraph": "children diagnosed between 1976 and 1987 as their birth certificates were being used in another study. The ages of 27 children were changed on the basis of the more accurate birthdates. For eight children (all with ALL), the change was sufficient to alter which 5 year age group the child was in.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "children diagnosed 1976 1987 birth certificates used another study ages 27 children changed basis accurate birthdates eight children change sufficient alter 5 year age group child"
  },
  {
    "id": 714,
    "paragraph": "For one child, the corrected age was over 14 years, so the ft 1142 Childhood leukaemias in New Zealand JD Dockerty et a! child was excluded. For five of the eight, the corrections shifted the age group from that of 5 -9 to 0 -4. For one, the",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "one child corrected age 14 years ft 1142 childhood leukaemias new zealand jd dockerty et child excluded five eight corrections shifted age group 5 9 0 4 one"
  },
  {
    "id": 715,
    "paragraph": "shift was from ages 10- 14 to ages 0 -4, and for the remaining child, the shift was from ages 10 -14 to 5 -9. The numbers of deaths from childhood leukaemia (1948- 90) were obtained from the New Zealand Health Information",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "shift ages 10 14 ages 0 4 remaining child shift ages 10 14 5 9 numbers deaths childhood leukaemia 1948 90 obtained new zealand health information"
  },
  {
    "id": 716,
    "paragraph": "Service (for 1948 and 1949); and from annual publications of the Ministry of Health. Annual mean population estimates, based on national census data, were used for the calculation of age -specific and age- standardised rates. Registration rates were calculated for all the leukaemias combined (1948 -90); and for ALL,",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "service 1948 1949 annual publications ministry health annual mean population estimates based national census data used calculation age specific age standardised rates registration rates calculated leukaemias combined 1948 90"
  },
  {
    "id": 717,
    "paragraph": "ANLL, and other and unspecified leukaemias (1968 -90). Five year age groups were used, and the standard was the world standard population (Waterhouse et al., 1976). The rates were calculated using pooled quinquennial periods, except that the last period was truncated to 3 years (1988-",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "anll unspecified leukaemias 1968 90 five year age groups used standard world standard population waterhouse et al 1976 rates calculated using pooled quinquennial periods except last period truncated 3 years 1988"
  },
  {
    "id": 718,
    "paragraph": "90). Rates were calculated for both sexes, Maori and non- Maori, and the total population. For combined leukaemias and ALL, the age group 0-4 was further subdivided, into the year' and '1 -4 years'. ages quinquennial age-specific and age-standardised rates, and",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "90 rates calculated sexes maori non maori total population combined leukaemias age group 04 subdivided year 1 4 years ages quinquennial agespecific agestandardised rates"
  },
  {
    "id": 719,
    "paragraph": "heterogeneity among the age-specific rates, were examined 1987). The 95% (Mantel, confidence intervals for the age -standardised rates were based on the binomial approximation (Armitage and Berry, for 1987). Age -specific individual years of age using pooled data (1981-90 for ALL and 1968-90 for ANLL). Relative risks for sex and",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "heterogeneity among agespecific rates examined 1987 95 mantel confidence intervals age standardised rates based binomial approximation armitage berry 1987 age specific individual years age using pooled data 198190 196890 anll relative risks sex"
  },
  {
    "id": 720,
    "paragraph": "ethnic group were also calculated, using pooled data from 1968-90. These were age-adjusted relative risks with 95% confidence intervals, calculated using the formulae described by Breslow (1984). 1963; Armitage and Berry, rates were calculated Trends in incidence 'under 1 Results The number of children registered with leukaemia of any type",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "ethnic group also calculated using pooled data 196890 ageadjusted relative risks 95 confidence intervals calculated using formulae described breslow 1984 1963 armitage berry rates calculated trends incidence 1 results number children registered leukaemia type"
  },
  {
    "id": 721,
    "paragraph": "during 1948-90 was 1409, among whom ALL (as defined in Materials and methods) was the commonest type. Of the 851 registrations for leukaemias during 1968-90, 633 (74%) were for ALL, 179 (21%) for ANLL and 39 (5%) for other and unspecified leukaemias. Ninety-five per cent of those classified",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "194890 1409 among defined materials methods commonest type 851 registrations leukaemias 196890 633 74 179 21 anll 39 5 unspecified leukaemias ninetyfive per cent classified"
  },
  {
    "id": 722,
    "paragraph": "as ALL had ICD codes corresponding to acute lymphatic or acute lymphoid leukaemias. Five per cent had ICD codes corresponding to other or unspecified lymphatic or acute leukaemias. In the first 5 years (1948 -52), the ratio of registrations to deaths was 0.86 (Table I). In every other",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "icd codes corresponding acute lymphatic acute lymphoid leukaemias five per cent icd codes corresponding unspecified lymphatic acute leukaemias first 5 years 1948 52 ratio registrations deaths 086 table every"
  },
  {
    "id": 723,
    "paragraph": "registrations outnumbered deaths, and the ratio period, increased continually, from 1.03 in 1953 - 57 to 2.62 in 1988 -90. Trends in the incidence of combined leukaemias In view of the incomplete registrations during 1948 - 52 (Table I), the presented results and the tests for trend for combined",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "registrations outnumbered deaths ratio period increased continually 103 1953 57 262 1988 90 trends incidence combined leukaemias view incomplete registrations 1948 52 table presented results tests trend combined"
  },
  {
    "id": 724,
    "paragraph": "leukaemias were restricted to the period 1953 -57 to 1988 -90. There was a continued increase in the recorded incidence of combined leukaemias during 1953 - 57 to 1968 - 72, then a drop to The from 1968 - 72 to 1973 - 77, followed by a further increase from",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "leukaemias restricted period 1953 57 1988 90 continued increase recorded incidence combined leukaemias 1953 57 1968 72 drop 1968 72 1973 77 followed increase"
  },
  {
    "id": 725,
    "paragraph": "1973 - 77 to 1983 - 87 (to a higher rate than before), with similar rates in 1983 -87 and 1988 -90 (Figure 1 and Table II). 1988 -90 1953 -57 (P=0.02). which explained In the total population, for all leukaemias combined, there",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "1973 77 1983 87 higher rate similar rates 1983 87 1988 90 figure 1 table ii 1988 90 1953 57 p002 explained total population leukaemias combined"
  },
  {
    "id": 726,
    "paragraph": "was a significant increase in the age- standardised rates annual during percentage increase in the rate, relative to the average rate, was 0.81 % per year. There was significant heterogeneity among the rates in the different age groups (P= 0.02). Children aged under 5 years had a highly significant increase",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "significant increase age standardised rates annual percentage increase rate relative average rate 081 per year significant heterogeneity among rates different age groups p 002 children aged 5 years highly significant increase"
  },
  {
    "id": 727,
    "paragraph": "the age- (P = 0.0004), standardised rates (Table II), while no overall trends were found for children aged 5-9 and 10-14. The increase in incidence for children under 5 years of age was present among boys (P=0.01), girls (P=0.01), and non-Maori",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "age p 00004 standardised rates table ii overall trends found children aged 59 1014 increase incidence children 5 years age present among boys p001 girls p001 nonmaori"
  },
  {
    "id": 728,
    "paragraph": "(P = 0.0003). For age groups 5-9 and 10- 14, there were no overall trends in boys or girls or among non-Maori. For Maori, there was no overall statistical trend in the rates among those aged under 5 years, and for ages 5 -9 and 10-",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "p 00003 age groups 59 10 14 overall trends boys girls among nonmaori maori overall statistical trend rates among aged 5 years ages 5 9 10"
  },
  {
    "id": 729,
    "paragraph": "14 there were too few Maori children with leukaemia to allow interpretation of the trends. trend the in Trends in the incidence of ALL and ANLL Different trends in incidence were observed for ALL and 1 and Table III). The age -standardised",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "14 maori children leukaemia allow interpretation trends trend trends incidence anll different trends incidence observed 1 table iii age standardised"
  },
  {
    "id": 730,
    "paragraph": "ANLL (Figure incidence rate of ALL decreased from 1968-72 to 1973-77, then increased steadily in each quinquennium until 1988-90 (the rates were 3.22, 2.74, 3.22, 3.67 and 4.10 per 100 000 person-years). The incidence of ANLL decreased steadily between 1968-72 and 1978-82, then increased in 1983-87,",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "anll figure incidence rate decreased 196872 197377 increased steadily quinquennium 198890 rates 322 274 322 367 410 per 100 000 personyears incidence anll decreased steadily 196872 197882 increased 198387"
  },
  {
    "id": 731,
    "paragraph": "and decreased to a low point in 1988-90 (the rates were 1.13, 0.97, 0.78, 0.92 and 0.59 per 100 000 person-years). For ALL, the trend tests showed that the increase in the age-standardised rate was significant (1968-72 to 1988-90, P = 0.02) and there was no significant departure from",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "decreased low point 198890 rates 113 097 078 092 059 per 100 000 personyears trend tests showed increase agestandardised rate significant 196872 198890 p 002 significant departure"
  },
  {
    "id": 732,
    "paragraph": "5 4 3 2 1 0 U) cn a)c 0 L- U) a) CR @ '2R~~~969> 9~ 79~& 790 Time period Figure 1 Age- standardised registration for childhood leukaemias in New Zealand, ages 0- 14. *, All leukaemias combined; EI, acute lymphoblastic leukaemia; 0, acute non-",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "5 4 3 2 1 0 u cn ac 0 l u cr 2r969 9 79 790 time period figure 1 age standardised registration childhood leukaemias new zealand ages 0 14 leukaemias combined ei acute lymphoblastic leukaemia 0 acute non"
  },
  {
    "id": 733,
    "paragraph": "lymphoblastic leukaemia; 0, other and unspecified leukaemias. rates Table I Childhood leukaemia registrations and deathsa in New Zealand, 1948-90: all leukaemias combined, for ages 0-14 Time period 1948- 52 1953 -57 1958-62 1963 -67 1968 -72 1973- 77 1978-82 1983-87 1988 -90",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "lymphoblastic leukaemia 0 unspecified leukaemias rates table childhood leukaemia registrations deathsa new zealand 194890 leukaemias combined ages 014 time period 1948 52 1953 57 195862 1963 67 1968 72 1973 77 197882 198387 1988 90"
  },
  {
    "id": 734,
    "paragraph": "Number of registrations 90 126 151 191 207 175 169 190 110 Number of deaths 105 122 144 160 159 134 91 104 42 Ratio of registrations to deaths 0.86 1.03 1.05 1.19 1.30 1.31 1.86 1.83 2.62 aIn 1948, only non-Maori were included in the deaths. In all other years, Maori and non-Maori deaths were included.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "number registrations 90 126 151 191 207 175 169 190 110 number deaths 105 122 144 160 159 134 91 104 42 ratio registrations deaths 086 103 105 119 130 131 186 183 262 1948 nonmaori included deaths years maori nonmaori deaths included"
  },
  {
    "id": 735,
    "paragraph": "Childhood leukaemias in New Zealand JD Dockerty et al $_ 1143 Table II Childhood leukaemia registrations (numbers, and rates per 100000 person-years) in New Zealand, 1953-90: combined leukaemias Time period 1953 -57 1958-62 1963-67 1968-72 1973-77 1978 -82 1983-87 1988-90 0-4",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "childhood leukaemias new zealand jd dockerty et al 1143 table ii childhood leukaemia registrations numbers rates per 100000 personyears new zealand 195390 combined leukaemias time period 1953 57 195862 196367 196872 197377 1978 82 198387 198890 04"
  },
  {
    "id": 736,
    "paragraph": "Rate 4.89 4.93 6.63 6.91 5.58 6.62 7.92 7.92 No. 62 71 102 103 83 85 100 63 5-9 No. 39 53 53 57 48 46 43 29 Age group (years) Rate 3.39 4.13 3.62 3.69 3.13 3.12 3.33 3.87 No.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "rate 489 493 663 691 558 662 792 792 62 71 102 103 83 85 100 63 59 39 53 53 57 48 46 43 29 age group years rate 339 413 362 369 313 312 333 387"
  },
  {
    "id": 737,
    "paragraph": "25 27 36 47 44 38 47 18 10-14 Rate 2.72 2.30 2.75 3.19 2.78 2.50 3.18 2.30 ASR, age-standardised rate; CI, confidence interval. 0-14 Crude rate ASR (with 95% CI) 3.78 3.88 4.43 4.59 3.80 3.95 4.71 4.73 3.70 (3.41-3.99)",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "25 27 36 47 44 38 47 18 1014 rate 272 230 275 319 278 250 318 230 asr agestandardised rate ci confidence interval 014 crude rate asr 95 ci 378 388 443 459 380 395 471 473 370 341399"
  },
  {
    "id": 738,
    "paragraph": "3.84 (3.57-4.11) 4.38 (4.11-4.66) 4.64 (4.36-4.93) 3.87 (3.61-4.12) 4.13 (3.85-4.41) 4.87 (4.56-5.18) 4.78 (4.38-5.18) No. 126 151 191 207 175 169 190 110 Table III Childhood leukaemia registrations (numbers and rates per 100000 person-years) by age, sex, and ethnic group, 1968-90:",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "384 357411 438 411466 464 436493 387 361412 413 385441 487 456518 478 438518 126 151 191 207 175 169 190 110 table iii childhood leukaemia registrations numbers rates per 100000 personyears age sex ethnic group 196890"
  },
  {
    "id": 739,
    "paragraph": "by type of leukaemia 0-4 Rate No. No. Age group (years) 5-9 10-14 Rate No. Rate 0-14 ASR No. Sex Boys ASR Girls ASR No. No. Maori ASR Non-Maori ASR No. Ethnic group Leukaemia type, time period ALL 1968-72 1973-77 1978-82",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "type leukaemia 04 rate age group years 59 1014 rate rate 014 asr sex boys asr girls asr maori asr nonmaori asr ethnic group leukaemia type time period 196872 197377 197882"
  },
  {
    "id": 740,
    "paragraph": "1983 -87 1988-90 ANLL 1968-72 1973-77 1978-82 1983-87 1988-90 72 60 71 81 56 23 19 12 15 5 4.83 4.04 5.53 6.42 7.04 1.54 1.28 0.93 1.19 0.63 46 34 36 31 26 9 12 9 8 3 2.98 2.22",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "1983 87 198890 anll 196872 197377 197882 198387 198890 72 60 71 81 56 23 19 12 15 5 483 404 553 642 704 154 128 093 119 063 46 34 36 31 26 9 12 9 8 3 298 222"
  },
  {
    "id": 741,
    "paragraph": "2.44 2.40 3.47 0.58 0.78 0.61 0.62 0.40 25 30 23 30 12 19 13 12 14 6 1.69 1.89 1.51 2.03 1.53 1.29 0.82 0.79 0.95 0.77 3.22 2.74 3.22 3.67 4.10 1.13 0.97 0.78 0.92 0.59 79 79 78",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "244 240 347 058 078 061 062 040 25 30 23 30 12 19 13 12 14 6 169 189 151 203 153 129 082 079 095 077 322 274 322 367 410 113 097 078 092 059 79 79 78"
  },
  {
    "id": 742,
    "paragraph": "90 45 30 24 21 18 9 3.49 3.45 3.76 4.58 3.83 1.30 1.03 0.97 0.87 0.74 64 45 52 52 49 21 20 12 19 5 2.94 2.01 2.66 2.71 4.39 0.96 0.90 0.58 0.97 0.44 21 5 13 13",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "90 45 30 24 21 18 9 349 345 376 458 383 130 103 097 087 074 64 45 52 52 49 21 20 12 19 5 294 201 266 271 439 096 090 058 097 044 21 5 13 13"
  },
  {
    "id": 743,
    "paragraph": "10 7 8 11 10 2 Other/unspecified 1968-72 2 1973-77 1 1978-82 2 2 1983 -87 1988-90 1 ASR, age -standardised rate; ALL, acute lymphoblastic leukaemia; ANLL, acute non-lymphoblastic leukaemia. 0.40 0.14 0.19 0.14 0.08 0.54 0.27 0.16 0.32 0.25 0.13",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "10 7 8 11 10 2 otherunspecified 196872 2 197377 1 197882 2 2 1983 87 198890 1 asr age standardised rate acute lymphoblastic leukaemia anll acute nonlymphoblastic leukaemia 040 014 019 014 008 054 027 016 032 025 013"
  },
  {
    "id": 744,
    "paragraph": "0.13 0.07 0.31 0.00 0.29 0.16 0.14 0.28 0.09 0.18 0.18 0.08 0.43 0.09 0.20 0.06 0.20 0.20 0.00 8 4 2 4 2 2 2 1 4 0 9 3 4 3 1 4 4 2 8 1 3 1",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "013 007 031 000 029 016 014 028 009 018 018 008 043 009 020 006 020 020 000 8 4 2 4 2 2 2 1 4 0 9 3 4 3 1 4 4 2 8 1 3 1"
  },
  {
    "id": 745,
    "paragraph": "3 3 0 3.80 0.88 2.41 2.63 3.45 1.28 1.40 1.94 1.91 0.70 0.36 0.18 0.40 0.37 0.35 122 119 117 129 84 44 36 22 27 12 11 6 4 9 1 3.14 3.02 3.34 3.83 4.20 1.11 0.90 0.60",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "3 3 0 380 088 241 263 345 128 140 194 191 070 036 018 040 037 035 122 119 117 129 84 44 36 22 27 12 11 6 4 9 1 314 302 334 383 420 111 090 060"
  },
  {
    "id": 746,
    "paragraph": "0.77 0.57 0.28 0.15 0.10 0.27 0.05 linearity, although the rate during 1973-77 was lower than the rates in adjacent time periods. The annual percentage increase in the rate of ALL (1968-90), relative to the average rate, was 2.2% per year. The increase in total leukaemias",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "077 057 028 015 010 027 005 linearity although rate 197377 lower rates adjacent time periods annual percentage increase rate 196890 relative average rate 22 per year increase total leukaemias"
  },
  {
    "id": 747,
    "paragraph": "among children aged under 5 years (Table II), at least during 1968-90, was due to a significant (P = 0.002) increase in ALL for this age group (Table III). There were no overall trends in ALL incidence for ages 5 -9 or 10-14.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "among children aged 5 years table ii least 196890 due significant p 0002 increase age group table iii overall trends incidence ages 5 9 1014"
  },
  {
    "id": 748,
    "paragraph": "During 1968-72 to 1988-90, boys aged under 5 years had a significant increase in incidence (P = 0.04), and there was no significant departure from linearity. Girls aged under 5 years also had an increase in ALL incidence, but the trend was",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "196872 198890 boys aged 5 years significant increase incidence p 004 significant departure linearity girls aged 5 years also increase incidence trend"
  },
  {
    "id": 749,
    "paragraph": "significantly rate was 4.7 per 100 000 person-years in 1968-72, 2.6 in 1973-77, 4.9 in 1978-82, 4.2 in 1983-87 and 8.0 in 1988-90). Non-Maori aged under 5 years had a highly significant increase in the incidence of ALL (P = 0.004).",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "significantly rate 47 per 100 000 personyears 196872 26 197377 49 197882 42 198387 80 198890 nonmaori aged 5 years highly significant increase incidence p 0004"
  },
  {
    "id": 750,
    "paragraph": "(the incidence non-linear In the total population, there were too few children aged under 1 year for the interpretation of time trends, though ALL incidence rates for ages under 1 year increased steadily in each quinquennium from 1968-72 to 1988-90. Children",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "incidence nonlinear total population children aged 1 year interpretation time trends though incidence rates ages 1 year increased steadily quinquennium 196872 198890 children"
  },
  {
    "id": 751,
    "paragraph": "aged 1-4 experienced a significant increase in the incidence of ALL over the period (P=0.007). For ANLL, there was a significant linear decrease in the incidence rates (1968-72 to 1988-90; Figure 1 and Table III). There was no significant heterogeneity among the",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "aged 14 experienced significant increase incidence period p0007 anll significant linear decrease incidence rates 196872 198890 figure 1 table iii significant heterogeneity among"
  },
  {
    "id": 752,
    "paragraph": "decrease, different relative to the average rate, was 3.8% per year. In boys, no overall trend in the age- standardised rates was found, and in girls the trend tests could not be interpreted owing to small numbers. Among non-Maori, there was a significant linear",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "decrease different relative average rate 38 per year boys overall trend age standardised rates found girls trend tests could interpreted owing small numbers among nonmaori significant linear"
  },
  {
    "id": 753,
    "paragraph": "decrease in the incidence of ANLL (P=0.02). groups. The annual percentage age Age, sex and ethnic group For ALL, the age distribution by individual years of age showed a marked peak at ages 2-3 (the peak incidence rate was 9.3 per 100 000 person-years). Sequential data for",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "decrease incidence anll p002 groups annual percentage age age sex ethnic group age distribution individual years age showed marked peak ages 23 peak incidence rate 93 per 100 000 personyears sequential data"
  },
  {
    "id": 754,
    "paragraph": "combined leukaemias revealed that the size of the age peak increased during 1953-90. The early ALL age peak was marked for both Maori and non-Maori. The pooled (1968- 90) ALL registration rates for each 5 year age group (per 100 000 person-years) were: ages 0-4 Maori 6.0, non-Maori",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "combined leukaemias revealed size age peak increased 195390 early age peak marked maori nonmaori pooled 1968 90 registration rates 5 year age group per 100 000 personyears ages 04 maori 60 nonmaori"
  },
  {
    "id": 755,
    "paragraph": "6.6; ages 5-9 Maori 1.6, non-Maori 2.9; and ages 10-14 Maori 1.0, non-Maori 1.8. For ANLL, although the total numbers were small, there were clearly high registration rates at ages 0-2, with lower rates at ages 3-14 years. Compared with girls, boys had a greater risk of both types",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "66 ages 59 maori 16 nonmaori 29 ages 1014 maori 10 nonmaori 18 anll although total numbers small clearly high registration rates ages 02 lower rates ages 314 years compared girls boys greater risk types"
  },
  {
    "id": 756,
    "paragraph": "of leukaemia (statistically significant for ALL but not for ANLL, Table IV). Maori had a lower risk of ALL and a higher risk of ANLL than non-Maori (Table IV). The crude relative risks (boys vs girls and Maori vs non-Maori) were",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "leukaemia statistically significant anll table iv maori lower risk higher risk anll nonmaori table iv crude relative risks boys vs girls maori vs nonmaori"
  },
  {
    "id": 757,
    "paragraph": "virtually identical to the age-adjusted relative risks. Discussion The most interesting finding was the clear increase in leukaemia incidence rates for children aged 0-4 during 1953-57 to 1988-90 (Table II). During 1973-77 to 1988- 90 (and probably in earlier years), this was due to an increase",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "virtually identical ageadjusted relative risks discussion interesting finding clear increase leukaemia incidence rates children aged 04 195357 198890 table ii 197377 1988 90 probably earlier years due increase"
  },
  {
    "id": 758,
    "paragraph": "in ALL (Table III). The incidence of ANLL decreased during 1968-72 to 1988-90 (Figure 1, Table III). What are the due to explanations trends? masking by other causes of death such as pneumonia in the Underdiagnosis these for 1144 Childhood leukaemias in New Zealand",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "table iii incidence anll decreased 196872 198890 figure 1 table iii due explanations trends masking causes death pneumonia underdiagnosis 1144 childhood leukaemias new zealand"
  },
  {
    "id": 759,
    "paragraph": "JD Dockerty et al Table IV Relative risks for sex and ethnicity, 1968-90: by type of leukaemia, for ages 0 -14 Age-adjusted relative risk boys/girls (95% CI) Age-standardised incidence rate per 100000 person -years Age-standardised incidence rate per 100 000 person -years",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "jd dockerty et al table iv relative risks sex ethnicity 196890 type leukaemia ages 0 14 ageadjusted relative risk boysgirls 95 ci agestandardised incidence rate per 100000 person years agestandardised incidence rate per 100 000 person years"
  },
  {
    "id": 760,
    "paragraph": "Leukaemia type Acute lymphoblastic Acute non-lymphoblastic Boys 3.95 1.01 Girls 2.90 0.84 1.36 (1.16-1.59) 1.27 (0.94-1.70) Maori 2.65 1.55 Non-Maori 3.56 0.83 Age-adjusted relative risk Maori/non-Maori (95% CI) 0.73 (0.57-0.95) 1.84 (1.29-2.62) preantibiotic age (Stewart and Kneale, 1969) may have had",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "leukaemia type acute lymphoblastic acute nonlymphoblastic boys 395 101 girls 290 084 136 116159 127 094170 maori 265 155 nonmaori 356 083 ageadjusted relative risk maorinonmaori 95 ci 073 057095 184 129262 preantibiotic age stewart kneale 1969 may"
  },
  {
    "id": 761,
    "paragraph": "an effect on the accuracy of diagnosis in the early years, but could not account for the continuation of the trends beyond the introduction of antibiotics. separates classification The childhood leukaemias in this study were classified into three types (ALL, ANLL and 'other and unspecified'), based",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "effect accuracy diagnosis early years could account continuation trends beyond introduction antibiotics separates classification childhood leukaemias study classified three types anll unspecified based"
  },
  {
    "id": 762,
    "paragraph": "on ICD site codes. Childhood cancers are better suited to classifications based on morphology rather than site. The the Birch and Marsden (1987) childhood leukaemias into five types (acute lymphocytic, other lymphoid, acute non-lymphocytic, chronic myeloid and based on ICD-O (oncology)",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "icd site codes childhood cancers better suited classifications based morphology rather site birch marsden 1987 childhood leukaemias five types acute lymphocytic lymphoid acute nonlymphocytic chronic myeloid based icdo oncology"
  },
  {
    "id": 763,
    "paragraph": "'other and unspecified'), morphology codes. ICD-O codes have only been used by the New Zealand Cancer Registry since 1978. Site-based classifications were used in this study, and the aim was to enable the two main types of childhood leukaemia (ALL and",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "unspecified morphology codes icdo codes used new zealand cancer registry since 1978 sitebased classifications used study aim enable two main types childhood leukaemia"
  },
  {
    "id": 764,
    "paragraph": "ANLL) to be distinguished, from 1968 onwards. classification separate of leukaemia is considered to have been relatively accurate since the late 1960s in New Zealand (personal communica- tions from D Becroft, C Beresford and J Carter). There may have been some under-reporting of the myeloid leukaemias,",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "anll distinguished 1968 onwards classification separate leukaemia considered relatively accurate since late 1960s new zealand personal communica tions becroft c beresford j carter may underreporting myeloid leukaemias"
  },
  {
    "id": 765,
    "paragraph": "because specialists might have expected children to have lymphoid leukaemias and have classified them as such. Misclassification is likely to have had a moderating effect on the observed trends, rather than an effect that would lead to spurious trends. If anything, one would have expected a",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "specialists might expected children lymphoid leukaemias classified misclassification likely moderating effect observed trends rather effect would lead spurious trends anything one would expected"
  },
  {
    "id": 766,
    "paragraph": "decrease in ALL and an increase in ANLL rather than the converse, which has been found. The trends are therefore unlikely to be related to changes in the diagnosis of the two main types of childhood leukaemia. Histological types the of",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "decrease increase anll rather converse found trends therefore unlikely related changes diagnosis two main types childhood leukaemia histological types"
  },
  {
    "id": 767,
    "paragraph": "is al., that there good Comparable analyses have shown that there were no rates of the significant time trends in the non-Hodgkin's lymphomas in New Zealand childhood during 1953-90 (work in progress). Thus, the leukaemia trends do not seem to be due to diagnostic shifts between",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "al good comparable analyses shown rates significant time trends nonhodgkins lymphomas new zealand childhood 195390 work progress thus leukaemia trends seem due diagnostic shifts"
  },
  {
    "id": 768,
    "paragraph": "ALL and the non-Hodgkin's lymphomas. registration assuming One indication of the quality of a cancer registry is the proportion of cases for which the diagnosis has a histological of basis, registration, and that the histology is accurate. During 1970-79, 100% of the children with ALL and ANLL on",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "nonhodgkins lymphomas registration assuming one indication quality cancer registry proportion cases diagnosis histological basis registration histology accurate 197079 100 children anll"
  },
  {
    "id": 769,
    "paragraph": "the New Zealand Cancer Register had a histological basis for 1988a). There is no published diagnosis (Parkin et earlier information on this for childhood leukaemias in periods. completeness The 5 year survival from childhood leukaemia in Britain was very low (2%) for children diagnosed during 1954-63",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "new zealand cancer register histological basis 1988a published diagnosis parkin et earlier information childhood leukaemias periods completeness 5 year survival childhood leukaemia britain low 2 children diagnosed 195463"
  },
  {
    "id": 770,
    "paragraph": "(Birch et al., 1988), and is not likely to have been higher in New Zealand at the time. The recording of more registrations than deaths in 1953 -57 and in 1958-62 is evidence that case during ascertainment was nearly those ascertainment do not",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "birch et al 1988 likely higher new zealand time recording registrations deaths 1953 57 195862 evidence case ascertainment nearly ascertainment"
  },
  {
    "id": 771,
    "paragraph": "periods. explain the trends. The subsequent increases in the ratio of registrations to deaths (Table I) reflect improvements in treatment over time. Thus, improvements in complete, Researchers from other countries have reported increases in the incidence of ALL among children aged 0-4 or 1-4.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "periods explain trends subsequent increases ratio registrations deaths table reflect improvements treatment time thus improvements complete researchers countries reported increases incidence among children aged 04 14"
  },
  {
    "id": 772,
    "paragraph": "These include studies in Britain 1953-91 (Draper et al., 1994); north-west England 1954 - 77 (Birch et al., 1980; Birch et al., 1981); the Netherlands 1973-86 (temporary increase 1974-82) (Coebergh et al., 1989); and Connecticut 1935-79 (van Hoff et al., 1988). The data from north-west England",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "include studies britain 195391 draper et al 1994 northwest england 1954 77 birch et al 1980 birch et al 1981 netherlands 197386 temporary increase 197482 coebergh et al 1989 connecticut 193579 van hoff et al 1988 data northwest england"
  },
  {
    "id": 773,
    "paragraph": "were recently updated to include 1954-88, and although even there was an overall increase for ages 0- 14, there were no significant time trends for boys or girls aged 1-4 (Blair and Birch, 1994). A study of childhood ALL in Baltimore 1960-",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "recently updated include 195488 although even overall increase ages 0 14 significant time trends boys girls aged 14 blair birch 1994 study childhood baltimore 1960"
  },
  {
    "id": 774,
    "paragraph": "74 (Gordis et al., 1981) did not show an increase for children aged 1 - 4. Two other studies (limited to all leukaemias combined) have shown increases among young children, including a study from Sweden 1958-74 (Ericsson et al., 1978), and one from Denmark 1943-84 (de Nully Brown et",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "74 gordis et al 1981 show increase children aged 1 4 two studies limited leukaemias combined shown increases among young children including study sweden 195874 ericsson et al 1978 one denmark 194384 de nully brown et"
  },
  {
    "id": 775,
    "paragraph": "al., 1989). A study of combined leukaemias in upstate New York (1969-80) did not record a significant change in incidence among boys or girls aged under 5 years (Polednak, 1986). The New Zealand increase was one of the more latter obvious secular trends among young children in",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "al 1989 study combined leukaemias upstate new york 196980 record significant change incidence among boys girls aged 5 years polednak 1986 new zealand increase one latter obvious secular trends among young children"
  },
  {
    "id": 776,
    "paragraph": "decades. For childhood ANLL, temporal decreases in incidence rates have been reported in two other studies: one in Britain 1962-91 (Draper et al., 1994), and another in Japan (Osaka) 1971 -88 (Ajiki et al., 1994). The decrease in Osaka may have",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "decades childhood anll temporal decreases incidence rates reported two studies one britain 196291 draper et al 1994 another japan osaka 1971 88 ajiki et al 1994 decrease osaka may"
  },
  {
    "id": 777,
    "paragraph": "been partly due to changes in the diagnosis or classification of ALL and ANLL, although the authors were of the opinion that most of the leukaemia changes they observed were real (Ajiki et al., 1994). Significant increases have been reported in Queensland 1973-88 (McWhirter and Pet-",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "partly due changes diagnosis classification anll although authors opinion leukaemia changes observed real ajiki et al 1994 significant increases reported queensland 197388 mcwhirter pet"
  },
  {
    "id": 778,
    "paragraph": "roeschevsky, 1991); and among black children in Baltimore 1965-74 (Gordis et al., 1981). Incidence rates of childhood ANLL in the Netherlands 1973 -86 are reported to have been 1989). In north-west relatively constant (Coebergh et al., England 1954-88, there was no significant trend in the",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "roeschevsky 1991 among black children baltimore 196574 gordis et al 1981 incidence rates childhood anll netherlands 1973 86 reported 1989 northwest relatively constant coebergh et al england 195488 significant trend"
  },
  {
    "id": 779,
    "paragraph": "incidence of childhood ANLL (Blair and Birch, 1994). Relevance of time trends to aetiologicalfactors and hypotheses ALL Because ALL was by far the commonest type, the trends in combined leukaemias should mostly reflect trends in the incidence of ALL. Up until 1953 (at least), childhood",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "incidence childhood anll blair birch 1994 relevance time trends aetiologicalfactors hypotheses far commonest type trends combined leukaemias mostly reflect trends incidence 1953 least childhood"
  },
  {
    "id": 780,
    "paragraph": "leukaemia was 'rapidly and universally fatal', and mortality and incidence were equivalent (Draper et al., 1994). If the correct number of incident cases of childhood leukaemia for 1948-52 was 105 (deaths) and not 90 (registrations), the crude incidence rate for 1948-52 would be 3.77 per 100 000",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "leukaemia rapidly universally fatal mortality incidence equivalent draper et al 1994 correct number incident cases childhood leukaemia 194852 105 deaths 90 registrations crude incidence rate 194852 would 377 per 100 000"
  },
  {
    "id": 781,
    "paragraph": "person-years, little different from 3.78 in 1953-57 (Table II). The increase for young children in 1958-62 was minor, but there were clear increases in 1963-67 and 1968-72 (Table II). Incidence dropped between 1968-72 and 1973- 77, then increased again in 1978-82 and 1983-87. Thus the",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "personyears little different 378 195357 table ii increase young children 195862 minor clear increases 196367 196872 table ii incidence dropped 196872 1973 77 increased 197882 198387 thus"
  },
  {
    "id": 782,
    "paragraph": "combined leukaemia results suggest that the incidence of ALL in young children began to increase clearly in 1963-67. The risks of childhood leukaemia from ionising radiation exposure have been established (Doll, 1989). In New Zealand, we have no nuclear power stations or reprocessing plants. A",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "combined leukaemia results suggest incidence young children began increase clearly 196367 risks childhood leukaemia ionising radiation exposure established doll 1989 new zealand nuclear power stations reprocessing plants"
  },
  {
    "id": 783,
    "paragraph": "study of childhood leukaemia incidence rates in Nordic countries in relation to fallout from nuclear weapons testing found no strong overall childhood leukaemia trends (Darby et al., 1992). However, the rates of childhood leukaemia were slightly higher in the late 1960s, when the effect would have",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "study childhood leukaemia incidence rates nordic countries relation fallout nuclear weapons testing found strong overall childhood leukaemia trends darby et al 1992 however rates childhood leukaemia slightly higher late 1960s effect would"
  },
  {
    "id": 784,
    "paragraph": "been greatest (Darby et al., 1992). Fallout from nuclear weapons testing has been monitored in New Zealand by the of National strontium-90 and caesium-137 in cows' milk peaked in 1965 ..... and had decreased to the limits of detection by 1986',",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "greatest darby et al 1992 fallout nuclear weapons testing monitored new zealand national strontium90 caesium137 cows milk peaked 1965 decreased limits detection 1986"
  },
  {
    "id": 785,
    "paragraph": "(Matthews, 1994). Initially (after the 1965 peak), the average radionuclide was less half-life 2 years effect on fallout had a (Matthews, If leukaemia in young children in New Zealand, it would be Laboratory, and 'concentrations of each 1994). than material Radiation",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "matthews 1994 initially 1965 peak average radionuclide less halflife 2 years effect fallout matthews leukaemia young children new zealand would laboratory concentrations 1994 material radiation"
  },
  {
    "id": 786,
    "paragraph": "to in 1946 expected to have led to a peak in incidence soon after 1965, followed by a decline. Thus, the continued increase in the incidence of childhood leukaemia in New Zealand does not appear to be related to fallout. Several case -control studies (and one cohort study) of",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "1946 expected led peak incidence soon 1965 followed decline thus continued increase incidence childhood leukaemia new zealand appear related fallout several case control studies one cohort study"
  },
  {
    "id": 787,
    "paragraph": "childhood leukaemia and electromagnetic field exposures have been reported. While some have shown increased risks, others have not, and no firm conclusions can yet be drawn (Advisory Group on Non-ionising Radiation, 1992; 1994). Detailed data on domestic electricity Ross et al.,",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "childhood leukaemia electromagnetic field exposures reported shown increased risks others firm conclusions yet drawn advisory group nonionising radiation 1992 1994 detailed data domestic electricity ross et al"
  },
  {
    "id": 788,
    "paragraph": "consumption, supplied by Transpower New Zealand, showed a remarkably consistent and continued increase in average annual consumption from 2.5 megawatt hours (MWh) per Domestic household consumption then reached a plateau, remaining between 7.1 1993. The and 7.9 MWh per household from 1977 to",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "consumption supplied transpower new zealand showed remarkably consistent continued increase average annual consumption 25 megawatt hours mwh per domestic household consumption reached plateau remaining 71 1993 79 mwh per household 1977"
  },
  {
    "id": 789,
    "paragraph": "incidence of childhood ALL has followed a different course, so it is unlikely that the leukaemia increases are related to household consumption of electricity (a crude measure of exposure to electromagnetic fields). 8.1 MWh in 1976. In a case-control study, Golding et al. (1990) reported",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "incidence childhood followed different course unlikely leukaemia increases related household consumption electricity crude measure exposure electromagnetic fields 81 mwh 1976 casecontrol study golding et al 1990 reported"
  },
  {
    "id": 790,
    "paragraph": "that babies given drugs (mainly vitamin K) in the neonatal period had an increased risk of childhood cancer. Golding et al. (1992) tested the association in a second study, finding a doubling of the risk of childhood cancer in relation to",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "babies given drugs mainly vitamin k neonatal period increased risk childhood cancer golding et al 1992 tested association second study finding doubling risk childhood cancer relation"
  },
  {
    "id": 791,
    "paragraph": "intramuscular vitamin K administration, but no elevation in risk for oral administration. Three further studies of this issue risks of childhood leukaemia have not found elevated including a cohort following vitamin K administration, study from Sweden (Ekelund et al., 1993), a nested case-",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "intramuscular vitamin k administration elevation risk oral administration three studies issue risks childhood leukaemia found elevated including cohort following vitamin k administration study sweden ekelund et al 1993 nested case"
  },
  {
    "id": 792,
    "paragraph": "control study from the USA (Klebanoff et al., 1993) and a descriptive study (of birth cohorts) from Denmark (Olsen et Health, of Department the al., for use in intramuscular vitamin K had been available neonates in New Zealand since the late 1960s. (K Ronaldson,",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "control study usa klebanoff et al 1993 descriptive study birth cohorts denmark olsen et health department al use intramuscular vitamin k available neonates new zealand since late 1960s k ronaldson"
  },
  {
    "id": 793,
    "paragraph": "given But personal 5000 National Women's Hospital, routinely deliveries per year as early as 1962 (R Howie, personal communication). Thus, some of the New Zealand time trends are consistent with the vitamin K hypothesis. The British time trends for childhood leukaemia in relation to trends in",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "given personal 5000 national womens hospital routinely deliveries per year early 1962 r howie personal communication thus new zealand time trends consistent vitamin k hypothesis british time trends childhood leukaemia relation trends"
  },
  {
    "id": 794,
    "paragraph": "intramuscular vitamin K administration, on the other hand, are probably not consistent with this hypothesis (Draper and Stiller, 1992). vitamin K was with communication). at According 1994). to Childhood ALL has been associated with advanced maternal age in some, but not all, studies (Ross et al.,",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "intramuscular vitamin k administration hand probably consistent hypothesis draper stiller 1992 vitamin k communication according 1994 childhood associated advanced maternal age studies ross et al"
  },
  {
    "id": 795,
    "paragraph": "1994). The median age at which women had their first child in New Zealand increased by 5.7 years between 1962 and 1993, compared with a rise of only 2.1 years for all mothers (rather than new mothers) between these years (Statistics",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "1994 median age women first child new zealand increased 57 years 1962 1993 compared rise 21 years mothers rather new mothers years statistics"
  },
  {
    "id": 796,
    "paragraph": "New Zealand, 1995). However, these figures conceal the fact that for all mothers there was a slight drop in the median maternal age at delivery between 1962 and 1972, at which point the increase began and continued until 1993 (Statistics New Zealand, 1995). Thus, the later childhood leukaemia",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "new zealand 1995 however figures conceal fact mothers slight drop median maternal age delivery 1962 1972 point increase began continued 1993 statistics new zealand 1995 thus later childhood leukaemia"
  },
  {
    "id": 797,
    "paragraph": "trends (after the early 1970s), but not the earlier trends might be consistent with increasing maternal age. However, an effect of maternal age on childhood ALL risks has not been observed consistently in analytical studies, and the overall change in the age of New Zealand mothers has not been",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "trends early 1970s earlier trends might consistent increasing maternal age however effect maternal age childhood risks observed consistently analytical studies overall change age new zealand mothers"
  },
  {
    "id": 798,
    "paragraph": "large. Changes in maternal age do not seem to offer a sufficient explanation for the increase in the incidence of childhood ALL observed in this study. Several studies (but not all) have reported a higher risk of childhood leukaemia for firstborn children (Ross et al., 1994).",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "large changes maternal age seem offer sufficient explanation increase incidence childhood observed study several studies reported higher risk childhood leukaemia firstborn children ross et al 1994"
  },
  {
    "id": 799,
    "paragraph": "The proportion of firstborn children in the population is likely to have increased as family sizes have decreased. Family size in New Zealand increased in the post war years; there was a peak in the total fertility rate in 1961, then a",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "proportion firstborn children population likely increased family sizes decreased family size new zealand increased post war years peak total fertility rate 1961"
  },
  {
    "id": 800,
    "paragraph": "decline until 1983, followed by a small increase (Department of Statistics, 1993b). Between 1976 and 1991, the average size of the New Zealand household declined from 3.2 to 2.8 members (Public Health Commission of New Zealand, 1993). Thus, if there is a real association between birth order and",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "decline 1983 followed small increase department statistics 1993b 1976 1991 average size new zealand household declined 32 28 members public health commission new zealand 1993 thus real association birth order"
  },
  {
    "id": 801,
    "paragraph": "Childhood leukaemias in New Zealand JD Dockerty et al x 1145 childhood leukaemia, one might expect to have seen an increase in incidence rates beginning after the 1961 peak in the fertility rate. The results of this study have suggested that",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "childhood leukaemias new zealand jd dockerty et al x 1145 childhood leukaemia one might expect seen increase incidence rates beginning 1961 peak fertility rate results study suggested"
  },
  {
    "id": 802,
    "paragraph": "the incidence of childhood leukaemia probably began to increase in about 1963-67. Thus, the trends in family size may at least partly explain the increase in the incidence of childhood leukaemia. Studies of the class and childhood leukaemia have not been consistent, but some",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "incidence childhood leukaemia probably began increase 196367 thus trends family size may least partly explain increase incidence childhood leukaemia studies class childhood leukaemia consistent"
  },
  {
    "id": 803,
    "paragraph": "have found an increased risk among higher social classes (Draper and Elliott, 1991). Social class is a complex concept involving such factors as employment, housing, income and education. A detailed analysis of time trends in social class (and its component factors) is beyond the scope of the",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "found increased risk among higher social classes draper elliott 1991 social class complex concept involving factors employment housing income education detailed analysis time trends social class component factors beyond scope"
  },
  {
    "id": 804,
    "paragraph": "present work, but such work would be useful, as temporal changes in socioeconomic level could have a bearing on the leukaemia trends. relationship between social Kinlen (1988) hypothesised that childhood leukaemia occurs as a rare response to a common infection, and that",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "present work work would useful temporal changes socioeconomic level could bearing leukaemia trends relationship social kinlen 1988 hypothesised childhood leukaemia occurs rare response common infection"
  },
  {
    "id": 805,
    "paragraph": "population influxes into areas of low herd immunity favour the occurrence of epidemics of the infection, and increases in leukaemia incidence. If a virus that could cause childhood leukaemia was introduced into New Zealand, and if more and more people gradually became infected, one might expect",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "population influxes areas low herd immunity favour occurrence epidemics infection increases leukaemia incidence virus could cause childhood leukaemia introduced new zealand people gradually became infected one might expect"
  },
  {
    "id": 806,
    "paragraph": "to see an increase in incidence rates. But Kinlen's hypothesis local population has been tested mainly in movements, and the hypothesis cannot be confirmed or refuted by this study of national time trends. relation to in its pure form. precursor) ALL. The first",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "see increase incidence rates kinlens hypothesis local population tested mainly movements hypothesis confirmed refuted study national time trends relation pure form precursor first"
  },
  {
    "id": 807,
    "paragraph": "Greaves and Chan (1986) hypothesised that spontaneous mutations in B-cell precursors could account for the majority of cases of ALL. The clear and continued increases in the incidence of ALL among children aged under 5 years, but not among older age groups, argue against this spontaneous",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "greaves chan 1986 hypothesised spontaneous mutations bcell precursors could account majority cases clear continued increases incidence among children aged 5 years among older age groups argue spontaneous"
  },
  {
    "id": 808,
    "paragraph": "Greaves (1988) mutation hypothesis elaborated the hypothesis by suggesting that two genetic events, both spontaneous mutations, were needed to produce common (B-cell event was in utero (following developmentally hypothesised to occur stress on B-cell precursors), and the driven proliferative second in infancy, (following proliferative stress resulting",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "greaves 1988 mutation hypothesis elaborated hypothesis suggesting two genetic events spontaneous mutations needed produce common bcell event utero following developmentally hypothesised occur stress bcell precursors driven proliferative second infancy following proliferative stress resulting"
  },
  {
    "id": 809,
    "paragraph": "1988). from exposure to exogenous antigens) (Greaves, Greaves suggested that the incidence of ALL was associated with a certain pattern of exposure to infections and other antigens; such exposure would be affected by socioeconomic circumstances, and the responses to exposure would be",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "1988 exposure exogenous antigens greaves greaves suggested incidence associated certain pattern exposure infections antigens exposure would affected socioeconomic circumstances responses exposure would"
  },
  {
    "id": 810,
    "paragraph": "modulated by genetic background, duration of breastfeeding and vaccinations (Greaves, 1988). The weak associations of common ALL with higher socioeconomic level and firstborn children could be due to delayed exposure to infections, 1988). A leading to more proliferative corollary of all this (if the hypothesis is correct) is that",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "modulated genetic background duration breastfeeding vaccinations greaves 1988 weak associations common higher socioeconomic level firstborn children could due delayed exposure infections 1988 leading proliferative corollary hypothesis correct"
  },
  {
    "id": 811,
    "paragraph": "temporal changes in the factors related to the exposure of infants to antigens could lead to secular time trends. During there have been changes in the period of this breastfeeding, vaccinations, socialisation, education, family structure and income. The effect of this mixture of changes",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "temporal changes factors related exposure infants antigens could lead secular time trends changes period breastfeeding vaccinations socialisation education family structure income effect mixture changes"
  },
  {
    "id": 812,
    "paragraph": "(in terms of Greaves' hypothesis) is complicated, and it is not practical to offer a simple interpretation of the ALL time trends in relation to it. Some factors relevant to Greaves' hypothesis (and infections in general) would also be relevant to certain specific infections.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "terms greaves hypothesis complicated practical offer simple interpretation time trends relation factors relevant greaves hypothesis infections general would also relevant certain specific infections"
  },
  {
    "id": 813,
    "paragraph": "stress (Greaves, study, In adults, there is strong Acute non-lymphoblastic leukaemia evidence that benzene exposure can cause ANLL (Austin et al., 1988). It is not known whether this is also the case for children. There are no long-term time trend data on the",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "stress greaves study adults strong acute nonlymphoblastic leukaemia evidence benzene exposure cause anll austin et al 1988 known whether also case children longterm time trend data"
  },
  {
    "id": 814,
    "paragraph": "exposure of New Zealanders to benzene. Age and ethnic group This study confirms previous work by Gunz (1966), who identified a peak in the age distribution of childhood acute leukaemias at ages 2-3. The present work showed that the peak increased in size, in tandem with the increase in the",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "exposure new zealanders benzene age ethnic group study confirms previous work gunz 1966 identified peak age distribution childhood acute leukaemias ages 23 present work showed peak increased size tandem increase"
  },
  {
    "id": 815,
    "paragraph": "9 1146 cmi,o.d Ii aenas in New Zdanad JD Dockerty et al ra incidence of ALL for young children. A similar peak developed in Britain in the 1920s and 1930s (Neglia and Robison, 1988) and increased in size between 1931 and 1953",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "9 1146 cmiod ii aenas new zdanad jd dockerty et al ra incidence young children similar peak developed britain 1920s 1930s neglia robison 1988 increased size 1931 1953"
  },
  {
    "id": 816,
    "paragraph": "(Hewitt, 1955). After 1940, there was an increase in the age peak among US Whites (Court Brown and Doll, 1961). The early age peak has not been found in tropical Africa, even when an intensive search for cases of ALL has been made",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "hewitt 1955 1940 increase age peak among us whites court brown doll 1961 early age peak found tropical africa even intensive search cases made"
  },
  {
    "id": 817,
    "paragraph": "(Fleming, 1988). The early age peak is due to common ALL (Greaves et al., 1981; 1985). In New Zealand health statistics, ethnicity is not assigned in a uniform way, leading to possible bias because of differences in the ways numerator and denominator data",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "fleming 1988 early age peak due common greaves et al 1981 1985 new zealand health statistics ethnicity assigned uniform way leading possible bias differences ways numerator denominator data"
  },
  {
    "id": 818,
    "paragraph": "are collected and classified (Brown, 1983; Smith and Pearce, 1984; Review Committee on Ethnic Statistics, 1988). In this study, population estimates were based on the national census. The census currently relies on self-identification of ethnic group. The registration data come mainly from",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "collected classified brown 1983 smith pearce 1984 review committee ethnic statistics 1988 study population estimates based national census census currently relies selfidentification ethnic group registration data come mainly"
  },
  {
    "id": 819,
    "paragraph": "hospitals. In hospital admission records, ethnicity could be assigned on the basis either of self/parent-identification or of observation by the admitting staff. is not possible to the properly trends and rates, comparisons that involve ethnic groups. The long time period of this study makes such assessments very difficult,",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "hospitals hospital admission records ethnicity could assigned basis either selfparentidentification observation admitting staff possible properly trends rates comparisons involve ethnic groups long time period study makes assessments difficult"
  },
  {
    "id": 820,
    "paragraph": "because of the the comparability of the numerator and denominator data for Maori and non-Maori. likelihood of temporal changes in It of the validity The lower rates of ALL (and higher rates of ANLL) among Maori than non-Maori may be due to genetic",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "comparability numerator denominator data maori nonmaori likelihood temporal changes validity lower rates higher rates anll among maori nonmaori may due genetic"
  },
  {
    "id": 821,
    "paragraph": "differences that affect susceptibility to ALL, or to causes of it. Alternatively (or additionally), lifestyle or environmental assess differences might result in differences in exposure to risk factors. Compared with the total New Zealand population, Maori have on average greater unemployment, lower income,",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "differences affect susceptibility causes alternatively additionally lifestyle environmental assess differences might result differences exposure risk factors compared total new zealand population maori average greater unemployment lower income"
  },
  {
    "id": 822,
    "paragraph": "fewer educational qualifications, higher levels of overcrowd- ing in homes and lower levels of home ownership (Public Health Commission of New Zealand, 1994). It is of interest to compare the incidence rates for New Zealand Maori with those found in a previous study of",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "fewer educational qualifications higher levels overcrowd ing homes lower levels home ownership public health commission new zealand 1994 interest compare incidence rates new zealand maori found previous study"
  },
  {
    "id": 823,
    "paragraph": "another Polynesian population. Goodman et (1989) calculated the incidence of childhood ALL (ages 0-14) among Hawaiians in Hawaii, 1960-84. Their rates (per 100 000 person-years) were 2.5 for Hawaiian boys and 2.1 for Hawaiian girls, based on small numbers (19 girls and 14",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "another polynesian population goodman et 1989 calculated incidence childhood ages 014 among hawaiians hawaii 196084 rates per 100 000 personyears 25 hawaiian boys 21 hawaiian girls based small numbers 19 girls 14"
  },
  {
    "id": 824,
    "paragraph": "boys). New Zealand Maori had a similar incidence rate for ALL (2.5 per 100 000 person-years for both sexes combined, 1968-90). The temporal changes in the incidence rates of ALL and ANLL in New Zealand highlight the likely importance of environmental factors in the aetiology of these cancers in",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "boys new zealand maori similar incidence rate 25 per 100 000 personyears sexes combined 196890 temporal changes incidence rates anll new zealand highlight likely importance environmental factors aetiology cancers"
  },
  {
    "id": 825,
    "paragraph": "children. al. Ackowkledgemests For the duration of this study. John Dockerty's salary was provided by a grant from the Health Research Council of New Zealand. This project was funded from Cancer Research Bequest Funds of the University of Otago Medical School. Mark Elwood,",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "children al ackowkledgemests duration study john dockertys salary provided grant health research council new zealand project funded cancer research bequest funds university otago medical school mark elwood"
  },
  {
    "id": 826,
    "paragraph": "(1994). Incidence of childhood cancer in Osaka, Japan, 1971- 1988: Reclassification of registered cases by Birch's scheme using information on clinical diagnosis, histology and primary site. Jpn. J. Cancer Res., 85, 139 - 146. ARMITAGE P AND BERRY G. (1987). Statistical Methods in Medical",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "1994 incidence childhood cancer osaka japan 1971 1988 reclassification registered cases birchs scheme using information clinical diagnosis histology primary site jpn j cancer res 85 139 146 armitage p berry g 1987 statistical methods medical"
  },
  {
    "id": 827,
    "paragraph": "Research, 2nd edn. Blackwell: Oxford. AUSTIN H, DELZELL E AND COLE P. (1988). Benzene and leukemia: a review of the literature and a risk assessment. Am. J. Epidemiol., 127, 419-439. BIRCH J AND MARSDEN HB. (1987). A classification scheme for childhood cancer. Int. J. Cancer, 40, 620- 624.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "research 2nd edn blackwell oxford austin h delzell e cole p 1988 benzene leukemia review literature risk assessment j epidemiol 127 419439 birch j marsden hb 1987 classification scheme childhood cancer int j cancer 40 620 624"
  },
  {
    "id": 828,
    "paragraph": "BIRCH JM, MARSDEN HB AND SWINDELL R. (1980). Incidence of malignant disease in childhood: A 24-year review of the Manchester Children's Tumour Registry data. Br. J. Cancer, 42, 215-223. BIRCH JM, SWINDELL R, MARSDEN HB AND MORRIS-JONES PH. (1981). Childhood leukaemia in north west England 1954-1977:",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "birch jm marsden hb swindell r 1980 incidence malignant disease childhood 24year review manchester childrens tumour registry data br j cancer 42 215223 birch jm swindell r marsden hb morrisjones ph 1981 childhood leukaemia north west england 19541977"
  },
  {
    "id": 829,
    "paragraph": "epidemiology, incidence and survival. Br. J. Cancer, 43, 324- 329. BIRCH JM, MARSDEN HB, MORRIS-JONES PH, PEARSON D AND BLAIR V. (1988). Improvements in survival from childhood cancer: results of a population based survey over 30 years. Br. Med. J., 296, 1372-1376.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "epidemiology incidence survival br j cancer 43 324 329 birch jm marsden hb morrisjones ph pearson blair v 1988 improvements survival childhood cancer results population based survey 30 years br med j 296 13721376"
  },
  {
    "id": 830,
    "paragraph": "BLAIR V AND BIRCH JM. (1994). Patterns and temporal trends in the incidence of malignant disease in children: I. Leukaemia and lymphoma. Eur. J. Cancer, 30A, 1490-1498. BRESLOW NE. (1984). Elementary methods ofcohort analysis. Int. J. Epidemiol., 13, 112- 115. BRESLOW NE AND LANGHOLZ B. (1983). Childhood cancer",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "blair v birch jm 1994 patterns temporal trends incidence malignant disease children leukaemia lymphoma eur j cancer 30a 14901498 breslow ne 1984 elementary methods ofcohort analysis int j epidemiol 13 112 115 breslow ne langholz b 1983 childhood cancer"
  },
  {
    "id": 831,
    "paragraph": "incidence: Geographical and temporal variations. Int. J. Cancer, 32, 703-716. BROWN PG. (1983). An Investigation of Official Ethnic Statistics. Department of Statistics: Wellington. COEBERGH JWW. VAN DER DOES-VAN DEN BERG A. VAN WERING ER. VAN STEENSEL-MOLL HA, VALKENBURG HA. VAN'T VEER MB, SCHMITZ PIM AND VAN ZANEN GE. (1989).",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "incidence geographical temporal variations int j cancer 32 703716 brown pg 1983 investigation official ethnic statistics department statistics wellington coebergh jww van der doesvan den berg van wering er van steenselmoll ha valkenburg ha vant veer mb schmitz pim van zanen ge 1989"
  },
  {
    "id": 832,
    "paragraph": "Childhood leukaemia in The Netherlands, 1973 - 1986: temporary variation of the incidence of acute lymphocytic leukaemia in young children. Br. J. Cancer, 59, 100 - 105. COLEMAN MP. ESTEVE J, DAMIECKI P. ARSLAN A AND RENARD H. (1993). Trends in Cancer Incidence and Mortality. Interna-",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "childhood leukaemia netherlands 1973 1986 temporary variation incidence acute lymphocytic leukaemia young children br j cancer 59 100 105 coleman mp esteve j damiecki p arslan renard h 1993 trends cancer incidence mortality interna"
  },
  {
    "id": 833,
    "paragraph": "tional Agency for Research on Cancer: Lyon. COOKE KR. GRAY AJ, BURRY AF AND STEWART RJ. (1988). Cancer Registration in New Zealand: report of the Cancer Registration Working Group. Department of Statistics: Wellington. COURT BROWN WM AND DOLL R. (1961). Leukaemia in childhood",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "tional agency research cancer lyon cooke kr gray aj burry af stewart rj 1988 cancer registration new zealand report cancer registration working group department statistics wellington court brown wm doll r 1961 leukaemia childhood"
  },
  {
    "id": 834,
    "paragraph": "and young adult life: Trends in mortality in relation to aetiology. Br. Med. J., 1. 981 -988. DARBY SC. OLSEN JH. DOLL R. THAKRAR B. DE NULLY BROWN P. STORM HH, BARLOW L, LANGMARK F, TEPPO L AND TULINIUS H. (1992). Trends in childhood leukaemia in the Nordic countries",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "young adult life trends mortality relation aetiology br med j 1 981 988 darby sc olsen jh doll r thakrar b de nully brown p storm hh barlow l langmark f teppo l tulinius h 1992 trends childhood leukaemia nordic countries"
  },
  {
    "id": 835,
    "paragraph": "in relation to fallout from atmospheric nuclear weapons testing. Br. Med. J., 304, 1005 - 1009. DE NULLY BROWN P. HERTZ H. OLSEN JH. YSSING M, SCHEIBEL E AND JENSEN OM. (1989). Incidence of childhood cancer in Denmark 1963-1984. Int. J. Epidemiol., 18, 546-555.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "relation fallout atmospheric nuclear weapons testing br med j 304 1005 1009 de nully brown p hertz h olsen jh yssing scheibel e jensen om 1989 incidence childhood cancer denmark 19631984 int j epidemiol 18 546555"
  },
  {
    "id": 836,
    "paragraph": "DEPARTMENT OF STATISTICS. (1992). 1991 Census of Population and Dwellings. New Zealand Maori population and dwellings. Department of Statistics: Wellington. DEPARTMENT OF STATISTICS. (I 993a). 1991 New Zealand census of population and dwellings. New Zealand's multicultural society. Department of Statistics: Wellington.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "department statistics 1992 1991 census population dwellings new zealand maori population dwellings department statistics wellington department statistics 993a 1991 new zealand census population dwellings new zealands multicultural society department statistics wellington"
  },
  {
    "id": 837,
    "paragraph": "DEPARTMENT OF STATISTICS. (1993b). New Zealand Official Yearbook 1993. 96th edn. Department of Statistics: Wellington. DOLL R. (1989). The epidemiology of childhood leukaemia. J. R. Stat. Soc. A., 152, 341-351. DRAPER GJ. KROLL ME AND STILLER CA. (1994). Childhood cancer. Cancer Surv., 19/20, 493 - 517.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "department statistics 1993b new zealand official yearbook 1993 96th edn department statistics wellington doll r 1989 epidemiology childhood leukaemia j r stat soc 152 341351 draper gj kroll stiller ca 1994 childhood cancer cancer surv 1920 493 517"
  },
  {
    "id": 838,
    "paragraph": "DRAPER GJ AND ELLIOTT P. (1991). Variations in incidence rates and factors affecting them - summary. In: The Geographical Epidemiology of Childhood Leukaemia and non-Hodgkin Lympho- mas in Great Britain, 1966-83. Draper G (ed.) pp. 57-60. HMSO: London. DRAPER GJ AND STILLER CA. (1992). Intramuscular vitamin K and",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "draper gj elliott p 1991 variations incidence rates factors affecting summary geographical epidemiology childhood leukaemia nonhodgkin lympho mas great britain 196683 draper g ed pp 5760 hmso london draper gj stiller ca 1992 intramuscular vitamin k"
  },
  {
    "id": 839,
    "paragraph": "childhood cancer (letter). Br. Med. J., 305, 709. EKELUND H, FINNSTROM 0, GUNNARSKOG J. KALLEN B AND LARSSON Y. (1993). Administration of vitamin K to newborn infants and childhood cancer. Br. Med. J., 307, 89-91. ERICSSON IL. KARNSTROM L AND MATTSSON B. (1978). Child-",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "childhood cancer letter br med j 305 709 ekelund h finnstrom 0 gunnarskog j kallen b larsson 1993 administration vitamin k newborn infants childhood cancer br med j 307 8991 ericsson il karnstrom l mattsson b 1978 child"
  },
  {
    "id": 840,
    "paragraph": "hood cancer in Sweden, 1958-1974. Acta Paediatr. Scand., 67, 425-432. CMhood beeicauiias in Ne D Dockerty et a Zealand 9 1147 NEGLIA JP AND ROBISON LL. (1988). Epidemiology of the childhood acute leukemias. Pediatr. Clin. N. Am., 35, 675 -692. NEW ZEALAND HEALTH INFORMATION SERVICE. (1995). Cancer:",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "hood cancer sweden 19581974 acta paediatr scand 67 425432 cmhood beeicauiias ne dockerty et zealand 9 1147 neglia jp robison 1988 epidemiology childhood acute leukemias pediatr clin n 35 675 692 new zealand health information service 1995 cancer"
  },
  {
    "id": 841,
    "paragraph": "New Registrations and Deaths 1992. Ministry of Health: Well- ington. OLSEN JH, HERTZ H, BLINKENBERG K AND VERDER H (1994). Vitamin K regimens and incidence of childhood cancer in Denmark. Br. Med. J., 308, 895 - 896. PARKIN DM, STILLER CA. DRAPER GJ. BIEBER CA. TERRACINI B",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "new registrations deaths 1992 ministry health well ington olsen jh hertz h blinkenberg k verder h 1994 vitamin k regimens incidence childhood cancer denmark br med j 308 895 896 parkin dm stiller ca draper gj bieber ca terracini b"
  },
  {
    "id": 842,
    "paragraph": "AND YOUNG JL. (1988a). International Incidence of Childhood Cancer. International Agency For Research on Cancer: Lyon. PARKIN DM, STILLER CA, DRAPER GJ AND BIEBER CA. (1988b). The international incidence of childhood cancer. Int. J. Cancer. 42, 511-520. POLEDNAK AP. (1986). Recent trends in incidence and mortality",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "young jl 1988a international incidence childhood cancer international agency research cancer lyon parkin dm stiller ca draper gj bieber ca 1988b international incidence childhood cancer int j cancer 42 511520 polednak ap 1986 recent trends incidence mortality"
  },
  {
    "id": 843,
    "paragraph": "rates for leukemias, and in survival rates for childhood acute lymphocytic leukemia, in Upstate New York. Cancer, 57, 1850- 1858. PUBLIC HEALTH COMMISSION OF NEW ZEALAND. (1993). Our Health, Our Future. The State of The Public Health in New Zealand 1993. Public Health Commission: Wellington.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "rates leukemias survival rates childhood acute lymphocytic leukemia upstate new york cancer 57 1850 1858 public health commission new zealand 1993 health future state public health new zealand 1993 public health commission wellington"
  },
  {
    "id": 844,
    "paragraph": "PUBLIC HEALTH COMMISSION OF NEW ZEALAND. (1994). Our Health, Our Future. The State ofthe Public Health in New Zealand 1994. Public Health Commission: Wellington. REVIEW COMMITTEE ON ETHNIC STATISTICS. (1988). Report of the Review Committee on Ethnic Statistics. pp. I - 132. Department",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "public health commission new zealand 1994 health future state ofthe public health new zealand 1994 public health commission wellington review committee ethnic statistics 1988 report review committee ethnic statistics pp 132 department"
  },
  {
    "id": 845,
    "paragraph": "of Statistics: Wellington. ROSS JA, DAVIES SM, POTTER JD AND ROBISON LL. (1994). Epidemiology of childhood leukemia. with a focus on infants. Epidemiol. Rev., 16, 243-272. SMITH AH AND PEARCE NE. (1984). Determinants of differences in mortality between New Zealand Maonrs and non-Maonrs aged",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "statistics wellington ross ja davies sm potter jd robison 1994 epidemiology childhood leukemia focus infants epidemiol rev 16 243272 smith ah pearce ne 1984 determinants differences mortality new zealand maonrs nonmaonrs aged"
  },
  {
    "id": 846,
    "paragraph": "15-64. N. Z. Med. J., 97, 101 - 108. STATISTICS NEW ZEALAND. (1995). Demographic Trends 1994. Statistics New Zealand: Wellington. STEWART A AND KNEALE GW. (1969). Role of local infections in the recognition of haemopoietic neoplasms. Nature, 223, 741 - 742.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "1564 n z med j 97 101 108 statistics new zealand 1995 demographic trends 1994 statistics new zealand wellington stewart kneale gw 1969 role local infections recognition haemopoietic neoplasms nature 223 741 742"
  },
  {
    "id": 847,
    "paragraph": "VAN HOFF J. SCHYMURA MJ AND MCCREA CURNEN MG. (1988). Trends in the incidence of childhood and adolescent cancer in Connecticut, 1935- 1979. Med. Pediatr. Oncol., 16, 78- 87. WATERHOUSE J, MUIR C, CORREA P. POWELL J AND DAVIS W. (1976). Cancer Incidence in Five Continents. Vol III. International",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "van hoff j schymura mj mccrea curnen mg 1988 trends incidence childhood adolescent cancer connecticut 1935 1979 med pediatr oncol 16 78 87 waterhouse j muir c correa p powell j davis w 1976 cancer incidence five continents vol iii international"
  },
  {
    "id": 848,
    "paragraph": "Agency for Research on Cancer: Lyon. FLEMING AF. (1988). Possible aetiological factors in leukaemias in Africa. Leuk. Res., 12, 33-43. GOLDING J. PATERSON M AND KINLEN Li. (1990). Factors associated with childhood cancer in a national cohort study. Br. J. Cancer, 62, 304-308.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "agency research cancer lyon fleming af 1988 possible aetiological factors leukaemias africa leuk res 12 3343 golding j paterson kinlen li 1990 factors associated childhood cancer national cohort study br j cancer 62 304308"
  },
  {
    "id": 849,
    "paragraph": "GOLDING J. GREENWOOD R. BIRMINGHAM K AND MOTT M. vitamin K, and (1992). Childhood cancer, pethidine given during labour. Br. Med. J., 305, 341- 346. intramuscular GOODMAN MT, YOSHIZAWA CN AND KOLONEL LN. (1989). Incidence trends and ethnic patterns for childhood leukaemia in",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "golding j greenwood r birmingham k mott vitamin k 1992 childhood cancer pethidine given labour br med j 305 341 346 intramuscular goodman mt yoshizawa cn kolonel ln 1989 incidence trends ethnic patterns childhood leukaemia"
  },
  {
    "id": 850,
    "paragraph": "Hawaii: 1960- 1984. Br. J. Cancer, 60, 93 - 97. in the GORDIS L, SZKLO M, THOMPSON B, KAPLAN E AND TONASCIA JA. of acute (1981). An apparent nonlymphocytic leukemia in black children. Cancer, 47, 2763- 2768. incidence increase GREAVES MF, JANOSSY G. PETO J AND KAY H.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "hawaii 1960 1984 br j cancer 60 93 97 gordis l szklo thompson b kaplan e tonascia ja acute 1981 apparent nonlymphocytic leukemia black children cancer 47 2763 2768 incidence increase greaves mf janossy g peto j kay h"
  },
  {
    "id": 851,
    "paragraph": "(1981). Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br. J. Haematol., 48, 179-197. GREAVES MF, PEGRAM SM AND CHAN LC. (1985). Collaborative group study of the epidemiology of acute lymphoblastic leukaemia subtypes: Background and first report. Leuk. Res.. 9,",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "1981 immunologically defined subclasses acute lymphoblastic leukaemia children relationship presentation features prognosis br j haematol 48 179197 greaves mf pegram sm chan lc 1985 collaborative group study epidemiology acute lymphoblastic leukaemia subtypes background first report leuk res 9"
  },
  {
    "id": 852,
    "paragraph": "715-733. GREAVES MF. (1988). Speculations on the cause of childhood acute lymphoblastic leukaemia. Leukemia, 2, 120 - 125. GREAVES MF AND CHAN LC. (1986). Annotation: Is spontaneous mutation the major cause' of childhood acute lymphoblastic leukaemia? Br. J. Haematol., 64, 1 - 13.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "715733 greaves mf 1988 speculations cause childhood acute lymphoblastic leukaemia leukemia 2 120 125 greaves mf chan lc 1986 annotation spontaneous mutation major cause childhood acute lymphoblastic leukaemia br j haematol 64 1 13"
  },
  {
    "id": 853,
    "paragraph": "GUNZ FW. (1966). Studies on the incidence and aetiology of leukaemia in New Zealand. N. Z. Med. J., Haematologv Supplement. 65, 857-862. HEWITT D. (1955). Some features of leukaemia mortality. Br. J. Prev. Soc. Med., 9, 81-88. KINLEN L. (1988). Evidence for an infective cause of childhood",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "gunz fw 1966 studies incidence aetiology leukaemia new zealand n z med j haematologv supplement 65 857862 hewitt 1955 features leukaemia mortality br j prev soc med 9 8188 kinlen l 1988 evidence infective cause childhood"
  },
  {
    "id": 854,
    "paragraph": "leukaemia: Comparison of a Scottish new town with nuclear reprocessing sites in Britain. Lancet, 2, 1323 - 1327. KLEBANOFF MA, READ JS, MILLS JL AND SHIONO PH. (1993). The risk of childhood cancer after neonatal exposure to vitamin K. N. Engi. J. Med., 329, 905-908.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "leukaemia comparison scottish new town nuclear reprocessing sites britain lancet 2 1323 1327 klebanoff read js mills jl shiono ph 1993 risk childhood cancer neonatal exposure vitamin k n engi j med 329 905908"
  },
  {
    "id": 855,
    "paragraph": "MANTEL N. (1963). Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J. Am. Stat. Assoc., 58, 690-700. MATrHEWS M. (1994). A review of fallout deposition and milk contamination. Radiat. Protection News Notes, 26, 15-17. MCWHIRTER WR AND PETROESCHEVSKY AL. (1991). Incidence",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "mantel n 1963 chisquare tests one degree freedom extensions mantelhaenszel procedure j stat assoc 58 690700 matrhews 1994 review fallout deposition milk contamination radiat protection news notes 26 1517 mcwhirter wr petroeschevsky al 1991 incidence"
  },
  {
    "id": 856,
    "paragraph": "trends in childhood cancer in Queensland, 1973- 1988. Med. J. Aust., 154, 453-455. MEDICAL STATISTICS BRANCH OF THE DEPARTMENT OF HEALTH. (1955). Report of the Medical Statistician on Cancer Morbidity and Mortality in New Zealand. Department of Health: Wellington.",
    "jurnal": "brjcancer00037-0121.pdf",
    "processed": "trends childhood cancer queensland 1973 1988 med j aust 154 453455 medical statistics branch department health 1955 report medical statistician cancer morbidity mortality new zealand department health wellington"
  },
  {
    "id": 857,
    "paragraph": "Br. J. Cancer (1980) 41, 966 IMMUNIZATION AGAINST PRIMARY, TRANSPLANTED AND SPONTANEOUS MURINE LEUKAEMIA USING A LIVE MOLONEY SARCOMA VIRUS VACCINE A. M. S. MAYER,* M. A. BASOMBRIOt AND C. D. PASQUALINIt From the Seccion Leucemia Experimental, Instituto de Investiqaciones Hematologicas,",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "br j cancer 1980 41 966 immunization primary transplanted spontaneous murine leukaemia using live moloney sarcoma virus vaccine mayer basombriot c pasqualinit seccion leucemia experimental instituto de investiqaciones hematologicas"
  },
  {
    "id": 858,
    "paragraph": "Academia Nacional de Medicina, Las Heras 3092, 1425, Buenos Aires, Argentina Received 9 October 1979 Accepted 16 January 1980 Summary.-The purpose of this study was to use an immunization protocol with Moloney sarcoma virus (MSV-M) as active immunogen against exogenous and endo-",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "academia nacional de medicina las heras 3092 1425 buenos aires argentina received 9 october 1979 accepted 16 january 1980 summarythe purpose study use immunization protocol moloney sarcoma virus msvm active immunogen exogenous endo"
  },
  {
    "id": 859,
    "paragraph": "genous leukaemia. The s.c. route was chosen since it offered advantages over the i.m. route: the primary sarcomas were smaller, the regression faster, there were fewer recurrences and there was good persistent immunity. Strong protection was obtained against primary leukaemias induced by Friend leukaemia virus (FLV), Moloney",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "genous leukaemia sc route chosen since offered advantages im route primary sarcomas smaller regression faster fewer recurrences good persistent immunity strong protection obtained primary leukaemias induced friend leukaemia virus flv moloney"
  },
  {
    "id": 860,
    "paragraph": "leukaemia virus (MLV), Rauscher leukaemia virus (RLV), Precerutti-Law leukaemia virus (PLLV/T2), and H179A leukaemia virus. It was not possible to protect against leukaemia induced by Gross leukaemia virus (GLV). With transplantable leukaemias the results varied: partial protection was observed against H110 leukaemia (induced",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "leukaemia virus mlv rauscher leukaemia virus rlv preceruttilaw leukaemia virus pllvt2 h179a leukaemia virus possible protect leukaemia induced gross leukaemia virus glv transplantable leukaemias results varied partial protection observed h110 leukaemia induced"
  },
  {
    "id": 861,
    "paragraph": "with human material) and R14 leukaemia (induced by X-irradiation) whilst no pro- tection was obtained against P277 leukaemia (induced by Moloney leukaemia virus). As for spontaneous leukaemias, immunized BALB/c mice showed an increased incidence over the controls, while in Fl (Swiss x AKR) mice the incidence was similar",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "human material r14 leukaemia induced xirradiation whilst pro tection obtained p277 leukaemia induced moloney leukaemia virus spontaneous leukaemias immunized balbc mice showed increased incidence controls fl swiss x akr mice incidence similar"
  },
  {
    "id": 862,
    "paragraph": "but the latent period was shorter. Furthermore, in long-term observations the MSV- M-immunized mice showed an increased mortality, which could be related to (1) new phenotypic mixtures between MSV-M and leukaemia viruses; (2) reactivation of MSV-M sarcoma-genesis with age, and (3) genotype susceptibility to MSV-M.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "latent period shorter furthermore longterm observations msv mimmunized mice showed increased mortality could related 1 new phenotypic mixtures msvm leukaemia viruses 2 reactivation msvm sarcomagenesis age 3 genotype susceptibility msvm"
  },
  {
    "id": 863,
    "paragraph": "To DATE, no standardized system has been used to compare the results of one and the same immunization protocol on the prevention of transplanted, primary and spontaneous leukaemia in the mouse. However, on different occasions, active immunization methods have been used,",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "date standardized system used compare results one immunization protocol prevention transplanted primary spontaneous leukaemia mouse however different occasions active immunization methods used"
  },
  {
    "id": 864,
    "paragraph": "transplantable such as: syngeneic leukaemia in sub-threshold doses (Axelrad, 1963; Klein & Klein, 1964; Pasternak & Graffi, 1963); (2) allogeneic transplantable leukaemia (Klein & Klein, 1964; McCoy et al., 1967; Pasternak & Graffi, 1963); (3) culture cells chronically infected with virus (Barski & Youn, 1965; Mayyasi et",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "transplantable syngeneic leukaemia subthreshold doses axelrad 1963 klein klein 1964 pasternak graffi 1963 2 allogeneic transplantable leukaemia klein klein 1964 mccoy et al 1967 pasternak graffi 1963 3 culture cells chronically infected virus barski youn 1965 mayyasi et"
  },
  {
    "id": 865,
    "paragraph": "(1) virus leukaemia al., 1968); (4) infectious leukaemia virus (Bianco et al., 1966; Glynn et al., 1964, 1968; Klein & Klein, 1964; Mayyasi & Moloney, 1967; McCoy et al., 1967; Sachs, 1962; Slettenmark & Klein, 1962); (5) attenuated (Fink & Rauscher, 1964; Friend, 1959; Huebner",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "1 virus leukaemia al 1968 4 infectious leukaemia virus bianco et al 1966 glynn et al 1964 1968 klein klein 1964 mayyasi moloney 1967 mccoy et al 1967 sachs 1962 slettenmark klein 1962 5 attenuated fink rauscher 1964 friend 1959 huebner"
  },
  {
    "id": 866,
    "paragraph": "et al., 1976; Kelloff et al., 1976; Mayyasi & Moloney, 1967; McCoy et 1967; Tyndall, et al., 1967); (6) infectious murine sarcoma virus (Fefer et al., 1967; Huebner et al., 1976; Basombrio et al., 1977); and (7) purified viral components (Hunsmann",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "et al 1976 kelloff et al 1976 mayyasi moloney 1967 mccoy et 1967 tyndall et al 1967 6 infectious murine sarcoma virus fefer et al 1967 huebner et al 1976 basombrio et al 1977 7 purified viral components hunsmann"
  },
  {
    "id": 867,
    "paragraph": "et al., 1975; Ihle et al., 1976a,b). The varia- bility among experimental protocols makes al., Philosophy in Biological Sciences at the University of Buenos Aires, Buenos Aires, Argentina. * By wlhom tlhis work was submitted in partial fulfilment of the requirements for the degree of Doctor of",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "et al 1975 ihle et al 1976ab varia bility among experimental protocols makes al philosophy biological sciences university buenos aires buenos aires argentina wlhom tlhis work submitted partial fulfilment requirements degree doctor"
  },
  {
    "id": 868,
    "paragraph": "t Member of Research Career, CONICET (Consejo Nacional de Inves tigaciones Cientificas y T&cnicas). Address for reprints: Christiane Dosne Pasqualini, Academia Nacional dIe Medicina, Las Heras 3092, 1425 Buenos Aires, Argentina. MURINE LEUKAEMIA IMMUNIZATION WITH MSV 967 it a direct comparison of the different results",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "member research career conicet consejo nacional de inves tigaciones cientificas tcnicas address reprints christiane dosne pasqualini academia nacional die medicina las heras 3092 1425 buenos aires argentina murine leukaemia immunization msv 967 direct comparison different results"
  },
  {
    "id": 869,
    "paragraph": "extremely difficult. replicates preferentially The Moloney sarcoma virus system (MSV-M) has been well characterized (Harvey & East, 1971). Its tissue tropism is different from that of leukaemic viruses, since in muscle and not in haemopoietic tissue (Perk & Maloney, 1966) and induces",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "extremely difficult replicates preferentially moloney sarcoma virus system msvm well characterized harvey east 1971 tissue tropism different leukaemic viruses since muscle haemopoietic tissue perk maloney 1966 induces"
  },
  {
    "id": 870,
    "paragraph": "atypical granulomas (Simons & McCully, 1970). The tumours induced by MSV-M in normal adult mice regress after attain- ing considerable size, leaving the animals free of disease (Fefer, 1968). Immuno- logically, MSV-M has been studied ex- tensively; both the humoral and the",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "atypical granulomas simons mccully 1970 tumours induced msvm normal adult mice regress attain ing considerable size leaving animals free disease fefer 1968 immuno logically msvm studied ex tensively humoral"
  },
  {
    "id": 871,
    "paragraph": "cellular immune responses (Lamon et al., 1974) have been characterized. It has also been observed that MSV-M shares anti- gens with the Friend-Moloney-Rauscher complex (Fefer et al., 1967); its neutraliza- tion with rat anti-Gross serum (Fefer, 1967) opened up the possibility of using",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "cellular immune responses lamon et al 1974 characterized also observed msvm shares anti gens friendmoloneyrauscher complex fefer et al 1967 neutraliza tion rat antigross serum fefer 1967 opened possibility using"
  },
  {
    "id": 872,
    "paragraph": "this virus for vaccination against Gross leukaemias. On the basis of the accumulated data, MSV-M seems to be the best characterized of all murine oncorna viral systems. There- fore, the purpose of this study was to use a with MSV-M as a live viral vaccine for the pre-",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "virus vaccination gross leukaemias basis accumulated data msvm seems best characterized murine oncorna viral systems fore purpose study use msvm live viral vaccine pre"
  },
  {
    "id": 873,
    "paragraph": "vention of primary, transplanted and spontaneous leukaemia in the mouse. standardized protocol unique MATERIALS AND METHODS Mice.-Inbred BALB/c and outbred Swiss mice, raised in our colony, 2 months old and of either sex, were used for immunization against primary and transplanted leukaemia.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "vention primary transplanted spontaneous leukaemia mouse standardized protocol unique materials methods miceinbred balbc outbred swiss mice raised colony 2 months old either sex used immunization primary transplanted leukaemia"
  },
  {
    "id": 874,
    "paragraph": "(Swiss x AKR) Fl hybrids and BALB/c mice were used in studies involving spontaneous leukaemia. Leukaemia viruses. Six strains of murine leukaemia were Lyophilized Friend leukaemia virus (FLV, Lot 245 No. 5) frozen Rauscher leukaemia virus (RLV, Lot No. 1) and lyophilized Gross leukaemia",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "swiss x akr fl hybrids balbc mice used studies involving spontaneous leukaemia leukaemia viruses six strains murine leukaemia lyophilized friend leukaemia virus flv lot 245 5 frozen rauscher leukaemia virus rlv lot 1 lyophilized gross leukaemia"
  },
  {
    "id": 875,
    "paragraph": "virus (GLV, Lot 2D) were obtained from the American Type Culture Collection, Rockville, Md, U.S.A. Moloney leukaemia virus (MLV) was obtained from culture fluids of 3T3- murine leukaemia cells, provided by Dr Saal, used. virus 65 Centre Hayem, Hopital Saint Louis, Paris,",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "virus glv lot 2d obtained american type culture collection rockville md usa moloney leukaemia virus mlv obtained culture fluids 3t3 murine leukaemia cells provided dr saal used virus 65 centre hayem hopital saint louis paris"
  },
  {
    "id": 876,
    "paragraph": "France. Precerutti-Law leukaemia virus (PLLV/ T2) was introduced to our laboratory by Dr Precerutti 10 years ago as a BALB leukaemia of short latency, propagated by acellular extracts (Precerutti & Law, 1963). H179A leukaemia virus (H179A LV) was obtained from acellular extracts of leukaemia that",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "france preceruttilaw leukaemia virus pllv t2 introduced laboratory dr precerutti 10 years ago balb leukaemia short latency propagated acellular extracts precerutti law 1963 h179a leukaemia virus h179a lv obtained acellular extracts leukaemia"
  },
  {
    "id": 877,
    "paragraph": "appeared in a female BALB/c mouse, 2 months of age, 17 days after it had been inoculated with AKR leukaemic material (Pasqualini et al., 1968). Transplantable leukaemias.-Different leu- kaemias have been induced in our laboratory in the course of 20 years; many are main-",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "appeared female balbc mouse 2 months age 17 days inoculated akr leukaemic material pasqualini et al 1968 transplantable leukaemiasdifferent leu kaemias induced laboratory course 20 years many main"
  },
  {
    "id": 878,
    "paragraph": "tained by serial cell passage (Pasqualini et al., 1968) of which the following were studied: HlIO Leukaemia, obtained from a 3 month old BALB female, 37 days after being inocu- lated with human material via the intra- splenic route; R14 leukaemia, obtained from",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "tained serial cell passage pasqualini et al 1968 following studied hlio leukaemia obtained 3 month old balb female 37 days inocu lated human material via intra splenic route r14 leukaemia obtained"
  },
  {
    "id": 879,
    "paragraph": "a 10-month-old BALB/c female mouse that had received 3 weekly doses of 150 rad; P277 leukaemia, obtained from mice inocu- lated with Moloney leukaemia virus. a since strain, high-leukaemia Spontaneous leukaemias.-High- and low- leukaemia strains were needed for the experi- ments. (AKR x Swiss) Fl hybrids were used",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "10monthold balbc female mouse received 3 weekly doses 150 rad p277 leukaemia obtained mice inocu lated moloney leukaemia virus since strain highleukaemia spontaneous leukaemiashigh low leukaemia strains needed experi ments akr x swiss fl hybrids used"
  },
  {
    "id": 880,
    "paragraph": "as they proved to have a 30% incidence of leukemia at an average age of 12 months. The BALB/c strain was selected as a low-leukaemia strain, having a 15% spontaneous incidence at an average age of 18 months, in our laboratory.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "proved 30 incidence leukemia average age 12 months balbc strain selected lowleukaemia strain 15 spontaneous incidence average age 18 months laboratory"
  },
  {
    "id": 881,
    "paragraph": "Preparation and titration of Moloney sar- coma virus vaccine.-MSV-M used in the ex- periments originated from lot SVR-P166 kindly forwarded by Dr. K. E. Hellstrom, University of Washington, Seattle, U.S.A. A large number of newborn BALB/c mice were sarcomas originating from this inoculum were disrupted",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "preparation titration moloney sar coma virus vaccinemsvm used ex periments originated lot svrp166 kindly forwarded dr k e hellstrom university washington seattle usa large number newborn balbc mice sarcomas originating inoculum disrupted"
  },
  {
    "id": 882,
    "paragraph": "in 10 volumes of cold phosphate-buffer saline plus streptomycin and penicillin (PBS) and then homogenized in a Virtis blender Model S23. The homogenate was centrifuged twice at 5000 and 10,000 revs/min for 15 and 20 min respectively. Supernatants were then transferred to glass ampoules, sealed and",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "10 volumes cold phosphatebuffer saline plus streptomycin penicillin pbs homogenized virtis blender model s23 homogenate centrifuged twice 5000 10000 revsmin 15 20 min respectively supernatants transferred glass ampoules sealed"
  },
  {
    "id": 883,
    "paragraph": "frozen at - 196°C for storage. Subcutaneous inoculated. The titre of MSV-M was calculated in vivo using the Reed-Muench method, estimating take doses at Day 35. 0-2 ml of 10-fold dilu- tions of MSV-M stock were inoculated i.m. into 2-month-old BALB/c and Swiss mice.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "frozen 196°c storage subcutaneous inoculated titre msvm calculated vivo using reedmuench method estimating take doses day 35 02 ml 10fold dilu tions msvm stock inoculated im 2monthold balbc swiss mice"
  },
  {
    "id": 884,
    "paragraph": "968 A. M. S. MAYER, M. A. BASOMBRIO AND C. D. PASQUALINI Stock MSV-M, used in all experiments, con- tained 1P5 x 10J Take-dose 50/ml. Preparation and titration of murine leu- kaemia virus.-Leukaemic tissues (spleen and lymph nodes) were disrupted in 10 volumes of",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "968 mayer basombrio c pasqualini stock msvm used experiments con tained 1p5 x 10j takedose 50ml preparation titration murine leu kaemia virusleukaemic tissues spleen lymph nodes disrupted 10 volumes"
  },
  {
    "id": 885,
    "paragraph": "PBS with a glass homogenizer and processed in the same manner as for MSV-M sarcomas. Murine leukaemia viruses used to challenge MSV-M immunized mice were titrated in vivo in 2-3-month-old BALB/c mice. Tenfold dilutions of stored stock viruses were inocu- lated i.p., each mouse receiving 0-1 ml, and",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "pbs glass homogenizer processed manner msvm sarcomas murine leukaemia viruses used challenge msvm immunized mice titrated vivo 23monthold balbc mice tenfold dilutions stored stock viruses inocu lated ip mouse receiving 01 ml"
  },
  {
    "id": 886,
    "paragraph": "the proportion of mice dying with leukaemia within 3 months was recorded. The titre of the murine leukaemia viruses used was cal- culated by the Reed-Muench method esti- mating lethal doses at the day indicated between brackets in each case. Titres were:",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "proportion mice dying leukaemia within 3 months recorded titre murine leukaemia viruses used cal culated reedmuench method esti mating lethal doses day indicated brackets case titres"
  },
  {
    "id": 887,
    "paragraph": "RLV: 3-7x102 LD50 (69)/ml; FLV: 5x102 LD50 (74)/ml; PLLV-T2LV: 51 x 103 LD50 (66)/ml and H179ALV: 5 x 104 LD50 (56)/ml. MLV and GLV were not titrated in this way, since they induced splenomegaly and death after prolonged periods. Massive doses of",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "rlv 37x102 ld50 69ml flv 5x102 ld50 74ml pllvt2lv 51 x 103 ld50 66ml h179alv 5 x 104 ld50 56ml mlv glv titrated way since induced splenomegaly death prolonged periods massive doses"
  },
  {
    "id": 888,
    "paragraph": "these viruses were inoculated in the challenge experiments. Preparation and titration of transplantable Transplantable leukaemias leukaemia cells. were maintained by in vivo cellular passage every 7-14 days. Stock material was prepared by mincing leukaemic tissues in 10 volumes of PBS, filtering through a cotton gauze and",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "viruses inoculated challenge experiments preparation titration transplantable transplantable leukaemias leukaemia cells maintained vivo cellular passage every 714 days stock material prepared mincing leukaemic tissues 10 volumes pbs filtering cotton gauze"
  },
  {
    "id": 889,
    "paragraph": "storing in glass ampoules, sealed and frozen at - 196TC for storage. For titration, the number of viable cells was determined in the material by Trypan-blue unfrozen exclusion. The concentration was adjusted so as to inoculate 101-105 cells per mouse in",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "storing glass ampoules sealed frozen 196tc storage titration number viable cells determined material trypanblue unfrozen exclusion concentration adjusted inoculate 101105 cells per mouse"
  },
  {
    "id": 890,
    "paragraph": "0-2 ml, i.p. Death by 25 days was recorded and LD50 calculated. The LD50 of the leu- stock kaemias used was respectively: H110: 80 cells in 19 days, R14: 100 cells in 25 days, and P277: 50 cells in 20 days.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "02 ml ip death 25 days recorded ld50 calculated ld50 leu stock kaemias used respectively h110 80 cells 19 days r14 100 cells 25 days p277 50 cells 20 days"
  },
  {
    "id": 891,
    "paragraph": "The experimental protocol for immuno- prevention studies.-In order to test the live MSV-M immunogen, mice were subjected to a standardized protocol: inoculation of 0-2 ml MSV-M s.c. which induced localized sarcomas which quickly regressed, followed by a booster immunization 30-40 days later. The control",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "experimental protocol immuno prevention studiesin order test live msvm immunogen mice subjected standardized protocol inoculation 02 ml msvm sc induced localized sarcomas quickly regressed followed booster immunization 3040 days later control"
  },
  {
    "id": 892,
    "paragraph": "group received 0-2 ml of a supernatant of normal BALB/c muscle extracts. Challenge of the MSV-M immunized mice with either leukaemia virus or cells was accomplished 30 days after the booster immunization, when 4 months old. The incidence of mice were",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "group received 02 ml supernatant normal balbc muscle extracts challenge msvm immunized mice either leukaemia virus cells accomplished 30 days booster immunization 4 months old incidence mice"
  },
  {
    "id": 893,
    "paragraph": "primary and transplanted leukaemia in experi- mental and control mice was carefully recor- ded. All sick animals with evident spleno- megaly were sacrified and autopsied: presence of enlarged spleen, thymus or lymph nodes indicated leukaemia. The data were evaluated by the x2 and",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "primary transplanted leukaemia experi mental control mice carefully recor ded sick animals evident spleno megaly sacrified autopsied presence enlarged spleen thymus lymph nodes indicated leukaemia data evaluated x2"
  },
  {
    "id": 894,
    "paragraph": "Mann-Whitney U tests. RESULTS Characterization of MS V-M stock using dilutions Tumour incidence, tumour growth, sur- vival rate and immunological status were of studied different MSV-M stock inoculated either i.m. or route, tumour incidence s.c. By s.c. (Table I) and growth (Fig. 1) were greatly",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "mannwhitney u tests results characterization ms vm stock using dilutions tumour incidence tumour growth sur vival rate immunological status studied different msvm stock inoculated either im route tumour incidence sc sc table growth fig 1 greatly"
  },
  {
    "id": 895,
    "paragraph": "reduced, tumour regression was complete in all animals and the survival rate was considerably greater (Table I). MSV-M of the immunized survivors challenge TABLE I. Comparison of tumour incidence and survival rate of BALB/c mice inoculated with MSV-M s.c. and i.an.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "reduced tumour regression complete animals survival rate considerably greater table msvm immunized survivors challenge table comparison tumour incidence survival rate balbc mice inoculated msvm sc ian"
  },
  {
    "id": 896,
    "paragraph": "S.c. route I_ Incidence at Day 35 Sur-ival at Tumours/ No. mice* 11/12 10/12 9/12 2/10 0/1 2 ( 0 /o) 9 8 .3 7 75 2 0 D,_ ,y 35 0o/) DO 1( M() O( O() Of) 1( -- D)av 97",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "sc route incidence day 35 surival tumours mice 1112 1012 912 210 01 2 0 9 8 3 7 75 2 0 35 0o 1 1 dav 97"
  },
  {
    "id": 897,
    "paragraph": "(0%) 91 100 100 t100 100 I.m. route Inci(Ience at Day 35 -_- - Tumouirs/ No. mice* 12/12 12/12 12/12 8/12 0/12 (0) 100 100 loo 66 0 Survival at A D)ay '35 (0) 90 66 100 100 100 D)ay 97",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "0 91 100 100 t100 100 im route inciience day 35 tumouirs mice 1212 1212 1212 812 012 0 100 100 loo 66 0 survival day 35 0 90 66 100 100 100 day 97"
  },
  {
    "id": 898,
    "paragraph": "( 00) 30 16 70 100 100 Log of MSV-M (lillit ion - 1 -3 -4 -5 * Each mouise received 0-2 ml of MSV-INI, (liluitp(1 from a stock -with a titre of 15 x 105 TD50(35)/ml. MURINE LEUKAEMIA IMMIJNIZATION WITH MSV",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "00 30 16 70 100 100 log msvm lillit ion 1 3 4 5 mouise received 02 ml msvini liluitp1 stock titre 15 x 105 td5035ml murine leukaemia immijnization msv"
  },
  {
    "id": 899,
    "paragraph": "969 Subcutaneo I litramtisc l ar 12 .-..-.-.---------- 800 J 500 450 i 400 .350 x = 207 mg x = 329 mg 5 1 S1S 20 30 25 days S 10 1 '()20 5 30 .5 days @0 ~~~~~00 FiG. 1.- Tumour growth in BALB/c mice",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "969 subcutaneo litramtisc l ar 12 800 j 500 450 400 350 x 207 mg x 329 mg 5 1 s1s 20 30 25 days 10 1 20 5 30 5 days 0 00 fig 1 tumour growth balbc mice"
  },
  {
    "id": 900,
    "paragraph": "andl i.m. as average of dilution 10-1 - - --1 - - dilution 10-3; inoculated Tumour size 3 diam. (mm). dlilution ...... (lilution 10-4. with MSV-M s.c. calculated 10-2; - TABLE II. Comparison of tumour inci- dence (at 35 days) after MS V-M challenge",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "andl im average dilution 101 1 dilution 103 inoculated tumour size 3 diam mm dlilution lilution 104 msvm sc calculated 102 table ii comparison tumour inci dence 35 days ms vm challenge"
  },
  {
    "id": 901,
    "paragraph": "of BALB/c mice previously MS V-M- immunized s.c. or i.m. S.c. route Ttumour takes/ total challenged* 0/11 0/12 0/12 1/12 5/12 8/12 Log (lilution of immunizing inocultum -I -2 -3 -4 -5 Controls challengedc % 0 0 0 10 50 I.m. route",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "balbc mice previously ms vm immunized sc im sc route ttumour takes total challenged 011 012 012 112 512 812 log lilution immunizing inocultum 2 3 4 5 controls challengedc 0 0 0 10 50 im route"
  },
  {
    "id": 902,
    "paragraph": "Tumour takes/ total 0/2 0/1 0/7 1/9 6/12 0 0 0 8 41 66 * Witlh 0-1 ml of a 10-1 diltution of stock MSV-M i.m. showed that the s.c. route immunized as well as the i.m. one, even though 3 months",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "tumour takes total 02 01 07 19 612 0 0 0 8 41 66 witlh 01 ml 101 diltution stock msvm im showed sc route immunized well im one even though 3 months"
  },
  {
    "id": 903,
    "paragraph": "had since tumour regression (Table II). These data indicated clearly that with our MSV-M stock the s.c. route of immunization was the better of the two. elapsed Immunoprevention leukaemias of primary miurine Immunization against Moloney leuk- aemia.-Since the susceptibility to MLV",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "since tumour regression table ii data indicated clearly msvm stock sc route immunization better two elapsed immunoprevention leukaemias primary miurine immunization moloney leuk aemiasince susceptibility mlv"
  },
  {
    "id": 904,
    "paragraph": "decreased with age, adult BALB/c mice developed a moderate splenomegaly which progressed slowly, with many mice sur- viving beyond 1 year, so that immunity was evaluated by recording the inhibition of leukaemic splenomegaly (Basombrio et al., 1977). A group 15 MSV-M-immunized",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "decreased age adult balbc mice developed moderate splenomegaly progressed slowly many mice sur viving beyond 1 year immunity evaluated recording inhibition leukaemic splenomegaly basombrio et al 1977 group 15 msvmimmunized"
  },
  {
    "id": 905,
    "paragraph": "BALB/c mice received 0 5 ml of MLV i.p., of 150 u)iso 0 FIG. 2. immunized MSV-M Immunization Controls against primary Moloney leukaemia ........ Normal spleen. indicating leukaemia simultaneously with 1 5 controls. All mice were killed on Day 86 and the spleens",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "balbc mice received 0 5 ml mlv ip 150 uiso 0 fig 2 immunized msvm immunization controls primary moloney leukaemia normal spleen indicating leukaemia simultaneously 1 5 controls mice killed day 86 spleens"
  },
  {
    "id": 906,
    "paragraph": "weighed. There was a noticeable inhibition of splenomegaly protection against Moloney (P = 0 02, Mann-Whitney U test) in the MSV-M immunized mice (x = 207 mg; s.d. = 44 6 mg) with respect to the controls (x=329 mg; s.d. = 166 mg).",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "weighed noticeable inhibition splenomegaly protection moloney p 0 02 mannwhitney u test msvm immunized mice x 207 mg sd 44 6 mg respect controls x329 mg sd 166 mg"
  },
  {
    "id": 907,
    "paragraph": "Immunization against Rauscher leuk- aemia. Seventeen BALB/c mice immu- nized with MSV-M, together with 21 con- trols, received 0-2 ml of a 10-2 dilution of Survival % 100 90a 80- 70- , *\\ 60 50 40 30 - 20 10 50 100 150 200 250 300 350",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "immunization rauscher leuk aemia seventeen balbc mice immu nized msvm together 21 con trols received 02 ml 102 dilution survival 100 90a 80 70 60 50 40 30 20 10 50 100 150 200 250 300 350"
  },
  {
    "id": 908,
    "paragraph": "days FIG. 3. Immunization witlh MSV-M against im- primary Rauscher leukaemia. munized with MSV-M; ....... controls. 970 A. M. S. MAYER, M. A. BASOMBRIO AND C. D. PASQUALINI TABLE III. Palpable splenomegaly (at 32 days) in BALB/c mice immunized with MS V-M and challenged with FL V",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "days fig 3 immunization witlh msvm im primary rauscher leukaemia munized msvm controls 970 mayer basombrio c pasqualini table iii palpable splenomegaly 32 days balbc mice immunized ms vm challenged fl v"
  },
  {
    "id": 909,
    "paragraph": "Positive splenomegaly /Total mice Group o/ O MSV-M immunize(l Controls 5/20 16/23 25 69 <0-001 * Calculated by x2 test. the RLV stock. Both groups were ob- served for 358 days. A clear protection against the development of leukaemia was observed at Day 120 (Fig. 3). 14/17 (82%)",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "positive splenomegaly total mice group msvm immunizel controls 520 1623 25 69 0001 calculated x2 test rlv stock groups ob served 358 days clear protection development leukaemia observed day 120 fig 3 1417 82"
  },
  {
    "id": 910,
    "paragraph": "of MSV-M immunized mice surviving controls against (P < 0'00 1). Further observation showed that mortality progressively increased in both groups, only 4/17 (23%) of the MSV-M immunized mice and 2/21 (90) of the controls surviving at 369 days. (19%) 4/21",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "msvm immunized mice surviving controls p 000 1 observation showed mortality progressively increased groups 417 23 msvm immunized mice 221 90 controls surviving 369 days 19 421"
  },
  {
    "id": 911,
    "paragraph": "the of of group Immunization against Friend leukaemia. 21 MSV-M-immunized A group BALB/c mice, together with 23 controls, were challenged with FLV, each mouse receiving 0 2 ml of a 1/500 dilution of FLV stock. The survival rate was similar in both groups after 169 days of observa-",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "group immunization friend leukaemia 21 msvmimmunized group balbc mice together 23 controls challenged flv mouse receiving 0 2 ml 1500 dilution flv stock survival rate similar groups 169 days observa"
  },
  {
    "id": 912,
    "paragraph": "tion (7/21 immunized and 7/23 controls). As shown in Table III, there was a sig- inhibition of palpable spleno- nificant megaly 32 days after FLV challenge in the (P < 0-00 1) MSV-M immunized though this difference was not reflected in",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "tion 721 immunized 723 controls shown table iii sig inhibition palpable spleno nificant megaly 32 days flv challenge p 000 1 msvm immunized though difference reflected"
  },
  {
    "id": 913,
    "paragraph": "the survival data. Imnmunization Precerutti-Law against leukaemia.-A group of 19 MSV-M-im- munized BALB/c mice, together with 18 controls, were challenged i.p. with 0-2 ml of a 10-3 dilution of PLLV/T2. After 130 days clear protection was seen in the pre- treated group (Fig. 4) where 13/19 (68%)",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "survival data imnmunization preceruttilaw leukaemiaa group 19 msvmim munized balbc mice together 18 controls challenged ip 02 ml 103 dilution pllvt2 130 days clear protection seen pre treated group fig 4 1319 68"
  },
  {
    "id": 914,
    "paragraph": "survived whereas all the controls had died (P < 0.001; x2 test). On further observa- tion, immunized mice showed a pro- gressive mortality, since after 365 days, only 6/19 (32%) survived. Immunization against HI 79A leukaemia. 14 MSV-M-immunized -A group BALB/c mice, together with 18 controls,",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "survived whereas controls died p 0001 x2 test observa tion immunized mice showed pro gressive mortality since 365 days 619 32 survived immunization hi 79a leukaemia 14 msvmimmunized group balbc mice together 18 controls"
  },
  {
    "id": 915,
    "paragraph": "of Survival % 100 90 80 \\ . K '.\\ 70 60 50 40 30 20 10 N* 50 100 150 200 250 300 350 days FIG. 4.-Immunization with MSV-M against primary PLLV/T2 leukaemia. Key as in Fig. 3. were challenged i.p. with 0-2 ml of a 10-3",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "survival 100 90 80 k 70 60 50 40 30 20 10 n 50 100 150 200 250 300 350 days fig 4immunization msvm primary pllvt2 leukaemia key fig 3 challenged ip 02 ml 103"
  },
  {
    "id": 916,
    "paragraph": "dilution of H179A LV. At Day 46, 11/14 survived, of immunized mice (78%) 5; (Fig. against none of the controls P < 0001, x2 test). The animals were observed for 137 days, at which time 7/14 (50%o) had survived. Survival %",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "dilution h179a lv day 46 1114 survived immunized mice 78 5 fig none controls p 0001 x2 test animals observed 137 days time 714 50o survived survival"
  },
  {
    "id": 917,
    "paragraph": "100 \\_--' 90 80 0 70 60 50 40 30 20 10 20 40 60 80 100 120 140 days FIG. 5.- Immunization witli MSV-M against primary H 179 A leukaemia. Key as in Fig. 3. MURINE LEUKAEMIA IMMUNIZATION WITH MSV",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "100 90 80 0 70 60 50 40 30 20 10 20 40 60 80 100 120 140 days fig 5 immunization witli msvm primary h 179 leukaemia key fig 3 murine leukaemia immunization msv"
  },
  {
    "id": 918,
    "paragraph": "971 Survival % 100 F- 90 80 70 60 50 40 30 20 10 40 80 120 160 200 240 2'89 days of FIG. 6. Immunization with MSV-M against primary Gross leukaemia. Key as in Fig. 3. Immunization against Gross leukaemia.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "971 survival 100 f 90 80 70 60 50 40 30 20 10 40 80 120 160 200 240 289 days fig 6 immunization msvm primary gross leukaemia key fig 3 immunization gross leukaemia"
  },
  {
    "id": 919,
    "paragraph": "-A group 20 MSV-M-immunized Swiss mice, together with 22 controls, were challenged i.p. with 0-2 ml of a GLV supernatant. After 296 days, 9/20 (45%) immunized and 7/22 (31%) of control mice had survived (Fig. 6). There is no protection by MSV-M imnmunization",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "group 20 msvmimmunized swiss mice together 22 controls challenged ip 02 ml glv supernatant 296 days 920 45 immunized 722 31 control mice survived fig 6 protection msvm imnmunization"
  },
  {
    "id": 920,
    "paragraph": "against the development of Gross leuk- aemia. Imnmunoprotection of transplantable murine leukuaemias of Immunization against HI 1O leukaemnia. -A group 22 MSV-M-immunized BALB/c mice and 21 matched controls received 400 H1110 leukaemic cells in 0-2 ml i.p. Thirteen days after challenge,",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "development gross leuk aemia imnmunoprotection transplantable murine leukuaemias immunization hi 1o leukaemnia group 22 msvmimmunized balbc mice 21 matched controls received 400 h1110 leukaemic cells 02 ml ip thirteen days challenge"
  },
  {
    "id": 921,
    "paragraph": "21/22 (950) of the immunized mice sur- vived, compared to only 9/21 (47%o) of the controls (P < 0001; Fig. 7). However, this significant inhibition of leukaemia was eventually lost, since at Day 165 6/22 (27%) of immunized and 4/21 (19%) of",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "2122 950 immunized mice sur vived compared 921 47o controls p 0001 fig 7 however significant inhibition leukaemia eventually lost since day 165 622 27 immunized 421 19"
  },
  {
    "id": 922,
    "paragraph": "control mice survived. Protection against H1110 leukaemia was evident, but not long-lasting. Immunization against R14 leukaemia.- A group of 17 MSV-M-immunized BALB/c mice and 16 controls received 103 R14 Survival % 100 90 80 70 60 50 40 30 20 10",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "control mice survived protection h1110 leukaemia evident longlasting immunization r14 leukaemia group 17 msvmimmunized balbc mice 16 controls received 103 r14 survival 100 90 80 70 60 50 40 30 20 10"
  },
  {
    "id": 923,
    "paragraph": "10 20 30 40 50 100 165 days FIG. 7.- Immunization with MSV-M against transplantable HIIO leukaemia. Key as in Fig. 3. leukaemic cells in 0.2 ml i.p. Forty-four days later 12/17 (70%) of immunized and 6/16 (37%) of control mice survived",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "10 20 30 40 50 100 165 days fig 7 immunization msvm transplantable hiio leukaemia key fig 3 leukaemic cells 02 ml ip fortyfour days later 1217 70 immunized 616 37 control mice survived"
  },
  {
    "id": 924,
    "paragraph": "(P<0 001; Fig. 8). However, at Day 102 only 1/17 (6%) of immunized and 3/16 (18%) of control mice survived. Thus, protection against R 14 leukaemia was evident but not long-lasting. Immunization against P277 leukaernia.- A group of 19 MSV-M-immunized mice",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "p0 001 fig 8 however day 102 117 6 immunized 316 18 control mice survived thus protection r 14 leukaemia evident longlasting immunization p277 leukaernia group 19 msvmimmunized mice"
  },
  {
    "id": 925,
    "paragraph": "Survival % 100 LO 90 - 80 - 70 60 \"'*I * 50 40- 30- 20 - 10o 15 30 45 60 75 90 105 days FIG. 8. Immunization with MSV-M against transplantable RI4 leukaemia. Key as in Fig. 3. 972",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "survival 100 lo 90 80 70 60 50 40 30 20 10o 15 30 45 60 75 90 105 days fig 8 immunization msvm transplantable ri4 leukaemia key fig 3 972"
  },
  {
    "id": 926,
    "paragraph": "A. M. S. MAYER, M. A. BASOMBRIO AND C. D. PASQUALINI and 20 controls received only 14 cells of P277 leukaemia in 0-2 ml, i.p., since this leukaemia was highly lethal in very small cell doses. Neither the immunized nor the",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "mayer basombrio c pasqualini 20 controls received 14 cells p277 leukaemia 02 ml ip since leukaemia highly lethal small cell doses neither immunized"
  },
  {
    "id": 927,
    "paragraph": "control mice survived more than 14 days, all mice dying of progressive leukaemia, against which it was not possible to detect any protection. MSV-M immunization against spontaneous leukaemias Effect in BALB/c mice.-A group of 47 BALB/c mice received consecutive MSV-M inoculations at 3, 4 and 9 months",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "control mice survived 14 days mice dying progressive leukaemia possible detect protection msvm immunization spontaneous leukaemias effect balbc micea group 47 balbc mice received consecutive msvm inoculations 3 4 9 months"
  },
  {
    "id": 928,
    "paragraph": "of age, while 51 matched controls re- After 504 days of mained untreated. observation (Fig. 9) mortality was greater 3 Survival 90 . 80 - 60 50 40 30 20 10 '0 0. 0 250 300 350 400 450 500 550",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "age 51 matched controls 504 days mained untreated observation fig 9 mortality greater 3 survival 90 80 60 50 40 30 20 10 0 0 0 250 300 350 400 450 500 550"
  },
  {
    "id": 929,
    "paragraph": "days FIG. 9. Immunization against spontaneous leukaemia in BALB/c mice. Key as in Fig. 3. in the immunized than in the control mice; 29/36 (55%o) of the observed deaths in the MSV-M-immnunized group occurred between 300 and 370 days of age, which",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "days fig 9 immunization spontaneous leukaemia balbc mice key fig 3 immunized control mice 2936 55o observed deaths msvmimmnunized group occurred 300 370 days age"
  },
  {
    "id": 930,
    "paragraph": "was 30 days after the final MSV-M booster inoculation. An analysis of leukaemia incidence (Table IV) showed that 4 con- firmed and 14 presumptive leukaemias appeared in the immunized group and in the controls. This protocol only 1 actually increased the incidence of spon-",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "30 days final msvm booster inoculation analysis leukaemia incidence table iv showed 4 con firmed 14 presumptive leukaemias appeared immunized group controls protocol 1 actually increased incidence spon"
  },
  {
    "id": 931,
    "paragraph": "taneous leukaemia in BALB/c mice. Effect in (Swiss x AKR) F1 mice. (Swiss x AKR) F1 mice presented a 350o incidence of spontaneous leukaemia in an average of 18 months. In this experiment only one inoculation of MSV-M was used to immunize the mice, in order to reduce",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "taneous leukaemia balbc mice effect swiss x akr f1 mice swiss x akr f1 mice presented 350o incidence spontaneous leukaemia average 18 months experiment one inoculation msvm used immunize mice order reduce"
  },
  {
    "id": 932,
    "paragraph": "TABLE IV. Incidence of spontaneous leuk- aemias in MSV-M-immunized BALB/c mice observed for 504 days Leukaemia Palpable spleens + lymph nodes* Normal Other causes of dleath* Other tumours Total MSV-MI immtunized Controls 4 14 11 18 47 1 27 22 1",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "table iv incidence spontaneous leuk aemias msvmimmunized balbc mice observed 504 days leukaemia palpable spleens lymph nodes normal causes dleath tumours total msvmi immtunized controls 4 14 11 18 47 1 27 22 1"
  },
  {
    "id": 933,
    "paragraph": "51 * Mice died suddenly so possible. that no necropsy was Sunrival °O 100 90 80 70 60 50 40 30 20 10 150 200 300 350 400 450 500 330 days FiG. 10. Immunization against spontaneous leukaemia in F1 (Swiss x AKR) mice. Key",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "51 mice died suddenly possible necropsy sunrival °o 100 90 80 70 60 50 40 30 20 10 150 200 300 350 400 450 500 330 days fig 10 immunization spontaneous leukaemia f1 swiss x akr mice key"
  },
  {
    "id": 934,
    "paragraph": "as in Fig. 3. the possibility of increased mortality as seen in MSV-M-immunized BALB/c mice. After 528 days of observation (Fig. 10) both the MSV-M-immunized and the con- trol mice showed a very similar pattern of mortality. However, pathological observa- tion demonstrated that although the inci-",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "fig 3 possibility increased mortality seen msvmimmunized balbc mice 528 days observation fig 10 msvmimmunized con trol mice showed similar pattern mortality however pathological observa tion demonstrated although inci"
  },
  {
    "id": 935,
    "paragraph": "I . tf I10 9 9 8 7 6 = ,, 0 5 4 r-: 3 m 2 i1 It- 0 If 7 8 9 10 l1l 12 13 14 15 16 17 18 Mornths (;age) FIG. 11. Immunization against spontaneous",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "tf i10 9 9 8 7 6 0 5 4 r 3 2 i1 0 7 8 9 10 l1l 12 13 14 15 16 17 18 mornths age fig 11 immunization spontaneous"
  },
  {
    "id": 936,
    "paragraph": "leukaemia in F1 (Swiss x AKR) mice. Key as in Fig. 3. MURINE LEUKAEMIA IMMUNIZATION WITH MSV 973 27°,) groups was similar, dence of leukaemia in both MSV-M- immunized (10/42, 23%) and control (11/47, the leukaemias appearing in the MSV-M- immunized mice up to 13 months of age",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "leukaemia f1 swiss x akr mice key fig 3 murine leukaemia immunization msv 973 27° groups similar dence leukaemia msvm immunized 1042 23 control 1147 leukaemias appearing msvm immunized mice 13 months age"
  },
  {
    "id": 937,
    "paragraph": "had shorter latency than those seen in the controls (P < 0.02) (Fig. 11). Thus this protocol did not prevent spontaneous leukaemogenesis (Swiss x AKR) F1 hybrids, but rather accelerated the onset of leukaemia. in DISCUSSION Because of the different biological be-",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "shorter latency seen controls p 002 fig 11 thus protocol prevent spontaneous leukaemogenesis swiss x akr f1 hybrids rather accelerated onset leukaemia discussion different biological"
  },
  {
    "id": 938,
    "paragraph": "haviour of MSV-M strains (Lavrin et al., 1973) our studies began with an immuno- logical and virological characterization of the MSV-M viral strain to be used. The s.c. route of inoculation was chosen be- cause it induced smaller tumours which regressed more rapidly, so that survival",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "haviour msvm strains lavrin et al 1973 studies began immuno logical virological characterization msvm viral strain used sc route inoculation chosen cause induced smaller tumours regressed rapidly survival"
  },
  {
    "id": 939,
    "paragraph": "was greater, though the immunity in- duced was as strong as with the i.m. route. Moreover, the long-term pathogenicity responsible for recurrences of sarcoma in sites different from the first inoculation (diaphragm, spleen, liver) was also sig- nificantly reduced. The explanation may",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "greater though immunity duced strong im route moreover longterm pathogenicity responsible recurrences sarcoma sites different first inoculation diaphragm spleen liver also sig nificantly reduced explanation may"
  },
  {
    "id": 940,
    "paragraph": "be that in the s.c. region there is less muscular tissue available for the replica- tion of the virus with special tropism for this tissue. The effectiveness of the experi- mental protocol using MSV-M as a live vaccine for immunoprevention studies",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "sc region less muscular tissue available replica tion virus special tropism tissue effectiveness experi mental protocol using msvm live vaccine immunoprevention studies"
  },
  {
    "id": 941,
    "paragraph": "was confirmed in the first group of experi- ments in which immunized mice were challenged with FLV, RLV7 and MLV, also used in other laboratories for immuno- prevention assays. Extension of the ex- periments to other leukaemia viruses originating our laboratory showed",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "confirmed first group experi ments immunized mice challenged flv rlv7 mlv also used laboratories immuno prevention assays extension ex periments leukaemia viruses originating laboratory showed"
  },
  {
    "id": 942,
    "paragraph": "in effective protection against primary leuk- aemias induced by PLLV and HI 79A/LV. However, although serological data (Fefer, 1967) and in immunization with MSV-G (Basombrio et al., 1977) have indicated the presence of cross-reacting antigens in GLV' and MSV-M, no significant",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "effective protection primary leuk aemias induced pllv hi 79alv however although serological data fefer 1967 immunization msvg basombrio et al 1977 indicated presence crossreacting antigens glv msvm significant"
  },
  {
    "id": 943,
    "paragraph": "protection against GLV could be detected. Transplantable cellular leukaemias, to on the found in long-term negative to sensitive in vivo virus onco- genicity assays, were also tested. It was observed that the evolution of H 110 leukaemia, and to a lesser degree R 14",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "protection glv could detected transplantable cellular leukaemias found longterm negative sensitive vivo virus onco genicity assays also tested observed evolution h 110 leukaemia lesser degree r 14"
  },
  {
    "id": 944,
    "paragraph": "leukaemia, could be retarded. However, P277, an extremely fast-growing and lethal leukaemia, could not be prevented, in spite of being originally induced by Moloney virus. The studies on the effect of MSV-M immunity leukaemo- spontaneous genesis in BALB/c and (Swiss x AKR) F1",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "leukaemia could retarded however p277 extremely fastgrowing lethal leukaemia could prevented spite originally induced moloney virus studies effect msvm immunity leukaemo spontaneous genesis balbc swiss x akr f1"
  },
  {
    "id": 945,
    "paragraph": "hybrids were complicated by difficulties related observations. In BALB/c mice, which had received 3 MSV-M injections, mortality was in- creased: MSV-M was shown to exist in leukaemic spleens of these mice, since acellular s.c. passage led to local growth of sarcoma. This increased mortality was",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "hybrids complicated difficulties related observations balbc mice received 3 msvm injections mortality creased msvm shown exist leukaemic spleens mice since acellular sc passage led local growth sarcoma increased mortality"
  },
  {
    "id": 946,
    "paragraph": "(Swiss x AKR) F1 not hybrids, probably because only one MSV- M immunizing dose was used; leukaemia incidence was similar in both experimental and control groups, MSV-M-immunized mice showing significantly earlier spon- taneous leukaemia up to 13 months of age. observation",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "swiss x akr f1 hybrids probably one msv immunizing dose used leukaemia incidence similar experimental control groups msvmimmunized mice showing significantly earlier spon taneous leukaemia 13 months age observation"
  },
  {
    "id": 947,
    "paragraph": "of MSV-M- immunized mice challenged with leuk- aemia viruses, transplantable leukaemias or controlled for the incidence of spon- taneous leukaemias, revealed increased mortality. How can this be explained? In the first place, in vivo interaction between infectious FLV, MLV, RLV and MSV-M",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "msvm immunized mice challenged leuk aemia viruses transplantable leukaemias controlled incidence spon taneous leukaemias revealed increased mortality explained first place vivo interaction infectious flv mlv rlv msvm"
  },
  {
    "id": 948,
    "paragraph": "could increase the oncogenicity of MSV-M (Chirigos et al., 1968; Turner & Chirigos, 1969). New phenotypic mixtures might assemble between the inoculated leuk- aemia virus and the MSV-M used for immunization (Chieco-Bianchi et al., 1975). In certain mouse strains, notably C58 and",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "could increase oncogenicity msvm chirigos et al 1968 turner chirigos 1969 new phenotypic mixtures might assemble inoculated leuk aemia virus msvm used immunization chiecobianchi et al 1975 certain mouse strains notably c58"
  },
  {
    "id": 949,
    "paragraph": "AKR, the MSV-M forms phenotypic mix- tures with the endogenous GLV, pro- ducing new pseudotypes that could induce sarcomas of lethal and progressive growth (Chieco-Bianchi et al., 1974). Thus pheno- typic mixing could provide new genetic information which would modify the",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "akr msvm forms phenotypic mix tures endogenous glv pro ducing new pseudotypes could induce sarcomas lethal progressive growth chiecobianchi et al 1974 thus pheno typic mixing could provide new genetic information would modify"
  },
  {
    "id": 950,
    "paragraph": "biology and pathogenicity of the original pseudotype used as immunogen. Secondly, Long-term 974 A. M. S. MAYER, M. A. BASOMBRIO AND C. D. PASQUALINI it has been observed that after regression of MSV-M-induced sarcomas the virus remains in the lymphoid tissues of the",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "biology pathogenicity original pseudotype used immunogen secondly longterm 974 mayer basombrio c pasqualini observed regression msvminduced sarcomas virus remains lymphoid tissues"
  },
  {
    "id": 951,
    "paragraph": "mouse as a persistent infection controlled by the host (Chieco-Bianchi & Collavo, 1976; Giuliani et al., 1973). On the other hand, 6-month-old mice show again a great sensitivity to MSV-M oncogenesis (Pazmifio & Yuhas, 1973). Thus renewed MSV-M sarcomagenesis might cause un-",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "mouse persistent infection controlled host chiecobianchi collavo 1976 giuliani et al 1973 hand 6monthold mice show great sensitivity msvm oncogenesis pazmifio yuhas 1973 thus renewed msvm sarcomagenesis might cause un"
  },
  {
    "id": 952,
    "paragraph": "expected mortality in long-term experi- ments due to reactivation of the virus. Thirdly, the genotype of mice has a great bearing on the result of MSV-M onco- genesis: BALB/c mice are known to be very susceptible, whilst (Swiss x AKR) F1",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "expected mortality longterm experi ments due reactivation virus thirdly genotype mice great bearing result msvm onco genesis balbc mice known susceptible whilst swiss x akr f1"
  },
  {
    "id": 953,
    "paragraph": "hybrids are very resistant (Colombatti et al., 1975) which could account for the observed difference in mortality. Could inactivation of the immunizing MSV-M virus override these difficulties? Probably not, since recent observations have shown that the protein fraction gp7l from FLV inoculated in C57 and AKR",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "hybrids resistant colombatti et al 1975 could account observed difference mortality could inactivation immunizing msvm virus override difficulties probably since recent observations shown protein fraction gp7l flv inoculated c57 akr"
  },
  {
    "id": 954,
    "paragraph": "mice produces viral activation (Ihle et al., 1976a). This would suggest a mechanism mediated by viral components, an effect capable of complicating any study on the viral immunoprevention of murinie leuk- aemia. The blocking of viral replication would not be a sufficient guarantee to",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "mice produces viral activation ihle et al 1976a would suggest mechanism mediated viral components effect capable complicating study viral immunoprevention murinie leuk aemia blocking viral replication would sufficient guarantee"
  },
  {
    "id": 955,
    "paragraph": "hinder the activation of endogenous virus which would lead to leukaemic transforma- tion in mice subjected to long observation. Recapitulating, our protocol, using a live MSV-M vaccine, proved successful in short-term experiments, protecting against the induction of primary leukaemias and leuk-",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "hinder activation endogenous virus would lead leukaemic transforma tion mice subjected long observation recapitulating protocol using live msvm vaccine proved successful shortterm experiments protecting induction primary leukaemias leuk"
  },
  {
    "id": 956,
    "paragraph": "BARsKI, G. & YOUN, J. K. (1965) Immunization against Rauscher Mouse Leukemia with tissue culture material. Science, 149, 751. isotransplanted B SOMBRIO, M. A., MAYER, M. A. S. & PASQUALINI, Gross C. D. (1977) Murine sarcoma virus pseudotypes used as immunogens against viral and chemical",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "barski g youn j k 1965 immunization rauscher mouse leukemia tissue culture material science 149 751 isotransplanted b sombrio mayer pasqualini gross c 1977 murine sarcoma virus pseudotypes used immunogens viral chemical"
  },
  {
    "id": 957,
    "paragraph": "oncogenesis. Cancer Res., 37, 1768. BIANCO, A. R., GLYNN, J. P. & GOLDIN, A. (1966) Induction of resistance against the transplanta- tion of leukemias induced by Rauscher virus. Cancer Res., 26, 1722. CHIECO-BIANCHI, L., COLLAVO, D., COLOMBATTI, A., SENDO, F., AOKI, T. & FIsCHINGER, P. J. (1974)",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "oncogenesis cancer res 37 1768 bianco r glynn j p goldin 1966 induction resistance transplanta tion leukemias induced rauscher virus cancer res 26 1722 chiecobianchi l collavo colombatti sendo f aoki fischinger p j 1974"
  },
  {
    "id": 958,
    "paragraph": "Tumor induction by murine sarcoma virus in AKR and C58 mice. J. Exp. Med., 140, 1162. CHIECO-BIANCHI, L., COLLAVO, D., COLOMBATTI, A. & BIASI, G. (1975) In vivo interactions between murine leukemia and sarcoma viruses. In Com- parative Leukemia Research, 1973. p. 613.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "tumor induction murine sarcoma virus akr c58 mice j exp med 140 1162 chiecobianchi l collavo colombatti biasi g 1975 vivo interactions murine leukemia sarcoma viruses com parative leukemia research 1973 p 613"
  },
  {
    "id": 959,
    "paragraph": "CHIECO-BIANCHI, L. & COLLAVO, D. (1976) Some illustrative systems of viral carcinogenesis: The leukemia sarcoma virus complex in the mouse. In Scientiftc Foundations of Oncology. Ed. Sym- mington & Carter. CHIRIGos, M. A., PERK, K., TURNER, W., BURKA, B. & GOMEZ, M. (1968) Increased oncogenicity of the",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "chiecobianchi l collavo 1976 illustrative systems viral carcinogenesis leukemia sarcoma virus complex mouse scientiftc foundations oncology ed sym mington carter chirigos perk k turner w burka b gomez 1968 increased oncogenicity"
  },
  {
    "id": 960,
    "paragraph": "murine sarcoma virus (Moloney) by coinfection with murine leukemia viruses. Cancer Res., 28, 1055. COLOMBATTI, A., COLLAVO, D., BIASI, G. & CHIECO- BIANCHI, L. (1975) Genetic control of oncogenesis by murine sarcoma virus Moloney pseudotype. I. Genetics of resistance in AKR mice. Int. J.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "murine sarcoma virus moloney coinfection murine leukemia viruses cancer res 28 1055 colombatti collavo biasi g chieco bianchi l 1975 genetic control oncogenesis murine sarcoma virus moloney pseudotype genetics resistance akr mice int j"
  },
  {
    "id": 961,
    "paragraph": "Cancer, 16, 427. FEFER, A. FEFER, A., McCoy, J. L. & GLYNN, J. P. (1967) Antigenicity of a virus induced murine sarcoma (Moloney). Cancer Res., 27, 962. FEFER, A. (1967) Neutralization of the oncogenicity of Moloney Sarcoma virus and Moloney leukemia",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "cancer 16 427 fefer fefer mccoy j l glynn j p 1967 antigenicity virus induced murine sarcoma moloney cancer res 27 962 fefer 1967 neutralization oncogenicity moloney sarcoma virus moloney leukemia"
  },
  {
    "id": 962,
    "paragraph": "virus by anti-Gross serum. Int. J. Cancer, 3, 647. virologic and pathologic studies of regression of autochthonous Moloney Sarcoma virus induced tumors in mice. Cancer Res., 28, 1577. Immunologic, FINK, M. A. & RAUSCHER, F. J. (1964) Immune reactions to a murine leukemia virus. I. Induction",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "virus antigross serum int j cancer 3 647 virologic pathologic studies regression autochthonous moloney sarcoma virus induced tumors mice cancer res 28 1577 immunologic fink rauscher f j 1964 immune reactions murine leukemia virus induction"
  },
  {
    "id": 963,
    "paragraph": "of immunity to infection with virus in the natural host. J. Natl Cancer Inst., 32, 1075. (1968) FRIEND, C. (1959) Immunological relationships of a filterable agent causing leukemia in mice (adult). I. Neutralization of infectivity by specific anti- serum. J. Exp. Med., 109, 217.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "immunity infection virus natural host j natl cancer inst 32 1075 1968 friend c 1959 immunological relationships filterable agent causing leukemia mice adult neutralization infectivity specific anti serum j exp med 109 217"
  },
  {
    "id": 964,
    "paragraph": "GIULIANI, F., SORANZO, C., CASAZZA, A. M. & DI MARCO, A. (1973) Oncogenicita de celule linfoidi inmuni verso il sarcoma murino di Moloney. Tumori, 59, 269. GLYNN, J. P., BIANCO, A. R. & GOLDIN, A. (1964) Studies on induced resistance against isotrans-",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "giuliani f soranzo c casazza di marco 1973 oncogenicita de celule linfoidi inmuni verso il sarcoma murino di moloney tumori 59 269 glynn j p bianco r goldin 1964 studies induced resistance isotrans"
  },
  {
    "id": 965,
    "paragraph": "plants of virus-induced leukemia. Cancer Res., 24, 502. GLYNN, J. P., McCoy, J. L. & FEFER, A. (1968) Cross-resistance to the transplantation of syn- geneic Friend, Moloney and Rauscher virus- induced tumors. Cancer Res., 28, 434. HARVEY, J. J. & EAST, J. (1971) The murine sarcoma",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "plants virusinduced leukemia cancer res 24 502 glynn j p mccoy j l fefer 1968 crossresistance transplantation syn geneic friend moloney rauscher virus induced tumors cancer res 28 434 harvey j j east j 1971 murine sarcoma"
  },
  {
    "id": 966,
    "paragraph": "virus (MSV). Int. Rev. Exp. Pathol., 10, 265. HUEBNER, R. J., GILDEN, R. V., LANE, W. T., TONI, R., TRIMMER, R. W. & HILL, P. (1976) Suppression of murine type-C-RNA virogenes by type-specific oncornavirus vaccines: Prospects for prevention of cancer. Proc. Natl Acad. Sci.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "virus msv int rev exp pathol 10 265 huebner r j gilden r v lane w toni r trimmer r w hill p 1976 suppression murine typecrna virogenes typespecific oncornavirus vaccines prospects prevention cancer proc natl acad sci"
  },
  {
    "id": 967,
    "paragraph": "U.S.A., 73, 620. HUNSMANN, G., MOENNIG, V. & SCHAFER, W. (1975) Properties of mouse leukemia viruses: IX. Active MURINE LEUKAEMIA IMMUNIZATION WITH MSV 975 passive immunization and against Friend Leukemia with isolated viral gp7l glyco- protein and its corresponding antiserum. Virology,",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "usa 73 620 hunsmann g moennig v schafer w 1975 properties mouse leukemia viruses ix active murine leukaemia immunization msv 975 passive immunization friend leukemia isolated viral gp7l glyco protein corresponding antiserum virology"
  },
  {
    "id": 968,
    "paragraph": "66, 327. of mice (gp7l) (gp7l) IHLE, J. N., COLLINS, J. J., LEE, J. C. & 5 others (1976a) Characterization of the immune response of Friend to leukemia virus I. Response in BALB/c mice. Virology, 75, 74. the major glycoprotein IHLE, J. N., COLLINS, J. J., LEE, J. C. & 5 others",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "66 327 mice gp7l gp7l ihle j n collins j j lee j c 5 others 1976a characterization immune response friend leukemia virus response balbc mice virology 75 74 major glycoprotein ihle j n collins j j lee j c 5 others"
  },
  {
    "id": 969,
    "paragraph": "(1976b) Characterization of the immune response to the major glycoprotein of Friend leukemia virus. II. Response in C57BL/6 mice. Virology, 75, 88. KELLOFF, G. J., PETERS, R. L., DONAHOE, R. M. & 4 others (1976) An approach to C-type virus immunoprevention of spontaneously occurring",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "1976b characterization immune response major glycoprotein friend leukemia virus ii response c57bl6 mice virology 75 88 kelloff g j peters r l donahoe r 4 others 1976 approach ctype virus immunoprevention spontaneously occurring"
  },
  {
    "id": 970,
    "paragraph": "tumours in laboratory mice. Cancer Res., 36, 622. KLEIN, E. & KLEIN, G. (1964) Antigenic properties of lymphomas induced by the Moloney Agent. J. Natl Cancer Inst., 32, 547. LAMON, E. W., ANDERSSON, B., WIGZELL, H., FENYO, E. M. & KLEIN, E. (1974) The immune",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "tumours laboratory mice cancer res 36 622 klein e klein g 1964 antigenic properties lymphomas induced moloney agent j natl cancer inst 32 547 lamon e w andersson b wigzell h fenyo e klein e 1974 immune"
  },
  {
    "id": 971,
    "paragraph": "to primary Moloney sarcoma virus response tumors in BALB/c mice: Cellular and humoral activity of long-term regressors. Int. J. Cancer, 13, 91. LAVRIN, D. H., HERBERMAN, R. B., NUNN, M. & SOARES, N. (1973) In vitro cytotoxicity studies of Murine Sarcoma virus-induced immunity in mice.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "primary moloney sarcoma virus response tumors balbc mice cellular humoral activity longterm regressors int j cancer 13 91 lavrin h herberman r b nunn soares n 1973 vitro cytotoxicity studies murine sarcoma virusinduced immunity mice"
  },
  {
    "id": 972,
    "paragraph": "J. Natl Cancer Inst., 51, 1497. MAYYASI, S. A. & MOLONEY, J. B. (1967) Induced resistance of mice to a lymphoid strain of leukemia virus (Moloney). Cancer, 20, 1124. MAYYASI, S. A., FOSTER, H. F., BULFONE, L. M., WRIGHT, B. S. & SHIBLEY, G. P. (1968) Induction",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "j natl cancer inst 51 1497 mayyasi moloney j b 1967 induced resistance mice lymphoid strain leukemia virus moloney cancer 20 1124 mayyasi foster h f bulfone l wright b shibley g p 1968 induction"
  },
  {
    "id": 973,
    "paragraph": "of immunity in mice with tissue culture cells chronically infected with Rauscher leukemia virus. Proc. Soc. Exp. Biol. Med., 128, 1088. McCoy, J. L., FEFER, A. & GLYNN, J. P. (1967) Influence of infectious virus on the induction of transplantation resistance in the Friend tumor",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "immunity mice tissue culture cells chronically infected rauscher leukemia virus proc soc exp biol med 128 1088 mccoy j l fefer glynn j p 1967 influence infectious virus induction transplantation resistance friend tumor"
  },
  {
    "id": 974,
    "paragraph": "system. Cancer Re8., 27, 2266. PASQUALINI, C. D., SAAL, F., SEN, L. & RABASA, S. L. (1968) Leucemia murina. Medicina (B. Aires), 28, 116. PASTERNAK, G. & GRAFFI, A. (1963) Induction of resistance against isotransplantation of virus- induced myeloid leukaemias. Br. J. Cancer, 17,",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "system cancer re8 27 2266 pasqualini c saal f sen l rabasa l 1968 leucemia murina medicina b aires 28 116 pasternak g graffi 1963 induction resistance isotransplantation virus induced myeloid leukaemias br j cancer 17"
  },
  {
    "id": 975,
    "paragraph": "532. PAZMJNO, N. H. & YUHAS, J. M. (1973) Senescent loss of resistance to murine sarcoma virus (Molo- ney) in the mouse. Cancer Res., 33, 2668. PERK, K. & MOLONEY, J. B. (1966) Pathogenesis of a virus-induced rhabdomyosarcoma in mice. J.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "532 pazmjno n h yuhas j 1973 senescent loss resistance murine sarcoma virus molo ney mouse cancer res 33 2668 perk k moloney j b 1966 pathogenesis virusinduced rhabdomyosarcoma mice j"
  },
  {
    "id": 976,
    "paragraph": "Natl Cancer Inst., 37, 581. PRECERRUTTI, A. & LAW, L. W. (1963) Isolation of a murine leukaemogenic virus PLLV. Nature, 198, 801. SACHS, L. (1962) Transplantability of an X-ray- induced and a virus-induced leukemia in isologous mice inoculated with a leukemia virus. J. Natl",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "natl cancer inst 37 581 precerrutti law l w 1963 isolation murine leukaemogenic virus pllv nature 198 801 sachs l 1962 transplantability xray induced virusinduced leukemia isologous mice inoculated leukemia virus j natl"
  },
  {
    "id": 977,
    "paragraph": "Cancer Inst., 29, 759. SIMONS, P. J. & MCCULLY, D. J. (1970) Pathologic and virologic studies of tumors induced in mice by two strains of murine sarcoma virus. J. Natl Cancer Inst., 44, 1289. SLETTENMARK, B. & KLEIN, E. (1962) Cytotoxic",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "cancer inst 29 759 simons p j mccully j 1970 pathologic virologic studies tumors induced mice two strains murine sarcoma virus j natl cancer inst 44 1289 slettenmark b klein e 1962 cytotoxic"
  },
  {
    "id": 978,
    "paragraph": "and neutralization tests with serum and lymph node cells of isologous mice with induced resistance against Gross lymphoma. Cancer Res., 22, 947. TURNER, W. & CHIRIGOS, M. A. (1969) Enhancement of murine sarcoma virus (Moloney) infection and tumorigenesis in vivo by coinfection with Rauscher",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "neutralization tests serum lymph node cells isologous mice induced resistance gross lymphoma cancer res 22 947 turner w chirigos 1969 enhancement murine sarcoma virus moloney infection tumorigenesis vivo coinfection rauscher"
  },
  {
    "id": 979,
    "paragraph": "leukemia virus. Cancer Res., 29, 1956. TYNDALL, R. L., OTTEN, J. A., TEETER, E. & BOWLES, N. D. (1967) Inhibition of solid tumor formation by prior immunization with formalized neoplastic spleen extracts. Proc. Soc. Exp. Biol. Med., 125, 399.",
    "jurnal": "brjcancer00465-0111.pdf",
    "processed": "leukemia virus cancer res 29 1956 tyndall r l otten j teeter e bowles n 1967 inhibition solid tumor formation prior immunization formalized neoplastic spleen extracts proc soc exp biol med 125 399"
  },
  {
    "id": 980,
    "paragraph": "Article CRISPR Gene Editing of Murine Blood Stem and Progenitor Cells Induces MLL-AF9 Chromosomal Translocation and MLL-AF9 Leukaemogenesis Evgenia Sarrou 1, Laura Richmond 1, Ruaidhrí J. Carmody 2 Karen Keeshan 1,* , Brenda Gibson 3 and 1 Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow,",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "article crispr gene editing murine blood stem progenitor cells induces mllaf9 chromosomal translocation mllaf9 leukaemogenesis evgenia sarrou 1 laura richmond 1 ruaidhrí j carmody 2 karen keeshan 1 brenda gibson 3 1 paul ’ gorman leukaemia research centre institute cancer sciences university glasgow"
  },
  {
    "id": 981,
    "paragraph": "Glasgow G12 0YN, UK; t.sarrou@gmail.com (E.S.); Laura.Richmond@glasgow.ac.uk (L.R.) 2 Centre for Immunobiology, Institute of Infection, Immunity & Inﬂammation, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK; ruaidhri.carmody@glasgow.ac.uk 3 Royal Hospital for Children, Glasgow G51 4TF, UK; Brenda.Gibson@ggc.scot.nhs.uk",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "glasgow g12 0yn uk tsarrougmailcom es laurarichmondglasgowacuk lr 2 centre immunobiology institute infection immunity inﬂammation college medicine veterinary life sciences university glasgow glasgow g12 8ta uk ruaidhricarmodyglasgowacuk 3 royal hospital children glasgow g51 4tf uk brendagibsonggcscotnhsuk"
  },
  {
    "id": 982,
    "paragraph": "* Correspondence: Karen.keeshan@glasgow.ac.uk Received: 21 May 2020; Accepted: 10 June 2020; Published: 15 June 2020 Abstract: Chromosomal rearrangements of the mixed lineage leukaemia (MLL, also known as KMT2A) gene on chromosome 11q23 are amongst the most common genetic abnormalities observed in human",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "correspondence karenkeeshanglasgowacuk received 21 may 2020 accepted 10 june 2020 published 15 june 2020 abstract chromosomal rearrangements mixed lineage leukaemia mll also known kmt2a gene chromosome 11q23 amongst common genetic abnormalities observed human"
  },
  {
    "id": 983,
    "paragraph": "acute leukaemias. MLL rearrangements (MLLr) are the most common cytogenetic abnormalities in infant and childhood acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL) and do not normally acquire secondary mutations compared to other leukaemias. To model these leukaemias, we have used clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "acute leukaemias mll rearrangements mllr common cytogenetic abnormalities infant childhood acute myeloid leukaemia aml acute lymphocytic leukaemia normally acquire secondary mutations compared leukaemias model leukaemias used clustered regularly interspaced short palindromic repeats crisprcas9"
  },
  {
    "id": 984,
    "paragraph": "gene editing to induce MLL-AF9 (MA9) chromosomal rearrangements in murine hematopoietic stem and progenitor cell lines and primary cells. By utilizing a dual-single guide RNA (sgRNA) approach targeting the breakpoint cluster region of murine Mll and Af9 equivalent to that in human",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "gene editing induce mllaf9 ma9 chromosomal rearrangements murine hematopoietic stem progenitor cell lines primary cells utilizing dualsingle guide rna sgrna approach targeting breakpoint cluster region murine mll af9 equivalent human"
  },
  {
    "id": 985,
    "paragraph": "MA9 rearrangements, we show eﬃcient de novo generation of MA9 fusion product at the DNA and RNA levels in the bulk population. The leukaemic features of MA9-induced disease were observed including increased clonogenicity, enrichment of c-Kit-positive leukaemic stem cells and increased MA9 target gene expression. This approach provided a rapid and reliable means of de",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "ma9 rearrangements show eﬃcient de novo generation ma9 fusion product dna rna levels bulk population leukaemic features ma9induced disease observed including increased clonogenicity enrichment ckitpositive leukaemic stem cells increased ma9 target gene expression approach provided rapid reliable means de"
  },
  {
    "id": 986,
    "paragraph": "novo generation of Mll-Af9 genetic rearrangements in murine haematopoietic stem and progenitor cells (HSPCs), using CRISPR/Cas9 technology to produce a cellular model of MA9 leukaemias which faithfully reproduces many features of the human disease in vitro. Keywords: CRISPR/Cas9; chromosomal translocation; mixed lineage leukaemia; tumourigenesis;",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "novo generation mllaf9 genetic rearrangements murine haematopoietic stem progenitor cells hspcs using crisprcas9 technology produce cellular model ma9 leukaemias faithfully reproduces many features human disease vitro keywords crisprcas9 chromosomal translocation mixed lineage leukaemia tumourigenesis"
  },
  {
    "id": 987,
    "paragraph": "stem cells 1. Introduction Rearrangements of the mixed lineage leukaemia gene (MLLr) are the most common cytogenetic abnormalities found in infant and childhood acute lymphocytic leukaemia (ALL) and acute myeloid leukaemia (AML) [1] and are found in 80% and 35–50% of all paediatric ALL and AML cases",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "stem cells 1 introduction rearrangements mixed lineage leukaemia gene mllr common cytogenetic abnormalities found infant childhood acute lymphocytic leukaemia acute myeloid leukaemia aml 1 found 80 35–50 paediatric aml cases"
  },
  {
    "id": 988,
    "paragraph": "respectively [1]. These leukaemias do not typically acquire many secondary mutations [2] and are thought to result from inappropriate repair of DNA double strand breaks (DSBs) via nonhomologous end joining (NHEJ) in haematopoietic cells [3]. As the 8.3-kb breakpoint cluster region of mixed",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "respectively 1 leukaemias typically acquire many secondary mutations 2 thought result inappropriate repair dna double strand breaks dsbs via nonhomologous end joining nhej haematopoietic cells 3 83kb breakpoint cluster region mixed"
  },
  {
    "id": 989,
    "paragraph": "lineage leukaemia (MLL) is located between exons 8 and 13 for almost all MLLr cases [4], these fusion genes contain the ﬁrst 8–13 exons of MLL and a variable number of exons from the fusion partner genes (FPGs). Up to 135 MLL FPGs have been identiﬁed and are well described elsewhere [5–7].",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "lineage leukaemia mll located exons 8 13 almost mllr cases 4 fusion genes contain ﬁrst 8–13 exons mll variable number exons fusion partner genes fpgs 135 mll fpgs identiﬁed well described elsewhere 5–7"
  },
  {
    "id": 990,
    "paragraph": "proteins. This category contains the most common FPGs such as ENL, ELL, AF4, AF9 and AF10, which account for approximately 80% of all MLL fusions [5]. Of these, MLL-AF9 (MA9) t(9;11)(p22;q23) translocations are found in 30% of MLLr AML cases [5] irrespective of age and are commonly found in",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "proteins category contains common fpgs enl ell af4 af9 af10 account approximately 80 mll fusions 5 mllaf9 ma9 t911p22q23 translocations found 30 mllr aml cases 5 irrespective age commonly found"
  },
  {
    "id": 991,
    "paragraph": "a subset of adult patients with therapy-related AML [8]. Although the precise functional properties of AF9 are unknown, it has been demonstrated to form multimer complexes with members of the polycomb repressive complex 1 (PRC1) complex and disruptor of telomere silencing (DOT1L) via a conserved ANC1 homology domain (AHD),",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "subset adult patients therapyrelated aml 8 although precise functional properties af9 unknown demonstrated form multimer complexes members polycomb repressive complex 1 prc1 complex disruptor telomere silencing dot1l via conserved anc1 homology domain ahd"
  },
  {
    "id": 992,
    "paragraph": "indicating a role in transcriptional regulation [9,10]. These properties appear to play a critical role in leukaemic transformation [11,12]. Oncogenic properties of MLL fusion proteins include interference with transcriptional elongation, resulting in dysregulation of target genes [13,14]. Aberrant expression of MLL target genes is strongly dependent on DOT1L-mediated H3K79 methylation [15], which is",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "indicating role transcriptional regulation 910 properties appear play critical role leukaemic transformation 1112 oncogenic properties mll fusion proteins include interference transcriptional elongation resulting dysregulation target genes 1314 aberrant expression mll target genes strongly dependent dot1lmediated h3k79 methylation 15"
  },
  {
    "id": 993,
    "paragraph": "a critical requirement for MA9 leukaemogensis [16]. Members of the Homeobox (HOX) family are commonly overexpressed in MLLr leukaemias as a direct target of MLL fusion proteins [4,17]. The HOX family are critical factors in the self-renewing properties of haematopoietic stem cells (HSCs) and their",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "critical requirement ma9 leukaemogensis 16 members homeobox hox family commonly overexpressed mllr leukaemias direct target mll fusion proteins 417 hox family critical factors selfrenewing properties haematopoietic stem cells hscs"
  },
  {
    "id": 994,
    "paragraph": "overexpression results in a diﬀerentiation block and an increase in self-renewal of immature myeloid progenitor cells. The HOX cofactors MEIS1 [18,19] and PBX3 [20] are also direct targets of MLL fusion proteins [21] frequently found upregulated in coordination with HOX targets. Importantly, there is",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "overexpression results diﬀerentiation block increase selfrenewal immature myeloid progenitor cells hox cofactors meis1 1819 pbx3 20 also direct targets mll fusion proteins 21 frequently found upregulated coordination hox targets importantly"
  },
  {
    "id": 995,
    "paragraph": "evidence to suggest that MA9-mediated leukaemia can progress even in the absence of HOX genes such as HOXA9 [22], indicating an important role of non-HOX family genes. This includes CDK6 [23], EVI-1 [24,25] and EYA1 [26,27], which are also found upregulated in MLLr leukaemias as a result of",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "evidence suggest ma9mediated leukaemia progress even absence hox genes hoxa9 22 indicating important role nonhox family genes includes cdk6 23 evi1 2425 eya1 2627 also found upregulated mllr leukaemias result"
  },
  {
    "id": 996,
    "paragraph": "direct binding of MLL-FPG proteins to gene promoters [26,28,29], and play a vital role in leukaemic transformation including cellular immortalization [26], hyperproliferation [23,24], chemoresistance [24] and dysregulated self-renewal [25,27]. CDK6 speciﬁcally has been highlighted as a critical eﬀector of MLLr leukemogenesis as its depletion in mice with MA9-driven AML was shown to overcome the",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "direct binding mllfpg proteins gene promoters 262829 play vital role leukaemic transformation including cellular immortalization 26 hyperproliferation 2324 chemoresistance 24 dysregulated selfrenewal 2527 cdk6 speciﬁcally highlighted critical eﬀector mllr leukemogenesis depletion mice ma9driven aml shown overcome"
  },
  {
    "id": 997,
    "paragraph": "myeloid diﬀerentiation block and to prolong survival in vivo [29]. Numerous murine models of MLLr have been generated and have each oﬀered valuable insights. Limitations with murine models are in large part due to the technology used to mimic MLL chromosomal",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "myeloid diﬀerentiation block prolong survival vivo 29 numerous murine models mllr generated oﬀered valuable insights limitations murine models large part due technology used mimic mll chromosomal"
  },
  {
    "id": 998,
    "paragraph": "rearrangements. An early knock-in model [30] utilized homologous recombination (HR) to generate an Mll-Af9 fusion gene and displayed a myeloproliferative disorder (MPD), leading primarily to AML characterized by expansion of immature myeloid populations with a small percentage developing B-cell ALL (B-ALL) [31]; thus, this model resembles the phenotypic heterogeneity of MLLr leukaemias,",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "rearrangements early knockin model 30 utilized homologous recombination hr generate mllaf9 fusion gene displayed myeloproliferative disorder mpd leading primarily aml characterized expansion immature myeloid populations small percentage developing bcell ball 31 thus model resembles phenotypic heterogeneity mllr leukaemias"
  },
  {
    "id": 999,
    "paragraph": "which can manifest as AML; ALL; or in a minority of cases, mixed phenotype acute leukaemia (MPAL). However, this system lacked tissue-speciﬁc control of MA9 expression throughout development and mice were prone to developmental defects as a result of heterozygosity for wild type (WT) Mll [32].",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "manifest aml minority cases mixed phenotype acute leukaemia mpal however system lacked tissuespeciﬁc control ma9 expression throughout development mice prone developmental defects result heterozygosity wild type wt mll 32"
  },
  {
    "id": 1000,
    "paragraph": "To gain more insight into cell-type speciﬁc eﬀects, a subsequent approach involved enrichment of haematopoietic populations from these HR-generated MA9 knock-in mice, followed by secondary transplantation into WT recipients [33]. This also demonstrated eﬃcient generation of AML, especially when Lin−Sca-1+c-Kit+ (LSK) cells, which include HSCs and haematopoietic stem and progenitor",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "gain insight celltype speciﬁc eﬀects subsequent approach involved enrichment haematopoietic populations hrgenerated ma9 knockin mice followed secondary transplantation wt recipients 33 also demonstrated eﬃcient generation aml especially lin−sca1ckit lsk cells include hscs haematopoietic stem progenitor"
  },
  {
    "id": 1001,
    "paragraph": "(HSPCs), were transplanted. An advantage of these methods is the expression of the MA9 transgene from the endogenous Mll promoter, which results in physiological transgene expression levels. This model cannot however address the leukaemia stem cell origin with respect to de novo AML initiation.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "hspcs transplanted advantage methods expression ma9 transgene endogenous mll promoter results physiological transgene expression levels model however address leukaemia stem cell origin respect de novo aml initiation"
  },
  {
    "id": 1002,
    "paragraph": "Translocator models utilizing the Cre-loxP system have generated MA9 translocations via loxP sites inserted into those intronic regions of endogenous Mll and Af9 genes where breakpoints are most frequently found in human MLLr patients [34]. Using Lmo2-Cre to express Cre recombinase,",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "translocator models utilizing creloxp system generated ma9 translocations via loxp sites inserted intronic regions endogenous mll af9 genes breakpoints frequently found human mllr patients 34 using lmo2cre express cre recombinase"
  },
  {
    "id": 1003,
    "paragraph": "Mll-Af9 was generated in pluripotent stem cells and led exclusively to myeloid leukaemia whereas T-cell-restricted expression using lck-Cre did not lead to leukomogeneis [35]. The advantage of this Cre-loxP system is that MA9 expression can be driven by lineage-restricted promoters from",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "mllaf9 generated pluripotent stem cells led exclusively myeloid leukaemia whereas tcellrestricted expression using lckcre lead leukomogeneis 35 advantage creloxp system ma9 expression driven lineagerestricted promoters"
  },
  {
    "id": 1004,
    "paragraph": "the endogenous loci [35], reﬂecting physiological expression. Further models targeting Mll-Af9 Int. J. Mol. Sci. 2020, 21, 4266 3 of 15 expression to speciﬁc cells within the haematopoietic system have utilized retrovirus-driven expression followed by transduction and transplantation approaches. These methods beneﬁt from its speed",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "endogenous loci 35 reﬂecting physiological expression models targeting mllaf9 int j mol sci 2020 21 4266 3 15 expression speciﬁc cells within haematopoietic system utilized retrovirusdriven expression followed transduction transplantation approaches methods beneﬁt speed"
  },
  {
    "id": 1005,
    "paragraph": "and ease of use [36,37] and has led to the identiﬁcation of both the HSC and the granulocyte and macrophage progenitor (GMP) as potential leukaemic stem cells-of-origin with divergent clinical features [38]. Retrovirus-mediated expression models however drive transgene expressions that are not physiological. To gain greater control over the level of cell-restricted transgene expression,",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "ease use 3637 led identiﬁcation hsc granulocyte macrophage progenitor gmp potential leukaemic stem cellsoforigin divergent clinical features 38 retrovirusmediated expression models however drive transgene expressions physiological gain greater control level cellrestricted transgene expression"
  },
  {
    "id": 1006,
    "paragraph": "Dox-inducible transgenic models have since been developed [39,40] enabling close-to-physiological levels and reversible transgene expression in a Dox dose-dependent manner. Using this model, it was demonstrated that long-term HSC (LT-HSC) populations result in an invasive and chemoresistant AML with a primitive progenitor phenotype and a distinct stemness-related gene expression pattern [39].",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "doxinducible transgenic models since developed 3940 enabling closetophysiological levels reversible transgene expression dox dosedependent manner using model demonstrated longterm hsc lthsc populations result invasive chemoresistant aml primitive progenitor phenotype distinct stemnessrelated gene expression pattern 39"
  },
  {
    "id": 1007,
    "paragraph": "Dox-inducible transgene expression is however not controlled by an endogenous promoter. “Leaky” Cre expression from tissue-speciﬁc promoters together with the expensive and time-consuming nature of tissue-restricted strain generation are major limitations with the Cre-loxP and Dox-inducible transgenic model systems. More recent attempts to circumvent some of the issues highlighted above have utilized",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "doxinducible transgene expression however controlled endogenous promoter “ leaky ” cre expression tissuespeciﬁc promoters together expensive timeconsuming nature tissuerestricted strain generation major limitations creloxp doxinducible transgenic model systems recent attempts circumvent issues highlighted utilized"
  },
  {
    "id": 1008,
    "paragraph": "transcription activator like eﬀector nucleases (TALEN) technology to generate endogenous MA9 [41,42]. These cells exhibited a signiﬁcantly higher clonogenic potential with colony morphologies consistent with an immature cell type and development of AML, ALL and MPAL upon xenotransplantation [41]. Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology facilitates",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "transcription activator like eﬀector nucleases talen technology generate endogenous ma9 4142 cells exhibited signiﬁcantly higher clonogenic potential colony morphologies consistent immature cell type development aml mpal upon xenotransplantation 41 clustered regularly interspaced short palindromic repeats crisprcas9 technology facilitates"
  },
  {
    "id": 1009,
    "paragraph": "creation of DSBs at almost any genomic sequence of interest technology and has revolutionised the way in which we are able to manipulate the genome, aﬀording a more ﬂexible and readily applicable method for generating novel disease models, including chromosomal translocations, with an ease and",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "creation dsbs almost genomic sequence interest technology revolutionised way able manipulate genome aﬀording ﬂexible readily applicable method generating novel disease models including chromosomal translocations ease"
  },
  {
    "id": 1010,
    "paragraph": "simplicity far outweighing prior technologies such as TALEN and Cre-LoxP. CRISPR technology has facilitated generation of chromosomal deletions [43] and rearrangements, including inversions [44] and translocations [45–48]. Here, we demonstrate eﬃcient CRISPR-mediated generation of an endogenous Mll-Af9 reciprocal translocation in a murine cell line and primary HSPCs. By utilizing a dual-single",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "simplicity far outweighing prior technologies talen creloxp crispr technology facilitated generation chromosomal deletions 43 rearrangements including inversions 44 translocations 45–48 demonstrate eﬃcient crisprmediated generation endogenous mllaf9 reciprocal translocation murine cell line primary hspcs utilizing dualsingle"
  },
  {
    "id": 1011,
    "paragraph": "guide RNA (sgRNA) approach to target the most common breakpoints in human MA9 rearrangements, we show rapid, reliable generation of simultaneous breakpoints and a fusion product at the DNA and RNA levels. The resultant transformed cells reliably recapitulated features of human MLLr",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "guide rna sgrna approach target common breakpoints human ma9 rearrangements show rapid reliable generation simultaneous breakpoints fusion product dna rna levels resultant transformed cells reliably recapitulated features human mllr"
  },
  {
    "id": 1012,
    "paragraph": "leukaemias. These include increased expression of MA9 target genes, reduced IL3 dependency, higher clonogenic potential and self-renewal in primary murine HSPCs. This multiplexed CRISPR technology oﬀers a robust and malleable approach for generating murine models of the multitude of human translocation-associated leukaemias.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "leukaemias include increased expression ma9 target genes reduced il3 dependency higher clonogenic potential selfrenewal primary murine hspcs multiplexed crispr technology oﬀers robust malleable approach generating murine models multitude human translocationassociated leukaemias"
  },
  {
    "id": 1013,
    "paragraph": "2. Results 2.1. A CRISPR/Cas9 System for Mll-Af9 Genome Editing (302) We utilized a CRISPR/Cas9 system for the generation of murine t(4;9) MA9 chromosomal translocations in murine HSPCs, utilizing simultaneous targeting of the Mll and Af9 genes by CRISPR sgRNAs directed to chromosomes. Based on prior investigation of common MLL and AF9 breakpoint",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "2 results 21 crisprcas9 system mllaf9 genome editing 302 utilized crisprcas9 system generation murine t49 ma9 chromosomal translocations murine hspcs utilizing simultaneous targeting mll af9 genes crispr sgrnas directed chromosomes based prior investigation common mll af9 breakpoint"
  },
  {
    "id": 1014,
    "paragraph": "regions in AML patient samples [49] and murine models of MA9 [35], we designed guides targeting frequently translocated intronic regions between Mll exons 8 and 9 (Mll sg1 and 2) and exons 10 and 11 (Mll sg3 and 4) and between Af9 exons 8 and 9 (Af9 sg1, 2 and 3) (Figure 1A) to generate two potential",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "regions aml patient samples 49 murine models ma9 35 designed guides targeting frequently translocated intronic regions mll exons 8 9 mll sg1 2 exons 10 11 mll sg3 4 af9 exons 8 9 af9 sg1 2 3 figure 1a generate two potential"
  },
  {
    "id": 1015,
    "paragraph": "MLL-AF9 fusion products (Figure 1B). Guide sequences were generated using the CRISPR.MIT web tool (http://crispr.mit.edu) [50,51], which scores each sequence based on a combination of on- and oﬀ-target potentials. We selected those guides with the highest scores, indicating an appropriate eﬃciency of on-target cleavage with minimal oﬀ-target potential. Single guide sequences were cloned",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "mllaf9 fusion products figure 1b guide sequences generated using crisprmit web tool httpcrisprmitedu 5051 scores sequence based combination oﬀtarget potentials selected guides highest scores indicating appropriate eﬃciency ontarget cleavage minimal oﬀtarget potential single guide sequences cloned"
  },
  {
    "id": 1016,
    "paragraph": "into a lentiviral CRISPR-green ﬂuorescent protein (GFP) vector (Supplementary Figure S1), and the resultant high-titre lentivirus was used to transduce the murine HSPC myeloid progenitor 32D cell line, which is IL3-dependent. At day 5 post-transduction, cells were ﬂuorescent activated cell sorting (FACS)",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "lentiviral crisprgreen ﬂuorescent protein gfp vector supplementary figure s1 resultant hightitre lentivirus used transduce murine hspc myeloid progenitor 32d cell line il3dependent day 5 posttransduction cells ﬂuorescent activated cell sorting facs"
  },
  {
    "id": 1017,
    "paragraph": "Int. J. Mol. Sci. 2020, 21, 4266 4 of 15 sorted for GFP expression and indel formation in GFP (Figure 1C). + populations were assessed by a surveyor assay Figure 1. Design and validation of clustered regularly interspaced short palindromic repeats",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "int j mol sci 2020 21 4266 4 15 sorted gfp expression indel formation gfp figure 1c populations assessed surveyor assay figure 1 design validation clustered regularly interspaced short palindromic repeats"
  },
  {
    "id": 1018,
    "paragraph": "(CRISPR)/Cas9 gene editing tools targeting murine mixed lineage leukaemia (Mll) and Af9 genes: (A) Schematic representation of partial Mll and Af9 genomic regions with sgRNA location. Four guides were designed targeting either introns 8 and 9 (Mll sg1 and -2) or introns 10 and 11 (Mll sg3 and",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "crisprcas9 gene editing tools targeting murine mixed lineage leukaemia mll af9 genes schematic representation partial mll af9 genomic regions sgrna location four guides designed targeting either introns 8 9 mll sg1 2 introns 10 11 mll sg3"
  },
  {
    "id": 1019,
    "paragraph": "-4) of the Mll gene, and three were designed to target introns 8 and 9 (AF9 sg1–3) of Af9. sgRNA locations/Cas9 cleavage sites are shown in orange. Red (Mll) and green (Af9) arrows represent PCR primers ﬂanking cleavage sites. Blue and purple arrows represent RT-PCR primers on MLL and AF9",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "4 mll gene three designed target introns 8 9 af9 sg1–3 af9 sgrna locationscas9 cleavage sites shown orange red mll green af9 arrows represent pcr primers ﬂanking cleavage sites blue purple arrows represent rtpcr primers mll af9"
  },
  {
    "id": 1020,
    "paragraph": "transcripts, respectively. (B) Representation of two predicted Mll-Af9 fusion gene products following editing with either set of Mll and Af9-targeting sgRNAs. (C) Surveyor assay of 32D cells transduced with a CRISPR vector expressing the indicated sgRNAs. PCR was performed on genomic DNA from",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "transcripts respectively b representation two predicted mllaf9 fusion gene products following editing either set mll af9targeting sgrnas c surveyor assay 32d cells transduced crispr vector expressing indicated sgrnas pcr performed genomic dna"
  },
  {
    "id": 1021,
    "paragraph": "transfected GFP cell populations using primers as indicated in Figure 1A. Products were assayed by the surveyor and analysed by 2% gel electrophoresis. Percentage indel formation was calculated by quantiﬁcation of each DNA band. Cells transduced with an empty CRISPR vector (Cas9 only) were",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "transfected gfp cell populations using primers indicated figure 1a products assayed surveyor analysed 2 gel electrophoresis percentage indel formation calculated quantiﬁcation dna band cells transduced empty crispr vector cas9"
  },
  {
    "id": 1022,
    "paragraph": "used as the control sample for each. + Of those guides targeting Mll introns, Mll sg1-3 showed approximately equal indel eﬃciencies of 31–38%, with no cleavage seen using sg4 (Figure 1C and Figure S2). Similarly, Af9-targeting sgRNA1 and -3 showed approximately equal eﬃciencies of 28–37%, while sg2 gave a signiﬁcantly poorer indel",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "used control sample guides targeting mll introns mll sg13 showed approximately equal indel eﬃciencies 31–38 cleavage seen using sg4 figure 1c figure s2 similarly af9targeting sgrna1 3 showed approximately equal eﬃciencies 28–37 sg2 gave signiﬁcantly poorer indel"
  },
  {
    "id": 1023,
    "paragraph": "frequency of 7% (Figure 1C). These data demonstrate eﬃcient cleavage of Mll and Af9 loci using a CRISPR system detectable in the bulk population. Based on these results, Mll sg2 was selected for targeting of Mll introns 8 and 9, sg3 was selected for introns 10 and 11, and Af9 sg1 and –3 were",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "frequency 7 figure 1c data demonstrate eﬃcient cleavage mll af9 loci using crispr system detectable bulk population based results mll sg2 selected targeting mll introns 8 9 sg3 selected introns 10 11 af9 sg1 –3"
  },
  {
    "id": 1024,
    "paragraph": "selected for Af9 introns 8 and 9. 2.2. Endogenous Generation of MA9 Translocation in Murine HSPCs (368) To generate MLL-AF9 translocations, simultaneous DNA DSBs in the Mll and Af9 genes of murine 32D HSPCs were created (Figure 2A). Cells were transduced with a CRISPR lentivirus",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "selected af9 introns 8 9 22 endogenous generation ma9 translocation murine hspcs 368 generate mllaf9 translocations simultaneous dna dsbs mll af9 genes murine 32d hspcs created figure 2a cells transduced crispr lentivirus"
  },
  {
    "id": 1025,
    "paragraph": "targeting either the Mll or Af9 loci or both in combination and were FACS sorted for GFP at day 5 post-transduction. In 32D murine HSPCs, GFP expression > 20% was noted with each combination Int. J. Mol. Sci. 2020, 21, 4266 4 of 15 frequency of 7% (Figure 1C). These data demonstrate efficient cleavage of Mll and Af9 loci using a CRISPR system detectable in the bulk population. Based on these results, Mll sg2 was selected for targeting of Mll introns 8 and 9, sg3 was selected for introns 10 and 11, and Af9 sg1 and –3 were selected for Af9 introns 8 and 9. Figure 1. Design and validation of clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing tools targeting murine mixed lineage leukaemia (Mll) and Af9 genes: (A) Schematic representation of partial Mll and Af9 genomic regions with sgRNA location. Four guides were designed targeting either introns 8 and 9 (Mll sg1 and -2) or introns 10 and 11 (Mll sg3 and -4) of the Mll gene, and three were designed to target introns 8 and 9 (AF9 sg1–3) of Af9. sgRNA locations/Cas9 cleavage sites are shown in orange. Red (Mll) and green (Af9) arrows represent PCR primers flanking cleavage sites. Blue and purple arrows represent RT-PCR primers on MLL and AF9 transcripts, respectively. (B) Representation of two predicted Mll-Af9 fusion gene products following editing with either set of Mll and Af9-targeting sgRNAs. (C) Surveyor assay of 32D cells transduced with a CRISPR vector expressing the indicated sgRNAs. PCR was performed on genomic DNA from transfected GFP+ cell populations using primers as indicated in Figure 1A. Products were assayed by the surveyor and analysed by 2% gel electrophoresis. Percentage indel formation was calculated by quantification of each DNA band. Cells transduced with an empty CRISPR vector (Cas9 only) were used as the control sample for each. 2.2. Endogenous Generation of MA9 Translocation in Murine HSPCs (368) To generate MLL-AF9 translocations, simultaneous DNA DSBs in the Mll and Af9 genes of murine 32D HSPCs were created (Figure 2A). Cells were transduced with a CRISPR lentivirus targeting either the Mll or Af9 loci or both in combination and were FACS sorted for GFP at day 5 post-transduction. In 32D murine HSPCs, GFP expression > 20% was noted with each combination of dual guides (Figure 2B) and GFP+ populations were sorted for verification of the MA9 translocation and downstream functional analysis. Verification of the MA9 translocation was carried out in GFP+ 32D cells at both the DNA and transcript levels by utilizing PCR primers flanking the breakpoint region (Figure 2A) followed by Sanger sequencing of PCR amplicons. Unique banding patterns were seen following electrophoretic analysis of PCR products from 3/4 Mll and Af9 guide combinations (Figures 2C and S3), with sg3/sg3 as the only guide combination which did not generate a product. Amplicons as indicated in Figure 2C were further analysed by Sanger sequencing and alignment to reference Mll and Af9 genomic Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "targeting either mll af9 loci combination facs sorted gfp day 5 posttransduction 32d murine hspcs gfp expression 20 noted combination int j mol sci 2020 21 4266 4 15 frequency 7 figure 1c data demonstrate efficient cleavage mll af9 loci using crispr system detectable bulk population based results mll sg2 selected targeting mll introns 8 9 sg3 selected introns 10 11 af9 sg1 –3 selected af9 introns 8 9 figure 1 design validation clustered regularly interspaced short palindromic repeats crisprcas9 gene editing tools targeting murine mixed lineage leukaemia mll af9 genes schematic representation partial mll af9 genomic regions sgrna location four guides designed targeting either introns 8 9 mll sg1 2 introns 10 11 mll sg3 4 mll gene three designed target introns 8 9 af9 sg1–3 af9 sgrna locationscas9 cleavage sites shown orange red mll green af9 arrows represent pcr primers flanking cleavage sites blue purple arrows represent rtpcr primers mll af9 transcripts respectively b representation two predicted mllaf9 fusion gene products following editing either set mll af9targeting sgrnas c surveyor assay 32d cells transduced crispr vector expressing indicated sgrnas pcr performed genomic dna transfected gfp cell populations using primers indicated figure 1a products assayed surveyor analysed 2 gel electrophoresis percentage indel formation calculated quantification dna band cells transduced empty crispr vector cas9 used control sample 22 endogenous generation ma9 translocation murine hspcs 368 generate mllaf9 translocations simultaneous dna dsbs mll af9 genes murine 32d hspcs created figure 2a cells transduced crispr lentivirus targeting either mll af9 loci combination facs sorted gfp day 5 posttransduction 32d murine hspcs gfp expression 20 noted combination dual guides figure 2b gfp populations sorted verification ma9 translocation downstream functional analysis verification ma9 translocation carried gfp 32d cells dna transcript levels utilizing pcr primers flanking breakpoint region figure 2a followed sanger sequencing pcr amplicons unique banding patterns seen following electrophoretic analysis pcr products 34 mll af9 guide combinations figures 2c s3 sg3sg3 guide combination generate product amplicons indicated figure 2c analysed sanger sequencing alignment reference mll af9 genomic int j mol sci 2020 21 4266"
  },
  {
    "id": 1026,
    "paragraph": "5 of 15 of dual guides (Figure 2B) and GFP and downstream functional analysis. + populations were sorted for veriﬁcation of the MA9 translocation Figure 2. Endogenous generation of MLL-AF9 (MA9) translocation in murine haematopoietic cells: (A) Workﬂow schematic for generation of t(4;9) translocated 32D HSPCs. Cells were transduced with",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "5 15 dual guides figure 2b gfp downstream functional analysis populations sorted veriﬁcation ma9 translocation figure 2 endogenous generation mllaf9 ma9 translocation murine haematopoietic cells workﬂow schematic generation t49 translocated 32d hspcs cells transduced"
  },
  {
    "id": 1027,
    "paragraph": "single or dual CRISPR/Cas9 lentivirus and sorted for GFP at day 5 for downstream analysis. (B) Flow + cells at day 5 post-transduction. (C) Validation of cytometry histograms showing percentage of GFP populations and PCR genomic MA9 translocation: Genomic DNA was extracted from sorted GFP",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "single dual crisprcas9 lentivirus sorted gfp day 5 downstream analysis b flow cells day 5 posttransduction c validation cytometry histograms showing percentage gfp populations pcr genomic ma9 translocation genomic dna extracted sorted gfp"
  },
  {
    "id": 1028,
    "paragraph": "ampliﬁed using primers ﬂanking the MA9 breakpoint. PCR products were then resolved by agarose gel electrophoresis. (D) Sanger sequencing of the PCR product from the sg2/sg3 sample (red “b” arrow, part C): Alignment of the sequence to reference genome veriﬁed the alignment with murine",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "ampliﬁed using primers ﬂanking ma9 breakpoint pcr products resolved agarose gel electrophoresis sanger sequencing pcr product sg2sg3 sample red “ b ” arrow part c alignment sequence reference genome veriﬁed alignment murine"
  },
  {
    "id": 1029,
    "paragraph": "Mll and Af9. (E) RT-PCR analysis of the MA9 breakpoint region verifying MA9 translocation at RNA resolution: cDNA was reverse transcribed from RNA and PCR ampliﬁed using primers ﬂanking the MA9 breakpoint. (F) Sanger sequencing of the sg2/sg3 RT-PCR product: Alignment of the sequence to",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "mll af9 e rtpcr analysis ma9 breakpoint region verifying ma9 translocation rna resolution cdna reverse transcribed rna pcr ampliﬁed using primers ﬂanking ma9 breakpoint f sanger sequencing sg2sg3 rtpcr product alignment sequence"
  },
  {
    "id": 1030,
    "paragraph": "reference RNA showed alignment to murine Mll and Af9 transcripts. + + Veriﬁcation of the MA9 translocation was carried out in GFP 32D cells at both the DNA and transcript levels by utilizing PCR primers ﬂanking the breakpoint region (Figure 2A) followed by",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "reference rna showed alignment murine mll af9 transcripts veriﬁcation ma9 translocation carried gfp 32d cells dna transcript levels utilizing pcr primers ﬂanking breakpoint region figure 2a followed"
  },
  {
    "id": 1031,
    "paragraph": "Sanger sequencing of PCR amplicons. Unique banding patterns were seen following electrophoretic analysis of PCR products from 3/4 Mll and Af9 guide combinations (Figure 2C and Figure S3), with sg3/sg3 as the only guide combination which did not generate a product. Amplicons as indicated",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "sanger sequencing pcr amplicons unique banding patterns seen following electrophoretic analysis pcr products 34 mll af9 guide combinations figure 2c figure s3 sg3sg3 guide combination generate product amplicons indicated"
  },
  {
    "id": 1032,
    "paragraph": "in Figure 2C were further analysed by Sanger sequencing and alignment to reference Mll and Af9 genomic sequences, which identiﬁed the sg2/sg3-transduced sample (band b, Figure 2C) as having correct alignment to both murine Mll (NCBI gene ID: 214162) and Af9 (NCBI gene ID: 70122), validating",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "figure 2c analysed sanger sequencing alignment reference mll af9 genomic sequences identiﬁed sg2sg3transduced sample band b figure 2c correct alignment murine mll ncbi gene id 214162 af9 ncbi gene id 70122 validating"
  },
  {
    "id": 1033,
    "paragraph": "generation of the MA9 translocation at the genomic level (Figure 2D). Sequence alignment of amplicons from samples transduced with alternative guide combinations (Figure 2C, red arrows excluding b) Int. J. Mol. Sci. 2020, 21, 4266 5 of 15 sequences, which identified the sg2/sg3-transduced sample (band b, Figure 2C) as having correct alignment to both murine Mll (NCBI gene ID: 214162) and Af9 (NCBI gene ID: 70122), validating generation of the MA9 translocation at the genomic level (Figure 2D). Sequence alignment of amplicons from samples transduced with alternative guide combinations (Figure 2C, red arrows excluding b) identified matches in exonic and intronic regions of the mouse genome, including a noncoding region of chromosome 14 and the Pigz gene on chromosome 16. This may be indicative of a potential off-target effect of these sgRNA combinations, in line with current knowledge regarding the off-target potential of Cas9 cleavage. RT-PCR and subsequent electrophoresis of RNA from the dual sg2/sg3-transduced sample further validated the translocation at the transcript level; utilizing primers flanking the mRNA breakpoint region (Figure 2B), we generated an amplicon unique to this sample (Figure 2E) which correctly aligned to murine Mll (NM_001357549.1) and Af9 (NM_027326.3) reference transcripts, thus supporting formation of the MA9 mRNA fusion (Figure 2F). Taken together, these data indicate that CRISPR/Cas9-mediated genome editing can be used to induce formation of a murine t(4;9) MA9 translocation in 32D HSPCs and that this fusion gene product is transcribed appropriately. Figure 2. Endogenous generation of MLL-AF9 (MA9) translocation in murine haematopoietic cells: (A) Workflow schematic for generation of t(4;9) translocated 32D HSPCs. Cells were transduced with single or dual CRISPR/Cas9 lentivirus and sorted for GFP at day 5 for downstream analysis. (B) Flow cytometry histograms showing percentage of GFP+ cells at day 5 post-transduction. (C) Validation of genomic MA9 translocation: Genomic DNA was extracted from sorted GFP+ populations and PCR amplified using primers flanking the MA9 breakpoint. PCR products were then resolved by agarose gel electrophoresis. (D) Sanger sequencing of the PCR product from the sg2/sg3 sample (red “b” arrow, part C): Alignment of the sequence to reference genome verified the alignment with murine Mll and Af9. (E) RT-PCR analysis of the MA9 breakpoint region verifying MA9 translocation at RNA resolution: cDNA was reverse transcribed from RNA and PCR amplified using primers flanking the Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "generation ma9 translocation genomic level figure 2d sequence alignment amplicons samples transduced alternative guide combinations figure 2c red arrows excluding b int j mol sci 2020 21 4266 5 15 sequences identified sg2sg3transduced sample band b figure 2c correct alignment murine mll ncbi gene id 214162 af9 ncbi gene id 70122 validating generation ma9 translocation genomic level figure 2d sequence alignment amplicons samples transduced alternative guide combinations figure 2c red arrows excluding b identified matches exonic intronic regions mouse genome including noncoding region chromosome 14 pigz gene chromosome 16 may indicative potential offtarget effect sgrna combinations line current knowledge regarding offtarget potential cas9 cleavage rtpcr subsequent electrophoresis rna dual sg2sg3transduced sample validated translocation transcript level utilizing primers flanking mrna breakpoint region figure 2b generated amplicon unique sample figure 2e correctly aligned murine mll nm0013575491 af9 nm0273263 reference transcripts thus supporting formation ma9 mrna fusion figure 2f taken together data indicate crisprcas9mediated genome editing used induce formation murine t49 ma9 translocation 32d hspcs fusion gene product transcribed appropriately figure 2 endogenous generation mllaf9 ma9 translocation murine haematopoietic cells workflow schematic generation t49 translocated 32d hspcs cells transduced single dual crisprcas9 lentivirus sorted gfp day 5 downstream analysis b flow cytometry histograms showing percentage gfp cells day 5 posttransduction c validation genomic ma9 translocation genomic dna extracted sorted gfp populations pcr amplified using primers flanking ma9 breakpoint pcr products resolved agarose gel electrophoresis sanger sequencing pcr product sg2sg3 sample red “ b ” arrow part c alignment sequence reference genome verified alignment murine mll af9 e rtpcr analysis ma9 breakpoint region verifying ma9 translocation rna resolution cdna reverse transcribed rna pcr amplified using primers flanking int j mol sci 2020 21 4266"
  },
  {
    "id": 1034,
    "paragraph": "6 of 15 identiﬁed matches in exonic and intronic regions of the mouse genome, including a noncoding region of chromosome 14 and the Pigz gene on chromosome 16. This may be indicative of a potential oﬀ-target eﬀect of these sgRNA combinations, in line with current knowledge regarding the oﬀ-target potential",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "6 15 identiﬁed matches exonic intronic regions mouse genome including noncoding region chromosome 14 pigz gene chromosome 16 may indicative potential oﬀtarget eﬀect sgrna combinations line current knowledge regarding oﬀtarget potential"
  },
  {
    "id": 1035,
    "paragraph": "of Cas9 cleavage. RT-PCR and subsequent electrophoresis of RNA from the dual sg2/sg3-transduced sample further validated the translocation at the transcript level; utilizing primers ﬂanking the mRNA breakpoint region (Figure 2B), we generated an amplicon unique to this sample (Figure 2E) which",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "cas9 cleavage rtpcr subsequent electrophoresis rna dual sg2sg3transduced sample validated translocation transcript level utilizing primers ﬂanking mrna breakpoint region figure 2b generated amplicon unique sample figure 2e"
  },
  {
    "id": 1036,
    "paragraph": "correctly aligned to murine Mll (NM_001357549.1) and Af9 (NM_027326.3) reference transcripts, thus supporting formation of the MA9 mRNA fusion (Figure 2F). Taken together, these data indicate that CRISPR/Cas9-mediated genome editing can be used to induce formation of a murine t(4;9) MA9",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "correctly aligned murine mll nm0013575491 af9 nm0273263 reference transcripts thus supporting formation ma9 mrna fusion figure 2f taken together data indicate crisprcas9mediated genome editing used induce formation murine t49 ma9"
  },
  {
    "id": 1037,
    "paragraph": "translocation in 32D HSPCs and that this fusion gene product is transcribed appropriately. 2.3. CRISPR-Mediated MA9 Translocations Recapitulate Features of MA9 Leukaemia In Vitro (622) Multifactorial functional analysis was carried out ﬁrstly on MA9-validated 32D murine HSPCs, in which we examined proliferative capability, IL3-dependency and expression of MA9-target genes.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "translocation 32d hspcs fusion gene product transcribed appropriately 23 crisprmediated ma9 translocations recapitulate features ma9 leukaemia vitro 622 multifactorial functional analysis carried ﬁrstly ma9validated 32d murine hspcs examined proliferative capability il3dependency expression ma9target genes"
  },
  {
    "id": 1038,
    "paragraph": "Over 30 days in liquid culture, we saw no signiﬁcant diﬀerence in proliferation between 32D cells transduced with the sg2/sg3 guide combination compared to those transduced with either single guide (Figure 3A), indicating that the MA9 translocation does not confer a demonstrable proliferative",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "30 days liquid culture saw signiﬁcant diﬀerence proliferation 32d cells transduced sg2sg3 guide combination compared transduced either single guide figure 3a indicating ma9 translocation confer demonstrable proliferative"
  },
  {
    "id": 1039,
    "paragraph": "advantage in this already immortalised cell line. MA9 leukemic cells have previously shown only moderate IL3 dependency in contrast to 32D cells which are strictly IL3 dependent [52]. Thus, we sought to examine the eﬀects of IL3 starvation on MA9 32D cells in culture. Over 24 h of IL3 starvation, we noted",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "advantage already immortalised cell line ma9 leukemic cells previously shown moderate il3 dependency contrast 32d cells strictly il3 dependent 52 thus sought examine eﬀects il3 starvation ma9 32d cells culture 24 h il3 starvation noted"
  },
  {
    "id": 1040,
    "paragraph": "a slight but nonsigniﬁcant growth advantage and resistance to starvation-induced stress in the MA9 cells when compared with single guide controls (Figure 3B), suggesting a decrease in IL-3 dependency conferred by CRISPR-generated MA9 translocation in this cell type, consistent with previous data [52].",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "slight nonsigniﬁcant growth advantage resistance starvationinduced stress ma9 cells compared single guide controls figure 3b suggesting decrease il3 dependency conferred crisprgenerated ma9 translocation cell type consistent previous data 52"
  },
  {
    "id": 1041,
    "paragraph": "Analysis of the expression of common MA9-associated genes in sg2/sg3 double-transduced cells revealed signiﬁcant upregulation of Dot1l, Cdk6 and Sirt1 mRNA (Figure 3C). Both DOT1l and CDK6 have critical and well-established roles in MLLr function and leukemogenesis [16,29], and Sirt1 has",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "analysis expression common ma9associated genes sg2sg3 doubletransduced cells revealed signiﬁcant upregulation dot1l cdk6 sirt1 mrna figure 3c dot1l cdk6 critical wellestablished roles mllr function leukemogenesis 1629 sirt1"
  },
  {
    "id": 1042,
    "paragraph": "been shown to be upregulated in response to MA9 expression in murine models [53]. Taken together, these data strongly support that CRISPR-mediated generation of MA9 using the endogenous loci can recapitulate the functional properties of MA9 leukaemic features. + + Following veriﬁcation of the MA9 translocation in 32D murine HSPCs, we next sought to use our",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "shown upregulated response ma9 expression murine models 53 taken together data strongly support crisprmediated generation ma9 using endogenous loci recapitulate functional properties ma9 leukaemic features following veriﬁcation ma9 translocation 32d murine hspcs next sought use"
  },
  {
    "id": 1043,
    "paragraph": "approach in primary murine HSPCs. C-Kit bone marrow (BM) cells were isolated from WT mice and transduced using the validated sg2/sg3 sgRNA singly or in combination. At day 5 post-transduction, and expanded in liquid culture for an additional 5 days prior to beginning",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "approach primary murine hspcs ckit bone marrow bm cells isolated wt mice transduced using validated sg2sg3 sgrna singly combination day 5 posttransduction expanded liquid culture additional 5 days prior beginning"
  },
  {
    "id": 1044,
    "paragraph": "cells were sorted for GFP functional analysis of the translocation in the primary bulk cell population. Equal numbers of cells from liquid cultures were assessed in colony forming cell (CFC) assays to determine self-renewal, proliferation and diﬀerentiation capabilities. Following 20 days in a CFC assay, cells transduced",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "cells sorted gfp functional analysis translocation primary bulk cell population equal numbers cells liquid cultures assessed colony forming cell cfc assays determine selfrenewal proliferation diﬀerentiation capabilities following 20 days cfc assay cells transduced"
  },
  {
    "id": 1045,
    "paragraph": "with the sg2/sg3 combination of guides displayed signiﬁcantly increased cell numbers and formed more colonies when compared to single transduced samples (Figure 3D,E). We next carried out immunophenotyping of day 20 CFC colonies in order to assess the myeloid diﬀerentiation status of",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "sg2sg3 combination guides displayed signiﬁcantly increased cell numbers formed colonies compared single transduced samples figure 3de next carried immunophenotyping day 20 cfc colonies order assess myeloid diﬀerentiation status"
  },
  {
    "id": 1046,
    "paragraph": "the cells. We saw diﬀerences neither in the live/viable population (Figure 3G) nor in the CD11bGr1- or CD11b+F4/80+ myeloid fractions in any of the samples (Figure 3F,I,J), suggesting that the MA9 translocation in this model does not have a negative impact on cell viability or myeloid diﬀerentiation.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "cells saw diﬀerences neither liveviable population figure 3g cd11bgr1 cd11bf480 myeloid fractions samples figure 3fij suggesting ma9 translocation model negative impact cell viability myeloid diﬀerentiation"
  },
  {
    "id": 1047,
    "paragraph": "However, the sg2/sg3 MA9 cells showed a signiﬁcantly larger population of cells expressing the c-Kit progenitor marker (Figure 3F,H), which has been associated with the leukaemia stem cell (LSC) in AMLs including MA9 [36,37]. This highlights not only a proliferative advantage in the double-transduced",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "however sg2sg3 ma9 cells showed signiﬁcantly larger population cells expressing ckit progenitor marker figure 3fh associated leukaemia stem cell lsc amls including ma9 3637 highlights proliferative advantage doubletransduced"
  },
  {
    "id": 1048,
    "paragraph": "MA9 population but also an enrichment of a self-renewing LSC-type population. These data indicate that the CRISPR-mediated generation of the MA9 translocation in murine HSPCs mediates leukaemic transformation, indicated by a proliferative advantage and an increase in self-renewal properties. Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "ma9 population also enrichment selfrenewing lsctype population data indicate crisprmediated generation ma9 translocation murine hspcs mediates leukaemic transformation indicated proliferative advantage increase selfrenewal properties int j mol sci 2020 21 4266"
  },
  {
    "id": 1049,
    "paragraph": "7 of 15 Figure 3. Cont. Int. J. Mol. Sci. 2020, 21, 4266 7 of 15 Int. J. Mol. Sci. 2020, 21, 4266 8 of 15 Figure 3. CRISPR-mediated MA9 translocation recapitulates features of MA9 leukaemia: (A) Cumulative cell number and growth curve of 32D HSPCs transduced with either Mll sg2 or",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "7 15 figure 3 cont int j mol sci 2020 21 4266 7 15 int j mol sci 2020 21 4266 8 15 figure 3 crisprmediated ma9 translocation recapitulates features ma9 leukaemia cumulative cell number growth curve 32d hspcs transduced either mll sg2"
  },
  {
    "id": 1050,
    "paragraph": "Af9 sg3 or combination. Cells did not show any signiﬁcant diﬀerence in proliferation following MA9 translocation. (B) Cell number and growth curve of 32D HSPCs transduced with Mll and/or Af9 guides as indicated with IL-3 starvation: MA9-translocated cells displayed reduced levels of IL-3 dependency",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "af9 sg3 combination cells show signiﬁcant diﬀerence proliferation following ma9 translocation b cell number growth curve 32d hspcs transduced mll andor af9 guides indicated il3 starvation ma9translocated cells displayed reduced levels il3 dependency"
  },
  {
    "id": 1051,
    "paragraph": "compared to single-guide controls. (C) Expression of MA9 target genes: ∆∆CT values of the sg2/sg3 sample are normalised to Mll sg2 single guide control. The graph shows mean ± SD of representative experiments. All samples were analysed in technical duplicates. Statistical signiﬁcance was calculated",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "compared singleguide controls c expression ma9 target genes ∆∆ct values sg2sg3 sample normalised mll sg2 single guide control graph shows mean ± sd representative experiments samples analysed technical duplicates statistical signiﬁcance calculated"
  },
  {
    "id": 1052,
    "paragraph": "by one-way ANOVA followed by Bonferroni posttest. p < 0.001 is represented as ***, and p < 0.05 is represented as *. (D) Representative colony pictures (400×) of CFC colonies after ten days in culture (left panel): Samples were plated in technical triplicates. (E) Mean ± SD of colony counts (left) and",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "oneway anova followed bonferroni posttest p 0001 represented p 005 represented representative colony pictures 400× cfc colonies ten days culture left panel samples plated technical triplicates e mean ± sd colony counts left"
  },
  {
    "id": 1053,
    "paragraph": "cell numbers (right). (F) Representative ﬂow cytometric plots from samples in Figure 3D with the percentage of relevant populations indicated numerically. (G–J) Percentage of each population in + samples shown as (G) live (DAPI-), (H) c-Kit , (I) CD11b . Each sample is",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "cell numbers right f representative ﬂow cytometric plots samples figure 3d percentage relevant populations indicated numerically g–j percentage population samples shown g live dapi h ckit cd11b sample"
  },
  {
    "id": 1054,
    "paragraph": "shown as mean ± SD from three technical triplicates. Statistical signiﬁcance was calculated by one-way ANOVA followed by Bonferroni posttest. p < 0.001 is represented as ***, p < 0.01 is represented as ** and p < 0.05 is represented as *.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "shown mean ± sd three technical triplicates statistical signiﬁcance calculated oneway anova followed bonferroni posttest p 0001 represented p 001 represented p 005 represented"
  },
  {
    "id": 1055,
    "paragraph": "and (J) CD11b + F4/80 Gr-1 + + + 3. Discussion Herein, we have demonstrated generation of a de novo MA9 translocation in murine HSPCs using state-of-the-art CRISPR/Cas9 technology to create a novel murine leukaemia model which faithfully recapitulates multiple features of human MA9 leukaemia. By rational design of sgRNA ﬂanking",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "j cd11b f480 gr1 3 discussion herein demonstrated generation de novo ma9 translocation murine hspcs using stateoftheart crisprcas9 technology create novel murine leukaemia model faithfully recapitulates multiple features human ma9 leukaemia rational design sgrna ﬂanking"
  },
  {
    "id": 1056,
    "paragraph": "breakpoint regions with common occurrence in MLLr AML patients and prior MA9 transgenic models, we identiﬁed optimal combinations of sgRNA sequences with which to induce simultaneous DSBs at the speciﬁc loci. Each guide was validated for individual cleavage eﬃciency, and subsequently,",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "breakpoint regions common occurrence mllr aml patients prior ma9 transgenic models identiﬁed optimal combinations sgrna sequences induce simultaneous dsbs speciﬁc loci guide validated individual cleavage eﬃciency subsequently"
  },
  {
    "id": 1057,
    "paragraph": "optimal combinations were identiﬁed for multiplexed CRISPR genome editing to induce an MA9 chromosomal translocation in HSPCs. Following CRISPR editing, the presence of a successful MA9 translocation was veriﬁed at both the genomic and transcriptional levels by PCR analysis and sequencing. Analysis of proliferation, clonogenicity, diﬀerentiation and gene expression robustly",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "optimal combinations identiﬁed multiplexed crispr genome editing induce ma9 chromosomal translocation hspcs following crispr editing presence successful ma9 translocation veriﬁed genomic transcriptional levels pcr analysis sequencing analysis proliferation clonogenicity diﬀerentiation gene expression robustly"
  },
  {
    "id": 1058,
    "paragraph": "demonstrated the functional ways in which this model recapitulates features of the disease in vitro. This novel approach circumvents common caveats of previous methods, with no requirement for transgenic or immunocompromised mice or primary human material. We have demonstrated the ease of use of this approach in cell line and primary murine HSPCs which can be applied to other",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "demonstrated functional ways model recapitulates features disease vitro novel approach circumvents common caveats previous methods requirement transgenic immunocompromised mice primary human material demonstrated ease use approach cell line primary murine hspcs applied"
  },
  {
    "id": 1059,
    "paragraph": "chromosomal translocations. Increased clonogenicity and enrichment of progenitor cells with increased self-renewal capacity is a fundamental characteristic of leukaemias with MLL rearrangements. Although we saw no proliferative advantage in MA9 32D HSPCs, we did observe a modest reduction in growth factor dependence",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "chromosomal translocations increased clonogenicity enrichment progenitor cells increased selfrenewal capacity fundamental characteristic leukaemias mll rearrangements although saw proliferative advantage ma9 32d hspcs observe modest reduction growth factor dependence"
  },
  {
    "id": 1060,
    "paragraph": "as previously demonstrated. Normal primary HSPC cells have limited growth potential in vitro, which showed increased colony growth and number when expressing MA9. Increased clonogenicity Int. J. Mol. Sci. 2020, 21, 4266 7 of 15 Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "previously demonstrated normal primary hspc cells limited growth potential vitro showed increased colony growth number expressing ma9 increased clonogenicity int j mol sci 2020 21 4266 7 15 int j mol sci 2020 21 4266"
  },
  {
    "id": 1061,
    "paragraph": "9 of 15 is associated with increased c-Kit expression, a cell surface marker found in myeloblasts in up to 80% of AML cases [54]. C-Kit expression has also been strongly associated with poor prognoses in other instances of chromosomal translocations such as t(8;21) [55]. We saw a signiﬁcant enrichment of",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "9 15 associated increased ckit expression cell surface marker found myeloblasts 80 aml cases 54 ckit expression also strongly associated poor prognoses instances chromosomal translocations t821 55 saw signiﬁcant enrichment"
  },
  {
    "id": 1062,
    "paragraph": "c-Kit-expressing cells, indicating an enrichment of colony-forming LSC-like early progenitor cells in MA9-expressing cells consistent with leukaemic transformation. Assessment of myeloid diﬀerentiation did not reveal a block in expression of diﬀerentiation markers in MA9-mediated cells, indicating that, although cells have acquired self-renewal properties, they maintain the ability to diﬀerentiate toward the",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "ckitexpressing cells indicating enrichment colonyforming lsclike early progenitor cells ma9expressing cells consistent leukaemic transformation assessment myeloid diﬀerentiation reveal block expression diﬀerentiation markers ma9mediated cells indicating although cells acquired selfrenewal properties maintain ability diﬀerentiate toward"
  },
  {
    "id": 1063,
    "paragraph": "myeloid lineage. A block in terminal myeloid diﬀerentiation cannot be ruled out, and whether cells can complete myeloid diﬀerentiation remains to be investigated. Cells that are unable to diﬀerentiate to the GMP stage of diﬀerentiation in murine models of MLLr do not undergo leukaemic transformation [56],",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "myeloid lineage block terminal myeloid diﬀerentiation ruled whether cells complete myeloid diﬀerentiation remains investigated cells unable diﬀerentiate gmp stage diﬀerentiation murine models mllr undergo leukaemic transformation 56"
  },
  {
    "id": 1064,
    "paragraph": "and so, it is understood that some level of diﬀerentiation down the myeloid pathway is required for MLLr AML transformation. Data produced by Stavropoulou et al. utilizing a Dox-inducible MA9 model show that surface marker analysis of colonies derived from iMLL-AF9 LT-HSC and GMP",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "understood level diﬀerentiation myeloid pathway required mllr aml transformation data produced stavropoulou et al utilizing doxinducible ma9 model show surface marker analysis colonies derived imllaf9 lthsc gmp"
  },
  {
    "id": 1065,
    "paragraph": "subpopulations showed cells expressing the Mac-1 and Gr-1 diﬀerentiation markers in addition to c-Kit in the presence of Dox [39]. MA9-initiated oncogenesis has been shown to depend on MA9 modiﬁcation of transcriptional elongation, resulting in dysregulated expression of target genes. We demonstrated an increase in",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "subpopulations showed cells expressing mac1 gr1 diﬀerentiation markers addition ckit presence dox 39 ma9initiated oncogenesis shown depend ma9 modiﬁcation transcriptional elongation resulting dysregulated expression target genes demonstrated increase"
  },
  {
    "id": 1066,
    "paragraph": "expression of Dot1 and Cdk6, both of which are essential for the oncogenic function of MA9-rearranged cells [29,57]. Interestingly, we also noted a signiﬁcant increase in expression of Sirt1, which is found signiﬁcantly overexpressed at the protein level in LSC populations from AML patients [53], where it",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "expression dot1 cdk6 essential oncogenic function ma9rearranged cells 2957 interestingly also noted signiﬁcant increase expression sirt1 found signiﬁcantly overexpressed protein level lsc populations aml patients 53"
  },
  {
    "id": 1067,
    "paragraph": "acts to maintain their survival, growth and drug resistance. The lack of increased HoxA9 expression observed in our cells may be due to low frequency of translocation within the bulk population analysed, as has been previously noted in TALEN-focused studies [41,42] and CRISPR-generated models [58].",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "acts maintain survival growth drug resistance lack increased hoxa9 expression observed cells may due low frequency translocation within bulk population analysed previously noted talenfocused studies 4142 crisprgenerated models 58"
  },
  {
    "id": 1068,
    "paragraph": "Recently, work by Jeong et al. [58] similarly demonstrated eﬃcient generation of MA9 translocations by CRISPR/Cas9 technology, utilizing methodologies in line with those described herein. The authors used the human system to generate MA9 translocation in human CD34+ cord blood (CB) cells in contrast",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "recently work jeong et al 58 similarly demonstrated eﬃcient generation ma9 translocations crisprcas9 technology utilizing methodologies line described herein authors used human system generate ma9 translocation human cd34 cord blood cb cells contrast"
  },
  {
    "id": 1069,
    "paragraph": "to the murine system we have presented here. Consistent with our results, human MA9-expressing CB cells in that study demonstrated a growth advantage in liquid culture and clonal expansion in CFC analysis and induction of AML, ALL and MPAL following transplantation in immunocompromised",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "murine system presented consistent results human ma9expressing cb cells study demonstrated growth advantage liquid culture clonal expansion cfc analysis induction aml mpal following transplantation immunocompromised"
  },
  {
    "id": 1070,
    "paragraph": "mice. The translocation eﬃciency achieved by Jeong et al. [58] is considerably higher than in previous TALEN-generated models of MA9 at around 0.5–1%. However, it is important to note that this eﬃciency remains low overall and so should be taken into consideration when analysing the bulk population.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "mice translocation eﬃciency achieved jeong et al 58 considerably higher previous talengenerated models ma9 around 05–1 however important note eﬃciency remains low overall taken consideration analysing bulk population"
  },
  {
    "id": 1071,
    "paragraph": "In contrast to the single-cell clonal analysis performed by Jeong et al. [58], we are able to demonstrate the leukaemic transformation eﬀects of CRISPR-generated MA9 in the bulk population that may be masking some eﬀects such as increased Hox gene expression. A considerable advantage of our",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "contrast singlecell clonal analysis performed jeong et al 58 able demonstrate leukaemic transformation eﬀects crisprgenerated ma9 bulk population may masking eﬀects increased hox gene expression considerable advantage"
  },
  {
    "id": 1072,
    "paragraph": "methodology which allows eﬀects to be seen in the bulk population is the reduction in time in culture of primary HSPCs that is required with single-clone selection. Further single-cell analysis from bulk populations in both the 32D cell line and primary HSPCS would give further insight into individual",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "methodology allows eﬀects seen bulk population reduction time culture primary hspcs required singleclone selection singlecell analysis bulk populations 32d cell line primary hspcs would give insight individual"
  },
  {
    "id": 1073,
    "paragraph": "aspects of MA9-mediated and context-speciﬁc gene regulation. A limitation with using primary human HSPCs is the requirement for immunocompromised mice for xenografts. Our work is the ﬁrst to show the use of this technology to generate the murine MA9 translocation from the endogenous loci",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "aspects ma9mediated contextspeciﬁc gene regulation limitation using primary human hspcs requirement immunocompromised mice xenografts work ﬁrst show use technology generate murine ma9 translocation endogenous loci"
  },
  {
    "id": 1074,
    "paragraph": "faithfully recapitulating MA9-mediated transformation in murine HSPCs. A signiﬁcant advantage of the murine system is the potential for investigation into immune-, gene- and cell-speciﬁc contexts using the myriad of murine genetic models and xenotransplantation approaches. Our methodology has several advantages for use in genetic models. The tractability of this system",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "faithfully recapitulating ma9mediated transformation murine hspcs signiﬁcant advantage murine system potential investigation immune gene cellspeciﬁc contexts using myriad murine genetic models xenotransplantation approaches methodology several advantages use genetic models tractability system"
  },
  {
    "id": 1075,
    "paragraph": "is such that we can readily study MA9 translocations in combination with other genetic or epigenetic abnormalities. Generation of new sgRNAs targeting sequences of interest are quickly and easily cloned into the CRISPR vector validated in this work and can be multiplexed as required. Our sgRNA target",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "readily study ma9 translocations combination genetic epigenetic abnormalities generation new sgrnas targeting sequences interest quickly easily cloned crispr vector validated work multiplexed required sgrna target"
  },
  {
    "id": 1076,
    "paragraph": "sequences were also selected not only for their commonality within MLLr patients but also for their prior use in alterative murine models of MA9, and as such, our approach oﬀers not only a robust model Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "sequences also selected commonality within mllr patients also prior use alterative murine models ma9 approach oﬀers robust model int j mol sci 2020 21 4266"
  },
  {
    "id": 1077,
    "paragraph": "10 of 15 of human disease but also a means of comparison to alterative methodologies [35,41,42]. The work presented here and by others [48,58] exempliﬁes the ongoing shift towards precise genome editing with CRISPR technologies to quickly and accurately recapitulate human disease in model systems.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "10 15 human disease also means comparison alterative methodologies 354142 work presented others 4858 exempliﬁes ongoing shift towards precise genome editing crispr technologies quickly accurately recapitulate human disease model systems"
  },
  {
    "id": 1078,
    "paragraph": "We have demonstrated the tractability and potential of this methodology in modelling human MA9 leukaemias, which represents an important advancement in the study of MA9-driven leukaemia. 4. Materials and Methods 4.1. Cell Culture ◦ All cell cultures were grown at 37",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "demonstrated tractability potential methodology modelling human ma9 leukaemias represents important advancement study ma9driven leukaemia 4 materials methods 41 cell culture ◦ cell cultures grown 37"
  },
  {
    "id": 1079,
    "paragraph": "C, 5% CO2. Human embryonic kidney (HEK)-239T and murine embryonic ﬁbroblast NIH-3T3 cells were maintained in Dulbecco Modiﬁed Eagle Medium (DMEM; Gibco, Paisley, UK) supplemented with 10% heat-inactivated foetal bovine serum (FBS; Gibco, Paisley, UK), 2 mM L-glutamine (Gibco, Paisley, UK) and 1% Penicillin/ Streptomycin (Pen/Strep;",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "c 5 co2 human embryonic kidney hek239t murine embryonic ﬁbroblast nih3t3 cells maintained dulbecco modiﬁed eagle medium dmem gibco paisley uk supplemented 10 heatinactivated foetal bovine serum fbs gibco paisley uk 2 mm lglutamine gibco paisley uk 1 penicillin streptomycin penstrep"
  },
  {
    "id": 1080,
    "paragraph": "Gibco, Paisley, UK). 32D murine myeloid progenitor cell line HSPCs were maintained in Roswell Park Memorial Institute-1640 (RPMI-1640; Gibco, Paisley, UK) supplemented with 10% FBS, 10% WEHI-3B conditioned media, 2 mM L-glutamine and 1% Pen/Strep. Primary murine HSPCs were cultured in DMEM pre-stimulation media supplemented with 15 % FBS, 2 mM L-glutamine, 1% Pen/Strep,",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "gibco paisley uk 32d murine myeloid progenitor cell line hspcs maintained roswell park memorial institute1640 rpmi1640 gibco paisley uk supplemented 10 fbs 10 wehi3b conditioned media 2 mm lglutamine 1 penstrep primary murine hspcs cultured dmem prestimulation media supplemented 15 fbs 2 mm lglutamine 1 penstrep"
  },
  {
    "id": 1081,
    "paragraph": "10 ng/mL recombinant murine interleukin-3 (rmIL3; PeproTech, London, UK), 10 ng/mL recombinant murine interleukin-6 (rmIL6; PeproTech, London, UK) and 100 ng/mL recombinant murine stem cell factor (rmSCF; PeproTech, London, UK) immediately following isolation and were transferred to DMEM activation media supplemented with 15% FBS, 2 mM L-glutamine, 1% Pen/Strep, 10 ng/mL",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "10 ngml recombinant murine interleukin3 rmil3 peprotech london uk 10 ngml recombinant murine interleukin6 rmil6 peprotech london uk 100 ngml recombinant murine stem cell factor rmscf peprotech london uk immediately following isolation transferred dmem activation media supplemented 15 fbs 2 mm lglutamine 1 penstrep 10 ngml"
  },
  {
    "id": 1082,
    "paragraph": "rmIL3, 10 ng/mL rmIL6, 100 ng/mL rmSCF and 4 µg/mL polybrene (Sigma-Aldrich, Dorset, UK) for transduction. 4.2. Murine Bone Marrow (BM) Harvest and c-Kit Enrichment C57BL/6 mice were purchased from Charles River UK and housed in the Beatson Biological Service and Research Units. All mouse experiments were approved by the local animal welfare ethical",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "rmil3 10 ngml rmil6 100 ngml rmscf 4 µgml polybrene sigmaaldrich dorset uk transduction 42 murine bone marrow bm harvest ckit enrichment c57bl6 mice purchased charles river uk housed beatson biological service research units mouse experiments approved local animal welfare ethical"
  },
  {
    "id": 1083,
    "paragraph": "review body (AWERB) committee and United Kingdom (UK) home oﬃce and performed according to UK Home Oﬃce project license 60/4512 approved 25 April 2013(Animal Scientiﬁc Procedures Act 1986) guidelines. Femur, tibia and pelvic girdle of wild-type (WT) C57BL/6 mice were crushed in",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "review body awerb committee united kingdom uk home oﬃce performed according uk home oﬃce project license 604512 approved 25 april 2013animal scientiﬁc procedures act 1986 guidelines femur tibia pelvic girdle wildtype wt c57bl6 mice crushed"
  },
  {
    "id": 1084,
    "paragraph": "phosphate buﬀered saline (PBS)/2% FBS and passed through a 40-µM cell strainer (Fisher Scientiﬁc, Loughborough, UK) to harvest BM. C-kit enrichment was carried out by magnetic activated cell sorting (MACS) separation of BM samples following incubation with anti-CD117 microbeads (Miltenyi Biotech,",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "phosphate buﬀered saline pbs2 fbs passed 40µm cell strainer fisher scientiﬁc loughborough uk harvest bm ckit enrichment carried magnetic activated cell sorting macs separation bm samples following incubation anticd117 microbeads miltenyi biotech"
  },
  {
    "id": 1085,
    "paragraph": "Bergisch Gladbach, Germany). 4.3. sgRNA Design, Synthesis and CRISPR Transduction Reference mRNA transcripts of genes of interest (http://www.ncbi.nlm.nih.gov/nucleotide/) were used for identiﬁcation of suitable protospacer sequences using the CRISPR MIT tool (previously available at http://crispr.mit.edu; accessed August 2015) [50,51]. Top and bottom strand protospacers",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "bergisch gladbach germany 43 sgrna design synthesis crispr transduction reference mrna transcripts genes interest httpwwwncbinlmnihgovnucleotide used identiﬁcation suitable protospacer sequences using crispr mit tool previously available httpcrisprmitedu accessed august 2015 5051 top bottom strand protospacers"
  },
  {
    "id": 1086,
    "paragraph": "were purchased as single stranded DNA (ssDNA) oligos (IDT, Surrey, UK) (Supplementary Table S1) and cloned into pL.CRISPR.EFS.GFP (Supplementary Methods and Figure S1). pL-CRISPR.EFS.GFP was a gift from Benjamin Ebert (Addgene plasmid # 57818) [59]. The all-in-one CRISPR lentivirus was used to constitutively express sgRNAs and Cas9 under the control of human U6 (hU6) and",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "purchased single stranded dna ssdna oligos idt surrey uk supplementary table s1 cloned plcrisprefsgfp supplementary methods figure s1 plcrisprefsgfp gift benjamin ebert addgene plasmid 57818 59 allinone crispr lentivirus used constitutively express sgrnas cas9 control human u6 hu6"
  },
  {
    "id": 1087,
    "paragraph": "elongation factor 1α (EF-1α) promotors, respectively. HEK-293T and NIH-3T3 cells were used for lentiviral production and titration, respectively, and 32D or primary murine HSPCs were transduced with high-titre CRISPR lentivirus as previously described [60]. 4.4. Flow Cytometry and Cell Sorting Samples were stained and analysed in PBS or PBS/2% FBS or sorted for GFP in the same buﬀer.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "elongation factor 1α ef1α promotors respectively hek293t nih3t3 cells used lentiviral production titration respectively 32d primary murine hspcs transduced hightitre crispr lentivirus previously described 60 44 flow cytometry cell sorting samples stained analysed pbs pbs2 fbs sorted gfp buﬀer"
  },
  {
    "id": 1088,
    "paragraph": "Single cells were gated by forward scatter area (FSC-A) vs height (FSC-H), and then viable cells were Int. J. Mol. Sci. 2020, 21, 4266 11 of 15 gated by FSC-A vs side scatter area (SSC-A). For viability staining, analysis was performed only in",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "single cells gated forward scatter area fsca vs height fsch viable cells int j mol sci 2020 21 4266 11 15 gated fsca vs side scatter area ssca viability staining analysis performed"
  },
  {
    "id": 1089,
    "paragraph": "(cid:48) single-cell gates and dead cells were excluded by 4 ,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, Dorset, UK) staining. Compensation was performed using unstained cells, single stained cells and single stained UltraComp eBeads (Thermo Scientiﬁc, Paisley, UK). A complete list of antibodies and dyes can be found in Supplementary Table S2.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "cid48 singlecell gates dead cells excluded 4 6diamidino2phenylindole dapi sigmaaldrich dorset uk staining compensation performed using unstained cells single stained cells single stained ultracomp ebeads thermo scientiﬁc paisley uk complete list antibodies dyes found supplementary table s2"
  },
  {
    "id": 1090,
    "paragraph": "4.5. Surveyor Assay Genomic DNA was extracted using QuickExtract™ DNA Extraction Solution (Epicentre Biotechnologies, Madison, WI, USA), and analysis with Surveyor Nuclease S was used to calculate indel frequency. Full methods and primer sequences can be found in the Supplementary Methods and",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "45 surveyor assay genomic dna extracted using quickextract™ dna extraction solution epicentre biotechnologies madison wi usa analysis surveyor nuclease used calculate indel frequency full methods primer sequences found supplementary methods"
  },
  {
    "id": 1091,
    "paragraph": "Table S3. 4.6. Genomic Target Ampliﬁcation (GTA) Genomic DNA was extracted from GFP-sorted cells (day 5 post-sorting) using Epicentre QuickExtract™ DNA Extraction Solution. PCR ampliﬁcation of target loci was performed using Q5 High-Fidelity DNA Polymerase (New England Biolabs; NEB, Herts, UK), and the products were",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "table s3 46 genomic target ampliﬁcation gta genomic dna extracted gfpsorted cells day 5 postsorting using epicentre quickextract™ dna extraction solution pcr ampliﬁcation target loci performed using q5 highfidelity dna polymerase new england biolabs neb herts uk products"
  },
  {
    "id": 1092,
    "paragraph": "analysed on 2% agarose (Sigma-Aldrich, Dorset, UK) gel. Bands of interest were excised using the GeneJET Gel Extraction and DNA Cleanup Micro Kit (Thermo Scientiﬁc, Paisley, UK) before analysis by Sanger sequencing. Primer sequences can be found in Supplementary Table S3.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "analysed 2 agarose sigmaaldrich dorset uk gel bands interest excised using genejet gel extraction dna cleanup micro kit thermo scientiﬁc paisley uk analysis sanger sequencing primer sequences found supplementary table s3"
  },
  {
    "id": 1093,
    "paragraph": "4.7. Reverse Transcription PCR Total RNA was isolated from GFP-sorted cells (day 5 post-sorting) by either Arcturus PicoPure RNA Isolation Kit (Thermo Scientiﬁc, Paisley, UK) or RNeasy Mini Kit (QIAGEN, Manchester, UK)), and target-speciﬁc cDNA synthesis was carried out by Superscript III (Thermo Scientiﬁc, Paisley,",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "47 reverse transcription pcr total rna isolated gfpsorted cells day 5 postsorting either arcturus picopure rna isolation kit thermo scientiﬁc paisley uk rneasy mini kit qiagen manchester uk targetspeciﬁc cdna synthesis carried superscript iii thermo scientiﬁc paisley"
  },
  {
    "id": 1094,
    "paragraph": "UK) using primers speciﬁc for locus of interest. cDNA was ampliﬁed using Taq DNA polymerase (NEB, Herts, UK) and target-speciﬁc primers. Puriﬁed products were analysed on 2% agarose gel, and bands of interest were excised and analysed by Sanger sequencing. Primer sequences can be found",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "uk using primers speciﬁc locus interest cdna ampliﬁed using taq dna polymerase neb herts uk targetspeciﬁc primers puriﬁed products analysed 2 agarose gel bands interest excised analysed sanger sequencing primer sequences found"
  },
  {
    "id": 1095,
    "paragraph": "in Supplementary Table S4. 4.8. Gene Expression Analysis (qRT-PCR) Total RNA was isolated from GFP-sorted cells, and gene expression analysis was carried out as previously described [60]. Results were calculated by the ∆∆Ct method with normalization to the Gusb housekeeping gene. Primer sequences can be found in Supplementary Table S5.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "supplementary table s4 48 gene expression analysis qrtpcr total rna isolated gfpsorted cells gene expression analysis carried previously described 60 results calculated ∆∆ct method normalization gusb housekeeping gene primer sequences found supplementary table s5"
  },
  {
    "id": 1096,
    "paragraph": "4.9. Colony-Forming Cell (CFC) Assay Methocult GF M3434 (Stem Cell Technologies, Vancouver, BC, Canada) methylcellulose media containing recombinant murine stem cell factor (rmSCF), recombinant murine interleukin-3 (rmIL-3), recombinant human interleukin-6 (rhIL-6) and recombinant human erythropoietin (rhEPO) was used. Equal numbers of BM c-kit-enriched, GFP-sorted cells were prepared in triplicate and resuspended",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "49 colonyforming cell cfc assay methocult gf m3434 stem cell technologies vancouver bc canada methylcellulose media containing recombinant murine stem cell factor rmscf recombinant murine interleukin3 rmil3 recombinant human interleukin6 rhil6 recombinant human erythropoietin rhepo used equal numbers bm ckitenriched gfpsorted cells prepared triplicate resuspended"
  },
  {
    "id": 1097,
    "paragraph": "in culture media. Cell suspension was added to methylcellulose and transferred to 3 × 35 mm dishes (Greiner-Bio-One, Gloucestershire, UK) for 10–20 days. Colonies were scored, and cells were analysed by ﬂow cytometry. If required, cells were replated to a second round of CFC following the",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "culture media cell suspension added methylcellulose transferred 3 × 35 mm dishes greinerbioone gloucestershire uk 10–20 days colonies scored cells analysed ﬂow cytometry required cells replated second round cfc following"
  },
  {
    "id": 1098,
    "paragraph": "same protocol. 4.10. Statistics GraphPad Prism (version 5.00.288; LA Jolla, CA, USA) was used for statistical analysis and graphing. Statistical signiﬁcance was determined by one-way ANOVA with Bonferroni posttest. Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/12/ 4266/s1. Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "protocol 410 statistics graphpad prism version 500288 la jolla ca usa used statistical analysis graphing statistical signiﬁcance determined oneway anova bonferroni posttest supplementary materials supplementary materials found httpwwwmdpicom142200672112 4266s1 int j mol sci 2020 21 4266"
  },
  {
    "id": 1099,
    "paragraph": "12 of 15 Author Contributions: E.S. designed and performed the experiments, analysed and interpreted the data, and made all ﬁgures. L.R. and R.J.C. provided data analysis and cowrote the manuscript. B.G. supervised the study. K.K. cowrote the manuscript, designed the research and supervised the study. All authors have read and agreed to the",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "12 15 author contributions es designed performed experiments analysed interpreted data made ﬁgures lr rjc provided data analysis cowrote manuscript bg supervised study kk cowrote manuscript designed research supervised study authors read agreed"
  },
  {
    "id": 1100,
    "paragraph": "published version of the manuscript. Funding: This research was funded by Kay Kendall Leukaemia Fund: NA, The Howat Foundation: NA, Cancer Research UK Glasgow Centre: C596/A18076, Cancer Research UK Beatson Institute: C596/A17196, Yorkhill Children’s Leukaemia Research Fund: NA, and Children with Cancer UK: NA.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "published version manuscript funding research funded kay kendall leukaemia fund na howat foundation na cancer research uk glasgow centre c596a18076 cancer research uk beatson institute c596a17196 yorkhill children ’ leukaemia research fund na children cancer uk na"
  },
  {
    "id": 1101,
    "paragraph": "Acknowledgments: We acknowledge the technical assistance of Jennifer Cassells and Karen Dunn for ﬂow cytometry and animal experiments respectively. We thank all staﬀ at the Paul O’Gorman Leukaemia Research Centre for their support and advice. Conﬂicts of Interest: The authors declare no conﬂict of interest.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "acknowledgments acknowledge technical assistance jennifer cassells karen dunn ﬂow cytometry animal experiments respectively thank staﬀ paul ’ gorman leukaemia research centre support advice conﬂicts interest authors declare conﬂict interest"
  },
  {
    "id": 1102,
    "paragraph": "Nat. Genet. 2015, 47, 330–337. [CrossRef] [PubMed] Richardson, C.; Jasin, M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature 2000, 405, 697–700. [CrossRef] [PubMed] Slany, R.K. When epigenetics kills: MLL fusion proteins in leukemia. Hematol. Oncol. 2005, 23, 1–9. [CrossRef]",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "nat genet 2015 47 330–337 crossref pubmed richardson c jasin frequent chromosomal translocations induced dna doublestrand breaks nature 2000 405 697–700 crossref pubmed slany rk epigenetics kills mll fusion proteins leukemia hematol oncol 2005 23 1–9 crossref"
  },
  {
    "id": 1103,
    "paragraph": "4. 5. Meyer, C.; Burmeister, T.; Gröger, D.; Tsaur, G.; Fechina, L.; Renneville, A.; Sutton, R.; Venn, N.C.; Emerenciano, M.; Pombo-De-Oliveira, M.S.; et al. The MLL recombinome of acute leukemias in 2017. Leukemia 2018, 32, 273–284. [CrossRef] 3. 6. Meyer, C.; Kowarz, E.; Hofmann, J.; Renneville, A.; Zuna, J.; Trka, J.; Ben Abdelali, R.; Macintyre, E.; De",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "4 5 meyer c burmeister gröger tsaur g fechina l renneville sutton r venn nc emerenciano pombodeoliveira ms et al mll recombinome acute leukemias 2017 leukemia 2018 32 273–284 crossref 3 6 meyer c kowarz e hofmann j renneville zuna j trka j ben abdelali r macintyre e de"
  },
  {
    "id": 1104,
    "paragraph": "Braekeleer, E.; De Braekeleer, M.; et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009, 23, 1490–1499. [CrossRef] 8. 7. Huret, J.L.; Ahmad, M.; Arsaban, M.; Bernheim, A.; Cigna, J.; Desangles, F.; Guignard, J.C.; Jacquemot-Perbal, M.C.; Labarussias, M.; Leberre, V.; et al. Atlas of genetics and cytogenetics in oncology",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "braekeleer e de braekeleer et al new insights mll recombinome acute leukemias leukemia 2009 23 1490–1499 crossref 8 7 huret jl ahmad arsaban bernheim cigna j desangles f guignard jc jacquemotperbal mc labarussias leberre v et al atlas genetics cytogenetics oncology"
  },
  {
    "id": 1105,
    "paragraph": "and haematology in 2013. Nucleic Acids Res. 2013, 41, D920–D924. [CrossRef] Super, H.J.G.; McCabe, N.R.; Thirman, M.J.; Larson, R.A.; Le Beau, M.M.; Pedersen- Bjergaard, J.; Philip, P.; Diaz, M.O.; Rowley, J.D. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "haematology 2013 nucleic acids res 2013 41 d920–d924 crossref super hjg mccabe nr thirman mj larson ra le beau mm pedersen bjergaard j philip p diaz mo rowley jd rearrangements mll gene therapyrelated acute myeloid leukemia"
  },
  {
    "id": 1106,
    "paragraph": "in patients previously treated with agents targeting DNA-topoisomerase II. Blood 1993, 82, 3705–3711. [CrossRef] 9. Malik, B.; Hemenway, C.S. CBX8, a component of the Polycomb PRC1 complex, modulates DOT1L-mediated gene expression through AF9/MLLT3. FEBS Lett. 2013, 587, 3038–3044. [CrossRef] 10. Zhang, W.; Xia, X.; Reisenauer, M.R.; Hemenway, C.S.; Kone, B.C. Dot1a-AF9 complex mediates histone H3",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "patients previously treated agents targeting dnatopoisomerase ii blood 1993 82 3705–3711 crossref 9 malik b hemenway cs cbx8 component polycomb prc1 complex modulates dot1lmediated gene expression af9mllt3 febs lett 2013 587 3038–3044 crossref 10 zhang w xia x reisenauer mr hemenway cs kone bc dot1aaf9 complex mediates histone h3"
  },
  {
    "id": 1107,
    "paragraph": "Lys-79 hypermethylation and repression of ENaCα in an aldosterone-sensitive manner. J. Biol. Chem. 2006, 281, 18059–18068. [CrossRef] 11. Erfurth, F.; Hemenway, C.S.; de Erkenez, A.C.; Domer, P.H. MLL fusion partners AF4 and AF9 interact at subnuclear foci. Leukemia 2004, 18, 92–102. [CrossRef] [PubMed]",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "lys79 hypermethylation repression enacα aldosteronesensitive manner j biol chem 2006 281 18059–18068 crossref 11 erfurth f hemenway cs de erkenez ac domer ph mll fusion partners af4 af9 interact subnuclear foci leukemia 2004 18 92–102 crossref pubmed"
  },
  {
    "id": 1108,
    "paragraph": "12. Leach, B.I.; Kuntimaddi, A.; Schmidt, C.R.; Cierpicki, T.; Johnson, S.A.; Bushweller, J.H. Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding. Structure 2013, 21, 176–183. [CrossRef] [PubMed] 13. Mueller, D.; Bach, C.; Zeisig, D.; Garcia-Cuellar, M.P.; Monroe, S.; Sreekumar, A.; Zhou, R.; Nesvizhskii, A.;",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "12 leach bi kuntimaddi schmidt cr cierpicki johnson sa bushweller jh leukemia fusion target af9 intrinsically disordered transcriptional regulator recruits multiple partners via coupled folding binding structure 2013 21 176–183 crossref pubmed 13 mueller bach c zeisig garciacuellar mp monroe sreekumar zhou r nesvizhskii"
  },
  {
    "id": 1109,
    "paragraph": "Chinnaiyan, A.; Hess, J.L.; et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modiﬁcation. Blood 2007, 110, 4445–4454. [CrossRef] [PubMed] 14. Mueller, D.; García-Cuéllar, M.P.; Bach, C.; Buhl, S.; Maethner, E.; Slany, R.K. Misguided transcriptional",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "chinnaiyan hess jl et al role mll fusion partner enl transcriptional elongation chromatin modiﬁcation blood 2007 110 4445–4454 crossref pubmed 14 mueller garcíacuéllar mp bach c buhl maethner e slany rk misguided transcriptional"
  },
  {
    "id": 1110,
    "paragraph": "elongation causes mixed lineage leukemia. PLoS Biol. 2009, 7, e1000249. [CrossRef] 15. Kuntimaddi, A.; Achille, N.J.; Thorpe, J.; Lokken, A.A.; Singh, R.; Hemenway, C.S.; Adli, M.; Zeleznik-Le, N.J.; Bushweller, J.H. Degree of Recruitment of DOT1L to MLL-AF9 Deﬁnes Level of H3K79 Di- and Tri-methylation",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "elongation causes mixed lineage leukemia plos biol 2009 7 e1000249 crossref 15 kuntimaddi achille nj thorpe j lokken aa singh r hemenway cs adli zeleznikle nj bushweller jh degree recruitment dot1l mllaf9 deﬁnes level h3k79 di trimethylation"
  },
  {
    "id": 1111,
    "paragraph": "on Target Genes and Transformation Potential. Cell Rep. 2015, 11, 808–820. [CrossRef] Int. J. Mol. Sci. 2020, 21, 4266 13 of 15 16. Nguyen, A.T.; Taranova, O.; He, J.; Zhang, Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9—Mediated leukemogenesis. Blood 2011, 117, 6912–6922. [CrossRef]",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "target genes transformation potential cell rep 2015 11 808–820 crossref int j mol sci 2020 21 4266 13 15 16 nguyen taranova j zhang dot1l h3k79 methyltransferase required mllaf9—mediated leukemogenesis blood 2011 117 6912–6922 crossref"
  },
  {
    "id": 1112,
    "paragraph": "17. Yokoyama, A.; Somervaille, T.C.P.; Smith, K.S.; Rozenblatt-Rosen, O.; Meyerson, M.; Cleary, M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005, 123, 207–218. [CrossRef] 18. Armstrong, S.A.; Staunton, J.E.; Silverman, L.B.; Pieters, R.; Den Boer, M.L.; Minden, M.D.; Sallan, S.E.;",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "17 yokoyama somervaille tcp smith ks rozenblattrosen meyerson cleary ml menin tumor suppressor protein essential oncogenic cofactor mllassociated leukemogenesis cell 2005 123 207–218 crossref 18 armstrong sa staunton je silverman lb pieters r den boer ml minden md sallan se"
  },
  {
    "id": 1113,
    "paragraph": "Lander, E.S.; Golub, T.R.; Korsmeyer, S.J. MLL translocations specify a distinct gene expression proﬁle that distinguishes a unique leukemia. Nat. Genet. 2002, 30, 41–47. [CrossRef] 19. Zeisig, B.B.; Milne, T.; Garcia-Cuellar, M.-P.; Schreiner, S.; Martin, M.-E.; Fuchs, U.; Borkhardt, A.; Chanda, S.K.;",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "lander es golub tr korsmeyer sj mll translocations specify distinct gene expression proﬁle distinguishes unique leukemia nat genet 2002 30 41–47 crossref 19 zeisig bb milne garciacuellar mp schreiner martin fuchs u borkhardt chanda sk"
  },
  {
    "id": 1114,
    "paragraph": "Walker, J.; Soden, R.; et al. Hoxa9 and Meis1 Are Key Targets for MLL-ENL-Mediated Cellular Immortalization. Mol. Cell. Biol. 2004, 24, 617–628. [CrossRef] 20. Guo, H.; Chu, Y.; Wang, L.; Chen, X.; Chen, Y.; Cheng, H.; Zhang, L.; Zhou, Y.; Yang, F.C.; Cheng, T.; et al.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "walker j soden r et al hoxa9 meis1 key targets mllenlmediated cellular immortalization mol cell biol 2004 24 617–628 crossref 20 guo h chu wang l chen x chen cheng h zhang l zhou yang fc cheng et al"
  },
  {
    "id": 1115,
    "paragraph": "PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia. Int. J. Cancer 2017, 141, 324–335. [CrossRef] 21. Prange, K.H.M.; Mandoli, A.; Kuznetsova, T.; Wang, S.Y.; Sotoca, A.M.; Marneth, A.E.; Van Der Reijden, B.A.; Stunnenberg, H.G.; Martens, J.H.A. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "pbx3 essential leukemia stem cell maintenance mllrearranged leukemia int j cancer 2017 141 324–335 crossref 21 prange khm mandoli kuznetsova wang sy sotoca marneth ae van der reijden ba stunnenberg hg martens jha mllaf9 mllaf4 oncofusion proteins bind distinct enhancer"
  },
  {
    "id": 1116,
    "paragraph": "repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. Oncogene 2017, 36, 3346–3356. [CrossRef] [PubMed] 22. Kumar, A.R.; Hudson, W.A.; Chen, W.; Nishiuchi, R.; Yao, Q.; Kersey, J.H. Hoxa9 inﬂuences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood 2004, 103, 1823–1828. [CrossRef] [PubMed]",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "repertoire target runx1 program 11q23 acute myeloid leukemia oncogene 2017 36 3346–3356 crossref pubmed 22 kumar ar hudson wa chen w nishiuchi r yao q kersey jh hoxa9 inﬂuences phenotype incidence mllaf9 fusion gene leukemia blood 2004 103 1823–1828 crossref pubmed"
  },
  {
    "id": 1117,
    "paragraph": "23. Van Der Linden, M.H.; Willekes, M.; Roon, E.; Seslija, L.; Schneider, P.; Pieters, R.; Stam, R.W. MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. Cell Cycle 2014, 13, 834–844. [CrossRef] 24. Bindels, E.M.J.; Havermans, M.; Lugthart, S.; Erpelinck, C.; Wocjtowicz, E.; Krivtsov, A.V.; Rombouts, E.;",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "23 van der linden mh willekes roon e seslija l schneider p pieters r stam rw mll fusiondriven activation cdk6 potentiates proliferation mllrearranged infant cell cycle 2014 13 834–844 crossref 24 bindels emj havermans lugthart erpelinck c wocjtowicz e krivtsov av rombouts e"
  },
  {
    "id": 1118,
    "paragraph": "Armstrong, S.A.; Taskesen, E.; Haanstra, J.R.; et al. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood 2012, 119, 5838–5849. [CrossRef] [PubMed] 25. Laricchia-Robbio, L.; Nucifora, G. Signiﬁcant increase of self-renewal in hematopoietic cells after forced expression of EVI1. Blood Cells Mol. Dis. 2008, 40, 141–147. [CrossRef] [PubMed]",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "armstrong sa taskesen e haanstra jr et al evi1 critical pathogenesis subset mllaf9rearranged amls blood 2012 119 5838–5849 crossref pubmed 25 laricchiarobbio l nucifora g signiﬁcant increase selfrenewal hematopoietic cells forced expression evi1 blood cells mol dis 2008 40 141–147 crossref pubmed"
  },
  {
    "id": 1119,
    "paragraph": "26. Wang, Q.F.; Wu, G.; Mi, S.; He, F.; Wu, J.; Dong, J.; Luo, R.T.; Mattison, R.; Kaberlein, J.J.; Prabhakar, S.; et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood 2011, 117, 6895–6905. [CrossRef]",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "26 wang qf wu g mi f wu j dong j luo rt mattison r kaberlein jj prabhakar et al mll fusion proteins preferentially regulate subset wildtype mll target genes leukemic genome blood 2011 117 6895–6905 crossref"
  },
  {
    "id": 1120,
    "paragraph": "27. Takacova, S.; Luzna, P.; Stranecky, V.; Divoky, V. The Potential Role of the Six1/Eya1 Pathway in the Establishment of Leukemia Stem Cells in MLL-ENL—Induced Leukemia. Blood 2011, 118, 1362. [CrossRef] 28. Arai, S.; Yoshimi, A.; Shimabe, M.; Ichikawa, M.; Nakagawa, M.; Imai, Y.; Goyama, S.; Kurokawa, M. Evi-1 is",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "27 takacova luzna p stranecky v divoky v potential role six1eya1 pathway establishment leukemia stem cells mllenl—induced leukemia blood 2011 118 1362 crossref 28 arai yoshimi shimabe ichikawa nakagawa imai goyama kurokawa evi1"
  },
  {
    "id": 1121,
    "paragraph": "a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 2011, 117, 6304–6314. [CrossRef] 29. Placke, T.; Faber, K.; Nonami, A.; Putwain, S.L.; Salih, H.R.; Heidel, F.H.; Krämer, A.; Root, D.E.; Barbie, D.A.; Krivtsov, A.V.; et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood 2014, 124,",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "transcriptional target mixedlineage leukemia oncoproteins hematopoietic stem cells blood 2011 117 6304–6314 crossref 29 placke faber k nonami putwain sl salih hr heidel fh krämer root de barbie da krivtsov av et al requirement cdk6 mllrearranged acute myeloid leukemia blood 2014 124"
  },
  {
    "id": 1122,
    "paragraph": "13–23. [CrossRef] 30. Corral, J.; Lavenir, I.; Impey, H.; Warren, A.J.; Forster, A.; Larson, T.A.; Bell, S.; McKenzie, A.N.J.; King, G.; Rabbitts, T.H. An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. Cell 1996, 85, 853–861. [CrossRef]",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "13–23 crossref 30 corral j lavenir impey h warren aj forster larson ta bell mckenzie anj king g rabbitts th miiaf9 fusion gene made homologous recombination causes acute leukemia chimeric mice method create fusion oncogenes cell 1996 85 853–861 crossref"
  },
  {
    "id": 1123,
    "paragraph": "31. Dobson, C.L.; Warren, A.J.; Pannell, R.; Forster, A.; Lavenir, I.; Corral, J.; Smith, A.J.H.; Rabbitts, T.H. The Mll-AF9 gene fusion in mice controls myeloproliferation and speciﬁes acute myeloid leukaemogenesis. EMBO J. 1999, 18, 3564–3574. [CrossRef] [PubMed] 32. Chen, W.; Li, Q.; Hudson, W.A.; Kumar, A.; Kirchhof, N.; Kersey, J.H. Amurine Mll-AF4 knock-in model",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "31 dobson cl warren aj pannell r forster lavenir corral j smith ajh rabbitts th mllaf9 gene fusion mice controls myeloproliferation speciﬁes acute myeloid leukaemogenesis embo j 1999 18 3564–3574 crossref pubmed 32 chen w li q hudson wa kumar kirchhof n kersey jh amurine mllaf4 knockin model"
  },
  {
    "id": 1124,
    "paragraph": "results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 2006, 108, 669–677. [CrossRef] [PubMed] 33. Chen, W.; Kumar, A.R.; Hudson, W.A.; Li, Q.; Wu, B.; Staggs, R.A.; Lund, E.A.; Sam, T.N.; Kersey, J.H. Malignant Transformation Initiated by Mll-AF9: Gene Dosage and Critical Target Cells. Cancer Cell 2008, 13,",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "results lymphoid myeloid deregulation hematologic malignancy blood 2006 108 669–677 crossref pubmed 33 chen w kumar ar hudson wa li q wu b staggs ra lund ea sam tn kersey jh malignant transformation initiated mllaf9 gene dosage critical target cells cancer cell 2008 13"
  },
  {
    "id": 1125,
    "paragraph": "432–440. [CrossRef] [PubMed] 34. Collins, E.C.; Pannell, R.; Simpson, E.M.; Forster, A.; Rabbitts, T.H. Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-lox in mouse development. EMBO Rep. 2000, 1, 127–132. [CrossRef] Int. J. Mol. Sci. 2020, 21, 4266 14 of 15",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "432–440 crossref pubmed 34 collins ec pannell r simpson em forster rabbitts th interchromosomal recombination mll af9 genes mediated crelox mouse development embo rep 2000 1 127–132 crossref int j mol sci 2020 21 4266 14 15"
  },
  {
    "id": 1126,
    "paragraph": "35. Drynan, L.F.; Pannell, R.; Forster, A.; Chan, N.M.M.; Cano, F.; Daser, A.; Rabbitts, T.H. Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis. EMBO J. 2005, 24, 3136–3146. [CrossRef] 36. Krivtsov, A.V.; Twomey, D.; Feng, Z.; Stubbs, M.C.; Wang, Y.; Faber, J.; Levine, J.E.; Wang, J.; Hahn, W.C.;",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "35 drynan lf pannell r forster chan nmm cano f daser rabbitts th mll fusions generated creloxpmediated de novo translocations induce lineage reassignment tumorigenesis embo j 2005 24 3136–3146 crossref 36 krivtsov av twomey feng z stubbs mc wang faber j levine je wang j hahn wc"
  },
  {
    "id": 1127,
    "paragraph": "Gilliland, D.G.; et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442, 818–822. [CrossRef] [PubMed] Somervaille, T.C.P.; Cleary, M.L. Identiﬁcation and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006, 10, 257–268. [CrossRef] [PubMed]",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "gilliland dg et al transformation committed progenitor leukaemia stem cell initiated mllaf9 nature 2006 442 818–822 crossref pubmed somervaille tcp cleary ml identiﬁcation characterization leukemia stem cells murine mllaf9 acute myeloid leukemia cancer cell 2006 10 257–268 crossref pubmed"
  },
  {
    "id": 1128,
    "paragraph": "37. 38. Krivtsov, A.V.; Figueroa, M.E.; Sinha, A.U.; Stubbs, M.C.; Feng, Z.; Valk, P.J.M.; Delwel, R.; Döhner, K.; Bullinger, L.; Kung, A.L.; et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia 2013, 27, 852–860. [CrossRef] Stavropoulou, V.; Kaspar, S.; Brault, L.; Sanders, M.A.; Juge, S.; Morettini, S.; Tzankov, A.; Iacovino, M.;",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "37 38 krivtsov av figueroa sinha au stubbs mc feng z valk pjm delwel r döhner k bullinger l kung al et al cell origin determines clinically relevant subtypes mllrearranged aml leukemia 2013 27 852–860 crossref stavropoulou v kaspar brault l sanders juge morettini tzankov iacovino"
  },
  {
    "id": 1129,
    "paragraph": "Lau, I.J.; Milne, T.A.; et al. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome. Cancer Cell 2016, 30, 43–58. [CrossRef] 39. 40. Chen, X.; Burkhardt, D.B.; Hartman, A.A.; Hu, X.; Eastman, A.E.; Sun, C.; Wang, X.; Zhong, M.;",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "lau ij milne ta et al mllaf9 expression hematopoietic stem cells drives highly invasive aml expressing emtrelated genes linked poor outcome cancer cell 2016 30 43–58 crossref 39 40 chen x burkhardt db hartman aa hu x eastman ae sun c wang x zhong"
  },
  {
    "id": 1130,
    "paragraph": "Krishnaswamy, S.; Guo, S. MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors. Nat. Commun. 2019, 10, 5767. [CrossRef] [PubMed] 41. Buechele, C.; Breese, E.H.; Schneidawind, D.; Lin, C.H.; Jeong, J.; Duque-Afonso, J.; Wong, S.H.K.; Smith, K.S.; Negrin, R.S.; Porteus, M.; et al. MLL leukemia induction by genome editing of human CD34+ hematopoietic",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "krishnaswamy guo mllaf9 initiates transformation fastproliferating myeloid progenitors nat commun 2019 10 5767 crossref pubmed 41 buechele c breese eh schneidawind lin ch jeong j duqueafonso j wong shk smith ks negrin rs porteus et al mll leukemia induction genome editing human cd34 hematopoietic"
  },
  {
    "id": 1131,
    "paragraph": "cells. Blood 2015, 126, 1683–1694. [CrossRef] [PubMed] 42. Breese, E.H.; Buechele, C.; Dawson, C.; Cleary, M.L.; Porteus, M.H. Use of genome engineering to create patient speciﬁc MLL translocations in primary human hematopoietic stem and progenitor cells. PLoS ONE 2015, 10, e0136644. [CrossRef] [PubMed]",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "cells blood 2015 126 1683–1694 crossref pubmed 42 breese eh buechele c dawson c cleary ml porteus mh use genome engineering create patient speciﬁc mll translocations primary human hematopoietic stem progenitor cells plos one 2015 10 e0136644 crossref pubmed"
  },
  {
    "id": 1132,
    "paragraph": "43. Adikusuma, F.; Williams, N.; Grutzner, F.; Hughes, J.; Thomas, P. Targeted Deletion of an Entire Chromosome Using CRISPR/Cas9. Mol. Ther. 2017, 25, 1736–1738. [CrossRef] [PubMed] 44. Maddalo, D.; Manchado, E.; Concepcion, C.P.; Bonetti, C.; Vidigal, J.A.; Han, Y.C.; Ogrodowski, P.; Crippa, A.;",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "43 adikusuma f williams n grutzner f hughes j thomas p targeted deletion entire chromosome using crisprcas9 mol ther 2017 25 1736–1738 crossref pubmed 44 maddalo manchado e concepcion cp bonetti c vidigal ja han yc ogrodowski p crippa"
  },
  {
    "id": 1133,
    "paragraph": "Rekhtman, N.; De Stanchina, E.; et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 2014, 516, 423–427. [CrossRef] 45. Torres, R.; Martin, M.C.; Garcia, A.; Cigudosa, J.C.; Ramirez, J.C.; Rodriguez-Perales, S. Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. Nat. Commun.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "rekhtman n de stanchina e et al vivo engineering oncogenic chromosomal rearrangements crisprcas9 system nature 2014 516 423–427 crossref 45 torres r martin mc garcia cigudosa jc ramirez jc rodriguezperales engineering human tumourassociated chromosomal translocations rnaguided crisprcas9 system nat commun"
  },
  {
    "id": 1134,
    "paragraph": "2014, 5, 3964. [CrossRef] Jiang, J.; Zhang, L.; Zhou, X.; Chen, X.; Huang, G.; Li, F.; Wang, R.; Wu, N.; Yan, Y.; Tong, C.; et al. Induction of site-speciﬁc chromosomal translocations in embryonic stem cells by CRISPR/Cas9. Sci. Rep. 2016, 6, 21918.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "2014 5 3964 crossref jiang j zhang l zhou x chen x huang g li f wang r wu n yan tong c et al induction sitespeciﬁc chromosomal translocations embryonic stem cells crisprcas9 sci rep 2016 6 21918"
  },
  {
    "id": 1135,
    "paragraph": "[CrossRef] 46. 48. 47. Reimer, J.; Knöß, S.; Labuhn, M.; Charpentier, E.M.; Göhring, G.; Schlegelberger, B.; Klusmann, J.H.; Heckl, D. CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo. Haematologica 2017, 102, 1558–1566. [CrossRef] Schneidawind, C.; Jeong, J.; Schneidawind, D.; Kim, I.S.; Duque-Afonso, J.; Wong, S.H.K.; Iwasaki, M.;",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "crossref 46 48 47 reimer j knöß labuhn charpentier em göhring g schlegelberger b klusmann jh heckl crisprcas9induced t1119mllenl translocations initiate leukemia human hematopoietic progenitor cells vivo haematologica 2017 102 1558–1566 crossref schneidawind c jeong j schneidawind kim duqueafonso j wong shk iwasaki"
  },
  {
    "id": 1136,
    "paragraph": "Breese, E.H.; Zehnder, J.L.; Porteus, M.; et al. MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing. Blood Adv. 2018, 2, 832–845. [CrossRef] Jansen, M.W.J.C.; van der Velden, V.H.J.; van Dongen, J.J.M. Eﬃcient and easy detection of MLL-AF4,",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "breese eh zehnder jl porteus et al mll leukemia induction t911 chromosomal translocation human hematopoietic stem cells using genome editing blood adv 2018 2 832–845 crossref jansen mwjc van der velden vhj van dongen jjm eﬃcient easy detection mllaf4"
  },
  {
    "id": 1137,
    "paragraph": "MLL-AF9 and MLL-ENL fusion gene transcripts by multiplex real-time quantitative RT-PCR in TaqMan and LightCycler [11,12]. Leukemia 2005, 19, 2016–2018. [CrossRef] [PubMed] 49. 50. Cong, L.; Ran, F.A.; Cox, D.; Lin, S.; Barretto, R.; Habib, N.; Hsu, P.D.; Wu, X.; Jiang, W.; Marraﬃni, L.A.; et al.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "mllaf9 mllenl fusion gene transcripts multiplex realtime quantitative rtpcr taqman lightcycler 1112 leukemia 2005 19 2016–2018 crossref pubmed 49 50 cong l ran fa cox lin barretto r habib n hsu pd wu x jiang w marraﬃni la et al"
  },
  {
    "id": 1138,
    "paragraph": "Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339, 819–823. [CrossRef] 51. Hsu, P.D.; Scott, D.A.; Weinstein, J.A.; Ran, F.A.; Konermann, S.; Agarwala, V.; Li, Y.; Fine, E.J.; Wu, X.; Shalem, O.; et al. DNA targeting speciﬁcity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 2013, 31, 827–832.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "multiplex genome engineering using crisprcas systems science 2013 339 819–823 crossref 51 hsu pd scott da weinstein ja ran fa konermann agarwala v li fine ej wu x shalem et al dna targeting speciﬁcity rnaguided cas9 nucleases nat biotechnol 2013 31 827–832"
  },
  {
    "id": 1139,
    "paragraph": "[CrossRef] [PubMed] 52. Metcalf, D.; Glaser, S.P.; Xu, Z.; Di Rago, L.; Mifsud, S. Reversible growth factor dependency and autonomy during murine myelomonocytic leukemia induced by oncogenes. Proc. Natl. Acad. Sci. USA 2013, 110, 17029–17034. [CrossRef] [PubMed] Int. J. Mol. Sci. 2020, 21, 4266",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "crossref pubmed 52 metcalf glaser sp xu z di rago l mifsud reversible growth factor dependency autonomy murine myelomonocytic leukemia induced oncogenes proc natl acad sci usa 2013 110 17029–17034 crossref pubmed int j mol sci 2020 21 4266"
  },
  {
    "id": 1140,
    "paragraph": "15 of 15 53. 54. Sasca, D.; Hähnel, P.S.; Szybinski, J.; Khawaja, K.; Kriege, O.; Pante, S.V.; Bullinger, L.; Strand, S.; Strand, D.; Theobald, M.; et al. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood 2014, 124, 121–133. [CrossRef] [PubMed]",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "15 15 53 54 sasca hähnel ps szybinski j khawaja k kriege pante sv bullinger l strand strand theobald et al sirt1 prevents genotoxic stressinduced p53 activation acute myeloid leukemia blood 2014 124 121–133 crossref pubmed"
  },
  {
    "id": 1141,
    "paragraph": "Ikeda, H.; Kanakura, Y.; Tamaki, T.; Kuriu, A.; Kitayama, H.; Ishikawa, J.; Kanayama, Y.; Yonezawa, T.; Tarui, S.; Griﬃn, J.D. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 1991, 78, 2962–2968. [CrossRef] 55. Paschka, P.; Marcucci, G.; Ruppert, A.S.; Mrózek, K.; Chen, H.; Kittles, R.A.; Vukosavljevic, T.; Perrotti, D.;",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "ikeda h kanakura tamaki kuriu kitayama h ishikawa j kanayama yonezawa tarui griﬃn jd expression functional role protooncogene ckit acute myeloblastic leukemia cells blood 1991 78 2962–2968 crossref 55 paschka p marcucci g ruppert mrózek k chen h kittles ra vukosavljevic perrotti"
  },
  {
    "id": 1142,
    "paragraph": "Vardiman, J.W.; Carroll, A.J.; et al. Adverse prognostic signiﬁcance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B study. J. Clin. Oncol. 2006, 24, 3904–3911. [CrossRef] 56. Ohlsson, E.; Hasemann, M.S.; Willer, A.; Lauridsen, F.K.B.; Rapin, N.; Jendholm, J.; Porse, B.T. Initiation of",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "vardiman jw carroll aj et al adverse prognostic signiﬁcance kit mutations adult acute myeloid leukemia inv16 t821 cancer leukemia group b study j clin oncol 2006 24 3904–3911 crossref 56 ohlsson e hasemann ms willer lauridsen fkb rapin n jendholm j porse bt initiation"
  },
  {
    "id": 1143,
    "paragraph": "MLL-rearranged AML is dependent on C/EBPα. J. Exp. Med. 2014, 211, 5–13. [CrossRef] 57. Chang, M.J.; Wu, H.; Achille, N.J.; Reisenauer, M.R.; Chou, C.W.; Zeleznik-Le, N.J.; Hemenway, C.S.; Zhang, W. Histone H3 Lysine 79 Methyltransferase Dot1 Is Required for Immortalization by MLL Oncogenes.",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "mllrearranged aml dependent cebpα j exp med 2014 211 5–13 crossref 57 chang mj wu h achille nj reisenauer mr chou cw zeleznikle nj hemenway cs zhang w histone h3 lysine 79 methyltransferase dot1 required immortalization mll oncogenes"
  },
  {
    "id": 1144,
    "paragraph": "Cancer Res. 2010, 70, 10234–10242. [CrossRef] Jeong, J.; Jager, A.; Domizi, P.; Pavel-Dinu, M.; Gojenola, L.; Iwasaki, M.; Wei, M.C.; Pan, F.; Zehnder, J.L.; Porteus, M.H.; et al. High-eﬃciency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells. Blood Adv. 2019, 3, 2825–2835. [CrossRef]",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "cancer res 2010 70 10234–10242 crossref jeong j jager domizi p paveldinu gojenola l iwasaki wei mc pan f zehnder jl porteus mh et al higheﬃciency crispr induction t911 chromosomal translocations acute leukemias human blood stem cells blood adv 2019 3 2825–2835 crossref"
  },
  {
    "id": 1145,
    "paragraph": "58. 59. Heckl, D.; Kowalczyk, M.S.; Yudovich, D.; Belizaire, R.; Puram, R.V.; McConkey, M.E.; Thielke, A.; Aster, J.C.; Regev, A.; Ebert, B.L. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat. Biotechnol. 2014, 32, 941–946. [CrossRef]",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "58 59 heckl kowalczyk ms yudovich belizaire r puram rv mcconkey thielke aster jc regev ebert bl generation mouse models myeloid malignancy combinatorial genetic lesions using crisprcas9 genome editing nat biotechnol 2014 32 941–946 crossref"
  },
  {
    "id": 1146,
    "paragraph": "60. O’Connor, C.; Yalla, K.; Salomé, M.; Ananyambica Moka, H.; Gómez Castañeda, E.; Eyers, P.A.; Keeshan, K. Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2. Oncotarget 2018, 9, 14977–14992. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "60 ’ connor c yalla k salomé ananyambica moka h gómez castañeda e eyers pa keeshan k trib2 expression granulocytemonocyte progenitors drives highly drug resistant acute myeloid leukaemia linked elevated bcl2 oncotarget 2018 9 14977–14992 © 2020 authors licensee mdpi basel switzerland article open access"
  },
  {
    "id": 1147,
    "paragraph": "article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).",
    "jurnal": "ijms-21-04266.pdf",
    "processed": "article distributed terms conditions creative commons attribution cc license httpcreativecommonsorglicensesby40"
  },
  {
    "id": 1148,
    "paragraph": "Immunology, 1971, 20, 1087. Specificity of Rabbit Antisera against Mouse Leukaemias in vitro A. E. REIF AND CHUNG-AI H. KIM Department of Surgery, Tufts University School of Medicine, and the First (Tufts) Surgical Service, Boston City Hospital, Boston, Massachusetts (Received 26th August 1970)",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "immunology 1971 20 1087 specificity rabbit antisera mouse leukaemias vitro e reif chungai h kim department surgery tufts university school medicine first tufts surgical service boston city hospital boston massachusetts received 26th august 1970"
  },
  {
    "id": 1149,
    "paragraph": "Summary. Rabbit antisera were prepared against mouse leukaemias from several inbred strains, and against a mixture of these leukaemias. The potencies of these antisera were tested against each of the different leukaemias, and against certain normal cells and tissues. As determined by immune cytolysis, the potencies of antisera were strongest",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "summary rabbit antisera prepared mouse leukaemias several inbred strains mixture leukaemias potencies antisera tested different leukaemias certain normal cells tissues determined immune cytolysis potencies antisera strongest"
  },
  {
    "id": 1150,
    "paragraph": "against the homologous leukaemias. The potencies against unrelated leukaemias were generally within 50 per cent of those against the homologous leukaemias, with some exceptions. Antisera prepared by injection of a mixture of the leukaemia cells showed remarkably high potencies against all leukaemias tested.",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "homologous leukaemias potencies unrelated leukaemias generally within 50 per cent homologous leukaemias exceptions antisera prepared injection mixture leukaemia cells showed remarkably high potencies leukaemias tested"
  },
  {
    "id": 1151,
    "paragraph": "As measured by C fixation, the same antisera showed less specificity for the homologous leukaemias. The potencies of antisera for C fixation on a variety of normal tissues was quite strong, and decreased approximately in the following order: testis, kidney, liver, lung, brain, muscle, erythrocytes. For antiserum pre-",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "measured c fixation antisera showed less specificity homologous leukaemias potencies antisera c fixation variety normal tissues quite strong decreased approximately following order testis kidney liver lung brain muscle erythrocytes antiserum pre"
  },
  {
    "id": 1152,
    "paragraph": "pared against DBA/2 leukaemia L1210, the C fixation reaction against normal lymph node lymphocytes was about 20 per cent as strong as the reaction against the homologous leukaemia L1210. A hypothesis concerning the mechanism of immune cytolysis is presented to explain these results. Exhaustive absorption of",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "pared dba2 leukaemia l1210 c fixation reaction normal lymph node lymphocytes 20 per cent strong reaction homologous leukaemia l1210 hypothesis concerning mechanism immune cytolysis presented explain results exhaustive absorption"
  },
  {
    "id": 1153,
    "paragraph": "anti-L1210 sera with normal DBA/2 tissues produced only a slight increase in anti- leukaemia specificity. INTRODUCTION A number of studies on the effect of heterologous antisera on experimental leukaemias have shown mild but significant therapeutic benefits (Mohos and Kidd, 1957; Levi,",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "antil1210 sera normal dba2 tissues produced slight increase anti leukaemia specificity introduction number studies effect heterologous antisera experimental leukaemias shown mild significant therapeutic benefits mohos kidd 1957 levi"
  },
  {
    "id": 1154,
    "paragraph": "Golden, Zerubavel and Fisher, 1966; Schabel, Skipper, Laster and Thompson, 1966; Miller, Molovanu, Kaplan and Tocci, 1968; Hill and Littlejohn, 1970; Mempel and Thierfelder, 1970; Siegel and Morton, 1970), despite the immunosuppressive nature of such sera (Witz, Yagi and Pressman, 1968). We recently found that passive therapy with",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "golden zerubavel fisher 1966 schabel skipper laster thompson 1966 miller molovanu kaplan tocci 1968 hill littlejohn 1970 mempel thierfelder 1970 siegel morton 1970 despite immunosuppressive nature sera witz yagi pressman 1968 recently found passive therapy"
  },
  {
    "id": 1155,
    "paragraph": "antileukaemia sera can give positive results only when the highest possible number of cytolytic potency units is administered (Reif and Kim, 1969). To prepare highly potent antisera, both immunization schedules and the dependence of the specificity of antisera on the types of leukaemias injected (Mohos and Kidd, 1957) require investigation. In a",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "antileukaemia sera give positive results highest possible number cytolytic potency units administered reif kim 1969 prepare highly potent antisera immunization schedules dependence specificity antisera types leukaemias injected mohos kidd 1957 require investigation"
  },
  {
    "id": 1156,
    "paragraph": "separate investigation (Kim and Reif, 1971), we have studied immunization schedules. In the present paper, the requirements for specificity of antisera, in terms of the strain of 1087 1088 A. E. Reif and Chung-Ai H. Kim origin of the injected leukaemia cells, are examined. This provides further insight into the",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "separate investigation kim reif 1971 studied immunization schedules present paper requirements specificity antisera terms strain 1087 1088 e reif chungai h kim origin injected leukaemia cells examined provides insight"
  },
  {
    "id": 1157,
    "paragraph": "preparation of such antisera. We previously determined the specificity of rabbit antisera to thymic, splenic and leukaemic lymphocytes (Asakuma and Reif, 1968). Cross-reactions between antisera prepared against leukaemia cells and normal lymphoid cells, rather than cross-reactions between antisera prepared against leukaemia cells from different inbred strains, were",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "preparation antisera previously determined specificity rabbit antisera thymic splenic leukaemic lymphocytes asakuma reif 1968 crossreactions antisera prepared leukaemia cells normal lymphoid cells rather crossreactions antisera prepared leukaemia cells different inbred strains"
  },
  {
    "id": 1158,
    "paragraph": "studied. We found that unabsorbed antisera to leukaemias showed little or no specificity against leukaemia cells relative to non-thymic lymphocytes, but specificity appeared after absorption with a mixture of liver, kidney, and spleen. Antisera prepared against normal tissues were also tested (Asakuma and Reif, 1968).",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "studied found unabsorbed antisera leukaemias showed little specificity leukaemia cells relative nonthymic lymphocytes specificity appeared absorption mixture liver kidney spleen antisera prepared normal tissues also tested asakuma reif 1968"
  },
  {
    "id": 1159,
    "paragraph": "In this study, antisera have been prepared against four different leukaemias, against a mixture of these leukaemias, and against an ovarian teratoma. These antisera were tested against each of the various leukaemias and against certain normal tissues. Two assays of antibody activity were used: immune cytolysis, and complement fixation.",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "study antisera prepared four different leukaemias mixture leukaemias ovarian teratoma antisera tested various leukaemias certain normal tissues two assays antibody activity used immune cytolysis complement fixation"
  },
  {
    "id": 1160,
    "paragraph": "MATERIALS AND METHODS Mice and leukaemias All mice were obtained from the Jackson Laboratory. Tumours and leukaemias were transplanted with sterile precautions in congenic strains. The route of transplantation was intraperitoneal (IP), unless stated otherwise. Leukaemia C is an abbreviation for myeloid leukaemia C1498 II of C57BL/6 mice,",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "materials methods mice leukaemias mice obtained jackson laboratory tumours leukaemias transplanted sterile precautions congenic strains route transplantation intraperitoneal ip unless stated otherwise leukaemia c abbreviation myeloid leukaemia c1498 ii c57bl6 mice"
  },
  {
    "id": 1161,
    "paragraph": "obtained from Miss Brown of the Children's Cancer Research Foundation, Boston, and converted into the ascites form in our laboratory. Leukaemia M is an abbreviation for plasma cell neoplasm MOPC-21A of BALB/c mice, obtained in generation 89 from Dr Michael Potter of the National Cancer Institute, and transplanted subcutaneously. The",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "obtained miss brown childrens cancer research foundation boston converted ascites form laboratory leukaemia abbreviation plasma cell neoplasm mopc21a balbc mice obtained generation 89 dr michael potter national cancer institute transplanted subcutaneously"
  },
  {
    "id": 1162,
    "paragraph": "C3HeB/Fe lymphosarcoma Gardner originated in a C3H mouse injected with estradiol benzoate (Gardner, Dougherty and Williams, 1944), and was transplanted in the low mammary tumour substrain C3HeB/Fe. E6A is an abbreviation for the ovarian teratoma E6496 of C3HeB/Fe mice, obtained in ascites form from Dr A. B. Griffen of the Jackson",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "c3hebfe lymphosarcoma gardner originated c3h mouse injected estradiol benzoate gardner dougherty williams 1944 transplanted low mammary tumour substrain c3hebfe e6a abbreviation ovarian teratoma e6496 c3hebfe mice obtained ascites form dr b griffen jackson"
  },
  {
    "id": 1163,
    "paragraph": "Laboratory. Lymphocytic leukaemia L1210 of DBA/2 mice was derived by Law, Dunn, Boyle and Miller (1949). Both Gardner and L1210 leukaemias were provided by Mr I. Wodinsky of Arthur D. Little, Inc. Leukaemia RA9 originated spontaneously in an AKR mouse; cells from the enlarged spleen and thymus were initially transplanted in our",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "laboratory lymphocytic leukaemia l1210 dba2 mice derived law dunn boyle miller 1949 gardner l1210 leukaemias provided mr wodinsky arthur little inc leukaemia ra9 originated spontaneously akr mouse cells enlarged spleen thymus initially transplanted"
  },
  {
    "id": 1164,
    "paragraph": "laboratory in May 1968. The H-2 genotype of the strains of origin of the various tumours and leukaemias are as follows: C57BL/6, H-2b; BALB/c and DBA/2, H-2d; AKR, C3H and C3HeB/Fe, H-2k (Snell and Stimpfling, 1966). Antisera Rabbits were immunized with mouse tissues by two courses of injection. Each course",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "laboratory may 1968 h2 genotype strains origin various tumours leukaemias follows c57bl6 h2b balbc dba2 h2d akr c3h c3hebfe h2k snell stimpfling 1966 antisera rabbits immunized mouse tissues two courses injection course"
  },
  {
    "id": 1165,
    "paragraph": "consisted of one subcutaneous injection of 1-2 ml of tumour cells incorporated in Freund- McDermott complete adjuvant (Reif and Norris, 1960), followed by five to seven intra- venous injections (spaced over 3 weeks) of5 ml of 1 per cent suspensions ofviable leukaemia",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "consisted one subcutaneous injection 12 ml tumour cells incorporated freund mcdermott complete adjuvant reif norris 1960 followed five seven intra venous injections spaced 3 weeks of5 ml 1 per cent suspensions ofviable leukaemia"
  },
  {
    "id": 1166,
    "paragraph": "cells in isotonic saline. Antisera were inactivated by heating at 560 for 30 minutes and absorbed with 1/13 volume of AKR plasma, followed by three absorptions, each with 1/10 volume of packed mouse erythrocytes for 30 minutes at room temperature, as previously",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "cells isotonic saline antisera inactivated heating 560 30 minutes absorbed 113 volume akr plasma followed three absorptions 110 volume packed mouse erythrocytes 30 minutes room temperature previously"
  },
  {
    "id": 1167,
    "paragraph": "Specificity of Antisera against Leukaemias 1089 described (Reif and Allen, 1964). Normal rabbit serum (NRS) was inactivated but not absorbed. Antisera were stored in small portions at -200 without preservative. Rabbit antisera were tested either whole (-w in Tables 1 and 2), or else yG fractions",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "specificity antisera leukaemias 1089 described reif allen 1964 normal rabbit serum nrs inactivated absorbed antisera stored small portions 200 without preservative rabbit antisera tested either whole w tables 1 2 else yg fractions"
  },
  {
    "id": 1168,
    "paragraph": "(-yG) were prepared by precipitation with 40 per cent ammonium sulphate, followed by batch-fractionation with DEAE-cellulose (Reif, 1969). Antisera to leukaemia M and ovarian tumour E6A were treated similarly, except that ammonium sulphate precipita- tion was omitted. Antiserum X was prepared by injection of a mixture of leukaemias",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "yg prepared precipitation 40 per cent ammonium sulphate followed batchfractionation deaecellulose reif 1969 antisera leukaemia ovarian tumour e6a treated similarly except ammonium sulphate precipita tion omitted antiserum x prepared injection mixture leukaemias"
  },
  {
    "id": 1169,
    "paragraph": "RA9, Gardner, L1210, C and M. Cytolysis assay system A small-scale assay system (Reif and Allen, 1964) was used. In outline, each assay tube contained 100,000 viable lymphocytes, suitably absorbed 10 per cent complement (Reif, 1962), and various dilutions of antiserum. Tubes were incubated for 1 hour at 370 and",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "ra9 gardner l1210 c cytolysis assay system smallscale assay system reif allen 1964 used outline assay tube contained 100000 viable lymphocytes suitably absorbed 10 per cent complement reif 1962 various dilutions antiserum tubes incubated 1 hour 370"
  },
  {
    "id": 1170,
    "paragraph": "placed in ice water. For each tube in turn, the supernatant was sucked off the cells that had settled, 0f02 ml of vital dye was added, and 200 cells were classified under the microscope as stained or unstained. Results, in percentage of stained cells, were plotted against final",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "placed ice water tube turn supernatant sucked cells settled 0f02 ml vital dye added 200 cells classified microscope stained unstained results percentage stained cells plotted final"
  },
  {
    "id": 1171,
    "paragraph": "antiserum concentration (per cent), and the cytolytic titre was read at 50 per cent stained cells, with a correction for stained cells in the control tube (Reif, 1962). The potency* of an antiserum was expressed as 100 divided by the cytolytic titre obtained in this assay",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "antiserum concentration per cent cytolytic titre read 50 per cent stained cells correction stained cells control tube reif 1962 potency antiserum expressed 100 divided cytolytic titre obtained assay"
  },
  {
    "id": 1172,
    "paragraph": "system (Reif and Allen, 1964). Complement fixation A small-scale modification (Asakuma and Reif, 1968) of the complement (C) fixation method of Mayer (1961) was used. In outline, serial doubling dilutions of antiserum were assayed for complement fixation with known numbers of tissue cells, or else with a known wet weight of a tissue homo-",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "system reif allen 1964 complement fixation smallscale modification asakuma reif 1968 complement c fixation method mayer 1961 used outline serial doubling dilutions antiserum assayed complement fixation known numbers tissue cells else known wet weight tissue homo"
  },
  {
    "id": 1173,
    "paragraph": "genate. Disappearance ofcomplement was determined by the failure ofantibody-sensitized sheep erythrocytes, which were added later, to haemolyse. Reaction conditions and controls were as previously described (Asakuma and Reif, 1968). The final concentration of antiserum in the experimental tubes was plotted against per",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "genate disappearance ofcomplement determined failure ofantibodysensitized sheep erythrocytes added later haemolyse reaction conditions controls previously described asakuma reif 1968 final concentration antiserum experimental tubes plotted per"
  },
  {
    "id": 1174,
    "paragraph": "cent haemolysis on semilogarithmic paper. From this plot, the C fixation titre of the anti- serum was read as the final percentage concentration of antiserum at 50 per cent haemo- lysis, after correction for C fixation in control tubes. The C fixation potency* was calcu-",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "cent haemolysis semilogarithmic paper plot c fixation titre anti serum read final percentage concentration antiserum 50 per cent haemo lysis correction c fixation control tubes c fixation potency calcu"
  },
  {
    "id": 1175,
    "paragraph": "lated as 100 divided by the C fixation titre (Asakuma and Reif, 1968). RESULTS IMMUNE CYTOLYSIS Rabbit antisera were prepared by hyperimmunization of groups of rabbits with different leukaemias or tumours. Both whole antisera and their yG fractions (named respectively -w",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "lated 100 divided c fixation titre asakuma reif 1968 results immune cytolysis rabbit antisera prepared hyperimmunization groups rabbits different leukaemias tumours whole antisera yg fractions named respectively w"
  },
  {
    "id": 1176,
    "paragraph": "and -yG in Table 1) were tested against various leukaemias, an ovarian tumour, and normal lymph node cells (Table 1). * The reason for a conversion from 'titre' to 'potency' is that titres are difficult to visualize, since the stronger an",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "yg table 1 tested various leukaemias ovarian tumour normal lymph node cells table 1 reason conversion titre potency titres difficult visualize since stronger"
  },
  {
    "id": 1177,
    "paragraph": "antiserum the lower its titre. Use of the reciprocal of titre which we have called potency (Reif and Allen, 1964), is more meaningful, because the potency increases in direct proportion to the strength of the antiserum. A factor of 100 is used to make the 'potency' numerically equal to the final dilution of the antiserum.",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "antiserum lower titre use reciprocal titre called potency reif allen 1964 meaningful potency increases direct proportion strength antiserum factor 100 used make potency numerically equal final dilution antiserum"
  },
  {
    "id": 1178,
    "paragraph": "Q 1090 A. E. Reif and Chung-Ai H. Kim C.) M m c() C,~w Ce4 cq4 eq ( V Vz-MoOOODo C14 00 At l- C14 v v_ I ce - 14 E~ rc Ce o CD tCa L CN ~. LO t",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "q 1090 e reif chungai h kim c c cw ce4 cq4 eq v vzmoooodo c14 00 l c14 v v ce 14 e rc ce cd tca l cn lo"
  },
  {
    "id": 1179,
    "paragraph": "0sX0 X + (D COO . ere 0 0 w 0 LO LO, ~c CO co u IL ao .Y8 Lr w C. 0e) s0; vv W L0_O _o e~w e - LO t- z. C; v C/\\,OO t- MO---X C4",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "0sx0 x coo ere 0 0 w 0 lo lo c co co u il ao y8 lr w c 0e s0 vv w l0o ew e lo z c v coo mox c4"
  },
  {
    "id": 1180,
    "paragraph": "4 o CO 14_ v vwoobt- V V + *nc. O - N Ccr4CO Cl?~~~~~~~ U.0 0 U- U: LO- U 0 .a r. w 0 c V C) 0 - 1-CO tD - r- CC °L ° _ C'4 X X",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "4 co 14 v vwoobt v v nc n ccr4co cl u0 0 u u lo u 0 r w 0 c v c 0 1co td r cc °l ° c4 x x"
  },
  {
    "id": 1181,
    "paragraph": "1-4 IM v E Y C13 . _i _o ,,: tDV v IL)- - v 3 4 z z to, -gOco m O U; U U 0 0) a.. a.) C._ U -e U) U C._ *. 6 U bO *3",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "14 im v e c13 tdv v il v 3 4 z z goco u u u 0 0 c u e u u c 6 u bo 3"
  },
  {
    "id": 1182,
    "paragraph": "0 C-U ~0. 0 4-a 0 0 .n C4.) o 0 U 0 r. C.) C- U 0 O Ca10 0 Xo el*B.a 02 C1) 6z*: E 0 ui z z z C a) Ca) z C' 0e Specificity of Antisera against Leukaemias",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "0 cu 0 0 4a 0 0 n c4 0 u 0 r c c u 0 ca10 0 xo elba 02 c1 6z e 0 ui z z z c ca z c 0e specificity antisera leukaemias"
  },
  {
    "id": 1183,
    "paragraph": "1091 _ < Q V V° VC-qc v itv e oa LO 4 0-- CE~, C~ ~~ ~'- VV~~~LL'4 V) I0CN uz zzb ; 6 u _ Q r~-cN~- ce~o - - t- - to Loeq t Q ~~~~rAchv - co v co",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "1091 q v v° vcqc v itv e oa lo 4 0 ce c vvll4 v i0cn uz zzb 6 u q rcn ceo loeq q rachv co v co"
  },
  {
    "id": 1184,
    "paragraph": "£ 0 o - o E~~~~~~~~~ Cfi cgv v J C1 C1 LO30 10 r-(.0>+ Lo J o 4 t Cl o o z4 o CV 0 o 4 V W4 m0L 0~~~~~~~ C\"~~~~~~~~~~C C ~v vvvv ,- ^ 0C~4CO_ w",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "£ 0 e cfi cgv v j c1 c1 lo30 10 r0 lo j 4 cl z4 cv 0 4 v w4 m0l 0 cc c v vvvv 0c4co w"
  },
  {
    "id": 1185,
    "paragraph": "_ w~~~ UX:_ F-~~~~~~~~~- o~ ~ ~~,o z IO.~ V 0~~~~~~~~~~~ F- 0 ~ 0~ \"~~~C9-~oV-0M o~o0 ~ ~ gigs0 1 092 A. E. Reif and Chung-Ai H. Kim Normal rabbit serum or its yG fraction (top two lines, Table 1) was either inactive, or else",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "w ux f z io v 0 f 0 0 c9ov0m oo0 gigs0 1 092 e reif chungai h kim normal rabbit serum yg fraction top two lines table 1 either inactive else"
  },
  {
    "id": 1186,
    "paragraph": "active at a very low potency, when tested similarly (Table 1). Antiserum C-yG (third line) was the weakest antiserum tested. While it reacted most strongly with the homologous leukaemia C, the reaction was almost as strong against leukaemias Gardner and RA9, which are of different H-2 genotype (both k rather than",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "active low potency tested similarly table 1 antiserum cyg third line weakest antiserum tested reacted strongly homologous leukaemia c reaction almost strong leukaemias gardner ra9 different h2 genotype k rather"
  },
  {
    "id": 1187,
    "paragraph": "b). The reaction against leukaemia L12 10 of DBA/2 mice was weak. Similarly low poten- cies against leukaemia L 1210 were also obtained with other antisera (see below); possible reasons for this are given in the Discussion. The reaction of antiserum C-yG with normal",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "b reaction leukaemia l12 10 dba2 mice weak similarly low poten cies leukaemia l 1210 also obtained antisera see possible reasons given discussion reaction antiserum cyg normal"
  },
  {
    "id": 1188,
    "paragraph": "lymph node lymphocytes (columns 6, 7 and 8) was strongest with the homologous (C57- BL/6) cells. Antiserum TM-yG (fourth line) reacted more strongly against the H-2k leukaemias Gardner and RA9 than to leukaemia L12 10, which originated in the same strain (H-2d) as",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "lymph node lymphocytes columns 6 7 8 strongest homologous c57 bl6 cells antiserum tmyg fourth line reacted strongly h2k leukaemias gardner ra9 leukaemia l12 10 originated strain h2d"
  },
  {
    "id": 1189,
    "paragraph": "the leukaemia against which the antiserum was prepared. Antiserum G-yG (fifth line) reacted almost as strongly against another H-2k leukaemia, RA9, as against the homologous leukaemia cells. The reaction against normal lympho- cytes was strongest against those of homologous genotype (column 7). There was little",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "leukaemia antiserum prepared antiserum gyg fifth line reacted almost strongly another h2k leukaemia ra9 homologous leukaemia cells reaction normal lympho cytes strongest homologous genotype column 7 little"
  },
  {
    "id": 1190,
    "paragraph": "cross-reaction with an ovarian teratoma which originated in the same strain. Again, the reaction against leukaemia L1210 (which differs in H-2 genotype) was remarkably low. Antiserum E6A yG (sixth line) reacted similarly, except that the reaction against the homologous ovarian tumour cells was far stronger. The higher potency seen versus",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "crossreaction ovarian teratoma originated strain reaction leukaemia l1210 differs h2 genotype remarkably low antiserum e6a yg sixth line reacted similarly except reaction homologous ovarian tumour cells far stronger higher potency seen versus"
  },
  {
    "id": 1191,
    "paragraph": "leukaemia L1210 may well reflect similarly higher potencies seen in the reactions with normal lymphocytes (columns 6, 7 and 8). Antiserum L-yG (seventh line), on the basis of a stronger reaction against homologous (DBA/2) normal lymph node cells (than against those of other strains: columns 6, 7 and",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "leukaemia l1210 may well reflect similarly higher potencies seen reactions normal lymphocytes columns 6 7 8 antiserum lyg seventh line basis stronger reaction homologous dba2 normal lymph node cells strains columns 6 7"
  },
  {
    "id": 1192,
    "paragraph": "8), was expected to react most strongly against the homologous (L1210) leukaemia cells. This was not the case (columns 1, 2, 3 and 5). This result is in line with the lower reactivi- ties against L12 10 cells also found for antisera prepared against other leukaemias (see above).",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "8 expected react strongly homologous l1210 leukaemia cells case columns 1 2 3 5 result line lower reactivi ties l12 10 cells also found antisera prepared leukaemias see"
  },
  {
    "id": 1193,
    "paragraph": "Antiserum X (last two lines, Table 1), from rabbits immunized with several leukaemias, showed as strong or stronger cytolytic potencies against the various leukaemias, than did any other antiserum tested. C FIXATION We previously used C fixation to evaluate the specificity of antilymphocyte sera",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "antiserum x last two lines table 1 rabbits immunized several leukaemias showed strong stronger cytolytic potencies various leukaemias antiserum tested c fixation previously used c fixation evaluate specificity antilymphocyte sera"
  },
  {
    "id": 1194,
    "paragraph": "(Asakuma and Reif, 1968). While immune cytolysis proved superior for this purpose, C fixation gives additional information and permits estimation of antibody binding with non- viable tissue residues, which is not possible with immune cytolysis. The same antisera were therefore tested by C fixation against leukaemias of three different H-2 genotypes, and",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "asakuma reif 1968 immune cytolysis proved superior purpose c fixation gives additional information permits estimation antibody binding non viable tissue residues possible immune cytolysis antisera therefore tested c fixation leukaemias three different h2 genotypes"
  },
  {
    "id": 1195,
    "paragraph": "against various normal DBA/2 tissues (Table 2). Normal rabbit serum (first two lines, Table 2) showed weak reactivity against leukaemia Antiserum C-yG (third line) showed stronger C fixation with leukaemia L1210 than with other leukaemias. Similar results were obtained with other antisera (see below). Such",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "various normal dba2 tissues table 2 normal rabbit serum first two lines table 2 showed weak reactivity leukaemia antiserum cyg third line showed stronger c fixation leukaemia l1210 leukaemias similar results obtained antisera see"
  },
  {
    "id": 1196,
    "paragraph": "results are in direct contrast to those obtained by immune cytolysis (Table 1); an explana- tion is suggested in the Discussion. Antiserum TM- yG (fourth line) reacted strongly against leukaemia L1210. Reactions against normal tissue residues were of comparable potencies to the reaction against",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "results direct contrast obtained immune cytolysis table 1 explana tion suggested discussion antiserum tm yg fourth line reacted strongly leukaemia l1210 reactions normal tissue residues comparable potencies reaction"
  },
  {
    "id": 1197,
    "paragraph": "leukaemias. L1210. Specificity of Antisera against Leukaemias 1093 Antiserum G-yG (fifth line) reacted more strongly against the homologous leukaemia than against leukaemia C. However, the reactions of this serum, and of Antiserum E6A-yG (sixth line), were strongest against leukaemia L1210. Antiserum L (seventh line) reacted very strongly with the homologous leukaemia L1 210.",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "leukaemias l1210 specificity antisera leukaemias 1093 antiserum gyg fifth line reacted strongly homologous leukaemia leukaemia c however reactions serum antiserum e6ayg sixth line strongest leukaemia l1210 antiserum l seventh line reacted strongly homologous leukaemia l1 210"
  },
  {
    "id": 1198,
    "paragraph": "Also, Antiserum X (last two lines, Table 2) prepared against mixed leukaemias, reacted very strongly with all leukaemias, but especially strongly with leukaemia L12 10. The reactions of all antisera with normal tissue residues was relatively strong, and decreased in approxi-",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "also antiserum x last two lines table 2 prepared mixed leukaemias reacted strongly leukaemias especially strongly leukaemia l12 10 reactions antisera normal tissue residues relatively strong decreased approxi"
  },
  {
    "id": 1199,
    "paragraph": "mately the following order: testis, kidney, liver, lung, brain, muscle, with very little reac- tion against erythrocytes. EXHAUSTIVE ABSORPTION OF ANTI-L1210 SERUM A potent rabbit antiserum prepared against L1 210 leukaemia cells was absorbed with 1/4 volume of packed mouse erythrocytes. Portions of this absorbed antiserum (AA) were",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "mately following order testis kidney liver lung brain muscle little reac tion erythrocytes exhaustive absorption antil1210 serum potent rabbit antiserum prepared l1 210 leukaemia cells absorbed 14 volume packed mouse erythrocytes portions absorbed antiserum aa"
  },
  {
    "id": 1200,
    "paragraph": "further absorbed with lymphocytes (lymph node, splenic and thymic) and once again with washed residues of liver and kidney. The ratio of the number of DBA/2 mice from which 1: 10, these tissues were derived to the volume of antiserum (ml) varied as follows: (a)",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "absorbed lymphocytes lymph node splenic thymic washed residues liver kidney ratio number dba2 mice 1 10 tissues derived volume antiserum ml varied follows"
  },
  {
    "id": 1201,
    "paragraph": "(b) 1:3, (c) 1:1, (d) 3:1. All absorptions were done for 30 minutes at 370. Each portion of separately absorbed antiserum was tested by immune cytolysis against L1 210 cells, lymph node lymphocytes, and splenic lymphocytes. Relative to antiserum AA, the mean cytolytic potencies ofportions absorbed according",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "b 13 c 11 31 absorptions done 30 minutes 370 portion separately absorbed antiserum tested immune cytolysis l1 210 cells lymph node lymphocytes splenic lymphocytes relative antiserum aa mean cytolytic potencies ofportions absorbed according"
  },
  {
    "id": 1202,
    "paragraph": "to schedules (a), (b), (c) and (d) above were 47, 25, 12 and 5-6 per cent, respectively, when determined against L1 210 cells. For any portion of antiserum, the cytolytic potency against L1 210 cells, divided by the cytolytic potency against lymph node lymphocytes,",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "schedules b c 47 25 12 56 per cent respectively determined l1 210 cells portion antiserum cytolytic potency l1 210 cells divided cytolytic potency lymph node lymphocytes"
  },
  {
    "id": 1203,
    "paragraph": "was a measure of the specificity of a particular portion of antiserum against leukaemia cells relative to normal lymphocytes (Reif, Allen and McVety, 1965). The values of this 'specificity ratio' for antiserum portions (a), (b), (c) and (d) were 0 54, 0-72, 0 74 and",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "measure specificity particular portion antiserum leukaemia cells relative normal lymphocytes reif allen mcvety 1965 values specificity ratio antiserum portions b c 0 54 072 0 74"
  },
  {
    "id": 1204,
    "paragraph": "1 26, compared to 0-65 for antiserum AA. The equivalent specificity ratios for the reaction against L1210 cells relative to splenic lymphocytes were 1 29, 1 38, 1-57 and 2 34, com- pared to 0 90 for antiserum AA. When compared to the reaction with either lymph node or",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "1 26 compared 065 antiserum aa equivalent specificity ratios reaction l1210 cells relative splenic lymphocytes 1 29 1 38 157 2 34 com pared 0 90 antiserum aa compared reaction either lymph node"
  },
  {
    "id": 1205,
    "paragraph": "splenic lymphocytes, a substantial increase in specificity against L1 210 leukaemia cells was thus obtained only with schedule (d), which represents very thorough absorption and concomitantly high loss of cytolytic potency. DISCUSSION Heterologous antisera have long been used for the treatment of human leukaemia",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "splenic lymphocytes substantial increase specificity l1 210 leukaemia cells thus obtained schedule represents thorough absorption concomitantly high loss cytolytic potency discussion heterologous antisera long used treatment human leukaemia"
  },
  {
    "id": 1206,
    "paragraph": "(Lindstrom, 1927; Brittingham and Chaplin, 1960). While interest has quickened recently (Sekla, Holeckova,Janele, Libnaisky and Hnevkovsky, 1967; Tsirimbas, Pfisterer, Hornung, Thierfelder, Michlmayr and Stich, 1969; Fernbach, Rossen and Butler, 1970; Mempel and Thierfelder, 1970), there is no convincing evidence that such sera produce",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "lindstrom 1927 brittingham chaplin 1960 interest quickened recently sekla holeckovajanele libnaisky hnevkovsky 1967 tsirimbas pfisterer hornung thierfelder michlmayr stich 1969 fernbach rossen butler 1970 mempel thierfelder 1970 convincing evidence sera produce"
  },
  {
    "id": 1207,
    "paragraph": "or prolong remissions in human leukaemia. The present model study in mice is not con- cerned with the in vivo effectiveness of such sera, but helps to answer questions that arise in their preparation. For instance, must antisera to human leukaemias be prepared by",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "prolong remissions human leukaemia present model study mice con cerned vivo effectiveness sera helps answer questions arise preparation instance must antisera human leukaemias prepared"
  },
  {
    "id": 1208,
    "paragraph": "immunizations of animals with leukaemias of the same HL-A type as the patient to be treated? Can immunization with a mixture of leukaemias produce antisera potent against leukaemias of different HL-A types ? Resolution of these questions must await experi- mentation in man. However, there is a sufficiently close parallel between the H-2 system",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "immunizations animals leukaemias hla type patient treated immunization mixture leukaemias produce antisera potent leukaemias different hla types resolution questions must await experi mentation man however sufficiently close parallel h2 system"
  },
  {
    "id": 1209,
    "paragraph": "A. E. Reif and Chung-Ai H. Kim 1094 of mice and the HL-A system of man, that work with mice is apt to provide useful sug- gestions as to the likely outcome of equivalent work in man. CELLULAR ANTIGENS What murine antigens are able to stimulate formation of antibodies in rabbits? Four",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "e reif chungai h kim 1094 mice hla system man work mice apt provide useful sug gestions likely outcome equivalent work man cellular antigens murine antigens able stimulate formation antibodies rabbits four"
  },
  {
    "id": 1210,
    "paragraph": "classes of cell surface antigens come into consideration: allogenic, organ-specific, tumour- specific and species-specific. With few exceptions (Snell and Stimpfling, 1966), allogenic specificities such as H-1 to H-l 1, TL and 0 are expressed on the cell surface of the corresponding leukaemias. To",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "classes cell surface antigens come consideration allogenic organspecific tumour specific speciesspecific exceptions snell stimpfling 1966 allogenic specificities h1 hl 1 tl 0 expressed cell surface corresponding leukaemias"
  },
  {
    "id": 1211,
    "paragraph": "predict the cross-reactions of antisera prepared against different leukaemias, it must be remembered that mouse strains (and therefore also leukaemias) of different H-2 genotype often share some H-2 antigens. For instance, leukaemia C (H-2b) shares H-2 specificity No. 5 with leukaemias Gardner and RA9 (both H-2k) and specificities Nos. 6, 14, 27, 28",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "predict crossreactions antisera prepared different leukaemias must remembered mouse strains therefore also leukaemias different h2 genotype often share h2 antigens instance leukaemia c h2b shares h2 specificity 5 leukaemias gardner ra9 h2k specificities nos 6 14 27 28"
  },
  {
    "id": 1212,
    "paragraph": "and 29 with leukaemia L1210 (H-2d), while L1210 shares specificities Nos. 3 and 8 with leukaemias Gardner and RA9 (Snell and Stimpfling, 1966). In the present study, antisera prepared by immunization with a leukaemia of a certaina genotype were most potent for immune cytolysis of leukaemias of the same H-2 genotype",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "29 leukaemia l1210 h2d l1210 shares specificities nos 3 8 leukaemias gardner ra9 snell stimpfling 1966 present study antisera prepared immunization leukaemia certaina genotype potent immune cytolysis leukaemias h2 genotype"
  },
  {
    "id": 1213,
    "paragraph": "in the case of antisera G and E6A (Table 1). Similarly, antiserum TM reacted more strongly against L1210 cells (also ofgenotype H-2d) than all sera other than those prepared by injection of L1210 cells (sera L and X). The results for antisera C and L are not readily",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "case antisera g e6a table 1 similarly antiserum tm reacted strongly l1210 cells also ofgenotype h2d sera prepared injection l1210 cells sera l x results antisera c l readily"
  },
  {
    "id": 1214,
    "paragraph": "evaluated, since these were the only leukaemias tested that were of H-2b and H-2d geno- types, respectively. With regard to the two allogenic specificities 6-AKR find O-C3H, we were only able to differentiate these with heterologous antisera after exhaustive absorptions (Asakama and",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "evaluated since leukaemias tested h2b h2d geno types respectively regard two allogenic specificities 6akr find oc3h able differentiate heterologous antisera exhaustive absorptions asakama"
  },
  {
    "id": 1215,
    "paragraph": "Reif, 1968). It seems questionable whether other alloantigens, such as the PC alloantigens of plasma cells (Takahashi, Old and Boyse, 1970), can be detected with heterologous anti- sera without similarly extensive absorptions. While such alloantigens possess characteristic organ distributions, the term 'organ-specific' should probably be reserved for antigens",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "reif 1968 seems questionable whether alloantigens pc alloantigens plasma cells takahashi old boyse 1970 detected heterologous anti sera without similarly extensive absorptions alloantigens possess characteristic organ distributions term organspecific probably reserved antigens"
  },
  {
    "id": 1216,
    "paragraph": "present only in a single organ, or else in cells of closely related type. Tumour-specific transplantation antigens (Gorer, 1938; Boyse, Old, Stockert and Shigeno, 1968; Klein, 1969; Watson, Ralph, Sarkar and Cohn, 1970) are relatively weakly immunogenic on allogenic immunization. Nevertheless, the more difficult feat of demon-",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "present single organ else cells closely related type tumourspecific transplantation antigens gorer 1938 boyse old stockert shigeno 1968 klein 1969 watson ralph sarkar cohn 1970 relatively weakly immunogenic allogenic immunization nevertheless difficult feat demon"
  },
  {
    "id": 1217,
    "paragraph": "strating such antigens with heterologous antisera has been accomplished for chronic lymphocytic leukaemia (Bentwitch, Cohen, Sulitzeanu, Izak and Weiss, 1970). No evidence of specificity to such antigens, nor to the species-specific antigens T, C and F (Boyle and Davies, 1966) and MSLA (Shigeno, Hammerling, Arpels, Boyse and Old,",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "strating antigens heterologous antisera accomplished chronic lymphocytic leukaemia bentwitch cohen sulitzeanu izak weiss 1970 evidence specificity antigens speciesspecific antigens c f boyle davies 1966 msla shigeno hammerling arpels boyse old"
  },
  {
    "id": 1218,
    "paragraph": "1968) was obtained here. In the present study, an antiserum with high cytolytic potency against leukaemias of three different H-2 genotypes was prepared by immunization with a mixture of leukaemia cells. Previously, a close correlation between the results of in vitro immune cytolysis and",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "1968 obtained present study antiserum high cytolytic potency leukaemias three different h2 genotypes prepared immunization mixture leukaemia cells previously close correlation results vitro immune cytolysis"
  },
  {
    "id": 1219,
    "paragraph": "in vivo antileukaemia therapy has been found (Mohos and Kidd, 1957; Reif and Kim, 1969). Therefore, such an antiserum would be expected to be effective in vivo. Finally, the present data suggest that heteroimmunization with a mixture of leukaemia cells from",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "vivo antileukaemia therapy found mohos kidd 1957 reif kim 1969 therefore antiserum would expected effective vivo finally present data suggest heteroimmunization mixture leukaemia cells"
  },
  {
    "id": 1220,
    "paragraph": "different patients might well result in antisera with high in vitro potencies against human leukaemias of different HL-A types. Specificity of Antisera against Leukaemias 1095 RELATIONSHIP BETWEEN C FIXATION AND IMMUNE CYTOLYSIS An interesting facet of the data is the apparent contradiction between the consistently",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "different patients might well result antisera high vitro potencies human leukaemias different hla types specificity antisera leukaemias 1095 relationship c fixation immune cytolysis interesting facet data apparent contradiction consistently"
  },
  {
    "id": 1221,
    "paragraph": "low potencies of various antisera for immune cytolysis of L1210 cells (Table 1) and the consistently high potencies for C fixation by the same cells (Table 2). The discrepancies in this connection were smaller for the other leukaemias. How can these data be explained?",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "low potencies various antisera immune cytolysis l1210 cells table 1 consistently high potencies c fixation cells table 2 discrepancies connection smaller leukaemias data explained"
  },
  {
    "id": 1222,
    "paragraph": "Recent work on immune lysis of erythrocytes or leukaemia cells suggests that after attachment to antigen sites on the cell surface, two molecules of the usual type of yG (Borsos and Rapp, 1965a), a single molecule of yM (Borsos and Rapp, 1965b), or a single",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "recent work immune lysis erythrocytes leukaemia cells suggests attachment antigen sites cell surface two molecules usual type yg borsos rapp 1965a single molecule ym borsos rapp 1965b single"
  },
  {
    "id": 1223,
    "paragraph": "molecule of an unusual type of yG (Frank and Gaither, 1970) are able to fix the first component of complement, C1. To explain why the efficiency of C1 for haemolysis of yM-sensitized sheep erythrocytes decreases dramatically as the density of antigen sites",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "molecule unusual type yg frank gaither 1970 able fix first component complement c1 explain efficiency c1 haemolysis ymsensitized sheep erythrocytes decreases dramatically density antigen sites"
  },
  {
    "id": 1224,
    "paragraph": "decreases (Linscott, 1970), it is suggested that two sites of antibody attachment to the cell ~~~~ ~~C complex ,YG Antibody a FIG. 1. A molecular model of immune cytolysis. It is suggested that penetration of the cell surface can occur only if the complement (C) complex is bound by one (yM) or two (yG) antibody molecules",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "decreases linscott 1970 suggested two sites antibody attachment cell c complex yg antibody fig 1 molecular model immune cytolysis suggested penetration cell surface occur complement c complex bound one ym two yg antibody molecules"
  },
  {
    "id": 1225,
    "paragraph": "attached to closely-spaced antigen sites, and if the C complex is oriented to make optimal contact with the cell surface. Antibody binding is illustrated (a) without binding of C, (b) with lytically ineffective binding of C, and (c) with lytically effective binding of C.",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "attached closelyspaced antigen sites c complex oriented make optimal contact cell surface antibody binding illustrated without binding c b lytically ineffective binding c c lytically effective binding c"
  },
  {
    "id": 1226,
    "paragraph": "surface are necessary before C1 can be fixed by any type of antibody. In the case of yM, a single molecule would attach to two adjacent antigen sites (Fig. 1), while the unusual property of 'unusual' yG (Frank and Gaither, 1970) might be a flexible structure that",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "surface necessary c1 fixed type antibody case ym single molecule would attach two adjacent antigen sites fig 1 unusual property unusual yg frank gaither 1970 might flexible structure"
  },
  {
    "id": 1227,
    "paragraph": "permits two-point contact with the cell surface. The above work suggests that lytically effective binding of the C complex can occur only when two antigen sites are relatively closely spaced. However, fixation of C1 to cell- bound molecules of antibodies does not guarantee either binding of the remaining C com-",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "permits twopoint contact cell surface work suggests lytically effective binding c complex occur two antigen sites relatively closely spaced however fixation c1 cell bound molecules antibodies guarantee either binding remaining c com"
  },
  {
    "id": 1228,
    "paragraph": "ponents or sufficient damage of the membrane to lyse the cell (Linscott, 1970). The effi- A. E. Reif and Chung-Ai H. Kim 1096 ciency of this latter step is 30-50 per cent with yG-sensitized sheep erythrocytes (Rapp and Borsos, 1966), but only about 0*03 per cent with yM-sensitized mouse leukaemia cells",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "ponents sufficient damage membrane lyse cell linscott 1970 effi e reif chungai h kim 1096 ciency latter step 3050 per cent ygsensitized sheep erythrocytes rapp borsos 1966 003 per cent ymsensitized mouse leukaemia cells"
  },
  {
    "id": 1229,
    "paragraph": "(Borsos, Colten, Spalter, Rogentine, and Rapp, 1968), a 1000-fold difference. To explain these data as well as our own, it is suggested that immune lysis can occur only when the antibody-bound complement complex is correctly oriented for optimal (and presumably close) contact with the cell surface. The illustration of this (Fig. 1) has been arranged to fit",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "borsos colten spalter rogentine rapp 1968 1000fold difference explain data well suggested immune lysis occur antibodybound complement complex correctly oriented optimal presumably close contact cell surface illustration fig 1 arranged fit"
  },
  {
    "id": 1230,
    "paragraph": "current concepts on the structure of antibody molecules (Svehag, Chesebro and Bloth, 1967; Green, 1969) and the attachment of C1 to the Fc portion of yG or yM antibodies (Weiser, Myrvik and Pearsall, 1969). According to the above explanation, the present anomalous data with L1210 would be",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "current concepts structure antibody molecules svehag chesebro bloth 1967 green 1969 attachment c1 fc portion yg ym antibodies weiser myrvik pearsall 1969 according explanation present anomalous data l1210 would"
  },
  {
    "id": 1231,
    "paragraph": "explicable on the basis of a lower surface antigen concentration on L 1210 cells relative to other mouse leukaemias: sufficient L1210 antigen sites would be available to fix 50 per cent of the small quantity of C added in the C fixation test (especially since 10 times more",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "explicable basis lower surface antigen concentration l 1210 cells relative mouse leukaemias sufficient l1210 antigen sites would available fix 50 per cent small quantity c added c fixation test especially since 10 times"
  },
  {
    "id": 1232,
    "paragraph": "cells were used than in the cytolysis assay), but would be insufficient to provide as ready immune cytolysis, with its more stringent requirement for closely-spaced antigen sites. Since different cell types possess widely different sensitivites to non-immune lysis, implying differences in the strength of different cell surfaces (Reif and Allen, 1966), the sensitivities",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "cells used cytolysis assay would insufficient provide ready immune cytolysis stringent requirement closelyspaced antigen sites since different cell types possess widely different sensitivites nonimmune lysis implying differences strength different cell surfaces reif allen 1966 sensitivities"
  },
  {
    "id": 1233,
    "paragraph": "leukemic lymphocytes.' Cancer Res., 28, 707. BENTWITCH, Z., COHEN, I., SULrrZEANU, D., IZAK, G. and WEwss, D. W. (1970). 'Antigenicity of lympho- cytes from chronic lymphocytic patients and from normal newborns.' Proc. Amer. Ass. Cancer Res., 11, 7. BORSOS, T., COLTEN, H. R., SPALTER, J. S., ROGEN-",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "leukemic lymphocytes cancer res 28 707 bentwitch z cohen sulrrzeanu izak g wewss w 1970 antigenicity lympho cytes chronic lymphocytic patients normal newborns proc amer ass cancer res 11 7 borsos colten h r spalter j rogen"
  },
  {
    "id": 1234,
    "paragraph": "TINE, N. and RAPP, H. J. (1968). 'The C'la fixation and transfer test: examples of its applicability to the detection and enumeration of antigens and anti- bodies at cell surfaces.'_7. Immunol., 101, 392. BoRsos, T. and RAPP, H. J. (1965a). 'Complement",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "tine n rapp h j 1968 cla fixation transfer test examples applicability detection enumeration antigens anti bodies cell surfaces7 immunol 101 392 borsos rapp h j 1965a complement"
  },
  {
    "id": 1235,
    "paragraph": "fixation on cell surfaces by 19S and 7S antibodies.' Science, 150, 505. BoRsos, T. and RAPP, H. J. (1965b). 'Hemolysin titration based on fixation of the activated first com- ponent of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte.'J.",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "fixation cell surfaces 19s 7s antibodies science 150 505 borsos rapp h j 1965b hemolysin titration based fixation activated first com ponent complement evidence one molecule hemolysin suffices sensitize erythrocytej"
  },
  {
    "id": 1236,
    "paragraph": "Immunol., 95, 559. BOYLE, W. and DAVIES, D. A. L. (1966). 'Antigens of the surface of mouse ascites tumour cells. I. Studies with rabbit anti-mouse cell sera.' Immunology, 11, 353. BOYSE, E. A., OLD, L. J., STOCKERT, E. and SHIGENO, 'Genetic origin of tumor antigens.'",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "immunol 95 559 boyle w davies l 1966 antigens surface mouse ascites tumour cells studies rabbit antimouse cell sera immunology 11 353 boyse e old l j stockert e shigeno genetic origin tumor antigens"
  },
  {
    "id": 1237,
    "paragraph": "N. (1968). Cancer Res., 28, 1280. BRrrINGM4, T. E. and CHAPLIN, H., JR (1960). 'Production of a human \"antileukemic leukocyte\" serum and its therapeutic trial.' Cancer, 13, 412. FERNBACH, D. J., ROSSEN, R. D. and BUTLER, W. T. (1970). 'Studies of antilymphocyte globulin (ALG)",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "n 1968 cancer res 28 1280 brrringm4 e chaplin h jr 1960 production human antileukemic leukocyte serum therapeutic trial cancer 13 412 fernbach j rossen r butler w 1970 studies antilymphocyte globulin alg"
  },
  {
    "id": 1238,
    "paragraph": "treatment of children with acute leukemia (AL).' Proc. Amer. Ass. Cancer Res., 11, 25. FRNK, M. M. and GAITHER, T. A. (1970). 'Comple- ment fixation by a single molecule of yG hemolysin.' J. Immunol., 104, 1458. GARDNER, W. U., DOUGHERTY, T. F. and WILLIAMS,",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "treatment children acute leukemia al proc amer ass cancer res 11 25 frnk gaither 1970 comple ment fixation single molecule yg hemolysin j immunol 104 1458 gardner w u dougherty f williams"
  },
  {
    "id": 1239,
    "paragraph": "W. L. (1944). 'Lymphoid tumors in mice receiving steroid hormones.' Cancer Res., 4, 73. GORER, P. A. (1938). 'The antigenic basis of tumor transplantation.' J. Path. Bact., 47, 231. GREEN, N. M. (1969). Advances in Immunology (Ed. by F. J. Dixon, Jr and H. G. Kunkel), p. 1. Academic",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "w l 1944 lymphoid tumors mice receiving steroid hormones cancer res 4 73 gorer p 1938 antigenic basis tumor transplantation j path bact 47 231 green n 1969 advances immunology ed f j dixon jr h g kunkel p 1 academic"
  },
  {
    "id": 1240,
    "paragraph": "Press, New York. HILL, G. J., II and LITTLEJOHN, K. (1970). 'Compari- son ofheterologous antiserum and cyclophosphamide in therapy of mouse leukemia.' Proc. Amer. Ass. Cancer Res., 11, 37. Kim, C.-A. H. and REIF, A. E. (1971). 'Immunization schedules for potent rabbit antisera to leukemia",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "press new york hill g j ii littlejohn k 1970 compari son ofheterologous antiserum cyclophosphamide therapy mouse leukemia proc amer ass cancer res 11 37 kim ca h reif e 1971 immunization schedules potent rabbit antisera leukemia"
  },
  {
    "id": 1241,
    "paragraph": "L12 10.' Cancer Res., 31, 7. KLEIN, G. (1969). 'Experimental studies in tumor im- munology.' Fed. Proc., 28, 1739. LAW, L. W., DUNN, T. B., BOYLE, P. J. and MILLER, J. H. (1949). 'Observations on the effect of a folic acid antagonist on transplantable lymphoid leu-",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "l12 10 cancer res 31 7 klein g 1969 experimental studies tumor im munology fed proc 28 1739 law l w dunn b boyle p j miller j h 1949 observations effect folic acid antagonist transplantable lymphoid leu"
  },
  {
    "id": 1242,
    "paragraph": "kemias in mice.' N. nat. Cancer Inst., 10, 179. LEVI, E., GOLDEN, R., ZERUBAVEL, R. and FISCHER, J. (1966). 'The activity of tolerant antileukemia sera. I. in vitro effects.' Cancer Res., 26, 659. LINDSTROM, G. A. (1927). 'An experimental study of",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "kemias mice n nat cancer inst 10 179 levi e golden r zerubavel r fischer j 1966 activity tolerant antileukemia sera vitro effects cancer res 26 659 lindstrom g 1927 experimental study"
  },
  {
    "id": 1243,
    "paragraph": "myelotoxic sera. Therapeutic attempts in myeloid leukemia.' Acta med. scand. (suppl.), 22, 1. Specificity of Antisera against Leukaemias LINSCOTT, W. D. (1970). 'An antigen density effect on the hemolytic efficiency of complement.' J. Im- munol., 104, 1307. MAYER, M. M. (1961). 'Complement and complement",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "myelotoxic sera therapeutic attempts myeloid leukemia acta med scand suppl 22 1 specificity antisera leukaemias linscott w 1970 antigen density effect hemolytic efficiency complement j im munol 104 1307 mayer 1961 complement complement"
  },
  {
    "id": 1244,
    "paragraph": "fixation.' Experimental Immunochemistry (Ed. by E. A. Kabat), 2nd edn, p. 133. Thomas, Springfield. MEMPEL, W. and THIERFELDER, S. (1970). 'Die Wirk- ung von Antilymphozytenserum allein oder in Ver- bindung mit einem Zytostatikum auf eine Mauseleu- kaemie.' Blut, 20, 37. MILLER, D. G., MOLOVANU, G., KAPLAN, A. and",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "fixation experimental immunochemistry ed e kabat 2nd edn p 133 thomas springfield mempel w thierfelder 1970 die wirk ung von antilymphozytenserum allein oder ver bindung mit einem zytostatikum auf eine mauseleu kaemie blut 20 37 miller g molovanu g kaplan"
  },
  {
    "id": 1245,
    "paragraph": "ToCCI, S. (1968). 'Antilymphocytic leukemic serum and chemotherapy in the treatment of murine leukemia.' Cancer, 22, 1192. MOHOS, S. C. and KIDD, J. G. (1957). 'Effects of various immune rabbit serums on the cells of several transplanted mouse lymphomas in vitro and in",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "tocci 1968 antilymphocytic leukemic serum chemotherapy treatment murine leukemia cancer 22 1192 mohos c kidd j g 1957 effects various immune rabbit serums cells several transplanted mouse lymphomas vitro"
  },
  {
    "id": 1246,
    "paragraph": "vivo.'_7. exp. Med., 105, 233. RAPP, H. J. and BORSOS, T. (1966). 'Forssman antigen and antibody: preparation of water soluble antigen and measurement of antibody concentration by pre- cipitin analysis, by C'la fixation and by hemolytic activity.'7. Immunol., 96, 913. ascites tumors.'_7. Immunol., 89, 849.",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "vivo7 exp med 105 233 rapp h j borsos 1966 forssman antigen antibody preparation water soluble antigen measurement antibody concentration pre cipitin analysis cla fixation hemolytic activity7 immunol 96 913 ascites tumors7 immunol 89 849"
  },
  {
    "id": 1247,
    "paragraph": "REIF, A. E. (1969). 'Batch preparation of rabbit yG globulin with DEAE-Cellulose.' Immunochemistiy, 6, 723. REIF, A. E. (1962). 'Immune cytolysis of three mouse REIF, A. E. and ALLEN, J. M. (1964). 'The AKR thymic antigen and its distribution in leukemias and",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "reif e 1969 batch preparation rabbit yg globulin deaecellulose immunochemistiy 6 723 reif e 1962 immune cytolysis three mouse reif e allen j 1964 akr thymic antigen distribution leukemias"
  },
  {
    "id": 1248,
    "paragraph": "nervous tissues.'7. exp. Med., 120, 413. REIF, A. E. and ALLEN, J. M. (1966). 'The fragility of normal and leukemic lymphocytes of AKR mice: a study of cell injury by physical agents.' Cancer Res., 26, 131. REIF, A. E., ALLEN, J. M. V. and MCVETY, L. M.",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "nervous tissues7 exp med 120 413 reif e allen j 1966 fragility normal leukemic lymphocytes akr mice study cell injury physical agents cancer res 26 131 reif e allen j v mcvety l"
  },
  {
    "id": 1249,
    "paragraph": "(1965). 'A general method for the calculation of serological specificity.' Immunology, 8, 384. REIF, A. F. and KIM, C.-A. H. (1969). 'Therapy of transplantable mouse leukaemias with antileukae- mia sera.' Nature (Lond.), 223, 1377. REIF, A. E. and NORRIS, H. J. (1960), 'A system for",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "1965 general method calculation serological specificity immunology 8 384 reif f kim ca h 1969 therapy transplantable mouse leukaemias antileukae mia sera nature lond 223 1377 reif e norris h j 1960 system"
  },
  {
    "id": 1250,
    "paragraph": "quantitative determination of cytotoxic activity of antisera to ascites tumor cells.' Cancer Res., 20, 1235. 1097 SCHABEL, F. M., JR, SKIPPER, H. E., LASTER, W. R., JR and THOMPSON, S. A. (1966). 'Experimental evaluation of potential anticancer agents. XX. Development of immunity to leukemia L1210 in",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "quantitative determination cytotoxic activity antisera ascites tumor cells cancer res 20 1235 1097 schabel f jr skipper h e laster w r jr thompson 1966 experimental evaluation potential anticancer agents xx development immunity leukemia l1210"
  },
  {
    "id": 1251,
    "paragraph": "BDF1 mice and effects of therapy.' Cancer Chem. Rep., 50, 55. SEKLA, B., HOLECKOVA, E., JANELE, J., LIBANSKI1, J. and HNEVKOVSKI+, 0. (1967). 'The effects of hetero- logous immune globulins upon human cancer in vivo.' Neoplasma, 14, 64 1. SHIGENO, N., HAMMERLING, U., ARPELS, C., BoYSE,",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "bdf1 mice effects therapy cancer chem rep 50 55 sekla b holeckova e janele j libanski1 j hnevkovski 0 1967 effects hetero logous immune globulins upon human cancer vivo neoplasma 14 64 1 shigeno n hammerling u arpels c boyse"
  },
  {
    "id": 1252,
    "paragraph": "E. A. and OLD, L. J. (1968). 'Preparation of lym- antibody from anti-lymphocyte phocyte-specific serum.' Lancet, ii, 320. SIEGEL, B. V. and MORTON, J. I. (1970). 'Rauscher viral leukemogenesis in BALB/c mice treated with rabbit antimouse thymocyte serum.' 7. nat. Cancer",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "e old l j 1968 preparation lym antibody antilymphocyte phocytespecific serum lancet ii 320 siegel b v morton j 1970 rauscher viral leukemogenesis balbc mice treated rabbit antimouse thymocyte serum 7 nat cancer"
  },
  {
    "id": 1253,
    "paragraph": "Inst., 44, 573. SNELL, G. D. and STIMPFLING, J. H. (1966). 'Genetics of tissue transplantation.' Biology of the Laboratory Mouse (Ed. by E. L. Green), 2nd edn, p. 457. McGraw-Hill, New York. SVEHAG, S.-E., CHESEBRO, B. and BLOTH, B. (1967). 'Ultrastructure of gamma M immunoglobulin and",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "inst 44 573 snell g stimpfling j h 1966 genetics tissue transplantation biology laboratory mouse ed e l green 2nd edn p 457 mcgrawhill new york svehag se chesebro b bloth b 1967 ultrastructure gamma immunoglobulin"
  },
  {
    "id": 1254,
    "paragraph": "alpha macroglobulin: electron-microscopic study.' Science, 158, 933. TAKAHASHI, T., OLD, L. J. and BOYSE, E. A. (1970). 'Surface allo-antigens of plasma cells.'J. exp. Med., 131, 1325. TSIRIMBAS, A. D., PFISTERER, H., HORNUNG, B., THIERFELDER, S., MICHLMAYR, G. and STICH, W. (1969). 'Studies with heterologous antilymphocytic",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "alpha macroglobulin electronmicroscopic study science 158 933 takahashi old l j boyse e 1970 surface alloantigens plasma cellsj exp med 131 1325 tsirimbas pfisterer h hornung b thierfelder michlmayr g stich w 1969 studies heterologous antilymphocytic"
  },
  {
    "id": 1255,
    "paragraph": "serum as a therapy for chronic lymphocytic leu- kemia.' Blut, 19, 420. WATSON, J., RALPH, P., SARKAR, S. and COHN, M. (1970). 'Leukemia viruses associated with mouse myeloma cells.' Proc. nat. Acad. Sci. (Wash.), 66, 344. WEISER, R. S., MYRVIK, Q. N. and PEARSALL, N. N.",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "serum therapy chronic lymphocytic leu kemia blut 19 420 watson j ralph p sarkar cohn 1970 leukemia viruses associated mouse myeloma cells proc nat acad sci wash 66 344 weiser r myrvik q n pearsall n n"
  },
  {
    "id": 1256,
    "paragraph": "(1969). Fundamentals of Immunology, p. 25. Lea & Febiger, Philadelphia, Pa. WITZ, I., YAGI, Y. and PRESSMAN, D. (1968). 'Immuno- directed suppressive against mouse lymphocytic leukemia L1210.' Proc. Soc. exp. Biol. (N.r.), 127, 562. activity of rabbit antisera",
    "jurnal": "immunology00365-0229.pdf",
    "processed": "1969 fundamentals immunology p 25 lea febiger philadelphia pa witz yagi pressman 1968 immuno directed suppressive mouse lymphocytic leukemia l1210 proc soc exp biol nr 127 562 activity rabbit antisera"
  },
  {
    "id": 1257,
    "paragraph": "LEUKEMIA/ KANKER DARAH Alyano Rantumbanua, Tania I.M Lampa Triana Virenza Madil, Vanessa Umboh DASAR BIOMEDIK III DR.dr. WULAN PINGKAN JULIA KAUNANG GRAD.DIP, M.KES FAKULTAS KESEHATAN MASYARAKAT UNIVERSITAS SAM RATULANGI MANADO 1 KATA PENGANTAR Puji dan Syukur kami panjatkan karena atas tuntunan dari Tuhan Yang Maha Esa,",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "leukemia kanker darah alyano rantumbanua tania im lampa triana virenza madil vanessa umboh dasar biomedik iii drdr wulan pingkan julia kaunang graddip mkes fakultas kesehatan masyarakat universitas sam ratulangi manado 1 kata pengantar puji dan syukur kami panjatkan karena atas tuntunan dari tuhan yang maha esa"
  },
  {
    "id": 1258,
    "paragraph": "Sehingga Kami dapat diberi kesempatan untuk menyelesaikan tugas yang berjudul “LEUKIMIA”, Tidak lupa juga diucapkan terimakasih Kepada dosen mata kuliah DASAR BIOMEDIK III yaitu Dr.dr. Wulan Pingkan Julia Kaunang Grad.Dip, M.Kes, yang telah memberikan tugas dan juga membimbing untuk menyelesaikan Tugas ini.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "sehingga kami dapat diberi kesempatan untuk menyelesaikan tugas yang berjudul “ leukimia ” tidak lupa juga diucapkan terimakasih kepada dosen mata kuliah dasar biomedik iii yaitu drdr wulan pingkan julia kaunang graddip mkes yang telah memberikan tugas dan juga membimbing untuk menyelesaikan tugas ini"
  },
  {
    "id": 1259,
    "paragraph": "Tugas ini ditulis untuk memperluas pengetahuan mengenai Penyakit menular khususnya LEUKIMIA, Semoga is dari Tugas ini dapat bermanfaat dan memberikan wawasan yang lebih luas bagi para pembaca terlebih bagi diri penulis sendiri. Akhirnya, dengan segala kerendahan hati kami penyusun menyadari masih terdapat",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "tugas ini ditulis untuk memperluas pengetahuan mengenai penyakit menular khususnya leukimia semoga dari tugas ini dapat bermanfaat dan memberikan wawasan yang lebih luas bagi para pembaca terlebih bagi diri penulis sendiri akhirnya dengan segala kerendahan hati kami penyusun menyadari masih terdapat"
  },
  {
    "id": 1260,
    "paragraph": "banyak kekurangan dalam penulisan dan pembuatan tugas ini, sehingga kami tim penysun mengharapkan adanya saran dan kritik yang membangun. Manado, 4 November 2024 Penulis, Kelompok 10 i DAFTAR ISI KATA PENGANTAR .............................................................................................. i DAFTAR ISI .............................................................................................................. ii",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "banyak kekurangan dalam penulisan dan pembuatan tugas ini sehingga kami tim penysun mengharapkan adanya saran dan kritik yang membangun manado 4 november 2024 penulis kelompok 10 daftar isi kata pengantar daftar isi ii"
  },
  {
    "id": 1261,
    "paragraph": "Pengertian Leukemia (Kanker darah) Leukemia adalah salah satu tipe kanker yang menyerang sel-sel darah putih. Dalam kasus leukemia, sel-sel darah putih yang seharusnya bertugas melawan infeksi tumbuh secara tidak normal dan tidak terkontrol. Keadaan ini dapat merusak kemampuan sumsum tulang untuk memproduksi sel",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "pengertian leukemia kanker darah leukemia adalah salah satu tipe kanker yang menyerang selsel darah putih dalam kasus leukemia selsel darah putih yang seharusnya bertugas melawan infeksi tumbuh secara tidak normal dan tidak terkontrol keadaan ini dapat merusak kemampuan sumsum tulang untuk memproduksi sel"
  },
  {
    "id": 1262,
    "paragraph": "darah. Salah satu penyakit paling berbahaya adalah kanker darah, yang juga dikenal sebagai leukemia. penyakit ini disebabkan oleh produksi berlebihan sel darah putih dan kurangnya sel darah merah dalam proses produksi darah di tubuh. Kanker ini menyerang sel darah putih yang diproduksi di sumsum tulang. Sumsum tulang",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "darah salah satu penyakit paling berbahaya adalah kanker darah yang juga dikenal sebagai leukemia penyakit ini disebabkan oleh produksi berlebihan sel darah putih dan kurangnya sel darah merah dalam proses produksi darah di tubuh kanker ini menyerang sel darah putih yang diproduksi di sumsum tulang sumsum tulang"
  },
  {
    "id": 1263,
    "paragraph": "Penyebab Meskipun penyebab pasti dari leukemia belum sepenuhnya dipahami, ada beberapa faktor yang dapat menyebabkan penyakit ini, seperti: a. Faktor genetik dari beberapa virus yang memodifikasi gen (virus limfoma sel t/HTLV) b. Paparan radiasi yang tinggi c. Penggunaan obat imunosupresif seperti dietilstilbestrol d. Faktor herediter, seperti kembar identik e.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "penyebab meskipun penyebab pasti dari leukemia belum sepenuhnya dipahami ada beberapa faktor yang dapat menyebabkan penyakit ini seperti faktor genetik dari beberapa virus yang memodifikasi gen virus limfoma sel thtlv b paparan radiasi yang tinggi c penggunaan obat imunosupresif seperti dietilstilbestrol faktor herediter seperti kembar identik e"
  },
  {
    "id": 1264,
    "paragraph": "Kelainan kromosom, seperti sindrom Down. Penyebab leukemia belum jelas. Beberapa faktor yang diduga berkontribusi pada kejadian leukemia meliputi: A. Radiasi: Berdasarkan penelitian yang ada, 1) Pekerja di bidang radiologi memiliki risiko lebih tinggi terkena leukemia, 2) Pasien yang mendapatkan radioterapi berisiko mengalami leukemia, dan",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "kelainan kromosom seperti sindrom penyebab leukemia belum jelas beberapa faktor yang diduga berkontribusi pada kejadian leukemia meliputi radiasi berdasarkan penelitian yang ada 1 pekerja di bidang radiologi memiliki risiko lebih tinggi terkena leukemia 2 pasien yang mendapatkan radioterapi berisiko mengalami leukemia dan"
  },
  {
    "id": 1265,
    "paragraph": "3) Penyakit leukemia terdeteksi pada korban yang selamat dari pemboman atom di Hiroshima dan Nagasaki di Jepang. B. Faktor Leukemogenik: Beberapa bahan kimia bisa menyebabkan leukemia: 1). Racun dari lingkungan seperti benzena: paparan tinggi terhadap benzena di tempat kerja dapat berisiko menyebabkan leukemia.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "3 penyakit leukemia terdeteksi pada korban yang selamat dari pemboman atom di hiroshima dan nagasaki di jepang b faktor leukemogenik beberapa bahan kimia bisa menyebabkan leukemia 1 racun dari lingkungan seperti benzena paparan tinggi terhadap benzena di tempat kerja dapat berisiko menyebabkan leukemia"
  },
  {
    "id": 1266,
    "paragraph": "2) Bahan kimia dari industri, seperti insektisida dan formaldehid. 3) Pasien kanker yang menjalani kemoterapi dengan obat tertentu kadang-kadang mengembangkan leukemia di kemudian hari. Sebagai contoh, ada hubungan antara pemakaian obat yang dikenal sebagai agen alkilasi dan munculnya leukemia di tahun-",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "2 bahan kimia dari industri seperti insektisida dan formaldehid 3 pasien kanker yang menjalani kemoterapi dengan obat tertentu kadangkadang mengembangkan leukemia di kemudian hari sebagai contoh ada hubungan antara pemakaian obat yang dikenal sebagai agen alkilasi dan munculnya leukemia di tahun"
  },
  {
    "id": 1267,
    "paragraph": "tahun berikutnya. A. Sindrom Down, yang disebabkan oleh kelainan kromosom, dapat meningkatkan risiko leukemia dengan insiden leukemia akut 20 kali lebih tinggi dibandingkan orang normal. B. Virus tertentu dapat menyebabkan leukemia, seperti retrovirus, virus leukemia kucing, dan virus HTLV-1 pada orang dewasa.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "tahun berikutnya sindrom yang disebabkan oleh kelainan kromosom dapat meningkatkan risiko leukemia dengan insiden leukemia akut 20 kali lebih tinggi dibandingkan orang normal b virus tertentu dapat menyebabkan leukemia seperti retrovirus virus leukemia kucing dan virus htlv1 pada orang dewasa"
  },
  {
    "id": 1268,
    "paragraph": "2 komplikasi kanker darah (leukemia) Jika tidak ditangani dengan benar, leukemia bisa menimbulkan beberapa komplikasi yang serius, berikut beberapa komplikasi yang dapat terjadi: • Tubuh akan mudah terkena infeksi karena minimnya sel darah putih dalam tubuh. • dapat terjadi Pendarahan pada bagian tubuh yang berbahaya atau pada bagian tubuh",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "2 komplikasi kanker darah leukemia jika tidak ditangani dengan benar leukemia bisa menimbulkan beberapa komplikasi yang serius berikut beberapa komplikasi yang dapat terjadi • tubuh akan mudah terkena infeksi karena minimnya sel darah putih dalam tubuh • dapat terjadi pendarahan pada bagian tubuh yang berbahaya atau pada bagian tubuh"
  },
  {
    "id": 1269,
    "paragraph": "yang sensitif, seperti otak, paru-paru, lambung, dan usus • Terjadi Gangguan pada tulang yang menyebabkan patah tulang, pengapuran dan nyeri . • Terjadi gangguan pada fungsi ginjal, bahkan bisa terkena penyakit gagal ginjal. • Beresiko timbulnya jenis penyakit kanker darah lain. Penanganan leukemia yang",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "yang sensitif seperti otak paruparu lambung dan usus • terjadi gangguan pada tulang yang menyebabkan patah tulang pengapuran dan nyeri • terjadi gangguan pada fungsi ginjal bahkan bisa terkena penyakit gagal ginjal • beresiko timbulnya jenis penyakit kanker darah lain penanganan leukemia yang"
  },
  {
    "id": 1270,
    "paragraph": "dilakukan juga mungkin menyebabkan komplikasi, seperti penyakit anemia hemolitik, penyakit sindrom lisis tumor, bahkan bisa terkena penyakit ketidaksuburan (infertilitas), dan juga sel kanker yang timbul kembali setelah melakukan pengobatan, dan juga bisa menyebabkan gangguan sistem pada bagian saraf pusat pada anak-anak,",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "dilakukan juga mungkin menyebabkan komplikasi seperti penyakit anemia hemolitik penyakit sindrom lisis tumor bahkan bisa terkena penyakit ketidaksuburan infertilitas dan juga sel kanker yang timbul kembali setelah melakukan pengobatan dan juga bisa menyebabkan gangguan sistem pada bagian saraf pusat pada anakanak"
  },
  {
    "id": 1271,
    "paragraph": "seperti katarak.. 1) Tombositopenia: Pada leukemia akut, penurunan jumlah trombosit biasanya disebabkan oleh kemoterapi bisa juga disebut dengan infiltrasi sumsun tulang , tetapi bisa juga disebabkan oleh yang lainnya contohnya koagulasi intravaskuler diseminata, dan proses imunologis, dan juga 3 hipersplenisme sekunder pada",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "seperti katarak 1 tombositopenia pada leukemia akut penurunan jumlah trombosit biasanya disebabkan oleh kemoterapi bisa juga disebut dengan infiltrasi sumsun tulang tetapi bisa juga disebabkan oleh yang lainnya contohnya koagulasi intravaskuler diseminata dan proses imunologis dan juga 3 hipersplenisme sekunder pada"
  },
  {
    "id": 1272,
    "paragraph": "proses pembesaran limpa. Trombositopenia yang selalu terjadi selalu juga bervariasi atau tidak sama dan kebanyakan selalu ditemukan saat leukemia didiagnosis. 3 2) Koagulasi Intravaskuler diseminata : penyakit ini juga ditandai terhadap aktivasi koagulasi intravaskuler sistemik, yang juga terdiri antara lain dari pembentukan",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "proses pembesaran limpa trombositopenia yang selalu terjadi selalu juga bervariasi atau tidak sama dan kebanyakan selalu ditemukan saat leukemia didiagnosis 3 2 koagulasi intravaskuler diseminata penyakit ini juga ditandai terhadap aktivasi koagulasi intravaskuler sistemik yang juga terdiri antara lain dari pembentukan"
  },
  {
    "id": 1273,
    "paragraph": "dan penyebaran deposit fibrin dalam proses sirkulasi. Penyakit ini juga dapat menimbulkan trombus mikrovaskuler pada beberapa organ, yang juga dapat mengakibatkan kegagalan multiorgan. Aktivasi koagulasi yang selalu tidak berhenti atau terus menerus dapat menyebabkan terjadinya pengonsumsian faktor pembekuan dan trombosit yang terlalu berlebihan, yang menyebabkan kegagalan.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "dan penyebaran deposit fibrin dalam proses sirkulasi penyakit ini juga dapat menimbulkan trombus mikrovaskuler pada beberapa organ yang juga dapat mengakibatkan kegagalan multiorgan aktivasi koagulasi yang selalu tidak berhenti atau terus menerus dapat menyebabkan terjadinya pengonsumsian faktor pembekuan dan trombosit yang terlalu berlebihan yang menyebabkan kegagalan"
  },
  {
    "id": 1274,
    "paragraph": "KID bukanlah penyakit sendiri, sebaliknya, itu adalah hasil dari penyakit lain yang mendasari. 3) Fibrinolisis Primer: peneliti telah menemukan bahwa sesungguhnya leukosit pada leukemia akut adalah melakukan aktivitas fibrinolitik, yang bisa mengakibatkan fibrinolisis primer. Terutama terjadinya kepada leukemia promielositik akut. Fibrinolisis primer, perdarahan dapat terjadi juga dikarenakan salah satu faktor",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "kid bukanlah penyakit sendiri sebaliknya itu adalah hasil dari penyakit lain yang mendasari 3 fibrinolisis primer peneliti telah menemukan bahwa sesungguhnya leukosit pada leukemia akut adalah melakukan aktivitas fibrinolitik yang bisa mengakibatkan fibrinolisis primer terutama terjadinya kepada leukemia promielositik akut fibrinolisis primer perdarahan dapat terjadi juga dikarenakan salah satu faktor"
  },
  {
    "id": 1275,
    "paragraph": "Faktor Risiko Leukemia Beberapa faktor dapat meningkatkan risiko terkena leukemia, meskipun Penyebab yang akurat dari penyakit ini masih belum sepenuhnya dipahami. Usia leukimia Lebih sering terjadi pada orang dewasa serta anak-anak. Riwayat keluarga: Memiliki seorang anggota keluarga yang pernah didiagnosis dengan",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "faktor risiko leukemia beberapa faktor dapat meningkatkan risiko terkena leukemia meskipun penyebab yang akurat dari penyakit ini masih belum sepenuhnya dipahami usia leukimia lebih sering terjadi pada orang dewasa serta anakanak riwayat keluarga memiliki seorang anggota keluarga yang pernah didiagnosis dengan"
  },
  {
    "id": 1276,
    "paragraph": "leukemia dapat meningkatkan risiko penyakit tersebut. - Paparan terhadap bahan kimia: seperti benzena yang terkandung dalam bahan bakar dan produk-produk industri, dapat meningkatkan risiko. - Radiasi: Paparan radiasi dalam dosis tinggi, seperti dari pengobatan kanker lainnya, dapat menjadi faktor risiko. - Kelainan genetik: Risiko terkena leukemia dapat meningkat karena sindrom Down",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "leukemia dapat meningkatkan risiko penyakit tersebut paparan terhadap bahan kimia seperti benzena yang terkandung dalam bahan bakar dan produkproduk industri dapat meningkatkan risiko radiasi paparan radiasi dalam dosis tinggi seperti dari pengobatan kanker lainnya dapat menjadi faktor risiko kelainan genetik risiko terkena leukemia dapat meningkat karena sindrom"
  },
  {
    "id": 1277,
    "paragraph": "dan beberapa kelainan genetik lainnya. - Merokok: Risiko terkena beberapa jenis leukemia lebih tinggi jika Anda merokok. Gejala Leukemia Gejala leukemia bervariasi tergantung pada jenis leukemia dan stadiumnya. • Kelelahan: Rasa lelah yang terus-menerus yang tidak hilang meskipun sedang beristirahat • Demam dan infeksi: Orang yang menderita leukemia memiliki sistem kekebalan",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "dan beberapa kelainan genetik lainnya merokok risiko terkena beberapa jenis leukemia lebih tinggi jika anda merokok gejala leukemia gejala leukemia bervariasi tergantung pada jenis leukemia dan stadiumnya • kelelahan rasa lelah yang terusmenerus yang tidak hilang meskipun sedang beristirahat • demam dan infeksi orang yang menderita leukemia memiliki sistem kekebalan"
  },
  {
    "id": 1278,
    "paragraph": "tubuh yang lemah, yang membuat mereka lebih rentan terhadap infeksi. • Pucat: Kulit dapat terlihat pucat karena anemia akibat kekurangan sel darah merah. • Mudah berdarah dan memar: Darah sulit membeku karena jumlah trombosit yang rendah. • Nyeri tulang: Sel-sel leukemia yang menumpuk di tulang dapat menyebabkan nyeri.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "tubuh yang lemah yang membuat mereka lebih rentan terhadap infeksi • pucat kulit dapat terlihat pucat karena anemia akibat kekurangan sel darah merah • mudah berdarah dan memar darah sulit membeku karena jumlah trombosit yang rendah • nyeri tulang selsel leukemia yang menumpuk di tulang dapat menyebabkan nyeri"
  },
  {
    "id": 1279,
    "paragraph": "• Pembesaran kelenjar getah bening: Akibat pembesaran sel leukemia, kelenjar getah bening dapat membesar. 5 • Turunnya berat badan tanpa sebab: penurunan berat badan yang signifikan dapat merupakan gejala leukemia. • Keringat malam: Keringat berlebih sering terjadi pada malam hari. • Bengkak pada perut: Rasa sakit perut dapat disebabkan oleh pembesaran limpa atau",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "• pembesaran kelenjar getah bening akibat pembesaran sel leukemia kelenjar getah bening dapat membesar 5 • turunnya berat badan tanpa sebab penurunan berat badan yang signifikan dapat merupakan gejala leukemia • keringat malam keringat berlebih sering terjadi pada malam hari • bengkak pada perut rasa sakit perut dapat disebabkan oleh pembesaran limpa atau"
  },
  {
    "id": 1280,
    "paragraph": "Pencegahan kanker darah (leukemia) Pencegahan kanker darah (leukemia) Semua penyakit keganasan pada anak, penyakit ini adalah yang paling umum. Dibandingkan dengan anak kulit hitam di negara berkembang, anak kulit putih bertanggung jawab atas 83% ALL dan 17% AML 93% terdiri dari leukemia akut,",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "pencegahan kanker darah leukemia pencegahan kanker darah leukemia semua penyakit keganasan pada anak penyakit ini adalah yang paling umum dibandingkan dengan anak kulit hitam di negara berkembang anak kulit putih bertanggung jawab atas 83 dan 17 aml 93 terdiri dari leukemia akut"
  },
  {
    "id": 1281,
    "paragraph": "yang dibagi menjadi 82% LLA, 18% LMA, dan 3% LMK. Dari segi epidemiologi, leukemia akut menyumbang 30-40% dari seluruh kasus keganasan pada anak, dengan puncak kejadian pada usia 2–5 tahun. Rata-rata, ada sekitar 4–4,5 kasus per 100.000 anak per tahun. Dari tahun 2006 hingga 2010, ada angka kematian anak akibat",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "yang dibagi menjadi 82 lla 18 lma dan 3 lmk dari segi epidemiologi leukemia akut menyumbang 3040 dari seluruh kasus keganasan pada anak dengan puncak kejadian pada usia 2–5 tahun ratarata ada sekitar 4–45 kasus per 100000 anak per tahun dari tahun 2006 hingga 2010 ada angka kematian anak akibat"
  },
  {
    "id": 1282,
    "paragraph": "leukemia di Rumah Sakit Cipto Mangunkusumo (RSCM) dan Rumah Sakit Kanker “Dharmais” (RSKD). Jumlah penderita laki-laki lebih tinggi 1,15 kali dibandingkan dengan perempuan untuk LLA, sementara jumlah penderita perempuan hampir sama untuk LMA. Sebagian besar, penyebab utama leukemia adalah terjadinya mutasi (perubahan) pada",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "leukemia di rumah sakit cipto mangunkusumo rscm dan rumah sakit kanker “ dharmais ” rskd jumlah penderita lakilaki lebih tinggi 115 kali dibandingkan dengan perempuan untuk lla sementara jumlah penderita perempuan hampir sama untuk lma sebagian besar penyebab utama leukemia adalah terjadinya mutasi perubahan pada"
  },
  {
    "id": 1283,
    "paragraph": "DNA sel darah, yang mengakibatkan sel darah tersebut tidak berfungsi dengan baik. Meskipun demikian, penyebab yang memicu kesembuhan leukemia masih belum dapat dipastikan. Jika sumsum tulang menghasilkan jumlah sel darah putih yang terlalu banyak dan tidak normal, kondisi ini dikenal dengan nama leukemia atau",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "dna sel darah yang mengakibatkan sel darah tersebut tidak berfungsi dengan baik meskipun demikian penyebab yang memicu kesembuhan leukemia masih belum dapat dipastikan jika sumsum tulang menghasilkan jumlah sel darah putih yang terlalu banyak dan tidak normal kondisi ini dikenal dengan nama leukemia atau"
  },
  {
    "id": 1284,
    "paragraph": "kanker darah. Karena penyebab kanker ini seringkali sulit dipastikan, pencegahan leukemia tidak sepenuhnya diketahui. Namun, melalui perubahan gaya hidup sehat dan menghindari paparan zat tertentu, beberapa faktor risiko dapat dikurangi. 6 Penyebab penyakit ini masih belum sepenuhnya dipahami. Namun, terdapat beberapa",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "kanker darah karena penyebab kanker ini seringkali sulit dipastikan pencegahan leukemia tidak sepenuhnya diketahui namun melalui perubahan gaya hidup sehat dan menghindari paparan zat tertentu beberapa faktor risiko dapat dikurangi 6 penyebab penyakit ini masih belum sepenuhnya dipahami namun terdapat beberapa"
  },
  {
    "id": 1285,
    "paragraph": "langkah yang dapat diambil untuk mengurangi risiko Anda mengalami leukemia, antara lain: • Melakukan olahraga secara teratur; baca juga manfaat olahraga di pagi hari untuk kesehatan yang lebih baik. • Menghentikan atau menjauhi kebiasaan merokok. • Menghindari paparan bahan kimia, seperti benzene",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "langkah yang dapat diambil untuk mengurangi risiko anda mengalami leukemia antara lain • melakukan olahraga secara teratur baca juga manfaat olahraga di pagi hari untuk kesehatan yang lebih baik • menghentikan atau menjauhi kebiasaan merokok • menghindari paparan bahan kimia seperti benzene"
  },
  {
    "id": 1286,
    "paragraph": "• Mengurangi paparan radiasi sinar-X yang tidak diperlukan. • Segera konsultasikan dengan dokter jika merasakan perubahan atau gejala tertentu pada tubuh. Berikut adalah beberapa langkah pencegahan yang dapat dilakukan: Leukemia, yang juga dikenal sebagai kanker darah, merupakan suatu kondisi di mana",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "• mengurangi paparan radiasi sinarx yang tidak diperlukan • segera konsultasikan dengan dokter jika merasakan perubahan atau gejala tertentu pada tubuh berikut adalah beberapa langkah pencegahan yang dapat dilakukan leukemia yang juga dikenal sebagai kanker darah merupakan suatu kondisi di mana"
  },
  {
    "id": 1287,
    "paragraph": "sumsum tulang memproduksi sel darah putih yang tidak normal dalam jumlah yang berlebihan. Pencegahan leukemia bukan sepenuhnya diketahui karena penyebab pasti dari kanker ini sering kali sulit dipastikan. Namun, beberapa faktor risiko dapat dikurangi melalui perubahan gaya hidup sehat dan menghindari paparan zat tertentu.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "sumsum tulang memproduksi sel darah putih yang tidak normal dalam jumlah yang berlebihan pencegahan leukemia bukan sepenuhnya diketahui karena penyebab pasti dari kanker ini sering kali sulit dipastikan namun beberapa faktor risiko dapat dikurangi melalui perubahan gaya hidup sehat dan menghindari paparan zat tertentu"
  },
  {
    "id": 1288,
    "paragraph": "Berikut adalah beberapa langkah pencegahan yang dapat dilakukan: 1. Menghindari Paparan Radiasi Paparan radiasi tinggi, seperti y terjadi pada pasien dengan riwayat pengobatan radiasi, dapat meningkatkan risiko leukemia. Hindari atau minimalkan paparan radiasi yang tidak diperlukan. 2. Mengurangi Paparan Bahan Kimia Berbahaya, seperti benzena yang terdapat",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "berikut adalah beberapa langkah pencegahan yang dapat dilakukan 1 menghindari paparan radiasi paparan radiasi tinggi seperti terjadi pada pasien dengan riwayat pengobatan radiasi dapat meningkatkan risiko leukemia hindari atau minimalkan paparan radiasi yang tidak diperlukan 2 mengurangi paparan bahan kimia berbahaya seperti benzena yang terdapat"
  },
  {
    "id": 1289,
    "paragraph": "dalam produk industri tertentu dan asap rokok terkait dengan peningkatan risiko leukemia. Hindari pekerjaan atau lingkungan yang sering terpapar bahan kimia berbahaya, atau gunakan perlindungan yang sesuai. 3. Tidak Merokok: Merokok dapat meningkatkan risiko terjadinya berbagai jenis kanker, termasuk leukemia. Oleh karena itu, hindarilah atau berhentilah merokok",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "dalam produk industri tertentu dan asap rokok terkait dengan peningkatan risiko leukemia hindari pekerjaan atau lingkungan yang sering terpapar bahan kimia berbahaya atau gunakan perlindungan yang sesuai 3 tidak merokok merokok dapat meningkatkan risiko terjadinya berbagai jenis kanker termasuk leukemia oleh karena itu hindarilah atau berhentilah merokok"
  },
  {
    "id": 1290,
    "paragraph": "adalah langkah penting dalam pencegahan kanker. 7 4. Menjaga Pola Makan Sehat dan Gaya Hidup Aktif: Pola makan yang kaya akan buah-buahan, sayuran, dan biji-bijian serta rendah lemak jenuh. Dapat meningkatkan daya tahan tubuh terhadap penyakit. Gaya hidup aktif dan olahraga",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "adalah langkah penting dalam pencegahan kanker 7 4 menjaga pola makan sehat dan gaya hidup aktif pola makan yang kaya akan buahbuahan sayuran dan bijibijian serta rendah lemak jenuh dapat meningkatkan daya tahan tubuh terhadap penyakit gaya hidup aktif dan olahraga"
  },
  {
    "id": 1291,
    "paragraph": "teratur juga berkontribusi pada kesehatan secara keseluruhan. 5. Menghindari Paparan Infeksi Tertentu Beberapa infeksi virus, seperti virus Epstein-Barr, terkait dengan risiko kanker darah tertentu. Menjaga kebersihan diri, terutama dalam kontak fisik yang intensif, dapat membantu mengurangi risiko terinfeksi virus ini. 6. Konsultasi Medis Rutin Menjalani pemeriksaan kesehatan rutin dan melaporkan",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "teratur juga berkontribusi pada kesehatan secara keseluruhan 5 menghindari paparan infeksi tertentu beberapa infeksi virus seperti virus epsteinbarr terkait dengan risiko kanker darah tertentu menjaga kebersihan diri terutama dalam kontak fisik yang intensif dapat membantu mengurangi risiko terinfeksi virus ini 6 konsultasi medis rutin menjalani pemeriksaan kesehatan rutin dan melaporkan"
  },
  {
    "id": 1292,
    "paragraph": "gejala yang tidak biasa kepada dokter dapat membantu mendeteksi. Masalah kesehatan sejak dini. Ini termasuk tes darah atau pemeriksaan tambahan untuk individu yang mungkin berisiko lebih tinggi. Menjalani gaya hidup sehat dan meminimalkan paparan terhadap faktor risiko dapat membantu menurunkan kemungkinan terjadinya kanker ini.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "gejala yang tidak biasa kepada dokter dapat membantu mendeteksi masalah kesehatan sejak dini ini termasuk tes darah atau pemeriksaan tambahan untuk individu yang mungkin berisiko lebih tinggi menjalani gaya hidup sehat dan meminimalkan paparan terhadap faktor risiko dapat membantu menurunkan kemungkinan terjadinya kanker ini"
  },
  {
    "id": 1293,
    "paragraph": "Pengobatan Leukemia 1. Kemoterapi Kemoterapi merupakan terapi yang bersifat sitotoksik yang bertujuan untuk mencegah perluasan keganasan dan penyebaran [Tomlinson, 2019). Terdapat zangkaian protokol (fase) kemoterapi pada LLA diantaranya adalah: a) Fase induksi b) Fase Konsolidast c) Fase Reintensifikasi d) Terapi CNS-Directed",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "pengobatan leukemia 1 kemoterapi kemoterapi merupakan terapi yang bersifat sitotoksik yang bertujuan untuk mencegah perluasan keganasan dan penyebaran tomlinson 2019 terdapat zangkaian protokol fase kemoterapi pada lla diantaranya adalah fase induksi b fase konsolidast c fase reintensifikasi terapi cnsdirected"
  },
  {
    "id": 1294,
    "paragraph": "e) Fase Maintenance f) Fase Maintenance 2. Transplantasi sel induk hematopoetik/ Hematopoietic Stem Cell 8 Transplantasi sel induk hematopoietik (HSCT) dilakukan untuk menggantikan HSC yang sakit, rusak, atau tidak ada. Dengan ISC yang umumnya sehat, transplantasi alogenik digunakan ketika sel induk hematopoietik sakit (seperti leukemia), rusak",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "e fase maintenance f fase maintenance 2 transplantasi sel induk hematopoetik hematopoietic stem cell 8 transplantasi sel induk hematopoietik hsct dilakukan untuk menggantikan hsc yang sakit rusak atau tidak ada dengan isc yang umumnya sehat transplantasi alogenik digunakan ketika sel induk hematopoietik sakit seperti leukemia rusak"
  },
  {
    "id": 1295,
    "paragraph": "(seperti penyakit sel sabit), atau tidak ada (seperti penyakit defisiensi imun berat). Sel punca dapat diselamatkan melalui transplantasi autologus setelah dosis kemoterapi atau radiasi yang lebih tinggi; ini digunakan dalam pengobatan tumor padat (Tomlinson, 2019). Anak leukemia yang menunjukkan respons baik terhadap",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "seperti penyakit sel sabit atau tidak ada seperti penyakit defisiensi imun berat sel punca dapat diselamatkan melalui transplantasi autologus setelah dosis kemoterapi atau radiasi yang lebih tinggi ini digunakan dalam pengobatan tumor padat tomlinson 2019 anak leukemia yang menunjukkan respons baik terhadap"
  },
  {
    "id": 1296,
    "paragraph": "perawatan atau yang kambuh lebih awal setelah masuk ke dalam remisi dapat diobati dengan transplantasi sel punca sumsum tulang. Tidak jelas apakah SCT harus digunakan pada anak-anak dengan LLA yang muncul lebih dari enam bulan setelah kemoterați pertama. Anak- anak ini biasanya dirawat dengan Daik.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "perawatan atau yang kambuh lebih awal setelah masuk ke dalam remisi dapat diobati dengan transplantasi sel punca sumsum tulang tidak jelas apakah sct harus digunakan pada anakanak dengan lla yang muncul lebih dari enam bulan setelah kemoterați pertama anak anak ini biasanya dirawat dengan daik"
  },
  {
    "id": 1297,
    "paragraph": "3. Radioterapi Menurut Tomlinson (2019), radioterapi adalah jenis pengobatan ganas yang menggunakan radiasi pengion. Pada pengobatan kanker masa kanak-kanak, radioterapi kurang penting karena rejimen kemoterapi yang sangat efektif dan efek lambat radioterapi, yang dapat berdampak pada anak yang masih dalam tahap perkembangan.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "3 radioterapi menurut tomlinson 2019 radioterapi adalah jenis pengobatan ganas yang menggunakan radiasi pengion pada pengobatan kanker masa kanakkanak radioterapi kurang penting karena rejimen kemoterapi yang sangat efektif dan efek lambat radioterapi yang dapat berdampak pada anak yang masih dalam tahap perkembangan"
  },
  {
    "id": 1298,
    "paragraph": "Kira-kira 20% anak dan remaja yang menderita kanker masih membutuhkan radioterapi. Radioterapi adalah salah satu metode utama pengobatan tumor otak dan sangat penting dalam gejala paliatif . Radioterapi memainkan peran penting dalam pengobatan anak-anak dengan kanker karena tujuannya adalah untuk mencapai kontrol",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "kirakira 20 anak dan remaja yang menderita kanker masih membutuhkan radioterapi radioterapi adalah salah satu metode utama pengobatan tumor otak dan sangat penting dalam gejala paliatif radioterapi memainkan peran penting dalam pengobatan anakanak dengan kanker karena tujuannya adalah untuk mencapai kontrol"
  },
  {
    "id": 1299,
    "paragraph": "HEMATOLOGI, p.69. Kementerian Kesehatan RI 2023, Pedoman nasional pelayanan kedokteran tata laksana leukemia, Kemenkes RI, Jakarta. Panca, R., 2024. PENGARUH EDUKASI PENGOBATAN PALIATIF DENGAN METODE KONSELING KEPADA ORANG TUA TERHADAP KEPATUHAN PEMBERIAN OBAT PADA ANAK LEUKEMIA LIMFOBLASTIK AKUT DI IRNA ANAK RSUD Dr. SOETOMO (Doctoral",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "hematologi p69 kementerian kesehatan ri 2023 pedoman nasional pelayanan kedokteran tata laksana leukemia kemenkes ri jakarta panca r 2024 pengaruh edukasi pengobatan paliatif dengan metode konseling kepada orang tua terhadap kepatuhan pemberian obat pada anak leukemia limfoblastik akut di irna anak rsud dr soetomo doctoral"
  },
  {
    "id": 1300,
    "paragraph": "dissertation, STIKES HANG TUAH SURABAYA). Putri, A., Sihotang, M.M., Pane, M.G.O.V., Agustina, M., Rangkuti, N.S. and Lubis, F., 2024. Penggalangan Dana Bersama Yayasan Kanker Indonesia Melalui Penjualan Minuman Inovatif Berbahan Dasar Bunga Telang Dan Melon. Innovative: Journal Of Social Science Research, 4(5), pp.5658-5668.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "dissertation stikes hang tuah surabaya putri sihotang mm pane mgov agustina rangkuti ns lubis f 2024 penggalangan dana bersama yayasan kanker indonesia melalui penjualan minuman inovatif berbahan dasar bunga telang dan melon innovative journal social science research 45 pp56585668"
  },
  {
    "id": 1301,
    "paragraph": "Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia 2022, Panduan praktik klinis: diagnosis dan tatalaksana leukemia, PAPDI, Jakarta. Safitri, A., Rasyid, H., Bukhari, A. and Madjid, M., 2018. Pengaruh Gizi Terhadap Respon Terapi Pasien Chronic Myelocystic Leukimia (Cml). Ijcnp (Jurnal Dokter Gizi Klinik Indonesia) , 1 (1), pp.57-66.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "perhimpunan dokter spesialis penyakit dalam indonesia 2022 panduan praktik klinis diagnosis dan tatalaksana leukemia papdi jakarta safitri rasyid h bukhari madjid 2018 pengaruh gizi terhadap respon terapi pasien chronic myelocystic leukimia cml ijcnp jurnal dokter gizi klinik indonesia 1 1 pp5766"
  },
  {
    "id": 1302,
    "paragraph": "Sismonika Putri, R., 2022. ASUHAN KEPERAWATAN PADA NN. F DENGAN ACUTE LYMPHOCYTIC LEUKIMIA (ALL) DI RUANG DAHLIA 1 RSUP Dr. SARDJITO YOGYAKARTA (Doctoral dissertation, Poltekkes Kemenkes Yogyakarta). 10 Ramatillah, D.L., Lucyanawati, S., Pangestu, A.A. and Kurniatu, A., 2019. Edukasi dan Deteksi Dini Penyakit Leukimia Kepada Masyarakat di RPTRA Tunas",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "sismonika putri r 2022 asuhan keperawatan pada nn f dengan acute lymphocytic leukimia di ruang dahlia 1 rsup dr sardjito yogyakarta doctoral dissertation poltekkes kemenkes yogyakarta 10 ramatillah dl lucyanawati pangestu aa kurniatu 2019 edukasi dan deteksi dini penyakit leukimia kepada masyarakat di rptra tunas"
  },
  {
    "id": 1303,
    "paragraph": "Harapan Sunter Jakarta. BERDIKARI, 2(2). World Health Organization, 2023, ‘Leukemia Fact Sheet’, WHO International Agency for Research on Cancer. Yulianti, E. and Adnan, N., 2020. Faktor-Faktor Prognostik Kesintasan 5 Tahun Leukemia Limfoblastik Akut Pada Anak Usia 1-18 Tahun. Promotif: Jurnal Kesehatan Masyarakat, 10(2), pp.86-96.",
    "jurnal": "LEUKEMIAMATERI.pdf",
    "processed": "harapan sunter jakarta berdikari 22 world health organization 2023 ‘ leukemia fact sheet ’ international agency research cancer yulianti e adnan n 2020 faktorfaktor prognostik kesintasan 5 tahun leukemia limfoblastik akut pada anak usia 118 tahun promotif jurnal kesehatan masyarakat 102 pp8696"
  },
  {
    "id": 1304,
    "paragraph": "A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n",
    "jurnal": "nihms934397.pdf",
    "processed": "u h r n u c r p u h r n u c r p u h r n"
  },
  {
    "id": 1305,
    "paragraph": "u s c r i p t A u t h o r M a n u s c r i p t HHS Public Access Author manuscript Br J Haematol. Author manuscript; available in PMC 2019 March 01. Published in final edited form as:",
    "jurnal": "nihms934397.pdf",
    "processed": "u c r p u h r n u c r p hhs public access author manuscript br j haematol author manuscript available pmc 2019 march 01 published final edited form"
  },
  {
    "id": 1306,
    "paragraph": "Harvard Medical School, Boston, Massachusetts, USA 2Molecular Pharmacology Program, Sloan Kettering Institute, and Department of Pediatrics, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, New York, USA Summary Advances in the classification of acute leukaemias have led to improved outcomes for a substantial",
    "jurnal": "nihms934397.pdf",
    "processed": "harvard medical school boston massachusetts usa 2molecular pharmacology program sloan kettering institute department pediatrics weill cornell medical college memorial sloan kettering cancer center new york new york usa summary advances classification acute leukaemias led improved outcomes substantial"
  },
  {
    "id": 1307,
    "paragraph": "fraction of patients. However, chemotherapy resistance remains a major problem for specific subsets of acute leukaemias. Here, we propose that a molecularly distinct subtype of acute leukaemia with shared myeloid and T cell lymphoblastic features, which we term acute myeloid/T- lymphoblastic leukaemia (AMTL), is divided across 3 diagnostic categories owing to variable",
    "jurnal": "nihms934397.pdf",
    "processed": "fraction patients however chemotherapy resistance remains major problem specific subsets acute leukaemias propose molecularly distinct subtype acute leukaemia shared myeloid cell lymphoblastic features term acute myeloidt lymphoblastic leukaemia amtl divided across 3 diagnostic categories owing variable"
  },
  {
    "id": 1308,
    "paragraph": "expression of markers deemed to be defining of myeloid and T-lymphoid lineages, such as myeloperoxidase and CD3. This proposed diagnostic group is supported by i) retained myeloid differentiation potential during early T cell lymphoid development, ii) recognition that some cases of acute myeloid leukaemia (AML) harbour hallmarks of T cell development, such as T-cell",
    "jurnal": "nihms934397.pdf",
    "processed": "expression markers deemed defining myeloid tlymphoid lineages myeloperoxidase cd3 proposed diagnostic group supported retained myeloid differentiation potential early cell lymphoid development ii recognition cases acute myeloid leukaemia aml harbour hallmarks cell development tcell"
  },
  {
    "id": 1309,
    "paragraph": "receptor gene rearrangements and iii) common gene mutations in subsets of AML and T cell acute lymphoblastic leukaemia (T-ALL), including WT1, PHF6, RUNX1 and BCL11B. This proposed diagnostic entity overlaps with early T cell precursor (ETP) T-ALL and T cell/myeloid mixed",
    "jurnal": "nihms934397.pdf",
    "processed": "receptor gene rearrangements iii common gene mutations subsets aml cell acute lymphoblastic leukaemia tall including wt1 phf6 runx1 bcl11b proposed diagnostic entity overlaps early cell precursor etp tall cellmyeloid mixed"
  },
  {
    "id": 1310,
    "paragraph": "phenotype acute leukaemias (MPALs), and also includes a subset of leukaemias currently classified as AML with features of T-lymphoblastic development. The proposed classification of AMTL as a distinct entity would enable more precise prospective diagnosis and permit the development of improved therapies for patients whose treatment is inadequate with current",
    "jurnal": "nihms934397.pdf",
    "processed": "phenotype acute leukaemias mpals also includes subset leukaemias currently classified aml features tlymphoblastic development proposed classification amtl distinct entity would enable precise prospective diagnosis permit development improved therapies patients whose treatment inadequate current"
  },
  {
    "id": 1311,
    "paragraph": "approaches. Keywords acute leukaemia; classifications; AML; ALL *Correspondence to: Professor Alex Kentsis, Memorial Sloan-Kettering Cancer Center, Sloan Kettering Institute, 1275 York Ave, Box 223, New York, NY 10065-6007, USA, Tel: 1-646-888-2593, kentsisresearchgroup@gmail.com And Dr. Alejandro Gutierrez, Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.",
    "jurnal": "nihms934397.pdf",
    "processed": "approaches keywords acute leukaemia classifications aml correspondence professor alex kentsis memorial sloankettering cancer center sloan kettering institute 1275 york ave box 223 new york ny 100656007 usa tel 16468882593 kentsisresearchgroupgmailcom dr alejandro gutierrez division hematologyoncology boston childrens hospital danafarber cancer institute boston massachusetts usa"
  },
  {
    "id": 1312,
    "paragraph": "alejandro.gutierrez@childrens.harvard.edu. DR. ALEJANDRO GUTIERREZ (Orcid ID : 0000-0002-0249-9007) PROF. ALEX KENTSIS (Orcid ID : 0000-0002-8063-9191) A u t h o r M a n u s c r i p t A u t h o r M a n u",
    "jurnal": "nihms934397.pdf",
    "processed": "alejandrogutierrezchildrensharvardedu dr alejandro gutierrez orcid id 0000000202499007 prof alex kentsis orcid id 0000000280639191 u h r n u c r p u h r n u"
  },
  {
    "id": 1313,
    "paragraph": "s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t Gutierrez and Kentsis",
    "jurnal": "nihms934397.pdf",
    "processed": "c r p u h r n u c r p u h r n u c r p gutierrez kentsis"
  },
  {
    "id": 1314,
    "paragraph": "Introduction Page 2 Acute leukaemias are aggressive neoplasms characterized by the pathological accumulation of immature haematopoietic progenitors. Improvements in clinical outcomes for patients with acute leukaemias treated with modern chemotherapy regimens have been variable. The introduction of molecularly targeted therapies has had a major impact on a small subset of",
    "jurnal": "nihms934397.pdf",
    "processed": "introduction page 2 acute leukaemias aggressive neoplasms characterized pathological accumulation immature haematopoietic progenitors improvements clinical outcomes patients acute leukaemias treated modern chemotherapy regimens variable introduction molecularly targeted therapies major impact small subset"
  },
  {
    "id": 1315,
    "paragraph": "genetically-defined acute leukaemias. For example, arsenic trioxide and retinoic acid, which target the PML-RARA fusion oncoprotein via distinct mechanisms (de The, 2015), can now cure the majority of patients with acute promyelocytic leukaemia without exposure to cytotoxic chemotherapies (Lo-Coco et al, 2013). However, clinical outcomes for a",
    "jurnal": "nihms934397.pdf",
    "processed": "geneticallydefined acute leukaemias example arsenic trioxide retinoic acid target pmlrara fusion oncoprotein via distinct mechanisms de 2015 cure majority patients acute promyelocytic leukaemia without exposure cytotoxic chemotherapies lococo et al 2013 however clinical outcomes"
  },
  {
    "id": 1316,
    "paragraph": "substantial fraction of acute leukaemias have seen little improvement despite the application of treatment regimens that are among the most intensive and toxic used for any disease. Consequently, improving clinical outcomes for these patients will require linking an improved molecular understanding to the application of effective targeted therapies.",
    "jurnal": "nihms934397.pdf",
    "processed": "substantial fraction acute leukaemias seen little improvement despite application treatment regimens among intensive toxic used disease consequently improving clinical outcomes patients require linking improved molecular understanding application effective targeted therapies"
  },
  {
    "id": 1317,
    "paragraph": "Classification of acute leukaemias Acute leukaemias have traditionally been classified based on the normal cell types most closely resembling the leukaemic cell population. Lymphoblastic leukaemias are those with evidence of differentiation arrest at immature stages of B- or T-cell lymphoid development,",
    "jurnal": "nihms934397.pdf",
    "processed": "classification acute leukaemias acute leukaemias traditionally classified based normal cell types closely resembling leukaemic cell population lymphoblastic leukaemias evidence differentiation arrest immature stages b tcell lymphoid development"
  },
  {
    "id": 1318,
    "paragraph": "whereas acute myeloid leukaemias encompass malignancies with immunophenotypic features that lie along a broad spectrum of haematopoietic progenitors, ranging from minimally differentiated leukaemias to those with evidence of granulocytic, monocytic, erythroid or megakaryocytic differentiation. Although this classification scheme is intuitive, lineage assignment is complicated by the high frequency of aberrant differentiation states in",
    "jurnal": "nihms934397.pdf",
    "processed": "whereas acute myeloid leukaemias encompass malignancies immunophenotypic features lie along broad spectrum haematopoietic progenitors ranging minimally differentiated leukaemias evidence granulocytic monocytic erythroid megakaryocytic differentiation although classification scheme intuitive lineage assignment complicated high frequency aberrant differentiation states"
  },
  {
    "id": 1319,
    "paragraph": "acute leukaemias. Indeed, the simultaneous expression of markers that are not known to be co-expressed in any normal haematopoietic progenitor is common. To address the requirement for consistent diagnostic criteria for the successful performance and interpretation of clinical trials, the World Health Organization (WHO) has devised a",
    "jurnal": "nihms934397.pdf",
    "processed": "acute leukaemias indeed simultaneous expression markers known coexpressed normal haematopoietic progenitor common address requirement consistent diagnostic criteria successful performance interpretation clinical trials world health organization devised"
  },
  {
    "id": 1320,
    "paragraph": "classification scheme that allows most acute leukaemias to be unambiguously classified as specific diagnostic entities, which has been regularly revised (Swerdlow et al 2008; Arber et al, 2016). The genetics of leukaemia are beginning to be incorporated into the WHO classification,",
    "jurnal": "nihms934397.pdf",
    "processed": "classification scheme allows acute leukaemias unambiguously classified specific diagnostic entities regularly revised swerdlow et al 2008 arber et al 2016 genetics leukaemia beginning incorporated classification"
  },
  {
    "id": 1321,
    "paragraph": "with increasing weight being given to specific chromosomal translocations and, in some cases, somatic gene mutations, as disease-defining genetic lesions (Arber et al, 2016). Thus, the presence of a characteristic genetic feature can define a disease, independent of the phenotypic lineage which can be difficult to assign in practice. For example, leukaemias",
    "jurnal": "nihms934397.pdf",
    "processed": "increasing weight given specific chromosomal translocations cases somatic gene mutations diseasedefining genetic lesions arber et al 2016 thus presence characteristic genetic feature define disease independent phenotypic lineage difficult assign practice example leukaemias"
  },
  {
    "id": 1322,
    "paragraph": "with FGFR1 translocations that can present with T cell lymphoblastic or myeloid markers are defined as a single diagnostic entity, regardless of the immunophenotype of the presenting leukaemic cells (Arber et al, 2016; Macdonald et al, 2002). Similarly, acute myeloid leukaemia (AML) cases with t(8;21) translocations exhibit aberrant expression of",
    "jurnal": "nihms934397.pdf",
    "processed": "fgfr1 translocations present cell lymphoblastic myeloid markers defined single diagnostic entity regardless immunophenotype presenting leukaemic cells arber et al 2016 macdonald et al 2002 similarly acute myeloid leukaemia aml cases t821 translocations exhibit aberrant expression"
  },
  {
    "id": 1323,
    "paragraph": "CD19, a marker typically associated with B cell lymphoid malignancies, due to lineage- inappropriate PAX5 expression induced by the RUNX1-RUNX1T1 (previously termed AML1-ETO) oncogene (Walter et al, 2010). While we anticipate that genomic classification will have an increasingly important role in defining leukaemia subsets in the future, the",
    "jurnal": "nihms934397.pdf",
    "processed": "cd19 marker typically associated b cell lymphoid malignancies due lineage inappropriate pax5 expression induced runx1runx1t1 previously termed aml1eto oncogene walter et al 2010 anticipate genomic classification increasingly important role defining leukaemia subsets future"
  },
  {
    "id": 1324,
    "paragraph": "Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i",
    "jurnal": "nihms934397.pdf",
    "processed": "br j haematol author manuscript available pmc 2019 march 01 u h r n u c r p u h r n u c r"
  },
  {
    "id": 1325,
    "paragraph": "p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t Gutierrez and Kentsis Page 3 current diagnostic classification for most acute leukaemias does not rely on genetic",
    "jurnal": "nihms934397.pdf",
    "processed": "p u h r n u c r p u h r n u c r p gutierrez kentsis page 3 current diagnostic classification acute leukaemias rely genetic"
  },
  {
    "id": 1326,
    "paragraph": "mutations. Thus, phenotypic lineage assignment remains a central component of diagnostic classification and treatment assignment for most patients with acute leukaemia. The current WHO classification considers strong expression of a small number of immunophenotypic markers to be lineage-assigning: myeloperoxidase (MPO) or at least two",
    "jurnal": "nihms934397.pdf",
    "processed": "mutations thus phenotypic lineage assignment remains central component diagnostic classification treatment assignment patients acute leukaemia current classification considers strong expression small number immunophenotypic markers lineageassigning myeloperoxidase mpo least two"
  },
  {
    "id": 1327,
    "paragraph": "monocytic markers (CD11c, CD14, CD64 or lysozyme) for myeloid lineage; surface or cytoplasmic CD3 expression for T cell lineage; and CD19 with at least one additional B cell marker (CD79a, cytoplasmic CD22, or CD10) for B cell lineage (Arber et al, 2016). While",
    "jurnal": "nihms934397.pdf",
    "processed": "monocytic markers cd11c cd14 cd64 lysozyme myeloid lineage surface cytoplasmic cd3 expression cell lineage cd19 least one additional b cell marker cd79a cytoplasmic cd22 cd10 b cell lineage arber et al 2016"
  },
  {
    "id": 1328,
    "paragraph": "the specificity of these markers is widely agreed upon, some prominent clinical trials groups use subtly different criteria for lineage assignment (Dworzak et al, 2017). Nevertheless, it is recognized that these classification schemes are imperfect, and the strict application of the",
    "jurnal": "nihms934397.pdf",
    "processed": "specificity markers widely agreed upon prominent clinical trials groups use subtly different criteria lineage assignment dworzak et al 2017 nevertheless recognized classification schemes imperfect strict application"
  },
  {
    "id": 1329,
    "paragraph": "WHO criteria for lineage assignment is not required to make a diagnosis of AML, T cell acute lymphoblastic leukaemia (T-ALL) or B cell acute lymphoblastic leukaemia (B-ALL) unless a diagnosis of mixed phenotype acute leukaemia (MPAL) is also being considered (Arber et al, 2016). Thus, while MPALs that meet formal criteria for assignment to two",
    "jurnal": "nihms934397.pdf",
    "processed": "criteria lineage assignment required make diagnosis aml cell acute lymphoblastic leukaemia tall b cell acute lymphoblastic leukaemia ball unless diagnosis mixed phenotype acute leukaemia mpal also considered arber et al 2016 thus mpals meet formal criteria assignment two"
  },
  {
    "id": 1330,
    "paragraph": "distinct lineages are very rare, leukaemias classified as AML, T-ALL or B-ALL based on their predominant morphology and immunophenotype commonly co-express markers that indicate aberrant differentiation towards another lineage. Acute myeloid/T-lymphoblastic leukaemia (AMTL): Acute leukaemias with shared T cell lymphoid and myeloid features",
    "jurnal": "nihms934397.pdf",
    "processed": "distinct lineages rare leukaemias classified aml tall ball based predominant morphology immunophenotype commonly coexpress markers indicate aberrant differentiation towards another lineage acute myeloidtlymphoblastic leukaemia amtl acute leukaemias shared cell lymphoid myeloid features"
  },
  {
    "id": 1331,
    "paragraph": "The classical model of haematopoiesis postulates an early binary split between common myeloid and lymphoid progenitors that subsequently give rise to both B- and T-cell lymphocytes. However, more recent work using clonal tracking assays has shown the existence of progenitors that retain T cell/myeloid or B cell/myeloid bi-lineage potential. By",
    "jurnal": "nihms934397.pdf",
    "processed": "classical model haematopoiesis postulates early binary split common myeloid lymphoid progenitors subsequently give rise b tcell lymphocytes however recent work using clonal tracking assays shown existence progenitors retain cellmyeloid b cellmyeloid bilineage potential"
  },
  {
    "id": 1332,
    "paragraph": "contrast, individual progenitors whose potential is restricted to T cell and B cell (but not myeloid) lineages have been difficult to identify (Kawamoto et al, 2010). These findings fit the clinical observation that MPALs most commonly present with B cell/myeloid or T cell/",
    "jurnal": "nihms934397.pdf",
    "processed": "contrast individual progenitors whose potential restricted cell b cell myeloid lineages difficult identify kawamoto et al 2010 findings fit clinical observation mpals commonly present b cellmyeloid cell"
  },
  {
    "id": 1333,
    "paragraph": "myeloid marker co-expression, whereas B/T cell MPALs are very rare (Matutes et al, 2011). Here, we propose AMTL as a molecularly distinct subtype of acute leukaemias associated with shared T cell lymphoid and myeloid features. Expression of markers deemed to be",
    "jurnal": "nihms934397.pdf",
    "processed": "myeloid marker coexpression whereas bt cell mpals rare matutes et al 2011 propose amtl molecularly distinct subtype acute leukaemias associated shared cell lymphoid myeloid features expression markers deemed"
  },
  {
    "id": 1334,
    "paragraph": "defining of the myeloid and T cell lymphoid lineages, including myeloperoxidase and CD3, is variable in this disease, resulting in its separation across three diagnostic categories in the current WHO classification scheme: early T cell precursor (ETP) T-ALL, T/myeloid MPAL, and a specific subset of AML harbouring hallmarks of T-lymphoblastic differentiation.",
    "jurnal": "nihms934397.pdf",
    "processed": "defining myeloid cell lymphoid lineages including myeloperoxidase cd3 variable disease resulting separation across three diagnostic categories current classification scheme early cell precursor etp tall tmyeloid mpal specific subset aml harbouring hallmarks tlymphoblastic differentiation"
  },
  {
    "id": 1335,
    "paragraph": "This proposed diagnostic entity overlaps with subsets of ETP T-ALL, which is characterized by differentiation arrest at early stages of T cell development. While a number of biomarkers have been described to identify these cases (Coustan-Smith et al, 2009; Gutierrez et al, 2010;",
    "jurnal": "nihms934397.pdf",
    "processed": "proposed diagnostic entity overlaps subsets etp tall characterized differentiation arrest early stages cell development number biomarkers described identify cases coustansmith et al 2009 gutierrez et al 2010"
  },
  {
    "id": 1336,
    "paragraph": "Homminga et al, 2011; Zuurbier et al, 2014), these are most commonly defined clinically using an immunophenotypic classifier that includes absent expression of CD1a and CD8, CD5 expression that is substantially lower than that of normal peripheral blood T cells, and",
    "jurnal": "nihms934397.pdf",
    "processed": "homminga et al 2011 zuurbier et al 2014 commonly defined clinically using immunophenotypic classifier includes absent expression cd1a cd8 cd5 expression substantially lower normal peripheral blood cells"
  },
  {
    "id": 1337,
    "paragraph": "the presence of one or more markers of myeloid or haematopoietic progenitors (CD117, Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a n u s c r i p t A",
    "jurnal": "nihms934397.pdf",
    "processed": "presence one markers myeloid haematopoietic progenitors cd117 br j haematol author manuscript available pmc 2019 march 01 u h r n u c r p"
  },
  {
    "id": 1338,
    "paragraph": "u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u",
    "jurnal": "nihms934397.pdf",
    "processed": "u h r n u c r p u h r n u c r p u h r n u"
  },
  {
    "id": 1339,
    "paragraph": "s c r i p t Gutierrez and Kentsis Page 4 CD34, HLA-DR, CD13, CD33, CD11b or CD65) (Conter et al, 2016; Coustan-Smith et al, 2009; Patrick et al, 2014). Currently, ETP is classified as a subtype of T-ALL due to the",
    "jurnal": "nihms934397.pdf",
    "processed": "c r p gutierrez kentsis page 4 cd34 hladr cd13 cd33 cd11b cd65 conter et al 2016 coustansmith et al 2009 patrick et al 2014 currently etp classified subtype tall due"
  },
  {
    "id": 1340,
    "paragraph": "expression of CD3, but has a genetic mutational profile that is similar to those observed in myeloid malignancies, such as AML, whereas mutations characteristic of other subtypes of T-ALL, such as CDKN2A deletions, are less common (Gutierrez et al, 2010; Van",
    "jurnal": "nihms934397.pdf",
    "processed": "expression cd3 genetic mutational profile similar observed myeloid malignancies aml whereas mutations characteristic subtypes tall cdkn2a deletions less common gutierrez et al 2010 van"
  },
  {
    "id": 1341,
    "paragraph": "Vlierberghe et al, 2011a; Zhang et al, 2012). While similarities between ETP T-ALL and AML have been previously recognized (Van Vlierberghe et al, 2011a; Zhang et al, 2012; Zuurbier et al, 2014), we propose that the biological overlap of AMTL is not with AML per se, but with a specific subset of AML",
    "jurnal": "nihms934397.pdf",
    "processed": "vlierberghe et al 2011a zhang et al 2012 similarities etp tall aml previously recognized van vlierberghe et al 2011a zhang et al 2012 zuurbier et al 2014 propose biological overlap amtl aml per se specific subset aml"
  },
  {
    "id": 1342,
    "paragraph": "cases that also exhibit T cell lymphoid features. Namely, a subset of AMLs has long been recognized to harbour clonal T-cell receptor (TCR) or immunoglobulin (Ig) gene rearrangements, indicating activity of the RAG recombinase that is responsible for generating somatic V(D)J recombination at these loci at specific stages of lymphoid",
    "jurnal": "nihms934397.pdf",
    "processed": "cases also exhibit cell lymphoid features namely subset amls long recognized harbour clonal tcell receptor tcr immunoglobulin ig gene rearrangements indicating activity rag recombinase responsible generating somatic vdj recombination loci specific stages lymphoid"
  },
  {
    "id": 1343,
    "paragraph": "development (Norton et al, 1987; Parreira et al, 1992; Schmidt et al, 1992). These AML cases can also express the lymphoid marker terminal deoxynucleotidyltransferase (TdT, also known as DNTT), which generates diversity at the TCR and Ig genes by mutating the",
    "jurnal": "nihms934397.pdf",
    "processed": "development norton et al 1987 parreira et al 1992 schmidt et al 1992 aml cases also express lymphoid marker terminal deoxynucleotidyltransferase tdt also known dntt generates diversity tcr ig genes mutating"
  },
  {
    "id": 1344,
    "paragraph": "junctions of rearrangements during V(D)J recombination (Drexler et al, 1993; Patel et al, 2013). Non-megakaryoblastic AMLs with TCR rearrangements typically co-express phenotypic markers of T-lymphoblastic differentiation, such as CD7, CD2 and CD4 (Schmidt et al, 1992). We postulate that this is the subset of AMLs that also harbour",
    "jurnal": "nihms934397.pdf",
    "processed": "junctions rearrangements vdj recombination drexler et al 1993 patel et al 2013 nonmegakaryoblastic amls tcr rearrangements typically coexpress phenotypic markers tlymphoblastic differentiation cd7 cd2 cd4 schmidt et al 1992 postulate subset amls also harbour"
  },
  {
    "id": 1345,
    "paragraph": "mutations that are commonly observed in a distinct subset of T-ALL, including WT1, PHF6, RUNX1 and BCL11B (The Cancer Genome Atlas Research Network, 2013; Della Gatta et al, 2012; Ding et al, 2012; Klco et al, 2015; Tosello et al, 2009; Van Vlierberghe et al, 2010;",
    "jurnal": "nihms934397.pdf",
    "processed": "mutations commonly observed distinct subset tall including wt1 phf6 runx1 bcl11b cancer genome atlas research network 2013 della gatta et al 2012 ding et al 2012 klco et al 2015 tosello et al 2009 van vlierberghe et al 2010"
  },
  {
    "id": 1346,
    "paragraph": "Van Vlierberghe et al, 2011b; Zhang et al, 2012). Thus, a similar group of acute leukaemias exhibit shared features of myeloid and T cell lymphoid differentiation, and shared genetic mutations, which will need to be formally assessed in future studies. Potential mechanisms for combined T-lymphoblastic and myeloid",
    "jurnal": "nihms934397.pdf",
    "processed": "van vlierberghe et al 2011b zhang et al 2012 thus similar group acute leukaemias exhibit shared features myeloid cell lymphoid differentiation shared genetic mutations need formally assessed future studies potential mechanisms combined tlymphoblastic myeloid"
  },
  {
    "id": 1347,
    "paragraph": "differentiation in acute leukaemia At least two non-mutually exclusive mechanisms can explain the development of acute leukaemias with differentiation potential shared with myeloid and T-lymphoid lineages: 1. Transformation of normal haematopoietic progenitors with T-lymphoblastic and myeloid bi-lineage potential. While studies of endogenous haematopoiesis have",
    "jurnal": "nihms934397.pdf",
    "processed": "differentiation acute leukaemia least two nonmutually exclusive mechanisms explain development acute leukaemias differentiation potential shared myeloid tlymphoid lineages 1 transformation normal haematopoietic progenitors tlymphoblastic myeloid bilineage potential studies endogenous haematopoiesis"
  },
  {
    "id": 1348,
    "paragraph": "revealed limited evidence of a putative normal progenitor whose fate is restricted to T-lymphoid and myeloid lineages, the identification of such a progenitor may have been hindered by differences in the lifespan of mature myeloid versus T- lymphoid cells. Nevertheless, even if a normal progenitor whose differentiation",
    "jurnal": "nihms934397.pdf",
    "processed": "revealed limited evidence putative normal progenitor whose fate restricted tlymphoid myeloid lineages identification progenitor may hindered differences lifespan mature myeloid versus lymphoid cells nevertheless even normal progenitor whose differentiation"
  },
  {
    "id": 1349,
    "paragraph": "fate is restricted to T-lymphocytes and myeloid cells is lacking, such leukaemias can arise from cells that retain multi-lineage potential, even though their fate is normally restricted to a single lineage by microenvironmental signals. Immature intrathymic T cell progenitors at early double-negative stages of differentiation",
    "jurnal": "nihms934397.pdf",
    "processed": "fate restricted tlymphocytes myeloid cells lacking leukaemias arise cells retain multilineage potential even though fate normally restricted single lineage microenvironmental signals immature intrathymic cell progenitors early doublenegative stages differentiation"
  },
  {
    "id": 1350,
    "paragraph": "represent one potential cell of origin for such leukaemias. Indeed, the most immature intrathymic T cell progenitors retain myeloid (but not B-lymphoid) Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a",
    "jurnal": "nihms934397.pdf",
    "processed": "represent one potential cell origin leukaemias indeed immature intrathymic cell progenitors retain myeloid blymphoid br j haematol author manuscript available pmc 2019 march 01 u h r"
  },
  {
    "id": 1351,
    "paragraph": "n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A",
    "jurnal": "nihms934397.pdf",
    "processed": "n u c r p u h r n u c r p u h r n u c r p"
  },
  {
    "id": 1352,
    "paragraph": "u t h o r M a n u s c r i p t Gutierrez and Kentsis Page 5 2. potential until they progress through a BCL11B-dependent commitment to the T cell lineage (Balciunaite et al, 2005; Ikawa et al, 2010; Li et al, 2010) (Figure 1).",
    "jurnal": "nihms934397.pdf",
    "processed": "u h r n u c r p gutierrez kentsis page 5 2 potential progress bcl11bdependent commitment cell lineage balciunaite et al 2005 ikawa et al 2010 li et al 2010 figure 1"
  },
  {
    "id": 1353,
    "paragraph": "Further, lineage tracing studies have demonstrated that immature T cell progenitors give rise to some macrophages and neutrophils harbouring TCR gene rearrangements in vivo (Bell & Bhandoola, 2008; Wada et al, 2008). Ectopic expression of Myc and Bcl2 in mouse early double-negative T cell progenitors",
    "jurnal": "nihms934397.pdf",
    "processed": "lineage tracing studies demonstrated immature cell progenitors give rise macrophages neutrophils harbouring tcr gene rearrangements vivo bell bhandoola 2008 wada et al 2008 ectopic expression myc bcl2 mouse early doublenegative cell progenitors"
  },
  {
    "id": 1354,
    "paragraph": "can drive development of acute leukaemias with variable expression of markers of myeloid and T-lymphoid lineages (Riemke et al, 2016), demonstrating that early T cell progenitors can function as the potential cell of origin of AMTL. Induction of aberrant trans-differentiation by leukemogenic mutations. It is now",
    "jurnal": "nihms934397.pdf",
    "processed": "drive development acute leukaemias variable expression markers myeloid tlymphoid lineages riemke et al 2016 demonstrating early cell progenitors function potential cell origin amtl induction aberrant transdifferentiation leukemogenic mutations"
  },
  {
    "id": 1355,
    "paragraph": "established that specific gene mutations can induce T cell lymphoid or myeloid differentiation. For example, activation of NOTCH1 signalling in mouse bone marrow cells causes aberrant T cell differentiation independent of thymic microenvironmental signals (Pui et al, 1999). Likewise, mutations inactivating",
    "jurnal": "nihms934397.pdf",
    "processed": "established specific gene mutations induce cell lymphoid myeloid differentiation example activation notch1 signalling mouse bone marrow cells causes aberrant cell differentiation independent thymic microenvironmental signals pui et al 1999 likewise mutations inactivating"
  },
  {
    "id": 1356,
    "paragraph": "Runx1 in haematopoietic progenitors cause, aberrant myeloid differentiation (Goyama et al, 2013). Thus, aberrant trans-differentiation of AMTL cells can in principle, occur as a result of combinations of mutations that cooperatively result in combined myeloid and T-lymphoid lineage commitment with differentiation",
    "jurnal": "nihms934397.pdf",
    "processed": "runx1 haematopoietic progenitors cause aberrant myeloid differentiation goyama et al 2013 thus aberrant transdifferentiation amtl cells principle occur result combinations mutations cooperatively result combined myeloid tlymphoid lineage commitment differentiation"
  },
  {
    "id": 1357,
    "paragraph": "arrest (Figure 1). These mutations include genes encoding regulators of chromatin and DNA remodelling, and transcription factors with key functions in controlling lymphoid and myeloid cell fate specification. Future studies using emerging approaches for combinatorial gene editing and conditional gene manipulation in vivo may reveal how the specific combinations of mutations in",
    "jurnal": "nihms934397.pdf",
    "processed": "arrest figure 1 mutations include genes encoding regulators chromatin dna remodelling transcription factors key functions controlling lymphoid myeloid cell fate specification future studies using emerging approaches combinatorial gene editing conditional gene manipulation vivo may reveal specific combinations mutations"
  },
  {
    "id": 1358,
    "paragraph": "specific cell progenitor populations cooperate to induce AMTL and other non- canonical leukaemia subtypes. Identification of Acute Myeloid/T-Lymphoblastic Leukaemia To a first approximation, AMTL can be defined as acute leukaemias that fit the diagnostic criteria of ETP T-ALL or of T/myeloid MPALs, together with AMLs with clonal TCR gene",
    "jurnal": "nihms934397.pdf",
    "processed": "specific cell progenitor populations cooperate induce amtl non canonical leukaemia subtypes identification acute myeloidtlymphoblastic leukaemia first approximation amtl defined acute leukaemias fit diagnostic criteria etp tall tmyeloid mpals together amls clonal tcr gene"
  },
  {
    "id": 1359,
    "paragraph": "rearrangements and evidence of T-lymphoid differentiation (CD3, CD7, CD2 or CD4 expression). However, we note that aberrant expression of CD4 and CD7 is relatively common in acute megakaryoblastic leukaemia (AMKL), a subtype of AML that is molecularly distinct from AMTL (de Rooij et al, 2017). Therefore, AMKL should be",
    "jurnal": "nihms934397.pdf",
    "processed": "rearrangements evidence tlymphoid differentiation cd3 cd7 cd2 cd4 expression however note aberrant expression cd4 cd7 relatively common acute megakaryoblastic leukaemia amkl subtype aml molecularly distinct amtl de rooij et al 2017 therefore amkl"
  },
  {
    "id": 1360,
    "paragraph": "excluded from the definition of AMTL, based on absence of megakaryblastic morphology and expression of the platelet markers CD41 or CD61. Thus, our initial proposal for AMTL as a diagnostic entity includes all cases currently classified as ETP T-ALL and T/myeloid",
    "jurnal": "nihms934397.pdf",
    "processed": "excluded definition amtl based absence megakaryblastic morphology expression platelet markers cd41 cd61 thus initial proposal amtl diagnostic entity includes cases currently classified etp tall tmyeloid"
  },
  {
    "id": 1361,
    "paragraph": "MPALs, together with the subset of AMLs with TCR rearrangements and expression of T- lymphoblastic markers. Given the variability in cell surface marker expression in acute leukaemias, we propose that clinical genomic profiling will enhance the classification of AMTL as a specific diagnostic",
    "jurnal": "nihms934397.pdf",
    "processed": "mpals together subset amls tcr rearrangements expression lymphoblastic markers given variability cell surface marker expression acute leukaemias propose clinical genomic profiling enhance classification amtl specific diagnostic"
  },
  {
    "id": 1362,
    "paragraph": "entity. Indeed, ETP T-ALLs harbour mutations of several genes that are commonly mutated in myeloid neoplasms, such as RAS family members, ETV6, MEF2C and EZH2, but whose mutations are rare in other T-ALL subtypes, (Homminga et al, 2011; Van Vlierberghe et al,",
    "jurnal": "nihms934397.pdf",
    "processed": "entity indeed etp talls harbour mutations several genes commonly mutated myeloid neoplasms ras family members etv6 mef2c ezh2 whose mutations rare tall subtypes homminga et al 2011 van vlierberghe et al"
  },
  {
    "id": 1363,
    "paragraph": "Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i",
    "jurnal": "nihms934397.pdf",
    "processed": "br j haematol author manuscript available pmc 2019 march 01 u h r n u c r p u h r n u c r"
  },
  {
    "id": 1364,
    "paragraph": "p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t Gutierrez and Kentsis Page 6 2011a; Zhang et al, 2012; Zuurbier et al, 2014). We also suggest that the subset of AML",
    "jurnal": "nihms934397.pdf",
    "processed": "p u h r n u c r p u h r n u c r p gutierrez kentsis page 6 2011a zhang et al 2012 zuurbier et al 2014 also suggest subset aml"
  },
  {
    "id": 1365,
    "paragraph": "cases harbouring clonal TCR gene rearrangements should demonstrate substantial overlap with those AML cases harbouring mutations that are common in T-ALL, such as WT1, RUNX1, PHF6 and BCL11B (The Cancer Genome Atlas Research Network, 2013; Ding et al, 2012; Klco et al, 2015; Zhang et al, 2012). We anticipate that future investigation will",
    "jurnal": "nihms934397.pdf",
    "processed": "cases harbouring clonal tcr gene rearrangements demonstrate substantial overlap aml cases harbouring mutations common tall wt1 runx1 phf6 bcl11b cancer genome atlas research network 2013 ding et al 2012 klco et al 2015 zhang et al 2012 anticipate future investigation"
  },
  {
    "id": 1366,
    "paragraph": "lead to an improved classifier of AMTL based on both immunophenotypic and genetic diagnostic markers. Conclusions We propose acute myeloid/T-lymphoblastic leukaemia (AMTL) as a new diagnostic entity for acute leukaemias with shared myeloid and T cell lymphoblastic features. Defining the detailed molecular mechanisms of aberrant cell differentiation may lead to the development",
    "jurnal": "nihms934397.pdf",
    "processed": "lead improved classifier amtl based immunophenotypic genetic diagnostic markers conclusions propose acute myeloidtlymphoblastic leukaemia amtl new diagnostic entity acute leukaemias shared myeloid cell lymphoblastic features defining detailed molecular mechanisms aberrant cell differentiation may lead development"
  },
  {
    "id": 1367,
    "paragraph": "of improved therapies by targeting specific molecular dependencies in these cells. For example, mutant transcription factors function in the context of corepressor and coactivator complexes, which have specific enzymatic functions, such as histone deacetylase (HDAC) inhibitors (Haberland et al, 2009). Isoform-specific HDAC inhibitors are beginning to be",
    "jurnal": "nihms934397.pdf",
    "processed": "improved therapies targeting specific molecular dependencies cells example mutant transcription factors function context corepressor coactivator complexes specific enzymatic functions histone deacetylase hdac inhibitors haberland et al 2009 isoformspecific hdac inhibitors beginning"
  },
  {
    "id": 1368,
    "paragraph": "developed (West & Johnstone, 2014), and specific inhibitors may warrant therapeutic investigation in AMTL with dysregulation of MEF2 family members, for example. Likewise, specific mutations may engender synthetic lethal dependencies, such as, for example, inhibition of the EZH2 methyltransferase in cases of cancers with mutations of",
    "jurnal": "nihms934397.pdf",
    "processed": "developed west johnstone 2014 specific inhibitors may warrant therapeutic investigation amtl dysregulation mef2 family members example likewise specific mutations may engender synthetic lethal dependencies example inhibition ezh2 methyltransferase cases cancers mutations"
  },
  {
    "id": 1369,
    "paragraph": "genes encoding components of the SWItch/Sucrose Non-Fermentable/BRG1-associated factors (SWI/SNF/BAF) chromatin remodelling complex (Kim et al, 2015). Recently, acetyltranferase inhibitors have been found to have therapeutic efficacy in CBP-deficient lymphomas (Ogiwara et al, 2016). Finally, many leukaemias exhibit aberrant resistance to mitochondrial apoptosis, conferring resistance to intensive combination chemotherapies,",
    "jurnal": "nihms934397.pdf",
    "processed": "genes encoding components switchsucrose nonfermentablebrg1associated factors swisnfbaf chromatin remodelling complex kim et al 2015 recently acetyltranferase inhibitors found therapeutic efficacy cbpdeficient lymphomas ogiwara et al 2016 finally many leukaemias exhibit aberrant resistance mitochondrial apoptosis conferring resistance intensive combination chemotherapies"
  },
  {
    "id": 1370,
    "paragraph": "such as those used for treatment of refractory AML and T-ALL. Recent data suggest that AMTLs are particularly susceptible to inhibitors of BCL2 (Chonghaile et al, 2014; Pan et al, 2014), and emerging inhibitors of other regulators of intrinsic apoptosis are expected to offer",
    "jurnal": "nihms934397.pdf",
    "processed": "used treatment refractory aml tall recent data suggest amtls particularly susceptible inhibitors bcl2 chonghaile et al 2014 pan et al 2014 emerging inhibitors regulators intrinsic apoptosis expected offer"
  },
  {
    "id": 1371,
    "paragraph": "useful therapeutic strategies for AMTL patients as well. Acknowledgments We thank Misha Roshal, Mark Fleming, and Peter Steinherz for helpful discussions. This work was supported by NIH R01 CA204396 and CA193651, and P30 CA008748. A.G. and A.K. are Damon Runyon Clinical Investigators.",
    "jurnal": "nihms934397.pdf",
    "processed": "useful therapeutic strategies amtl patients well acknowledgments thank misha roshal mark fleming peter steinherz helpful discussions work supported nih r01 ca204396 ca193651 p30 ca008748 ag ak damon runyon clinical investigators"
  },
  {
    "id": 1372,
    "paragraph": "T, significant macrophage, and natural killer cell but no B-lymphocyte potential. Blood. 2005; 105:1930–1936. [PubMed: 15522952] Bell JJ, Bhandoola A. The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature. 2008; 452:764–767. [PubMed: 18401411] The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo",
    "jurnal": "nihms934397.pdf",
    "processed": "significant macrophage natural killer cell blymphocyte potential blood 2005 1051930–1936 pubmed 15522952 bell jj bhandoola earliest thymic progenitors cells possess myeloid lineage potential nature 2008 452764–767 pubmed 18401411 cancer genome atlas research network genomic epigenomic landscapes adult de novo"
  },
  {
    "id": 1373,
    "paragraph": "acute myeloid leukemia. N Engl J Med. 2013; 368:2059–2074. [PubMed: 23634996] Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a n u s c r i p t A u t",
    "jurnal": "nihms934397.pdf",
    "processed": "acute myeloid leukemia n engl j med 2013 3682059–2074 pubmed 23634996 br j haematol author manuscript available pmc 2019 march 01 u h r n u c r p u"
  },
  {
    "id": 1374,
    "paragraph": "h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c",
    "jurnal": "nihms934397.pdf",
    "processed": "h r n u c r p u h r n u c r p u h r n u c"
  },
  {
    "id": 1375,
    "paragraph": "r i p t Gutierrez and Kentsis Page 7 Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, Loh ML, Hunger SP, Wood B, DeAngelo DJ, Stone R, Harris M, Gutierrez A, Kelliher MA, Letai A. Maturation stage of",
    "jurnal": "nihms934397.pdf",
    "processed": "r p gutierrez kentsis page 7 chonghaile tn roderick je glenfield c ryan j sallan se silverman lb loh ml hunger sp wood b deangelo dj stone r harris gutierrez kelliher letai maturation stage"
  },
  {
    "id": 1376,
    "paragraph": "T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014; 4:1074–1087. [PubMed: 24994123] Conter V, Valsecchi MG, Buldini B, Parasole R, Locatelli F, Colombini A, Rizzari C, Putti MC, Barisone E, Lo Nigro L, Santoro N, Ziino O, Pession A, Testi AM, Micalizzi C, Casale F, Pierani P,",
    "jurnal": "nihms934397.pdf",
    "processed": "tcell acute lymphoblastic leukemia determines bcl2 versus bclxl dependence sensitivity abt199 cancer discov 2014 41074–1087 pubmed 24994123 conter v valsecchi mg buldini b parasole r locatelli f colombini rizzari c putti mc barisone e lo nigro l santoro n ziino pession testi micalizzi c casale f pierani p"
  },
  {
    "id": 1377,
    "paragraph": "Cesaro S, Cellini M, Silvestri D, Cazzaniga G, Biondi A, Basso G. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematol. 2016; 3:e80–86. [PubMed: 26853647] Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz",
    "jurnal": "nihms934397.pdf",
    "processed": "cesaro cellini silvestri cazzaniga g biondi basso g early tcell precursor acute lymphoblastic leukaemia children treated aieop centres aieopbfm protocols retrospective analysis lancet haematol 2016 3e80–86 pubmed 26853647 coustansmith e mullighan cg onciu behm fg raimondi sc pei cheng c su x rubnitz"
  },
  {
    "id": 1378,
    "paragraph": "JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009; 10:147–156. [PubMed: 19147408] de Rooij JD, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, Obulkasim A, Dang J, Easton J, Verboon",
    "jurnal": "nihms934397.pdf",
    "processed": "je basso g biondi pui ch downing jr campana early tcell precursor leukaemia subtype highrisk acute lymphoblastic leukaemia lancet oncol 2009 10147–156 pubmed 19147408 de rooij jd branstetter c j li walsh mp cheng j obulkasim dang j easton j verboon"
  },
  {
    "id": 1379,
    "paragraph": "LJ, Mulder HL, Zimmermann M, Koss C, Gupta P, Edmonson M, Rusch M, Lim JY, Reinhardt K, Pigazzi M, Song G, Yeoh AE, Shih LY, Liang DC, Halene S, Krause DS, Zhang J, Downing JR, Locatelli F, Reinhardt D, van den Heuvel-Eibrink MM, Zwaan CM, Fornerod M, Gruber TA.",
    "jurnal": "nihms934397.pdf",
    "processed": "lj mulder hl zimmermann koss c gupta p edmonson rusch lim jy reinhardt k pigazzi song g yeoh ae shih ly liang dc halene krause ds zhang j downing jr locatelli f reinhardt van den heuveleibrink mm zwaan cm fornerod gruber ta"
  },
  {
    "id": 1380,
    "paragraph": "Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat Genet. 2017; 49:451–456. [PubMed: 28112737] de The H. Lessons taught by acute promyelocytic leukemia cure. Lancet. 2015; 386:247–248. [PubMed: 26194524] Della Gatta G, Palomero T, Perez-Garcia A, Ambesi-Impiombato A, Bansal M, Carpenter ZW, De",
    "jurnal": "nihms934397.pdf",
    "processed": "pediatric nondown syndrome acute megakaryoblastic leukemia characterized distinct genomic subsets varying outcomes nat genet 2017 49451–456 pubmed 28112737 de h lessons taught acute promyelocytic leukemia cure lancet 2015 386247–248 pubmed 26194524 della gatta g palomero perezgarcia ambesiimpiombato bansal carpenter zw de"
  },
  {
    "id": 1381,
    "paragraph": "Keersmaecker K, Sole X, Xu L, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Meijerink JP, Califano A, Ferrando AA. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat Med. 2012; 18:436–440. [PubMed: 22366949] Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T,",
    "jurnal": "nihms934397.pdf",
    "processed": "keersmaecker k sole x xu l paietta e racevskis j wiernik ph rowe jm meijerink jp califano ferrando aa reverse engineering tlx oncogenic transcriptional networks identifies runx1 tumor suppressor tall nat med 2012 18436–440 pubmed 22366949 ding l ley tj larson de miller ca koboldt dc welch js ritchey jk young lamprecht"
  },
  {
    "id": 1382,
    "paragraph": "McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S,",
    "jurnal": "nihms934397.pdf",
    "processed": "mclellan md mcmichael jf wallis jw lu c shen harris cc dooling dj fulton rs fulton chen k schmidt h kalickiveizer j magrini vj cook l mcgrath sd vickery tl wendl mc heath watson link dc tomasson mh shannon wd payton je kulkarni"
  },
  {
    "id": 1383,
    "paragraph": "Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481:506– 510. [PubMed: 22237025] Drexler HG, Sperling C, Ludwig WD. Terminal deoxynucleotidyl transferase (TdT) expression in",
    "jurnal": "nihms934397.pdf",
    "processed": "westervelt p walter mj graubert ta mardis er wilson rk dipersio jf clonal evolution relapsed acute myeloid leukaemia revealed wholegenome sequencing nature 2012 481506– 510 pubmed 22237025 drexler hg sperling c ludwig wd terminal deoxynucleotidyl transferase tdt expression"
  },
  {
    "id": 1384,
    "paragraph": "acute myeloid leukemia. Leukemia. 1993; 7:1142–1150. [PubMed: 7688837] Dworzak MN, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, Rosenthal E, Bourquin JP, Sartor M, Schumich A, Karawajew L, Mejstrikova E, Maglia O, Mann G, Ludwig WD, Biondi A, Schrappe",
    "jurnal": "nihms934397.pdf",
    "processed": "acute myeloid leukemia leukemia 1993 71142–1150 pubmed 7688837 dworzak mn buldini b gaipa g ratei r hrusak luria rosenthal e bourquin jp sartor schumich karawajew l mejstrikova e maglia mann g ludwig wd biondi schrappe"
  },
  {
    "id": 1385,
    "paragraph": "Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest. 2013; 123:3876–3888. [PubMed: 23979164] Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, Protopopov A, Tosello V, Kutok J, Larson RS, Borowitz MJ, Loh ML, Ferrando AA, Winter SS, Mullighan CG, Silverman",
    "jurnal": "nihms934397.pdf",
    "processed": "transcription factor runx1 promotes survival acute myeloid leukemia cells j clin invest 2013 1233876–3888 pubmed 23979164 gutierrez dahlberg se neuberg ds zhang j grebliunaite r sanda protopopov tosello v kutok j larson rs borowitz mj loh ml ferrando aa winter ss mullighan cg silverman"
  },
  {
    "id": 1386,
    "paragraph": "LB, Chin L, Hunger SP, Sallan SE, Look AT. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol. 2010; 28:3816–3823. [PubMed: 20644084] Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and",
    "jurnal": "nihms934397.pdf",
    "processed": "lb chin l hunger sp sallan se look absence biallelic tcrgamma deletion predicts early treatment failure pediatric tcell acute lymphoblastic leukemia j clin oncol 2010 283816–3823 pubmed 20644084 haberland montgomery rl olson en many roles histone deacetylases development"
  },
  {
    "id": 1387,
    "paragraph": "physiology: implications for disease and therapy. Nat Rev Genet. 2009; 10:32–42. [PubMed: 19065135] Homminga I, Pieters R, Langerak AW, de Rooi JJ, Stubbs A, Verstegen M, Vuerhard M, Buijs- Gladdines J, Kooi C, Klous P, van Vlierberghe P, Ferrando AA, Cayuela JM, Verhaaf B, Beverloo",
    "jurnal": "nihms934397.pdf",
    "processed": "physiology implications disease therapy nat rev genet 2009 1032–42 pubmed 19065135 homminga pieters r langerak aw de rooi jj stubbs verstegen vuerhard buijs gladdines j kooi c klous p van vlierberghe p ferrando aa cayuela jm verhaaf b beverloo"
  },
  {
    "id": 1388,
    "paragraph": "HB, Horstmann M, de Haas V, Wiekmeijer AS, Pike-Overzet K, Staal FJ, de Laat W, Soulier J, Sigaux F, Meijerink JP. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as Br J Haematol. Author manuscript; available in PMC 2019 March 01.",
    "jurnal": "nihms934397.pdf",
    "processed": "hb horstmann de haas v wiekmeijer pikeoverzet k staal fj de laat w soulier j sigaux f meijerink jp integrated transcript genome analyses reveal nkx21 mef2c br j haematol author manuscript available pmc 2019 march 01"
  },
  {
    "id": 1389,
    "paragraph": "A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n",
    "jurnal": "nihms934397.pdf",
    "processed": "u h r n u c r p u h r n u c r p u h r n"
  },
  {
    "id": 1390,
    "paragraph": "u s c r i p t A u t h o r M a n u s c r i p t Gutierrez and Kentsis Page 8 potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell. 2011; 19:484–497. [PubMed: 21481790]",
    "jurnal": "nihms934397.pdf",
    "processed": "u c r p u h r n u c r p gutierrez kentsis page 8 potential oncogenes cell acute lymphoblastic leukemia cancer cell 2011 19484–497 pubmed 21481790"
  },
  {
    "id": 1391,
    "paragraph": "Kawamoto H. An essential developmental checkpoint for production of the T cell lineage. Science. 2010; 329:93–96. [PubMed: 20595615] Kawamoto H, Ikawa T, Masuda K, Wada H, Katsura Y. A map for lineage restriction of progenitors during hematopoiesis: the essence of the myeloid-based model. Immunol Rev. 2010; 238:23–36.",
    "jurnal": "nihms934397.pdf",
    "processed": "kawamoto h essential developmental checkpoint production cell lineage science 2010 32993–96 pubmed 20595615 kawamoto h ikawa masuda k wada h katsura map lineage restriction progenitors hematopoiesis essence myeloidbased model immunol rev 2010 23823–36"
  },
  {
    "id": 1392,
    "paragraph": "[PubMed: 20969582] Kim KH, Kim W, Howard TP, Vazquez F, Tsherniak A, Wu JN, Wang W, Haswell JR, Walensky LD, Hahn WC, Orkin SH, Roberts CW. SWI/SNF-mutant cancers depend on catalytic and non- catalytic activity of EZH2. Nat Med. 2015; 21:1491–1496. [PubMed: 26552009]",
    "jurnal": "nihms934397.pdf",
    "processed": "pubmed 20969582 kim kh kim w howard tp vazquez f tsherniak wu jn wang w haswell jr walensky ld hahn wc orkin sh roberts cw swisnfmutant cancers depend catalytic non catalytic activity ezh2 nat med 2015 211491–1496 pubmed 26552009"
  },
  {
    "id": 1393,
    "paragraph": "Klco JM, Miller CA, Griffith M, Petti A, Spencer DH, Ketkar-Kulkarni S, Wartman LD, Christopher M, Lamprecht TL, Helton NM, Duncavage EJ, Payton JE, Baty J, Heath SE, Griffith OL, Shen D, Hundal J, Chang GS, Fulton R, O'Laughlin M, Fronick C, Magrini V, Demeter RT, Larson DE,",
    "jurnal": "nihms934397.pdf",
    "processed": "klco jm miller ca griffith petti spencer dh ketkarkulkarni wartman ld christopher lamprecht tl helton nm duncavage ej payton je baty j heath se griffith ol shen hundal j chang gs fulton r olaughlin fronick c magrini v demeter rt larson de"
  },
  {
    "id": 1394,
    "paragraph": "Kulkarni S, Ozenberger BA, Welch JS, Walter MJ, Graubert TA, Westervelt P, Radich JP, Link DC, Mardis ER, DiPersio JF, Wilson RK, Ley TJ. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA. 2015; 314:811–822. [PubMed: 26305651]",
    "jurnal": "nihms934397.pdf",
    "processed": "kulkarni ozenberger ba welch js walter mj graubert ta westervelt p radich jp link dc mardis er dipersio jf wilson rk ley tj association mutation clearance induction therapy outcomes acute myeloid leukemia jama 2015 314811–822 pubmed 26305651"
  },
  {
    "id": 1395,
    "paragraph": "Li L, Leid M, Rothenberg EV. An early T cell lineage commitment checkpoint dependent on the transcription factor Bcl11b. Science. 2010; 329:89–93. [PubMed: 20595614] Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L,",
    "jurnal": "nihms934397.pdf",
    "processed": "li l leid rothenberg ev early cell lineage commitment checkpoint dependent transcription factor bcl11b science 2010 32989–93 pubmed 20595614 lococo f avvisati g vignetti thiede c orlando sm iacobelli ferrara f fazi p cicconi l"
  },
  {
    "id": 1396,
    "paragraph": "Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lubbert M, Hanel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La",
    "jurnal": "nihms934397.pdf",
    "processed": "di bona e specchia g sica divona levis fiedler w cerqui e breccia fioritoni g salih hr cazzola melillo l carella brandts ch morra e von lilienfeldtoal hertenstein b wattad lubbert hanel schmitz n link h kropp mg rambaldi la"
  },
  {
    "id": 1397,
    "paragraph": "Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Dohner K, Sauer M, Ganser A, Amadori S, Mandelli F, Dohner H, Ehninger G, Schlenk RF, Platzbecker U, Gruppo Italiano Malattie Ematologiche dA, German-Austrian Acute Myeloid Leukemia Study G, Study Alliance",
    "jurnal": "nihms934397.pdf",
    "processed": "nasa g luppi ciceri f finizio venditti fabbiano f dohner k sauer ganser amadori mandelli f dohner h ehninger g schlenk rf platzbecker u gruppo italiano malattie ematologiche da germanaustrian acute myeloid leukemia study g study alliance"
  },
  {
    "id": 1398,
    "paragraph": "L. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369:111–121. [PubMed: 23841729] Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002; 107:101–107. [PubMed:",
    "jurnal": "nihms934397.pdf",
    "processed": "l retinoic acid arsenic trioxide acute promyelocytic leukemia n engl j med 2013 369111–121 pubmed 23841729 macdonald reiter cross nc 8p11 myeloproliferative syndrome distinct clinical entity caused constitutive activation fgfr1 acta haematol 2002 107101–107 pubmed"
  },
  {
    "id": 1399,
    "paragraph": "11919391] Matutes E, Pickl WF, Van't Veer M, Morilla R, Swansbury J, Strobl H, Attarbaschi A, Hopfinger G, Ashley S, Bene MC, Porwit A, Orfao A, Lemez P, Schabath R, Ludwig WD. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to",
    "jurnal": "nihms934397.pdf",
    "processed": "11919391 matutes e pickl wf vant veer morilla r swansbury j strobl h attarbaschi hopfinger g ashley bene mc porwit orfao lemez p schabath r ludwig wd mixedphenotype acute leukemia clinical laboratory features outcome 100 patients defined according"
  },
  {
    "id": 1400,
    "paragraph": "the WHO 2008 classification. Blood. 2011; 117:3163–3171. [PubMed: 21228332] Norton JD, Campana D, Hoffbrand AV, Janossy G, Coustan-Smith E, Jani H, Yaxley JC, Prentice HG. Rearrangement of immunoglobulin and T cell antigen receptor genes in acute myeloid leukemia with lymphoid-associated markers. Leukemia. 1987; 1:757–761. [PubMed: 3500372]",
    "jurnal": "nihms934397.pdf",
    "processed": "2008 classification blood 2011 1173163–3171 pubmed 21228332 norton jd campana hoffbrand av janossy g coustansmith e jani h yaxley jc prentice hg rearrangement immunoglobulin cell antigen receptor genes acute myeloid leukemia lymphoidassociated markers leukemia 1987 1757–761 pubmed 3500372"
  },
  {
    "id": 1401,
    "paragraph": "Ogiwara H, Sasaki M, Mitachi T, Oike T, Higuchi S, Tominaga Y, Kohno T. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. Cancer Discov. 2016; 6:430–445. [PubMed: 26603525] Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu",
    "jurnal": "nihms934397.pdf",
    "processed": "ogiwara h sasaki mitachi oike higuchi tominaga kohno targeting p300 addiction cbpdeficient cancers causes synthetic lethality apoptotic cell death due abrogation myc expression cancer discov 2016 6430–445 pubmed 26603525 pan r hogdal lj benito jm bucci han l borthakur g cortes j deangelo dj debose l mu"
  },
  {
    "id": 1402,
    "paragraph": "H, Dohner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Muschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG. Selective",
    "jurnal": "nihms934397.pdf",
    "processed": "h dohner h gaidzik vi galinsky golfman ls haferlach harutyunyan kg hu j leverson jd marcucci g muschen newman r park e ruvolo pp ruvolo v ryan j schindela zweidlermckay p stone rm kantarjian h andreeff konopleva letai ag selective"
  },
  {
    "id": 1403,
    "paragraph": "BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014; 4:362–375. [PubMed: 24346116] Parreira L, Carvalho C, Moura H, Melo A, Santos P, Guimaraes JE, Parreira A. Configuration of immunoglobulin and T cell receptor beta and gamma genes in acute myeloid leukaemia: pitfalls in",
    "jurnal": "nihms934397.pdf",
    "processed": "bcl2 inhibition abt199 causes ontarget cell death acute myeloid leukemia cancer discov 2014 4362–375 pubmed 24346116 parreira l carvalho c moura h melo santos p guimaraes je parreira configuration immunoglobulin cell receptor beta gamma genes acute myeloid leukaemia pitfalls"
  },
  {
    "id": 1404,
    "paragraph": "the analysis of 40 cases. J Clin Pathol. 1992; 45:193–200. [PubMed: 1372916] Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a n u s c r i p t A u",
    "jurnal": "nihms934397.pdf",
    "processed": "analysis 40 cases j clin pathol 1992 45193–200 pubmed 1372916 br j haematol author manuscript available pmc 2019 march 01 u h r n u c r p u"
  },
  {
    "id": 1405,
    "paragraph": "t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u s",
    "jurnal": "nihms934397.pdf",
    "processed": "h r n u c r p u h r n u c r p u h r n u"
  },
  {
    "id": 1406,
    "paragraph": "c r i p t Gutierrez and Kentsis Page 9 Patel KP, Khokhar FA, Muzzafar T, James You M, Bueso-Ramos CE, Ravandi F, Pierce S, Medeiros LJ. TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell",
    "jurnal": "nihms934397.pdf",
    "processed": "c r p gutierrez kentsis page 9 patel kp khokhar fa muzzafar james buesoramos ce ravandi f pierce medeiros lj tdt expression acute myeloid leukemia minimal differentiation associated distinctive clinicopathological features better overall survival following stem cell"
  },
  {
    "id": 1407,
    "paragraph": "transplantation. Mod Pathol. 2013; 26:195–203. [PubMed: 22936064] Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, Jenkinson S, Hough R, Vora A. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014; 166:421–424.",
    "jurnal": "nihms934397.pdf",
    "processed": "transplantation mod pathol 2013 26195–203 pubmed 22936064 patrick k wade r goulden n mitchell c moorman av rowntree c jenkinson hough r vora outcome children young people early tcell precursor acute lymphoblastic leukaemia treated contemporary protocol ukall 2003 br j haematol 2014 166421–424"
  },
  {
    "id": 1408,
    "paragraph": "[PubMed: 24708207] Pui JC, Allman D, Xu L, DeRocco S, Karnell FG, Bakkour S, Lee JY, Kadesch T, Hardy RR, Aster JC, Pear WS. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity. 1999; 11:299–308. [PubMed: 10514008] Riemke P, Czeh M, Fischer J, Walter C, Ghani S, Zepper M, Agelopoulos K, Lettermann S, Gebhardt",
    "jurnal": "nihms934397.pdf",
    "processed": "pubmed 24708207 pui jc allman xu l derocco karnell fg bakkour lee jy kadesch hardy rr aster jc pear ws notch1 expression early lymphopoiesis influences b versus lineage determination immunity 1999 11299–308 pubmed 10514008 riemke p czeh fischer j walter c ghani zepper agelopoulos k lettermann gebhardt"
  },
  {
    "id": 1409,
    "paragraph": "ML, Mah N, Weilemann A, Grau M, Groning V, Haferlach T, Lenze D, Delwel R, Prinz M, Andrade-Navarro MA, Lenz G, Dugas M, Muller-Tidow C, Rosenbauer F. Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors. EMBO J. 2016; 35:2399–2416. [PubMed: 27572462]",
    "jurnal": "nihms934397.pdf",
    "processed": "ml mah n weilemann grau groning v haferlach lenze delwel r prinz andradenavarro lenz g dugas mullertidow c rosenbauer f myeloid leukemia transdifferentiation plasticity developing tcell progenitors embo j 2016 352399–2416 pubmed 27572462"
  },
  {
    "id": 1410,
    "paragraph": "Schmidt CA, Oettle H, Neubauer A, Seeger K, Thiel E, Huhn D, Siegert W, Ludwig WD. Rearrangements of T-cell receptor delta, gamma and beta genes in acute myeloid leukemia coexpressing T-lymphoid features. Leukemia. 1992; 6:1263–1267. [PubMed: 1333555] Swerdlow, SH., Campo, E., Harris, NL., Jaffe, ES., Pileri, SA., Stein, H., Thiele, J., Vardiman, JW.",
    "jurnal": "nihms934397.pdf",
    "processed": "schmidt ca oettle h neubauer seeger k thiel e huhn siegert w ludwig wd rearrangements tcell receptor delta gamma beta genes acute myeloid leukemia coexpressing tlymphoid features leukemia 1992 61263–1267 pubmed 1333555 swerdlow sh campo e harris nl jaffe es pileri sa stein h thiele j vardiman jw"
  },
  {
    "id": 1411,
    "paragraph": "WHO classification of tumours of haematopoietic and lymphoid tissues. 4. International Agency for Research on Cancer Press; Lyon, France: 2008. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368:2059–2074. [PubMed: 23634996]",
    "jurnal": "nihms934397.pdf",
    "processed": "classification tumours haematopoietic lymphoid tissues 4 international agency research cancer press lyon france 2008 cancer genome atlas research network genomic epigenomic landscapes adult de novo acute myeloid leukemia n engl j med 2013 3682059–2074 pubmed 23634996"
  },
  {
    "id": 1412,
    "paragraph": "Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, Allen CG, Gale RE, Linch DC, Palomero T, Real P, Murty V, Yao X, Richards SM, Goldstone A, Rowe J, Basso G, Wiernik PH, Paietta E, Pieters R, Horstmann M, Meijerink JP, Ferrando AA. WT1 mutations in T-ALL. Blood.",
    "jurnal": "nihms934397.pdf",
    "processed": "tosello v mansour mr barnes k paganin sulis ml jenkinson allen cg gale linch dc palomero real p murty v yao x richards sm goldstone rowe j basso g wiernik ph paietta e pieters r horstmann meijerink jp ferrando aa wt1 mutations tall blood"
  },
  {
    "id": 1413,
    "paragraph": "2009; 114:1038–1045. [PubMed: 19494353] Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, De Moerloose B, Philippe J, Gonzalez-Garcia S, Toribio ML, Taghon T, Zuurbier L, Cauwelier B, Harrison CJ, Schwab C, Pisecker M, Strehl S, Langerak AW, Gecz J, Sonneveld E, Pieters R,",
    "jurnal": "nihms934397.pdf",
    "processed": "2009 1141038–1045 pubmed 19494353 van vlierberghe p palomero khiabanian h van der meulen j castillo van roy n de moerloose b philippe j gonzalezgarcia toribio ml taghon zuurbier l cauwelier b harrison cj schwab c pisecker strehl langerak aw gecz j sonneveld e pieters r"
  },
  {
    "id": 1414,
    "paragraph": "Paietta E, Rowe JM, Wiernik PH, Benoit Y, Soulier J, Poppe B, Yao X, Cordon-Cardo C, Meijerink J, Rabadan R, Speleman F, Ferrando A. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010; 42:338–342. [PubMed: 20228800] Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, Haydu JE, Rigo I, Hadler M, Tosello V,",
    "jurnal": "nihms934397.pdf",
    "processed": "paietta e rowe jm wiernik ph benoit soulier j poppe b yao x cordoncardo c meijerink j rabadan r speleman f ferrando phf6 mutations tcell acute lymphoblastic leukemia nat genet 2010 42338–342 pubmed 20228800 van vlierberghe p ambesiimpiombato perezgarcia haydu je rigo hadler tosello v"
  },
  {
    "id": 1415,
    "paragraph": "Della Gatta G, Paietta E, Racevskis J, Wiernik PH, Luger SM, Rowe JM, Rue M, Ferrando AA. ETV6 mutations in early immature human T cell leukemias. J Exp Med. 2011a; 208:2571–2579. [PubMed: 22162831] Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, Nicolas C, Payer AR,",
    "jurnal": "nihms934397.pdf",
    "processed": "della gatta g paietta e racevskis j wiernik ph luger sm rowe jm rue ferrando aa etv6 mutations early immature human cell leukemias j exp med 2011a 2082571–2579 pubmed 22162831 van vlierberghe p patel j abdelwahab lobry c hedvat cv balbin nicolas c payer ar"
  },
  {
    "id": 1416,
    "paragraph": "Fernandez HF, Tallman MS, Paietta E, Melnick A, Vandenberghe P, Speleman F, Aifantis I, Cools J, Levine R, Ferrando A. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011b; 25:130–134. [PubMed: 21030981] Wada H, Masuda K, Satoh R, Kakugawa K, Ikawa T, Katsura Y, Kawamoto H. Adult T-cell",
    "jurnal": "nihms934397.pdf",
    "processed": "fernandez hf tallman ms paietta e melnick vandenberghe p speleman f aifantis cools j levine r ferrando phf6 mutations adult acute myeloid leukemia leukemia 2011b 25130–134 pubmed 21030981 wada h masuda k satoh r kakugawa k ikawa katsura kawamoto h adult tcell"
  },
  {
    "id": 1417,
    "paragraph": "progenitors retain myeloid potential. Nature. 2008; 452:768–772. [PubMed: 18401412] Walter K, Cockerill PN, Barlow R, Clarke D, Hoogenkamp M, Follows GA, Richards SJ, Cullen MJ, Bonifer C, Tagoh H. Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5. Oncogene. 2010; 29:2927–2937. [PubMed: 20208555]",
    "jurnal": "nihms934397.pdf",
    "processed": "progenitors retain myeloid potential nature 2008 452768–772 pubmed 18401412 walter k cockerill pn barlow r clarke hoogenkamp follows ga richards sj cullen mj bonifer c tagoh h aberrant expression cd19 aml t821 involves poised chromatin structure pax5 oncogene 2010 292927–2937 pubmed 20208555"
  },
  {
    "id": 1418,
    "paragraph": "West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124:30–39. [PubMed: 24382387] Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A,",
    "jurnal": "nihms934397.pdf",
    "processed": "west ac johnstone rw new emerging hdac inhibitors cancer treatment j clin invest 2014 12430–39 pubmed 24382387 zhang j ding l holmfeldt l wu g heatley sl payneturner easton j chen x wang j rusch lu c chen sc wei l collinsunderwood jr j roberts kg pounds sb ulyanov"
  },
  {
    "id": 1419,
    "paragraph": "Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S,",
    "jurnal": "nihms934397.pdf",
    "processed": "becksfort j gupta p huether r kriwacki rw parker mcgoldrick dj zhao alford espy bobba kc song g pei cheng c roberts barbato mi campana coustansmith e shurtleff sa raimondi sc kleppe cools j shimano ka hermiston ml doulatov"
  },
  {
    "id": 1420,
    "paragraph": "Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o r M a n u s c",
    "jurnal": "nihms934397.pdf",
    "processed": "eppert k laurenti e notta f dick je basso g hunger sp loh ml devidas wood b br j haematol author manuscript available pmc 2019 march 01 u h r n u c"
  },
  {
    "id": 1421,
    "paragraph": "r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o",
    "jurnal": "nihms934397.pdf",
    "processed": "r p u h r n u c r p u h r n u c r p u h"
  },
  {
    "id": 1422,
    "paragraph": "r M a n u s c r i p t Gutierrez and Kentsis Page 10 Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui CH, Naeve CW, Ley TJ, Mardis ER, Wilson RK,",
    "jurnal": "nihms934397.pdf",
    "processed": "r n u c r p gutierrez kentsis page 10 winter dunsmore kp fulton rs fulton hong x harris cc dooling dj ochoa k johnson kj obenauer jc evans pui ch naeve cw ley tj mardis er wilson rk"
  },
  {
    "id": 1423,
    "paragraph": "Downing JR, Mullighan CG. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481:157–163. [PubMed: 22237106] Zuurbier L, Gutierrez A, Mullighan CG, Cante-Barrett K, Gevaert AO, de Rooi J, Li Y, Smits WK, Buijs-Gladdines JG, Sonneveld E, Look AT, Horstmann M, Pieters R, Meijerink JP. Immature",
    "jurnal": "nihms934397.pdf",
    "processed": "downing jr mullighan cg genetic basis early tcell precursor acute lymphoblastic leukaemia nature 2012 481157–163 pubmed 22237106 zuurbier l gutierrez mullighan cg cantebarrett k gevaert ao de rooi j li smits wk buijsgladdines jg sonneveld e look horstmann pieters r meijerink jp immature"
  },
  {
    "id": 1424,
    "paragraph": "MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors. Haematologica. 2014; 99:94–102. [PubMed: 23975177] Br J Haematol. Author manuscript; available in PMC 2019 March 01. A u t h o",
    "jurnal": "nihms934397.pdf",
    "processed": "mef2cdysregulated tcell leukemia patients early tcell precursor acute lymphoblastic leukemia gene signature typically nonrearranged tcell receptors haematologica 2014 9994–102 pubmed 23975177 br j haematol author manuscript available pmc 2019 march 01 u h"
  },
  {
    "id": 1425,
    "paragraph": "r M a n u s c r i p t A u t h o r M a n u s c r i p t A u t h o r M a n u s c r i",
    "jurnal": "nihms934397.pdf",
    "processed": "r n u c r p u h r n u c r p u h r n u c r"
  },
  {
    "id": 1426,
    "paragraph": "p t A u t h o r M a n u s c r i p t Gutierrez and Kentsis Page 11 Figure 1. Potential mechanisms leading to acute leukaemia with shared myeloid and T- lymphoblastic features The fate of multipotent haematopoietic progenitors first entering the thymus is directed to",
    "jurnal": "nihms934397.pdf",
    "processed": "p u h r n u c r p gutierrez kentsis page 11 figure 1 potential mechanisms leading acute leukaemia shared myeloid lymphoblastic features fate multipotent haematopoietic progenitors first entering thymus directed"
  },
  {
    "id": 1427,
    "paragraph": "the T cell lineage via thymic microenvironmental signals, but these cells retain myeloid potential until BCL11B-dependent commitment to the T cell lineage at the DN2a to DN2b transition (Hosokawa & Rothenberg, 2017). Such T cell progenitors with myeloid potential can function as a cell of origin of AMTL (Riemke et al, 2016) (A). Alternatively, AMTL can",
    "jurnal": "nihms934397.pdf",
    "processed": "cell lineage via thymic microenvironmental signals cells retain myeloid potential bcl11bdependent commitment cell lineage dn2a dn2b transition hosokawa rothenberg 2017 cell progenitors myeloid potential function cell origin amtl riemke et al 2016 alternatively amtl"
  },
  {
    "id": 1428,
    "paragraph": "in principle arise from mutations that induce aberrant T cell differentiation in myeloid or multipotent haematopoietic progenitors (B), or from mutations in T cell restricted progenitors leading to their myeloid differentiation (C). Note that the developmental stages shown (top) are based on mouse T cell development, because human early T cell",
    "jurnal": "nihms934397.pdf",
    "processed": "principle arise mutations induce aberrant cell differentiation myeloid multipotent haematopoietic progenitors b mutations cell restricted progenitors leading myeloid differentiation c note developmental stages shown top based mouse cell development human early cell"
  },
  {
    "id": 1429,
    "paragraph": "development is less well-defined. AMTL: acute myeloid/T-lymphoblastic leukaemia; DN: CD4/CD8 double-negative T cell progenitor; DP: CD4/CD8 double-positive T cell progenitor; ETP: early T cell precursor; HSC: haematopoietic stem cell; MPP: multipotent progenitor. Br J Haematol. Author manuscript; available in PMC 2019 March 01.",
    "jurnal": "nihms934397.pdf",
    "processed": "development less welldefined amtl acute myeloidtlymphoblastic leukaemia dn cd4cd8 doublenegative cell progenitor dp cd4cd8 doublepositive cell progenitor etp early cell precursor hsc haematopoietic stem cell mpp multipotent progenitor br j haematol author manuscript available pmc 2019 march 01"
  },
  {
    "id": 1430,
    "paragraph": "Original Article Densitometry of STR-PAGE for donor chimerism in acute leukemia’s: A simple method for routine use Ayesha Nayyar1, Suhaib Ahmed2 ABSTRACT Objective: To evaluate a PCR based method of polyacrylamide gel electrophoresis of short tandem repeats and its quantification for detecting donor chimerism after haematopoietic stem cell transplantation in acute leukaemias.",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "original article densitometry strpage donor chimerism acute leukemia ’ simple method routine use ayesha nayyar1 suhaib ahmed2 abstract objective evaluate pcr based method polyacrylamide gel electrophoresis short tandem repeats quantification detecting donor chimerism haematopoietic stem cell transplantation acute leukaemias"
  },
  {
    "id": 1431,
    "paragraph": "Methods: The descriptive study was conducted at Genetic Resource Centre (GRC) Lab Rawalpindi from Feb 2018 - Nov 2020. A total of twenty patients with acute leukaemias having undergone HSCT were selected and assessed for the analysis of chimerism status. DNA extraction from the whole blood was done by chelex method and short tandem",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "methods descriptive study conducted genetic resource centre grc lab rawalpindi feb 2018 nov 2020 total twenty patients acute leukaemias undergone hsct selected assessed analysis chimerism status dna extraction whole blood done chelex method short tandem"
  },
  {
    "id": 1432,
    "paragraph": "repeats were amplified by using conventional STR- PCR assay. Electrophoresis was carried out and 6% polyacrylamide gels were used for the resultant amplified DNA products and then followed by their densitometry. These patients had undergone HSCT from Pakistan Institute of Medical Science and Armed Forces Bone Marrow Transplant Centre.",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "repeats amplified using conventional str pcr assay electrophoresis carried 6 polyacrylamide gels used resultant amplified dna products followed densitometry patients undergone hsct pakistan institute medical science armed forces bone marrow transplant centre"
  },
  {
    "id": 1433,
    "paragraph": "Results: The peaks in the PAGE densitometry represented the donor chimerism in all post transplant samples of the patients. Conclusion: Our study showed that densitometry of STR PCR PAGE is a useful and cheaper method for demonstration of donor chimerism in acute leukaemia patients having undergone HSCT. Hence this method can be a valuable option",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "results peaks page densitometry represented donor chimerism post transplant samples patients conclusion study showed densitometry str pcr page useful cheaper method demonstration donor chimerism acute leukaemia patients undergone hsct hence method valuable option"
  },
  {
    "id": 1434,
    "paragraph": "in the monitoring of chimerism status in these patients and therefore helps in preventing graft failure by fast and early treatment strategies for these patients. KEYWORDS: DC, STR, PCR, PAGE, Densitometry, Informative allele. How to cite this: Nayyar A, Ahmed S. Densitometry of STR-PAGE for donor chimerism in acute leukemia’s: A simple method for routine use. Pak J",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "monitoring chimerism status patients therefore helps preventing graft failure fast early treatment strategies patients keywords dc str pcr page densitometry informative allele cite nayyar ahmed densitometry strpage donor chimerism acute leukemia ’ simple method routine use pak j"
  },
  {
    "id": 1435,
    "paragraph": "INTRODUCTION repeats tandem Short (STRs), also known as Microsatellites are small sequences of DNA (two to six base pairs) which are tandemly repeated and these repeat units are different among individuals, making them highly distinguishable1 and are highly useful and widely",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "introduction repeats tandem short strs also known microsatellites small sequences dna two six base pairs tandemly repeated repeat units different among individuals making highly distinguishable1 highly useful widely"
  },
  {
    "id": 1436,
    "paragraph": "used in human identity testing applications.2,3 Ayesha Nayyar, M. Phil, PhD 1. 2. Suhaib Ahmed, FCPS, PhD 1-2: Department of Pathology, Islamic International Medical College, Riphah International University, Islamabad, Pakistan. Correspondence: Prof. Ayesha Nayyar, MBBS, M.Phil, PhD Pathology Department, Islamic International Medical College,",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "used human identity testing applications23 ayesha nayyar phil phd 1 2 suhaib ahmed fcps phd 12 department pathology islamic international medical college riphah international university islamabad pakistan correspondence prof ayesha nayyar mbbs mphil phd pathology department islamic international medical college"
  },
  {
    "id": 1437,
    "paragraph": "Riphah International University, Islamabad, Pakistan. Email: ayesha.nayyar@riphah.edu.pk * Received for Publication: * Edited & Corrected: * Accepted for Publication: December 3, 2023 January 18, 2024 February 5, 2024 Analysis of short tandem repeats (STR-PCR) is thought to be the standard PCR based assay for detection of chi-",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "riphah international university islamabad pakistan email ayeshanayyarriphahedupk received publication edited corrected accepted publication december 3 2023 january 18 2024 february 5 2024 analysis short tandem repeats strpcr thought standard pcr based assay detection chi"
  },
  {
    "id": 1438,
    "paragraph": "merism4 Chimerism refers to the presence of mixture of DNA of both the donor and recipient after a hematopoi- etic stem cell transplant as HSCT has been widely used for the cure of patients suffering from malignant and nonmalignant hematological disorders and considered.5",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "merism4 chimerism refers presence mixture dna donor recipient hematopoi etic stem cell transplant hsct widely used cure patients suffering malignant nonmalignant hematological disorders considered5"
  },
  {
    "id": 1439,
    "paragraph": "Nevertheless testing of hematopoietic chimerism influ- ences clinical decision and therapeutic intervention in patients after haematopoietic stem cell transplantation but HSCT may get failed due to relapse, and graft-versus- host disease (GVHD).6 Estimation of chimerism pattern has a central part in monitoring of patients having un-",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "nevertheless testing hematopoietic chimerism influ ences clinical decision therapeutic intervention patients haematopoietic stem cell transplantation hsct may get failed due relapse graftversus host disease gvhd6 estimation chimerism pattern central part monitoring patients un"
  },
  {
    "id": 1440,
    "paragraph": "dergone stem cell transplant 7 and short tandem repeats (STR-PCR) are considered the standard PCR based meth- od for detecting chimerism.8 The method of STR-PCR us- ing a genetic analyzer is sensitive but costly. The analysis of polyacrylamide gel electrophoresis with subsequent densitometric quantification of the",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "dergone stem cell transplant 7 short tandem repeats strpcr considered standard pcr based meth od detecting chimerism8 method strpcr us ing genetic analyzer sensitive costly analysis polyacrylamide gel electrophoresis subsequent densitometric quantification"
  },
  {
    "id": 1441,
    "paragraph": "DNA fragments is another alternative which is cheaper than the use of genetic analyzer.9 PCR of short tandem repeats using PAGE by genetic analyzer is having lesser sensitivity with high coefficient of variation.10 The troubles most likely faced using genetic analyzer are",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "dna fragments another alternative cheaper use genetic analyzer9 pcr short tandem repeats using page genetic analyzer lesser sensitivity high coefficient variation10 troubles likely faced using genetic analyzer"
  },
  {
    "id": 1442,
    "paragraph": "Pak J Med Sci May - June 2024 Vol. 40 No. 5 www.pjms.org.pk 875 Ayesha Nayyar et al. the artifacts of polymerase slippages i.e stutter peaks, ultimately interfering with the analysis of chimerism pattern.11 Hence by analyzing the samples of peripheral blood",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "pak j med sci may june 2024 vol 40 5 wwwpjmsorgpk 875 ayesha nayyar et al artifacts polymerase slippages ie stutter peaks ultimately interfering analysis chimerism pattern11 hence analyzing samples peripheral blood"
  },
  {
    "id": 1443,
    "paragraph": "or bone marrow of the recipient over time may help in detecting the patterns of Chimerism by conventional STR-PCR PAGE after a stem cell transplant in several malignant and non-malignant hematological diseases. Therefore a continuous monitoring of chimerism is of primary importance in the effective tailoring of the",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "bone marrow recipient time may help detecting patterns chimerism conventional strpcr page stem cell transplant several malignant nonmalignant hematological diseases therefore continuous monitoring chimerism primary importance effective tailoring"
  },
  {
    "id": 1444,
    "paragraph": "treatment strategies wherever required.12 This paper provides a simple, reliable and successful use of STR- PCR by densitometric evaluation of donor chimerism pattern in acute leukaemias. METHODS This descriptive study was conducted at Genetic Resource Centre Rawalpindi. The Twenty post- transplant samples of the patients with acute leukaemias",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "treatment strategies wherever required12 paper provides simple reliable successful use str pcr densitometric evaluation donor chimerism pattern acute leukaemias methods descriptive study conducted genetic resource centre rawalpindi twenty post transplant samples patients acute leukaemias"
  },
  {
    "id": 1445,
    "paragraph": "who had their stem cell transplanr were studied. About 3-ml of peripheral blood was taken in EDTA container. DNA was extracted using ChelexTM method.11 To flank the repeat units in the gene regions, specific STR primers were designed and PCR conditions for STR were same",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "stem cell transplanr studied 3ml peripheral blood taken edta container dna extracted using chelextm method11 flank repeat units gene regions specific str primers designed pcr conditions str"
  },
  {
    "id": 1446,
    "paragraph": "as described by Ahmed.11 Each sibling pair (donor and recipient) were first run at ten different autosomal STR loci (Table-I). The informative locus was identified i.e. donor and recipient had at least one exclusive allele. The donor and the recipient post-transplant",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "described ahmed11 sibling pair donor recipient first run ten different autosomal str loci tablei informative locus identified ie donor recipient least one exclusive allele donor recipient posttransplant"
  },
  {
    "id": 1447,
    "paragraph": "samples were run for the informative STR locus. The STR amplified products were analysed on 10 X 20 cm polyacrylamide gels (PAGE) after silver staining. The results of PAGE results were photographed and were analysed by a software image analysis (http://thal-it.",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "samples run informative str locus str amplified products analysed 10 x 20 cm polyacrylamide gels page silver staining results page results photographed analysed software image analysis httpthalit"
  },
  {
    "id": 1448,
    "paragraph": "com). The donor Chimerism was then calculated and demonstrated as percent of complete donor Chimerism. Ethical Approval: The study was approved by the institutional ethical review board, Faculty of Medical Sciences, Riphah International University Islamabad- Pakistan (Ref. # Riphah/IIMC/IRC/23/3036). Table-I: Relative informative-ness of eight",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "com donor chimerism calculated demonstrated percent complete donor chimerism ethical approval study approved institutional ethical review board faculty medical sciences riphah international university islamabad pakistan ref riphahiimcirc233036 tablei relative informativeness eight"
  },
  {
    "id": 1449,
    "paragraph": "STR loci in the 20 sibling (donor/recipient) pairs. STR Loci Informative in sibling pairs % Common D5S818 D3S1358 D7S820 D8S1179 Uncommon FGA TH01 TPOX D13S317 Rare D18S51-R D21S1411-F 8/20 8/20 5/20 5/20 4/20 3/20 2/20 2/20 1/20 1/20 40.0 (0.40) 40.0 (0.40)",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "str loci 20 sibling donorrecipient pairs str loci informative sibling pairs common d5s818 d3s1358 d7s820 d8s1179 uncommon fga th01 tpox d13s317 rare d18s51r d21s1411f 820 820 520 520 420 320 220 220 120 120 400 040 400 040"
  },
  {
    "id": 1450,
    "paragraph": "25.0 (0.25) 25.0 (0.25) 20.0 (0.20) 15.0 (0.15) 10.0 (0.10) 10.0 (0.10) 5 (0.05) 5 (0.05) Fig.1: Silver stained polyacrylamide gel electrophoresis of STR PCR at D5S818 locus. Lane 1 shows two distinct alleles in the recipient pre-transplant sample. Lane 2 shows two alleles of the",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "250 025 250 025 200 020 150 015 100 010 100 010 5 005 5 005 fig1 silver stained polyacrylamide gel electrophoresis str pcr d5s818 locus lane 1 shows two distinct alleles recipient pretransplant sample lane 2 shows two alleles"
  },
  {
    "id": 1451,
    "paragraph": "same size (homozygous) appearing as a single thick band in the donor sample. Lane 3 shows the recipient post-transplant sample with two alleles but the intensity of the shorter allele (lower band) is significantly less than the larger allele (upper band). The reap-",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "size homozygous appearing single thick band donor sample lane 3 shows recipient posttransplant sample two alleles intensity shorter allele lower band significantly less larger allele upper band reap"
  },
  {
    "id": 1452,
    "paragraph": "pearance of the recipient specific allele (lower band) indicates a reappearance of the recipient’s tissue (decreasing chimerism). RESULTS Informative STR loci in the Donor/Recipient pairs (sibling pairs): All the twenty sibling pairs when analyzed by STR-PCR showed that at least one",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "pearance recipient specific allele lower band indicates reappearance recipient ’ tissue decreasing chimerism results informative str loci donorrecipient pairs sibling pairs twenty sibling pairs analyzed strpcr showed least one"
  },
  {
    "id": 1453,
    "paragraph": "informative STR locus was found in every pair (Table-I). The informative STR loci were divided into “Common”, “Uncommon” loci and “rare”. In each donor/recipient pair the number of informative loci varied from 1 to 8. The usefulness of each STR locus,",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "informative str locus found every pair tablei informative str loci divided “ common ” “ uncommon ” loci “ rare ” donorrecipient pair number informative loci varied 1 8 usefulness str locus"
  },
  {
    "id": 1454,
    "paragraph": "Fig.1.1: Densitometric evaluation of the polyacrylamide gel electrophoresis of the recipient’s post-transplant sample shown in the figure 1. Peak 2 (39.4%) is the recipient specific allele and its reappearance indicates a reappearance of the recipient’s tissue (decreasing chimerism). The donor chimerism in this",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "fig11 densitometric evaluation polyacrylamide gel electrophoresis recipient ’ posttransplant sample shown figure 1 peak 2 394 recipient specific allele reappearance indicates reappearance recipient ’ tissue decreasing chimerism donor chimerism"
  },
  {
    "id": 1455,
    "paragraph": "case was reported as 60.6% (60.6% donor component and 39.4% recipient component). Pak J Med Sci May - June 2024 Vol. 40 No. 5 www.pjms.org.pk 876 Ayesha Nayyar et al. Fig.2: Silver stained polyacrylamide gel electrophoresis of STR PCR at D3S1358 locus. Lane 1 shows two closely",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "case reported 606 606 donor component 394 recipient component pak j med sci may june 2024 vol 40 5 wwwpjmsorgpk 876 ayesha nayyar et al fig2 silver stained polyacrylamide gel electrophoresis str pcr d3s1358 locus lane 1 shows two closely"
  },
  {
    "id": 1456,
    "paragraph": "packed alleles in the recipient pre-transplant sample. Lane 2 shows two distinct alleles in the donor sample. Lanes 3 & 4 show the recipient post-transplant samples with three alleles. The middle allele (indicated by arrow) is the recipient’s exclusive allele. Its reappearance in the",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "packed alleles recipient pretransplant sample lane 2 shows two distinct alleles donor sample lanes 3 4 show recipient posttransplant samples three alleles middle allele indicated arrow recipient ’ exclusive allele reappearance"
  },
  {
    "id": 1457,
    "paragraph": "post-transplant sample indicates a reappearance of the recipient’s tissue (decreasing chimerism). defined by the number of informative loci, varied from 5% to 40% as shown in Table-I. Donor Chimerism by STR PCR: The results achieved from STR-PCR in all the sibling pairs were obtained",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "posttransplant sample indicates reappearance recipient ’ tissue decreasing chimerism defined number informative loci varied 5 40 shown tablei donor chimerism str pcr results achieved strpcr sibling pairs obtained"
  },
  {
    "id": 1458,
    "paragraph": "and read from the silver stained polyacrylamide gels. Densitometric evaluation of the polyacrylamide gel of STR-PCR was done later on. (Fig.1 to Fig.2.2). The densitometric evaluation of PAGE clearly showed donor chimerism in post transplant samples of the patients in regards to their percentages estimated. The",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "read silver stained polyacrylamide gels densitometric evaluation polyacrylamide gel strpcr done later fig1 fig22 densitometric evaluation page clearly showed donor chimerism post transplant samples patients regards percentages estimated"
  },
  {
    "id": 1459,
    "paragraph": "overall results of the 20 sibling pairs and the level of chimerism in these pairs ranged from 13.2% to 98.9%. Donor Chimerism by STR-PCR: Results of donor chi- merism by STR PCR in the 20 sibling pairs were read from the silver-stained polyacrylamide gels and their",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "overall results 20 sibling pairs level chimerism pairs ranged 132 989 donor chimerism strpcr results donor chi merism str pcr 20 sibling pairs read silverstained polyacrylamide gels"
  },
  {
    "id": 1460,
    "paragraph": "densitometry. DISCUSSION for managing different Currently Haematopoietic stem cell transplant is considered to be an effective and efficient therapeutic strategy hematologic malignancies, but alongwith is compounded by various complications, such as disease recurrence, toxicity related to treatment related toxicity, Graft rejection and",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "densitometry discussion managing different currently haematopoietic stem cell transplant considered effective efficient therapeutic strategy hematologic malignancies alongwith compounded various complications disease recurrence toxicity related treatment related toxicity graft rejection"
  },
  {
    "id": 1461,
    "paragraph": "GVHD.13 The main cause of failure of haematopoietic stem cell transplant is relapse inspite of continuous improvement in this therapeutic modality especially in patients with acute leukemia. As recommended by EuroChimerism consortium PCR analysis of STR is the standard method for estimation of quantitative",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "gvhd13 main cause failure haematopoietic stem cell transplant relapse inspite continuous improvement therapeutic modality especially patients acute leukemia recommended eurochimerism consortium pcr analysis str standard method estimation quantitative"
  },
  {
    "id": 1462,
    "paragraph": "chimerism in the prediction of relapses.14 Fig.2.2: Densitometric evaluation of polyacrylamide gel electrophoresis of the recipient’s post-transplant sample shown in the figure 2. Peak 2 (20.6%) is the recipient specific allele and its reappearance in a post-transplant sample indicates a reappearance of the recipient’s tissue",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "chimerism prediction relapses14 fig22 densitometric evaluation polyacrylamide gel electrophoresis recipient ’ posttransplant sample shown figure 2 peak 2 206 recipient specific allele reappearance posttransplant sample indicates reappearance recipient ’ tissue"
  },
  {
    "id": 1463,
    "paragraph": "(decreasing chimerism). The donor chimerism in this case was reported as 79.4% (79.4% donor component and 20.6% recipient component). Regarding routine chimerism monitoring there are promising investigations on the new methods; however, for monitoring of chimerism status currently STR-PCR is the established method which not only determines",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "decreasing chimerism donor chimerism case reported 794 794 donor component 206 recipient component regarding routine chimerism monitoring promising investigations new methods however monitoring chimerism status currently strpcr established method determines"
  },
  {
    "id": 1464,
    "paragraph": "the type of chimeras, but also determines the percentage of both donor and recipient cells.8 Hence after HSCT reappearance or persistence of recipient cells can indicate the recurrence of the recipient’s hematopoietic cells or presence of malignant cells or both.15 Many",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "type chimeras also determines percentage donor recipient cells8 hence hsct reappearance persistence recipient cells indicate recurrence recipient ’ hematopoietic cells presence malignant cells both15 many"
  },
  {
    "id": 1465,
    "paragraph": "researchers have proved that the PCR analysis of short tandem repeat profiles of DNA sequences and single nucleotide polymorphisms analysis with real-time quantitative PCR based methods are major techniques used for detection of chimerism.12,16 The STRs have an advantage over other molecular markers for estimating",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "researchers proved pcr analysis short tandem repeat profiles dna sequences single nucleotide polymorphisms analysis realtime quantitative pcr based methods major techniques used detection chimerism1216 strs advantage molecular markers estimating"
  },
  {
    "id": 1466,
    "paragraph": "the chimerism because of increase number of allels and low amount of DNA required in a PCR reaction.17 The detection limit of STR-PCR for recipient chimerism is ranging from 1 to 10% in few studies. Although technical variability among laboratories may be noticeable.18,19",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "chimerism increase number allels low amount dna required pcr reaction17 detection limit strpcr recipient chimerism ranging 1 10 studies although technical variability among laboratories may noticeable1819"
  },
  {
    "id": 1467,
    "paragraph": "Few researchers found out that by using STR markers in 56 children with ALL after HSCT early detection of chimerism can be found out easily.20 Hence for analysis of chimerism, the preferred technique should be easy to perform, rapid, cheap, easily interpretable and",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "researchers found using str markers 56 children hsct early detection chimerism found easily20 hence analysis chimerism preferred technique easy perform rapid cheap easily interpretable"
  },
  {
    "id": 1468,
    "paragraph": "applicable to every patient. In addition, results should have less variation between the samples and should be highly reproducible. However these consideration should be taken into account for analyzing the exact quantification of donor/recipient DNA for assessing engraftment of the donor DNA and diagnosing the",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "applicable every patient addition results less variation samples highly reproducible however consideration taken account analyzing exact quantification donorrecipient dna assessing engraftment donor dna diagnosing"
  },
  {
    "id": 1469,
    "paragraph": "failure of graft in an early manner.4 In a study by Andrikovics et al a total of 12 STR markers are needed to obtain 95% informativity for the analysis of chimerism.21 A group of researchers in Pak J Med Sci May - June 2024 Vol. 40 No. 5 www.pjms.org.pk 877",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "failure graft early manner4 study andrikovics et al total 12 str markers needed obtain 95 informativity analysis chimerism21 group researchers pak j med sci may june 2024 vol 40 5 wwwpjmsorgpk 877"
  },
  {
    "id": 1470,
    "paragraph": "Ayesha Nayyar et al. their study of 230 patients of malignant hematological disorders found out that five STR informative markers were able to find chimerism in all patients except ten patients who deceased and also suggested that STR is more informative in detecting mixed chimerism",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "ayesha nayyar et al study 230 patients malignant hematological disorders found five str informative markers able find chimerism patients except ten patients deceased also suggested str informative detecting mixed chimerism"
  },
  {
    "id": 1471,
    "paragraph": "as compared to other method.22 A Japanese study suggested that using 20 STR markers and the KMR kit markers the informativity in donor/recipient pairs for estimation of chimerism may be detected in a large variety of donor/recipient pairs.23 Few researchers have suggested that at least 40",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "compared method22 japanese study suggested using 20 str markers kmr kit markers informativity donorrecipient pairs estimation chimerism may detected large variety donorrecipient pairs23 researchers suggested least 40"
  },
  {
    "id": 1472,
    "paragraph": "markers are required to discriminate a large number of the donor recipient pairs. 24 A group of researchers in their study have observed the status of chimerism by using STR markers in 39 donor/recipient pairs and found chimerism in all the pairs.25",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "markers required discriminate large number donor recipient pairs 24 group researchers study observed status chimerism using str markers 39 donorrecipient pairs found chimerism pairs25"
  },
  {
    "id": 1473,
    "paragraph": "CONCLUSION Our study demonstrates that STR -PCR using densitometric evaluation is a simple and favourable technique without use of any special instrumentation and expensive reagents making it suitable for a use in routine laboratory practices. Hopefully this will help in analysis of the outcomes after hematopoietic stem",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "conclusion study demonstrates str pcr using densitometric evaluation simple favourable technique without use special instrumentation expensive reagents making suitable use routine laboratory practices hopefully help analysis outcomes hematopoietic stem"
  },
  {
    "id": 1474,
    "paragraph": "haematopoietic stem cell transplantation for malignant and non ma- lignat diseases. Transplantation and Cellular Therapy. 2021; 27:872 doi.org/10.1016/j.jtct.2021.07.014 4. 5. 6. Waterhouse M., Pfeifer D., Duque-Afonso J., Follo M., Duyster J., Depner M., et al. Development and Performance of a next Generation",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "haematopoietic stem cell transplantation malignant non lignat diseases transplantation cellular therapy 2021 27872 doiorg101016jjtct202107014 4 5 6 waterhouse pfeifer duqueafonso j follo duyster j depner et al development performance next generation"
  },
  {
    "id": 1475,
    "paragraph": "detection after allogeneic haematopoietic stem cell transplantation by chimerism assays: Digital PCR versus quantitative real-time PCR of insertion/deletion polymorphisms. PLoS ONE 2019; 14(2): e0212708. https://doi.org/10.1371/journal.pone.0212708 15. Peter B, Carreras E, Dufour C , Mohty M , Kröger N. Documentation of Engraftment and Chimerism After HSCT 7th edition. The EBMT",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "detection allogeneic haematopoietic stem cell transplantation chimerism assays digital pcr versus quantitative realtime pcr insertiondeletion polymorphisms plos one 2019 142 e0212708 httpsdoiorg101371journalpone0212708 15 peter b carreras e dufour c mohty kröger n documentation engraftment chimerism hsct 7th edition ebmt"
  },
  {
    "id": 1476,
    "paragraph": "17. Deniskova TE, Sermyagin AA, Bagirov VA, Okhlopkov IM, Gladyr EA, Ivanov RV et al. 18. Comparative analysis of the effectiveness of STR and SNP markers for intraspecific and interspecific differentiation of the genus Ovis. Russ J Genet. 2016; 52: 79–84.",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "17 deniskova te sermyagin aa bagirov va okhlopkov im gladyr ea ivanov rv et al 18 comparative analysis effectiveness str snp markers intraspecific interspecific differentiation genus ovis russ j genet 2016 52 79–84"
  },
  {
    "id": 1477,
    "paragraph": "19. Pedini P, Cherouat N , Basire A , Simon S, Budon L , Pourtein M et al. Evaluation of next-generation sequencing and crystal digital PCR for chimerism monitoring of post-allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021; 27, 89.e1-89.e10",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "19 pedini p cherouat n basire simon budon l pourtein et al evaluation nextgeneration sequencing crystal digital pcr chimerism monitoring postallogeneic hematopoietic stem cell transplantation transplant cell ther 2021 27 89e189e10"
  },
  {
    "id": 1478,
    "paragraph": "20. Llaurador G , Nicoletti E , Prockop SE , Hsu S, Fuller K, Mauguen A et al. Donor-host lineage-specific chimerism monitoring and analysis in pediatric patients following allogeneic stem cell transplantation: In- fluence of pretransplantation variables and correlation with post-trans-",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "20 llaurador g nicoletti e prockop se hsu fuller k mauguen et al donorhost lineagespecific chimerism monitoring analysis pediatric patients following allogeneic stem cell transplantation fluence pretransplantation variables correlation posttrans"
  },
  {
    "id": 1479,
    "paragraph": "merism test that uses selection of short tandem repeat or quantitative PCR depending on patient’s chimerism status. J. Mol. Diagn. 2019; 21: 483–490 24. Minakawa K, Ono S, Watanabe M, Sato Y, Suzuki S, Odawara S, et al. Evaluation of a quantitative PCR-based method for chimerism",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "merism test uses selection short tandem repeat quantitative pcr depending patient ’ chimerism status j mol diagn 2019 21 483–490 24 minakawa k ono watanabe sato suzuki odawara et al evaluation quantitative pcrbased method chimerism"
  },
  {
    "id": 1480,
    "paragraph": "analysis of Japanese donor/recipient pairs. Sci Rep 2022; 12: 21328 https://doi.org/10.1038/s41598-022-25878-9 25. Vynck, M, Nollet, F, Sibbens, L., Devos, H. Chimerism monitoring us- ing biallelic single nucleotide or insertion/deletion polymorphisms: How many markers to screen? Clin. Chim. Acta 2022; 532: 123–129",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "analysis japanese donorrecipient pairs sci rep 2022 12 21328 httpsdoiorg101038s41598022258789 25 vynck nollet f sibbens l devos h chimerism monitoring us ing biallelic single nucleotide insertiondeletion polymorphisms many markers screen clin chim acta 2022 532 123–129"
  },
  {
    "id": 1481,
    "paragraph": "AN: literature search, study design and concept, data collection, data analysis, data interpretation, drafting. SA: Study design and concept, data analysis, data interpretation, Critical Review, Final approval. Pak J Med Sci May - June 2024 Vol. 40 No. 5 www.pjms.org.pk 878",
    "jurnal": "PJMS-40-875.pdf",
    "processed": "literature search study design concept data collection data analysis data interpretation drafting sa study design concept data analysis data interpretation critical review final approval pak j med sci may june 2024 vol 40 5 wwwpjmsorgpk 878"
  }
]